<SEC-DOCUMENT>0001854270-23-000064.txt : 20230509
<SEC-HEADER>0001854270-23-000064.hdr.sgml : 20230509
<ACCEPTANCE-DATETIME>20230509160804
ACCESSION NUMBER:		0001854270-23-000064
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		75
CONFORMED PERIOD OF REPORT:	20230331
FILED AS OF DATE:		20230509
DATE AS OF CHANGE:		20230509

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Senti Biosciences, Inc.
		CENTRAL INDEX KEY:			0001854270
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				862437900
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40440
		FILM NUMBER:		23901996

	BUSINESS ADDRESS:	
		STREET 1:		2 CORPORATE DRIVE, FIRST FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		(650) 382-3281

	MAIL ADDRESS:	
		STREET 1:		2 CORPORATE DRIVE, FIRST FLOOR
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Senti Biosciences, Inc.\
		DATE OF NAME CHANGE:	20220615

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Dynamics Special Purpose Corp.
		DATE OF NAME CHANGE:	20210331
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>snti-20230331.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:7af4709b-ea9b-4a83-bec7-2aee05be3f39,g:bb811bd4-927a-481b-aaf3-dcf961c572fd,d:d08c0d7bd703495d970d203330d59b2f--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:snti="http://www.sentibio.com/20230331" xmlns:srt="http://fasb.org/srt/2022" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>snti-20230331</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80L2ZyYWc6MmFlZTUwYjA5NzhmNGNjM2IxODk0YWZkZWMyNTg1NzQvdGFibGU6NDZhNmZmYTlhOWVjNGNlODljYjM1ZWJiNzMwOGZlYzYvdGFibGVyYW5nZTo0NmE2ZmZhOWE5ZWM0Y2U4OWNiMzVlYmI3MzA4ZmVjNl8yLTItMS0xLTEzMDc4Mw_4bbf7482-d3ed-4b2e-9eee-fb22c3723041">0001854270</ix:nonNumeric><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80L2ZyYWc6MmFlZTUwYjA5NzhmNGNjM2IxODk0YWZkZWMyNTg1NzQvdGFibGU6NDZhNmZmYTlhOWVjNGNlODljYjM1ZWJiNzMwOGZlYzYvdGFibGVyYW5nZTo0NmE2ZmZhOWE5ZWM0Y2U4OWNiMzVlYmI3MzA4ZmVjNl8zLTItMS0xLTEzMDc4Mw_d8c1c19a-d8d6-42c7-8c6e-40dcd8ccd9b2">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80L2ZyYWc6MmFlZTUwYjA5NzhmNGNjM2IxODk0YWZkZWMyNTg1NzQvdGFibGU6NDZhNmZmYTlhOWVjNGNlODljYjM1ZWJiNzMwOGZlYzYvdGFibGVyYW5nZTo0NmE2ZmZhOWE5ZWM0Y2U4OWNiMzVlYmI3MzA4ZmVjNl80LTItMS0xLTEzMDc4Mw_f4df1221-fbfc-48fe-b7fc-d0fa2afbad42">2023</ix:nonNumeric><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80L2ZyYWc6MmFlZTUwYjA5NzhmNGNjM2IxODk0YWZkZWMyNTg1NzQvdGFibGU6NDZhNmZmYTlhOWVjNGNlODljYjM1ZWJiNzMwOGZlYzYvdGFibGVyYW5nZTo0NmE2ZmZhOWE5ZWM0Y2U4OWNiMzVlYmI3MzA4ZmVjNl81LTItMS0xLTEzMDc4Mw_a8e0c684-dada-4436-aeec-a2e4cd092653">Q1</ix:nonNumeric><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80L2ZyYWc6MmFlZTUwYjA5NzhmNGNjM2IxODk0YWZkZWMyNTg1NzQvdGFibGU6NDZhNmZmYTlhOWVjNGNlODljYjM1ZWJiNzMwOGZlYzYvdGFibGVyYW5nZTo0NmE2ZmZhOWE5ZWM0Y2U4OWNiMzVlYmI3MzA4ZmVjNl82LTItMS0xLTEzMDc4Mw_575d84aa-ae16-4f30-967a-b3bf2763b38e">false</ix:nonNumeric><ix:nonNumeric contextRef="i2cf3659743e3408a95f042ce0308c736_D20220608-20220608" name="snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNTE5OA_43c54c31-da11-473c-9a9b-97c930e0d994">P20D</ix:nonNumeric><ix:nonNumeric contextRef="i73952d58d72347dd9b9031f6d875bf3d_D20220608-20220608" name="snti:ReverseRecapitalizationContingentConsiderationEquityTerm" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NTIxMA_4c4a7b87-cc7a-4ee5-be63-48c4f60a7afc">P2Y0M0D</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="snti-20230331.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i839f745b74bd42b2b4ae2745233146b4_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a1e89939cfa42e790464e0d1aafd27c_I20230501"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-05-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i2db00a77192f4255a898540eac49878e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie93d0f28fa434fdd8b2c267c63e09208_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">snti:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b11b2dbf83b49388972be2c36307328_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">snti:RelatedPartyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i81b11644709349c9bc306b63606105cc_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e8c2a57c818445b8ad0d8224990f182_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28bc0e58798a48d59cce5700cab14713_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5910a2afac7e44af947c9bd551313533_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia327828af3c64db9a9c8cc328000bcb5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78a270744c2d4a1f98a4a39f1d1043d3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id81fb690a0ac44c7b7413c241996b920_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e696449bb8f473ba9b98e6d54a4196f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a290377bb464be7a1011652879be414_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic47933b228a74660947c56c9928b9097_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83c0f0002c6640cf8e492cd72f557b7f_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i521e15cacfab469899d7fc2c91390f18_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id07031ea08724f1eb814c4d290dec411_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id453bf1b5a4b44eb97fecc35ef14b460_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81684dd89952407fad1331a3c1ba7940_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia120b6b0d53947b9858a5dbe0b78569f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1f5158cc8cb4ef09ae38b5dc0f801bf_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4026bb920b246c6ab69bb9a495e015c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ec8395b47bf40878513f3f1f51bfab2_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2611a18b085f44fa80ee121714ee9959_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c7cf871f8f445ce8ffd3b796c78114b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72961400d84f441aa4a9de049fb9ea0f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if20ddea8370b47e2a8d0cc41b5712871_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3400e851c0774865aacdc65833967f02_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id70d23838a974b229e80c5c9278df638_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa14ff1d6afd4a6aaad076de554b3054_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="businessactivitiy"><xbrli:measure>snti:businessActivitiy</xbrli:measure></xbrli:unit><xbrli:unit id="reportablesegment"><xbrli:measure>snti:reportableSegment</xbrli:measure></xbrli:unit><xbrli:context id="ia1507455ae4545acb5c5e77c20ccf10c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5a57a126aad418cab737f9098520762_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78139b1e342f47d9b902943821cf2036_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4705a76340e438cbf1fd59d574befef_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4a0a24d2beff407985996abce370fac1_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic853c11d285841a9a58448f68290872e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54edccfe021d431689266dad3928a2bf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic621dc1a5dd1488e9267eea6f23d8049_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3e4f2aae937b4d63890360a721452a0a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38ec92e6b86d4514acf595c514672dce_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07bc91a53f5a459baf1197c27ade6ed2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1249a7ce3f54ef5bb8002ca6d310e15_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04e58e5594694539a02749f71be310dd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i806026a6a971437f8a3ed419e043f3f8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0599314ad55c451a80b55746b2dc9bfd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7093d18319c4542a600a6987750ebc6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56248ee32fc0485f8d3c8bad91562cee_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e20fb37f0c44033bc88e5d7cdb0ff33_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie612beff75d94ee5b9518fe9ad917d8c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9a0ba519d4ef4fc6aeabfe9afc583b1a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibcdf00099f6948e394392540bc14975f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i182e6b0e83c74e2e91736e7bb9c35972_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i201af4811a374b0d85692aa3b41f79b5_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3359592a1b094bac8319cc1e2408c43f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3c09c639dac47edb944ea9ecf3b0299_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic8d224f088f74ed28515d75a9ea6d258_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31c096de9b294cce82f4eddee4fe3e1a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i613e04533fcc42e9b6435b116c5cf0be_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66db0287b069499789e51d16f875e403_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1967ceac06c041718a989a37273e427a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iecaecf3f762f4965b2caf2cdaec72352_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8df3f77390c94af5886983ba9c67ce4c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i738f1818b2ee440b81ae9395474ef8a6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i77067e3a647e4bcf86bbaa6aecc10bc6_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d690099dd934e29ab16020f70f61c81_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i04776ba3407e4211bf944ba32f788c04_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0c53dece0f4746dca63507589ca1b33f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic975f5329514459cb776591a8393e656_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i341995b37eeb4178a439a3e4c98245c3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c01bb3709c34dd49620a247ad1fbc01_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i230fd69e00ae4f99b1e3a2d854b95850_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5289294e32684de3b46e5ac39b5c1c4c_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb5bf968a6f341f1a417ef865d2b0373_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8cf2e03c3b7044dd8f4d13d428853cad_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0493e8bc17624187bbe1a3959ac97b33_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i45596385065544378327410d696e5e0f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae83b8ab01644353acb71b4d4fcf3c2b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a9825b53292444882e4b80aee4ca647_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibba6c7e42d174d4dad4f3aa9b26cc841_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86691c0476ba404f814077f7c6873c81_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7dddc4574d1483ca39ac475a557c315_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ed753b6656243da8485cb9941f77565_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i031d672c83f54e5596727cbdebf7ddce_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i369efc411a944e0ab23af95aeaed1da3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf727ea3cbd14cc599d0b296bd695c30_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2dd1486f0094652a61e2542b663d473_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac83004296dc489eb73145ef1a50ed6f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i652407f4e1424c81a265a8aeb53e2c9f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb62e4f0d0f34a19a5af68bf3ca4be90_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i758da6ca9a82424fbac7ce29a91ab127_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3913e52d42bd4b0584295d1000454575_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4bf17ca1c12485a95f53564217086b7_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i057bc7826d4b4c84aacdd029762ebfee_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">snti:ContingentEarnoutLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc3b98e8794d4db98f8a5bec44536adc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">snti:ContingentEarnoutLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d7515206e374c2f8b3ba0988b6e7cc6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">snti:ContingentEarnoutLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84c054ca47f34f0fb57a2cc22fa7ebb3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">snti:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib151b972fd8f4cd79d899cda2eeb31e2_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">snti:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3df465c4a0264659996eb97c82a869a6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9622647ee0c949e0a3c0188f49fed90f_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a54633d73574574bcdce66f8f30a522_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">snti:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i092aed2ed1dc43bba672fdbaa11ea98d_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">snti:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie51e5a8e9f5f4b7a82df0ce23e6b0e47_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2de56f4fdc344660850e0c6380cf9deb_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55a0a250ecba480e9d2984321a23058c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie5a7787f606c4694a34c9edafbf1c9a3_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13c2b1f5934440b19195e3dc99ca0b84_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">snti:CorporateHeadquartersMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffa91051becf44e9bef166d4fa25aabf_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">snti:AlamedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0a2f740c54a4460bdf1870465e2fd28_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">snti:AlamedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="tradingday"><xbrli:measure>snti:tradingDay</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i13d4209f114b48ae802f8c70848bac8d_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">snti:AlamedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a99c95357954ece87322f3f9568adc0_D20210730-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">snti:AlamedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-30</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="vote"><xbrli:measure>snti:vote</xbrli:measure></xbrli:unit><xbrli:context id="i81d4d8a5f9114d1886175ca8b72ce10a_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7840bf286e7b4bce9183521fe23e6524_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id20463a91ddd421ea41fcb5abe035d56_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e6ef9d05bdb4e6ab4465b3414f327a9_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i16305f4a1b8449d1a35861d9aa0fc5c8_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ee3457100c84c3d87184e1e135ba640_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i47d461e06c0441f3bf66aa005d566b32_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:CommonStockUnderEquityPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i52cce8c44b9b4333a95f74f60f360543_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:CommonStockUnderEquityPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cabf5a80a1a48298b9edf643135beb0_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0381c522846d4ca6a0f0602fe5c59dc0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4027bdb9ad2f4e6c85d6878c9bb667fc_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:ContingentEarnoutCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5f4bb6471d7488ba9e91594b407b669_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:ContingentEarnoutCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i066bdaf0f5a0401387fa517ed3d8324c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i190ad14af5cf48d182dd17a670b1c6b0_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">snti:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-31</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2695814ca4b34861bbd946616eacf91a_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">snti:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3301414885c64fcb913d8ab29a5a4c1d_I20220831"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">snti:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf30c96ccd494c5792c0230ca1a3d6db_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">snti:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29d9a37c9c3b447eb4fb6ec96fa1dd2b_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">snti:CommonStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cf3659743e3408a95f042ce0308c736_D20220608-20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-08</xbrli:startDate><xbrli:endDate>2022-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic402157e4d8841ffabfdea65ced1a7b6_I20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="tranche"><xbrli:measure>snti:tranche</xbrli:measure></xbrli:unit><xbrli:context id="ic0e7bfd5199240fe911cf1a70a64d6a8_I20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">snti:ContingentConsiderationTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a8876a6338d4250b6c025cf2cd85bf7_I20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="snti:ContingentConsiderationTranchesAxis">snti:ContingentConsiderationTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i73952d58d72347dd9b9031f6d875bf3d_D20220608-20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">snti:ContingentConsiderationTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-08</xbrli:startDate><xbrli:endDate>2022-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i987337493e8f4d6b95c95a50303ac90b_D20220608-20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">snti:ContingentConsiderationTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-08</xbrli:startDate><xbrli:endDate>2022-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i478aae25e06348e2896c5435db3def08_I20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d50e05b3f964b1e8bd1212007d0f5b2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4303eca5071e4e959e6a005f6949bbc0_I20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i585e64a0dde84731b30a56a965b3502e_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22fe4e8df6ab4d1dab35a6b9027729c0_I20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4dfd924deef14485b70ba9b749718b18_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iebf31f1f016a4897aeecc0db5ee0375f_I20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i743280c266ac4be9bba0b85a394d535f_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c5f60d8079a4c929fb01b0c4238eb77_I20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="years"><xbrli:measure>snti:Years</xbrli:measure></xbrli:unit><xbrli:context id="i74c815e4a7ff416083bff82a684e4da6_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7e5dfb75c5345e0908face1c31bf68c_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SparkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i928b078b707f45d4ab1ac6398e73bf1b_I20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-05-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SparkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i766f28525f3748399d68ffe1034f13d1_D20221201-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SparkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b3c57ec032744ba8f6125f37486a864_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SparkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27014437a0604c6493a324456d9bebc5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SparkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if8ecffc42af64ac98c375ec96588e97e_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SparkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb49597653b64cf59b45a61e885d9cab_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SparkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4caf954de824dcfa399375ed1463740_D20210401-20210430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SparkMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27aef62b1f3e4bffb3dd2df12b5856fe_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71c1a8f9ff524518959d9a765706749d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8b4557210454abca1e04086bd66db43_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">snti:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icaa788b9dd8d4c5989a84143f00ba716_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">snti:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39380c3017c0443ea9d9f875c6d12c89_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">snti:CustomerAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0b118498cc947c4a737ef007df909ed_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">snti:CustomerBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e7073ad95d14237a686257c1f249847_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2016StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bbb2d044d4540fba0cfd4b952348522_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i109dbba609114d389a60bbd41cab5bfc_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0157834a97314a79aab287cf1bcc1d2d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d089448db5c47ac864b335700ebdf6c_I20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fdc25c4786948e396c80e21496eaec2_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65140541deed4a8a9d94a28b4b349127_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022InducementEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93b6fc338c6a44bfac709886289913e3_D20220805-20220805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022InducementEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-08-05</xbrli:startDate><xbrli:endDate>2022-08-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84ff68234e48415aabc730672a424709_I20220805"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022InducementEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3b946e4dc38a43f985ff9ce7ef855a78_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022InducementEquityPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifb4c537cd827433eb1fd0857cc6e392f_D20220608-20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-08</xbrli:startDate><xbrli:endDate>2022-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ab0adeec3bc495a85352b6cd04f0ea6_I20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i921a457818234d30b26fac9b4d02f4a7_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie25bf12b097d4142a80c4443e8e34b7c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6f53a18a05e4e3e9c95c5959b5464af_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2016StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09e65d7dd7ff4a518134d5af6af7496b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2016StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iecb98f68e3f54315adf9e9038dadf418_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2016StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cba8c98475b4484aa393d6615db82dd_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2016StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc61cf9dbb914210b3fe39d9d8805450_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2016StockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09d1b2b0e78f4a2a9de67b5ef64622f8_D20211219-20211219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-19</xbrli:startDate><xbrli:endDate>2021-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55f59dff27474019a6a976d08d32c7a5_D20220608-20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-08</xbrli:startDate><xbrli:endDate>2022-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5aee551dc4424308a0cbe423b5aa00f5_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f3e04de252e4ab9ad665ce2c64c8f64_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i787b64c59226487c91cbebde035a735d_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if95b9a3a21314a64be95e971b65657ab_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i148f91500cfa448b90c1ca1b3fe51ddd_D20211219-20211219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:MarketAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-19</xbrli:startDate><xbrli:endDate>2021-12-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i342ee2fd8d6845069313253e24f45e30_I20211219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:MarketAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1d8a71f2d75d44fd822915e608589a18_D20220608-20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:MarketAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-08</xbrli:startDate><xbrli:endDate>2022-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4e222fd06584beba7f3df061459dfd0_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:MarketAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb827c206b774ff486fdcdc6ed921a68_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:MarketAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic26e10f702604471b0ad4cc00f011d6c_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:MarketAwardsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i24a619ba2bc2425c8c531466ceb3022f_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib140873ca1da43bab9fd62b4810057e8_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6537e1d4905e4ed2b36a8e22e7ed2fde_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba81969c6f8347389b8d4c2ac513fd4e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f71e36b64d04c6589346f18f9cf047d_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dfd433797ae4a47a3afcd51ca0bd98b_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie599948bb538493ca54ae5c945c4b314_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">snti:SeriesAAndBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2546b82138745239b77f03d5bb97902_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">snti:SeriesAAndBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ce095b293ee421697f3e146ad0f8453_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1ba20d9c2a54249ad151ad0d937ed15_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1c8a87aa2e340119590adac4cec8f56_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">snti:UnvestedEarlyExercisedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9531c149469c43a9ac1f3916d2cb652f_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">snti:UnvestedEarlyExercisedOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c36144fc5464645b44250cb81efdb06_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7307cc0c5600489eb471edc1bd0b09e3_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45a6fb8c66694eb9a022dbc503607f1c_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">snti:ContingentEarnoutCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i162569ca541746a58397f1201089485e_D20220101-20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">snti:ContingentEarnoutCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43648233679b4319915d781e0fdea7bf_I20210603"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i082b5a0a6bc54f70b3e73ff4d25c3e03_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">snti:CGMPFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i591e3e2787ef4aa3b0dde7a4158d5d4e_D20210521-20210521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:BlueRockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-21</xbrli:startDate><xbrli:endDate>2021-05-21</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ddb97ef409844f1b6d57e39963c1d3d_I20210521"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:BlueRockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id747b950a62d4ac19aee5dcc6cf15399_D20230101-20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:BlueRockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f79f3be18db4668bcb3b5370e9cecd3_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:NEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c26ec28b64d45bc9036cc8d57f2140b_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:NEAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f7c274bcbdf4ef58b92b5848babde15_I20220519"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">snti:May2022NoteMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib7a73372076e4e89a384e72fe0e3c45e_D20220608-20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-08</xbrli:startDate><xbrli:endDate>2022-06-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i057310d2a92b4448be2ea0e4a9991828_I20220608"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie37202655afe400799f589b98e2e9296_I20230331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fc3f895e15c4c5e96890aa6215ca746_I20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:BayerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib8899c630b094438a9d71777a8d3774a_D20230101-20230131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001854270</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SeerIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-01-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id08c0d7bd703495d970d203330d59b2f_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%">WASHINGTON, D.C. 20549</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:25.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6MThmMTBjZWQ4OWE3NDA3YWE5YzliYjNmZTMxZGQ3NGEvdGFibGVyYW5nZToxOGYxMGNlZDg5YTc0MDdhYTljOWJiM2ZlMzFkZDc0YV8wLTAtMS0xLTEzMDc4My90ZXh0cmVnaW9uOjcyMmY0MWIwNjUxZDQ2NzhiYWE2MzAyMDc3MzQxNTRiXzk_b87463f8-f2c7-43a2-a4f7-83cb93e3e804">10-Q</ix:nonNumeric></span></div></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.638%"><tr><td style="width:0.1%"></td><td style="width:2.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.052%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(Mark One)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6NjA1NTY5ZjgxYzEyNDBjOWFjOGRkZGZlY2EzZjFlYmEvdGFibGVyYW5nZTo2MDU1NjlmODFjMTI0MGM5YWM4ZGRkZmVjYTNmMWViYV8xLTAtMS0xLTEzMDc4Mw_2e1f839f-b312-41d1-b47d-34dc3716e97a">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">For the quarterly period ended <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6NjA1NTY5ZjgxYzEyNDBjOWFjOGRkZGZlY2EzZjFlYmEvdGFibGVyYW5nZTo2MDU1NjlmODFjMTI0MGM5YWM4ZGRkZmVjYTNmMWViYV8yLTEtMS0xLTEzMDc4My90ZXh0cmVnaW9uOjI1YTk4ODE5M2ZkMTRiNWFhYmVhNGZmODk4NWJmNDU4XzM1_ccfca7e1-b240-4418-93d0-8ba6a308164a">March&#160;31, 2023</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6NjA1NTY5ZjgxYzEyNDBjOWFjOGRkZGZlY2EzZjFlYmEvdGFibGVyYW5nZTo2MDU1NjlmODFjMTI0MGM5YWM4ZGRkZmVjYTNmMWViYV8zLTAtMS0xLTEzMDc4Mw_e12d965e-287f-4ecc-8835-d55f0eb17935">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">For the quarterly period from _______ to _______</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Commission File Number <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMjk3_095685de-f492-4016-b833-cf8c0294dfaf">001-40440</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">_________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:24pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMjk4_c7bdbec9-890a-48d8-a566-6050eccb3931">Senti Biosciences, Inc.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(Exact name of registrant as specified in its charter)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">_________________________</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6MTM4NzFiM2I5OTIyNDhhZWE2YWNhMzc4YjA3NDM5MDYvdGFibGVyYW5nZToxMzg3MWIzYjk5MjI0OGFlYTZhY2EzNzhiMDc0MzkwNl8wLTAtMS0xLTEzMDc4Mw_78b4cd7a-7a37-42e7-8f0c-510cfc43448c">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6MTM4NzFiM2I5OTIyNDhhZWE2YWNhMzc4YjA3NDM5MDYvdGFibGVyYW5nZToxMzg3MWIzYjk5MjI0OGFlYTZhY2EzNzhiMDc0MzkwNl8wLTItMS0xLTEzMDc4Mw_e1217af3-64d2-4b34-a5c8-beec5f252ae8">86-2437900</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(State or other jurisdiction of</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">incorporation or organization)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">(I.R.S. Employer</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Identification Number)</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzA1_d97f8539-6a82-4da7-9f29-9b2d26b1900b">2 Corporate Drive, First Floor</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzAw_aa0bcee3-6082-4201-a760-f23eda838230">South San Francisco</ix:nonNumeric>, <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzAx_a01be5e4-0653-4a71-ab74-802271144130">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8zNTM_5887e94f-3fe5-43a8-bae4-c3e577b066a0">94080</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(Address of principal executive offices and zip code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzA2_b118cfe9-cbe6-432e-901b-e36de22a9407">(650)</ix:nonNumeric> <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzAz_a740de6e-b863-4b75-a1e8-6b50e770ad6e">239-2030</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(Registrant&#8217;s telephone number, including area code)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Dynamics Special Purpose Corp.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i839f745b74bd42b2b4ae2745233146b4_D20230101-20230331" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMjk1_4268c8e3-a2c4-4dd2-a554-133405781634">2875 El Camino Real</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i839f745b74bd42b2b4ae2745233146b4_D20230101-20230331" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzA3_1fac5021-cda8-4075-bf1d-4f18ee4147e9">Redwood City</ix:nonNumeric>, <ix:nonNumeric contextRef="i839f745b74bd42b2b4ae2745233146b4_D20230101-20230331" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMjk2_f56da2a0-0dea-41de-a27d-87ebde2a11d8">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i839f745b74bd42b2b4ae2745233146b4_D20230101-20230331" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF81NDY_89910846-8048-4795-b018-0c7dae9c9d37">94061</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(408) 212-0200</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">(Former name, former address and former fiscal year, if changed since last report)</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">_________________________</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Securities registered pursuant to Section 12(b) of the Act:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.261%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.096%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange<br/>on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6ZTBiYjdjMzRhMGM4NGI3ZmI4ZDg0MTZhZDdjNTRjOTkvdGFibGVyYW5nZTplMGJiN2MzNGEwYzg0YjdmYjhkODQxNmFkN2M1NGM5OV8xLTAtMS0xLTEzMDc4Mw_aa3e9123-733a-43be-b34b-58cbf0f9fe28">Common stock, par value $0.0001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6ZTBiYjdjMzRhMGM4NGI3ZmI4ZDg0MTZhZDdjNTRjOTkvdGFibGVyYW5nZTplMGJiN2MzNGEwYzg0YjdmYjhkODQxNmFkN2M1NGM5OV8xLTItMS0xLTEzMDc4Mw_51b92ea2-98ea-448a-b7df-9ed740586f80">SNTI</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6ZTBiYjdjMzRhMGM4NGI3ZmI4ZDg0MTZhZDdjNTRjOTkvdGFibGVyYW5nZTplMGJiN2MzNGEwYzg0YjdmYjhkODQxNmFkN2M1NGM5OV8xLTQtMS0xLTEzMDc4Mw_02851960-6727-4a7a-a0a0-72b1f15db744">The Nasdaq Global Market</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt;margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzA4_073780fe-7739-4a17-8101-969ea97d810c">Yes</ix:nonNumeric>  &#9746;    No  &#9744;</span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Section 232.405 of this chapter) during the preceding 12 months (or such shorter period that the registrant was required to submit such files).    <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMjk0_2c9cde58-294d-4cf1-af25-273a453042bc">Yes</ix:nonNumeric>  &#9746;    No  &#9744;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.666%"><tr><td style="width:1.0%"></td><td style="width:17.008%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.508%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.214%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.870%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Large accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6MGU0MjVkNDNkMWY1NDk0OWIxNGUxOTMxNGJjMzMzNDEvdGFibGVyYW5nZTowZTQyNWQ0M2QxZjU0OTQ5YjE0ZTE5MzE0YmMzMzM0MV8xLTAtMS0xLTEzMDc4Mw_556688c0-c07e-402d-b047-331b77a7b438">Non-accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6MGU0MjVkNDNkMWY1NDk0OWIxNGUxOTMxNGJjMzMzNDEvdGFibGVyYW5nZTowZTQyNWQ0M2QxZjU0OTQ5YjE0ZTE5MzE0YmMzMzM0MV8xLTMtMS0xLTEzMDc4Mw_e066fb52-f5b0-431d-b558-4d223b1f85a3">&#9746;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6MGU0MjVkNDNkMWY1NDk0OWIxNGUxOTMxNGJjMzMzNDEvdGFibGVyYW5nZTowZTQyNWQ0M2QxZjU0OTQ5YjE0ZTE5MzE0YmMzMzM0MV8yLTMtMS0xLTEzMDc4Mw_cc978c67-1ca6-44dc-909d-390245f785dd">&#9746;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.    <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzA5_170f9b35-8a30-4c2b-89c0-ee4e1e07e4f9">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  &#9744;    <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzA0_f231734c-4075-470e-90a0-b38f088e5ea4">No</ix:nonNumeric>  &#9746;</span></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%">As of May&#160;1, 2023 there were <ix:nonFraction unitRef="shares" contextRef="i5a1e89939cfa42e790464e0d1aafd27c_I20230501" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMTky_eab774f3-1430-4e21-a618-f2ddcfb7741a">44,168,034</ix:nonFraction> shares of the registrant&#8217;s common stock, par value $0.0001 per share, issued and outstanding.</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div></div><div id="id08c0d7bd703495d970d203330d59b2f_7"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">TABLE OF CONTENTS</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.194%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:80.951%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.555%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_10">PART I - FINANCIAL STATEMENTS</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_13">FINANCIAL STATEMENTS (UNAUDITED)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_16">1</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_19">Condensed Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_19">2</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_22">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_22">3</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_25">5</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_28">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_28">6</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_79">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_79">22</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_115">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_115">31</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_118">CONTROLS AND PROCEDURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_118">32</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_121">PART II - OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_124">LEGAL PROCEEDINGS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_124">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_127">RISK FACTORS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_127">33</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_130">UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_130">103</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_133">DEFAULTS UPON SENIOR SECURITIES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_133">103</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_136">MINE SAFETY DISCLOSURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_136">103</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_139">OTHER INFORMATION</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_139">103</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_142">EXHIBITS</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_142">104</a></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_145">SIGNATURES</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_145">105</a></span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">i</span></div></div></div><div id="id08c0d7bd703495d970d203330d59b2f_10"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PART 1 - FINANCIAL INFORMATION</span></div><div id="id08c0d7bd703495d970d203330d59b2f_13"></div><div style="margin-bottom:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 1.&#160;&#160;&#160;&#160;FINANCIAL STATEMENTS (UNAUDITED)</span></div><div id="id08c0d7bd703495d970d203330d59b2f_16"></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">(unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">(in thousands, except share and per share data)</span></div><div style="margin-bottom:3pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.038%"><tr><td style="width:1.0%"></td><td style="width:72.362%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.844%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfNC0xLTEtMS0xMzA3ODM_ca5e63d0-a82e-481f-bfb7-f57e0d8aaff0">31,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfNC0zLTEtMS0xMzA3ODM_8fb61176-ed21-441c-be46-b5eca64b770c">57,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfNS0xLTEtMS0xMzA3ODM_fbf380b8-2555-44fc-9ad8-7547989a6bdb">791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfNS0zLTEtMS0xMzA3ODM_aaddf1f1-4bc3-48d7-a591-df614e5473a7">626</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfNi0xLTEtMS0xMzA3ODM_bb48551f-db03-4369-85c8-1c60f3076bf8">44,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:ShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfNi0zLTEtMS0xMzA3ODM_450b4b12-7f3d-4e02-80c8-2c57025da40e">40,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfNy0xLTEtMS0xMzA3ODM_9077dd0d-a655-4e42-89e6-06fd1a7286dc">3,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfNy0zLTEtMS0xMzA3ODM_80cca51d-9c6c-409a-b2d3-04c1fadaab5b">3,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfOC0xLTEtMS0xMzA3ODM_51f801d3-e569-43f2-9d68-b2ac8e1d76f4">80,511</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfOC0zLTEtMS0xMzA3ODM_3ef9ed74-3da4-4cfd-9e56-bd3c13100e10">102,579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfOS0xLTEtMS0xMzA3ODM_93c92854-2e14-4f02-9b9a-8faaf927fff0">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfOS0zLTEtMS0xMzA3ODM_3e59ec70-7971-4ed8-89cc-c07b28346855">3,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTAtMS0xLTEtMTMwNzgz_2b38fc5d-4ab0-403b-ad41-bc82a9a4ea23">58,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTAtMy0xLTEtMTMwNzgz_fa9aaa20-ab96-413f-ad77-5bb62c4240dc">56,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTEtMS0xLTEtMTMwNzgz_fe1d26f5-d059-49c5-9c83-e376bc216b90">17,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTEtMy0xLTEtMTMwNzgz_840fffc9-199a-44e0-b9b2-5f54b944546a">18,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTItMS0xLTEtMTMwNzgz_47a3372c-b217-475e-b152-fd84cd453b29">471</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTItMy0xLTEtMTMwNzgz_2948b36c-854d-4a23-96b6-52d15d996652">293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTMtMS0xLTEtMTMwNzgz_186831ff-08f8-423a-99b8-45a0bb1bdcc9">161,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTMtMy0xLTEtMTMwNzgz_5f99e36b-3e5d-442a-b99b-1ffa15eec6cf">180,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liabilities and Stockholders&#8217; Equity (Deficit)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTYtMS0xLTEtMTMwNzgz_7fe4cf79-3042-4892-8af3-d3573a7d3b89">2,582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTYtMy0xLTEtMTMwNzgz_c527a421-e627-4874-be18-280506587a6a">2,267</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities - related party, current portion </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie93d0f28fa434fdd8b2c267c63e09208_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTctMS0xLTEtMTM3Njcy_f77db9f9-fa87-49d1-88b2-3a5c93026c74">95</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b11b2dbf83b49388972be2c36307328_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityCurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTctMy0xLTEtMTM3Njcy_627f0f91-aa8d-4e8d-bef3-d8f3c889a4b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Early exercise liability, current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="snti:EarlyExerciseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTctMS0xLTEtMTMwNzgz_e145495b-fe9c-4036-8cc7-2eaffc3400ce">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="snti:EarlyExerciseLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTctMy0xLTEtMTMwNzgz_5af0ae16-f1f5-4256-a771-538fc5f222bb">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTktMS0xLTEtMTMwNzgz_2a9029bc-05e3-4de2-a6ef-80ac28a7e84c">407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTktMy0xLTEtMTMwNzgz_2322430d-33f4-4680-9a47-676708e15fed">799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjAtMS0xLTEtMTMwNzgz_b44a3a8c-36e9-4c16-91df-07bcc543857f">7,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjAtMy0xLTEtMTMwNzgz_6997476e-b3fa-47c0-bdd7-b9631d0ec0f4">12,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjEtMS0xLTEtMTMwNzgz_8d88f537-6eb9-443e-ad9d-fe5c4c018d5e">2,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjEtMy0xLTEtMTMwNzgz_cf99c223-73f1-4abf-9ab4-767fbdde5a17">1,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjItMS0xLTEtMTMwNzgz_ddf9f1c9-74ec-4b63-9a00-bc5dda78cd08">12,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjItMy0xLTEtMTMwNzgz_e727611e-08ca-43d8-908e-d6bb5718cc85">18,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finance lease liabilities - related party, net of current portion </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie93d0f28fa434fdd8b2c267c63e09208_I20230331" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjQtMS0xLTEtMTM3Njc4_3058cdb6-957c-4aee-a591-861b9f2a85bf">73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b11b2dbf83b49388972be2c36307328_I20221231" decimals="-3" name="us-gaap:FinanceLeaseLiabilityNoncurrent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjQtMy0xLTEtMTM3Njc4_474869f2-e7f8-4d71-8347-f8fcc7cf7d12">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjMtMS0xLTEtMTMwNzgz_e231ca23-490d-49bd-9854-d47bbf22221f">35,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjMtMy0xLTEtMTMwNzgz_f3698e68-d924-4937-96de-e0106f538686">35,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent earnout liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjQtMS0xLTEtMTMwNzgz_31984982-c619-41d6-8237-b05f4454847d">168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjQtMy0xLTEtMTMwNzgz_0e80b1d4-47de-48d7-bdcd-abc74ecea592">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Early exercise liability, net of current portion</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="snti:EarlyExerciseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjUtMS0xLTEtMTMwNzgz_d4fc8c39-7216-487f-b92b-6e1af8dbe960">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="snti:EarlyExerciseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjUtMy0xLTEtMTMwNzgz_4e19c33f-d211-4231-94c1-094b4759ea28">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjctMS0xLTEtMTMwNzgz_b59c843b-1cad-4792-9272-3fbc52556b6c">49,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjctMy0xLTEtMTMwNzgz_ee06fc20-d567-47e8-90f7-4885bf1c8ccf">53,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Commitments and contingencies (Note 11)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjgtMS0xLTEtMTMwNzgz_2575610e-c255-4b9b-895f-542f9398d99a"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjgtMy0xLTEtMTMwNzgz_d7f01959-6f22-46a4-9e57-01971add4a9f"></ix:nonFraction></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stockholders&#8217; equity (deficit):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMC0xLTEtMTMwNzgzL3RleHRyZWdpb246NjA1ODg3NmUzMjdjNGE2MDk5MmJjZjliODY5YTNmNzBfMjE_46dd7eb1-8454-4b9e-8687-ad614e5cadd1"><ix:nonFraction unitRef="usdPerShare" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMC0xLTEtMTMwNzgzL3RleHRyZWdpb246NjA1ODg3NmUzMjdjNGE2MDk5MmJjZjliODY5YTNmNzBfMjE_80a251bb-69c3-40f4-b8d9-3143c7a1c859">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMC0xLTEtMTMwNzgzL3RleHRyZWdpb246NjA1ODg3NmUzMjdjNGE2MDk5MmJjZjliODY5YTNmNzBfMzU_1ae03aeb-cf40-4dbb-8b92-315e741378fb"><ix:nonFraction unitRef="shares" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMC0xLTEtMTMwNzgzL3RleHRyZWdpb246NjA1ODg3NmUzMjdjNGE2MDk5MmJjZjliODY5YTNmNzBfMzU_c151700f-a09f-4b9c-a616-9f3741f9f663">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2023 and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMC0xLTEtMTMwNzgzL3RleHRyZWdpb246NjA1ODg3NmUzMjdjNGE2MDk5MmJjZjliODY5YTNmNzBfNzg_408466dd-a356-456d-8f13-3ec70f2f6148"><ix:nonFraction unitRef="shares" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMC0xLTEtMTMwNzgzL3RleHRyZWdpb246NjA1ODg3NmUzMjdjNGE2MDk5MmJjZjliODY5YTNmNzBfNzg_56cb8f3e-26dc-4ee5-b816-016a5c74d6f5"><ix:nonFraction unitRef="shares" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMC0xLTEtMTMwNzgzL3RleHRyZWdpb246NjA1ODg3NmUzMjdjNGE2MDk5MmJjZjliODY5YTNmNzBfNzg_851e37c7-2582-4392-9f49-62d4e849a6a9"><ix:nonFraction unitRef="shares" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMC0xLTEtMTMwNzgzL3RleHRyZWdpb246NjA1ODg3NmUzMjdjNGE2MDk5MmJjZjliODY5YTNmNzBfNzg_c3d8dc32-1cf8-4535-9b58-7deb3baa8cfe">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMS0xLTEtMTMwNzgz_5178f703-96f6-4355-8bb1-a21da53b3674">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMy0xLTEtMTMwNzgz_ff6ebe90-a650-4fb4-a820-9e8822848287">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMC0xLTEtMTMwNzgzL3RleHRyZWdpb246Yzc0NGMwYzc0MzQ1NGVhZGI2ZGIwMTAwZWJmZGRkZWNfMTg_10a5fd8e-b521-4701-ae82-ac9ae0c4ec90"><ix:nonFraction unitRef="usdPerShare" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMC0xLTEtMTMwNzgzL3RleHRyZWdpb246Yzc0NGMwYzc0MzQ1NGVhZGI2ZGIwMTAwZWJmZGRkZWNfMTg_999b0d92-0ece-4709-ac2a-f5c40fb983b5">0.0001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMC0xLTEtMTMwNzgzL3RleHRyZWdpb246Yzc0NGMwYzc0MzQ1NGVhZGI2ZGIwMTAwZWJmZGRkZWNfMzI_b4d0a300-cfe6-4d53-8cde-336f78bc4ac3"><ix:nonFraction unitRef="shares" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMC0xLTEtMTMwNzgzL3RleHRyZWdpb246Yzc0NGMwYzc0MzQ1NGVhZGI2ZGIwMTAwZWJmZGRkZWNfMzI_fd2c793b-219a-47ac-81fc-e06a29cd4351">500,000,000</ix:nonFraction></ix:nonFraction> shares authorized at March&#160;31, 2023 and December&#160;31, 2022; <ix:nonFraction unitRef="shares" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMC0xLTEtMTMwNzgzL3RleHRyZWdpb246Yzc0NGMwYzc0MzQ1NGVhZGI2ZGIwMTAwZWJmZGRkZWNfNzQ_151cbf6d-f3bc-477c-b775-c5bc183f7e53"><ix:nonFraction unitRef="shares" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMC0xLTEtMTMwNzgzL3RleHRyZWdpb246Yzc0NGMwYzc0MzQ1NGVhZGI2ZGIwMTAwZWJmZGRkZWNfNzQ_396fb435-4719-4f54-b620-5c524bcdecf2">44,075,194</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMC0xLTEtMTMwNzgzL3RleHRyZWdpb246Yzc0NGMwYzc0MzQ1NGVhZGI2ZGIwMTAwZWJmZGRkZWNfODE_474f3d32-fbe3-4e33-a804-f6b4c749ddb3"><ix:nonFraction unitRef="shares" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMC0xLTEtMTMwNzgzL3RleHRyZWdpb246Yzc0NGMwYzc0MzQ1NGVhZGI2ZGIwMTAwZWJmZGRkZWNfODE_d32b2ff7-cb63-4175-affd-7df54db19f24">44,062,534</ix:nonFraction></ix:nonFraction> shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMS0xLTEtMTMwNzgz_1b674d3d-a5f7-4e71-a18b-e59c77369d4d">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMy0xLTEtMTMwNzgz_18317fe3-0f95-4c87-a9f8-08e9f26ef2ac">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzMtMS0xLTEtMTMwNzgz_6ef9925a-41e4-4068-b9ad-53fcb74bb4cb">304,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzMtMy0xLTEtMTMwNzgz_3d6ac4a5-24e3-4474-a81f-1a7d37f6a835">300,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzQtMS0xLTEtMTMwNzgz_bb1c9f3c-f0e5-4d9e-9a4e-6bed38992e68">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzQtMy0xLTEtMTMwNzgz_5f6cda5d-c42b-4e9c-ab95-83e7355c7b7f">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzUtMS0xLTEtMTMwNzgz_e79f5732-5b40-40bf-9d92-1aec0ce22fef">192,008</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzUtMy0xLTEtMTMwNzgz_b6a3f725-df8b-49ed-9305-f4769da1a859">173,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzYtMS0xLTEtMTMwNzgz_0dab6424-f4a7-45ba-9baa-e3b6f85ea585">112,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzYtMy0xLTEtMTMwNzgz_c9f4f3a0-ba1f-4b7c-934a-102f2d8dd5f7">127,263</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities, preferred stock and stockholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzctMS0xLTEtMTMwNzgz_ad5d4060-5aea-4bbf-b0ac-c8383451a22d">161,425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzctMy0xLTEtMTMwNzgz_c486fa98-b502-44d6-a9df-9c602d44d927">180,792</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1</span></div></div></div><div id="id08c0d7bd703495d970d203330d59b2f_19"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Condensed Consolidated Statements of Operations and Comprehensive Loss </span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">(unaudited)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"><br/></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">(in thousands, except share and per share data)</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Revenue</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contract revenue</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMy0xLTEtMS0xMzA3ODM_cae3b20d-725f-4841-a60c-e75d26d8ee70">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMy0zLTEtMS0xMzA3ODM_5277609e-7b22-4ee0-bb11-c79be6892e53">854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Grant income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfNC0xLTEtMS0xMzA3ODM_e95ff1ce-6c4f-428e-9769-80668814b67d">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:RevenueNotFromContractWithCustomer" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfNC0zLTEtMS0xMzA3ODM_320be741-fc7e-41bf-8aca-fc02e39999ec">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfNS0xLTEtMS0xMzA3ODM_756f9706-eb71-4f2e-b090-e51b14efd14e">1,286</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfNS0zLTEtMS0xMzA3ODM_166165dc-a796-4d59-9833-b1a94c908a9a">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfOC0xLTEtMS0xMzA3ODM_6f325d22-f3d0-4815-9c32-8ddb6d42feff">11,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfOC0zLTEtMS0xMzA3ODM_9f92404d-ab44-4c15-9203-36b0ee91d6c2">7,603</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfOS0xLTEtMS0xMzA3ODM_d582358d-a42c-45e1-bf20-823a8cc20f39">9,802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfOS0zLTEtMS0xMzA3ODM_50bba16b-9c32-4107-8a18-5b1912b5641d">5,259</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTAtMS0xLTEtMTMwNzgz_5bc04af8-a906-4a7d-9114-3f5b8a5a8843">21,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTAtMy0xLTEtMTMwNzgz_1b700bcb-14ae-4f07-83cb-0f5560e6b477">12,862</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTEtMS0xLTEtMTMwNzgz_52943476-8605-4f76-9764-34491bfae42e">19,834</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTEtMy0xLTEtMTMwNzgz_9571cceb-8931-4da0-b0cc-a367b1603cea">11,758</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other income (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTQtMS0xLTEtMTMwNzgz_8545aefd-1059-4290-b477-cbba53d77aca">1,061</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTQtMy0xLTEtMTMwNzgz_3a19b28c-fbfb-4553-837f-bc8023013d14">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent earnout liability</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTUtMS0xLTEtMTMwNzgz_bb828665-f221-4b7d-b772-ab8415b9c123">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTUtMy0xLTEtMTMwNzgz_b6b3f0ca-c750-45cf-be88-e16e2bbf4ab1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other income (expense)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTktMS0xLTEtMTMwNzgz_0c6596b3-4b7e-47a9-a046-98bce6b0a03c">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTktMy0xLTEtMTMwNzgz_34d72a14-aa07-4731-ab24-3c7648ad5068">54</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:NonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjAtMS0xLTEtMTMwNzgz_a97cc60f-74ca-4e78-8dda-9e1ee6ce451e">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjAtMy0xLTEtMTMwNzgz_b7efe616-b45a-478a-8c40-f2965baa8cce">50</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjEtMS0xLTEtMTMwNzgz_dada71f3-ed65-49fb-b83a-dc958ecd5dc1">18,722</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjEtMy0xLTEtMTMwNzgz_6e34f3d1-9ea3-4217-bb77-7ba38a8dc085">11,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjQtMS0xLTEtMTMwNzgz_1f8b34c9-b62e-4a76-95c6-c9f56311a1b7">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjQtMy0xLTEtMTMwNzgz_2b473f4b-4ad9-459b-b16c-e0d0f9f56037">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Comprehensive loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjUtMS0xLTEtMTMwNzgz_1512d639-d74c-45ba-95a1-a7ea8e8f7a56">18,720</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjUtMy0xLTEtMTMwNzgz_77d60d48-11ca-4063-9066-049591d196dd">11,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share, basic and diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjYtMS0xLTEtMTMwNzgz_79d88443-fb76-487f-94c6-cba8d5cbf6b6"><ix:nonFraction unitRef="usdPerShare" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjYtMS0xLTEtMTMwNzgz_d24e9fcf-6a78-4cdf-8254-1ade9bbc33db">0.42</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjYtMy0xLTEtMTMwNzgz_2a110e56-2b5a-4656-aa82-824d1daf6643"><ix:nonFraction unitRef="usdPerShare" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjYtMy0xLTEtMTMwNzgz_5e0a2780-02d6-4402-90b5-e5db275c7d1c">3.72</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted-average shares outstanding, basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjctMS0xLTEtMTMwNzgz_229eac0d-2652-4932-907a-a70fb7651127"><ix:nonFraction unitRef="shares" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjctMS0xLTEtMTMwNzgz_d3f1bd7b-6c53-45fe-9d24-2b766edf6be8">44,070,974</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjctMy0xLTEtMTMwNzgz_2f184849-e80c-4509-9b60-f894e04b226c"><ix:nonFraction unitRef="shares" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjctMy0xLTEtMTMwNzgz_5a8fa117-bfed-4cf8-b2e1-cad78032bfd8">3,171,254</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">2</span></div></div></div><div id="id08c0d7bd703495d970d203330d59b2f_22"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">(in thousands, except share data)</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:28.182%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.043%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.001%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.770%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.171%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Redeemable Convertible<br/>Preferred&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity (Deficit)</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4e8c2a57c818445b8ad0d8224990f182_I20211231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfMi0xLTEtMS0xMzA3ODM_ca59f377-899e-4b52-a972-7909d7c5295a">19,517,988</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e8c2a57c818445b8ad0d8224990f182_I20211231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfMi0zLTEtMS0xMzA3ODM_7f32b3bb-51a9-4eec-ac93-74a36d48c1fa">171,833</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i28bc0e58798a48d59cce5700cab14713_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfMi02LTEtMS0xMzA3ODM_667f3c41-c06d-4d8e-8112-caacb23cb4fb">2,972,409</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28bc0e58798a48d59cce5700cab14713_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfMi04LTEtMS0xMzA3ODM_933e41ca-175f-4e3b-873c-7a0a25aff560">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5910a2afac7e44af947c9bd551313533_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfMi0xMC0xLTEtMTMwNzgz_260af3e5-b163-48eb-9461-e68d42293eec">3,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia327828af3c64db9a9c8cc328000bcb5_I20211231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfMi0xMi0xLTEtMTM4MjM1_6d4d9d67-a8f8-46fa-95f0-ae715ff07097">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78a270744c2d4a1f98a4a39f1d1043d3_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfMi0xMi0xLTEtMTMwNzgz_963a793c-8ee7-44a7-95df-83ad1ba92805">115,076</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4e8c2a57c818445b8ad0d8224990f182_I20211231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfMi0xNi0xLTEtMTMwNzgz_ca972155-5c3a-4c51-9146-d05fd0f6f38b">111,457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercise of common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id81fb690a0ac44c7b7413c241996b920_D20220101-20220331" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNC02LTEtMS0xMzA3ODM_0c46c578-f34f-4b28-b3d2-5cfb35ecd593">172,606</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e696449bb8f473ba9b98e6d54a4196f_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNC0xMC0xLTEtMTMwNzgz_599a2ff9-27de-47d3-a997-f16773286648">422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNC0xNi0xLTEtMTMwNzgz_f0f1dd1a-4f32-48c2-9782-822e30bfec65">422</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of early exercise of common stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id81fb690a0ac44c7b7413c241996b920_D20220101-20220331" decimals="INF" name="snti:StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNC02LTEtMS0xMzgwNDI_44a674f7-5f35-41e1-9995-4d6b26afb6e1">143,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e696449bb8f473ba9b98e6d54a4196f_D20220101-20220331" decimals="-3" name="snti:StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNi0xMC0xLTEtMTMwNzgz_9d00ea4f-18bf-4894-ad0d-0af3533f303b">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="snti:StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNC0xNi0xLTEtMTM4MDQy_c919c9ae-c2c3-46ba-ac9c-48baa5297fab">375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e696449bb8f473ba9b98e6d54a4196f_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNy0xMC0xLTEtMTMwNzgz_3a347b61-d9c2-4235-8f5f-4384b8813f32">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNy0xNi0xLTEtMTMwNzgz_bb0188cd-9333-40ab-b135-93eb42de83df">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6a290377bb464be7a1011652879be414_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOC0xMi0xLTEtMTMwNzgz_370acdcd-11d4-4042-939d-21606c559701">11,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOC0xNi0xLTEtMTMwNzgz_84918021-f76c-456a-8dbf-3f146d154433">11,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance as of March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic47933b228a74660947c56c9928b9097_I20220331" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOS0xLTEtMS0xMzA3ODM_4c4d9f4f-dfad-4a33-833f-d8931f813747">19,517,988</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic47933b228a74660947c56c9928b9097_I20220331" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOS0zLTEtMS0xMzA3ODM_9d9d3b8a-4f6c-458b-b904-4223531af992">171,833</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i83c0f0002c6640cf8e492cd72f557b7f_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOS02LTEtMS0xMzA3ODM_79533c32-14ae-4488-8147-b3117e143161">3,288,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83c0f0002c6640cf8e492cd72f557b7f_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOS04LTEtMS0xMzA3ODM_e4034571-9471-4e88-ab0d-2895863ea634">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i521e15cacfab469899d7fc2c91390f18_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOS0xMC0xLTEtMTMwNzgz_aabc3607-f9fb-4297-be87-39791f021db0">5,077</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id07031ea08724f1eb814c4d290dec411_I20220331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNy0xMi0xLTEtMTM5MzM0_96c0b5ce-b332-4614-8a63-4c1b4376e336">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id453bf1b5a4b44eb97fecc35ef14b460_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOS0xMi0xLTEtMTMwNzgz_6abc5f5d-698d-4ab5-a8d6-335ac85a9892">126,884</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic47933b228a74660947c56c9928b9097_I20220331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOS0xNi0xLTEtMTMwNzgz_545ea259-ef6e-49cf-87a5-5adbf28ac69c">121,807</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">(in thousands, except share data)</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.884%"><tr><td style="width:1.0%"></td><td style="width:27.984%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.054%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.127%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.273%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.169%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.779%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.177%"></td><td style="width:0.1%"></td></tr><tr style="height:21pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Redeemable Convertible<br/>Preferred&#160;Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Common Stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Additional Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Other Comprehensive Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Accumulated<br/>Deficit</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Total<br/>Stockholders&#8217;<br/>Equity (Deficit)</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Balance as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfMi0xLTEtMS0xMzA3ODM_d56e3bc1-9d90-403a-837c-9effb42de9e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfMi0zLTEtMS0xMzA3ODM_46f1b5f5-4461-40f5-813e-5469cd658654">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81684dd89952407fad1331a3c1ba7940_I20221231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfMi02LTEtMS0xMzA3ODM_f39231dc-2e73-457e-9664-08022bb2ca7f">44,062,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81684dd89952407fad1331a3c1ba7940_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfMi04LTEtMS0xMzA3ODM_a7f42828-8a9a-4c3d-8702-2e2a8c9aafa3">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia120b6b0d53947b9858a5dbe0b78569f_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfMi0xMC0xLTEtMTMwNzgz_cd64d3b6-27de-4754-bbcc-b4eeb367acfa">300,544</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1f5158cc8cb4ef09ae38b5dc0f801bf_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfMi0xMi0xLTEtMTM4NTM4_f8f25427-17db-455e-af75-ec90c1f21a51">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4026bb920b246c6ab69bb9a495e015c_I20221231" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfMi0xMi0xLTEtMTMwNzgz_4e8cfc1c-3eae-417e-ab11-fc8b47862d70">173,286</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfMi0xNi0xLTEtMTMwNzgz_c920cdef-a9ae-4019-84f0-7e36829f2a05">127,263</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vesting of early exercise of common stock options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5ec8395b47bf40878513f3f1f51bfab2_D20230101-20230331" decimals="INF" name="snti:StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNC02LTEtMS0xMzA3ODM_2dfd0f61-65a4-4674-b3cd-eb78078dd802">12,660</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2611a18b085f44fa80ee121714ee9959_D20230101-20230331" decimals="-3" name="snti:StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNC0xMC0xLTEtMTMwNzgz_ceb72f16-2216-49a8-aebf-5829bfb9c74c">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="snti:StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNC0xNi0xLTEtMTMwNzgz_28e72fdb-e5ac-481c-a0e3-77cc238c673e">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2611a18b085f44fa80ee121714ee9959_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNi0xMC0xLTEtMTMwNzgz_f3cebb6b-6098-4984-b2fe-35ff325c066b">3,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNi0xNi0xLTEtMTMwNzgz_6bb18f75-359d-4281-a81c-ca521ae7ec4e">3,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain on investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c7cf871f8f445ce8ffd3b796c78114b_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNy0xMi0xLTEtMTM4NzU3_299ab8b1-91b5-4ae8-9c1b-3908851f7c5b">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNy0xNi0xLTEtMTM5MzYw_a1b04332-3dfd-4ff5-b5f4-148479be2a5a">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72961400d84f441aa4a9de049fb9ea0f_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNy0xMi0xLTEtMTMwNzgz_f12a87d0-e4e9-4398-b05e-a558d6c04910">18,722</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNy0xNi0xLTEtMTMwNzgz_6dec4281-e189-4f4c-81a9-278b497f8cdc">18,722</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Balance as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:TemporaryEquitySharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfOC0xLTEtMS0xMzA3ODM_e2275e9c-bdad-4c72-b3a6-ed60cca12ae0">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfOC0zLTEtMS0xMzA3ODM_2a9237a2-5b84-4e7f-bd04-844abdd27786">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if20ddea8370b47e2a8d0cc41b5712871_I20230331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfOC02LTEtMS0xMzA3ODM_a507779c-54af-4b2a-a233-e8156856dc29">44,075,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if20ddea8370b47e2a8d0cc41b5712871_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfOC04LTEtMS0xMzA3ODM_eb04596e-4d48-4cc2-8584-0f9153211aaa">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3400e851c0774865aacdc65833967f02_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfOC0xMC0xLTEtMTMwNzgz_b914dbd0-4894-4145-93ad-a6d36becb7da">304,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id70d23838a974b229e80c5c9278df638_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfOS0xMi0xLTEtMTM4NTM4_5c9a18e8-2d76-4af1-96db-8e058f556107">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaa14ff1d6afd4a6aaad076de554b3054_I20230331" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfOC0xMi0xLTEtMTMwNzgz_1e7d669c-99b7-4d45-8a33-3cdfd1004062">192,008</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfOC0xNi0xLTEtMTMwNzgz_e8f9ecfd-0575-4326-aab8-3d8f06643cc8">112,340</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4</span></div></div></div><div id="id08c0d7bd703495d970d203330d59b2f_25"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">  &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">(unaudited)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">(in thousands)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.557%"><tr><td style="width:1.0%"></td><td style="width:72.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.450%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.909%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMy0xLTEtMS0xMzA3ODM_5bca2960-979c-4a52-9968-bfa5c1c15326">18,722</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMy0zLTEtMS0xMzA3ODM_65f8da88-11ff-467a-8f70-016bc9239826">11,808</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNS0xLTEtMS0xMzA3ODM_1a6a13b7-a486-48bb-900d-a2698106673d">467</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:Depreciation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNS0zLTEtMS0xMzA3ODM_890d4df1-5547-4b19-a397-ecbd1ff1010f">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of operating lease right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNi0xLTEtMS0xMzA3ODM_f00e9031-8f5e-4a7f-8fbb-9742b00e6be4">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNi0zLTEtMS0xMzA3ODM_5c1f0425-4acd-4de7-a54d-95cafb3369b8">770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of discount on short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNy0xLTEtMS0xMzA3ODM_ffb4bd4e-df5d-46a6-b7ce-529c4ce86f54">572</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNy0zLTEtMS0xMzA3ODM_5b504f7a-4923-4f28-bd08-e6af721a852b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in fair value of contingent earnout liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfOS0xLTEtMS0xMzA3ODM_593b6b6a-19b5-4bf3-a214-8f80b24990af">59</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfOS0zLTEtMS0xMzA3ODM_74853b97-a3b1-45ca-bf83-7309a65403bd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock-based compensation expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTEtMS0xLTEtMTMwNzgz_50332f0d-72b0-4b2f-a936-bb000a9bdfde">3,763</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTEtMy0xLTEtMTMwNzgz_c9d706e8-b051-4286-bfa8-95eff017a7d6">661</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on write-off of fixed assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTItMS0xLTEtMTMwNzgz_4ad85e74-f9ad-4d85-b322-bd1797a0c0da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTItMy0xLTEtMTMwNzgz_c35a1b8e-60b9-4c79-be26-1e2d6531c4fb">12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest income accrued and not received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" sign="-" name="snti:InterestIncomeAccruedAndNotReceived" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTMtMS0xLTEtMTQ0NDY1_e300a33d-8628-41f8-959f-62a089e54aee">30</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="snti:InterestIncomeAccruedAndNotReceived" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTMtMy0xLTEtMTQ0NDY1_f7242b65-0fc2-43a2-bdb6-44deaa1c312e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Changes in assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTYtMS0xLTEtMTMwNzgz_f1b35cd3-e9d6-40b2-bbd2-4b47766f0125">135</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTYtMy0xLTEtMTMwNzgz_554fa748-69e4-48c9-84a0-a01795312da0">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTctMS0xLTEtMTMwNzgz_42b23c8f-2b7f-4eca-99e9-a69df5042991">402</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTctMy0xLTEtMTMwNzgz_9371c594-57fd-46b7-bcd5-f0dce90e732f">381</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTgtMS0xLTEtMTMwNzgz_4d2edab2-7001-408d-89e3-c8c483f9407f">280</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTgtMy0xLTEtMTMwNzgz_82c85045-8239-49f0-ba4e-67ba62234e1f">164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses and other current liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTktMS0xLTEtMTMwNzgz_d77bfedd-401f-48d3-bed8-0bc806f3ecfa">1,846</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTktMy0xLTEtMTMwNzgz_cfbbea0b-2ef2-499d-8374-7152a3c53277">1,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjAtMS0xLTEtMTMwNzgz_0c0e423c-f4fd-4ad5-91b3-2459c368cc87">392</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjAtMy0xLTEtMTMwNzgz_37bc1068-f222-4b1e-a3c3-239569e344c2">453</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjEtMS0xLTEtMTMwNzgz_5273565c-3567-4f20-a523-c119a2df5dbc">882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjEtMy0xLTEtMTMwNzgz_49d8effb-e6a8-4a94-b571-57d03feefb92">2,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash from operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjItMS0xLTEtMTMwNzgz_8ed3bcd4-331d-470e-870a-37e315a7162c">16,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjItMy0xLTEtMTMwNzgz_48093626-7ab3-454b-9ece-32a8b43eaab3">10,059</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjQtMS0xLTEtMTMwNzgz_f1a30ed0-cb35-4af0-8791-bd1a33a905b3">17,990</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquireShortTermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjQtMy0xLTEtMTMwNzgz_c0717fe9-c3d6-47a2-93ac-4e94676bfc1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Maturities of short-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjUtMS0xLTEtMTMwNzgz_c7816c58-5dc4-4d3c-a958-12a9685ddab0">15,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjUtMy0xLTEtMTMwNzgz_9b005799-84cd-4d6c-a790-70e1f81dd4ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjctMS0xLTEtMTMwNzgz_48365d37-3a67-4437-8944-d4326cb3df32">6,507</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjctMy0xLTEtMTMwNzgz_8225bf3f-15de-434c-8e22-91c479017652">7,380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash from investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjktMS0xLTEtMTMwNzgz_1acaf024-1661-4081-9eb5-584231a8a61a">9,497</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjktMy0xLTEtMTMwNzgz_6304fb40-4934-4886-af66-cfa09b4f9b5e">7,380</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock upon exercise of stock options</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzItMS0xLTEtMTMwNzgz_7308f09f-a235-4e67-acf0-f28c75e54433">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzItMy0xLTEtMTMwNzgz_883fe413-4f39-4506-810c-1ef2a840a6df">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Principal finance lease payments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzctMS0xLTEtMTQ0NTE0_ec810cfb-0c51-4dbb-8f9e-88721abb55a9">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:FinanceLeasePrincipalPayments" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzctMy0xLTEtMTQ0NTE0_edc43069-cc0d-4dab-905e-67038b81c693">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payment of deferred transaction costs related to Merger</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzctMS0xLTEtMTMwNzgz_63f838d6-c666-45a1-be8a-a91bd39c42c7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzctMy0xLTEtMTMwNzgz_d0a234c7-d777-4e5c-b2db-b22ca4e7454f">595</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash from financing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzgtMS0xLTEtMTMwNzgz_d5474e1d-d546-4f4c-96b2-6a581d464cf7">35</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzgtMy0xLTEtMTMwNzgz_45ad2b5d-ebab-425d-8697-01bcf16af81d">455</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net decrease in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzktMS0xLTEtMTMwNzgz_00cf3663-6f60-414e-9a01-3c5a7e80c4e1">25,836</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzktMy0xLTEtMTMwNzgz_362f965d-01d9-4f20-bce3-97e996a07bee">17,894</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, beginning of period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDAtMS0xLTEtMTMwNzgz_aba0060e-08e6-4505-a508-fb22c28ba330">60,987</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e8c2a57c818445b8ad0d8224990f182_I20211231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDAtMy0xLTEtMTMwNzgz_87c826cc-45b5-4943-80dd-7d67022ddf6a">59,291</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash, end of period</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDEtMS0xLTEtMTMwNzgz_61b92bbb-9c7c-445e-998f-9fb2b6d07e1c">35,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic47933b228a74660947c56c9928b9097_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDEtMy0xLTEtMTMwNzgz_17f5c3a4-ad68-4a2f-8af6-dfb9b67dfada">41,397</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reconciliation of cash, cash equivalents and restricted cash</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDQtMS0xLTEtMTMwNzgz_637429b2-d889-43f1-b60e-61efae3fffef">31,600</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic47933b228a74660947c56c9928b9097_I20220331" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDQtMy0xLTEtMTMwNzgz_97392fc2-2088-454f-9b43-be04323b9a30">38,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDUtMS0xLTEtMTMwNzgz_637fe490-a2e5-4459-a899-2c967c0b4d77">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic47933b228a74660947c56c9928b9097_I20220331" decimals="-3" name="us-gaap:RestrictedCash" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDUtMy0xLTEtMTMwNzgz_e20f4f80-f1ee-4bb6-8b31-7587419d3a2b">3,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total cash, cash equivalents and restricted cash</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDYtMS0xLTEtMTMwNzgz_0f237789-d9d0-48b1-90bb-278b3682f84e">35,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic47933b228a74660947c56c9928b9097_I20220331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDYtMy0xLTEtMTMwNzgz_785836ef-f51a-4641-a7f1-69f50e26d6fd">41,397</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental disclosures of noncash financing and investing items</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment in accounts payable and accrued expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNTEtMS0xLTEtMTMwNzgz_6b4ea0d8-ffdd-40fa-9ca0-df2555b8e0fe">4,758</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNTEtMy0xLTEtMTMwNzgz_583375d2-0806-4c4b-b926-24babb862a76">8,920</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Merger and related PIPE financing costs included in accounts payable and accrued expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="snti:MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNTQtMS0xLTEtMTMwNzgz_bc3bccb4-a499-4e5f-840d-8cba27fbfda6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="snti:MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNTQtMy0xLTEtMTMwNzgz_2b7e2a93-352f-460c-ab19-8552c0713822">2,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receivables in transit from issuance of common stock upon exercise of stock options</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="snti:ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNTYtMS0xLTEtMTMwNzgz_3e64e07b-d133-4b3f-8eee-48eb8ec6a75a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="snti:ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNTYtMy0xLTEtMTMwNzgz_d64568f3-a0d4-4070-85c9-c117792ace42">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5</span></div></div></div><div id="id08c0d7bd703495d970d203330d59b2f_28"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:center"><span><br/></span></div><div id="id08c0d7bd703495d970d203330d59b2f_31"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zMS9mcmFnOmNjMTY4MjNhMDU2NzRiMWViNDdmNTdkZTcxYmEzYWFjL3RleHRyZWdpb246Y2MxNjgyM2EwNTY3NGIxZWI0N2Y1N2RlNzFiYTNhYWNfMzM5Mw_80bb2af6-9cab-4f93-81d9-edac413afbbd" continuedAt="ifb8b511db57c448eb30e8b4de3128dc9" escape="true">Organization and Description of Business</ix:nonNumeric></span></div><ix:continuation id="ifb8b511db57c448eb30e8b4de3128dc9"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Senti Biosciences, Inc. and its subsidiaries (the &#8220;Company&#8221; or &#8220;Senti&#8221;), is a biotechnology company that was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti has built a synthetic biology platform that enables it to program next-generation cell and gene therapies with what the Company refers to as &#8220;gene circuits.&#8221; These gene circuits, which are created from novel and proprietary combinations of DNA sequences, reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. The Company is headquartered in South San Francisco, California.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 8, 2022 (the &#8220;Closing Date&#8221;), Dynamics Special Purpose Acquisition Corp. (&#8220;Dynamics&#8221; or &#8220;DYNS&#8221;) consummated a merger pursuant to which Explore Merger Sub, Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and wholly owned subsidiary of Dynamics, merged with and into Senti Sub I, Inc., formerly named Senti Biosciences, Inc. (&#8220;Legacy Senti&#8221;), with Legacy Senti surviving as a wholly-owned subsidiary of Dynamics (such transactions, the &#8220;Merger,&#8221; and, collectively with the other transactions described in the merger agreement (as defined below, the &#8220;Reverse Recapitalization&#8221;)). As a result of the Merger, Dynamics was renamed Senti Biosciences, Inc.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company were unable to continue as a going concern.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has devoted substantially all of its efforts to organizing and staffing, business planning, raising capital, and conducting preclinical studies and has not realized substantial revenues from its planned principal operations.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> To date, the Company raised aggregate gross proceeds of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-5" name="snti:CashAcquiredThroughReverseRecapitalization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zMS9mcmFnOmNjMTY4MjNhMDU2NzRiMWViNDdmNTdkZTcxYmEzYWFjL3RleHRyZWdpb246Y2MxNjgyM2EwNTY3NGIxZWI0N2Y1N2RlNzFiYTNhYWNfMjE5OTAyMzI2MzM1MQ_c0c0bf70-b7eb-44d9-9285-1efadea936a0">298.8</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from the Merger and PIPE Financing, the issuance of shares of our redeemable convertible preferred stock, the issuance of convertible notes and, to a less extent, through collaboration agreements and government grants.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At March&#160;31, 2023 and December&#160;31, 2022, the Company had an accumulated deficit of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zMS9mcmFnOmNjMTY4MjNhMDU2NzRiMWViNDdmNTdkZTcxYmEzYWFjL3RleHRyZWdpb246Y2MxNjgyM2EwNTY3NGIxZWI0N2Y1N2RlNzFiYTNhYWNfMjAxNw_6cd49b96-bc5c-49ab-857d-202b1f77605c">192.0</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zMS9mcmFnOmNjMTY4MjNhMDU2NzRiMWViNDdmNTdkZTcxYmEzYWFjL3RleHRyZWdpb246Y2MxNjgyM2EwNTY3NGIxZWI0N2Y1N2RlNzFiYTNhYWNfMjAyNA_2eeb832d-2036-4338-9314-7a086e95ad82">173.3</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, respectively. The Company&#8217;s net losses were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zMS9mcmFnOmNjMTY4MjNhMDU2NzRiMWViNDdmNTdkZTcxYmEzYWFjL3RleHRyZWdpb246Y2MxNjgyM2EwNTY3NGIxZWI0N2Y1N2RlNzFiYTNhYWNfMjA3Mg_89de034c-6312-4b96-b43e-2a99a77b1b8c">18.7</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zMS9mcmFnOmNjMTY4MjNhMDU2NzRiMWViNDdmNTdkZTcxYmEzYWFjL3RleHRyZWdpb246Y2MxNjgyM2EwNTY3NGIxZWI0N2Y1N2RlNzFiYTNhYWNfMjA3OQ_a47d6e68-f7e4-4d1d-964c-ac4e4f4be745">11.8</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the three months ended March&#160;31, 2023 and 2022, respectively. Substantially all of the Company&#8217;s net losses resulted from costs incurred in connection with the Company&#8217;s research and development programs and from general and administrative costs associated with the Company&#8217;s operations. The Company expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future as the Company advances its</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> preclinical activities and clinical trials for its product candidates in development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023 and December&#160;31, 2022, the Company had cash, cash equivalents and short-term investments of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$<ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zMS9mcmFnOmNjMTY4MjNhMDU2NzRiMWViNDdmNTdkZTcxYmEzYWFjL3RleHRyZWdpb246Y2MxNjgyM2EwNTY3NGIxZWI0N2Y1N2RlNzFiYTNhYWNfMjY2OA_a06b2c55-f3f4-47b5-bcd5-05911e215fe6">76.1</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-5" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zMS9mcmFnOmNjMTY4MjNhMDU2NzRiMWViNDdmNTdkZTcxYmEzYWFjL3RleHRyZWdpb246Y2MxNjgyM2EwNTY3NGIxZWI0N2Y1N2RlNzFiYTNhYWNfNjU5NzA2OTc3MjI1Mg_737f0dbf-468b-459a-80bc-1380043751dc">98.6</ix:nonFraction> million, respectively. As of May&#160;9, 2023, the issuance date of the condensed consolidated financial statements as of for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;31, 2023, there is uncertainty about whether the Company&#8217;s combined cash, cash equivalents, and short-term investments will be sufficient to fund operations, including clinical trial expenses and capital expenditure requirements, beyond twelve months from the issuance date of these financial statements and therefore the Company concluded that substantial doubt existed about the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s continued existence is dependent upon management&#8217;s ability to raise capital and develop profitable op</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">erations. Management is devoting substantially all of its efforts to developing its business and raising capital and there can be no assurance that the Company&#8217;s efforts will be successful. No assurance can be given that management&#8217;s actions will result in profitable operations or the meeting of ongoing liquidity needs.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">6</span></div></div></div><div id="id08c0d7bd703495d970d203330d59b2f_34"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">          2. <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zNC9mcmFnOjVlMzhiZjFmZmQ1ZDQwOTI5NmY2YzZhN2ZhOGU3MTU2L3RleHRyZWdpb246NWUzOGJmMWZmZDVkNDA5Mjk2ZjZjNmE3ZmE4ZTcxNTZfNjUwNQ_9ca7266e-2072-4eac-a03c-698001ce3608" continuedAt="ief1a34dcd8e940bba067bc19f61d0856" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="ief1a34dcd8e940bba067bc19f61d0856"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zNC9mcmFnOjVlMzhiZjFmZmQ1ZDQwOTI5NmY2YzZhN2ZhOGU3MTU2L3RleHRyZWdpb246NWUzOGJmMWZmZDVkNDA5Mjk2ZjZjNmE3ZmE4ZTcxNTZfNjUwMg_c43bf8f5-1801-4b0e-be14-333902c31de7" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) and the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and as amended by Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The condensed consolidated financial statements include the accounts of Senti Biosciences, Inc., and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. We have <ix:nonFraction unitRef="businessactivitiy" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="INF" name="snti:NumberOfBusinessActivities" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zNC9mcmFnOjVlMzhiZjFmZmQ1ZDQwOTI5NmY2YzZhN2ZhOGU3MTU2L3RleHRyZWdpb246NWUzOGJmMWZmZDVkNDA5Mjk2ZjZjNmE3ZmE4ZTcxNTZfODQx_e0040d51-7cf0-4ba0-84cb-ad4dd4ed7b66">one</ix:nonFraction> business activity and operate in <ix:nonFraction unitRef="reportablesegment" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zNC9mcmFnOjVlMzhiZjFmZmQ1ZDQwOTI5NmY2YzZhN2ZhOGU3MTU2L3RleHRyZWdpb246NWUzOGJmMWZmZDVkNDA5Mjk2ZjZjNmE3ZmE4ZTcxNTZfODc3_38fb26b4-2395-4c1f-b56c-a4f42b269968">one</ix:nonFraction> reportable segment.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related price information to give effect to the exchange ratio established in the Merger Agreement.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zNC9mcmFnOjVlMzhiZjFmZmQ1ZDQwOTI5NmY2YzZhN2ZhOGU3MTU2L3RleHRyZWdpb246NWUzOGJmMWZmZDVkNDA5Mjk2ZjZjNmE3ZmE4ZTcxNTZfNjUwNw_41452d54-9d0b-4808-895e-ed8ec464408e" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the valuation of stock-based awards, the accrual for research and development expenses, the valuation of contingent earnout, the valuation of convertible notes, the valuation of common and redeemable convertible preferred stock, the valuation of preferred stock tranche liability, standalone selling price (&#8220;SSP&#8221;) and the determination of the incremental borrowing rate. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Unaudited Interim Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying interim condensed consolidated financial statements and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared on the same basis as the audited financial statements, and in management&#8217;s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of March&#160;31, 2023 and its results of operations for the three months ended March&#160;31, 2023 and 2022, and cash flows for the three months ended March&#160;31, 2023 and 2022. The results of operations for the three months ended March&#160;31, 2023 are not necessarily indicative of the results to be expected for the year ended December&#160;31, 2023 or any other period. The December&#160;31, 2022 year-end condensed consolidated balance sheet was derived from audited annual financial statements but does not include all disclosures from the annual financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2022 and the related notes included in the Company&#8217;s Form 10-K, filed with the SEC on March&#160;22, 2023, which provides a more complete discussion of the Company&#8217;s accounting policies and certain other information. There have been no material changes to the Company&#8217;s significant accounting policies as of and for the three months ended March&#160;31, 2023, as compared to the significant accounting policies described in the Company&#8217;s audited annual consolidated financial statements as of and for the year ended December&#160;31, 2022, except as discussed below.</span></div><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zNC9mcmFnOjVlMzhiZjFmZmQ1ZDQwOTI5NmY2YzZhN2ZhOGU3MTU2L3RleHRyZWdpb246NWUzOGJmMWZmZDVkNDA5Mjk2ZjZjNmE3ZmE4ZTcxNTZfNjUwNA_9ab5f135-2062-4c44-a9f4-1ab0e2137eea" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company believes that the impact of recently issued accounting standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</span></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7</span></div></div></div><div id="id08c0d7bd703495d970d203330d59b2f_40"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RleHRyZWdpb246OTk4ZTQzN2QzZWQ2NDFhNzllY2QyYTM3Y2ZkYmJiNmRfMTIwOQ_d6411ee5-25e8-408d-a40e-043a48004777" continuedAt="i47c9ef908c374beba793a419d5aad201" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i47c9ef908c374beba793a419d5aad201"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RleHRyZWdpb246OTk4ZTQzN2QzZWQ2NDFhNzllY2QyYTM3Y2ZkYmJiNmRfMTIxMA_8c78c01e-2d29-4123-8587-e64439c02e4a" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize the estimated value of cash equivalents and restricted cash (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted cash</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia1507455ae4545acb5c5e77c20ccf10c_I20230331" decimals="-3" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMi0xLTEtMS0xNDE1MDk_e793df43-f68c-4252-af14-3dc2b56770fa">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia1507455ae4545acb5c5e77c20ccf10c_I20230331" decimals="-3" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMi03LTEtMS0xNDU5MTU_8b5a533c-5910-4617-9f96-d8fc08582c21">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="id5a57a126aad418cab737f9098520762_I20230331" decimals="-3" name="us-gaap:Cash" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMi05LTEtMS0xNDE1MjA_402a071e-db5d-46fd-bc07-2738ffe7f0f0">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i78139b1e342f47d9b902943821cf2036_I20230331" decimals="-3" name="us-gaap:Cash" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMi0xMS0xLTEtMTQxNTIw_c5829d76-60d1-4ebe-8b74-ac4661a534ad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="if4705a76340e438cbf1fd59d574befef_I20230331" decimals="-3" name="us-gaap:Cash" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMi0xMy0xLTEtMTQxNTIw_64d673d0-e270-45bf-8797-40f5411c2bfc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a0a24d2beff407985996abce370fac1_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMy0xLTEtMS0xNDEzMDM_4a6527cc-3382-4fe5-b288-a89719b1a25c">35,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4a0a24d2beff407985996abce370fac1_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNC03LTEtMS0xNDU5MjE_090cc618-2257-4d17-aad6-5c8d0d47d258">35,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic853c11d285841a9a58448f68290872e_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMy05LTEtMS0xNDEzMTU_8cba1c9c-dc7a-4975-90dd-2e0a19c31474">31,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54edccfe021d431689266dad3928a2bf_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMy0xMS0xLTEtMTQxMzE1_e7f70959-2a92-4bcd-a186-d1ecae3ce7d4">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic621dc1a5dd1488e9267eea6f23d8049_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNC0xMy0xLTEtMTQ1OTIx_573f5d34-2cfb-4e60-bb5b-f1127e808c5c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1507455ae4545acb5c5e77c20ccf10c_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNS0xLTEtMS0xNDU5MTU_693be55b-375f-47e1-8ee9-9ed7daed6a4a">35,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ia1507455ae4545acb5c5e77c20ccf10c_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNS03LTEtMS0xNDU5MTU_d0138086-0a48-4f29-ba64-265ed0414797">35,105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5a57a126aad418cab737f9098520762_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNS05LTEtMS0xNDU5MTU_039bf6f9-27f1-4e96-8028-36b859e5fcf1">31,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78139b1e342f47d9b902943821cf2036_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNS0xMS0xLTEtMTQ1OTE1_bd47c50d-1de9-4287-9edc-914c95be26a1">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if4705a76340e438cbf1fd59d574befef_I20230331" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNS0xMy0xLTEtMTQ1OTE1_d9991b67-686a-45d1-884a-011c26cf5b50">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4f2aae937b4d63890360a721452a0a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNi0xLTEtMS0xNDEzNDg_1ca0ea65-7e48-43c8-aa59-8de6ea317a1a">11,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4f2aae937b4d63890360a721452a0a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNi0zLTEtMS0xNDEzNDg_a1fcba30-8048-4f9d-914f-71b122d07e44">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e4f2aae937b4d63890360a721452a0a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNi01LTEtMS0xNDEzNDg_9180acd6-5250-432e-8cb9-919adbf52e46">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i3e4f2aae937b4d63890360a721452a0a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNy03LTEtMS0xNDU5MTU_17be97c9-8f31-4225-abfd-4ce8bd3acc55">11,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38ec92e6b86d4514acf595c514672dce_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNi05LTEtMS0xNDEzNTY_c4c8eb7d-c992-4d7f-9fa8-2e0cb3fe8497">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07bc91a53f5a459baf1197c27ade6ed2_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNi0xMS0xLTEtMTQxMzU2_f545a1c9-7516-4156-909a-c298bf935699">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1249a7ce3f54ef5bb8002ca6d310e15_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNi0xMy0xLTEtMTQxMzU2_e69cc028-8cf8-45d2-82c8-1fddc46676d3">11,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e58e5594694539a02749f71be310dd_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNy0xLTEtMS0xNDEzNDg_dc9c23a6-b3ac-4b1b-95aa-e7b6d5bb7f7a">13,744</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i04e58e5594694539a02749f71be310dd_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNy0zLTEtMS0xNDEzNDg_775cc10e-6035-4c96-9873-c3e618655b83">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i04e58e5594694539a02749f71be310dd_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNy01LTEtMS0xNDEzNDg_0931e8bb-3058-4c79-abb7-43f5a1b15dae">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i04e58e5594694539a02749f71be310dd_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOC03LTEtMS0xNDU5MTU_d38371ee-2763-426b-aaaf-9fa366f1f688">13,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i806026a6a971437f8a3ed419e043f3f8_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNy05LTEtMS0xNDEzNTY_8b3660c2-e82e-4c19-bf1a-0e9f0c9251e4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0599314ad55c451a80b55746b2dc9bfd_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNy0xMS0xLTEtMTQxMzU2_56ab0974-78d8-4450-bb9c-a7e5ec6edfc1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7093d18319c4542a600a6987750ebc6_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNy0xMy0xLTEtMTQxMzU2_c57756a0-5d64-487a-81f9-70523fed70ab">13,746</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56248ee32fc0485f8d3c8bad91562cee_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOC0xLTEtMS0xNDEzNDg_bef50f71-fb54-4a51-9284-ef2333511ed5">17,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56248ee32fc0485f8d3c8bad91562cee_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOC0zLTEtMS0xNDEzNDg_10f150e1-4197-4d38-8d8d-347dea3fa84a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56248ee32fc0485f8d3c8bad91562cee_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOC01LTEtMS0xNDEzNDg_8f2a0d69-10eb-4df1-a0a8-7be6080dbb8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i56248ee32fc0485f8d3c8bad91562cee_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOS03LTEtMS0xNDU5MTU_235ce73b-2462-4372-8799-91516d8680cb">17,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e20fb37f0c44033bc88e5d7cdb0ff33_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOC05LTEtMS0xNDEzNTY_b2652ae6-e138-46d9-bfaf-127717cdcb19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie612beff75d94ee5b9518fe9ad917d8c_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOC0xMS0xLTEtMTQxMzU2_87caa5bf-5607-47c2-8bd6-7214185665f8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a0ba519d4ef4fc6aeabfe9afc583b1a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOC0xMy0xLTEtMTQxMzU2_4e86d962-7d5e-4549-968e-b65d5ca93918">17,381</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcdf00099f6948e394392540bc14975f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOS0xLTEtMS0xNDEzNDg_7ec0ca1c-e66c-4b62-8269-00788c05401f">1,998</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibcdf00099f6948e394392540bc14975f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOS0zLTEtMS0xNDEzNDg_95571804-5dd8-4f8f-b8e4-4257d2787107">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibcdf00099f6948e394392540bc14975f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOS01LTEtMS0xNDEzNDg_cb68f95b-6725-4f92-bff1-4d45790fa6ba">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibcdf00099f6948e394392540bc14975f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTAtNy0xLTEtMTQ1OTE1_c267f25a-c858-4832-b086-6fb2fe81a590">1,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i182e6b0e83c74e2e91736e7bb9c35972_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOS05LTEtMS0xNDEzNTY_b8370cb2-4317-4f9e-a6da-87440c705778">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i201af4811a374b0d85692aa3b41f79b5_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOS0xMS0xLTEtMTQxMzU2_472b9126-c1b4-4552-a854-004be5fcf11a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3359592a1b094bac8319cc1e2408c43f_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOS0xMy0xLTEtMTQxMzU2_97b32122-518b-4ff3-bbd5-6261605609ab">1,997</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c09c639dac47edb944ea9ecf3b0299_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTEtMS0xLTEtMTQ1OTE1_8f06717e-c126-4ba0-a481-de424a2b26a2">44,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3c09c639dac47edb944ea9ecf3b0299_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTEtMy0xLTEtMTQ1OTE1_7d68d4e8-b853-43d2-891a-a2e9f7caa596">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic3c09c639dac47edb944ea9ecf3b0299_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTEtNS0xLTEtMTQ1OTE1_8399d340-c78c-448a-ba25-06ff19d574d3">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ic3c09c639dac47edb944ea9ecf3b0299_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTEtNy0xLTEtMTQ1OTE1_d3762056-94a3-446c-adc7-fe6f932cdd7e">44,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic8d224f088f74ed28515d75a9ea6d258_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTEtOS0xLTEtMTQ1OTE1_3cd6dd85-5fa4-4d75-b5ce-21461158e79f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31c096de9b294cce82f4eddee4fe3e1a_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTEtMTEtMS0xLTE0NTkxNQ_e3723bdc-fb76-40aa-8890-0f15094944cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i613e04533fcc42e9b6435b116c5cf0be_I20230331" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTEtMTMtMS0xLTE0NTkxNQ_7a58bdd5-f68c-41a1-b79c-c4cba229417e">44,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTItMS0xLTEtMTQ1OTE1_985d9baa-8821-4ae3-b329-068457bee797">79,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTItMy0xLTEtMTQ1OTIx_8da525fb-3184-4035-bff7-2cb3b107b39e">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTItNS0xLTEtMTQ1OTIx_da4e7d37-cddc-4199-8f85-83cf49648077">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTItNy0xLTEtMTQ1OTE1_0070e338-5e49-49f6-8df2-82a0fd51a104">79,657</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i66db0287b069499789e51d16f875e403_I20230331" decimals="-3" name="snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTItOS0xLTEtMTQ1OTE1_5be53b93-95ee-4261-bb69-0d3fab971291">31,600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1967ceac06c041718a989a37273e427a_I20230331" decimals="-3" name="snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTItMTEtMS0xLTE0NTkxNQ_85ff2e31-ba64-475c-80fc-bb7fbca7406a">3,551</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iecaecf3f762f4965b2caf2cdaec72352_I20230331" decimals="-3" name="snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTItMTMtMS0xLTE0NTkxNQ_d63d7906-298b-4165-b992-fba972c53db3">44,506</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.307%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.159%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.167%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted cash</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i8df3f77390c94af5886983ba9c67ce4c_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMy0xLTEtMS0xNDEyMDU_78304ebc-23bc-4c73-831b-361be88524d9">45,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i8df3f77390c94af5886983ba9c67ce4c_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNC03LTEtMS0xNDU5MjU_2004f53d-9bf6-49b2-a438-981278c5263f">45,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i738f1818b2ee440b81ae9395474ef8a6_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMy05LTEtMS0xNDEyNTQ_0efc09a4-ad34-4450-9e25-743cd720ca28">42,046</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i77067e3a647e4bcf86bbaa6aecc10bc6_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMy0xMS0xLTEtMTQxMjU0_4298537f-a455-4ac8-aef6-026128a022b2">3,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i6d690099dd934e29ab16020f70f61c81_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMy0xMy0xLTEtMTQxMjU0_b36b03b8-2d61-403f-b5fe-93fd4081a0a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i04776ba3407e4211bf944ba32f788c04_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNS0xLTEtMS0xNDU5MjU_ec704813-75a3-4629-b2c9-eaf79cd63753">45,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i04776ba3407e4211bf944ba32f788c04_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNS03LTEtMS0xNDU5MjU_789300b3-28ec-46e2-8771-a7630ca00ea1">45,412</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0c53dece0f4746dca63507589ca1b33f_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNS05LTEtMS0xNDU5MjU_b2c6b2e7-5f2c-4a02-b707-cbabe6c3fd08">42,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ic975f5329514459cb776591a8393e656_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNS0xMS0xLTEtMTQ1OTI1_8ebccc20-5d7b-4ef7-9370-37ce6e5d8543">3,366</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i341995b37eeb4178a439a3e4c98245c3_I20221231" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNS0xMy0xLTEtMTQ1OTI1_9727837d-3260-43fe-8cb2-323a9c72a2ec">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4c01bb3709c34dd49620a247ad1fbc01_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNi0xLTEtMS0xNDEyNTI_8b472114-6925-490f-9d95-5637426ca1a4">14,866</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4c01bb3709c34dd49620a247ad1fbc01_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNi0zLTEtMS0xNDEyNTI_058cc2df-c2d5-4da1-9deb-d20bfe9998bf">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i4c01bb3709c34dd49620a247ad1fbc01_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNi01LTEtMS0xNDEyNTI_1fff7be4-211e-48c3-a3b9-826c0a7832df">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i4c01bb3709c34dd49620a247ad1fbc01_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNy03LTEtMS0xNDU5MjU_81465a10-f537-463e-86b4-9d4ab80879d8">14,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i230fd69e00ae4f99b1e3a2d854b95850_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNi05LTEtMS0xNDEyNTU_f720e723-c03d-4911-a05a-d923a76200e1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i5289294e32684de3b46e5ac39b5c1c4c_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNi0xMS0xLTEtMTQxMjU1_eb35d1ac-4d47-464d-918c-c79fa929410f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibb5bf968a6f341f1a417ef865d2b0373_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNi0xMy0xLTEtMTQxMjU1_15e4f214-039e-439f-a50f-3d97f331c715">14,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i8cf2e03c3b7044dd8f4d13d428853cad_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNy0xLTEtMS0xNDEyNTI_b2f27b51-ca0c-4671-8501-e08812180b2b">5,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i8cf2e03c3b7044dd8f4d13d428853cad_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNy0zLTEtMS0xNDEyNTI_bf1a026e-7ee2-4a37-956b-6affd25de6c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i8cf2e03c3b7044dd8f4d13d428853cad_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNy01LTEtMS0xNDEyNTI_a01b086c-65c0-48ea-99f2-d3b0c3f3fda6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i8cf2e03c3b7044dd8f4d13d428853cad_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOC03LTEtMS0xNDU5MjU_9dddc4d8-83a0-44da-afe6-7c8cb1aad981">5,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i0493e8bc17624187bbe1a3959ac97b33_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNy05LTEtMS0xNDEyNTU_3fedcb6c-700c-4af0-b328-afe28665c1d5">3,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i45596385065544378327410d696e5e0f_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNy0xMS0xLTEtMTQxMjU1_dc548ac4-1347-4c5e-a9ed-87909f703170">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iae83b8ab01644353acb71b4d4fcf3c2b_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNy0xMy0xLTEtMTQxMjU1_ef45723a-b2e7-4459-bc3f-efaa5bea07df">1,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i5a9825b53292444882e4b80aee4ca647_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOC0xLTEtMS0xNDEyNTI_085c7339-b917-468a-ba17-5bf92db75870">28,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i5a9825b53292444882e4b80aee4ca647_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOC0zLTEtMS0xNDEyNTI_2370f587-8ec0-4d48-96fe-3c13a94bd0dc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i5a9825b53292444882e4b80aee4ca647_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOC01LTEtMS0xNDEyNTI_d069d743-64fb-41e0-824c-636ceca94c68">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i5a9825b53292444882e4b80aee4ca647_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOS03LTEtMS0xNDU5MjU_80f0a9ef-ab85-47fd-b214-cd7d4485fd2a">28,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="ibba6c7e42d174d4dad4f3aa9b26cc841_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOC05LTEtMS0xNDEyNTU_86765c7a-71bb-4794-a9d3-1771e3354f0d">5,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i86691c0476ba404f814077f7c6873c81_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOC0xMS0xLTEtMTQxMjU1_d6334333-6d7a-4263-a822-eef75bfa44e7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="id7dddc4574d1483ca39ac475a557c315_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOC0xMy0xLTEtMTQxMjU1_007b2804-263f-435d-afe1-319b6635dc22">22,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2ed753b6656243da8485cb9941f77565_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOS0xLTEtMS0xNDEyNTI_0d368525-7c76-460e-91a1-26d33fc1a365">7,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2ed753b6656243da8485cb9941f77565_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOS0zLTEtMS0xNDEyNTI_5834d85f-7a24-4b94-83ec-edbda19e7102">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="i2ed753b6656243da8485cb9941f77565_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOS01LTEtMS0xNDEyNTI_bd4fbf94-7454-4ca2-831b-62f0a82fcca0">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i2ed753b6656243da8485cb9941f77565_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTAtNy0xLTEtMTQ1OTI1_0dbac4d0-8e23-4682-a02a-e5ed8da66d24">7,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i031d672c83f54e5596727cbdebf7ddce_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOS05LTEtMS0xNDEyNTU_b405b914-4e79-4b47-855c-2055db7de9ff">5,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i369efc411a944e0ab23af95aeaed1da3_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOS0xMS0xLTEtMTQxMjU1_6720f62c-70c6-445d-a4c2-f8a1362a0b5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iaf727ea3cbd14cc599d0b296bd695c30_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOS0xMy0xLTEtMTQxMjU1_8c9cb1a9-0058-44a7-971e-ae49d038274f">1,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="id2dd1486f0094652a61e2542b663d473_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTEtMS0xLTEtMTQ1OTI1_7453da90-dbe5-4656-9c9a-3aa12f6d4421">56,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="id2dd1486f0094652a61e2542b663d473_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTEtMy0xLTEtMTQ1OTI1_3404b28d-8fff-4b8e-a994-750710e97a63">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(<ix:nonFraction unitRef="usd" contextRef="id2dd1486f0094652a61e2542b663d473_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTEtNS0xLTEtMTQ1OTI1_6985d11a-fc69-4975-ac67-94fdd9540bd1">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="id2dd1486f0094652a61e2542b663d473_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTEtNy0xLTEtMTQ1OTI1_1c84ceb0-7aba-4f10-bd5e-25ce7807a974">56,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="iac83004296dc489eb73145ef1a50ed6f_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTEtOS0xLTEtMTQ1OTI1_411964b7-e98d-43c1-b88d-66f175169767">15,575</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="i652407f4e1424c81a265a8aeb53e2c9f_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTEtMTEtMS0xLTE0NTkyNQ_8b9e1c41-6b2c-4147-8f5d-9ada6852ee5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usd" contextRef="icb62e4f0d0f34a19a5af68bf3ca4be90_I20221231" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTEtMTMtMS0xLTE0NTkyNQ_bfca7d0d-2e95-4777-8ee9-d01986ba29ff">40,942</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTItMS0xLTEtMTQ1OTI1_22752595-148b-4195-b09e-11f9586e3f6d">101,928</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTItMy0xLTEtMTQ1OTI1_45902db8-72d4-4134-8780-42aa0d9c39c0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTItNS0xLTEtMTQ1OTI1_766d4baa-190d-4470-86e3-47d4f1cfd69a">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTItNy0xLTEtMTQ1OTI1_74642b94-c9fb-4c68-8e9f-559f6e37c01e">101,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i758da6ca9a82424fbac7ce29a91ab127_I20221231" decimals="-3" name="snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTItOS0xLTEtMTQ1OTI1_03e5651c-f767-4180-8051-5aa4a475831c">57,621</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3913e52d42bd4b0584295d1000454575_I20221231" decimals="-3" name="snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTItMTEtMS0xLTE0NTkyNQ_e32d999e-c7a0-43bf-bf6c-f7a22b136e08">3,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4bf17ca1c12485a95f53564217086b7_I20221231" decimals="-3" name="snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTItMTMtMS0xLTE0NTkyNQ_d8129b31-1781-4a9b-a27a-f6098f234f5c">40,942</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No securities have contractual maturities of longer than one year. There were no transfers between Levels 1, 2, or 3 for any of the periods presented.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">8</span></div></div></div><div id="id08c0d7bd703495d970d203330d59b2f_386"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zODYvZnJhZzpjMGFhODNlMjQ3ZTM0ZTYwYTcyZjI5MmJhMDU2YTI2Zi90ZXh0cmVnaW9uOmMwYWE4M2UyNDdlMzRlNjBhNzJmMjkyYmEwNTZhMjZmXzExNTQ0ODcyMDkzMjYx_67891004-3985-48e9-aaba-799245f4eee4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents a summary of the changes in the fair value of the Company&#8217;s Level 3 financial instruments (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:85.438%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.721%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Earnout Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i057bc7826d4b4c84aacdd029762ebfee_I20221231" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zODYvZnJhZzpjMGFhODNlMjQ3ZTM0ZTYwYTcyZjI5MmJhMDU2YTI2Zi90YWJsZTowNTIzM2FjMDBlNmQ0MTQ3OGJhMjU0MDM4YWYxNzY5NC90YWJsZXJhbmdlOjA1MjMzYWMwMGU2ZDQxNDc4YmEyNTQwMzhhZjE3Njk0XzEtMi0xLTEtMTQxMTI3_03cfd33f-8870-43de-a171-6ba4555d52d4">227</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in other income (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc3b98e8794d4db98f8a5bec44536adc_D20230101-20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zODYvZnJhZzpjMGFhODNlMjQ3ZTM0ZTYwYTcyZjI5MmJhMDU2YTI2Zi90YWJsZTowNTIzM2FjMDBlNmQ0MTQ3OGJhMjU0MDM4YWYxNzY5NC90YWJsZXJhbmdlOjA1MjMzYWMwMGU2ZDQxNDc4YmEyNTQwMzhhZjE3Njk0XzMtMi0xLTEtMTQxMTI3_eb6e2647-e83e-4c05-82fe-766dd5b05c7c">59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0d7515206e374c2f8b3ba0988b6e7cc6_I20230331" decimals="-3" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zODYvZnJhZzpjMGFhODNlMjQ3ZTM0ZTYwYTcyZjI5MmJhMDU2YTI2Zi90YWJsZTowNTIzM2FjMDBlNmQ0MTQ3OGJhMjU0MDM4YWYxNzY5NC90YWJsZXJhbmdlOjA1MjMzYWMwMGU2ZDQxNDc4YmEyNTQwMzhhZjE3Njk0XzQtMi0xLTEtMTQyMTU3_50f8bbde-42ab-46b1-bf06-aabcaac43474">168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The fair value of the Contingent Earnout Liability is based on significant unobservable inputs, which represent Level 3 measurements within the fair value hierarchy.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In determining the fair value of the Contingent Earnout Liability, the Company used a Monte Carlo simulation value model using a distribution of potential outcomes. The assumptions utilized in the calculation were based on the achievement of certain stock price milestones, including the current Company common stock price, expected volatility, risk-free rate, expected term and expected dividend yield. Refer to Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Stockholders&#8217; Equity (Deficit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, for further details of the Contingent Earnout.</span></div><div id="id08c0d7bd703495d970d203330d59b2f_46"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:AdditionalFinancialInformationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RleHRyZWdpb246MDA3ZTc2MTFjNGEzNDc4MDkyMDViYjA1ZDRlMzVkMjNfNDk2_d7db5650-2c22-4482-9774-6f0e85aeb6f1" continuedAt="ib64b6a91b2074b678f73cb803a143f96" escape="true">Other Financial Statement information</ix:nonNumeric></span></div><ix:continuation id="ib64b6a91b2074b678f73cb803a143f96" continuedAt="i65c8395accbe41dd9e5a0465f499dfb1"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RleHRyZWdpb246MDA3ZTc2MTFjNGEzNDc4MDkyMDViYjA1ZDRlMzVkMjNfNDk3_22d132b9-2257-4eca-a27c-9cc73dea0654" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses (including prepaid rent)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmU2NGQ2NDhkNjQ2NzQ1NzRhZTc2Zjg5OWI3NmFhYjFmL3RhYmxlcmFuZ2U6ZTY0ZDY0OGQ2NDY3NDU3NGFlNzZmODk5Yjc2YWFiMWZfMi0xLTEtMS0xMzA3ODM_ca789ad6-1f39-4261-82f0-0455598032be">2,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmU2NGQ2NDhkNjQ2NzQ1NzRhZTc2Zjg5OWI3NmFhYjFmL3RhYmxlcmFuZ2U6ZTY0ZDY0OGQ2NDY3NDU3NGFlNzZmODk5Yjc2YWFiMWZfMi0zLTEtMS0xMzA3ODM_753ebcf5-4386-4693-ade6-f768d932f024">1,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:DepositsAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmU2NGQ2NDhkNjQ2NzQ1NzRhZTc2Zjg5OWI3NmFhYjFmL3RhYmxlcmFuZ2U6ZTY0ZDY0OGQ2NDY3NDU3NGFlNzZmODk5Yjc2YWFiMWZfMy0xLTEtMS0xMzA3ODM_825c6732-558e-41e0-a525-5b7d363589ce">1,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:DepositsAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmU2NGQ2NDhkNjQ2NzQ1NzRhZTc2Zjg5OWI3NmFhYjFmL3RhYmxlcmFuZ2U6ZTY0ZDY0OGQ2NDY3NDU3NGFlNzZmODk5Yjc2YWFiMWZfMy0zLTEtMS0xMzA3ODM_754d9825-3de0-47df-a0d0-8c2112367272">1,418</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmU2NGQ2NDhkNjQ2NzQ1NzRhZTc2Zjg5OWI3NmFhYjFmL3RhYmxlcmFuZ2U6ZTY0ZDY0OGQ2NDY3NDU3NGFlNzZmODk5Yjc2YWFiMWZfNS0xLTEtMS0xMzA3ODM_ac1664ad-dab2-4385-8bf1-e7b99ac21bde">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmU2NGQ2NDhkNjQ2NzQ1NzRhZTc2Zjg5OWI3NmFhYjFmL3RhYmxlcmFuZ2U6ZTY0ZDY0OGQ2NDY3NDU3NGFlNzZmODk5Yjc2YWFiMWZfNS0zLTEtMS0xMzA3ODM_7255a441-c6b6-44cb-bd24-60159b9102fb">101</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmU2NGQ2NDhkNjQ2NzQ1NzRhZTc2Zjg5OWI3NmFhYjFmL3RhYmxlcmFuZ2U6ZTY0ZDY0OGQ2NDY3NDU3NGFlNzZmODk5Yjc2YWFiMWZfNi0xLTEtMS0xMzA3ODM_accec37b-da13-440a-b96e-015021874e61">3,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmU2NGQ2NDhkNjQ2NzQ1NzRhZTc2Zjg5OWI3NmFhYjFmL3RhYmxlcmFuZ2U6ZTY0ZDY0OGQ2NDY3NDU3NGFlNzZmODk5Yjc2YWFiMWZfNi0zLTEtMS0xMzA3ODM_70f86676-13b8-4204-8ef1-699a956a4cec">3,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RleHRyZWdpb246MDA3ZTc2MTFjNGEzNDc4MDkyMDViYjA1ZDRlMzVkMjNfNDk4_438bb0ab-1755-47b1-bb09-7ff344fd8bbe" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84c054ca47f34f0fb57a2cc22fa7ebb3_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfMi0xLTEtMS0xMzA3ODM_ceebfd9b-ad18-4dab-a4fc-0c8eb020c1d0">8,474</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib151b972fd8f4cd79d899cda2eeb31e2_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfMi0zLTEtMS0xMzA3ODM_4a09bc09-5559-4cc0-b4ea-b0af1ae35725">8,265</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3df465c4a0264659996eb97c82a869a6_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfMy0xLTEtMS0xMzA3ODM_3079ddf9-6672-4f97-9bdf-daa654366e4a">1,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9622647ee0c949e0a3c0188f49fed90f_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfMy0zLTEtMS0xMzA3ODM_395f6bd5-87b0-4ed9-8c38-20c2d252c68d">1,869</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a54633d73574574bcdce66f8f30a522_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfNC0xLTEtMS0xMzA3ODM_d97cf308-9262-4573-9272-dd20f676d10e">390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i092aed2ed1dc43bba672fdbaa11ea98d_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfNC0zLTEtMS0xMzA3ODM_ea8580de-1828-4604-a145-8bdf2f69d604">389</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie51e5a8e9f5f4b7a82df0ce23e6b0e47_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfNS0xLTEtMS0xMzA3ODM_aadac17f-44aa-4f57-844e-82eaa36ecb09">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de56f4fdc344660850e0c6380cf9deb_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfNS0zLTEtMS0xMzA3ODM_c4d2af3d-8739-4b9f-818e-484d918aded6">326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55a0a250ecba480e9d2984321a23058c_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfNi0xLTEtMS0xMzA3ODM_f0915ecc-ffeb-493e-b9f2-b2b811bdfd4f">51,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5a7787f606c4694a34c9edafbf1c9a3_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfNi0zLTEtMS0xMzA3ODM_83600048-4b93-4735-9bfe-93d4d34fa209">48,273</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment at cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfNy0xLTEtMS0xMzA3ODM_72a44c47-c3be-47cd-a5b9-16d1a0b93d81">62,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfNy0zLTEtMS0xMzA3ODM_610e1736-98be-4e9d-9622-317b9f22b97c">59,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfOC0xLTEtMS0xMzA3ODM_7cb1867e-a51c-4790-8ff8-6486327b2420">3,419</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfOC0zLTEtMS0xMzA3ODM_40cb39fd-33c9-49a7-b44d-530700b6046f">2,986</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfOS0xLTEtMS0xMzA3ODM_513d352f-83a9-4198-8dac-bf32ce791c7b">58,987</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfOS0zLTEtMS0xMzA3ODM_ba2e971a-adb5-4178-8871-48fb40f0a212">56,136</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation totaled $<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RleHRyZWdpb246MDA3ZTc2MTFjNGEzNDc4MDkyMDViYjA1ZDRlMzVkMjNfMzM3_20b60795-db2c-4780-afe6-8d34125e2a09">0.5</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-5" name="us-gaap:Depreciation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RleHRyZWdpb246MDA3ZTc2MTFjNGEzNDc4MDkyMDViYjA1ZDRlMzVkMjNfMzQ0_49be05ce-c734-4a51-90d8-b11da58b3699">0.2</ix:nonFraction>&#160;million for the three months ended March 31, 2023 and 2022, respectively. </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i65c8395accbe41dd9e5a0465f499dfb1"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Liabilities</span></div><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RleHRyZWdpb246MDA3ZTc2MTFjNGEzNDc4MDkyMDViYjA1ZDRlMzVkMjNfNDk1_eba77bd5-6821-42e5-a36f-ec86b6252918" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional and service fees related to facility construction</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfMi0xLTEtMS0xMzA3ODM_7e2ea589-ff2c-4239-b7cc-87fd444feaa0">3,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfMi0zLTEtMS0xMzA3ODM_9992951f-85d3-479e-9f35-56d689416885">7,342</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfMy0xLTEtMS0xNDEwNTM_51696754-a545-43be-8ba1-7d8b845dae44">1,799</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfMy0zLTEtMS0xNDEwNTM_557b97d4-b942-47aa-841f-d57eedfd80f0">3,743</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional and service fees other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="snti:AccruedProfessionalFeesOtherCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfMy0xLTEtMS0xMzA3ODM_c885e878-95f4-4f9c-be82-5a8b221de871">1,749</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="snti:AccruedProfessionalFeesOtherCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfMy0zLTEtMS0xMzA3ODM_730ed523-f9a5-4401-a305-63d6803c8d84">1,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfNS0xLTEtMS0xMzA3ODM_b54f12fb-76cb-409f-be68-5e12db5db468">53</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfNS0zLTEtMS0xMzA3ODM_b6271ff5-18cf-4a51-aac7-79ab9eaa4350">29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfNi0xLTEtMS0xMzA3ODM_726915cf-c34b-4b0d-ac2b-524f9bf7ad6f">7,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfNi0zLTEtMS0xMzA3ODM_07b58988-6f94-4107-828f-007ab2a5d19e">12,864</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="id08c0d7bd703495d970d203330d59b2f_49"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5. Operating <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfMjI5OQ_84465294-5c67-42b7-939f-c95c745908f2" continuedAt="i980e9bdb34ca4f789229393f8dfa0ff3" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i980e9bdb34ca4f789229393f8dfa0ff3" continuedAt="i990c9560350247d1a037cd6ce4a2d248"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating leases are primarily for its corporate headquarters located in South San Francisco, California (&#8220;HQ lease&#8221;) and for additional office and laboratory space located in Alameda, California (&#8220;Alameda lease&#8221;) that commenced on July 30, 2021, and is expected to be placed into service in June 2023. The corporate headquarters lease has an initial term of <ix:nonNumeric contextRef="i13c2b1f5934440b19195e3dc99ca0b84_I20230331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfMzQz_7c4d12f0-d30f-45b9-8e4f-4fa884d75767">eight years</ix:nonNumeric> expiring in 2027, with an option to renew for an additional <ix:nonNumeric contextRef="i13c2b1f5934440b19195e3dc99ca0b84_I20230331" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfNDA2_7703b1f6-fa32-4f4c-ac05-9f39d521bcbf">eight years</ix:nonNumeric> unless canceled by either party thereafter. The Alameda lease has an initial term of <ix:nonNumeric contextRef="iffa91051becf44e9bef166d4fa25aabf_I20230331" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfNDk0_a8255312-59c5-4547-94fc-b302eb88ffea">eleven years</ix:nonNumeric> expiring in 2032, with an option to renew the lease for up to <ix:nonFraction unitRef="tradingday" contextRef="if0a2f740c54a4460bdf1870465e2fd28_D20230101-20230331" decimals="INF" name="snti:LesseeOperatingLeaseNumberOfRenewalOptions" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfNTU5_f8a57f8f-63c2-41dd-8ba7-7a32080542a2">two</ix:nonFraction> additional terms of <ix:nonNumeric contextRef="iffa91051becf44e9bef166d4fa25aabf_I20230331" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfNTgy_e7da9500-530c-419e-8e4f-9efdc3d85644">five years</ix:nonNumeric>. The exercise of these renewal options is not recognized as part of the ROU assets and lease liabilities, as the Company did not conclude, at the commencement date of the leases, that the exercise of renewal options or termination options was reasonably certain. The Alameda lease provides for a tenant improvement allowance of up to $<ix:nonFraction unitRef="usd" contextRef="iffa91051becf44e9bef166d4fa25aabf_I20230331" decimals="-5" name="snti:TenantImprovementAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfOTE5_427a9513-af06-49c1-b87e-2dbfc0fa11a6">17.5</ix:nonFraction>&#160;million for the costs relating to the design, permitting and construction of the improvements, to be disbursed by the landlord no later than December 31, 2023. The Company is deemed to be the accounting owner of the tenant improvements primarily because the Company is the principal in the construction and design of the assets, is responsible for costs overruns and retains substantially all economic benefits from the leasehold improvements over their economic lives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, the tenant improvement allowance is considered an incentive and was deducted from the initial measurement of the ROU asset and lease liability. The Company estimated the timing of tenant improvement reimbursements at the lease commencement date and upon receipt of the cash incentives, the Company recognized the cash received as an increase in the lease liability.</span></div><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfMjMwMA_fd6c971f-cae2-4483-8fb0-20c60685f03e" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of total lease costs and other information for the period relating to the Company&#8217;s operating leases is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjM1NDI1Yjk5NTRhYTQwOThiYzlmYjhhZTc4MWFmZDQyL3RhYmxlcmFuZ2U6MzU0MjViOTk1NGFhNDA5OGJjOWZiOGFlNzgxYWZkNDJfMi0xLTEtMS0xMzA3ODM_abd0ac36-cdd2-4a1c-9954-7205ebd1fcfc">1,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjM1NDI1Yjk5NTRhYTQwOThiYzlmYjhhZTc4MWFmZDQyL3RhYmxlcmFuZ2U6MzU0MjViOTk1NGFhNDA5OGJjOWZiOGFlNzgxYWZkNDJfMi0zLTEtMS0xMzA3ODM_8d433d12-011c-46ef-837a-0c51a1a496b2">1,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjM1NDI1Yjk5NTRhYTQwOThiYzlmYjhhZTc4MWFmZDQyL3RhYmxlcmFuZ2U6MzU0MjViOTk1NGFhNDA5OGJjOWZiOGFlNzgxYWZkNDJfMy0xLTEtMS0xMzA3ODM_ab088dac-5b39-46bf-bbb8-43ca9b3b2731">31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:ShortTermLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjM1NDI1Yjk5NTRhYTQwOThiYzlmYjhhZTc4MWFmZDQyL3RhYmxlcmFuZ2U6MzU0MjViOTk1NGFhNDA5OGJjOWZiOGFlNzgxYWZkNDJfMy0zLTEtMS0xMzA3ODM_b98c21c0-3243-45b6-9191-bcaba01e1890">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjM1NDI1Yjk5NTRhYTQwOThiYzlmYjhhZTc4MWFmZDQyL3RhYmxlcmFuZ2U6MzU0MjViOTk1NGFhNDA5OGJjOWZiOGFlNzgxYWZkNDJfNC0xLTEtMS0xMzA3ODM_8dbe8b9f-d91c-4db5-ab42-c21d0bf77d00">244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:VariableLeaseCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjM1NDI1Yjk5NTRhYTQwOThiYzlmYjhhZTc4MWFmZDQyL3RhYmxlcmFuZ2U6MzU0MjViOTk1NGFhNDA5OGJjOWZiOGFlNzgxYWZkNDJfNC0zLTEtMS0xMzA3ODM_f51552f3-13fe-450c-96e7-0a10be79b25e">172</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjM1NDI1Yjk5NTRhYTQwOThiYzlmYjhhZTc4MWFmZDQyL3RhYmxlcmFuZ2U6MzU0MjViOTk1NGFhNDA5OGJjOWZiOGFlNzgxYWZkNDJfNS0xLTEtMS0xMzA3ODM_7be0277c-7272-45b9-87dc-157bd93ca755">1,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:LeaseCost" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjM1NDI1Yjk5NTRhYTQwOThiYzlmYjhhZTc4MWFmZDQyL3RhYmxlcmFuZ2U6MzU0MjViOTk1NGFhNDA5OGJjOWZiOGFlNzgxYWZkNDJfNS0zLTEtMS0xMzA3ODM_91f58105-cf74-470e-ad95-8d0790e976a2">1,500</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows net inflows and (outflows) from operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="snti:OperatingLeaseProceedsPayments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjY4OTRmZTlkODE2YzQzMTU5YzhhMzBmYTc1MjFkMzA3L3RhYmxlcmFuZ2U6Njg5NGZlOWQ4MTZjNDMxNTljOGEzMGZhNzUyMWQzMDdfMy0xLTEtMS0xMzA3ODM_0e810c07-a31f-4cba-9186-812e88b86810">37</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="snti:OperatingLeaseProceedsPayments" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjY4OTRmZTlkODE2YzQzMTU5YzhhMzBmYTc1MjFkMzA3L3RhYmxlcmFuZ2U6Njg5NGZlOWQ4MTZjNDMxNTljOGEzMGZhNzUyMWQzMDdfMy0zLTEtMS0xMzA3ODM_50050e47-6327-44a2-9e02-696b6ade049f">1,874</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for operating lease obligations (including remeasurement of ROU and lease liabilities due to changes in the timing of receipt of lease incentives)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjY4OTRmZTlkODE2YzQzMTU5YzhhMzBmYTc1MjFkMzA3L3RhYmxlcmFuZ2U6Njg5NGZlOWQ4MTZjNDMxNTljOGEzMGZhNzUyMWQzMDdfNC0xLTEtMS0xMzA3ODM_a8063246-2890-481b-a7a7-cba728ba3a59">51</ix:nonFraction>)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjY4OTRmZTlkODE2YzQzMTU5YzhhMzBmYTc1MjFkMzA3L3RhYmxlcmFuZ2U6Njg5NGZlOWQ4MTZjNDMxNTljOGEzMGZhNzUyMWQzMDdfNC0zLTEtMS0xMzA3ODM_647e5ff6-4e16-43a0-8760-5afb4bcb4b72">239</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i2db00a77192f4255a898540eac49878e_I20230331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjY4OTRmZTlkODE2YzQzMTU5YzhhMzBmYTc1MjFkMzA3L3RhYmxlcmFuZ2U6Njg5NGZlOWQ4MTZjNDMxNTljOGEzMGZhNzUyMWQzMDdfNS0xLTEtMS0xMzA3ODM_13e635b9-149d-4d2e-b5cc-080f45fb85d1">8.0</ix:nonNumeric> years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ic47933b228a74660947c56c9928b9097_I20220331" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjY4OTRmZTlkODE2YzQzMTU5YzhhMzBmYTc1MjFkMzA3L3RhYmxlcmFuZ2U6Njg5NGZlOWQ4MTZjNDMxNTljOGEzMGZhNzUyMWQzMDdfNS0zLTEtMS0xMzA3ODM_d55883a7-d790-40d1-b573-d506ed685940">7.9</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjY4OTRmZTlkODE2YzQzMTU5YzhhMzBmYTc1MjFkMzA3L3RhYmxlcmFuZ2U6Njg5NGZlOWQ4MTZjNDMxNTljOGEzMGZhNzUyMWQzMDdfNi0xLTEtMS0xMzA3ODM_303229b3-4627-42e6-b08f-13215baaccce">9.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic47933b228a74660947c56c9928b9097_I20220331" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjY4OTRmZTlkODE2YzQzMTU5YzhhMzBmYTc1MjFkMzA3L3RhYmxlcmFuZ2U6Njg5NGZlOWQ4MTZjNDMxNTljOGEzMGZhNzUyMWQzMDdfNi0zLTEtMS0xMzA3ODM_892a3179-fd60-497e-b813-525d1493adf0">9.1</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i990c9560350247d1a037cd6ce4a2d248"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, the Company received $<ix:nonFraction unitRef="usd" contextRef="if0a2f740c54a4460bdf1870465e2fd28_D20230101-20230331" decimals="-5" name="snti:TenantImprovementReimbursements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfNzE0NjgyNTU4Mjk1Mg_5df71c39-11ea-4a6c-b71a-714ea620cefd">1.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i13d4209f114b48ae802f8c70848bac8d_D20220101-20220331" decimals="-5" name="snti:TenantImprovementReimbursements" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfNzE0NjgyNTU4Mjk2OA_fdd989be-c710-4ea4-9333-c1b1552dbd39">2.5</ix:nonFraction> million, respectively, of the $<ix:nonFraction unitRef="usd" contextRef="iffa91051becf44e9bef166d4fa25aabf_I20230331" decimals="-5" name="snti:TenantImprovementAllowance" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfNzE0NjgyNTU4MzAyMQ_427a9513-af06-49c1-b87e-2dbfc0fa11a6">17.5</ix:nonFraction>&#160;million tenant improvement allowance. Through March&#160;31, 2023, the Company utilized $<ix:nonFraction unitRef="usd" contextRef="i5a99c95357954ece87322f3f9568adc0_D20210730-20230331" decimals="-5" name="snti:TenantImprovementAllowanceUtilized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfNzE0NjgyNTU4MzEyOA_2d472a9a-69a5-48d0-afe9-e99606dec7d0">15.1</ix:nonFraction> million of the tenant improvement allowance inception-to-date. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2023 and 2022, amounts disclosed for ROU assets obtained in exchange for lease obligations include amounts added to the carrying amount of ROU assets resulting from lease modifications and reassessments.</span></div><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfMjI5OA_89594aac-e349-4d0d-93cd-15375b82e014" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of the Company&#8217;s lease liabilities as of March&#160;31, 2023, were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:86.079%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.721%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023, for the remainder of the year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfMC0xLTEtMS0xMzA3ODM_892f7268-a210-4929-af5e-ee7454e07780">5,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfMS0xLTEtMS0xMzA3ODM_a37c23ec-eadc-44b4-883e-5d26c0d1be7c">7,254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfMi0xLTEtMS0xMzA3ODM_8239dce6-d82b-47c4-bb27-c0f5e881c1ca">7,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfMy0xLTEtMS0xMzA3ODM_feda0600-7cbf-4a37-8a87-7d5aea940874">7,712</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfNC0xLTEtMS0xMzA3ODM_866a879f-9b22-4424-8fdd-5f8046a3393c">5,769</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="snti:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfNS0xLTEtMS0xMzA3ODM_9c26e630-b30c-4252-82e6-7a1cc0d67d23">24,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfNi0xLTEtMS0xMzA3ODM_8671f35c-aab8-4faf-a0f8-d74ee5797b29">57,904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfNy0xLTEtMS0xMzA3ODM_2ac03d6a-a9a4-45e8-afcc-4aae5f542139">17,637</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant improvement allowance remaining</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="snti:TenantImprovementAllowanceRemainingAmount" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfOC0xLTEtMS0xMzA3ODM_a9a97169-2bd1-424c-9477-eb33a36863df">2,345</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfOS0xLTEtMS0xMzA3ODM_9130de8a-9a24-4e32-a1e9-1591c14b05cd">37,922</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="id08c0d7bd703495d970d203330d59b2f_55"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNjY0OQ_4f83abfd-595a-4c22-9c01-c19350cea875" continuedAt="i908f434ae5b44dafa93e421d57d56d48" escape="true">Stockholders&#8217; Equity (Deficit)</ix:nonNumeric></span></div><ix:continuation id="i908f434ae5b44dafa93e421d57d56d48" continuedAt="i851b235149ab4b7a94148664920848b6"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Common Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="snti:NumberOfVotesPerCommonShare" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNjM3_e20538da-45fe-4a89-9a4c-febfe82ca462">one</ix:nonFraction> vote per share, and to receive dividends and, upon liquidation or dissolution, are entitled to receive all assets available for distribution to stockholders. The holders have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such shares. Common stock is subordinate to the preferred stock with respect to dividend rights and rights upon liquidation, winding up, and dissolution of the Company; although, <ix:nonFraction unitRef="shares" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjc0ODc3OTA4MDEwNA_602415b9-2c29-44b3-a0bf-dc0f3085ae1d"><ix:nonFraction unitRef="shares" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjc0ODc3OTA4MDEwNA_e9792861-a8cf-4c02-aacd-0083f86fa5f7">no</ix:nonFraction></ix:nonFraction> preferred stock is outstanding as of March&#160;31, 2023 and December&#160;31, 2022. Through March&#160;31, 2023, <ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="INF" name="us-gaap:DividendsCommonStockCash" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMTEzNA_d254e9e8-a430-42f1-9a42-6da6215ecf6c">no</ix:nonFraction> cash dividends have been declared or paid.</span></div><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="snti:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNjY1NQ_4ee35c2e-7726-40f9-b582-9ee4887209d9" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At March&#160;31, 2023 and December&#160;31, 2022, the Company was authorized to issue <ix:nonFraction unitRef="shares" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMTIzMA_b4d0a300-cfe6-4d53-8cde-336f78bc4ac3"><ix:nonFraction unitRef="shares" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMTIzMA_fd2c793b-219a-47ac-81fc-e06a29cd4351">500,000,000</ix:nonFraction></ix:nonFraction> shares of common stock, all at a par value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMTI5OQ_10a5fd8e-b521-4701-ae82-ac9ae0c4ec90"><ix:nonFraction unitRef="usdPerShare" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMTI5OQ_999b0d92-0ece-4709-ac2a-f5c40fb983b5">0.0001</ix:nonFraction></ix:nonFraction> per share, and had reserved the following shares for future issuance:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:72.617%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Purchase Agreement</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81d4d8a5f9114d1886175ca8b72ce10a_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfMy0xLTEtMS0xMzA3ODM_0659b5c0-e61e-41ff-920b-5b99343edd1c">8,327,049</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7840bf286e7b4bce9183521fe23e6524_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfMy0zLTEtMS0xMzA3ODM_2a9f308e-9551-432d-b7fa-5f194ba27da2">8,327,049</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options issued and outstanding </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id20463a91ddd421ea41fcb5abe035d56_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfNC0xLTEtMS0xMzA3ODM_68d14bb0-3be4-4683-a18d-c5f5813f253b">11,792,908</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6e6ef9d05bdb4e6ab4465b3414f327a9_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfNC0zLTEtMS0xMzA3ODM_27b57b43-1628-452d-879d-eb1a6edf9737">9,875,675</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs issued and outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16305f4a1b8449d1a35861d9aa0fc5c8_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfNS0xLTEtMS0xMzA3ODM_1e8954ea-e072-4eee-bbd4-204d2fc88e67">388,322</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ee3457100c84c3d87184e1e135ba640_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfNS0zLTEtMS0xMzA3ODM_512c6bd3-91a5-4d8c-8d19-569a7b2f858d">447,948</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock shares available for future issuance under equity plans </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i47d461e06c0441f3bf66aa005d566b32_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfNi0xLTEtMS0xMzA3ODM_2050c2a2-20b3-4631-af77-9ed6a40ea5af">3,299,266</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i52cce8c44b9b4333a95f74f60f360543_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfNi0zLTEtMS0xMzA3ODM_f0e98af2-f76e-461e-afa0-e45183e6ed65">2,948,472</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock shares available for future issuance under the 2022 Employee Stock Purchase Plan (the "ESPP") </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1cabf5a80a1a48298b9edf643135beb0_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfNy0xLTEtMS0xMzA3ODM_7f7940bf-ae2f-41d3-ab84-11729c252e92">923,307</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0381c522846d4ca6a0f0602fe5c59dc0_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfNy0zLTEtMS0xMzA3ODM_5b551e2e-882e-47f6-9a30-81a03b9a6afe">481,627</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earnout common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i4027bdb9ad2f4e6c85d6878c9bb667fc_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfOC0xLTEtMS0xNDQ5MjI_8052f32d-9d19-46e0-bc27-9e73f5a7fbb7">2,000,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id5f4bb6471d7488ba9e91594b407b669_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfOC0zLTEtMS0xNDQ5MjI_b53984fb-0578-4ecf-a49e-6d08bd64439a">2,000,000</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested early exercised common stock </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i066bdaf0f5a0401387fa517ed3d8324c_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfOC0xLTEtMS0xMzA3ODM_f50013b2-db98-45ab-b07a-c4d5f4058c40">92,840</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i190ad14af5cf48d182dd17a670b1c6b0_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfOC0zLTEtMS0xMzA3ODM_723737c4-df09-4d81-a174-3981e0d043c6">105,500</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfOS0xLTEtMS0xMzA3ODM_2f74db74-e977-4e20-9887-b964348e0a89">26,823,692</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfOS0zLTEtMS0xMzA3ODM_0663a4d6-9615-41e5-8eae-a0c20970a4ce">24,186,271</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the close of the Merger, the Company&#8217;s Amended and Restated Certificate of Incorporation provides the Company&#8217;s board of directors with the authority to issue $<ix:nonFraction unitRef="usdPerShare" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMTkzNA_46dd7eb1-8454-4b9e-8687-ad614e5cadd1"><ix:nonFraction unitRef="usdPerShare" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMTkzNA_80a251bb-69c3-40f4-b8d9-3143c7a1c859">0.0001</ix:nonFraction></ix:nonFraction> par value preferred stock in one or more series and to establish from time to time the number of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating, optional, special and other rights shall be stated and expressed in such resolutions. There were </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i851b235149ab4b7a94148664920848b6" continuedAt="icf868231344048b9b25f7e278c4eba2f"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjMyMQ_1ae03aeb-cf40-4dbb-8b92-315e741378fb"><ix:nonFraction unitRef="shares" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjMyMQ_c151700f-a09f-4b9c-a616-9f3741f9f663">10,000,000</ix:nonFraction></ix:nonFraction> shares designated as preferred stock and <ix:nonFraction unitRef="shares" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NDQwNw_408466dd-a356-456d-8f13-3ec70f2f6148"><ix:nonFraction unitRef="shares" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NDQwNw_56cb8f3e-26dc-4ee5-b816-016a5c74d6f5"><ix:nonFraction unitRef="shares" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NDQwNw_851e37c7-2582-4392-9f49-62d4e849a6a9"><ix:nonFraction unitRef="shares" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NDQwNw_c3d8dc32-1cf8-4535-9b58-7deb3baa8cfe">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> were outstanding as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Common Stock Purchase Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 31, 2022, the Company entered into a Common Stock Purchase Agreement and a Registration Rights Agreement (collectively referred to as the &#8220;Purchase Agreement&#8221;) with Chardan Capital Markets LLC (&#8220;Chardan&#8221;). Pursuant to the Purchase Agreement, the Company has the right, in its sole discretion, to sell to Chardan up to the lesser of (i) $<ix:nonFraction unitRef="usd" contextRef="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831" decimals="-5" name="snti:SaleOfStockMaximumAmountAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjc3Mw_b15e2565-717c-4986-a8ef-e61c9f3df83c">50.0</ix:nonFraction> million of newly issued shares of the Company&#8217;s common stock, and (ii) the Exchange Cap (as defined below) (subject to certain conditions and limitations), from time to time during the <ix:nonNumeric contextRef="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831" name="snti:SaleOfStockTermOfAgreement" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjk1Mw_0ae3abfc-301a-493d-85ff-ceac34530690">36</ix:nonNumeric>-month term of the Purchase Agreement. Under the applicable NASDAQ rules, the Company may not issue to Chardan under the Purchase Agreement more than <ix:nonFraction unitRef="shares" contextRef="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831" decimals="INF" name="snti:SaleOfStockNumberOfSharesIssuedInTransactionThreshold" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMzEwNQ_a55938c1-63ac-46ad-9ddc-2218eb624b45">8,727,049</ix:nonFraction> shares of common stock, which number of shares is equal to <ix:nonFraction unitRef="number" contextRef="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831" decimals="4" name="snti:SaleOfStockSharesIssuedInTransactionThresholdPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMzE2Nw_0e21faf4-1821-47eb-97e6-520d266a4e7c">19.99</ix:nonFraction>% of the common shares outstanding immediately prior to the execution of the Purchase Agreement unless certain exceptions are met (the &#8220;Exchange Cap&#8221;). The purchase price of the shares of common stock will be determined by reference to the Volume Weighted Average Price (&#8220;VWAP&#8221;) of the common stock during the applicable purchase date, less a fixed <ix:nonFraction unitRef="number" contextRef="i2695814ca4b34861bbd946616eacf91a_I20220831" decimals="2" name="snti:SaleOfStockDiscountRatePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMzUxNw_a9388494-341c-463b-92fa-b5f50a2d9164">3</ix:nonFraction>% discount to such VWAP. However, the total shares to be purchased on any day may not exceed <ix:nonFraction unitRef="number" contextRef="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831" decimals="2" name="snti:SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMzYxMQ_b2de3f3c-66b1-4b9d-820c-b67eebef87a7">20</ix:nonFraction>% of the trading volume, and the total purchase price on any day may not exceed $<ix:nonFraction unitRef="usd" contextRef="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831" decimals="-5" name="snti:SaleOfStockDailyAmountToBeSoldThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMzY5Mg_75c3b9f4-2399-488e-95e9-3a45c019bfa1">3.0</ix:nonFraction> million. As consideration for Chardan&#8217;s commitment to purchase shares of common stock at the Company&#8217;s direction upon the terms and subject to the conditions set forth in the Purchase Agreement, upon execution of the Purchase Agreement, the Company issued <ix:nonFraction unitRef="shares" contextRef="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMzk0Mw_eaecc037-7325-453f-b15f-3484155c0ac6">100,000</ix:nonFraction> shares of its common stock to Chardan and paid a $<ix:nonFraction unitRef="usd" contextRef="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831" decimals="-5" name="snti:SaleOfStockDocumentPreparationFees" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMzk5NQ_6ee582a2-bc80-4392-b847-13c95b07e636">0.4</ix:nonFraction> million document preparation fee. Upon execution of the Purchase Agreement, the Company recognized an expense of $<ix:nonFraction unitRef="usd" contextRef="i3301414885c64fcb913d8ab29a5a4c1d_I20220831" decimals="-5" name="snti:SaleOfStockIssuanceCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNDA2MQ_0185c08a-363d-4cfa-b05c-99da6d66988a">0.7</ix:nonFraction> million within general and administrative expenses in the Company&#8217;s Condensed Consolidated Statements of Operations and Comprehensive Loss for the Chardan related costs and legal fees incurred in connection with the agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other than the issuance of the commitment shares of the Company&#8217;s common stock to Chardan, the Company issued <ix:nonFraction unitRef="shares" contextRef="iaf30c96ccd494c5792c0230ca1a3d6db_D20220101-20221231" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NDQzOQ_43f80abf-6fc8-4d1b-9d35-94e82d7f57c4">300,000</ix:nonFraction> Class A common stock shares up until December&#160;31, 2022 aggregating to net proceeds of $<ix:nonFraction unitRef="usd" contextRef="iaf30c96ccd494c5792c0230ca1a3d6db_D20220101-20221231" decimals="-5" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NDYwMA_b32c179d-8414-469e-b40d-d1e956d67c75">0.7</ix:nonFraction> million, under the Purchase Agreement. There were <ix:nonFraction unitRef="shares" contextRef="i29d9a37c9c3b447eb4fb6ec96fa1dd2b_D20230101-20230331" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NDY2Mg_77a777ef-e23c-4222-a431-250d5b6a0b07">no</ix:nonFraction> shares issued within three months ended March 31, 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Contingent Earnout Equity</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the closing of the Merger, former holders of Legacy Senti common stock and preferred stock may receive up to <ix:nonFraction unitRef="shares" contextRef="i2cf3659743e3408a95f042ce0308c736_D20220608-20220608" decimals="INF" name="snti:ReverseRecapitalizationContingentConsiderationEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNDc5Ng_7bd49395-58cb-4457-8c3f-64ec7d2dd357">2,000,000</ix:nonFraction> additional shares of the Company&#8217;s common stock in the aggregate, in <ix:nonFraction unitRef="tranche" contextRef="ic402157e4d8841ffabfdea65ced1a7b6_I20220608" decimals="INF" name="snti:ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NTIwNA_907f1e1d-d663-49ae-b3a0-20de11f1af43">two</ix:nonFraction> equal tranches of <ix:nonFraction unitRef="shares" contextRef="i2cf3659743e3408a95f042ce0308c736_D20220608-20220608" decimals="INF" name="snti:ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNDg4OQ_d07f892f-81b1-48e5-9d7a-d320d8af9553">1,000,000</ix:nonFraction> shares of common stock per tranche. The first and second tranches are issuable if the closing volume weighted average price (&#8220;VWAP&#8221;) per share of common stock quoted on the Nasdaq (or the exchange on which the shares of common stock are then listed) is greater or equal to $<ix:nonFraction unitRef="usdPerShare" contextRef="ic0e7bfd5199240fe911cf1a70a64d6a8_I20220608" decimals="2" name="snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNTE2NQ_b8a6732c-d055-4917-999f-659e094fada4">15.00</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i3a8876a6338d4250b6c025cf2cd85bf7_I20220608" decimals="2" name="snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNTE3Mg_ecea7e00-a68e-42ba-88dc-d262e4e60a47">20.00</ix:nonFraction>, respectively over any <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNTE5OA_43c54c31-da11-473c-9a9b-97c930e0d994">twenty</span> trading days within any <ix:nonNumeric contextRef="i2cf3659743e3408a95f042ce0308c736_D20220608-20220608" name="snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNjY1Ng_ea196930-2f17-469f-9af8-c083715ba54e">thirty-day</ix:nonNumeric> trading period. The first and second tranche term is <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NTIxMA_4c4a7b87-cc7a-4ee5-be63-48c4f60a7afc">two</span> and <ix:nonNumeric contextRef="i987337493e8f4d6b95c95a50303ac90b_D20220608-20220608" name="snti:ReverseRecapitalizationContingentConsiderationEquityTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NTIxNQ_7d51b4a4-bbea-459a-af6d-7c0b92e1f1d3">three years</ix:nonNumeric>, respectively, from the closing of the Merger. If there is a change of control within the <ix:nonNumeric contextRef="i2cf3659743e3408a95f042ce0308c736_D20220608-20220608" name="snti:ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNjY1Nw_86e0a29d-af52-4c66-af6c-4bfe54529993">three-year</ix:nonNumeric> following the closing of the Merger that results in a per share price equal to or in excess of the $<ix:nonFraction unitRef="usdPerShare" contextRef="ic0e7bfd5199240fe911cf1a70a64d6a8_I20220608" decimals="2" name="snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNTQ5Mg_b8a6732c-d055-4917-999f-659e094fada4">15.00</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i3a8876a6338d4250b6c025cf2cd85bf7_I20220608" decimals="2" name="snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNTQ5OQ_ecea7e00-a68e-42ba-88dc-d262e4e60a47">20.00</ix:nonFraction> share price milestones not previously met, then Company shall issue the earnout shares to the holders of Legacy Senti common stock and preferred stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The estimated fair value of the total Contingent Earnout Shares at the Closing on June 8, 2022, was $<ix:nonFraction unitRef="usd" contextRef="ic402157e4d8841ffabfdea65ced1a7b6_I20220608" decimals="-5" name="snti:ReverseRecapitalizationContingentConsiderationFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NTI1NQ_dde17d2c-60d2-491f-a6d3-a2c0428ad509">9.8</ix:nonFraction>&#160;million based on a Monte Carlo simulation valuation model. Of this amount, $<ix:nonFraction unitRef="usd" contextRef="ic402157e4d8841ffabfdea65ced1a7b6_I20220608" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NTI2Mg_b5b9d4e5-ec7d-41f0-949c-2b9ea6b45c5c">9.7</ix:nonFraction>&#160;million was accounted for as a Contingent Earnout Liability because the triggering events that determine the number of Contingent Earnout Shares required to be issued include events that are not solely indexed to the common stock of the Company. The remaining balance of  $<ix:nonFraction unitRef="usd" contextRef="ic402157e4d8841ffabfdea65ced1a7b6_I20220608" decimals="-5" name="us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NTI2OA_2f385032-2d33-48b8-8b3c-b4a5d03e1d4d">0.1</ix:nonFraction>&#160;million relates to holders of Legacy Senti common stock that are subject to repurchase were accounted for as stock-based compensation expense and recorded as an expense, as there was no remaining service period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Contingent Earnout Liability was remeasured to fair value as of March&#160;31, 2023, resulting in the recording of a non-cash gain of $<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-5" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNjQxMA_5a00fa44-37fb-46cb-bd32-16fcfd3dbf34">0.1</ix:nonFraction>&#160;million for the three months ended March&#160;31, 2023, classified within change in fair value of contingent earnout liability in the condensed consolidated statements of operations and comprehensive loss.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="icf868231344048b9b25f7e278c4eba2f"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNjY1Mw_c8959904-2f9e-44c2-b78e-b3cf3e85db68" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assumptions used in the valuation are described below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current stock price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i478aae25e06348e2896c5435db3def08_I20220608" decimals="2" name="snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfMi0yLTEtMS0xMzA3ODM_a802abc1-947b-42c5-aab2-8181d4a0354e">1.18</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i1d50e05b3f964b1e8bd1212007d0f5b2_I20230331" decimals="2" name="snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfMi00LTEtMS0xMzA3ODM_5a095fde-6596-48b5-bc64-921c9e0d9bcf">1.41</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4303eca5071e4e959e6a005f6949bbc0_I20220608" decimals="3" name="snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfMy0yLTEtMS0xMzA3ODM_499154b7-b79b-4a6b-ba92-1e736a8fc6ac">95.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i585e64a0dde84731b30a56a965b3502e_I20230331" decimals="3" name="snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfMy00LTEtMS0xMzA3ODM_b47bea94-4be5-4872-8def-a50352f62d39">85.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i22fe4e8df6ab4d1dab35a6b9027729c0_I20220608" decimals="4" name="snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfNC0yLTEtMS0xMzA3ODM_23cfa9b5-922f-4412-ba46-9deef61c0148">4.1</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4dfd924deef14485b70ba9b749718b18_I20230331" decimals="4" name="snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfNC00LTEtMS0xMzA3ODM_07a71812-3b60-4e8c-8073-1b4fcb1a4598">4.3</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iebf31f1f016a4897aeecc0db5ee0375f_I20220608" decimals="INF" name="snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfNS0yLTEtMS0xMzA3ODM_2cc028df-9b41-44ba-a345-7d61455914b5">0.0</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i743280c266ac4be9bba0b85a394d535f_I20230331" decimals="INF" name="snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfNS00LTEtMS0xMzA3ODM_399ca1d8-201e-4e8f-8710-5e91b8a70594">0.0</ix:nonFraction>%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="years" contextRef="i6c5f60d8079a4c929fb01b0c4238eb77_I20220608" decimals="INF" name="snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfNi0yLTEtMS0xMzA3ODM_567f0328-6cfb-42a7-969a-457a2e23bbc2">2.2</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="years" contextRef="i74c815e4a7ff416083bff82a684e4da6_I20230331" decimals="INF" name="snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfNi00LTEtMS0xMzA3ODM_2cde6f16-97ef-4939-9911-611d8690b8e8">2.4</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div id="id08c0d7bd703495d970d203330d59b2f_58"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="snti:RevenueFromAndNotFromContractsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjgyMw_5d6fcbf2-1c03-48f8-894b-0a1286c7b926" continuedAt="i1a9cf9bb69914c49a49690c0196740cf" escape="true">Revenue</ix:nonNumeric></span></div><ix:continuation id="i1a9cf9bb69914c49a49690c0196740cf" continuedAt="i2d64029f022d457f869a05fbbe1eb00a"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s revenue consists of amounts received related to research services provided to customers.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Contract Revenue</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, the Company entered into a research collaboration and license agreement with Spark Therapeutics, Inc. (&#8220;Spark&#8221;). Under the agreement, the Company will be responsible for a research program, which includes designing, building and testing five cell type specific-synthetic promoters for use in developing certain gene therapies using the Company&#8217;s proprietary technology. The Company received an upfront payment from Spark of $<ix:nonFraction unitRef="usd" contextRef="if7e5dfb75c5345e0908face1c31bf68c_I20210430" decimals="-5" name="snti:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfMTU3Ng_dff3842e-f81b-412a-b6c3-d0a0bb76001c">3.0</ix:nonFraction> million and Spark is obligated to reimburse the Company for costs and expenses incurred for the research program. The Company expected to complete the research program over a <ix:nonNumeric contextRef="i928b078b707f45d4ab1ac6398e73bf1b_I20210430" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfMjc0ODc3OTA3ODU2OA_e197f646-c5ee-42bb-99e2-058745be2c9c">two-year</ix:nonNumeric> period. In December 2022, the Company amended the research collaboration and license agreement to allow for an increase in budget and a <ix:nonNumeric contextRef="i766f28525f3748399d68ffe1034f13d1_D20221201-20221231" name="snti:ContractWithCustomerExtensionOfTermModificationOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfMjc0ODc3OTA3ODU2OQ_7747e6f1-7f1b-45c9-8808-a087da9faf24">two-month</ix:nonNumeric> extension of the research program. As there were no changes to performance obligations and the services to be provided are not distinct from those already transferred, the transactions was accounted for as a contract modification and a cumulative catch-up of $(<ix:nonFraction unitRef="usd" contextRef="i766f28525f3748399d68ffe1034f13d1_D20221201-20221231" decimals="-5" sign="-" name="us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU5NzA2OTc3NDI2Nw_fdf918d4-ef2d-4933-a3e1-aa25a1a9026a">0.7</ix:nonFraction>) million was recognized in December 2022. As of March&#160;31, 2023 and December&#160;31, 2022, there was a total of $<ix:nonFraction unitRef="usd" contextRef="i9b3c57ec032744ba8f6125f37486a864_I20230331" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU5NzA2OTc3NDMyNg_3fcb9d90-afc0-4870-b7b5-9b4f3fce9d02">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i27014437a0604c6493a324456d9bebc5_I20221231" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU5NzA2OTc3NDMyMg_60dad0fb-db53-4744-947c-524c45f91d8f">0.8</ix:nonFraction> million, respectively, remaining of the upfront payment to be recognized over the remaining period of the research program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assessed this agreement in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue Recognition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(&#8220;ASC 606&#8221;) and concluded that the contract counterparty, Spark, is a customer. The Company identified only one combined performance obligation in the agreement, which is to perform research services, the related joint research plan and committees for the five specified promoters. The Company determined that the research activities for each of the five promoters are not distinct given there is one single research plan that is performed by the same research team and research results for one promoter may provide insights for other promoters. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the agreement, once the research program is completed and the Company delivers a data package to Spark, Spark has <ix:nonNumeric contextRef="if8ecffc42af64ac98c375ec96588e97e_D20210401-20210430" name="snti:RevenueFromContractWithCustomerEvaluationPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfMjUyMA_2f097596-3f94-425b-a0fd-a43ad6f9ba73">24</ix:nonNumeric> months (the &#8220;Evaluation Period&#8221;) to determine whether Spark will exercise its options to obtain field-limited, royalty-bearing licenses to develop, manufacture and commercialize promoters corresponding to each of the five specified promoters being researched. For each licensed promoter option that is exercised, the Company is eligible to receive a license fee, potential research, development and commercial milestone payments and royalties on product sales. Spark may generally terminate the agreement upon <ix:nonNumeric contextRef="ieb49597653b64cf59b45a61e885d9cab_D20210401-20210430" name="snti:RevenueFromContractWithCustomerTerminationNoticePeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfMzAzMw_0605d425-848d-4426-a62e-5491ac8d8aa4">90</ix:nonNumeric> days prior written notice or <ix:nonNumeric contextRef="id4caf954de824dcfa399375ed1463740_D20210401-20210430" name="snti:RevenueFromContractWithCustomerTerminationNoticePeriod" format="ixt-sec:durday" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfMzA2NQ_78513dfc-367d-48ab-a5f1-753ab28b2f56">180</ix:nonNumeric> days prior written notice if the licensed promoter is in clinical trials or is being commercialized at the time of termination.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company evaluated Spark&#8217;s optional rights to license, develop, manufacture and commercialize each of the promoter profiles to determine whether they provide Spark with any material rights to purchase the promoter licenses at an incremental discount.  The Company&#8217;s proprietary technology used to develop the promoters is in the early stages of development, so technological feasibility and probability of developing a product is highly uncertain. As a result, determining the SSP for the optional rights is subject to significant judgment. Given the subjectivity associated with determining the SSP for the right to a future license related to unproven technology at contract inception, the Company also evaluated whether the contract consideration associated with the research services represents the SSP for those services. The Company determined the transaction price, inclusive of the upfront payment and reimbursement of costs and expenses incurred for the research program, is commensurate with SSP for the research being conducted given the specialized nature and reliance on proprietary technology. Based on the Company&#8217;s assessment of the optional consideration and the qualitative factors of feasibility and probability of development combined with the quantitative assessment that research services are priced at their SSP, the Company </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i2d64029f022d457f869a05fbbe1eb00a"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">concluded that the license option does not provide Spark with an incremental discount and therefore does not constitute a material right. The transaction price associated with the research services in this agreement consists of the fixed upfront amount of $<ix:nonFraction unitRef="usd" contextRef="if7e5dfb75c5345e0908face1c31bf68c_I20210430" decimals="-5" name="snti:RevenueRemainingPerformanceObligationVariableConsiderationAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNDgwMw_dff3842e-f81b-412a-b6c3-d0a0bb76001c">3.0</ix:nonFraction> million and variable consideration.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For Spark collaboration agreement, the Company will recognize the transaction price as research and development services are provided, using a cost-based input method to measure the progress toward completion of its performance obligation and to calculate the corresponding amount of revenue to recognize each period. The Company believes that the cost-based input method is the best measure of progress because other measurements would not reflect how the Company transfers the control related to the performance obligation to our customers. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March 31, 2023 and 2022, the Company recorded revenue, which was previously included in deferred revenue at the beginning of each period, of $<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU5NzA2OTc3NDM0OQ_d5b18a71-2a30-4c31-b626-e9b147015927">0.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU5NzA2OTc3NDM1Ng_b202b396-a307-44d8-b6eb-c7e189262aff">0.4</ix:nonFraction> million, respectively. Contract asset balances related to unbilled revenue for our collaboration agreements were <ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:ContractWithCustomerAssetGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU5NzA2OTc3NDUyMQ_5007b975-7dbf-4d1e-a9a6-d75f20435c47"><ix:nonFraction unitRef="usd" contextRef="ic47933b228a74660947c56c9928b9097_I20220331" decimals="INF" name="us-gaap:ContractWithCustomerAssetGross" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU5NzA2OTc3NDUyMQ_549e212e-94b5-4a76-81f8-97f093fa11ae">zero</ix:nonFraction></ix:nonFraction> as of March 31, 2023 and 2022, and are presented within prepaid expenses and other current assets on the condensed consolidated balance sheets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant Income</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2021, the Small Business Innovation Research (&#8220;SBIR&#8221;) awarded the Company a grant in the amount of $<ix:nonFraction unitRef="usd" contextRef="i27aef62b1f3e4bffb3dd2df12b5856fe_D20210101-20211231" decimals="-5" name="us-gaap:RevenueNotFromContractWithCustomer" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjAyNA_2871b74f-4753-47ea-961a-8099713cf0b2">2.0</ix:nonFraction> million over <ix:nonNumeric contextRef="i71c1a8f9ff524518959d9a765706749d_I20211231" name="snti:GrantAssistancePeriodOfRecognition" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjAzMg_443677d7-ab5a-4fca-8eb5-ad2f1da2495b">two years</ix:nonNumeric> subject to meeting certain terms and conditions. The purpose of the grant is to support the further development of SENTI-202 for acute myeloid leukemia towards clinical development. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Grant income was recognized when qualified research and development costs were incurred and the Company obtained reasonable assurance that the terms and conditions of the grant were met.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Entity-wide information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March 31, 2023, Customers A and B accounted for <ix:nonFraction unitRef="number" contextRef="ie8b4557210454abca1e04086bd66db43_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjQ3Ng_885b5b4c-df2f-476a-ae5f-775d4bfb59d2">81</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="icaa788b9dd8d4c5989a84143f00ba716_D20230101-20230331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjQ4Mw_e506202b-d238-414e-8bf1-74a38082abcd">19</ix:nonFraction>%, respectively, of revenue. During the three months ended March 31, 2022, Customers A and B accounted for <ix:nonFraction unitRef="number" contextRef="i39380c3017c0443ea9d9f875c6d12c89_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU2MA_40f669f6-c744-4d02-8b17-a83fdaab1fd9">77</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="id0b118498cc947c4a737ef007df909ed_D20220101-20220331" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU2Nw_cd27dfa3-4fda-461f-b2c4-6932abeb8bcc">23</ix:nonFraction>%, respectively, of revenue.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All revenues were generated in the United States for the three months ended March 31, 2023 and 2022.</span></div></ix:continuation><div id="id08c0d7bd703495d970d203330d59b2f_61"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfOTE2Nw_07015c72-bdeb-4748-a227-24f16630afbe" continuedAt="i32121312c2a94503856a6b640c522e80" escape="true">Stock-Based Compensation</ix:nonNumeric></span></div><ix:continuation id="i32121312c2a94503856a6b640c522e80" continuedAt="i6f27506bb6944109bec6695f4cc83ac7"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2016 Stock Incentive Plan (as Amended and Restated)</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2016 Stock Incentive Plan (the &#8220;2016 Plan&#8221;) provides for the grant of incentive stock options, non-qualified stock options and restricted stock awards to employees, directors, and consultants of the Company. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock options granted under the 2016 Plan generally vest over <ix:nonNumeric contextRef="i3e7073ad95d14237a686257c1f249847_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NTU4Ng_9a5b1100-2a51-4cd2-af51-27fbdabcac0b">four years</ix:nonNumeric> and expire no later than <ix:nonNumeric contextRef="i3e7073ad95d14237a686257c1f249847_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NTU5Ng_778fc677-59c7-49c5-ad79-09c3392cbb10">ten years</ix:nonNumeric> after the grant date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the Merger, the 2016 Plan was terminated. No additional stock awards will be granted under the 2016 Plan. All awards previously granted and outstanding as of the effective date of the Merger, were adjusted to reflect the impact of the Merger, but otherwise remain in effect pursuant to their original terms. The shares underlying any award granted under the 2016 Plan that are forfeited back to or repurchased or reacquired by the Company, will revert to and again become available for issuance under the 2022 Plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022 Stock Incentive Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June&#160;8, 2022, upon the Merger, the Company adopted a 2022 Stock Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan provides for the grant of incentive stock options to employees, and for the grant of non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The exercise price of an option granted under the 2022 Plan shall not be less than the fair market value of a common stock share on the date of grant. With respect to a <ix:nonFraction unitRef="number" contextRef="i8bbb2d044d4540fba0cfd4b952348522_D20230101-20230331" decimals="2" name="snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3MjIwNQ_cb6c4c5b-b7b3-4e46-af20-b7cbdce83bff">10</ix:nonFraction>% stockholder, the exercise price of an option granted shall not be less than <ix:nonFraction unitRef="number" contextRef="i109dbba609114d389a60bbd41cab5bfc_D20230101-20230331" decimals="2" name="snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3MjIxOA_a04deef1-1041-4457-b194-f66bee7a9ad0">110</ix:nonFraction>% of the fair value of the common stock share on the date of grant.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i6f27506bb6944109bec6695f4cc83ac7" continuedAt="i8562f4b3a8064c26a630ae6241b133f1"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock options granted under the 2022 Plan generally vest over <ix:nonNumeric contextRef="i0157834a97314a79aab287cf1bcc1d2d_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3MzA0NQ_7c77c6e8-0140-4118-9ed1-e21174d1e505">four years</ix:nonNumeric> and expire no later than <ix:nonNumeric contextRef="i0157834a97314a79aab287cf1bcc1d2d_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3MzA1MQ_6e6107f5-f277-4744-b80c-b79894f940fa">ten years</ix:nonNumeric> after the grant date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company initially reserved <ix:nonFraction unitRef="shares" contextRef="i3d089448db5c47ac864b335700ebdf6c_I20220608" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3MzAzMQ_a471808b-96d7-414a-bbc6-51fabb3b9a49">2,492,735</ix:nonFraction> shares of common stock for issuance under the 2022 Plan. On the first day of each year commencing January 1, 2023, the 2022 Plan will automatically increase by <ix:nonFraction unitRef="number" contextRef="i8bbb2d044d4540fba0cfd4b952348522_D20230101-20230331" decimals="2" name="snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3MzA1OQ_624ec41a-17f2-4807-a5b9-94f407f793cf">5</ix:nonFraction>% of the outstanding number of shares of common stock of the Company on the last day of the preceding calendar year or such lesser number of shares as approved by the Company&#8217;s Board of Directors prior to the effective date of the annual increase. In addition, the shares underlying any award granted under the 2016 Plan that are forfeited back to or repurchased or reacquired by the Company, will revert to and again become available for issuance under the 2022 Plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the total number of shares of common stock available for issuance under the 2022 Plan is <ix:nonFraction unitRef="shares" contextRef="i1fdc25c4786948e396c80e21496eaec2_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxNjE0NA_42660eac-3877-42de-800c-6804a7d146b3">2,168,837</ix:nonFraction>.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022 Inducement Equity Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August&#160;5, 2022, the Company adopted a 2022 Inducement Equity Plan (the &#8220;2022 Inducement Plan&#8221;). The 2022 Plan provides for the grant of non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to persons not previously an employee of the Company and its affiliates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The exercise price of an option granted under the 2022 Inducement Plan shall not be less than the fair market value of a common stock share on the date of grant.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock options granted under the 2022 Inducement Plan generally vest over <ix:nonNumeric contextRef="i65140541deed4a8a9d94a28b4b349127_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3NTQwNQ_33a4c901-2e54-4419-8071-c523f194141e">four years</ix:nonNumeric> and expire no later than <ix:nonNumeric contextRef="i93b6fc338c6a44bfac709886289913e3_D20220805-20220805" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3NTM2NQ_bfe7bac7-e819-4550-bba5-33c29467f46b">ten years</ix:nonNumeric> after the grant date. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company initially reserved <ix:nonFraction unitRef="shares" contextRef="i84ff68234e48415aabc730672a424709_I20220805" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3NTM3Mg_96047995-b5a2-4da7-8348-7a61079622bc">2,000,000</ix:nonFraction> shares of common stock for issuance under the 2022 Inducement Plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the total number of shares of common stock available for issuance under the 2022 Inducement Plan is <ix:nonFraction unitRef="shares" contextRef="i3b946e4dc38a43f985ff9ce7ef855a78_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxNjE1MQ_4186e849-b920-4790-83fa-7136878f2732">1,130,429</ix:nonFraction>.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022 Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June&#160;8, 2022, upon the Merger, the Company adopted a 2022 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP allows eligible employees to purchase shares of the Company's common stock at a price equal to <ix:nonFraction unitRef="number" contextRef="ifb4c537cd827433eb1fd0857cc6e392f_D20220608-20220608" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4Mzk3Mg_b00795fc-dce5-446e-a0f8-7045db23019d">85</ix:nonFraction>% of the lower of the fair market values of the stock on the first day of an offering or on the date of purchase. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s ESPP operates with rolling offering periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">which are generally <ix:nonNumeric contextRef="ifb4c537cd827433eb1fd0857cc6e392f_D20220608-20220608" name="snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4Mzk4Nw_ec5ec3ae-9d7e-4560-8da3-28e85bca310c">24</ix:nonNumeric> months.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company initially reserved <ix:nonFraction unitRef="shares" contextRef="i7ab0adeec3bc495a85352b6cd04f0ea6_I20220608" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NDAwMw_c447af32-ced6-40d8-9b73-6d471d1dcef0">592,584</ix:nonFraction> shares of common stock for issuance under the ESPP. On the first day of each year commencing January 1, 2023, the 2022 Plan will automatically increase by <ix:nonFraction unitRef="number" contextRef="ifb4c537cd827433eb1fd0857cc6e392f_D20220608-20220608" decimals="2" name="snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NDAwNw_33bbb499-aa3a-4555-8117-9d43a6dfb969">1</ix:nonFraction>% of the outstanding number of shares of common stock of the Company on the last day of the preceding calendar year or such lesser number of shares as approved by the Company&#8217;s Board of Directors prior to the effective date of the annual increase.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i8562f4b3a8064c26a630ae6241b133f1" continuedAt="ic454f80d46d1465d8dd78494f6832282"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the total number of shares of common stock available for issuance under the ESPP is <ix:nonFraction unitRef="shares" contextRef="i1cabf5a80a1a48298b9edf643135beb0_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxNjE1Nw_d321e922-751e-434a-a4a3-8b107df715aa">923,307</ix:nonFraction>.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Stock options</span></div><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfOTE2NQ_2c79bc9d-61a4-4e1b-9dfb-606c94342d81" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity and related information under all equity plans, excluding performance and market awards:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfMS0xLTEtMS0xMzA3ODM_cd98e0d9-ff9e-487e-984d-cb85ebbcd332">4,191,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfMS0zLTEtMS0xMzA3ODM_5e7c460f-8a8c-4245-aa99-8f0959151f60">3.18</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i921a457818234d30b26fac9b4d02f4a7_D20220101-20221231" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfMS01LTEtMS0xMzA3ODM_92186b3d-ff6a-4d73-aa4d-b3ac2677b7a2">9.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfMS03LTEtMS0xMzA3ODM_43ded0e0-1441-4ed8-a481-f2a1f7db5cd6">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfMi0xLTEtMS0xMzA3ODM_dda03bed-1b1f-4650-9168-a6ed24168474">2,189,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfMi0zLTEtMS0xMzA3ODM_865978bf-e41b-4fb0-8a06-1afa891ffe61">1.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNC0xLTEtMS0xMzA3ODM_df91b106-20e3-4106-a93c-54752daee5d6">203,367</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNC0zLTEtMS0xMzA3ODM_f750652b-d9b3-4d42-aa55-f5554b34380c">3.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNS0xLTEtMS0xMzA3ODM_00ec04a4-47a1-4566-8d46-4e9e067b55b6">6,177,759</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNS0zLTEtMS0xMzA3ODM_144bec4a-617b-43b0-9ad1-0b89ab6375fb">2.69</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNS01LTEtMS0xMzA3ODM_66daa9e0-ba38-442a-a826-593e6f8eba25">8.9</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNS03LTEtMS0xMzA3ODM_7a8559eb-3ab8-4af1-a98a-e020ff124054">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNi0xLTEtMS0xMzA3ODM_a5802338-133e-4e84-8dec-2e442c6b7fa4">972,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNi0zLTEtMS0xMzA3ODM_64430257-1074-4aa8-bf2d-7016e138a117">3.97</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNi01LTEtMS0xMzA3ODM_92606c13-f6a4-45a4-9ae5-f56550d95bf8">7.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNi03LTEtMS0xMzA3ODM_bd8322b3-f782-4983-ad34-5855aa8da181">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted during the three months ended March 31, 2023 and 2022 were $<ix:nonFraction unitRef="usdPerShare" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NTc0MA_f9928e92-8019-4e13-8c0e-02db75544b21">1.30</ix:nonFraction> and <ix:nonFraction unitRef="usdPerShare" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NjAyMA_86a0fd76-90e2-48e9-a68d-585d32b0ef99">none</ix:nonFraction>, respectively. The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2023 and 2022 were <ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NjA5Mw_5c76eba1-9ee6-45a4-90b8-3cd5d067e05f">none</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NjA4OQ_bc96afe7-2b21-4153-9af3-1b7c19a634c5">1.2</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the unrecognized stock-based compensation expense related to stock options was approximately $<ix:nonFraction unitRef="usd" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NjE5OA_4d4f32c9-6520-4cfe-8a64-654d93fa1a9b">9.5</ix:nonFraction>&#160;million, expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="ie25bf12b097d4142a80c4443e8e34b7c_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzMwNjAzMg_e22ece62-bc0b-4733-9a7c-1020ac244c6e">2.8</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Exercise of Stock Options into Restricted Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March 31, 2023 and 2022, the Company issued <ix:nonFraction unitRef="shares" contextRef="ia6f53a18a05e4e3e9c95c5959b5464af_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjg5MQ_19d75fa1-f22b-4cd6-a4f7-fe5d33066351"><ix:nonFraction unitRef="shares" contextRef="i09e65d7dd7ff4a518134d5af6af7496b_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjg5MQ_511a993c-c1d3-415f-b20b-0e311e564bda">zero</ix:nonFraction></ix:nonFraction> shares of common stock upon exercise of unvested stock options. As of March&#160;31, 2023 and December&#160;31, 2022, <ix:nonFraction unitRef="shares" contextRef="ia6f53a18a05e4e3e9c95c5959b5464af_D20230101-20230331" decimals="INF" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjk5Nw_830c5468-2112-4d67-b4f8-3d6bb01f84d7">92,840</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="iecb98f68e3f54315adf9e9038dadf418_D20220101-20221231" decimals="INF" name="us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMzAwNA_64ca0751-37dc-4cf1-b7fe-326d10cf141f">105,500</ix:nonFraction> shares were held by employees subject to repurchase at an aggregate price of $<ix:nonFraction unitRef="usd" contextRef="i6cba8c98475b4484aa393d6615db82dd_I20230331" decimals="-5" name="snti:CommonStockSubjectToRepurchaseValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMzA4NA_7cbdff1e-d175-4f73-b2f9-aca3d0fc545f">0.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ifc61cf9dbb914210b3fe39d9d8805450_I20221231" decimals="-5" name="snti:CommonStockSubjectToRepurchaseValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMzA5MQ_e304a149-c2ed-4b49-b765-be80c9efe411">0.3</ix:nonFraction> million, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Performance Awards</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, on December 19, 2021, Legacy Senti approved <ix:nonFraction unitRef="shares" contextRef="i09d1b2b0e78f4a2a9de67b5ef64622f8_D20211219-20211219" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMzIwMw_3be3dae6-a6dc-4085-8d61-09fdddffb27c">8,400,892</ix:nonFraction> performance award options to existing employees that vest contingent upon the satisfaction of both a <ix:nonNumeric contextRef="i09d1b2b0e78f4a2a9de67b5ef64622f8_D20211219-20211219" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMzMwMA_ebcd9a99-261e-469a-ba4c-3b5aefd67c40">four</ix:nonNumeric>-year service condition and a performance condition tied to the consummation of the Merger. The awards and the associated recognition of stock-based compensation were contingent on the Merger being consummated. As of the approval date of the performance awards, Legacy Senti did not have sufficient common stock available for issuance. Upon the Merger, the Company increased the number of shares authorized and <ix:nonFraction unitRef="shares" contextRef="i55f59dff27474019a6a976d08d32c7a5_D20220608-20220608" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMzcxMw_cd32a3f7-a4ff-49a4-afc4-81d955d98632">6,796,074</ix:nonFraction> awards were granted on June&#160;8, 2022. Refer to Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Equity (Deficit),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details of the shares of common stock authorized.</span></div><div style="margin-bottom:9pt"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfOTE2OA_51ff319d-fe22-4fbb-bdf5-a4b696c6dc9e" continuedAt="ia6bf35cd13d04d8f90b523d2aa0191a4" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.723%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5aee551dc4424308a0cbe423b5aa00f5_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfMS0xLTEtMS0xMzA3ODM_600c2843-e09f-4c72-a152-fa8c312021a7">5,368,501</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5aee551dc4424308a0cbe423b5aa00f5_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfMS0zLTEtMS0xMzA3ODM_d43c1592-8235-4617-b5c9-46283a317536">9.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i3f3e04de252e4ab9ad665ce2c64c8f64_D20220101-20221231" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfMS01LTEtMS0xMzA3ODM_b78cd495-fd08-4476-a366-3e24201c7b1e">9.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfNC0xLTEtMS0xMzA3ODM_7e0fa9b1-6c37-4c36-afe7-a118df3dae8d">69,100</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfNC0zLTEtMS0xMzA3ODM_27d6a236-f8c5-4297-93bb-9844ecd4acc9">9.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i787b64c59226487c91cbebde035a735d_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfNS0xLTEtMS0xMzA3ODM_de52e281-5fa4-4544-8874-89811e600044">5,299,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i787b64c59226487c91cbebde035a735d_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfNS0zLTEtMS0xMzA3ODM_f4801345-3183-4be6-8377-982712e30143">9.92</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfNS01LTEtMS0xMzA3ODM_58e078d7-9b5e-4e0c-8292-aa788f902dd1">8.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfNi0xLTEtMS0xMzA3ODM_4165220e-8333-4bd8-a91f-e82d63b20289">334,586</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfNi0zLTEtMS0xMzA3ODM_ab23f3a1-27bf-4dc4-b22e-d88ae7204e5e">9.92</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331" name="snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfNi01LTEtMS0xMzA3ODM_2b38f4cd-63d4-4503-9ffa-d5f66d3157ef">7.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="ic454f80d46d1465d8dd78494f6832282" continuedAt="i70ae0a5acdf64e7fb47033e1de4a886b"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The were <ix:nonFraction unitRef="shares" contextRef="if95b9a3a21314a64be95e971b65657ab_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxMjE1Nw_2643f510-b6d2-47f4-bcf9-d3f2d45e20ae"><ix:nonFraction unitRef="shares" contextRef="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxMjE1Nw_285f8641-2bd3-481f-aa7b-09d71ed70146">no</ix:nonFraction></ix:nonFraction> performance based options granted or exercised during the three months ended March 31, 2023 and 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the unrecognized stock-based compensation expense related to performance based options was approximately $<ix:nonFraction unitRef="usd" contextRef="i787b64c59226487c91cbebde035a735d_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxMjc0Mg_f11becb2-25d3-4669-9de4-4f87367d749c">10.4</ix:nonFraction>&#160;million, expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzMwNjA0Mg_1d675ebb-ef4f-4bdd-a717-6cf430ec4028">1.8</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Market</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Awards </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Business Combination Agreement with DYNS, on December 19, 2021, Legacy Senti approved <ix:nonFraction unitRef="shares" contextRef="i148f91500cfa448b90c1ca1b3fe51ddd_D20211219-20211219" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMzk4MQ_00e178a9-1545-4d57-b529-1ae3aa4c4828">605,451</ix:nonFraction> market award options to its co-founder and Chief Executive Officer, Dr. Timothy Lu, that vest contingent upon the satisfaction of all three of the following conditions: a service condition, a performance condition tied to the consummation of the Merger, and market conditions. The market condition is achieved in <ix:nonFraction unitRef="tranche" contextRef="i342ee2fd8d6845069313253e24f45e30_I20211219" decimals="INF" name="snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNDI5MA_58b4961b-61c6-4b1e-8439-d5417637098c">four</ix:nonFraction> tranches, where <ix:nonFraction unitRef="number" contextRef="i148f91500cfa448b90c1ca1b3fe51ddd_D20211219-20211219" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNDMwOQ_41f36743-fe04-43a1-9ffe-3f0fcdceb090">25</ix:nonFraction>% of the options will vest when the trading price of the Company&#8217;s stock is above various thresholds of price per share. The award and the associated recognition of stock-based compensation were contingent on the Merger being consummated. The estimated fair value of the market awards at the grant date was based on a Monte Carlo simulation valuation model. As of the approval date, Legacy Senti did not have sufficient common stock available for issuance to allow for exercise of the stock options. Upon the Merger, the Company increased the number of shares authorized and <ix:nonFraction unitRef="shares" contextRef="i1d8a71f2d75d44fd822915e608589a18_D20220608-20220608" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNDc2NQ_d0dacccc-b78d-4a6e-8a09-e42963bae62f">315,748</ix:nonFraction> awards were granted on June&#160;8, 2022. Refer to Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Stockholders&#8217; Equity (Deficit),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for further details of the shares of common stock authorized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The were <ix:nonFraction unitRef="shares" contextRef="id4e222fd06584beba7f3df061459dfd0_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxMzAwMA_86092817-83ea-4564-8623-dfd7ee070f1c"><ix:nonFraction unitRef="shares" contextRef="ifb827c206b774ff486fdcdc6ed921a68_D20220101-20220331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxMzAwMA_ffcd3293-f743-44c6-8c37-81114ea16693">no</ix:nonFraction></ix:nonFraction> market based options granted or exercised during the three months ended March 31, 2023 and 2022. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the unrecognized stock-based compensation expense related to market based options was approximately $<ix:nonFraction unitRef="usd" contextRef="ic26e10f702604471b0ad4cc00f011d6c_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxMzAwOA_b02d788e-75d6-455c-a848-9d26aedc1ce4">0.6</ix:nonFraction>&#160;million, expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="id4e222fd06584beba7f3df061459dfd0_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxMzAxNQ_d3c07f59-788b-474c-b085-9c11bc23adc9">1.1</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Restricted Stock Units </span></div><ix:continuation id="ia6bf35cd13d04d8f90b523d2aa0191a4"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Company&#8217;s restricted stock units activity and related information under all equity plans:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9ee3457100c84c3d87184e1e135ba640_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjYzNjgxYTFhODUzYTQzYWViNWM2ZTE2NWE5OTBmYmFmL3RhYmxlcmFuZ2U6NjM2ODFhMWE4NTNhNDNhZWI1YzZlMTY1YTk5MGZiYWZfMS0yLTEtMS0xNDM1Nzg_5123fb85-807b-4800-9a55-98bd4a3ac530">447,948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i9ee3457100c84c3d87184e1e135ba640_I20221231" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjYzNjgxYTFhODUzYTQzYWViNWM2ZTE2NWE5OTBmYmFmL3RhYmxlcmFuZ2U6NjM2ODFhMWE4NTNhNDNhZWI1YzZlMTY1YTk5MGZiYWZfMS00LTEtMS0xNDM1Nzg_57ea9ee5-bb27-43ef-9124-3a05dca03f51">2.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i24a619ba2bc2425c8c531466ceb3022f_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjYzNjgxYTFhODUzYTQzYWViNWM2ZTE2NWE5OTBmYmFmL3RhYmxlcmFuZ2U6NjM2ODFhMWE4NTNhNDNhZWI1YzZlMTY1YTk5MGZiYWZfNC0yLTEtMS0xNDM1Nzg_c1f09dfd-b2fb-4bc3-a3c2-85f367061148">59,626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i24a619ba2bc2425c8c531466ceb3022f_D20230101-20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjYzNjgxYTFhODUzYTQzYWViNWM2ZTE2NWE5OTBmYmFmL3RhYmxlcmFuZ2U6NjM2ODFhMWE4NTNhNDNhZWI1YzZlMTY1YTk5MGZiYWZfNC00LTEtMS0xNDM1Nzg_aa7cfff5-ff02-4e20-8070-1cb30112c067">2.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i16305f4a1b8449d1a35861d9aa0fc5c8_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjYzNjgxYTFhODUzYTQzYWViNWM2ZTE2NWE5OTBmYmFmL3RhYmxlcmFuZ2U6NjM2ODFhMWE4NTNhNDNhZWI1YzZlMTY1YTk5MGZiYWZfNS0yLTEtMS0xNDM1Nzg_bc00839e-cc09-48c4-ba19-df73e08fdf85">388,322</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i16305f4a1b8449d1a35861d9aa0fc5c8_I20230331" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjYzNjgxYTFhODUzYTQzYWViNWM2ZTE2NWE5OTBmYmFmL3RhYmxlcmFuZ2U6NjM2ODFhMWE4NTNhNDNhZWI1YzZlMTY1YTk5MGZiYWZfNS00LTEtMS0xNDM1Nzg_f8f0ff57-a2e6-42f8-8a9d-70a4c478efd8">2.50</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the unrecognized stock-based compensation expense related to restricted stock units was approximately $<ix:nonFraction unitRef="usd" contextRef="i16305f4a1b8449d1a35861d9aa0fc5c8_I20230331" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxNTQ5NQ_967d936d-41d9-4034-be1c-8521f0936047">0.7</ix:nonFraction>&#160;million, expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="i24a619ba2bc2425c8c531466ceb3022f_D20230101-20230331" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxNTUwMA_42a092f8-7263-426c-ba8c-ddd5700e207c">1.5</ix:nonNumeric> years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In determining the fair value of the stock-based awards, the Company uses the assumptions below for the Black-Scholes option pricing model, which are subjective and generally require significant judgment.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Fair Value of Common Stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;The fair value of the shares of common stock has historically been determined by the Company&#8217;s board of directors as there was no public market for the common stock. The board of directors determined the fair value of the common stock by considering a number of objective and subjective factors, including: third-party valuations of the Company&#8217;s common stock, the valuation of comparable companies, the Company&#8217;s operating and financial performance, and general and industry-specific economic outlook, amongst other factors. As of the closing of the Merger and going forward, the fair value of common stock will be based on the publicly traded market value.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#8212; The expected term represents the period that the Company&#8217;s stock options are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="i70ae0a5acdf64e7fb47033e1de4a886b"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the end of the contractual term). The expected term for the ESPP purchase rights is the length of the purchase period.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#8212; The expected volatility is based on the average historical volatility of comparable publicly-traded peer companies, over a period equal to the expected term of the stock option grants, as the Company was not publicly traded prior to the Merger and does not have a trading history for its common stock for a sufficient period of time subsequent to the Merger. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk-free Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#8212; The risk-free rate assumption is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Dividends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#8212; The Company has never paid dividends on its common stock and does not anticipate paying dividends on common stock. Therefore, the Company uses an expected dividend yield of zero.</span></div><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfOTE2OQ_7671b3f5-3c4d-42a0-bed3-e188d49dda70" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The assumptions used to determine the grant date fair value of non-market based, stock options granted were as follows, presented on a weighted-average basis:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:71.976%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie25bf12b097d4142a80c4443e8e34b7c_D20230101-20230331" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOmY4ZGQxYmFlNTA1YjQ2NjliM2Y2ZTVmZThjNjgwZDlhL3RhYmxlcmFuZ2U6ZjhkZDFiYWU1MDViNDY2OWIzZjZlNWZlOGM2ODBkOWFfMi0xLTEtMS0xMzA3ODM_d45a69c2-440f-4c2e-be16-8aa03208433b">6.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie25bf12b097d4142a80c4443e8e34b7c_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOmY4ZGQxYmFlNTA1YjQ2NjliM2Y2ZTVmZThjNjgwZDlhL3RhYmxlcmFuZ2U6ZjhkZDFiYWU1MDViNDY2OWIzZjZlNWZlOGM2ODBkOWFfMy0xLTEtMS0xMzA3ODM_b906d875-8278-417b-829a-8f9484d86cca">82</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib140873ca1da43bab9fd62b4810057e8_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOmY4ZGQxYmFlNTA1YjQ2NjliM2Y2ZTVmZThjNjgwZDlhL3RhYmxlcmFuZ2U6ZjhkZDFiYWU1MDViNDY2OWIzZjZlNWZlOGM2ODBkOWFfMy0zLTEtMS0xMzA3ODM_152b8dbb-3d20-4f4b-8e6b-f821abfd5735">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie25bf12b097d4142a80c4443e8e34b7c_D20230101-20230331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOmY4ZGQxYmFlNTA1YjQ2NjliM2Y2ZTVmZThjNjgwZDlhL3RhYmxlcmFuZ2U6ZjhkZDFiYWU1MDViNDY2OWIzZjZlNWZlOGM2ODBkOWFfNC0xLTEtMS0xMzA3ODM_f9713d49-77f5-45dd-9d13-a8d5b126a9f2">3.5</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib140873ca1da43bab9fd62b4810057e8_D20220101-20220331" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOmY4ZGQxYmFlNTA1YjQ2NjliM2Y2ZTVmZThjNjgwZDlhL3RhYmxlcmFuZ2U6ZjhkZDFiYWU1MDViNDY2OWIzZjZlNWZlOGM2ODBkOWFfNC0zLTEtMS0xMzA3ODM_b491e3e1-0d80-4846-9401-c3c5ce3ac2eb">&#8212;</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie25bf12b097d4142a80c4443e8e34b7c_D20230101-20230331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOmY4ZGQxYmFlNTA1YjQ2NjliM2Y2ZTVmZThjNjgwZDlhL3RhYmxlcmFuZ2U6ZjhkZDFiYWU1MDViNDY2OWIzZjZlNWZlOGM2ODBkOWFfNS0xLTEtMS0xMzA3ODM_38d32cf7-c5de-4dc3-af2d-44b6abe69971">&#8212;</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib140873ca1da43bab9fd62b4810057e8_D20220101-20220331" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOmY4ZGQxYmFlNTA1YjQ2NjliM2Y2ZTVmZThjNjgwZDlhL3RhYmxlcmFuZ2U6ZjhkZDFiYWU1MDViNDY2OWIzZjZlNWZlOGM2ODBkOWFfNS0zLTEtMS0xMzA3ODM_5f0f5c4b-ac19-467c-94c4-8ac372d27546">&#8212;</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfOTE2Ng_de5e4d2f-cf4e-49ac-a343-31d5d8bba438" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total stock-based compensation expense was as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"></td><td style="width:71.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.804%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6537e1d4905e4ed2b36a8e22e7ed2fde_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjFlY2QyNDg3NzJiNDRjNWM5ZjBkMWMxNmIyNGE4NDA1L3RhYmxlcmFuZ2U6MWVjZDI0ODc3MmI0NGM1YzlmMGQxYzE2YjI0YTg0MDVfMi0xLTEtMS0xMzA3ODM_3088c69b-287f-41aa-bc6e-cb50926ab0a6">3,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba81969c6f8347389b8d4c2ac513fd4e_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjFlY2QyNDg3NzJiNDRjNWM5ZjBkMWMxNmIyNGE4NDA1L3RhYmxlcmFuZ2U6MWVjZDI0ODc3MmI0NGM1YzlmMGQxYzE2YjI0YTg0MDVfMi0zLTEtMS0xMzA3ODM_0f79cb6d-d920-4f74-8b5e-cb67df1efeaa">458</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f71e36b64d04c6589346f18f9cf047d_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjFlY2QyNDg3NzJiNDRjNWM5ZjBkMWMxNmIyNGE4NDA1L3RhYmxlcmFuZ2U6MWVjZDI0ODc3MmI0NGM1YzlmMGQxYzE2YjI0YTg0MDVfMy0xLTEtMS0xMzA3ODM_f30496bf-db5c-4353-b66f-8a0bf11d8ff9">524</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dfd433797ae4a47a3afcd51ca0bd98b_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjFlY2QyNDg3NzJiNDRjNWM5ZjBkMWMxNmIyNGE4NDA1L3RhYmxlcmFuZ2U6MWVjZDI0ODc3MmI0NGM1YzlmMGQxYzE2YjI0YTg0MDVfMy0zLTEtMS0xMzA3ODM_6faba0a6-aeff-499a-9a8f-83a1e95b24cf">203</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjFlY2QyNDg3NzJiNDRjNWM5ZjBkMWMxNmIyNGE4NDA1L3RhYmxlcmFuZ2U6MWVjZDI0ODc3MmI0NGM1YzlmMGQxYzE2YjI0YTg0MDVfNC0xLTEtMS0xMzA3ODM_b7a1923e-378a-4453-bac4-41b32a41655f">3,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjFlY2QyNDg3NzJiNDRjNWM5ZjBkMWMxNmIyNGE4NDA1L3RhYmxlcmFuZ2U6MWVjZDI0ODc3MmI0NGM1YzlmMGQxYzE2YjI0YTg0MDVfNC0zLTEtMS0xMzA3ODM_97fd6b2f-dcdf-4296-a232-b50ace9aa44a">661</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div id="id08c0d7bd703495d970d203330d59b2f_64"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82NC9mcmFnOjcwNzExMGY2MDg4YzQyYTM4MGU0Y2QyNWQ2ZmI1ZTQ0L3RleHRyZWdpb246NzA3MTEwZjYwODhjNDJhMzgwZTRjZDI1ZDZmYjVlNDRfNzgy_c680e620-82f7-43f5-b33d-0cfb0b002f37" continuedAt="ic5940ca9ce314865b4afc1eaa261dcc0" escape="true">Income Tax</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ic5940ca9ce314865b4afc1eaa261dcc0"><ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82NC9mcmFnOjcwNzExMGY2MDg4YzQyYTM4MGU0Y2QyNWQ2ZmI1ZTQ0L3RleHRyZWdpb246NzA3MTEwZjYwODhjNDJhMzgwZTRjZDI1ZDZmYjVlNDRfMjA_04184775-3b03-407c-a270-cc2a076f2a38"><ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="INF" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82NC9mcmFnOjcwNzExMGY2MDg4YzQyYTM4MGU0Y2QyNWQ2ZmI1ZTQ0L3RleHRyZWdpb246NzA3MTEwZjYwODhjNDJhMzgwZTRjZDI1ZDZmYjVlNDRfMjA_c4783ebe-93fd-41b6-bd38-55f3b06dacbf">No</ix:nonFraction></ix:nonFraction> provision for income taxes was recorded for the three months ended March 31, 2023 and 2022, respectively. Deferred tax assets generated from the Company&#8217;s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized due to the Company&#8217;s cumulative losses generated to date.</ix:continuation></span></div><div id="id08c0d7bd703495d970d203330d59b2f_67"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RleHRyZWdpb246MmE4ZGIxOTFhMzcwNDFiNWE0N2Q2ZDc5ZjNlYmFmOWJfNDQ0_f739ce78-b853-4615-8700-8d300d8b7e42" continuedAt="i13680a8fdc4e4d13ab014afd84ff7f77" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><ix:continuation id="i13680a8fdc4e4d13ab014afd84ff7f77" continuedAt="ied49d208b33d4b05a9e992eecd0a021d"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RleHRyZWdpb246MmE4ZGIxOTFhMzcwNDFiNWE0N2Q2ZDc5ZjNlYmFmOWJfNDQ1_13b298af-8c69-4720-8f65-43ccecf5f6eb" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of net loss available to common stockholders and the number of shares in the calculation of basic and diluted loss per share is as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"></td><td style="width:67.760%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.827%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.829%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfMi0yLTEtMS0xMzA3ODM_e284c972-3a52-45e7-bc8f-7f616648fce8">18,722</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfMi00LTEtMS0xMzA3ODM_9fe71981-c9f0-487d-a2f8-cbfddc208d70">11,808</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in computing net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfNC0yLTEtMS0xMzA3ODM_229eac0d-2652-4932-907a-a70fb7651127"><ix:nonFraction unitRef="shares" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfNC0yLTEtMS0xMzA3ODM_d3f1bd7b-6c53-45fe-9d24-2b766edf6be8">44,070,974</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfNC00LTEtMS0xMzA3ODM_2f184849-e80c-4509-9b60-f894e04b226c"><ix:nonFraction unitRef="shares" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfNC00LTEtMS0xMzA3ODM_5a8fa117-bfed-4cf8-b2e1-cad78032bfd8">3,171,254</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfNS0yLTEtMS0xMzA3ODM_5192c1a8-3411-4d4d-a482-c378af344cf2"><ix:nonFraction unitRef="usdPerShare" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfNS0yLTEtMS0xMzA3ODM_d65c3847-0461-4227-a032-9dcff39af108">0.42</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfNS00LTEtMS0xMzA3ODM_4f6f224c-b669-4f1f-a11d-d037c0646838"><ix:nonFraction unitRef="usdPerShare" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfNS00LTEtMS0xMzA3ODM_b1e08cc9-3641-4a68-afc4-7efa366023cf">3.72</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><ix:continuation id="ied49d208b33d4b05a9e992eecd0a021d"><ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RleHRyZWdpb246MmE4ZGIxOTFhMzcwNDFiNWE0N2Q2ZDc5ZjNlYmFmOWJfNDQ2_0274fc40-8037-4cdd-bca4-cac6f471c5d7" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following potential common stock securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive (on an as-converted basis):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A and B redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie599948bb538493ca54ae5c945c4b314_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfMi0xLTEtMS0xMzA3ODM_4b76a9e6-4a83-4546-8bf8-7b95c15e88c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if2546b82138745239b77f03d5bb97902_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfMi0zLTEtMS0xMzA3ODM_9aa381f0-242c-49c9-9f10-3de38fe5200a">19,517,988</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i8ce095b293ee421697f3e146ad0f8453_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfMy0xLTEtMS0xMzA3ODM_913c65b2-8402-436e-8e77-c78940baed75">11,792,908</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia1ba20d9c2a54249ad151ad0d937ed15_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfMy0zLTEtMS0xMzA3ODM_b9c1972a-ee86-49df-add0-72e0acf534df">1,814,742</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested early exercised options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic1c8a87aa2e340119590adac4cec8f56_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfNC0xLTEtMS0xMzA3ODM_e7d87177-8313-4b42-9a2a-23b62a026d81">92,840</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9531c149469c43a9ac1f3916d2cb652f_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfNC0zLTEtMS0xMzA3ODM_a99309a8-7541-4fbc-9f90-551078c22960">329,850</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c36144fc5464645b44250cb81efdb06_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfNS0xLTEtMS0xNDAyNDM_f63f9288-ab86-442f-8126-a1412f26181b">388,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7307cc0c5600489eb471edc1bd0b09e3_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfNS0zLTEtMS0xNDAyNDM_066ff632-10d6-4a02-8b25-6b17a16c4dce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earnout common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i45a6fb8c66694eb9a022dbc503607f1c_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfNS0xLTEtMS0xMzA3ODM_a5c7a589-bffb-4dee-9592-aa43a08e5b4c">2,000,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i162569ca541746a58397f1201089485e_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfNS0zLTEtMS0xMzA3ODM_ca83d7fd-d226-4dbb-ab2a-bf4e6339fb85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfNi0xLTEtMS0xMzA3ODM_4a25e8ec-e44a-493b-89ec-29b84c55c1e4">14,274,070</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331" decimals="0" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfNi0zLTEtMS0xMzA3ODM_7808bd88-74e2-4424-a182-68477aa08d7a">21,662,580</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="id08c0d7bd703495d970d203330d59b2f_70"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfNDAxNg_3005a833-697b-4e97-b8f8-971f7823000b" continuedAt="i4185746334a6487e8ce1ae838954d58b" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="i4185746334a6487e8ce1ae838954d58b" continuedAt="ie1baa19d3ca143a18f2f6b7b006663e1"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the ordinary course of business, the Company enters into contractual agreements with third parties that include non-cancelable payment obligations, for which the Company is liable in future periods. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 3, 2021, the Company entered into a lease agreement for a new cGMP facility in Alameda, California to support planned initial clinical trials for our product candidates. Refer to Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Operating Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, for further details of the leases. The lease will expire in 2032 with future undiscounted operating lease payments of $<ix:nonFraction unitRef="usd" contextRef="i43648233679b4319915d781e0fdea7bf_I20210603" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfNTU3_89f48965-2fce-43bf-9518-015e6000df3e">46.0</ix:nonFraction> million over an initial lease period of <ix:nonNumeric contextRef="i43648233679b4319915d781e0fdea7bf_I20210603" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfNTky_7720cbf6-d5b8-41f7-a200-5d00ad2f3694">eleven years</ix:nonNumeric>.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2021, the Company began construction of the cGMP facility. As of March&#160;31, 2023 the Company paid $<ix:nonFraction unitRef="usd" contextRef="i082b5a0a6bc54f70b3e73ff4d25c3e03_D20230101-20230331" decimals="-5" name="us-gaap:PaymentsForConstructionInProcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfNjg0_0b54346b-761e-4de2-8141-24ebf2750c79">37.5</ix:nonFraction> million in construction costs of the $<ix:nonFraction unitRef="usd" contextRef="i082b5a0a6bc54f70b3e73ff4d25c3e03_D20230101-20230331" decimals="-5" name="us-gaap:LongTermPurchaseCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfNzE2_b182a72a-9eb4-4d20-847b-8571612a91df">42.2</ix:nonFraction> million purchase commitment. The agreements with the construction company provide for termination following a certain period after notice. Upon termination, the Company will be responsible for payment for work performed to date. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2021, the Company entered into a <ix:nonNumeric contextRef="i591e3e2787ef4aa3b0dde7a4158d5d4e_D20210521-20210521" name="snti:ResearchAndDevelopmentExpenseTermOfAgreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfNDAxNA_6039d384-1978-4030-b2f2-f88a538834a3">three-year</ix:nonNumeric> collaboration and option agreement with BlueRock Therapeutics LP (&#8220;BlueRock&#8221;) under which the Company granted BlueRock an option to acquire an exclusive or non-exclusive license to develop, manufacture and commercialize cell therapy products. Refer to Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Related Parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, for further details of the related parties. In consideration for the option, the Company is responsible for up to $<ix:nonFraction unitRef="usd" contextRef="i9ddb97ef409844f1b6d57e39963c1d3d_I20210521" decimals="-3" name="snti:ResearchAndDevelopmentArrangementExpectedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfMTM3Nw_ce65cafd-7645-445d-9e2d-afcefe083d41">10.0</ix:nonFraction> million in costs and expenses incurred over the <ix:nonNumeric contextRef="i591e3e2787ef4aa3b0dde7a4158d5d4e_D20210521-20210521" name="snti:ResearchAndDevelopmentExpenseTermOfAgreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfNDAxNQ_1d157912-003a-4f50-b5de-c2c989c4d079">three-year</ix:nonNumeric> term.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, purchase commitments related to sponsored research agreements amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="id747b950a62d4ac19aee5dcc6cf15399_D20230101-20230331" decimals="-5" name="us-gaap:LongTermPurchaseCommitmentAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfMTUzMg_890489d4-650f-43d0-aef4-977e89ff178a">0.8</ix:nonFraction> million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into license agreements under which they are obligated to make annual maintenance payments of $<ix:nonFraction unitRef="usd" contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" decimals="-5" name="snti:CollaborativeArrangementRightsAndObligationsContractualAnnualPayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfMTY1NA_ea9bad2a-7b4c-4484-a257-93ea299798a4">0.1</ix:nonFraction> million and specified milestone and royalty payments. Future milestone and royalty payments under these agreements are not considered contractual obligations since the payments under these agreements are contingent upon future events, such as the Company&#8217;s achievement of specified development, regulatory, and sales milestones, or generating product sales. As of March&#160;31, 2023, the Company is unable to estimate the timing or likelihood of achieving these milestones or generating future product sales.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the Closing, former holders of Legacy Senti common stock and preferred stock may receive up to <ix:nonFraction unitRef="shares" contextRef="i2cf3659743e3408a95f042ce0308c736_D20220608-20220608" decimals="INF" name="snti:ReverseRecapitalizationContingentConsiderationEquityShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfMjI0Nw_7bd49395-58cb-4457-8c3f-64ec7d2dd357">2,000,000</ix:nonFraction> additional shares of the Company&#8217;s common stock in the aggregate, in <ix:nonFraction unitRef="tranche" contextRef="ic402157e4d8841ffabfdea65ced1a7b6_I20220608" decimals="INF" name="snti:ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfMjc0ODc3OTA3MzU0NQ_eb8229b2-302b-473e-931a-59b2f57131dd">two</ix:nonFraction> equal tranches of <ix:nonFraction unitRef="shares" contextRef="i2cf3659743e3408a95f042ce0308c736_D20220608-20220608" decimals="INF" name="snti:ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfMjM0MA_d07f892f-81b1-48e5-9d7a-d320d8af9553">1,000,000</ix:nonFraction> shares of common stock per tranche. Refer to Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Stockholders&#8217; Equity (Deficit),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for further details of the contingent earnout liability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is subject to claims and assessments from time to time in the ordinary course of business but does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows.</span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"><ix:continuation id="ie1baa19d3ca143a18f2f6b7b006663e1" continuedAt="i6e9cfdf6d76e49f780d46698097d3f52">Indemnification</ix:continuation></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i6e9cfdf6d76e49f780d46698097d3f52">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions and has never accrued any liabilities related to such obligations in its condensed consolidated financial statements. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#8217; and officers&#8217; insurance.</ix:continuation> </span></div><div id="id08c0d7bd703495d970d203330d59b2f_73"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfNDM0Nw_9c799759-83cb-4fed-9f59-7cdaaa504aff" continuedAt="i1a8b8d1c97474a23a11496bd2ee3885c" escape="true">Related Parties</ix:nonNumeric></span></div><ix:continuation id="i1a8b8d1c97474a23a11496bd2ee3885c" continuedAt="ib1c658a5c5c247829580fe72f38aef04"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NEA</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NEA held <ix:nonFraction unitRef="shares" contextRef="i5f79f3be18db4668bcb3b5370e9cecd3_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMTI5OQ_3eb9fb80-37c9-461b-821a-e68964fce6ef">4,429,725</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7c26ec28b64d45bc9036cc8d57f2140b_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfNjU5NzA2OTc3MTUwMw_4cc6a4cc-426b-4cd5-ac94-2a957a9d856f">4,429,725</ix:nonFraction> shares, respectively, of common stock as of March&#160;31, 2023 and December&#160;31, 2022, respectively. NEA held <ix:nonFraction unitRef="tradingday" contextRef="i7c26ec28b64d45bc9036cc8d57f2140b_I20221231" decimals="INF" name="snti:NumberOfSeatsOnTheBoardOfDirectors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMTU5OA_341338dd-5da7-4d9b-8cc6-c851026b9b88"><ix:nonFraction unitRef="tradingday" contextRef="i5f79f3be18db4668bcb3b5370e9cecd3_I20230331" decimals="INF" name="snti:NumberOfSeatsOnTheBoardOfDirectors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMTU5OA_a29f9903-81fe-4be7-8033-14746dbeb121">one</ix:nonFraction></ix:nonFraction> of the <ix:nonFraction unitRef="tradingday" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="snti:NumberOfSeatsOnTheBoardOfDirectors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMTYwOA_cb536151-3fc3-4ab3-88d3-686f2d120523"><ix:nonFraction unitRef="tradingday" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="snti:NumberOfSeatsOnTheBoardOfDirectors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMTYwOA_f3146a5c-9017-4f01-a8c7-0d1e7b8ebd91">seven</ix:nonFraction></ix:nonFraction> seats on the Company&#8217;s Board of Directors as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer Healthcare LLC</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 19, 2022, Legacy Senti issued to Bayer a $<ix:nonFraction unitRef="usd" contextRef="i1f7c274bcbdf4ef58b92b5848babde15_I20220519" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMTczOQ_9a74abd2-2b14-403f-8cd7-c8aa4ee33354">5.2</ix:nonFraction>&#160;million unsecured convertible promissory note. On June 8, 2022, the May 2022 Note was automatically cancelled and exchanged for <ix:nonFraction unitRef="shares" contextRef="ib7a73372076e4e89a384e72fe0e3c45e_D20220608-20220608" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMTg2Mg_91d8cc98-8b27-45ac-923d-fdf1e048deab">517,500</ix:nonFraction> shares of Class A Common Stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i057310d2a92b4448be2ea0e4a9991828_I20220608" decimals="2" name="us-gaap:SharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMTkxMA_6801a393-009b-4aea-a3df-1c6e3505035c">10.00</ix:nonFraction> per share.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 21, 2021, the Company entered into a collaboration and option agreement (&#8220;BlueRock Agreement&#8221;) with BlueRock, a wholly-owned subsidiary of Bayer, pursuant to which the Company granted to BlueRock an option (&#8220;BlueRock Option&#8221;), on a collaboration program-by-collaboration program basis, to obtain an exclusive or non-exclusive license to develop, manufacture and commercialize cell therapy products that contain cells of specified types and which incorporate an option gene circuit from such collaboration program or a closely related derivative gene circuit. The Company is responsible for up to $<ix:nonFraction unitRef="usd" contextRef="i9ddb97ef409844f1b6d57e39963c1d3d_I20210521" decimals="-3" name="snti:ResearchAndDevelopmentArrangementExpectedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMjYzNw_a469580a-4d44-4608-9c2f-50d25950bc81">10</ix:nonFraction> million in costs and expenses incurred in connection with the research plan and related activities to be conducted over a term of <ix:nonNumeric contextRef="i591e3e2787ef4aa3b0dde7a4158d5d4e_D20210521-20210521" name="snti:ResearchAndDevelopmentExpenseTermOfAgreement" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMjc2Mg_be1fb0af-682a-4663-a2f7-068f7f18b0ab">three years</ix:nonNumeric> as specified in the collaboration and option agreement. If the Company and BlueRock agree to add new research activities to the research plan, then BlueRock will be obligated to reimburse the Company for the costs and expenses incurred that, together with costs and expenses incurred under the initial research plan, exceed $<ix:nonFraction unitRef="usd" contextRef="i9ddb97ef409844f1b6d57e39963c1d3d_I20210521" decimals="-3" name="snti:ResearchAndDevelopmentArrangementExpectedCosts" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMzA4OQ_a469580a-4d44-4608-9c2f-50d25950bc81">10</ix:nonFraction> million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company concluded that the Agreement is not within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, because the Company did not receive any consideration and therefore, is not exposed to both significant risks and rewards for the arrangement. The Company also determined that the agreement is also not currently within the scope of ASC 606 because the BlueRock Agreement does not currently meet the criteria of a contract with a customer, and will not be within the scope of ASC 606 until any consideration is paid. Potential future milestone payments and royalties are subject to BlueRock&#8217;s exercise of the BlueRock Option and execution of a commercial license agreement by both parties. Under the BlueRock Agreement, the specific financial terms for milestone payments and royalties will be negotiated and agreed to only after the option is exercised. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023 and December&#160;31, 2022, Bayer held <ix:nonFraction unitRef="shares" contextRef="ie37202655afe400799f589b98e2e9296_I20230331" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMzk3NA_3cbe7986-8067-422a-98ef-22e29e23a9a9">5,878,488</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i1fc3f895e15c4c5e96890aa6215ca746_I20221231" decimals="INF" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfNjU5NzA2OTc3MTY5OA_64ed8f40-790c-45c3-bb69-f9bd9a75d512">5,878,488</ix:nonFraction> shares, respectively, of the Company&#8217;s common stock. As of March&#160;31, 2023 and December&#160;31, 2022, Bayer held <ix:nonFraction unitRef="tradingday" contextRef="ie37202655afe400799f589b98e2e9296_I20230331" decimals="INF" name="snti:NumberOfSeatsOnTheBoardOfDirectors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfNDEwNg_835898bb-ec3e-4f7c-bea3-c5d76ad31887"><ix:nonFraction unitRef="tradingday" contextRef="i1fc3f895e15c4c5e96890aa6215ca746_I20221231" decimals="INF" name="snti:NumberOfSeatsOnTheBoardOfDirectors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfNDEwNg_bfd1ea42-e1a5-46da-86ea-87a26084f726">one</ix:nonFraction></ix:nonFraction> of the <ix:nonFraction unitRef="tradingday" contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231" decimals="INF" name="snti:NumberOfSeatsOnTheBoardOfDirectors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfNDExNg_30818b7f-95c2-4dee-b927-15c0503af23f"><ix:nonFraction unitRef="tradingday" contextRef="i2db00a77192f4255a898540eac49878e_I20230331" decimals="INF" name="snti:NumberOfSeatsOnTheBoardOfDirectors" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfNDExNg_5d17851e-f1d2-4ba6-bb18-8e0aa55cf7cd">seven</ix:nonFraction></ix:nonFraction> seats on the Board of Directors of the Company. Bayer&#8217;s parent company is Bayer AG, which served as the lead investor in our Series B financing through its Leaps by Bayer unit. Accordingly, Bayer is considered a related party.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Seer, Inc.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2023, the Company received lab automation equipment purchased from Seer, Inc. (&#8220;Seer&#8221;) (NASDAQ: SEER). Omid Farokhzad, a member of the Company&#8217;s board of directors is the Chief Executive Officer </span></div></ix:continuation><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SENTI BIOSCIENCES, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Notes to Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">(unaudited)</span></div><div style="margin-bottom:9pt;text-align:center"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="ib1c658a5c5c247829580fe72f38aef04">for Seer. The consideration of $<ix:nonFraction unitRef="usd" contextRef="ib8899c630b094438a9d71777a8d3774a_D20230101-20230131" decimals="-3" name="us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMjc0ODc3OTA3ODUxMQ_04c71340-77e7-42ae-9e3e-c251df567a50">200,000</ix:nonFraction>, plus interest, will be paid over a <ix:nonNumeric contextRef="ib8899c630b094438a9d71777a8d3774a_D20230101-20230131" name="snti:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMjc0ODc3OTA3ODUyOQ_e14f67e0-4c53-461f-a462-0830d4a6a0c7">two-year</ix:nonNumeric> period, and title will transfer to the Company upon final payment. The transaction was classified as a finance lease</ix:continuation> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div id="id08c0d7bd703495d970d203330d59b2f_76"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331" name="us-gaap:SubsequentEventsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83Ni9mcmFnOmE4ZmJiMTg3MWI3NjRkNGNiYmZiMmEyYThlNGY1MmI0L3RleHRyZWdpb246YThmYmIxODcxYjc2NGQ0Y2JiZmIyYTJhOGU0ZjUyYjRfMjk2_07bbabab-cc54-4661-8a97-4cf4657baca5" continuedAt="i1eb10413d5ac4ea78b476e04e0a2ba07" escape="true">Subsequent Events</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:continuation id="i1eb10413d5ac4ea78b476e04e0a2ba07">On April 26, 2023, Mr. David R. Epstein, informed the board of directors (the &#8220;Board&#8221;) of the Company of his intention to resign as a director, effective as of the close of business on June 16, 2023. Mr. Epstein has resigned in order to minimize potential conflict or the appearance of conflict with his role as Chief Executive Officer of Seagen, Inc. (an oncology company) rather than because of any disagreement relating to any of Senti&#8217;s operations, policies or practices.</ix:continuation></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21</span></div></div></div><div id="id08c0d7bd703495d970d203330d59b2f_79"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Senti Biosciences, Inc. (&#8220;Senti&#8221;) entered into a business combination agreement (the &#8220;Agreement&#8221;) with Dynamics Special Purpose Corp. (&#8220;DYNS&#8221;) on December 19, 2021. The transactions contemplated by the terms of the Agreement were completed on June 8, 2022 (the &#8220;Closing&#8221;), in conjunction with which DYNS changed its name to Senti Biosciences, Inc. (hereafter referred to, collectively with its subsidiaries, as &#8220;Senti&#8221;, the &#8220;Company&#8221;, &#8220;we&#8221;, &#8220;us&#8221; or &#8220;our&#8221;, unless the context otherwise requires). The transactions contemplated in the Agreement are collectively referred to as the &#8220;Merger&#8221;.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes included under Part I, Item 1 of this Quarterly Report on Form 10-Q (this &#8220;Quarterly Report&#8221;) as well as Senti&#8217;s audited consolidated financial statements and notes thereto included in the Annual Report on Form 10-K for the year ended December 31, 2022 (the &#8220;Annual Report&#8221;) and filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March&#160;22, 2023.Certain information contained in the discussion and analysis set forth below includes forward-looking statements that involve risks and uncertainties.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Cautionary Statement Regarding Forward-Looking Statements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">This Quarterly Report includes &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act that are not historical facts and involve risks and uncertainties that could cause actual results to differ materially from those expected and projected. All statements, other than statements of historical fact included in this Form 10&#8209;Q including, without limitation, statements in this &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; regarding the Company&#8217;s financial position, business strategy and the plans and objectives of management for future operations, are forward-looking statements. Words such as &#8220;expect,&#8221; &#8220;believe,&#8221; &#8220;anticipate,&#8221; &#8220;explore,&#8221; &#8220;intend,&#8221; &#8220;estimate,&#8221; &#8220;seek&#8221; and variations and similar words and expressions are intended to identify such forward-looking statements. Such forward-looking statements relate to future events or future performance, but reflect management&#8217;s current beliefs, based on information currently available. A number of factors could cause actual events, performance or results to differ materially from the events, performance and results discussed in the forward-looking statements. For information identifying important factors that could cause actual results to differ materially from those anticipated in the forward-looking statements, please refer to the Risk Factors section of the Annual Report and Part II, Item 1A of this Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;). The Company&#8217;s securities filings can be accessed on the EDGAR section of the SEC&#8217;s website at www.sec.gov. Except as expressly required by applicable securities law, the Company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.</span></div><div id="id08c0d7bd703495d970d203330d59b2f_82"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Senti is a preclinical biotechnology company developing next-generation cell and gene therapies engineered with its gene circuit platform technologies to fight challenging diseases. Senti&#8217;s mission is to create a new generation of smarter therapies that can outmaneuver complex diseases in ways previously not implemented by conventional medicines. To accomplish this mission, Senti has built a synthetic biology platform that it believes may enable it to program next-generation cell and gene therapies with what it refers to as &#8220;gene circuits.&#8221; These gene circuits, which Senti created from novel and proprietary combinations of genetic parts, are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their respective cellular environments. Senti&#8217;s gene circuit platform technologies can be applied in a modality-agnostic manner, with applicability to natural killer (NK) cells, T cells, tumor-infiltrating lymphocytes (&#8220;TILs&#8221;), stem cells including Hematopoietic Stem Cells (&#8220;HSCs&#8221;), </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">in vivo</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> gene therapy and messenger ribonucleic acid (mRNA). All of Senti&#8217;s current product candidates are in preclinical development. Senti&#8217;s lead product candidates utilize allogeneic chimeric antigen receptor (&#8220;CAR&#8221;) NK cells outfitted with its gene circuit technologies in several oncology indications with currently high unmet needs. Senti expects to file investigational new drug applications (&#8220;INDs&#8221;) for multiple product candidates starting in&#160;2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have incurred net losses of $18.7 million and $11.8 million for the three months ended March 31, 2023 and 2022, respectively. As of March&#160;31, 2023 and December&#160;31, 2022, we had cash, cash equivalents and short-term investments of $76.1 million and $98.6 million, respectively, and an accumulated deficit of $192.0 million and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$173.3 million, respectively. Net cash flows used in operating activities were $16.3 million and $10.1 million during the three months ended March 31, 2023 and 2022, respectively. Substantially all of our net losses resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations. We expect to continue to incur significant losses for the foreseeable future.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We anticipate that our expenses and operating losses will increase substantially over the foreseeable future. The expected increase in expenses will be driven in large part by our ongoing activities, if and as we:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to advance our gene circuit platform technologies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue preclinical development of our current and future product candidates and initiate additional preclinical studies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">commence clinical studies of our current and future product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establish our manufacturing capability, including developing our contract development and manufacturing relationships, and building our internal manufacturing facilities;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acquire and license technologies aligned with our gene circuit platform technologies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek regulatory approval of our current and future product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand our operational, financial, and management systems and increase personnel, including personnel to support our preclinical and clinical development, manufacturing and commercialization efforts;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue to develop, grow, maintain, enforce and defend our intellectual property portfolio; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">incur additional legal, accounting, or other expenses in operating our business, including the additional costs associated with operating as a public company.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, in 2021, we began construction on a dedicated in-house, state-of-the-art current good manufacturing practices &#8220;cGMP&#8221; facility to support clinical and commercial-scale production of multiple allogeneic NK cell product candidates. We anticipate that this facility will become operational in time to support initial clinical trials for our lead product candidates. Our manufacturing facility is designed to leverage the latest cell therapy process technologies as we strive to maximize scalability and minimize cost of goods.</span></div><div id="id08c0d7bd703495d970d203330d59b2f_85"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Developments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2023, we announced a strategic plan to focus internal resources on SENTI-202, SENTI-401 and, with potential partners, to continue to pursue the development of gene circuits for other programs, including solid tumors. We do not intend to invest in the clinical development of SENTI-301A, for the treatment of hepatocellular carcinoma (&#8220;HCC&#8221;), on our own at this time; however, we believe there is significant market opportunity for SENTI-301A, especially in territories within Asia where HCC is more prevalent than in the United States. Accordingly, we are actively pursuing strategic geographic partnerships for clinical development of SENTI-301A. This business realignment is intended to streamline internal efforts and is expected to extend our cash runway through at least the first quarter of 2024.</span></div><div id="id08c0d7bd703495d970d203330d59b2f_88"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Components of Results of Operations </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Total Revenue </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently have no therapeutic products approved for sale, and we have never generated any revenue from the sale of any therapeutic products. Total revenue consists of contract revenue related to research services provided to customers and grant income which is research funding received from grants. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our ability to generate product revenues will depend on our partners&#8217; ability to replicate our results and the successful development and eventual commercialization of our product candidates, which we do not expect for the foreseeable future, if ever. We may also look to generate revenue from collaboration and license agreements in the future.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Expenses </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses consist of research and development expenses and general and administrative expenses.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development Expenses</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development costs consist primarily of costs incurred for the discovery and preclinical development of our product candidates, which include: </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee-related expenses, including salaries, related benefits, and stock-based compensation expenses for employees engaged in research and development functions; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred in connection with research, laboratory consumables and preclinical studies;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of consultants engaged in research and development related services and the cost to manufacture drug products for use in our preclinical studies and trials; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facilities, depreciation and other expenses, which include allocated expenses for rent and maintenance of facilities, insurance and supplies; </span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs related to regulatory compliance; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of annual license fees. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have not historically tracked research and development expenses by program, with the exception of third-party research projects. We have various ongoing early-stage research and product candidate discovery projects and going forward, we expect to have various products undergoing clinical trials. Our internal resources, employees and infrastructure are not directly tied to any one research or product candidate discovery project and are typically deployed across multiple projects. As such, we do not maintain information regarding these costs incurred for these early-stage research and product candidate discovery programs on a project-specific basis. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our direct external development program expenses reflect external costs attributable to our preclinical development candidates selected for further development as well as investigational new drug applications (&#8220;INDs&#8221;) and clinical development. Such expenses include third-party contract costs relating to manufacturing, clinical trial activities, translational medicine and toxicology activities. We do not allocate internal research and development costs which include personnel, facility costs, laboratory consumables and discovery and research related activities associated with our pipeline because these costs are deployed across multiple programs and our platform, and, as such, are not separately classified.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses, including share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,808&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External services and supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,886&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,593&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,318&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,603&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Research and development activities are central to our business model. There are numerous factors associated with the successful commercialization of any of our product candidates, including future trial design and various regulatory requirements, many of which cannot be determined with accuracy at this time based on our stage of development. In addition, future regulatory factors beyond our control may impact our preclinical development programs. Product candidates in clinical development generally have higher development costs than those in preclinical stages of development, primarily due to the increased size and duration of clinical trials. At this time, we cannot reasonably estimate or know the nature, timing and costs of the efforts that will be necessary to complete the preclinical development of any of our product candidates. However, we expect that our research and development </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">expenses and manufacturing costs will increase substantially in connection with our planned preclinical and clinical development activities in the near term and in the future. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The successful development of our current and future product candidates is highly uncertain. This is due to numerous risks and uncertainties, including the following:</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">negative or inconclusive results from our preclinical studies or clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical studies or clinical trials or abandon any or all of our programs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product-related side effects experienced by participants in our clinical trials or by individuals using therapeutics similar to our product candidates;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in submitting IND applications or comparable foreign applications, or delays or failures to obtain the necessary approvals from regulators to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conditions imposed by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) or other regulatory authorities regarding the scope or design of our clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays in enrolling research subjects in clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">high drop-out rates of research subjects;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Chemistry, manufacturing and control (&#8220;CMC&#8221;) challenges associated with manufacturing and scaling up biologic product candidates to ensure consistent quality, stability, purity and potency among different batches used in clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">greater-than-anticipated clinical trial costs;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">poor potency or effectiveness of our product candidates during clinical trials;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unfavorable FDA or other regulatory authority inspection and review of a clinical trial or manufacturing site;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays as a result of the COVID-19 pandemic or events associated with the pandemic;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</span></div><div style="margin-bottom:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delays and changes in regulatory requirements, policies and guidelines; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA or other regulatory authorities interpret our data differently than we do.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A change in the outcome of any of these variables may significantly impact the costs and timing associated with the development of our product candidates. We may never succeed in obtaining regulatory approval for any of our product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General and Administrative Expenses </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses consist primarily of salaries and employee-related costs, including stock-based compensation, for personnel in executive, finance and other administrative functions. Other significant costs include legal fees relating to corporate matters, professional fees for accounting and consulting services and an allocation of facility-related costs. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">General and administrative expenses consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(unaudited)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel-related expenses, including share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,841&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">External services and supplies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">941&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Office and facilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Insurance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">505&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">381&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,802&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,259&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect our general and administrative expenses will increase for the foreseeable future to support our increased research and development, manufacturing activities, and preclinical and clinical activities and to reflect increased costs associated with operating as a public company. These increased costs will likely include increased expenses for audit, legal, regulatory, tax and related services associated with maintaining compliance with exchange listing and SEC requirements, director and officer insurance premiums and investor relations costs. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income (Expense)</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest Income, net </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Interest income, net consists of interest earned on our cash and cash equivalents, and short-term investments, if any, held during the year, net of interest expense.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Change in Fair Value of Contingent Earnout Liability</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The change in fair value of the contingent earnout liability that was accounted for as a liability as of the date of the Merger, and is remeasured to fair value at each reporting period, resulting in a non-cash gain or loss.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">26</span></div></div></div><div id="id08c0d7bd703495d970d203330d59b2f_91"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of the Three Months Ended March 31, 2023 and 2022</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes our results of operations for the three months ended March 31, 2023 and 2022 (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.265%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.806%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenue:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Grant income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,286&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">182&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,603&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,715&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,259&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,120&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,862&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,258&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss from operations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19,834)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,758)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,076)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,061&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,057&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent earnout liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(54)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,112&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(50)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,162&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,722)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,808)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,914)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Contract revenue</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.&#160;For the three months ended March 31, 2023 and 2022, we generated revenue from contracts and license agreements of $1.0 million and $0.9 million, respectively. The increase of $0.2 million was primarily due to increased services provided for collaboration agreements.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Grant income</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.&#160;For the three months ended March 31, 2023 and 2022, we generated revenue from grants of $0.3&#160;million and $0.3&#160;million, respectively, from the SBIR SENTI-202 grant funding.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Research and development expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Research and development expenses were $11.3&#160;million and $7.6&#160;million for the three months ended March 31, 2023 and 2022, respectively. The increase of $3.7&#160;million was primarily due to an increase of $2.0 million in personnel-related expenses, which includes a $0.3 million increase in stock-based compensation expense, an increase of $0.7 million in professional services costs and $0.8 million in facility costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">General and administrative expenses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.&#160;General and administrative expenses were $9.8&#160;million and $5.3&#160;million for the three months ended March 31, 2023 and 2022, respectively. The increase of $4.5&#160;million was primarily due to an increase of $3.3 million in personnel-related expenses, which includes a $2.8 million increase in stock-based compensation expense, an increase of $0.4 million in professional services costs, an increase in insurance of $0.5 million, and an increase of $0.2 million in facility costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interest income net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Interest income was $1.1&#160;million and nominal for the three months ended March 31, 2023 and 2022, respectively due to a higher cash balances as well as an increase in interest rates in the relevant periods.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Change in fair value of contingent earnout liability</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. For the three months ended March 31, 2023, the increase of $0.1 million resulted from a non-cash gain related to the remeasurement of the contingent earnout liability.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">27</span></div></div></div><div id="id08c0d7bd703495d970d203330d59b2f_94"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From inception to March&#160;31, 2023, we raised aggregate gross proceeds of $298.8 million from the Merger and PIPE Financing, the issuance of shares of our redeemable convertible preferred stock, the issuance of convertible notes and, to a less extent, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">through collaboration agreements and governmental grants.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 31, 2022, we entered into the Purchase Agreement with Chardan. Pursuant to the Purchase Agreement, we have the right, in our sole discretion, to sell to Chardan up to the lesser of: (i) $50.0 million of shares of our common stock; and (ii) 8,727,049 shares of common stock at 97% of the volume weighted average price (&#8220;VWAP&#8221;) of the common stock calculated in accordance with the Purchase Agreement, over a period of 36 months subject to certain limitations and conditions contained in the Purchase Agreement. Sales and timing of any sales of common stock are solely at our election, and we are under no obligation to sell any securities to Chardan under the Purchase Agreement. As consideration for Chardan&#8217;s commitment to purchase shares of our common stock at our direction upon the terms and subject to the conditions set forth in the Purchase Agreement, upon execution of the Purchase Agreement, we issued 100,000 shares of our common stock to Chardan and paid a $0.4 million document preparation fee. We recognized an expense of $0.7 million within general and administrative expenses in our Condensed Consolidated Statements of Operations and Comprehensive Loss for the Chardan related costs and legal fees incurred in connection with the agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other than the issuance of the commitment shares of the Company&#8217;s common stock to Chardan we issued 300,000 shares of common stock up until December&#160;31, 2022, aggregating to net proceeds of $0.7 million under the Purchase Agreement. There were no shares issued within three months ended March 31, 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not have any products approved for sale and have not generated any revenue from product sales or otherwise. We have incurred net losses and negative cash flows from operations since our inception and anticipate we will continue to incur net losses for the foreseeable future. As of March&#160;31, 2023, we had $76.1 million in cash, cash equivalents and short-term investments, and an accumulated deficit of $192.0 million, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will need substantial additional funding to support our continuing operations and pursue our development strategy. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our operations through the sale of equity, debt financings or other capital sources, including potential collaborations with other companies or other strategic transactions. Adequate funding may not be available to us on acceptable terms, if at all. Should we fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back, or discontinue the development and commercialization of our product candidates or delay our efforts to expand our product pipeline. We may also be required to sell or license to other parties rights to develop or commercialize our product candidates that we would prefer to retain.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table sets forth a summary of our cash flows for each of the periods indicated (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.810%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.803%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended<br/>March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;text-indent:-27pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash from operating activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,304)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,059)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash from investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9,497)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7,380)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash from financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(35)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(455)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25,836)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,894)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March 31, 2023, net cash used in operating activities of $16.3 million was primarily due to our loss of $18.7 million with non-cash adjustments of $3.8 million for stock-based compensation expense, $0.9 million for depreciation and amortization of operating lease right-of-use-assets and $0.6 million for accretion of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">discount on short-term investments. Other material changes comprised of $1.6 million decrease in accounts payable and accrued expenses and other current liabilities, $0.4&#160;million decrease in deferred revenue, $0.4&#160;million increase in prepaid expenses and other assets offset by $0.9&#160;million increase in operating lease liabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March 31, 2022, net cash used in operating activities of $10.1 million was primarily due to our net loss of $11.8 million with non-cash adjustments of $1.0 million for depreciation and amortization of operating lease right-of-use assets and $0.7 million for stock-based compensation expense, as well as a $1.6 million for a decrease in accounts payable and accrued expenses and other current liabilities and $0.5 million decrease in deferred revenue, offset by an increase of $2.4 million in operating lease liabilities and an increase of $0.4 million in prepaid expenses and other current assets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March 31, 2023, net cash used in investing activities of $9.5 million was due to $18.0 million purchases of short-term investments and $6.5 million purchases of property and equipment offset by $15.0 million cash received upon maturity of short-term investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March 31, 2022, net cash used in investing activities of $7.4 million, was entirely due to purchases of property and equipment.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March 31, 2023, $35 thousand cash was used by financing activities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March 31, 2022, net cash used in financing activities of $0.5 million was primarily due to $0.6 million payment of deferred transaction costs related to the Merger partially offset by $0.1 million proceeds from the issuance of common stock upon exercise of stock options.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based upon our current operating plans, we believe that our existing cash and cash equivalents will be sufficient to fund our operations for the next twelve months from the date of this Quarterly Report. We anticipate that we will continue to seek additional funding, though the precise timing of such may prove uncertain. Our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially. Our assumptions may prove to be inaccurate, and we could deplete our capital resources sooner than we expect. Additionally, the process of testing and manufacturing product candidates in preclinical studies and clinical trials is costly and the timing and expenses in these trials are uncertain.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our future capital requirements will depend on many factors, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope, rate of progress, results and costs of drug discovery, preclinical development, laboratory testing and clinical trials for our product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number and development requirements of product candidates that we may pursue, and other indications for our current product candidates that we may pursue;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the scope and costs of constructing and operating our planned cGMP facility and any commercial manufacturing activities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost associated with commercializing any approved product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost and timing of developing our ability to establish sales and marketing capabilities, if any;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of preparing, filing and prosecuting patent applications, maintaining, enforcing and protecting our intellectual property rights, defending intellectual property-related claims and obtaining licenses to third-party intellectual property;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing and amount of any milestone and royalty payments we are required to make under our present or future license agreements;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain collaborations on favorable terms, if at all; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the extent to which we acquire or in-license other product candidates and technologies and associated intellectual property.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to improve our liquidity, management is actively pursuing additional financing. We expect our expenses to increase substantially in connection with ongoing activities, particularly as we advance our preclinical activities and clinical trials for our product candidates in development. Accordingly, we will need to obtain substantial additional funding for continuing operations. If we are unable to raise capital when needed, or on attractive terms, we could be forced to delay, reduce or eliminate our research or drug development programs or any future commercialization efforts. Although management continues to pursue these plans, there is no assurance that we will be successful in obtaining sufficient funding on terms acceptable to us to fund continuing operations, if at all.</span></div><div id="id08c0d7bd703495d970d203330d59b2f_97"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations and Commitments </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 3, 2021, we entered into a lease agreement for a new cGMP facility in Alameda, California to support planned initial clinical trials for our product candidates. The lease will expire in 2032 with future undiscounted operating lease payments of $46.0 million over an initial lease period of eleven years. See Note 5 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Operating Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for details on our lease obligations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2021, we began construction of the cGMP facility. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, we have paid $37.5 million in construction costs of the $42.2 million purchase commitment. The agreements with the construction company provide for termination following a certain period after notice. Upon termination we will be responsible for payment for work performed to date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the year ended December 31, 2021, we entered into a three-year collaboration and option agreement with BlueRock Therapeutics LP (&#8220;BlueRock&#8221;) under which the Company granted BlueRock an option to execute an exclusive or non-exclusive license to develop, manufacture and commercialize cell therapy products (See Part I, Item 1, Notes to Condensed Consolidated Financial Statements (Unaudited), Note 12 - </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Related Parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for details into the BlueRock agreement). In consideration for the option, the Company is responsible for up to $10.0 million in research and development costs and expenses associated with the collaboration plan incurred over the three-year term.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have also entered into license agreements under which we are obligated to make annual maintenance payments of $0.1 million and specified milestone and royalty payments. Milestone and royalty payment obligations under these agreements are contingent upon future events, such as our achievement of specified development, regulatory, and sales milestones, or generating product sales. As of March&#160;31, 2023, we were unable to estimate the timing or likelihood of achieving these milestones or generating future product sales.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have entered into sponsored research agreements under which we are obligated to pay $0.6 million and $0.2 million in 2023 and 2024, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the closing of the Merger, former holders of Legacy Senti common stock and preferred stock may receive up to 2,000,000 additional shares of the Company&#8217;s common stock in the aggregate, in two equal tranches of 1,000,000 shares of common stock per tranche. Refer to Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Stockholders&#8217; Equity (Deficit),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for further details of the contingent earnout.</span></div><div id="id08c0d7bd703495d970d203330d59b2f_100"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the periods presented, we did not have, nor do we currently have, any off-balance sheet arrangements as defined under the rules and regulations of the SEC. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">30</span></div></div></div><div id="id08c0d7bd703495d970d203330d59b2f_103"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Significant Judgments and Estimates </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our management&#8217;s discussion and analysis of our financial condition and results of operations are based on our consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP. The preparation of these consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates and assumptions on historical experience, known trends and events, and various other factors that are believed to be reasonable and appropriate under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While our significant accounting policies are described in more detail in Note 2 to our condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q, we believe the following accounting policies and estimates to be most critical to the preparation of our consolidated financial statements. We define our critical accounting policies as those under U.S. GAAP that require us to make subjective estimates and judgments about matters that are inherently uncertain and are likely to have a material impact on our financial condition and results of operations, as well as the specific manner in which we apply those principles.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March 31, 2023, there have not been any other significant changes to our critical accounting policies and estimates from those presented in Part II, Item 7 of our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2022, that are of significance, or potential significance, to us.</span></div><div id="id08c0d7bd703495d970d203330d59b2f_106"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Emerging Growth Company Status</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Jumpstart Our Business Startups Act (&#8220;JOBS&#8221;) Act permits an emerging growth company to take advantage of an extended transition to comply with new or revised accounting standards applicable to public companies until those standards would otherwise apply to private companies. The Company is an &#8220;emerging growth company&#8221; as defined in Section 2(a) of the Securities Act, and has elected to not take advantage of the benefits of this extended transition period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to remain an emerging growth company until the earlier of: (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of the Dynamics Initial Public Offering (&#8220;IPO&#8221;) (which occurred on May 25, 2021), (b) in which we have total annual revenue of at least $1.235 billion, or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common equity that is held by non-affiliates exceeds $700 million as of the end of that fiscal year&#8217;s second fiscal quarter and our net sales for the year exceed $100 million; and (2) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the preceding, rolling three-year period.</span></div><div id="id08c0d7bd703495d970d203330d59b2f_109"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Smaller Reporting Company Status</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is a &#8220;smaller reporting company&#8221; as defined in Item 10(f)(1) of Regulation S-K. Smaller reporting companies may take advantage of certain reduced disclosure obligations, including, among other things, providing only two years of audited financial statements. We will remain a smaller reporting company if (1) the market value of our common stock held by non-affiliates is less than $250 million as of the last business day of the second fiscal quarter, or (2) our annual revenues in our most recent fiscal year completed before the last business day of our second fiscal quarter are less than $100 million and the market value of our common stock held by non-affiliates is less than $700 million as of the last business day of the second fiscal quarter.</span></div><div id="id08c0d7bd703495d970d203330d59b2f_112"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have one business activity and operate in one reportable segment.</span></div><div id="id08c0d7bd703495d970d203330d59b2f_115"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a &#8220;smaller reporting company,&#8221; we are not required to provide this information.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31</span></div></div></div><div id="id08c0d7bd703495d970d203330d59b2f_118"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to the Merger, we had been a private company with limited accounting personnel and other resources with which to address our internal control over financial reporting. In connection with our preparation and the audit of our consolidated financial statements as of and for the year ended December 31, 2021, we and our independent registered public accounting firm identified a material weakness, as defined under the Exchange Act and by the Public Company Accounting Oversight Board (United States), in our internal control over financial reporting. The material weakness related to a lack of sufficient and adequate resources in the finance and accounting function that resulted in a lack of formalized risk assessment process, lack of segregation of duties, and ineffective process level control activities over the management review of journal entries, account reconciliations and non-routine transactions. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have taken a number of remediation actions during the year ended December 31, 2022, and are continuing with our efforts. Remediation actions taken during the fiscal year ended December 31, 2022 and that continue include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">hiring personnel with appropriate levels of experience in accounting, technology, and internal controls;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">engaging a professional accounting services firm to help us commence the documentation and assessment of our internal controls for complying with the Sarbanes-Oxley Act;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">implementing a risk assessment over financial reporting controls; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">implementing new software tools.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While significant progress has been made to enhance our internal control over financial reporting, we are still in the process of building and enhancing our processes, procedures, and controls. Additional time is required to complete the remediation of these material weaknesses and the assessment to ensure the sustainability of these remediation actions. We believe the above actions, when complete, will be effective in the remediation of the material weaknesses described above.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the most recently completed fiscal quarter, there has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Limitations on Effectiveness of Controls and Procedures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives. In addition, the design of disclosure controls and procedures must reflect the fact that there are resource constraints and that management is required to apply judgment in evaluating the benefits of possible controls and procedures relative to their costs.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32</span></div></div></div><div id="id08c0d7bd703495d970d203330d59b2f_121"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">PART II - OTHER INFORMATION</span></div><div id="id08c0d7bd703495d970d203330d59b2f_124"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company currently is not aware of any legal proceedings or claims that management believes will have, individually or in the aggregate, a material adverse effect on the Company&#8217;s business, financial condition, results of operations, or cash flows.</span></div><div id="id08c0d7bd703495d970d203330d59b2f_127"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Investing in our common stock involves a high degree of risk. Before you decide to invest in common stock, you should consider carefully the risks described below, together with the information contained in the Annual Report on Form 10-K for the year ended December 31, 2022 (the &#8220;Annual Report&#8221;) filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on March&#160;22, 2023, including our financial statements and the related notes appearing in the Annual Report. We believe the risks described below are the risks that are material to us as of the date of the Annual Report. Factors that could cause our actual results to differ materially from those in the Annual Report are any of the risks described in the Item 1A below. Any of these factors could result in a significant or material adverse effect on our results of operations or financial condition. Additional risk factors not presently known to us or that we currently deem immaterial may also impair our business or results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">If any of the following risks actually occur, our business, results of operations and financial condition would likely be materially and adversely affected. In these circumstances, the market price of our common stock could decline, and you may lose part or all of your investment.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Summary Risk Factors</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The risk factors set forth below represent a summary of some of the principal risk factors which potential investors in our securities should be aware of. Although each of these risks is important, this list is not and is not intended to be a substitute for investors reviewing all of the information in this Quarterly Report, including all risk factors which follow this summary.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We are a preclinical stage biotechnology company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We have identified a material weakness in our internal control over financial reporting. If our remediation of the material weakness is not effective, or if we experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our common stock.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Members of our management team have limited experience in managing the day-to-day operations of a public company and, as a result, we may incur additional expenses associated with the management of our company.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our history of recurring losses and anticipated expenditures raises substantial doubt about our ability to continue as a going concern. Our ability to continue as a going concern requires that we obtain sufficient funding to finance our operations.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may not achieve the intended objectives of our strategic prioritization plan announced in January 2023.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our current product candidates are in preclinical development and have never been tested in humans. One or all of our current product candidates may fail in clinical development or suffer delays that materially and adversely affect their ability to receive regulatory approval or to attain commercial viability.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If any of our current or potential future product candidates is ever tested in humans, it may not demonstrate the safety, purity and potency, or efficacy, necessary to become approvable or commercially viable.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our gene circuit platform technologies are based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may not be successful in our efforts to use and expand our gene circuit platform to expand our pipeline of product candidates.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The market, physicians, patients, regulators and potential investors may not be receptive to our current or potential future product candidates and may be skeptical of the viability and benefits of our gene circuit pipeline technology because it is based on a relatively novel and complex technology.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The occurrence of serious complications or side effects in connection with use of our product candidates, either in clinical trials or post-approval, could lead to discontinuation of our clinical development programs, refusal of regulatory authorities to approve our product candidates or, post-approval, revocation of marketing authorizations or refusal to approve applications for new indications, which could severely harm our business, prospects, operating results and financial condition.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We and our collaborators may not achieve projected discovery and development milestones and other anticipated key events in the time frames that we or they announce, which could have an adverse impact on our business and could cause our stock price to decline.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we decide to seek orphan drug designation for one or more of our product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation for our current or future product candidates that we may develop.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may not be able to conduct, or contract with others to conduct, animal testing in the future, which could harm our research and development activities.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We rely on third parties to conduct our preclinical studies, and plan to rely on third parties to conduct clinical trials, and those third parties may not perform satisfactorily.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Supply of our product candidates for preclinical and clinical development may become limited or interrupted or may not be of satisfactory quantity or quality, and we will experience delays if we are unable to operate our own manufacturing facility and are required to rely on third-party back-up manufacturers.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We are exposed to a number of risks related to our supply chain for the materials required to manufacture our product candidates.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We face competition from companies that have developed or may develop product candidates for the treatment of the diseases that we may target, including companies developing novel therapies and platform technologies. If these companies develop platform technologies or product candidates more rapidly than we do, or if their platform technologies or product candidates are more effective or have fewer side effects, our ability to develop and successfully commercialize product candidates may be adversely affected.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our business entails a significant risk of product liability, and our inability to obtain sufficient insurance coverage could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our business, operations and clinical development plans and timelines could be adversely affected by the impact of global economic and political developments, including high inflation and capital market disruption, the war in Ukraine, economic sanctions and economic slowdowns or recession, including any that may result from the ongoing COVID-19 pandemic, or by the manufacturing, clinical trial and other business activities performed by us or by third parties with whom we may conduct business, including our anticipated contract manufacturers, CROs, shippers and others.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Limited Operating History and Financial Condition</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are a preclinical stage biotechnology company with a history of losses. We expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are a preclinical stage biotechnology company with a history of losses. Since our inception, we have devoted substantially all of our resources to research and development, preclinical studies, building our management team and building our intellectual property portfolio, and we have incurred significant operating losses. Our net losses were $18.7 million and $$11.8 million for the three months ended March 31, 2023 and 2022, respectively. As of March&#160;31, 2023, we had an accumulated deficit of $192.0 million. Substantially all of our losses have resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations. To date, we have not generated any revenue from product sales, and we have not sought or obtained regulatory approval for any product candidate. Furthermore, we do not expect to generate any revenue from product sales for the foreseeable future, and we expect to continue to incur significant operating losses for the foreseeable future due to the cost of research and development, preclinical studies, clinical trials, manufacturing and the regulatory approval process for our current and potential future product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect our net losses to increase substantially as we:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">continue to advance our gene circuit platform technologies;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">continue preclinical development of our current and future product candidates and initiate additional preclinical studies;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">commence clinical trials of our current and future product candidates;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">establish our manufacturing capability, including developing our contract development and manufacturing organization relationships and building our internal manufacturing facilities;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:5.435%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.821%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.107%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.137%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">acquire and license technologies aligned with our gene circuit platform technologies;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.711%"><tr><td style="width:1.0%"></td><td style="width:5.668%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.153%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.719%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">seek regulatory approval of our current and future product candidates;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">expand our operational, financial, and management systems and increase personnel, including personnel to support our preclinical and clinical development, manufacturing and commercialization efforts;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">continue to develop, maintain, expand, and defend our intellectual property portfolio; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">incur additional legal, accounting, or other expenses in operating our business, including the additional costs associated with operating as a public company.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">However, the amount of our future losses is uncertain. Our ability to achieve or sustain profitability, if ever, will depend on, among other things, successfully developing product candidates, obtaining regulatory approvals to market and commercialize product candidates, manufacturing any approved products on commercially reasonable terms, entering into potential future alliances, establishing a sales and marketing organization or suitable third-party alternatives for any approved product and raising sufficient funds to finance business activities. If we, or our existing or potential future collaborators, are unable to commercialize one or more of our product candidates, or if sales revenue from any product candidate that receives approval is insufficient, we will not achieve or sustain profitability, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We will need substantial additional funding. If we are unable to raise capital when needed on acceptable terms, or at all, we may be forced to restructure our business or delay, reduce, or terminate our research and product development programs, future commercialization efforts or other operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will need substantial additional funds to advance development of product candidates and our gene circuit platform, and we cannot guarantee that we will have sufficient funds available in the future to develop and commercialize our current or potential future product candidates and technologies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The development of biotechnology product candidates is capital-intensive. If any of our current or potential future product candidates enter and advance through preclinical studies and clinical trials, we will need substantial additional funds to expand our development, regulatory, manufacturing, marketing and sales capabilities. We have used substantial funds to develop our gene circuit platform, SENTI-202, SENTI-301A, SENTI-401 and other potential product candidates, and we will require significant funds to continue to develop our platform and conduct further research and development, including preclinical studies and clinical trials. In addition, we expect to incur significant additional costs associated with operating as a public company.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, we had $76.1 million in cash, cash equivalents, and short-term investments. Our future capital requirements and the period for which our existing resources will support our operations may vary significantly from what we expect. Our monthly spending levels vary based on new and ongoing research and development and other corporate activities. Because the length of time and activities associated with successful research and development of platform technologies and product candidates is highly uncertain, we are unable to estimate the actual funds we will require for development and any approved marketing and commercialization activities. Our future capital requirements and the timing and amount of our operating expenditures will depend largely on:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the timing and progress of preclinical and clinical development of our current and potential future product candidates;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the timing and progress of our development of our gene circuit platforms;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the number and scope of preclinical and clinical programs we decide to pursue;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the costs of building and operating our own dedicated Current Good Manufacturing Practice cGMP and cGTP facility to support clinical and commercial-scale production of multiple allogeneic natural killer (NK) cell product candidates, and the terms of any third-party manufacturing contract or biomanufacturing partnership we may enter into;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our ability to maintain our current licenses and collaborations, conduct our research and development programs and establish new strategic partnerships and collaborations;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the progress of the development efforts of our existing strategic partners and third parties with whom we may in the future enter into collaboration and research and development agreements;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the costs involved in obtaining, maintaining, enforcing and defending patents and other intellectual property rights;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the impact of the COVID-19 pandemic, supply chain disruptions, global political and market conditions, and inflationary pressures on our business;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the cost and timing of regulatory approvals; and</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our efforts to enhance operational systems and to hire and retain personnel, including personnel to support development of our product candidates, the operation of our manufacturing facility, and to satisfy our obligations as a public company.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To date, we have primarily financed our operations through the sale of equity securities. We may seek to raise any necessary additional capital through a combination of public or private equity offerings, debt financings, collaborations, strategic alliances, licensing arrangements, grants and other marketing and distribution arrangements. Any additional capital raising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to develop and commercialize our current and future product candidates, if approved.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot assure you that we will be successful in acquiring additional funding at levels sufficient to fund our operations or on terms acceptable to us, if at all. If we are unable to obtain adequate financing when needed, our business, financial condition and results of operations will be harmed, and we may need to significantly modify our operational plans, or else we may not be able to continue as a going concern beyond twelve months from the issuance date of this Form 10-Q. For example, in January 2023 we announced a strategic plan to focus internal resources on SENTI-202 and SENTI-401, to develop gene circuits for other programs with potential partners, and to suspend research and development efforts for SENTI-301A. In the future, we may have to delay, reduce the scope of or suspend one or more of our preclinical studies, clinical trials, research and development programs, manufacturing and process development activities, or commercialization efforts. Further, if we are unable to continue as a going concern, we might have to liquidate our assets, and the values we receive for our assets in liquidation or dissolution could be significantly lower than the values reflected in our consolidated financial statements. Because of the numerous risks and uncertainties associated with the development and commercialization of our current and potential future product candidates and the extent to which we may enter into collaborations with third parties to participate in their development and commercialization, we are unable to estimate the amounts of increased capital outlays and operating expenditures associated with our current and anticipated preclinical studies and clinical trials, including related manufacturing costs.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the extent that we raise additional capital through collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our current and potential future product candidates, future revenue streams or research programs or grant licenses on terms that may not be favorable to us. If we do raise additional capital through public or private equity or convertible debt offerings, the ownership interest of our existing stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. If we raise additional capital through debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Moreover, the issuance of additional securities by us, whether equity or debt, or the market perception that such issuances are likely to occur, could cause the market price of our common stock to decline.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not expect to realize revenue from product sales or royalties from licensed products for the foreseeable future, if at all, and unless and until our current and potential future product candidates are clinically tested, approved for commercialization and successfully marketed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We identified a material weakness in our internal control over financial reporting. If our remediation of the material weakness is not effective, or if we experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of shares of our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prior to the closing of the Merger, we were a private company with limited accounting personnel and other resources with which to address our internal control over financial reporting. In connection with our preparation and the audit of our consolidated financial statements as of and for the years ended December 31, 2021, we and our independent registered public accounting firm identified a material weakness, as defined under the Exchange Act and by the Public Company Accounting Oversight Board (United States), in our internal control over financial reporting. The material weakness related to a lack of sufficient and adequate resources in the finance and accounting function that resulted in a lack of formalized risk assessment process, lack of segregation of duties, and ineffective process level control activities over the management review of journal entries, account reconciliations and non-routine transactions.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our consolidated financial statements will not be prevented or detected on a timely basis.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We implemented a risk assessment process and measures designed to improve our internal control over financial reporting and remediate the control deficiencies that led to the material weakness, including hiring additional accounting personnel. However, the process of designing and implementing effective internal controls is a continuous effort that requires us to anticipate and react to changes in our business and the economic and regulatory environments and to expend significant resources to maintain a system of internal controls that is adequate to satisfy our reporting obligations as a public company. Moreover, the rules governing the standards that must be met for our management to assess our internal control over financial reporting are complex and require significant documentation, testing, and remediation. To maintain and improve the effectiveness of our financial reporting, we will need to commit significant resources, implement and strengthen existing disclosure processes controls, reporting systems, and procedures, train personnel and provide additional management oversight, all of which may divert attention away from other matters that are important to our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot be certain that the measures we have taken to date, and actions we may take in the future, will be sufficient to remediate the control deficiencies that led to our material weakness in our internal control over financial reporting or that they will prevent or avoid potential future material weaknesses. In addition, an independent registered public accounting firm has not yet performed an evaluation of our internal control over financial reporting, though such an evaluation will be required when we lose our status as an &#8220;emerging growth company&#8221; and become an &#8220;accelerated filer&#8221; or a &#8220;large accelerated filer.&#8221; When an evaluation by an independent registered public accounting firm is performed, such firm may issue a report that is qualified if it is not satisfied with our controls or the level at which our controls are documented, designed, operated, or reviewed. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our testing, or the subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses. A material weakness in internal controls could result in our failure to detect a material misstatement of our annual or quarterly consolidated financial statements or disclosures. We may not be able to conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404. If we are unable to conclude that we have effective internal controls over financial reporting, investors could lose confidence in our reported financial information, which could have a material adverse effect on the trading price of the shares of our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We cannot be certain as to the timing of completion of our evaluation, testing and any remediation actions or the impact of the same on our operations. If we are unable to successfully remediate our existing or any future material weaknesses in our internal control over financial reporting, or identify any additional material weaknesses, the accuracy and timing of our financial reporting may be negatively impacted, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting and our stock price may decline as a result. If we are not able to implement the requirements of Section 404 in a timely manner or with adequate compliance, our independent registered public accounting firm when required may issue an adverse opinion due to ineffective internal controls over financial reporting, and we may be subject to sanctions or investigation by regulatory authorities, such as the SEC. As a result, there could be a negative reaction in the financial markets due to a loss of confidence in the reliability of our consolidated financial statements. In addition, we may be required to incur costs in improving our internal control system and the hiring of additional personnel. Any such action could negatively affect our results of operations and cash flows.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Members of our management team have limited experience in managing the day-to-day operations of a public company and, as a result, we may incur additional expenses associated with the management of our company.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Members of our management team have limited experience in managing the day-to-day operations of a public company. As a result, we may need to obtain outside assistance from legal, accounting, investor relations, or other professionals that could be more costly than planned. We also plan to hire additional personnel to comply with additional SEC reporting requirements. These compliance costs will make some activities significantly more time-consuming and costly. If we lack cash resources to cover these costs in the future, our failure to comply with </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">reporting requirements and other provisions of securities laws could negatively affect our stock price and adversely affect our potential results of operations, cash flow and financial condition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our ability to use net operating loss carryforwards (&#8220; NOLs&#8221;) and credits to offset future taxable income may be subject to certain limitations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our NOLs could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. NOLs generated in taxable years beginning before January 1, 2018 are permitted to be carried forward for 20 taxable years under applicable U.S. federal income tax law. Under current U.S. federal income tax law, NOLs arising in tax years beginning after December 31, 2020 may not be carried back. Moreover, NOLs generated in taxable years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such NOLs generally will be limited in taxable years beginning after December 31, 2020 to 80% of current year taxable income. As of December&#160;31, 2022, we had NOLs for U.S. federal and state income tax purposes of approximately $100.3 million and $55.0 million, respectively, a portion of which expire beginning in 2036 if not utilized. NOLs for U.S. federal tax reporting purposes of approximately $96.8 million have an indefinite life.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In general, under Section 382 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), a corporation that undergoes an &#8220;ownership change&#8221; (defined under Section 382 of the Code and applicable Treasury Regulations as a greater than 50 percentage point change (by value) in a corporation&#8217;s equity ownership by certain stockholders over a rolling three-year period) is subject to limitations on its ability to utilize its pre-change NOLs to offset future taxable income. We have not determined whether our NOLs are limited under Section 382 of the Code. We may have experienced ownership changes in the past and may experience ownership changes in the future, including as a result of the Merger or subsequent shifts in our stock ownership (some of which are outside our control). Furthermore, our ability to utilize NOLs of companies that we may acquire in the future may be subject to limitations. There is also a risk that due to regulatory changes, such as suspensions on the use of NOLs or other unforeseen reasons, our existing NOLs could expire or otherwise be unavailable to reduce future income tax liabilities, including for state tax purposes. For these reasons, we may not be able to utilize a material portion of the NOLs reflected on our balance sheets, even if we attain profitability, which could potentially result in increased future tax liability to us and could adversely affect our operating results and financial condition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in tax law may adversely affect us or our investors.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The U.S. rules dealing with federal, state, and local taxation are constantly under review by those involved in the legislative process, as well as by the U.S. Treasury Department. Changes to tax laws, which may have retroactive application, could adversely affect us or holders of our common stock. For example, under Section 174 of the Code, in taxable years beginning after December 31, 2021, expenses that are incurred for research and development in the U.S. will be capitalized and amortized, which may have an adverse effect on our cash flow. In recent years, many such changes have been made and change are likely to continue to occur in the future.  Future changes in tax laws could have a material adverse effect on our business, cash flow, financial conditions, or results of operations. The existence, timing, and content of new tax laws are unpredictable, and could cause an increase in our or our shareholders&#8217; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law. We urge investors to consult with their legal and tax advisers regarding the implications of potential changes in tax laws on an investment in our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">It is not possible to predict the number of shares of our common stock, if any, that we may sell to Chardan Capital Markets LLC, or Chardan, under our common stock Purchase Agreement, or the Purchase Agreement, with Chardan, or the actual gross proceeds resulting from those sales, or the dilution to our stockholders from those sales.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 31, 2022, we entered into the Purchase Agreement with Chardan, pursuant to which Chardan may purchase from us up to $50.0 million in shares of our common stock (the &#8220;Total Commitment&#8221;), upon the terms and subject to the conditions and limitations set forth in the Purchase Agreement. To date, we have sold $0.7 million in shares of our common stock to Chardan. The shares of our common stock that may be issued under the Purchase Agreement may be sold by us to Chardan at our discretion from time to time until the earliest to occur of (i) October 1, 2025, (ii) the date on which Chardan has purchased the Total Commitment pursuant to the Purchase Agreement, (iii) the date on which our common stock fails to be listed or quoted on Nasdaq or any successor market, and (iv) the date on which, pursuant to or within the meaning of any bankruptcy law, we commence a voluntary case or any </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">person or entity commences a proceeding against us, a custodian is appointed for us or for all or substantially all of our property, or we make a general assignment for the benefit of our creditors.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We generally have the right to control the timing and amount of any sales of our common stock to Chardan under the Purchase Agreement. Sales of our common stock to Chardan under the Purchase Agreement will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to Chardan all or some of the common stock that may be available for us to sell to Chardan pursuant to the Purchase Agreement. Accordingly, we cannot guarantee that we will be able to sell all of the Total Commitment or how much in proceeds we may obtain under the Purchase Agreement. If we cannot sell securities under the Purchase Agreement, we may be required to utilize more costly and time-consuming means of accessing the capital markets, which could have a material adverse effect on our liquidity and cash position.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because the purchase price per share of common stock to be paid by Chardan for the common stock that we may elect to sell to Chardan under the Purchase Agreement will fluctuate based on the market prices of our common stock at the time we elect to sell shares to Chardan pursuant to the Purchase Agreement it is not possible for us to predict, as of the date of this Quarterly Report on Form 10-Q and prior to any such sales, the number of shares of common stock that we will sell to Chardan under the Purchase Agreement, the purchase price per share that Chardan will pay for shares of common stock purchased from us under the Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by Chardan under the Purchase Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The actual number of shares of our common stock issuable will vary depending on the then current market price of shares of our common stock sold to Chardan and the number of shares of common stock we ultimately elect to sell to Chardan under the Purchase Agreement. If it becomes necessary for us to issue and sell to Chardan under the Purchase Agreement more than the 8,727,049 shares of common stock we registered pursuant to the Purchase Agreement, in order to receive aggregate gross proceeds equal to $50.0 million under the Purchase Agreement, we will have to file with the SEC one or more additional registration statements to register under the Securities Act the resale by Chardan of any such additional shares of common stock we wish to sell from time to time under the Purchase Agreement, which the SEC must declare effective, in each case before we may elect to sell any additional shares of our common stock under the Purchase Agreement. Under applicable Nasdaq rules, in no event may we issue to Chardan more than 19.99% of the total number of shares of common stock that were outstanding immediately prior to the execution of the Purchase Agreement, unless we obtain prior stockholder approval or if such approval is not required in accordance with the applicable Nasdaq rules. In addition, Chardan is not obligated to buy any common stock under the Purchase Agreement if such shares, when aggregated with all other shares of our common stock then beneficially owned by Chardan and its affiliates (as calculated pursuant to Section 13(d) of the Exchange Act and Rule 13d-3 promulgated thereunder), would result in Chardan beneficially owning common stock in excess of 4.99% of our outstanding shares of common stock. Our inability to access a portion or the full amount available under the Purchase Agreement, in the absence of any other financing sources, could have a material adverse effect on our business or results of operation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Investors who buy common stock from Chardan at different times will likely pay different prices.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Purchase Agreement, the timing, price and number of shares sold to Chardan will vary depending on when we choose to sell shares, if any, to Chardan. If and when we elect to sell any additional common stock to Chardan pursuant to the Purchase Agreement, after Chardan has acquired such common stock, Chardan may resell all, some or none of such shares at any time or from time to time in its sole discretion and at different prices. As a result, investors who purchase shares from Chardan at different times will likely pay different prices for those shares, and so may experience different levels of dilution and in some cases substantial dilution and different outcomes in their investment results. Investors may experience a decline in the value of the shares they purchase from Chardan as a result of future sales made by us to Chardan at prices lower than the prices such investors paid for their shares from Chardan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The sale or issuance of shares of our common stock to Chardan will result in additional outstanding shares and the resale of shares of our common stock by Chardan that it acquires pursuant to the Purchase Agreement, or the perception that such sales may occur, could cause the price of shares of our common stock to decrease.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of the date of this Form 10-Q, we have issued 400,000 shares of common stock to Chardan under the Purchase Agreement, including 100,000 shares issued to Chardan as consideration for its execution and delivery of the Purchase Agreement. The shares of common stock issuable under the Purchase Agreement may be sold by us to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chardan at our sole discretion, subject to the satisfaction of certain conditions in the Purchase Agreement, from time to time, until the earliest to occur of (i) October 1, 2025, (ii) the date on which Chardan has purchased the Total Commitment pursuant to the Purchase Agreement, (iii) the date on which our common stock fails to be listed or quoted on Nasdaq or any successor market, and (iv) the date on which, pursuant to or within the meaning of any bankruptcy law, we commence a voluntary case or any person or entity commences a proceeding against us, a custodian is appointed for us or for all or substantially all of our property, or we make a general assignment for the benefit of our creditors. The purchase price for shares of our common stock that we may sell to Chardan under the Purchase Agreement will fluctuate based on the trading price of shares of our common stock. Depending on market liquidity at the time, sales of shares of our common stock may cause the trading price of shares of our common stock to decrease. We generally have the right to control the timing and amount of any future sales of shares of our common stock to Chardan. Additional sales of shares of our common stock, if any, to Chardan will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to Chardan all or some of the additional shares of our common stock that may be available for us to sell pursuant to the Purchase Agreement. If and when we do sell shares of our common stock to Chardan, after Chardan has acquired shares of our common stock, Chardan may resell all, some or none of such shares of common stock at any time or from time to time in its discretion. Therefore, sales to Chardan by us could result in substantial dilution to the interests of other holders of shares of our common stock. In addition, if we sell a substantial number of shares of our common stock to Chardan under the Purchase Agreement, or if investors expect that we will do so, the actual sales of shares of our common stock or the mere existence of our arrangement with Chardan may make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect such sales.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may use our cash resources, including proceeds from sales of our common stock made pursuant to the Purchase Agreement in ways with which you may not agree or in ways which may not yield a significant return.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have broad discretion over the use of capital we have raised, including proceeds from sales of our common stock made pursuant to the Purchase Agreement, and you will not have the opportunity, as part of any decision to invest in our common stock, to assess whether the proceeds are being used appropriately. Accordingly, you will have to rely on the judgment of our management with respect to the use of these funds, with only limited information regarding management&#8217;s specific intentions. We may spend all or a portion of the net proceeds of our prior financing activities, including sales of our common stock under the Purchase Agreement, in ways that are not what our stockholders may desire or that may not yield favorable results. Because of the number and variability of factors that will determine our use of the net proceeds, their ultimate use may vary substantially from their currently intended use. The failure by us to apply these funds effectively could harm our business, and the net proceeds may be used for corporate purposes that do not increase our operating results or enhance the value of our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect the Company&#8217;s current and projected business operations and its financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems.  For example, on March 10, 2023, Silicon Valley Bank (&#8220;SVB&#8221;) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) as receiver.  Similarly, on March 12, 2023, Signature Bank and Silvergate Capital Corp. were each swept into receivership, and on May 1, 2023, the FDIC announced that First Republic Bank had been closed by the California Department of Financial Protection and Innovation and its assets seized by the FDIC. Although a statement by the Department of the Treasury, the Federal Reserve and the FDIC indicated that all depositors of SVB would have access to all of their money after only one business day of closure, including funds held in uninsured deposit accounts, borrowers under credit agreements, letters of credit and certain other financial instruments with SVB, Signature Bank or any other financial institution that is placed into receivership by the FDIC may be unable to access undrawn amounts thereunder.  We have two letters of credit held with SVB in an aggregate amount of $3.3 million related to our facility lease. Due to the receivership of SVB, we may be unable to access such funds. In addition, if any of our suppliers or other parties with whom we conduct business are unable to access funds pursuant to such instruments or lending arrangements with </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">such a financial institution, such parties&#8217; ability to pay their obligations to us or to enter into new commercial arrangements requiring additional payments to us could be adversely affected. In this regard, counterparties to SVB credit agreements and arrangements, and third parties such as beneficiaries of letters of credit (among others), may experience direct impacts from the closure of SVB and uncertainty remains over liquidity concerns in the broader financial services industry. Similar impacts have occurred in the past, such as during the 2008-2010 financial crisis.  </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inflation and rapid increases in interest rates have led to a decline in the trading value of previously issued government securities with interest rates below current market interest rates. Although the U.S. Department of Treasury, FDIC and Federal Reserve Board have announced a program to provide up to $25 billion of loans to financial institutions secured by certain of such government securities held by financial institutions to mitigate the risk of potential losses on the sale of such instruments, widespread demands for customer withdrawals or other liquidity needs of financial institutions for immediately liquidity may exceed the capacity of such program. Additionally, there is no guarantee that the U.S. Department of Treasury, FDIC and Federal Reserve Board will provide access to uninsured funds in the future in the event of the closure of other banks or financial institutions, or that they would do so in a timely fashion.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although we assess our banking relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect the Company, the financial institutions with which we have or may enter into credit agreements or arrangements directly, or the financial services industry or economy in general.  These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets, or concerns or negative expectations about the prospects for companies in the financial services industry.  These factors could involve financial institutions with which we have or may enter into financial or business relationships, but could also include factors involving financial markets or the financial services industry generally. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations.  These could include, but may not be limited to, the following:</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Delayed access to deposits or other financial assets or the uninsured loss of deposits or other financial assets;</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Delayed or lost access to other working capital sources and/or delays, inability or reductions in our ability to enter into new credit facilities or access other working capital resources;</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Potential or actual breach of contractual obligations that require the Company to maintain letters of credit or other credit support arrangements; </span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Potential or actual breach of financial covenants in any credit agreements or credit arrangements; or</span></div><div style="margin-bottom:9pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Potential or actual cross-defaults in other credit agreements, credit arrangements or operating or financing agreements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all.  Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws and otherwise have a material adverse impact on our business.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to the Development and Clinical Testing of Our Product Candidates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our current product candidates are in preclinical development and have never been tested in humans. One or all of our current product candidates may fail in clinical development or suffer delays that materially and adversely affect their commercial viability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have no products on the market or that have gained regulatory approval or that have entered clinical trials. None of our product candidates has ever been tested in humans. Our ability to achieve and sustain profitability depends on obtaining regulatory approvals for and successfully commercializing product candidates, either alone or with collaborators.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Before obtaining regulatory approval for the commercial distribution of our product candidates, we or a collaborator must conduct extensive preclinical studies, followed by clinical trials to demonstrate the safety, purity and potency, or efficacy of our product candidates in humans. There is no guarantee that the FDA will permit us to conduct clinical trials. Further, we cannot be certain of the timely completion or outcome of our preclinical studies and cannot predict if the FDA or other regulatory authorities will accept our proposed clinical programs, our clinical protocols or if the outcome of our preclinical studies will ultimately support the further development of our preclinical programs or testing in humans. As a result, we cannot be sure that we will be able to submit IND or similar applications for our proposed clinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials for any of our product candidates to begin.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our current product candidates are in preclinical development and we are subject to the risks of failure inherent in the development of product candidates based on novel approaches, targets and mechanisms of action. Although we anticipate initiating clinical trials for our lead product candidates, there is no guarantee that we will be able to proceed with clinical development of any of these product candidates or that any product candidate will demonstrate a clinical benefit once we advance these candidates to testing in patients. Accordingly, you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by preclinical stage biotechnology companies such as ours.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may not be able to access the financial resources to continue development of, or to enter into any collaborations for, any of our current or potential future product candidates. This may be exacerbated if we experience any issues that delay or prevent regulatory approval of, or our ability to commercialize, a product candidate, such as:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">negative or inconclusive results from our preclinical studies or clinical trials or the clinical trials of others for product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical studies or clinical trials or abandon any or all of our programs;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">adverse events experienced by participants in our clinical trials or by individuals using therapeutics similar to our product candidates;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">delays in submitting INDs or comparable foreign applications, or delays or failures to obtain the necessary approvals from regulatory authorities to commence a clinical trial, or a suspension or termination of a clinical trial once commenced;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">conditions imposed by the FDA or other regulatory authorities regarding the scope or design of our clinical trials;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">delays in enrolling research subjects in clinical trials;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">high drop-out rates of research subjects;</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">inadequate supply or quality of product candidate components or materials or other supplies necessary for the conduct of our clinical trials;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">chemistry, manufacturing and control (&#8220;CMC&#8221;) challenges associated with manufacturing and scaling up biologic product candidates to ensure consistent quality, stability, purity and potency among different batches used in clinical trials;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">greater-than-anticipated clinical trial costs;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">poor potency or effectiveness of our product candidates during clinical trials;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">unfavorable FDA or other regulatory authority inspection and review of a clinical trial or manufacturing site;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">delays as a result of the COVID-19 pandemic or events associated with the pandemic;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their contractual obligations in a timely manner, or at all;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">delays and changes in regulatory requirements, policies and guidelines; or</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the FDA or other regulatory authorities interpreting our data differently than we do.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, we and any existing or potential future collaborator may never receive approval to market and commercialize any product candidate. Even if we or any existing or potential future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings. We or an existing or potential future collaborator may also be subject to post-marketing testing requirements to maintain regulatory approval.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If any of our current or potential future product candidates is ever tested in humans, it may not demonstrate the safety, purity and potency, or efficacy, necessary to become approvable or commercially viable.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None of our current product candidates have ever been tested in humans. We may ultimately discover that our current product candidates do not possess certain properties that we believe are helpful for therapeutic effectiveness and safety or would otherwise support the submission of an IND on the timelines we expect, or at all. We do not know if the observations we have made regarding our gene circuits generally and our product candidates in particular will translate into any clinical response when tested in humans. As an example, while the Tumor-Associated Antigen (&#8220;TAA&#8221;) CD33 has been clinically validated as a target for an approved antibody-drug conjugate therapy, it has not been clinically validated as a target for CAR-NK or CAR-T therapies, and may not prove to be a clinically sufficient target for the CAR-NK therapies we are developing. As a result of these uncertainties related to our gene circuit platform technologies and our product candidates, we may never succeed in developing a marketable product based on our current product candidates. If any of our current or potential future product candidates prove to be ineffective, unsafe or commercially unviable, our entire pipeline could have little, if any, value, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our gene circuit platform technologies are based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are seeking to identify and develop a broad pipeline of product candidates using our gene circuit platform technologies. The scientific research that forms the basis of our efforts to develop product candidates with our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">platforms is still ongoing. We are not aware of any FDA approved therapeutics utilizing similar technologies as ours. Further, the scientific evidence to support the feasibility of developing therapeutic treatments based on our platform technologies is preliminary. As a result, we are exposed to a number of unforeseen risks and it is difficult to predict the types of challenges and risks that we may encounter during development of our product candidates. For example, we have not tested any of our current product candidates in humans, and our current data is limited to animal models and preclinical cell lines, the results of which may not translate into humans. Further, relevant animal models and assays may not accurately predict the safety and efficacy of our product candidates in humans, and we may encounter significant challenges creating appropriate models and assays for demonstrating the safety and efficacy of our product candidates. In addition, our gene circuit technologies have potential safety risks. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Given the novelty of our technologies, we intend to work closely with the FDA and comparable foreign regulatory authorities to evaluate our proposed approaches to obtain regulatory approval for our product candidates; however, due to a lack of comparable experiences, the regulatory pathway with the FDA and comparable regulatory authorities may be more complex and time-consuming relative to other more well-known therapeutics. Even if we obtain human data to support our product candidates, the FDA or comparable foreign regulatory agencies may lack experience in evaluating the safety and efficacy of our product candidates developed using our platforms, which could result in a longer than expected regulatory review process, increase our expected development costs, and delay or prevent commercialization of our product candidates. The validation process takes time and resources, may require independent third-party analyses, and may not be accepted or approved by the FDA and comparable foreign regulatory authorities. We cannot be certain that our approach will lead to the development of approvable or marketable products, alone or in combination with other therapies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The occurrence of serious complications or side effects in connection with the use of our product candidates, either in clinical trials or post-approval, could lead to discontinuation of our clinical development programs, refusal of regulatory authorities to approve our product candidates, or, post-approval, revocation of marketing authorizations or refusal to approve applications for new indications, which could severely harm our business, prospects, operating results, and financial condition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Undesirable side effects caused by any of our current or potential future product candidates could cause regulatory authorities to interrupt, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities. While we have not yet initiated clinical trials for SENTI-202, SENTI-404, or any other product candidate, it is likely that there will be side effects associated with their use. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of these side effects. For example, if the NOT GATE gene circuit, as described below, engineered into one of our product candidates, such as SENTI-202, does not provide a clinically sufficient level of inhibition, it may kill healthy cells that it has been designed to preserve or may cause systemic immune cytotoxicity. It is possible that safety events or concerns such as these or others could negatively affect the development of our product candidates, including adversely impacting patient enrollment among the patient populations that we intend to treat. In such an event, our trials could be suspended or terminated, and the FDA or other regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. Such side effects could also affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. To date, we have not observed any such effects in our preclinical studies, but there can be no guarantee that our current or future product candidates will not cause such effects in clinical trials. Any of these occurrences may materially and adversely impact our business and financial condition and impair our ability to generate revenues.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, rare and severe side effects of a product candidate may only be uncovered when a significantly large number of patients are exposed to the product candidate or when patients are exposed for a longer period of time.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the event that any of our current or potential future product candidates receives regulatory approval and we or others identify undesirable side effects caused by one of these products, any of the following events could occur, which could result in the loss of significant revenue to us and materially and adversely impact our results of operations and business:</span></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">regulatory authorities may withdraw their approval of the product or seize the product;</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">we may be required to recall the product or change the way the product is administered to patients;</span></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">we may be subject to fines, injunctions, or the imposition of civil or criminal penalties;</span></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients;</span></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">we could be sued and held liable for harm caused to patients;</span></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">the product may become less competitive; and</span></div><div style="margin-bottom:9pt;padding-left:63pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:5.5pt">our reputation may suffer.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations, and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be successful in our efforts to use and expand our gene circuit platform to expand our pipeline of product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A key element of our strategy is to use and advance our gene circuit platform to design, test and build our portfolio of product candidates focused on allogeneic gene circuit-equipped CAR-NK cell therapies for the treatment of cancer. Although our research and development efforts to date have resulted in our discovery and preclinical development of SENTI-202, SENTI-401 and other potential product candidates, none of these product candidates has advanced to clinical development. We cannot assure you that any of our existing product candidates will advance to clinical trials or, if they do, that such trials will demonstrate these product candidates to be safe or effective therapeutics, and we may not be able to successfully develop any product candidates. Even if we are successful in expanding our pipeline of product candidates, any additional product candidates that we identify may not be suitable for clinical development or generate acceptable clinical data, including as a result of being shown to have unacceptable effects or other characteristics that indicate that they are unlikely to be products that will receive marketing approval from the FDA or other regulatory authorities or achieve market acceptance. If we do not successfully develop and commercialize product candidates, we will not be able to generate product revenue in the future.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Although we intend to explore other therapeutic opportunities in addition to the product candidates that we are currently developing, we may fail to identify viable new product candidates for clinical development for a number of reasons. If we fail to identify additional potential product candidates, our business could be materially harmed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although a substantial amount of our efforts will focus on the planned clinical trials and potential approval of the current and potential future product candidates we are evaluating, a key element of our strategy is to discover, develop, manufacture and globally commercialize additional targeted therapies beyond our current product candidates to treat various conditions and in a variety of therapeutic areas. Even if we identify investigational therapies that initially show promise, we may fail to successfully develop and commercialize such products for many reasons, including the following:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.519%"><tr><td style="width:1.0%"></td><td style="width:5.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.764%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.088%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the research methodology used may not be successful in identifying potential investigational therapies;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">competitors may develop alternatives that render our investigational therapies obsolete;</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">investigational therapies we develop may nevertheless be covered by third parties&#8217; patents or other exclusive rights;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">an investigational therapy may, on further study, be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">it may take greater human and financial resources than we will possess to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, thereby limiting our ability to develop, diversify and expand our product portfolio;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">an investigational therapy may not be capable of being produced in clinical or commercial quantities at an acceptable cost, or at all; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">an approved product may not be accepted as safe and effective by trial participants, the medical community or third-party payors.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Identifying new investigational therapies requires substantial technical, financial and human resources, whether or not any investigational therapies are ultimately identified. Because we have limited financial and human resources, we may initially focus on research programs and product candidates for a limited set of indications. As a result, we may forgo or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. For example, if we do not accurately evaluate the commercial potential or target market for a particular product candidate or technology, we may relinquish valuable rights to that product candidate or technology through collaborations, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate or technology.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our product candidates or to develop suitable potential product candidates through internal research programs, which could materially adversely affect our future growth and prospects. We may focus our efforts and resources on potential product candidates or other potential programs that ultimately prove to be unsuccessful.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The market, physicians, patients, regulators and potential investors may not be receptive to our current or potential future product candidates and may be skeptical of the viability and benefits of our gene circuit pipeline technology because it is based on a relatively novel and complex technology.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The market, physicians, patients, regulators and potential investors, may be skeptical of the viability and benefits of our gene circuit pipeline technology or our product candidates because they are based on a relatively novel and complex technology and there can be no assurance that our product candidates or platform technologies will be understood, approved, or accepted. If potential investors are skeptical of the success of our pipeline products, our ability to raise capital and the value of our stock may be adversely affected. If physicians, patients, or regulators do not understand or accept our gene circuit platform technologies or our product candidates, we may be delayed in or unable to develop our product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if regulatory approval is obtained for a product candidate, including SENTI-202 or SENTI-401, we may not generate or sustain revenue from sales of approved products. Market acceptance of our gene circuit platform technologies and our current and potential future product candidates, if approved, will depend on, among other factors:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the timing of our receipt of any marketing and commercialization approvals;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the terms of any approvals and the countries in which approvals are obtained;</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the safety and efficacy of our product candidates and gene circuit technologies in general;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the prevalence and severity of any adverse side effects associated with our product candidates;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">limitations or warnings contained in any labeling approved by the FDA or other regulatory authority;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">relative convenience and ease of administration of our product candidates;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the success of our physician education programs;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the availability of coverage and adequate government and third-party payor reimbursement;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the pricing of our products, particularly as compared to alternative treatments; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">availability of alternative effective treatments for the disease indications our product candidates are intended to treat and the relative risks, benefits and costs of those treatments.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any product candidate we commercialize fails to achieve market acceptance, it could have a material adverse impact on our business, financial condition, results of operations, and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">While we believe our pipeline will yield multiple INDs, we may not be able to file INDs to commence clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect our pipeline to yield multiple INDs beginning as early as 2023, including an IND for SENTI-202. We cannot be sure that submission of an IND will result in the FDA allowing testing and clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trials. The manufacturing of our product candidates, including SENTI-202 and SENTI-401, remains an emerging and evolving field. Accordingly, we expect chemistry, manufacturing and control related topics, including product specifications, will be a focus of IND reviews, which may delay the clearance of INDs. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to the submission of an IND to the FDA before initiation of a clinical trial in the United States, certain human clinical trials involving recombinant or synthetic nucleic acid molecules are subject to oversight of institutional biosafety committees (&#8220;IBCs&#8221;), as set forth in the National Institutes of Health (&#8220;NIH&#8221;), Guidelines for Research Involving Recombinant or Synthetic Nucleic Acid Molecules, NIH Guidelines. Under the NIH Guidelines, recombinant and synthetic nucleic acids are defined as: (i) molecules that are constructed by joining nucleic acid molecules and that can replicate in a living cell (i.e., recombinant nucleic acids); (ii) nucleic acid molecules that are chemically or by other means synthesized or amplified, including those that are chemically or otherwise modified but can base pair with naturally occurring nucleic acid molecules (i.e., synthetic nucleic acids); or (iii) molecules that result from the replication of those described in (i) or (ii). Specifically, under the NIH Guidelines, supervision of human gene transfer trials includes evaluation and assessment by an IBC, a local institutional committee that reviews and oversees research utilizing recombinant or synthetic nucleic acid molecules at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment, and such review may result in some delay before initiation of a clinical trial. While the NIH Guidelines are not mandatory unless the research in question is being conducted at or sponsored by institutions receiving NIH funding of recombinant or synthetic nucleic acid molecule research, many companies and other institutions not otherwise subject to the NIH Guidelines voluntarily follow them.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Interim, topline and preliminary data that we announce or publish from time to time for any clinical trials that we initiate may change as more patient data become available or as additional analyses are conducted, and as the data are subject to audit and verification procedures that could result in material changes in the final data.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we may publicly disclose interim, preliminary or topline data from our preclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular trial. We also make assumptions, estimates, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the interim, preliminary or topline results that we report may differ from future results of the same trials, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, topline data should be viewed with caution until the final data are available. From time to time, we may also disclose interim, preliminary or topline data from our clinical studies. Interim, topline or preliminary data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse differences between preliminary, topline or interim data and final data could significantly harm our business prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and the value of our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product, product candidate or our business. If the topline data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We and our collaborators may not achieve projected discovery and development milestones and other anticipated key events in the time frames that we or they announce, which could have an adverse impact on our business and could cause our stock price to decline.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we expect that we will make public statements regarding the expected timing of certain milestones and key events, such as the commencement and completion of preclinical and IND-enabling studies in our own internally-developed programs or in our product candidate discovery programs with collaborators, as well as the submission and clearance of INDs and the commencement and completion of planned clinical trials in those programs. The actual timing of these events can vary dramatically due to a number of factors such as delays or failures in our or any future collaborators&#8217; product candidate discovery and development programs, the amount of time, effort and resources committed by us and any future collaborators, and the numerous uncertainties inherent in the development of therapies. As a result, there can be no assurance that our or any future collaborators&#8217; programs will advance or be completed in the time frames we or they announce or expect. If we or any collaborators fail to achieve one or more of these milestones or other key events as planned, our business could be materially adversely affected, and the price of our common stock could decline.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical trials are expensive, time-consuming and difficult to design and implement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Because our current and potential future product candidates are based on new technologies and discovery approaches, we expect that they will require extensive research and development and have substantial manufacturing and processing costs. In addition, the FDA or other regulatory authorities may require us to perform additional testing before commencing clinical trials and be hesitant to allow us to enroll patients impacted with our targeted disease indications in our future clinical trials. If we are unable to enroll patients impacted by our targeted disease indications in our future clinical trials, we would be delayed in obtaining potential proof-of-concept data in humans, which could extend our development timelines. In addition, costs to treat patients </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and to treat potential side effects that may result from our product candidates may be significant. Accordingly, our clinical trial costs are likely to be high and could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may not be able to initiate or continue any clinical trials for our current or potential future product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or other regulatory authorities. We cannot predict how difficult it will be to enroll patients for trials in the indications we are studying. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The enrollment of patients depends on many factors, including:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the severity of the disease under investigation;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the patient eligibility criteria defined in the clinical trial protocol;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the size of the patient population required for analysis of the trial&#8217;s primary endpoints;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the proximity and availability of clinical trial sites for prospective patients;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">willingness of physicians to refer their patients to our clinical trials;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">clinicians&#8217; and patients&#8217; perceptions as to the potential risks and benefits of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our ability to obtain and maintain patient informed consents;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">patient eligibility and exclusion criteria for the trials;</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ability to monitor patients adequately during and after treatment;</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the risk that patients enrolled in clinical trials will drop out of the trials before completion; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">factors we may not be able to control, such as current or potential pandemics, including the ongoing COVID-19 pandemic, that may limit the availability of patients, principal investigators or staff or clinical sites to participate in our clinical trials.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, our future clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Additionally, because some of our clinical trials will be in patients with advanced disease who may experience disease progression or adverse events independent from our product candidates, such patients may be unevaluable for purposes of the trial and, as a result, we may require additional enrollment. Delays in patient enrollment may result in increased </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If clinical trials for our product candidates are prolonged, delayed or stopped, we may be unable to seek or obtain regulatory approval and commercialize our product candidates on a timely basis, or at all, which would require us to incur additional costs and delay our receipt of any product revenue.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may experience delays in our ongoing or future preclinical studies or clinical trials, and we do not know whether future preclinical studies or clinical trials will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. The commencement or completion of these clinical trials could be substantially delayed or prevented by many factors, including:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">further discussions with the FDA or comparable foreign regulatory authorities regarding the scope or design of our clinical trials, including the endpoint measures required for regulatory approval and our statistical plan;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the limited number of, and competition for, suitable study sites and investigators to conduct our clinical trials, many of which may already be engaged in other clinical trial programs with similar patients, including some that may be for the same indications as our product candidates;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">any delay or failure to obtain timely approval or agreement to commence a clinical trial in any of the countries where enrollment is planned;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">inability to obtain sufficient funds required for a clinical trial;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">clinical holds on, or other regulatory objections to, a new or ongoing clinical trial;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">delay or failure to manufacture sufficient quantities or inability to produce quantities of consistent quality, purity and potency of the product candidate for our clinical trials;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">delay or failure to reach agreement on acceptable clinical trial agreement terms or clinical trial protocols with prospective sites or contact research organizations (&#8220;CROs&#8221;), the terms of which can be subject to extensive negotiation and may vary significantly among different sites or CROs;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">delay or failure to obtain institutional review board (&#8220;IRB&#8221;) or ethics committee approval to conduct a clinical trial at a prospective site;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the FDA or other comparable foreign regulatory authorities may require us to submit additional data or impose other requirements before permitting us to initiate a clinical trial;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">slower than expected rates of patient recruitment and enrollment;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">failure of patients to complete the clinical trial;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the inability to enroll a sufficient number of patients in studies to ensure adequate statistical power to detect statistically significant treatment effects;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">unforeseen safety issues, including severe or unexpected drug-related adverse events experienced by patients, including possible deaths;</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">lack of efficacy or failure to measure a statistically significant clinical benefit within the dose range with an acceptable safety margin during clinical trials;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">termination of our clinical trials by one or more clinical trial sites;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">inability or unwillingness of patients or clinical investigators to follow our clinical trial protocols;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">inability to monitor patients adequately during or after treatment by us or our CROs;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our CROs or clinical trial sites failing to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, deviating from the protocol or dropping out of a study;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">inability to address any noncompliance with regulatory requirements or safety concerns that arise during the course of a clinical trial;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the impact of, and delays related to, health epidemics such as the COVID-19 pandemic;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the need to suspend, repeat or terminate clinical trials as a result of non-compliance with regulatory</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">requirements, inconclusive or negative results or unforeseen complications in testing; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the suspension or termination of our clinical trials upon a breach or pursuant to the terms of any agreement with, or for any other reason by, any future strategic collaborator that has responsibility for the clinical development of any of our product candidates.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in regulatory requirements, policies and guidelines may also occur and we may need to significantly modify our clinical development plans to reflect these changes with appropriate regulatory authorities. These changes may require us to renegotiate terms with CROs or resubmit clinical trial protocols to IRBs for re-examination, which may impact the costs, timing or successful completion of a clinical trial. Our clinical trials may be suspended or terminated at any time by us, the FDA, other regulatory authorities, the IRB overseeing the clinical trial at issue, any of our clinical trial sites with respect to that site, or us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any failure or significant delay in commencing or completing clinical trials for our product candidates, any failure to obtain positive results from clinical trials, any safety concerns related to our product candidates, or any requirement to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate would adversely affect our ability to obtain regulatory approval and our commercial prospects and ability to generate product revenue will be diminished.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we decide to seek orphan drug designation for one or more of our product candidates, we may be unsuccessful or may be unable to maintain the benefits associated with orphan drug designation for our current or future product candidates that we may develop.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Under the Orphan Drug Act, the FDA may designate a product candidate as an orphan drug if it is a drug or biologic product intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually in the United States, or where there is no reasonable expectation that the cost of developing the product will be recovered from sales in the United States. We may seek orphan drug designation for certain indications for our product candidates in the future. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the regulatory review or approval process. Orphan drug designation can entitle a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages and user-fee waivers.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">precludes the FDA from approving another marketing application for the same drug for the same indication for seven years. The FDA may reduce the seven-year exclusivity if the same drug from a competitor demonstrates clinical superiority to the product with orphan exclusivity or if the FDA finds that the holder of the orphan exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan product to meet the needs of patients with the disease or condition for which the drug was designated. Even if one of our product candidates receives orphan exclusivity, the FDA can still approve other drugs that have a different active ingredient for use in treating the same indication or disease.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan-designated indication or may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition, and while we may seek orphan drug designation for our product candidates, we may never receive such designations. In addition, the FDA may reevaluate the Orphan Drug Act and its regulations and policies. We do not know if, when, or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be able to conduct, or contract with others to conduct, animal testing in the future, which could harm our research and development activities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain laws and regulations relating to drug development require us to test our product candidates on animals before initiating clinical trials involving humans. Animal testing activities have been the subject of controversy and adverse publicity. Animal rights groups and other organizations and individuals have attempted to stop animal testing activities by pressing for legislation and regulation in these areas and by disrupting these activities through protests and other means. To the extent the activities of these groups are successful, our research and development activities may be interrupted or delayed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Third Parties</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We rely on third parties to conduct our preclinical studies, and plan to rely on third parties to conduct clinical trials, and those third parties may not perform satisfactorily.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect to rely on third-party clinical investigators, CROs, clinical data management organizations and consultants to design, conduct, supervise and monitor certain preclinical studies and any clinical trials. Because we intend to rely on these third parties and will not have the ability to conduct certain preclinical studies or clinical trials independently, we will have less control over the timing, quality and other aspects of such preclinical studies and clinical trials than we would have had we conducted them on our own. These investigators, CROs and consultants will not be our employees and we will have limited control over the amount of time and resources that they dedicate to our programs. Some of these third parties may terminate their engagements with us at any time. We also expect to have to negotiate budgets and contracts with CROs, clinical trial sites and contract manufacturing organizations and we may not be able to do so on favorable terms, which may result in delays to our development timelines and increased costs. If we need to enter into alternative arrangements with, or replace or add any third parties, it would involve substantial cost and require extensive management time and focus, or involve a transition period, and may delay our drug development activities, as well as materially impact our ability to meet our desired clinical development timelines. These third parties may have contractual relationships with other entities, some of which may be our competitors, which may draw time and resources from our programs. The third parties with which we may contract might not be diligent, careful or timely in conducting our preclinical studies or clinical trials, resulting in the preclinical studies or clinical trials being delayed or unsuccessful.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Despite our reliance on third parties, we will ultimately be responsible for ensuring that each of our studies and trials is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, including good laboratory practice, or GLP, good clinical practice, or GCP, cGMP, and cGTP. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols for the trial. Moreover, the FDA and other regulatory authorities require us to comply with GCP standards, regulations for conducting, recording and reporting the results of clinical trials to </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">assure that data and reported results are reliable and accurate and that the rights, integrity and confidentiality of trial participants are protected. Regulatory authorities enforce these GCP requirements through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of our CROs, clinical sites and investigators fail to comply with applicable GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA, European Medicines Agency, or EMA, or other regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials substantially comply with GCP regulations. In addition, our clinical trials must be conducted with product candidates produced under cGMP regulations and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients, may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates FDA regulatory requirements as well as federal or state healthcare laws and regulations or healthcare privacy and security laws.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If third parties do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, or if these third parties need to be replaced, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We depend on strategic partnerships and collaboration arrangements, such as our collaboration arrangements with Spark Therapeutics, Inc., or Spark, and BlueRock Therapeutics, Inc., or BlueRock, for the application of our gene circuit platform technology to the development and commercialization of potential product candidates in certain indications, and if these arrangements are unsuccessful, this could impair our ability to generate revenues and materially harm our results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business strategy for exploiting the potential of our gene circuit platform technology is dependent upon maintaining our current arrangements and establishing new arrangements with strategic partners, research collaborators and other third parties. We currently have collaboration agreements with Spark and BlueRock. These collaboration agreements provide for, among other things, research funding and significant future payments should certain development, regulatory and commercial milestones be achieved. Under these arrangements, our collaborators are typically responsible for:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">electing to advance product candidates through preclinical and into clinical development;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">conducting clinical development and obtaining required regulatory approvals for product candidates; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">commercializing any resulting products.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a result, we may not be able to conduct these collaborations in the manner or on the time schedule we currently contemplate, which may negatively impact our business operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the development and commercialization of potential product candidates under our collaboration agreements could be substantially delayed, and our ability to receive future funding could be substantially impaired if one or more of our collaborators:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">shifts its priorities and resources away from our collaborations due to a change in business strategies, or a merger, acquisition, sale or downsizing of its company or business unit;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ceases development in therapeutic areas which are the subject of our collaboration;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">fails to select a product candidate for advancement into preclinical development, clinical development, or subsequent clinical development into a marketed product;</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">changes the success criteria for a particular product candidate, thereby delaying or ceasing development of such product candidate;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">significantly delays the initiation or conduct of certain activities which could delay our receipt of milestone payments tied to such activities, thereby impacting our ability to fund our own activities;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">develops a product candidate that competes, either directly or indirectly, with our product candidates;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">does not obtain the requisite regulatory approval of a product candidate;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">does not successfully commercialize a product candidate;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">encounters regulatory, resource or quality issues and is unable to meet demand requirements;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">exercises its rights under the agreement to terminate the collaboration, or otherwise withdraws support for, or otherwise impairs development under the collaboration;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">disagrees on the research, development or commercialization of a product candidate resulting in a delay in milestones, royalty payments or termination of research and development activities for such product candidate; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">uses our proprietary information or intellectual property in such a way as to jeopardize our rights in such property.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the termination of our existing collaborations or any future strategic partnership or collaboration arrangement that we enter into may prevent us from receiving any milestone, royalty payment, sharing of profits, and other benefits under such agreement. Furthermore, disagreements with these parties could require or result in litigation or arbitration, which would be time-consuming and expensive. Any of these events could have a material adverse effect on our ability to develop and commercialize any of our product candidates and may adversely impact our business, prospects, financial condition, and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be able to enter into additional strategic transactions on acceptable terms, if at all, which could adversely affect our ability to develop and commercialize current and potential future product candidates and technologies, impact our cash position, increase our expenses and present significant distractions to our management.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">From time to time, we consider strategic transactions, such as collaborations, regional partnerships for the co-development and/or co-commercialization of our product candidates in selected territories, acquisitions of companies, asset purchases, joint ventures, out- or in-licensing of product candidates or technologies and biomanufacturing partnerships involving our manufacturing facilities and gene circuit platform technology. For example, we will evaluate and, if strategically attractive, seek to enter into collaborations, including with biotechnology or biopharmaceutical companies, contract development manufacturing organizations or hospitals. In addition, we announced in January, 2023 that we are actively pursuing strategic geographic partnerships for clinical development of SENTI-301A as part of a business realignment plan to extend our cash runway. The competition for collaborators is intense, and the negotiation process is time-consuming and complex. If we are not able to enter into strategic transactions, we may not have access to required liquidity or expertise to further develop our potential future product candidates or our gene circuit platform. Any such collaboration, or other strategic transaction, may require us to incur non-recurring or other charges, increase our near- and long-term expenditures and pose significant integration or implementation challenges or disrupt our management or business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also may acquire additional technologies and assets, form strategic alliances or create joint ventures with third parties that we believe will complement or augment our existing business, but we may not be able to realize the benefit of acquiring such assets. Conversely, any new collaboration that we do enter into may be on terms that are </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">not optimal for us, our product candidates or our technologies. These transactions would entail numerous operational and financial risks, including:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">exposure to unknown liabilities;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">disruption of our business and diversion of our management&#8217;s time and attention in order to negotiate and manage a collaboration or develop acquired products, product candidates or technologies;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">incurrence of substantial debt or dilutive issuances of equity securities to pay transaction consideration or costs;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">higher-than-expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">difficulty and cost in facilitating the collaboration or combining the operations and personnel of any acquired business;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the inability to retain key employees of any acquired business.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accordingly, although there can be no assurance that we will undertake or successfully complete any transactions of the nature described above, any transactions that we do complete may be subject to the foregoing or other risks and our business could be materially harmed by such transactions. Conversely, any failure to enter any collaboration or other strategic transaction that would be beneficial to us could delay the development and potential commercialization of our product candidates and technologies and have a negative impact on the competitiveness of any product candidate or technology that reaches market.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, to the extent that any future collaborators terminate a collaboration agreement, we may be forced to independently develop our current and future product candidates and technologies, including funding preclinical studies or clinical trials, assuming marketing and distribution costs and maintaining, enforcing and defending intellectual property rights, or, in certain instances, abandon product candidates and technologies altogether, any of which could result in a change to our business plan and have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Manufacturing</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The manufacturing of our product candidates is complex. We may encounter difficulties in production. If we encounter any such difficulties, our ability to supply our product candidates for clinical trials or, if approved, for commercial sale, could be delayed or halted entirely.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The manufacture of biopharmaceutical products is complex and requires significant expertise, including the development of advanced manufacturing techniques and process controls. The process of manufacturing our product candidates is also extremely susceptible to product loss due to contamination, equipment failure or improper installation or operation of equipment, operator error, contamination and inconsistency in yields, variability in product characteristics and difficulties in scaling the production process. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our product candidates or the manufacturing facilities in which they are made, the facilities may need to be closed for an extended period of time to investigate and remedy the contamination. As a result of the complexities, the cost to manufacture biologics in general, and our cell-based product candidates in particular, is generally higher than traditional small molecule chemical compounds, and the manufacturing process is less reliable and is more difficult to reproduce.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any adverse developments affecting manufacturing operations for our product candidates, if any are approved, may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Furthermore, it is too early to estimate our cost of goods sold. The actual cost to manufacture our product candidates could be greater than we expect because we are early in our development efforts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Construction of our planned in-house manufacturing may be delayed or, even if completed, supply of our product candidates for preclinical and clinical development may become limited or interrupted or may not be of satisfactory quantity or quality, and we will experience delays if we are unable to operate our own manufacturing facility and are required to relay on third-party back-up manufacturers.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A key to our strategy is operating our own manufacturing facility. We initiated construction in June 2021 of a dedicated in-house facility to support clinical and commercial-scale production of allogeneic NK cell product candidates in accordance with cGMP and cGTP requirements. We anticipate that this facility will become operational in time to support initial clinical trials for our lead product candidates. Initial manufacturing efforts at our planned facility will focus on our lead programs, SENTI-202 and SENTI-401.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The construction and commissioning of our planned facility may be delayed or may not be completed. As such, we cannot assure that our preclinical or future clinical development product supplies and commercial supplies will not be limited or interrupted. In particular, any change in our plans to construct and operate our own facility, including any decision to rely on third-party back-up manufacturers, could require significant effort and expertise because there may be a limited number, if any, of qualified third-party replacements. We do not currently have arrangements in place for a redundant or second-source supply in the event our planned facility does not become operational. Any delays in manufacturing our product candidates could impede, delay, limit or prevent our drug development efforts, which could harm our business, results of operations, financial condition and prospects. Additionally, we may pursue a biomanufacturing partnership in which we grant a third party certain rights to use our manufacturing facility for the manufacture of third parties&#8217; products or product candidates, which could divert our manufacturing capacity and management resources from the manufacture of our product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not currently produce our product candidates in quantities sufficient for preclinical and clinical development, and we do not currently have arrangements with any third parties to produce them for us. We cannot be sure that the manufacturing processes employed by us or the technologies that we incorporate for manufacturing will result in viable or scalable yields of our product candidates that will be safe, effective, and meet market demand.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The manufacturing process for a product candidate is subject to FDA and other regulatory authority review. We and any third-party manufacturers we may contract with must meet applicable manufacturing requirements and undergo rigorous facility and process validation tests required by regulatory authorities in order to comply with regulatory standards, such as cGMP and cGTP. In the event that we or any third-party manufacturer fails to comply with such requirements or to perform obligations in relation to quality, timing or otherwise, or if our supply of components or other materials becomes limited or interrupted for other reasons, we may be forced to or enter into an agreement with another third party, which we may not be able to do on reasonable terms, or at all. In some cases, the technical skills or technology required to manufacture our current and future product candidates may be difficult or impossible to transfer to a third party and a feasible alternative may not exist. If we are required to change manufacturing facilities or manufacturers for any reason, we will be required to verify that the new facilities and procedures comply with quality standards and with all applicable regulations and guidelines. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new manufacturing could negatively affect our ability to develop product candidates in a timely manner or within budget. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we receive regulatory approval for any product candidate and we are unable to for any reason to produce sufficient quantities of the product in our own facility, and we are unable to obtain or maintain third-party manufacturing on commercially reasonable terms, we may not be able to commercialize the product candidate </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">successfully. Our or a third party&#8217;s failure to execute on our manufacturing requirements and comply with cGMP and cGTP could adversely affect our business in a number of ways, including:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">an inability to initiate or continue clinical trials of product candidates under development;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">delay in submitting regulatory applications, or receiving regulatory approvals, for product candidates;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">loss of the cooperation of potential future collaborators;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">subjecting third-party manufacturing facilities or our potential future manufacturing facilities to additional inspections by regulatory authorities;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">requirements to cease distribution or to recall batches of product candidates; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in the event of approval to market and commercialize a product candidate, an inability to meet commercial demands for our products.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our in-house manufacturing facility and any third-party manufacturers that we use may be unable to successfully scale the manufacturing of our current or potential future product candidates in sufficient quality and quantity, which would delay or prevent us from developing our current and potential future product candidates and commercializing approved products candidates, if any. We have never operated a cGMP facility before.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In order to conduct clinical trials for our current and potential future product candidates or to commercialize any approved product candidates, we will need to manufacture large quantities of these product candidates. We expect to use our in-house manufacturing facility to produce required quantities of our product candidates. We, or any manufacturing partners, may be unable to successfully increase the manufacturing capacity for any current or potential future product candidate in a timely or cost-effective manner, or at all. In addition, quality issues may arise during scale-up activities and may result in lower yields than initially expected. While we believe our planned cGMP facility will be sufficiently scalable to produce commercial quantities, any significant revisions to the manufacturing process may create delays, which could negatively impact our overall development timelines. In addition, we have never operated a cGMP facility before. We may encounter difficulties in operating the facility or meeting the requirements of the FDA or other regulatory authorities that we have not anticipated. If we cannot successfully scale the manufacture of any current or potential future product candidate in sufficient quality and quantity, the development, testing, clinical trials and commercialization of that product candidate may be delayed or infeasible and regulatory approval or commercial launch of any potential resulting product may be delayed or not obtained, which could significantly harm our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are exposed to a number of risks related to our supply chain for the materials required to manufacture our product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Manufacturing our product candidates is highly complex and requires sourcing specialty materials. Many of the risks associated with the complexity of manufacturing our final products are applicable to the manufacture and supply of the raw materials. In particular, these starting materials are subject to inconsistency in yields, variability in characteristics, contamination, difficulties in scaling the production process and defects. Similar minor deviations in the manufacturing process for these starting materials could result in supply disruption and reduced production yields for our final product. In addition, we rely on third parties for the supply of these materials exposing us to similar risks of reliance on third parties as described above with respect to the manufacturing and supply of our drug products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our manufacturing processes requires many reagents, some of which are drug substance intermediates used in our manufacturing processes to bring about chemical or biological reactions, and other specialty materials and equipment, some of which are manufactured or supplied by small companies with limited resources and experience to support commercial production. We currently depend on a limited number of vendors for certain materials and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">equipment used in the manufacture of our product candidates. Some of these suppliers may not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms or may otherwise be ill-equipped to support our needs. Reagents and other key materials from these suppliers may have inconsistent attributes and introduce variability into our manufactured product candidates, which may contribute to variable patient outcomes and possible adverse events. We also do not have supply contracts with many of these suppliers and may not be able to obtain supply contracts with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key materials and equipment to support clinical or commercial manufacturing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For some of these reagents, equipment, and materials, we rely and may in the future rely on sole source vendors or a limited number of vendors. An inability to continue to source product from any of these suppliers, which could be due to regulatory actions or requirements affecting the supplier, adverse financial or other strategic developments experienced by a supplier, labor disputes or shortages, unexpected demands, or quality issues, could adversely affect our ability to satisfy demand for our product candidates, which could adversely and materially affect our product sales and operating results or our ability to conduct clinical trials, either of which could significantly harm our business. Additionally, in response to governmental shelter-in-place orders resulting from the ongoing COVID-19 pandemic, third-party suppliers and manufacturers on whom we rely may from time to time be required to limit their on-site staff&#8217;s availability to conduct activities at their respective facilities, and may encounter problems with shortages of qualified personnel and key contractors, and delays or pauses in the production and delivery of laboratory equipment, materials and supplies necessary for the manufacture of our product candidates. These problems may include workforce reductions, employee absenteeism and attrition, and supply chain failures or delays relating to the ongoing COVID-19 pandemic or other events affecting raw material supply or manufacturing capabilities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As we continue to develop and scale our manufacturing process, we expect that we will need to obtain rights to and supplies of certain materials and equipment to be used as part of that process. We may not be able to obtain rights to such materials on commercially reasonable terms, or at all, and if we are unable to alter our process in a commercially viable manner to avoid the use of such materials or find a suitable substitute, it would have a material adverse effect on our business. Even if we are able to alter our process so as to use other materials or equipment, such a change may lead to a delay in our clinical development and/or commercialization plans. If such a change occurs for a product candidate that is already in clinical testing, the change may require us to perform both comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in methods of product candidate manufacturing or formulation may result in the need to perform new clinical trials, which would require additional costs and cause delay.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As product candidates are developed through preclinical to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize yield and manufacturing batch size, minimize costs and achieve consistent quality and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of ongoing, planned or future clinical trials conducted with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence product sales and generate revenue.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Business and Operations</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If the market opportunities for our current and potential future product candidates, including SENTI 202 and SENTI-401, are smaller than we believe they are, our future product revenues may be adversely affected, and our business may suffer.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our understanding of the number of people who suffer from diseases that our current product candidates may be able to treat are based on estimates. These estimates may prove to be incorrect, and new studies may reduce the estimated incidence or prevalence of these diseases. The number of patients in the United States or elsewhere may turn out to be lower than expected, may not be otherwise amenable to treatment with our current or potential future product candidates or patients may become increasingly difficult to identify and access, all of which would adversely affect our business prospects and financial condition. In particular, the treatable population for our </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">candidates may further be reduced if our estimates of addressable populations are erroneous or sub-populations of patients do not derive benefit from our product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, there are several factors that could contribute to making the actual number of patients who receive our current or potential future product candidates less than the potentially addressable market. These include the lack of widespread availability of, and limited reimbursement for, new therapies in many underdeveloped markets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We face competition from companies that have developed or may develop product candidates for the treatment of the diseases that we may target, including companies developing novel therapies and platform technologies. If these companies develop platform technologies or product candidates more rapidly than we do, or if their platform technologies or product candidates are more effective or have fewer side effects, our ability to develop and successfully commercialize product candidates may be adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The development and commercialization of cell and gene therapies is highly competitive. We compete with a variety of large pharmaceutical companies, multinational biopharmaceutical companies, other biopharmaceutical companies and specialized biotechnology companies, as well as technology and/or therapeutics being developed at universities and other research institutions. Our competitors are often larger and better funded than we are. Our competitors have developed, are developing or will develop product candidates and processes competitive with ours. Competitive therapeutic treatments include those that have already been approved and accepted by the medical community and any new treatments that are currently in development or that enter the market. We believe that a significant number of product candidates are currently under development, and may become commercially available in the future, for the treatment of conditions for which we may try to develop product candidates. There is intense and rapidly evolving competition in the biotechnology and biopharmaceutical fields. We believe that while our gene circuit platform, its associated intellectual property portfolio, the characteristics of our current and potential future product candidates and our scientific and technical know-how together give us a competitive advantage in this space, competition from many sources remains.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many of our competitors have significantly greater financial, technical, manufacturing, marketing, sales and supply resources or experience than we do. If we successfully obtain approval for any product candidate, we will face competition based on many different factors, including the safety and effectiveness of our product candidates, the ease with which our product candidates can be administered, the timing and scope of regulatory approvals for these product candidates, the availability and cost of manufacturing, marketing and sales capabilities, price, reimbursement coverage and patent position. Competing products and product candidates could present superior treatment alternatives, including by being more effective, safer, less expensive or marketed and sold more effectively than any products we may develop. Competitive products and product candidates may make any product we develop obsolete or noncompetitive before we recover the expense of developing and commercializing such product. Such competitors could also recruit our employees, which could negatively impact our level of expertise and our ability to execute our business plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Any inability to attract and retain qualified key management, technical personnel and employees would impair our ability to implement our business plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success largely depends on the continued service of key executive management, advisors and other specialized personnel, including Timothy Lu, our Chief Executive Officer, Philip Lee, our Chief Technology Officer, Kanya Rajangam, our Chief Medical and Development Officer, and Deborah Knobelman, our Chief Financial Officer. Our senior management may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our employees. The loss of one or more members of our executive team, management team or other key employees or advisors could delay our research and development programs and have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Recruiting and retaining qualified scientific and clinical personnel and, if we progress the development of any of our product candidates, commercialization, manufacturing and sales and marketing personnel, will be critical to our success. The loss of the services of members of our senior management or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing members of our senior management and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize our product candidates. Our success also depends on our ability to continue to attract, retain and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">motivate highly skilled junior, mid-level and senior managers, as well as junior, mid-level and senior scientific and medical personnel. Competition to hire from this limited candidate pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high-quality personnel, our ability to pursue our growth strategy will be limited.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may experience difficulties in managing our growth and expanding our operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have limited experience in therapeutic development. As our current and potential future product candidates enter and advance through preclinical studies and any clinical trials, we will need to expand our development, regulatory and manufacturing capabilities or contract with other organizations to provide these capabilities for us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To manage our anticipated future growth, we will continue to implement and improve our managerial, operational, and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the complexity in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. In addition, we have limited experience in managing the manufacturing processes necessary for making cell and gene therapies. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, future growth imposes significant added responsibilities on members of management, including: identifying, recruiting, integrating, maintaining, and motivating additional employees; managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and improving our operational, financial and management controls, reporting systems and procedures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also experience difficulties in the discovery and development of potential future product candidates using our gene circuit platform if we are unable to meet demand as we grow our operations. In the future, we also expect to have to manage additional relationships with collaborators, suppliers and other organizations. Our ability to manage our operations and future growth will require us to continue to improve our operational, financial and management controls, reporting systems and procedures and secure adequate facilities for our operational needs. We may not be able to implement improvements to our management information and control systems in an efficient or timely manner and may discover deficiencies in existing systems and controls.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our strategic re-prioritization plan announced in January, 2023 may not result in the full anticipated benefits or may limit or disrupt our operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2023, we announced a pipeline re-prioritization plan to streamline our internal research and development efforts, and focus our internal resources on SENTI-202 and SENTI-401, and, with potential partners, to develop gene circuits for other programs. We may not realize the potential benefits, savings, cash runway extensions or improvements in our cost structure from our re-prioritization efforts due to unexpected difficulties, delays, or costs. In particular, we may not be able to enter into partnerships for SENTI-301A or other programs that we do not intend to develop internally on acceptable terms or within the timeframes that we expect, and we may be forced to dedicate additional time and resources to the maintenance of these programs or to our efforts to secure partnerships. If we are unable to realize anticipated cost savings from the reorganization, our operating results and financial condition may be adversely affected. Furthermore, implementing changes to our corporate strategy may be disruptive to our operations. For example, we may engage in workforce reductions that could yield unexpected consequences, such as turnover beyond planned reductions or increased difficulty in our day-to-day operations. Any workforce reductions could harm our ability to attract and retain qualified personnel who are critical to our business. Any failure to attract or retain qualified personnel could prevent us from successfully executing key technical and scientific initiatives.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If any of our product candidates is approved for marketing and commercialization in the future and we are unable to develop sales, marketing and distribution capabilities on our own or enter into agreements with third parties to perform these functions on acceptable terms, we will be unable to successfully commercialize any such future products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently have no sales, marketing or distribution capabilities or experience. We will need to develop internal sales, marketing and distribution capabilities to commercialize each current and potential future product candidate that gains, if ever, FDA or other regulatory authority approval, which would be expensive and time-consuming, or enter into collaborations with third parties to perform these services. If we decide to market any approved products directly, we will need to commit significant financial and managerial resources to develop a marketing and sales force with technical expertise and supporting distribution, administration and compliance capabilities. If we rely on third parties with such capabilities to market any approved products or decide to co-promote products with third parties, we will need to establish and maintain marketing and distribution arrangements with third parties, and there can be no assurance that we will be able to enter into such arrangements on acceptable terms or at all. In entering into third-party marketing or distribution arrangements, any revenue we receive will depend upon the efforts of the third parties and we cannot assure you that such third parties will establish adequate sales and distribution capabilities or be successful in gaining market acceptance for any approved product. If we are not successful in commercializing any product approved in the future, either on our own or through third parties, our business and results of operations could be materially and adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our potential future international operations may expose us to business, political, operational and financial risks associated with doing business outside of the United States.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business is subject to risks associated with conducting business internationally. Some of our future clinical trials may be conducted outside of the United States and we may enter into key supply arrangements or do other business with persons outside of the United States. Furthermore, if we or any future collaborator succeeds in developing any products, we anticipate marketing them in the European Union and other jurisdictions in addition to the United States. If approved, we or any future collaborator may hire sales representatives and conduct physician and patient association outreach activities outside of the United States. Doing business internationally involves a number of risks, including but not limited to:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">multiple, conflicting and changing laws and regulations such as those relating to privacy, data protection and cybersecurity, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">failure by us to obtain and maintain regulatory approvals for the commercialization of our product candidates in various countries;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">rejection or qualification of foreign clinical trial data by the competent authorities of other countries;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">additional potentially relevant third-party patent rights;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">complexities and difficulties in obtaining, maintaining, protecting and enforcing our intellectual property rights;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">difficulties in staffing and managing foreign operations;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">complexities associated with managing multiple payor reimbursement regimes, government payors or</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">patient self-pay systems;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">limits in our ability to penetrate international markets;</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease (including the COVID-19 pandemic), boycotts, curtailment of trade and other business restrictions;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">certain expenses including, among others, expenses for travel, translation and insurance; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">regulatory and compliance risks that relate to anti-corruption compliance and record-keeping that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its accounting provisions or its anti-bribery provisions or provisions of anti-corruption or anti-bribery laws in other countries.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any of these factors could harm our ongoing international operations and supply chain, as well as any future international expansion and operations and, consequently, our business, financial condition, prospects and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business entails a significant risk of product liability, and our inability to obtain sufficient insurance coverage could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As we conduct preclinical studies and future clinical trials of our current and potential future product candidates, we will be exposed to significant product liability risks inherent in the development, testing, manufacturing and marketing of these product candidates. Product liability claims could delay or prevent completion of our development programs. If we succeed in marketing products, such claims could result in an FDA investigation of the safety and effectiveness of our products, our manufacturing processes and facilities or our marketing programs and potentially a recall of our products or more serious enforcement action, limitations on the approved indications for which they may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our products, injury to our reputation, costs to defend the related litigation, a diversion of management&#8217;s time and our resources, substantial monetary awards to trial participants or patients and a decline in our stock price. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is becoming increasingly expensive. As a result, we or any future collaborators may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our employees, principal investigators, consultants and commercial collaborators may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial collaborators. Misconduct by employees could include intentional failures to comply with FDA regulations, provide accurate information to the FDA, comply with manufacturing standards we may establish, comply with federal and state healthcare fraud and abuse laws and regulations, report financial information or data accurately or disclose unauthorized activities to us. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a material adverse effect on our business and financial condition, including the imposition of significant criminal, civil </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and administrative fines or other sanctions, such as monetary penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government-funded healthcare programs, such as Medicare and Medicaid, integrity obligations, reputational harm and the curtailment or restructuring of our operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We depend on sophisticated information technology systems and data processing to operate our business. If we experience security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data or personal data, we may face costs, significant liabilities, harm to our brand and business disruption.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We rely on information technology systems and data processing that we or our service providers, collaborators, consultants, contractors or partners operate to collect, process, transmit and store electronic information in our day-to-day operations, including a variety of personal data, such as name, mailing address, email addresses, phone number and potentially clinical trial information. Additionally, we, and our service providers, collaborators, consultants, contractors or partners, do or will collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect and share personal information, health information and other information to host or otherwise process some of our anticipated future clinical data and that of users, develop our products, to operate our business, for clinical trial purposes, for legal and marketing purposes, and for other business-related purposes. Our internal computer systems and data processing and those of our third-party vendors, consultants, collaborators, contractors or partners, including future CROs may be vulnerable to a cyber-attack (including supply chain cyber-attacks), malicious intrusion, breakdown, destruction, loss of data privacy, actions or inactions by our employees or contractors that expose security vulnerabilities, theft or destruction of intellectual property or other confidential or proprietary information, business interruption or other significant security incidents. As the cyber-threat landscape evolves, these attacks are growing in frequency, level of persistence, sophistication and intensity, and are becoming increasingly difficult to detect. In addition to traditional computer &#8220;hackers,&#8221; threat actors, software bugs, malicious code (such as viruses and worms), employee theft or misuse, denial-of-service attacks (such as credential stuffing), phishing and ransomware attacks, sophisticated nation-state and nation-state supported actors now engage in attacks (including advanced persistent threat intrusions). These risks may be increased as a result of the COVID-19 pandemic, owing to an increase in personnel working remotely and higher reliance on internet technology. Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures. We may also experience security breaches that may remain undetected for an extended period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There can be no assurance that we, our service providers, collaborators, consultants, contractors or partners will be successful in efforts to detect, prevent or fully recover systems or data from all breakdowns, service interruptions, attacks or breaches of systems that could adversely affect our business and operations and/or result in the loss of critical or sensitive data. Any failure by us or our service providers, collaborators, consultants, contractors or partners to detect, prevent, respond to or mitigate security breaches or improper access to, use of, or inappropriate disclosure of any of this information or other confidential or sensitive information, including patients&#8217; personal data, or the perception that any such failure has occurred, could result in claims, litigation, regulatory investigations and other proceedings, significant liability under state, federal and international law, and other financial, legal or reputational harm to us. Further, such failures or perceived failures could result in liability and a material disruption of our development programs and our business operations, which could lead to significant delays or setbacks in our research, delays to commercialization of our product candidates, lost revenues or other adverse consequences, any of which could have a material adverse effect on our business, results of operations, financial condition, prospects and cashflow. For example, the loss or alteration of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, applicable laws and regulations relating to privacy, data protection or cybersecurity, external contractual commitments and internal privacy and security policies may require us to notify relevant stakeholders if there has been a security breach, including affected individuals, business partners and regulators. Such disclosures are costly, and the disclosures or any actual or alleged failure to comply with such requirements could lead to a materially adverse impact on the business, including negative publicity, a loss of confidence in our services or security measures by our business partners or breach of contract claims. There can be no assurance that the limitations of liability in our contracts would be enforceable or adequate or would otherwise protect us from liabilities or damages if we fail to comply with applicable data protection laws, privacy policies or other data protection obligations related to information security or security breaches.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our research, development and manufacturing involve the use of hazardous materials and various chemicals. We maintain quantities of various flammable and toxic chemicals in our facilities that are required for our research, development and manufacturing activities. We are subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. We believe our procedures for storing, handling and disposing of these materials in our facilities comply with the relevant guidelines of the state of California and the Occupational Safety and Health Administration of the U.S. Department of Labor. Although we believe that our safety procedures for handling and disposing of these materials comply with the standards mandated by applicable regulations, the risk of accidental contamination or injury from these materials cannot be eliminated. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures, exposure to blood-borne pathogens and the handling of animals and biohazardous materials. Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of these materials, this insurance may not provide adequate coverage against potential liabilities. Although we have some environmental liability insurance covering certain of our facilities, we may not maintain adequate insurance for all environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials. Additional federal, state and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with, and substantial fines or penalties if we violate, any of these laws or regulations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our business, operations and clinical development plans and timelines could be adversely affected by global economic and political developments, including high inflation and capital market disruption, the war in Ukraine, economic sanctions and economic slowdowns or recessions, the COVID-19 pandemic, or the manufacturing, clinical trial and other business activities performed by us or by third parties with whom we may conduct business, including our anticipated contract manufacturers, CROs, shippers and others.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any global financial crisis or slowdown could cause volatility and disruptions in the capital and credit markets. Similarly, any global health epidemic, such as the COVID-19 pandemic, could cause disruptions in our operations and in the operations of third-party manufacturers, CROs, and other third-parties on whom we rely. More recently, the global economy has been impacted by increasing interest rates and high inflation, as well as by the war in Ukraine and the possibility of a wider European or global conflict. A severe or prolonged economic downturn could result in a variety of risks to our business, including a reduced ability to raise additional capital when needed on acceptable terms, or at all. Additionally, a weak or declining economy or international trade disputes could strain our suppliers, some of whom are located outside the United States, potentially resulting in supply disruption. Also, the global COVID-19 pandemic and government measures taken in response have also had a significant impact on businesses and commerce worldwide. In connection with COVID-19, we implemented work-from-home policies for most employees. The effects of government orders and our work-from-home policies may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our relationships with our suppliers or other vendors are terminated or scaled back as a result of the COVID-19 pandemic or other health epidemics, we may not be able to enter into arrangements with alternative suppliers or vendors or do so on commercially reasonable terms or in a timely manner. Switching or adding additional suppliers or vendors involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new supplier or vendor commences work. As a result, delays may occur, which could adversely impact our ability to meet our desired clinical development and any future commercialization timelines. Although we carefully manage our relationships with our suppliers and vendors, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not harm our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, our preclinical studies and future clinical trials may be affected by the COVID-19 pandemic or other global health epidemics. Clinical site initiation, patient enrollment and activities that require visits to clinical sites, including data monitoring, may be delayed due to prioritization of hospital resources toward the COVID-19 pandemic or concerns among patients about participating in clinical trials during a pandemic. Some patients may </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">have difficulty following certain aspects of clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. These challenges may also increase the costs of completing our clinical trials. Similarly, if we are unable to successfully recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19 or experience additional restrictions by their institutions, city or state, our preclinical studies and future clinical trial operations could be adversely impacted.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The global COVID-19 pandemic has disrupted and may continue to disrupt healthcare delivery and healthcare regulatory systems. Such disruptions could divert healthcare resources, or delay the review and approval by the FDA or other regulatory bodies, thereby causing delay for our clinical trials. During a global health crisis, certain manufacturing facilities and materials may be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, which may make it more difficult to obtain materials or manufacturing slots for the product candidates needed for our clinical trials, which could lead to delays in these trials. These and similar, and perhaps more severe, disruptions in our operations could have a material adverse effect on our business, results of operations, cash flows, financial condition and/or prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We do not yet know the full extent of potential delays or impacts on our business, our future clinical trials, healthcare systems or the global economy as a whole that may result from the ongoing COVID-19 pandemic. However, these effects could have a material impact on our operations, and to the extent the COVID-19 pandemic adversely affects our business, results of operations, cash flows, financial condition and/or prospects, it may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Market volatility and economic downturns may harm our business and results of operations and negatively affect our stock price.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our overall performance depends, in part, on worldwide economic conditions. In recent months, we have observed increased economic uncertainty in the United States and abroad. Impacts of such economic weakness include:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">declining overall demand for goods and services, leading to reduced profitability;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reduced credit availability;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">higher borrowing costs; </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reduced liquidity; </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">volatility in credit, equity and foreign exchange markets; and </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">bankruptcies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These developments could lead to supply chain disruption, inflation, higher interest rates, and uncertainty about business continuity, which may adversely affect our business and our results of operations and negatively affect our stock price.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent volatility in capital markets and lower market prices for our securities may affect our ability to access new capital through sales of shares of our common stock or issuance of indebtedness, which may harm our liquidity, limit our ability to grow our business, pursue acquisitions or improve our operating infrastructure and restrict our ability to compete in our markets.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our operations consume substantial amounts of cash, and we intend to continue to make significant investments to support our business growth, respond to business challenges or opportunities, develop new solutions, retain or expand our current levels of personnel, improve our existing solutions, enhance our operating infrastructure, and potentially acquire complementary businesses and technologies. Our future capital requirements may be significantly different from our current estimates and will depend on many factors, including the need to:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">finance unanticipated working capital requirements;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">develop or enhance our technological infrastructure and our existing solutions;</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">pursue acquisitions or other strategic relationships; and</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">respond to competitive pressures.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accordingly, we may need to pursue equity or debt financings to meet our capital needs. With uncertainty in the capital markets and other factors, such financing may not be available on terms favorable to us or at all. If we raise additional funds through further issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution, and any new equity securities we issue could have rights, preferences, and privileges superior to those of holders of our common stock. Any debt financing secured by us in the future could involve additional restrictive covenants relating to our capital-raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. If we are unable to obtain adequate financing or financing on terms satisfactory to us, we could face significant limitations on our ability to invest in our operations and otherwise suffer harm to our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Rising inflation rates could negatively impact our revenues and profitability if increases in the prices of our products or a decrease in consumer spending results in lower sales. In addition, if our costs increase and we are not able to pass along these price increases to our customers, our net income would be adversely affected, and the adverse impact may be material.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Inflation rates, particularly in the United States, have increased recently to levels not seen in years. Increased inflation may result in decreased demand for our products and services, increased operating costs (including our labor costs), reduced liquidity, and limitations on our ability to access credit or otherwise raise debt and equity capital. In addition, the United States Federal Reserve has raised, and may again raise, interest rates in response to concerns about inflation. Increases in interest rates, especially if coupled with reduced government spending and volatility in financial markets, may have the effect of further increasing economic uncertainty and heightening these risks.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Intellectual Property</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to obtain or protect intellectual property rights related to our technology and current or future product candidates, or if our intellectual property rights are inadequate, our competitors could develop and commercialize products and technology similar or identical to ours, and we may not be able to compete effectively in our market or successfully commercialize any product candidates we may develop.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our success depends in part on our ability to obtain and maintain protection for our owned and in-licensed intellectual property rights and proprietary technology. We rely on a combination of patents, trademarks, trade secret protection and confidentiality agreements, including in-licenses of intellectual property rights and biologic materials of others, to protect our current or future platform technologies, product candidates, methods used to manufacture our current or future product candidates and methods for treating patients using our current or future product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We own or in-license patents and patent applications relating to our platform technologies and product candidates. There is no guarantee that any patents covering our platform technologies or product candidates will issue from the patent applications we own, in-license or may file in the future, or, if they do, that the issued claims will provide adequate protection for our platform technologies or product candidates, or any meaningful competitive advantage. Further, there cannot be any assurance that such patents issued will not be infringed, designed around, invalidated by third parties or effectively prevent others from commercializing competitive technologies, products or product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The patent prosecution process is expensive, complex and time-consuming. Patent license negotiations also can be complex and protracted, with uncertain results. We may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patents and patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own or in-license may fail to result in issued patents, and, even if they do issue as patents, such patents may not cover our current or future technologies or product candidates in the United States or in other countries or provide sufficient protection from competitors. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. We do not have exclusive control over the preparation, filing and prosecution of patent applications under certain of our in-license agreements, and we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the rights to patents, that we out-license to third parties. </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. Even if our owned or in-licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our patents by developing similar or alternative product candidates in a non-infringing manner.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, although we make reasonable efforts to ensure patentability of our inventions, we cannot guarantee that all of the potentially relevant prior art relating to our owned or in-licensed patents and patent applications has been found. For example, publications of discoveries in scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, and in some cases not at all. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our platform technologies, our product candidates, or the use of our technologies. We thus cannot know with certainty whether we or our licensors were the first to file for patent protection of such inventions. In addition, the United States Patent and Trademark Office, or USPTO, might require that the term of a patent issuing from a pending patent application be disclaimed and limited to the term of another patent that is commonly owned or names a common inventor. There is no assurance that all potentially relevant prior art relating to our owned or in-licensed patent applications has been found. For this reason, and because there is no guarantee that any prior art search is absolutely correct and comprehensive, we may be unaware of prior art that could be used to invalidate an issued patent or to prevent our owned or in-licensed patent applications from issuing as patents. Invalidation of any of our patent rights, including in-licensed patent rights, could materially harm our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Moreover, the patent positions of biotechnology companies like ours are generally uncertain because they may involve complex legal and factual considerations that have, in recent years, been the subject of legal development and change. The relevant patent laws and their interpretation, both inside and outside of the United States, is also uncertain. Changes in either the patent laws or their interpretation in the United States and other jurisdictions may diminish our ability to protect our platform technology or product candidates and could affect the value of such intellectual property. In particular, our ability to stop third parties from making, using, selling, offering to sell or importing products that infringe, misappropriate or otherwise violate our intellectual property will depend in part on our success in obtaining and enforcing patent claims that cover our platform technology, product candidates, inventions and improvements. We cannot guarantee that patents will be granted with respect to any of our owned or licensed pending patent applications or with respect to any patent applications we may file or license in the future, nor can we be sure that any patents that may be granted to us or our licensors in the future will be commercially useful in protecting our products, the methods of use or manufacture of those products. Additionally, third parties, including our former employees and collaborators, may challenge the ownership or inventorship of our patent rights to claim that they are entitled to ownership and inventorship interest, and we may not be successful in defending against such claims. However, we are not currently facing any such challenges. Moreover, issued patents do not guarantee the right to practice our technology in relation to the commercialization of our products. Issued patents only allow us to block&#8212;in some cases&#8212;potential competitors from practicing the claimed inventions of the issued patents.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The issuance, scope, validity, enforceability and commercial value of our pending patent rights are uncertain. The standards applied by the USPTO and foreign patent offices in granting patents are not always certain and moreover, are not always applied uniformly or predictably. For example, there is no uniform worldwide policy regarding patentable subject matter or the scope of claims allowable in patents. Our pending and future patent applications may not result in patents being issued in the United States or in other jurisdictions which protect our technology or products or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our owned or in-licensed patent applications or narrow the scope of any patent protection we may obtain from our owned or in-licensed patent applications. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, patents and other intellectual property rights in the pharmaceutical and biotechnology space are evolving and involve many risks and uncertainties. For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and any future product candidates and practicing our proprietary technology, and any issued patents may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">otherwise may exist for our product candidate and any future product candidates. In addition, the scope of the rights granted under any issued patents may not provide us with protection or competitive advantages against competitors or other parties with similar technology. Additionally, our competitors may initiate legal proceedings, such as declaratory judgment actions in federal court or reexaminations or an</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> review at the USPTO in an attempt to invalidate or narrow the scope of our patents. However, we are not currently facing any such proceedings. Furthermore, our competitors or other parties may independently develop similar technologies that are outside the scope of the rights granted under any issued patents. For these reasons, we may face competition with respect to our product candidates and any future product candidates. Moreover, because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that, before any particular product candidate can be commercialized, any patent protection for such product candidate may expire or remain in force for only a short period following commercialization, thereby reducing the commercial advantage the patent provides.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if patents do successfully issue from our owned or in-licensed patent application, and even if such patents cover our current or any future technologies or product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Any successful challenge to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any current or future technologies or product candidates that we may develop. Likewise, if patent applications we own or have in-licensed with respect to our development programs and current or future technologies or product candidates fail to issue, if their breadth or strength is threatened, or if they fail to provide meaningful exclusivity, other companies could be dissuaded from collaborating with us to develop current or future technologies or product candidates. Lack of valid and enforceable patent protection could threaten our ability to commercialize current or future products and could prevent us from maintaining exclusivity with respect to the invention or feature claimed in the patent applications. Any failure to obtain or any loss of patent protection could have a material adverse impact on our business and ability to achieve profitability. We may be unable to prevent competitors from entering the market with a product that is similar or identical to any of our current or potential future product candidates or from utilizing technologies similar to those in our gene circuit platform technologies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The filing of a patent application or the issuance of a patent is not conclusive as to its ownership, inventorship, scope, patentability, validity or enforceability. Issued patents and patent applications may be challenged in the courts and in the patent office in the United States and abroad. For example, our patent applications or patent applications filed by our licensors, or any patents that grant therefrom, may be challenged through third-party submissions, opposition or derivation proceedings. By further example, any issued patents that may result from our owned or in-licensed patent applications may be challenged through reexamination,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> review or post-grant review proceedings before the USPTO, or in declaratory judgment actions or counterclaims. An adverse determination in any such submission, proceeding or litigation could prevent the issuance of, reduce the scope of, invalidate or render unenforceable our owned or in-licensed patent rights, result in the loss of exclusivity, limit our ability to stop others from using or commercializing similar or identical platforms and product candidates, or allow third parties to compete directly with us without payment to us. In addition, if the breadth or strength of protection provided by any patents that might result from our owned or in-licensed patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future platforms or product candidates. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Moreover, we currently co-own certain patent applications with third parties and may in the future co-own additional patents and patent applications with third parties. If we are unable to obtain an exclusive license to any such third-party co-owners&#8217; interest in such patents or patent application, such co-owners may be able to license their rights to other third parties, including our competitors, and our competitors could market competing products and technology. We may need the cooperation of any such co-owners to enforce such patents against third parties, and such cooperation may not be provided to us. Any of the foregoing could have a material adverse effect on our competitive position, business prospects and financial conditions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our in-licensed patent rights may be subject to a reservation of rights by one or more third parties, such as the U.S. government. In addition, our rights in such inventions may be subject to certain requirements to manufacture product candidates embodying such inventions in the United States. Any exercise by the U.S. government of such rights could harm our competitive position, business, financial condition, results of operations and prospects.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The patent protection and patent prosecution for some of our product candidates and technologies may be dependent on third parties.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While we normally seek to obtain the right to control prosecution, maintenance and enforcement of the patents relating to our product candidates and technologies, there may be times when the filing and prosecution activities for patents and patent applications relating to our product candidates and technologies are controlled by our licensors or collaborators. Our licensors may not successfully prosecute the patent applications to which we are licensed. Even if patents are issued in respect of these patent applications, our licensors may fail to maintain these patents, may determine not to pursue litigation against other companies that are infringing these patents, or may pursue such litigation less aggressively than we would.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If any of our licensors or collaborators fail to prosecute, maintain and enforce such patents and patent applications in a manner consistent with the best interests of our business, including by payment of all applicable fees for patents covering our product candidates and technologies, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, our ability to develop and commercialize those product candidates and technologies may be adversely affected and we may not be able to prevent competitors from making, using and selling competing product candidates. In addition, even where we have the right to control patent prosecution of patents and patent applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensees, our current and future licensors and their counsel that took place prior to the date upon which we assumed control over patent prosecution.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our licensed European patents and patent applications could be challenged in the recently-created Unified Patent Court, or UPC, for the European Union, that is expected to be fully ratified in 2023. Under our current license agreements, we may not have the final or sole decision as to whether we are able to opt out certain of our in-licensed European patents and patent applications from the UPC. Our licensors may decide not to opt out of the UPC, which would subject our in-licensed European patents and patent applications to the jurisdiction of the UPC. Furthermore, even if our licensors decide to opt out of the UPC, we cannot guarantee that our licensors will comply with the legal formalities and requirements for properly opting out of the UPC. Thus, we cannot be certain that our in-licensed European patents and patent applications will not fall under the jurisdiction of the UPC. Under the UPC, a single European patent would be valid and enforceable in numerous European countries. A challenge to the validity of a European patent in a central revocation proceeding under the UPC, if successful, could result in a loss of patent protection in numerous European countries, which could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, we may have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend certain of the intellectual property that is licensed to us. It is possible that the licensors&#8217; infringement proceeding(s) or defense activities may be less vigorous than had we conducted them ourselves.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be unable to acquire or in-license any relevant third-party intellectual property rights that we identify as necessary or important to our business operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because our development programs may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, in-license or use these third-party proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing of third-party intellectual property rights is a competitive area, and more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. More established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. If we are unable to license such technology, or if we are forced to license such technology on unfavorable terms, our business could be materially harmed. If we are unable to obtain a necessary license, we may be unable to develop or commercialize the affected current or future product candidates, which could materially harm our business, and the third parties owning such intellectual property rights could seek either </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, our licensors may retain certain rights under their agreements with us, including the right to use the underlying technology for noncommercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, some intellectual property that we have in-licensed or that we own may have been discovered through government funded programs and thus may be subject to federal regulations such as &#8220;march-in&#8221; rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights, and limit our ability to contract with non-U.S. manufacturers.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> As a result, the U.S. government may have certain rights to intellectual property embodied in our current or future product candidates pursuant to the Bayh-Dole Act of 1980, or Bayh-Dole Act, and implementing regulations. These U.S. government rights in certain inventions developed under a government-funded program include a non-exclusive, non-transferable, irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government may have the right to require us or our licensors to grant exclusive, partially exclusive, or non-exclusive licenses to any of these inventions to a third party if it determines that: (i) adequate steps have not been taken to commercialize the invention; (ii) government action is necessary to meet public health or safety needs; or (iii) government action is necessary to meet requirements for public use under federal regulations (also referred to as &#8220;march-in rights&#8221;).</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> More specifically, certain currently in-licensed patents that cover certain split, universal and programmable chimeric antigen receptor technology may be subject to march-in-rights. This technology is not embodied in any of our current product candidates. In addition, certain currently in-licensed patents that cover certain components and process for regulating the expression of a fusion protein with the use of a protease inhibitor are subject to march-in-rights, which technology can be embodied in certain regulator dial gene circuits. We also own a patent family claiming an invention made under research partially funded by the federal government. Such invention covers mesenchymal stem cells that express combinations of immune effectors for autoimmunity. While the foregoing invention is not embodied in any current product candidates, it is subject to march-in-rights. The U.S. government also has the right to take title to these inventions made through government funded programs if we, or the applicable licensor, fail to disclose the invention to the government and fail to file an application to register the intellectual property within specified time limits. These time limits have recently been changed by regulation, and may change in the future. Intellectual property generated under a government-funded program is also subject to certain reporting requirements, compliance with which may require us or the applicable licensor to expend substantial resources. In addition, the U.S. government requires that any products embodying the subject invention or produced through the use of the subject invention be manufactured substantially in the United States. The manufacturing preference requirement can be waived if the owner of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. manufacturers may limit our ability to contract with non-U.S. product manufacturers for products covered by such intellectual property. To the extent any of our current or future intellectual property is generated through the use of U.S. government funding, the provisions of the Bayh-Dole Act may similarly apply.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We currently, and in the future may continue to, enter into agreements involving licenses or collaborations that provide for access or sharing of intellectual property. These intellectual property-related agreements may impose certain obligations and restrictions on our ability to develop and commercialize our product candidates and technologies that are the subject of such licenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We license rights from third parties to use certain intellectual property relevant to one or more of our current and future product candidates. In the future, we may need to obtain additional licenses from others to advance our research and development activities or allow the commercialization of our current and future product candidates we may identify and pursue. These existing license agreements impose, and any future license agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">insurance, patent prosecution and enforcement or other obligations on us. For example, we are a party to three license agreements with the U.S. Department of Health and Human Services, as represented by the National Cancer Institute, or NCI, for intellectual property relevant to our product candidates. For a more detailed description of the license agreements with NCI, see the section titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business&#8212;Material License and Collaboration Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; in this Form 10-K.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, certain of our future agreements with third parties may limit or delay our ability to consummate certain transactions, may impact the value of those transactions, or may limit our ability to pursue certain activities. For example, we may in the future enter into license agreements that are not assignable or transferable, or that require the licensor&#8217;s express consent in order for an assignment or transfer to take place.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, we or our licensors, if any, may fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. Therefore, we may miss potential opportunities to strengthen our patent position. It is possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, claim scope, or requests for patent term adjustments. If we or our licensors fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If our licensors are not fully cooperative or disagree with us as to the prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form, preparation, prosecution, or enforcement of our patents or patent applications, such patents may be invalid and/or unenforceable, and such applications may never result in valid, enforceable patents. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business, financial conditions, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, we may not have the right to control the preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications that we license from third parties. In certain circumstances, our licensed patent rights are subject to our reimbursing our licensors for their patent prosecution and maintenance costs. If our licensors and future licensors fail to prosecute, maintain, enforce and defend patents we may license, or lose rights to licensed patents or patent applications, our licensed rights may be reduced or eliminated. In such circumstances, our right to develop and commercialize any of our products or product candidates that is the subject of such licensed rights could be materially adversely affected. Even where we have the right to control prosecution of patents and patent applications under license from third parties, we may still be adversely affected or prejudiced by actions or inactions of our predecessors or licensors and their counsel that took place prior to us assuming control over patent prosecution.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our technology acquired or licensed currently or in the future from various third parties is or may be subject to retained rights. Our predecessors or licensors do and may retain certain rights under their agreements with us, including the right to use the underlying technology for non-commercial academic and research use, to publish general scientific findings from research related to the technology, and to make customary scientific and scholarly disclosures of information relating to the technology. It is difficult to monitor whether our predecessors or licensors limit their use of the technology to these uses, and we could incur substantial expenses to enforce our rights to our licensed technology in the event of misuse.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we are limited in our ability to utilize acquired or licensed technologies, or if we lose our rights to critical in-licensed technology, we may be unable to successfully develop, out-license, market and sell our product candidates, which could prevent or delay new product introductions. Our business strategy depends on the successful development of acquired technologies and licensed technology into commercial product candidates. Therefore, any limitations on our ability to utilize these technologies may impair our ability to develop, out-license or market and sell our product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to comply with our obligations under any existing or future license, collaboration or other intellectual property-related agreements, we may be required to pay damages and could lose intellectual property rights that may be necessary for developing, commercializing and protecting our current or future technologies or product candidates or we could lose certain rights to grant sublicenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have certain obligations to third-party licensors from whom we license certain patent rights that are relevant to one or more current and future product candidates. In the future, we may need to obtain additional licenses from other third parties to advance our research and development activities or allow the commercialization of our current </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and future product candidates. Our existing license agreements impose, and any future license agreements we enter into are likely to impose, various development, commercialization, funding, milestone, royalty, diligence, sublicensing, insurance, patent prosecution and enforcement or other obligations on us. For a more detailed description of our existing license agreements, see the section titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business&#8212;Material License and Collaboration Agreements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; in the Annual Report on Form 10-K for the year ended December 31, 2022. If we breach any of these obligations, including diligence obligations with respect to development and commercialization of product candidates covered by the intellectual property licensed to us, or use the intellectual property licensed to us in an unauthorized manner or we are subject to bankruptcy-related proceedings, we may be required to pay damages and the licensor may have the right to terminate the respective agreement or materially modify the terms of the license, such as by rendering currently exclusive licenses non-exclusive. License termination or modification could result in our inability to develop, manufacture and sell products that are covered by the licensed intellectual property or could enable a competitor to gain access to the licensed intellectual property.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In certain circumstances, our licensed patent rights are subject to our reimbursing our licensors for their patent prosecution and maintenance costs. If our licensors and future licensors fail to prosecute, maintain, enforce and defend patents we may license, or lose rights to licensed patents or patent applications, our licensed rights may be reduced or eliminated. In such circumstances, our right to develop and commercialize any of our products or product candidates that are the subject of such licensed rights could be materially adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our current or future licensors may own or control intellectual property that has not been licensed to us and, as a result, we may be subject to claims, regardless of their merit, that we are infringing, misappropriating or otherwise violating the licensor&#8217;s intellectual property rights. In addition, while we cannot currently determine the amount of the royalty obligations we would be required to pay on sales of future products if infringement or misappropriation were found, those amounts could be significant. The amount of our future royalty obligations will depend on the technology and intellectual property we use in products that we successfully develop and commercialize, if any. Therefore, even if we successfully develop and commercialize products, we may be unable to achieve or maintain profitability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Disputes may arise between us and our present and future licensors regarding intellectual property subject to a licensing agreement, including:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the scope of rights granted under the license agreement and other interpretation-related issues, including but not limited to our right to transfer or assign the license;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">whether and the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our right to sublicense patents and other rights to third parties, including the terms and conditions thereof;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our diligence obligations with respect to the development and commercialization of our product candidates that are covered by the license agreement, and what activities satisfy those diligence obligations;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our right to transfer or assign the license;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the inventorship and ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our collaborators; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the priority of invention of patented technology.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If disputes over intellectual property that we license in the future prevent or impair our ability to maintain our licensing arrangements on acceptable terms, we may not be able to successfully develop and commercialize the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">affected product candidates, which would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the agreements under which we currently license intellectual property or technology from the National Cancer Institute (&#8220;NCI&#8221;) and other third parties are complex, and certain provisions in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, while we currently do not have any liens, security interests, or other encumbrances on the intellectual property that we own, we may, in the future, need to obtain a loan or a line of credit that will require that we put up our intellectual property as collateral to our lenders or creditors. If we do so, and we violate the terms of any such loan or credit agreement, our lenders or creditors may take possession of such intellectual property, including the rights to receive proceeds derived from such intellectual property.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patent terms may not be able to protect our competitive position for an adequate period of time with respect to our current or future technologies or product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patents have a limited lifespan. The term of individual patents and applications in our portfolio depends upon the legal term of patents in the countries in which they are obtained. In most countries in which we file, including the United States, the patent term is 20 years from the earliest date of filing a non-provisional patent application. Extensions of patent term may be available, but there is no guarantee that we would have patents eligible for extension, or that we would succeed in obtaining any particular extension, and no guarantee any such extension would confer a patent term for a sufficient period of time to exclude others from commercializing product candidates similar or identical to ours. In the United States, the term of a patent may be eligible for patent term adjustment, which permits patent term restoration as compensation for delays incurred at the USPTO during the patent prosecution process. In addition, for patents that cover an FDA-approved drug, the Drug Price Competition and Patent Term Restoration Act of 1984 (the &#8220;Hatch-Waxman Act&#8221;) permits a patent term extension of up to five years beyond the expiration of the patent. While the length of the patent term extension is related to the length of time the drug is under regulatory review, patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval, and only one patent per approved drug&#8212;and only those claims covering the approved drug, a method for using it or a method for manufacturing it&#8212;may be extended under the Hatch-Waxman Act. Similar provisions are available in Europe and other foreign jurisdictions to extend the term of a patent that covers an approved drug. In the future, if and when our products receive FDA approval or applicable approval in other jurisdictions, we expect to apply for patent term extensions on issued patents covering those products in the United States and other jurisdiction where such extensions are available; however, there is no guarantee that the applicable authorities, including the FDA in the United States, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions. We also may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for the applicable product candidate will be shortened and our competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced. Further, if this occurs, our competitors may be able to launch their products earlier by taking advantage of our investment in development and clinical trials along with our clinical and preclinical data. This could have a material adverse effect on our business and ability to achieve profitability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The life of a patent and the protection it affords are limited. As a result, our owned and in-licensed patent portfolio provides us with limited rights that may not last for a sufficient period of time to exclude others from commercializing product candidates similar or identical to ours. Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products, including </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">generics or biosimilars. For example, given the large amount of time required for the research, development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our current or any future technologies or product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Changes in either the patent laws or interpretation of the patent laws in the United States or elsewhere could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. The United States has enacted and implemented wide-ranging patent reform legislation. On September 16, 2011, the Leahy-Smith America Invents Act (the &#8220;Leahy-Smith Act&#8221;) was signed into law, which could increase the uncertainties and costs surrounding the prosecution of our owned or in licensed patent applications and the enforcement or defense of any future owned or in-licensed issued patents. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications are prosecuted, redefine prior art, may affect patent litigation and switch the U.S. patent system from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system. Under a first-to-file system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled to the patent on an invention regardless of whether another inventor had made the invention earlier. A third party that files a patent application in the USPTO after March 16, 2013, but before us, could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or until issuance, we cannot be certain that we or our licensors were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our or our licensor&#8217;s patents or patent applications. The Leahy-Smith Act also allows third-party submission of prior art to the USPTO during patent prosecution and sets forth additional procedures to challenge the validity of a patent by USPTO-administered post-grant proceedings, including derivation, reexamination,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> review, post-grant review and interference proceedings. The USPTO developed additional regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and, in particular, the first-to-file provisions, became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. The Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or in-licensed patent applications and the enforcement or defense of our issued owned or in-licensed patents, all of which could have a material adverse impact on our business prospects and financial condition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As referenced above, for example, courts in the U.S. continue to refine the heavily fact-and-circumstance-dependent jurisprudence defining the scope of patent protection available for therapeutics, narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. This creates uncertainty about our ability to obtain patents in the future and the value of such patents. In addition, the patent positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future. We cannot provide assurance that future developments in U.S. Congress, the federal courts and the USPTO will not adversely impact our owned or in-licensed patents or patent applications. The laws and regulations governing patents could change in unpredictable ways that could weaken our and our licensors&#8217; ability to obtain new patents or to enforce our existing owned or in-licensed patents and patents that we might obtain or in-license in the future. Similarly, changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may have a material adverse effect on our and our licensors&#8217; ability to obtain new patents or to protect and enforce our owned or in-licensed patents or patents that we may obtain or in-license in the future.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be subject to lawsuits or litigation to protect or enforce our patents or other intellectual property, which could result in substantial costs and liability and prevent us from commercializing our potential products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third parties may attempt to invalidate our or our licensors&#8217; intellectual property rights via procedures including but not limited to patent infringement lawsuits, declaratory judgment actions, interferences, oppositions and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> reexamination proceedings before the USPTO, U.S. courts and foreign patent offices or foreign courts. An adverse determination in any such submission or proceeding could reduce the scope or enforceability of, or invalidate, our patent rights, which could adversely affect our competitive position. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party in a district court action. Even if such rights are not directly challenged, disputes could lead to the weakening of our or our licensors&#8217; intellectual property rights. Our defense against any attempt by third parties to circumvent or invalidate our intellectual property rights could be costly to us, could require significant time and attention of our management, and could have a material and adverse impact on our profitability, financial condition and prospects or ability to successfully compete.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We or our licensors may find it necessary to pursue claims or to initiate lawsuits to protect or enforce our owned or in-licensed patent or other intellectual property rights. The cost to us in defending or initiating any litigation or other proceeding relating to our owned or in-licensed patent or other intellectual property rights, even if resolved in our favor, could be substantial, particularly in a foreign jurisdiction, and any litigation or other proceeding would divert our management&#8217;s attention. Such litigation or proceedings could materially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. Some of our competitors may be able to more effectively sustain the costs of complex patent litigation because they have substantially greater resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could delay our research and development efforts and materially limit our ability to continue our operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we or our licensors were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates or our technology, the defendant could counterclaim that such patent is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, claiming patent-ineligible subject matter, lack of novelty, indefiniteness, lack of written description, non-enablement, anticipation or obviousness. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. The outcome of such invalidity and unenforceability claims is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art of which we or our licensors and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we could lose at least part, and perhaps all, of the patent protection for one or more of our product candidates or certain aspects of our platform technologies. Such a loss of patent protection could have a material adverse effect on our business, financial condition, results of operations and prospects. Patents and other intellectual property rights also will not protect our product candidates and technologies if competitors or third parties design around such product candidates and technologies without legally infringing, misappropriating or violating our owned or in-licensed patents or other intellectual property rights.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our European patents and patent applications could be challenged in the UPC. Though we may decide to opt out our European patents and patent applications from the UPC, if certain formalities and requirements are not met, our European patents and patent applications could be challenged for non-compliance and brought under the jurisdiction of the UPC. Potentially, a single proceeding under the UPC could result in loss of patent protection in numerous European countries rather than each validated country separately. Such a loss of patent protection could have a material adverse impact on our business and our ability to commercialize or license our technology and product candidates.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Filing, prosecuting and defending patents on current or future technologies or product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other countries. Competitors or other third parties may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export infringing product candidates to territories where we have patent protection or licenses, but enforcement is not as strong as that in the United States. These product candidates may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, including certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biotechnology, which could make it difficult for us to stop the infringement of any owned and in-licensed patents we may obtain in other countries, or the marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our owned or in-licensed intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and could divert our efforts and attention from other aspects of our business. Such proceedings could also put any owned or in-licensed patents at risk of being invalidated or interpreted narrowly, could put our owned or in-licensed patent applications at risk of not issuing, and could provoke third parties to assert claims against us or our licensors. We or our licensors may not prevail in any lawsuits or other adversarial proceedings that we or our licensors initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our and our licensors&#8217; efforts to enforce such intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or in-license.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of its patents. If we or any of our licensors are forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position in the relevant jurisdiction may be impaired and our business prospects may be materially adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or violating their intellectual property rights, the outcome of which would be uncertain and could have a material adverse impact on the success of our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our commercial success depends, in part, upon our ability or the ability of our potential future collaborators to develop, manufacture, market and sell our current or any future product candidates and to use our proprietary technologies without infringing, misappropriating or violating the proprietary and intellectual property rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> review proceedings before the USPTO, U.S. courts, foreign patent offices or foreign courts. As the field of gene and cell therapies advances, patent applications are being processed by national patent offices around the world. There is uncertainty about which patents will issue, and, if they do, there is uncertainty as to when, to whom, and with what claims. Any claims of patent infringement asserted by third parties would be time consuming and could:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">result in costly litigation that may cause negative publicity;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">divert the time and attention of our technical personnel and management;</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">cause development delays;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">prevent us from commercializing any of our product candidates until the asserted patent expires or is held finally invalid or not infringed in a court of law;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">require us to develop non-infringing technology, which may not be possible on a cost-effective basis;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">subject us to substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology at issue infringes on or violates the third party&#8217;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#8217;s attorneys&#8217; fees; or</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or at all, or which might be non-exclusive, which could result in our competitors gaining access to the same technology.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that we may be subject to claims of infringement of the patent rights of third parties. Because patent applications can take many years to issue, there may also be currently pending patent applications that may later result in issued patents that our technology or product candidates may infringe. Further, we cannot guarantee that we are aware of all patents and patent applications potentially relevant to our technology or products. We may not be aware of potentially relevant third-party patents or applications for several reasons. For example, U.S. applications filed before November 29, 2000, and certain U.S. applications filed after that date that will not be filed outside the U.S. remain confidential until a patent issues. Patent applications filed in the United States (after November 29, 2000) and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our product candidates or platform technologies could have been filed by others without our knowledge. Any such patent application may have priority over our patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. Additionally, claims pending in patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our platform, our product candidates or the use of our technologies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Although no third party has asserted a claim of patent infringement against us as of the date of this Quarterly Report, others may hold proprietary rights that could prevent our product candidates from being marketed. We or our licensors, or any future strategic collaborator, may be party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current or any potential future product candidates and technologies, including derivation, reexamination,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"> inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> review or post-grant review before the USPTO and similar proceedings in jurisdictions outside of the United States such as opposition proceedings. In some instances, we may be required to indemnify our licensors for the costs associated with any such adversarial proceedings or litigation. Third parties may assert infringement claims against us, our licensors or our strategic collaborators based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation or other adversarial proceedings with us, our licensors or our strategic collaborators to enforce or otherwise assert their patent rights. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are not invalid, enforceable and infringed, which could have a material adverse impact on our ability to utilize our platform technologies or to commercialize our current or any future product candidates. In order to successfully challenge the validity of any such U.S. patent in federal court, we would need to overcome a presumption of validity by presenting clear and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">convincing evidence of invalidity. There is no assurance that a court of competent jurisdiction, even if presented with evidence we believe to be clear and convincing, would invalidate the claims of any such U.S. patent.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, we cannot guarantee that we will be able to successfully settle or otherwise resolve such adversarial proceedings or litigation. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or to continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our product candidates. If we, or our licensors, or any future strategic collaborators are found to infringe, misappropriate or violate a third-party patent or other intellectual property rights, we could be required to pay damages, including treble damages and attorney&#8217;s fees, if we are found to have willfully infringed. In addition, we, or our licensors, or any future strategic collaborators may choose to seek, or be required to seek, a license from a third party, which may not be available on commercially reasonable terms, if at all. Even if a license can be obtained on commercially reasonable terms, the rights may be non-exclusive, which could give our competitors access to the same technology or intellectual property rights licensed to us, and we could be required to make substantial licensing and royalty payments. Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our current or future product candidates. We could be forced, including by court order, to cease utilizing, developing, manufacturing and commercializing our platform technologies or product candidates deemed to be infringing. We may be forced to redesign current or future technologies or products. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. Any of the foregoing could have a material adverse effect on our ability to generate revenue or achieve profitability and possibly prevent us from generating revenue sufficient to sustain our operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Thus, it is possible that one or more third parties will hold patent rights to which we will need a license, which may not be available on reasonable terms or at all. If such third parties refuse to grant us a license to such patent rights on reasonable terms or at all, we may be required to expend significant time and resources to redesign our technology, product candidates or the methods for manufacturing our product candidates, or to develop or license replacement technology, all of which may not be commercially or technically feasible. In such case, we may not be able to market such technology or product candidates and may not be able to perform research and development or other activities covered by these patents. This could have a material adverse effect on our ability to commercialize our product candidates and our business and financial condition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Lastly, if our technology or products are found to infringe the intellectual property rights of third parties, these third parties may assert infringement claims against our licensees and other parties with whom we have business relationships, and we may be required to indemnify those parties for any damages they suffer as a result of these claims. The claims may require us to initiate or defend protracted and costly litigation on behalf of licensees and other parties regardless of the merits of these claims. If any of these claims succeed, we may be forced to pay damages on behalf of those parties or may be required to obtain licenses for the products they use.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our shares of our common stock to decline.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of hearings, rulings on motions and other interim proceedings or developments in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing product candidates, approved products, programs or intellectual property could be diminished. Accordingly, the market price of shares of our common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Intellectual property rights of third parties could adversely affect our ability to commercialize our current or future technologies or product candidates, and we might be required to litigate or obtain licenses from third parties to develop or market our current or future technologies or product candidates, which may not be available on commercially reasonable terms or at all.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Because the gene and cell therapy landscape is still evolving, it is difficult to conclusively assess our freedom to operate without infringing, misappropriating or violating third-party rights. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent&#8217;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect. For example, we may incorrectly determine that our products are not covered by a third-party patent or may incorrectly predict </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">whether a third-party&#8217;s pending application will issue with claims of relevant scope. Also, our determination of the expiration date of any patent in the United States or abroad that we consider relevant may be incorrect.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There are numerous companies that have pending patent applications and issued patents broadly covering gene and cell therapy generally or covering related inventions that may be relevant for product candidates that we wish to develop. We are aware of third-party patents and patent applications that claim aspects of our current or potential future product candidates and modifications that we may need to apply to our current or potential future product candidates. There are also many issued patents that claim inventions that may be relevant to products we wish to develop. The holders of such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtain a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all, or it may be non-exclusive, which could result in our competitors gaining access to the same intellectual property.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our competitive position may materially suffer if patents issued to third parties or other third-party intellectual property rights cover our current or future technologies, product candidates or elements thereof or our manufacture or uses relevant to our development plans. In such cases, we may not be in a position to develop or commercialize current or future technologies or product candidates unless we successfully pursue litigation to narrow or invalidate the third-party intellectual property right concerned, or enter into a license agreement with the intellectual property right holder, if available on commercially reasonable terms. There may be issued patents of which we are not aware, held by third parties that, if found to be valid and enforceable, could be alleged to be infringed by our current or future technologies or product candidates. There also may be pending patent applications of which we are not aware that may result in issued patents, which could be alleged to be infringed by our current or future technologies or product candidates. If such an infringement claim should successfully be brought, we may be required to pay substantial damages or be forced to abandon our current or future technologies or product candidates or to seek a license from any patent holders. No assurances can be given that a license will be available on commercially reasonable terms, if at all.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Third-party intellectual property right holders may also actively bring infringement, misappropriation, or other claims alleging violations of intellectual property rights against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such claims. If we are unable to successfully settle future claims on terms acceptable to us, we may be required to engage in or to continue costly, unpredictable and time-consuming litigation and may be prevented from or experience substantial delays in marketing our product candidates. If we fail in any such dispute, in addition to being forced to pay damages, we may be temporarily or permanently prohibited from commercializing any of our current or future technologies or product candidates that are held to be infringing, misappropriating or otherwise violating third-party intellectual property rights. We might, if possible, also be forced to redesign current or future technologies or product candidates so that we no longer infringe, misappropriate or violate the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business, which could have a material adverse effect on our financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to seeking patent protection for certain aspects of our current or future technologies and product candidates, we rely on trade secrets, including confidential and unpatented know-how, technology and other proprietary information, to maintain our competitive position and to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Elements of our product candidates, including processes for their preparation and manufacture, may involve proprietary know-how, information, or technology that is not covered by patents, and thus for these aspects we may consider trade secrets and know-how to be our primary intellectual property. Our trade secrets include, for example, certain program specific synthesis, formulations, patient selection strategies and certain aspects of our research.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Trade secrets and know-how can be difficult to protect. We seek to protect trade secrets and confidential and unpatented know-how, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to such knowledge, such as our employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants under which they </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">are obligated to maintain confidentiality and to assign their inventions to us. However, we cannot be certain that such agreements have been entered into with all relevant parties, and we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access (such as through a cybersecurity breach) to our trade secrets or independently develop substantially equivalent information and techniques. Moreover, individuals with whom we have such agreements may not comply with their terms. Any of these parties may breach such agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for any such breaches. In addition, we take other appropriate precautions, such as physical and technological security measures, to guard against misappropriation of our proprietary technology by third parties.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also become involved in inventorship disputes relating to inventions and patents developed by our employees or consultants under such agreements. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret, or securing title to an employee-or consultant-developed invention if a dispute arises, is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts in the United States and certain foreign jurisdictions disfavor or are unwilling to protect trade secrets. We may need to share our proprietary information, including trade secrets, with future business partners, collaborators, contractors and others located in countries at heightened risk of theft of trade secrets, including through direct intrusion by private parties or foreign actors, and those affiliated with or controlled by state actors. Further, if any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent that competitor from using the technology or information to compete with us. If, in the future, any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be materially and adversely harmed.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be subject to claims that we or our employees or consultants have wrongfully used or disclosed alleged trade secrets or other proprietary information of third parties, including our employees&#8217; or consultants&#8217; former employers or their clients.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are party to various contracts under which we are obligated to maintain the confidentiality of trade secrets or other confidential and proprietary information of third parties, including our licensors and strategic partners. In addition, many of our employees or consultants and our licensors&#8217; employees or consultants were previously employed at universities or biotechnology or biopharmaceutical companies, including our competitors or potential competitors. We may be subject to claims that one or more of these employees or consultants or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of third parties, including former employers of our employees and consultants. Litigation or arbitration may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel or may be enjoined from using such intellectual property. Any such proceedings and possible aftermath would likely divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities. A loss of key research personnel or their work product could limit our ability to commercialize, or prevent us from commercializing, our current or future technologies or product candidates, which could materially harm our business. Even if we are successful in defending against any such claims, litigation or arbitration could result in substantial costs and could be a distraction to management.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We or our licensors may be subject to claims that former employees, collaborators or other third parties have an interest in our owned or in-licensed patents as an inventor or co-inventor, or in our trade secrets or other intellectual property as a contributor to its development. The failure to name the proper inventors on a patent application can result in the patents issuing thereon being unenforceable. Inventorship disputes may arise from conflicting views regarding the contributions of different individuals named as inventors, the effects of foreign laws where foreign nationals are involved in the development of the subject matter of the patent, conflicting obligations of third parties involved in developing our product candidates or as a result of questions regarding co-ownership of potential joint inventions. For example, we or our licensors may have inventorship disputes arise from conflicting obligations of employees, consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship or our or our licensors&#8217; ownership of our owned or in-licensed patents, trade secrets or other intellectual property. Alternatively, or additionally, we may enter into agreements to clarify the scope of our rights in such intellectual property. If we or our licensors fail in </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Also, our licensors may have relied on third-party consultants or collaborators or on funds from third parties, such as the U.S. government, such that our licensors are not the sole and exclusive owners of the patents we in-licensed. If other third parties have ownership rights or other rights to our in-licensed patents, they may be able to license such patents to our competitors, and our competitors could market competing products and technology. This could have a material adverse effect on our competitive position, business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Further, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. Such claims could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our owned and in-licensed patents or applications and any patent rights we may own or in-license in the future. The USPTO and various non-U.S. patent offices require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply with these requirements, and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our in-licensed intellectual property. In many cases, an inadvertent lapse, including due to the effect of the COVID-19 on us, our patent counsel or other applicable patent maintenance vendors, can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, potential competitors might be able to enter the market with similar or identical product candidates or platforms, which could have a material adverse effect on our business prospects and financial condition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We use and will continue to use registered and/or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged, infringed, circumvented, declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we use for name recognition by potential collaborators or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively, and our business may be materially adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may also license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide guidelines for how our trademarks and trade names may be used, a breach of these </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">agreements or misuse of our trademarks and trade names by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade names.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Intellectual property rights do not necessarily address all potential threats to our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business. The following examples are illustrative:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">others may be able to create gene circuit technologies that are similar to our technologies or our product candidates, but that are not covered by the claims of any patents that we own, license or control;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we or any strategic collaborators might not have been the first to make the inventions covered by the issued patents or pending patent applications that we own, license or control;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we or our licensors might not have been the first to file patent applications covering certain of our owned and in-licensed inventions;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">others may independently develop the same, similar, or alternative technologies without infringing, misappropriating or violating our owned or in-licensed intellectual property rights;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">it is possible that our owned or in-licensed pending patent applications will not lead to issued patents;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">issued patents that we own, in-license, or control may not provide us with any competitive advantages, or may be narrowed or held invalid or unenforceable, including as a result of legal challenges;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our competitors might conduct research and development activities in the United States and other countries that provide a safe harbor from patent infringement claims for certain research and development activities, as well as in countries where we do not have patent rights, and may then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">we may choose not to file a patent application in order to maintain certain trade secrets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">or know-how, and a third party may subsequently file a patent application covering such trade secrets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">or know-how; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the patents of others may have an adverse effect on our business.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Should any of these events occur, they could have a material adverse impact on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Government Regulation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Clinical development includes a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All of our current product candidates are in preclinical development and their risk of failure is high. It is impossible to predict when or if our candidates or any potential future product candidates will prove effective in humans or will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must complete preclinical studies for our current product candidates and then conduct extensive clinical trials to demonstrate the safety, purity and potency, or efficacy of that product candidate in humans. Clinical testing is expensive and can take many years to complete, and its outcome is inherently </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">uncertain. Failure can occur at any time during the development process. The results of preclinical studies and clinical trials of any of our current or potential future product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. A number of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or safety profiles, notwithstanding promising results in earlier trials.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are currently conducting IND-enabling studies for our current product candidates. We may experience delays in completing our preclinical studies and initiating or completing our clinical studies. We do not know whether planned preclinical studies and clinical trials will be completed on schedule or at all, or whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Our development programs may be delayed for a variety of reasons, including delays related to:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the FDA or other regulatory authorities requiring us to submit additional data or imposing other requirements before permitting us to initiate a clinical trial;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">obtaining regulatory approval to commence a clinical trial;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">obtaining IRB or ethics committee approval at each clinical trial site;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">recruiting suitable patients to participate in a clinical trial;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">having patients complete a clinical trial or return for post-treatment follow-up;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">clinical trial sites deviating from trial protocol or dropping out of a trial;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the FDA placing the clinical trial on hold;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">subjects failing to enroll or remain in our trial at the rate we expect;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">subjects choosing an alternative treatment for the indication for which we are developing or other product candidates, or participating in competing clinical trials;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">lack of adequate funding to continue the clinical trial;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">subjects experiencing severe or unexpected drug-related adverse events;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">any changes to our manufacturing process that may be necessary or desired;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">adding new clinical trial sites; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">manufacturing sufficient quantities of our product candidates for use in clinical trials.</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, we expect to rely on our CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we expect to enter into agreements governing their committed activities, we have limited influence over their actual performance.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We could encounter delays if prescribing physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our current or potential future product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, our collaborators, the IRBs of the institutions in which such trials are being conducted, the Data Safety Monitoring Board for such trial or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug or therapeutic biologic, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing our current or future product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we experience delays in the completion of, or termination of, any clinical trial of any of our current or potential future product candidates, the commercial prospects of such product candidate will be harmed, and our ability to generate product revenue from such product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow our product development and approval process and jeopardize our ability to commence product sales and generate revenue. Any of these occurrences may have a material adverse effect on our business, financial condition, results of operations and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our current or potential future product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be unable to obtain U.S. or foreign regulatory approval and, as a result, be unable to commercialize our current or potential future product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our current and any potential future product candidates are subject to extensive governmental regulations relating to, among other things, research, testing, development, manufacturing, safety, efficacy, approval, recordkeeping, reporting, labeling, storage, packaging, advertising and promotion, pricing, marketing and distribution of therapeutic biologics. Rigorous preclinical testing and clinical trials and an extensive regulatory approval process are required to be successfully completed in the U.S. and in many foreign jurisdictions before a new drug or therapeutic biologic can be marketed. Satisfaction of these and other regulatory requirements is costly, time-consuming, uncertain and subject to unanticipated delays. It is possible that none of the product candidates we may develop will obtain the regulatory approvals necessary for us or our potential future collaborators to begin selling them.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have very limited experience in conducting and managing the clinical trials necessary to obtain regulatory approvals, including approval by the FDA and other regulatory authorities. The time required to obtain FDA and other approvals is unpredictable but typically takes many years following the commencement of clinical trials, depending upon the type, complexity and novelty of the product candidate. The standards that the FDA and its foreign counterparts use when regulating us require judgment and can change, which makes it difficult to predict with certainty how they will be applied. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation by regulatory authorities, which could delay, limit or prevent regulatory approval. We may also encounter unexpected delays or increased costs due to new government regulations, for example, from future legislation or administrative action, or from changes in regulatory policy during the period of product development, clinical trials and FDA regulatory review in the United States and other jurisdictions. It is impossible to predict whether legislative changes will be enacted, or whether FDA or foreign regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any delay or failure in obtaining required approvals could have a material adverse effect on our ability to generate revenue from the particular product candidate for which we are seeking approval. Further, we and our potential future collaborators may never receive approval to market and commercialize any product candidate. Even if we or a potential future collaborator obtains regulatory approval, the approval may be for targets, disease indications or patient populations that are not as broad as we intended or desired or may require labeling that includes significant use or distribution restrictions or safety warnings.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Once a product obtains regulatory approval, numerous post approval requirements apply, including periodic monitoring and reporting obligations, review of promotional material, reports on ongoing clinical trials and adverse events and inspections of manufacturing facilities. In addition, material changes to approved products, including any changes to the manufacturing process or labeling, require further review by the appropriate authorities before marketing. Approvals may also be withdrawn or revoked due to safety, effectiveness or potency concerns, including as a result of adverse events reported in patients or ongoing clinical trials, or failure to comply with cGMP. In addition to revocation or withdrawal of approvals, we and our partners may be subject to warnings, fines, recalls, criminal prosecution or other sanctions if we fail to comply with regulatory requirements. If we or our partners are unable to obtain or maintain regulatory approvals for our products and product candidates, our business, financial position, results of operations and future growth prospects will be negatively impacted and we or our partners may be subject to sanctions. If any of our product candidates prove to be ineffective, unsafe or commercially unviable, we may have to re-engineer our current or potential future product candidates, and our entire pipeline could have little, if any, value, which could require us to change our focus and approach to product candidate discovery and therapeutic development, which would have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We will also be subject to numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials, manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and may include all of the risks associated with FDA approval described above as well as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ from that required to obtain FDA approval.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we succeed in developing any products, we intend to market them in the United States as well as the European Union and other foreign jurisdictions. In order to market and sell our products in other jurisdictions, we must obtain separate marketing approvals and comply with numerous and varying regulatory requirements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA or EMA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we or any partner we work with fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced, and our ability to realize the full market potential of our product candidates will be harmed.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may in the future conduct certain of our clinical trials for our product candidates outside of the United States. However, the FDA and other foreign equivalents may not accept data from such trials, in which case our development plans will be delayed, which could materially harm our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may in the future choose to conduct one or more of our clinical trials for our product candidates outside the United States. Although the FDA may accept data from clinical trials conducted outside the United States, acceptance of this data is subject to certain conditions imposed by the FDA. In cases where data from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will not approve the application on the basis of foreign data alone unless (i) those data are applicable to the U.S. population and U.S. medical practice; (ii) the studies were performed by clinical investigators of recognized competence; and (iii) the data are considered valid without the need for an on-site inspection by the FDA or, if the FDA considers such an inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means. For studies that are conducted only at sites outside of the United States and not subject to an IND, the FDA requires the clinical trial to have been conducted in accordance with GCPs, and the FDA must be able to validate the data from the clinical trial through an on-site inspection if it deems such inspection necessary. For such studies not subject to an IND, the FDA generally does not provide advance comment on the clinical protocols for the studies, and therefore there is an additional potential risk that the FDA could determine that the study design or protocol for a non-U.S. clinical trial was inadequate, which could require us to conduct additional clinical trials. There can be no assurance the FDA will accept data from clinical trials conducted outside of the United States. If the FDA does not accept data from our clinical trials of our product candidates, it would likely result in the need for additional clinical trials, which would be costly and time consuming and delay or permanently halt our development of our product candidates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Many foreign regulatory bodies have similar approval requirements. In addition, such foreign trials would be subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA or any similar foreign regulatory authority will accept data from trials conducted outside of the United States or the applicable jurisdiction. If the FDA or any similar foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan, and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Conducting clinical trials outside the United States also exposes us to additional risks, including risks associated with:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">additional foreign regulatory requirements;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">foreign exchange fluctuations;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">compliance with foreign manufacturing, customs, shipment and storage requirements;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">cultural differences in medical practice and clinical research; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">diminished protection of intellectual property in some countries.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Even if we receive regulatory approval for any of our current or potential future product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. Additionally, our current or potential future product candidates, if approved, could be subject to labeling and other restrictions and market withdrawal and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any regulatory approvals that we or potential future collaborators obtain for any of our current or potential future product candidates will be subject to limitations on the approved indicated uses for which a product may be marketed or may be subject to the conditions of approval, or contain requirements for potentially costly post-marketing testing, and surveillance to monitor the safety and efficacy of such product candidate. In addition, if the FDA or any other regulatory authority approves any of our current or potential future product candidates, the </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, import, export, advertising, promotion and recordkeeping for such product will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and good clinical practices for any clinical trials that we conduct post-approval. In addition, manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to cGMP and cGTP regulations and applicable product tracking and tracing requirements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Later discovery of previously unknown problems with a product candidate, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">restrictions on the marketing or manufacturing of the product candidate, withdrawal of the product candidate from the market or voluntary or mandatory product recalls;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">fines, warning letters, untitled letters or holds on clinical trials;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or our strategic collaborators;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">suspension or revocation of product approvals;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">suspension of any ongoing clinical trials;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">product seizure or detention or refusal to permit the import or export of products; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">injunctions or the imposition of civil or criminal penalties or monetary fines.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA has the authority to require a risk evaluation and mitigation strategy (&#8220;REMS&#8221;) as part of a biologics license application, or BLA, or after approval, which may impose further requirements or restrictions on the distribution or use of an approved product, such as limiting prescribing to certain physicians or medical centers that have undergone specialized training, limiting treatment to patients who meet certain safe-use criteria and requiring treated patients to enroll in a registry.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Furthermore, the FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Products may be promoted only for the approved indications and in accordance with the provisions of the approved label. While physicians may prescribe, in their independent professional medical judgment, products for off-label uses as the FDA does not regulate the behavior of physicians in their choice of drug treatments, the FDA does restrict a manufacturer&#8217;s communications on the subject of off-label use of their products. Companies may only share truthful and not misleading information that is otherwise consistent with a product&#8217;s FDA approved labeling. The FDA and other authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses and a company that is found to have improperly promoted off-label uses may be subject to significant liability including, among other things, adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. The federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined companies from engaging in off-label promotion.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The FDA and other regulatory authorities have also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Occurrence of any of the foregoing could have a material adverse effect on our business and results of operations. The FDA&#8217;s and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Any product candidates for which we intend to seek approval as biologic products may face competition sooner than anticipated.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Affordable Care Act includes a subtitle called the Biologics Price Competition and Innovation Act of 2009, or BPCIA, which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an FDA-licensed reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until twelve years from the date on which the reference product was first licensed. During this twelve-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#8217;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity and potency of its product. The law is complex. The BPCIA could have a material adverse effect on the future commercial prospects for our biological products.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that any of our future product candidates approved as a biological product under a BLA should qualify for the twelve-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to Congressional action or otherwise, or that the FDA will not consider our product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the extent to which a biosimilar, once approved, could be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biological products will depend on a number of marketplace and regulatory factors that are still developing.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Healthcare legislative reform measures may have a material adverse effect on our business and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The United States and several other jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell any of our product candidates profitably, if approved. Among policy-makers and payers in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems, with the stated goals of containing healthcare costs, improving quality and expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations, and other payers of healthcare services to contain or reduce the costs of healthcare may adversely affect:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the demand for any of our product candidates, if approved; </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to set a price that we believe is fair for any of our product candidates, if approved; </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to generate revenues or maintain profitability; </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the level of taxes that we are required to pay; and </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the availability of capital.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Legislative and regulatory proposals have been made to expand post-approval requirements and to restrict sales and promotional activities for pharmaceutical and biologic products. We cannot be sure whether additional </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">legislative changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our product candidates, if any, may be. In addition, increased scrutiny by Congress of the FDA&#8217;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other requirements. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Moreover, increasing efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates, if approved.. There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect that the healthcare reform measures that have been adopted and may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any approved product and could harm our future revenues. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Failure to comply with health and data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect our operating results and business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We may collect, receive, store, process, generate, use, transfer, disclose, make accessible, protect and share personal information, health information and other sensitive information to develop our products, to operate our business, for clinical trial purposes, for legal and marketing purposes, and for other business-related purposes.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We and any potential future collaborators, partners or service providers may be subject to federal, state and foreign data protection laws, regulations and regulatory guidance, the number and scope of which is changing, subject to differing applications and interpretations, and which may be inconsistent among jurisdictions, or in conflict with other rules, laws or contractual obligations. In the United States, numerous federal and state laws and regulations, including federal health information privacy laws, such as the Health Insurance Portability and Accountability Act (&#8220;HIPAA&#8221;), state data breach notification laws, state health information privacy laws and federal and state consumer protection laws, that govern the collection, use, disclosure and protection of health-related and other personal information could apply to our operations or the operations of any future potential collaborators or service providers.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we may obtain health information from third parties (including research institutions from which we obtain clinical trial data) that are subject to privacy and security requirements under HIPAA, or other privacy and data security laws. Depending on the facts and circumstances, we could be subject to civil or criminal penalties if we obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA, or if we otherwise violate applicable privacy and data security laws.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">International data protection laws, including the EU&#8217;s General Data Protection Regulation, and the UK&#8217;s implementation of the same, or GDPR, may also apply to health-related and other personal information obtained outside of the United States. The GDPR imposes stringent data protection requirements for processing personal data of individuals within the European Economic Area, or EEA, and the UK, as well as potential fines for noncompliant companies of up to the greater of &#8364;20 million (&#163;17.5 million) or 4% of annual global revenue. The GDPR imposes numerous requirements for the collection, use and disclosure of personal data, including stringent requirements relating to consent and the information that must be shared with data subjects about how their personal information is used, the obligation to notify regulators and affected individuals of personal data breaches, extensive internal privacy governance obligations and obligations to honor expanded rights of individuals in relation to their personal information.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the GDPR places restrictions on cross-border data transfers. On June 4, 2021, the European Commission issued new forms of standard contractual clauses (one of the primary mechanisms for U.S. companies to import personal information from Europe) for data transfers from controllers or processors in the EEA (or otherwise subject to the GDPR) to controllers or processors established outside the EEA (and not subject to the GDPR). The new standard contractual clauses do not apply in the UK, but the UK Information Commissioner&#8217;s Office issued a UK-specific transfer mechanism, the International Data Transfer Agreement. We are required to transition to the new forms of transfer mechanisms and doing so will require significant effort and cost. The new transfer mechanisms may also impact our business as companies based in Europe may be reluctant to utilize the new clauses to legitimize transfers of personal information to third countries given the burdensome requirements of transfer impact assessments and the substantial obligations that the new standard contractual clauses impose upon exporters. If we are investigated by a European data protection authority, we may face fines and other penalties. Any such investigation or charges by European data protection authorities could have a negative effect on our existing business and on our ability to attract and retain new clients or pharmaceutical partners. We may also experience hesitancy, reluctance, or refusal by European or multi-national clients or pharmaceutical partners to continue to use our products due to the potential risk exposure as a result of the current (and, in particular, future) data protection obligations imposed on them by certain data protection authorities in interpretation of current law, including the GDPR. Such clients or pharmaceutical partners may also view any alternative approaches to compliance as being too costly, too burdensome, too legally uncertain, or otherwise objectionable and therefore decide not to do business with us. Any of the foregoing could materially harm our business, prospects, financial condition, and results of operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The GDPR has increased our responsibilities and potential liability in relation to personal data processed subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as implemented by individual countries. In addition, any failure by us (or our business partners who handle personal data) to comply with GDPR and applicable laws and regulations relating to privacy and data protection of EEA member states and the UK may result in regulators prohibiting our processing of the personal data of EEA and UK data subjects, which could impact our operations and ability to develop our products and provide our services, including interrupting or ending EEA and UK clinical trials.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the U.S., state laws also govern the privacy and security of personal information and states are constantly adopting new laws or amending existing laws, requiring attention to frequently changing regulatory requirements. For example, the California Consumer Privacy Act, as amended by the California Privacy Rights Act (the &#8220;CCPA&#8221;) gives California residents expanded rights to access, correct, and delete their personal information, opt out of certain personal information sharing and certain uses of sensitive data, and receive detailed information about how their personal information is used by requiring covered companies to provide disclosures to California consumers (as that term is broadly defined and includes any of our current or future employees who may be California residents) and provide such residents ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches and statutory damages, which is expected to increase data breach class action litigation and result in significant exposure to costly legal judgments and settlements. It will also create a new California data protection agency authorized to issue substantive regulations which could result in increased privacy and information security enforcement. Although the law includes limited exceptions for health-related information, including clinical trial data, such exceptions may not apply to all of our operations and processing activities. As we expand our operations and trials (both preclinical and clinical), the CCPA may increase our compliance costs and potential liability. The CCPA has prompted the enactment of similar, comprehensive privacy and data protection legislation in other states, such as Virginia, Colorado, Utah, and Connecticut, which will all become effective in 2023. Furthermore, a number of other U.S. states have proposed similar privacy and data protection legislation, and it is possible that certain of these proposals will pass. In the event that we are subject to or affected by HIPAA, the GDPR, the CCPA, the CPRA or other domestic privacy and data protection laws, any liability from failure to comply with the requirements of these laws could adversely affect our financial condition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Compliance with U.S. and international data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Laws and regulations worldwide relating to privacy, data protection and cybersecurity are, and are likely to remain, uncertain for the foreseeable future. While we strive to comply with applicable laws and regulations relating to privacy, data protection and cybersecurity, external and internal privacy and security policies and contractual obligations relating to privacy, data protection and cybersecurity to the extent </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">possible, we may at times fail to do so, or may be perceived to have failed to do so. Moreover, despite our efforts, we may not be successful in achieving compliance if our personnel, collaborators, partners or vendors do not comply with applicable laws and regulations relating to privacy, data protection and cybersecurity, external and internal privacy and security policies and contractual obligations relating to privacy, data protection and cybersecurity. Actual or perceived failure to comply with any laws and regulations relating to privacy, data protection or cybersecurity in the U.S. or foreign jurisdictions could result in government enforcement actions (which could include civil or criminal penalties), private litigation or adverse publicity and could negatively affect our operating results and business. Moreover, clinical trial subjects about whom we or our potential collaborators or service providers obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we have violated individuals&#8217; privacy rights, failed to comply with applicable laws or regulations, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend, result in regulatory actions and proceedings, in addition to private claims and litigation, and could result in adverse publicity that could harm our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also are, or may be asserted to be, subject to the terms of our external and internal privacy and security policies, representations, certifications, publications and frameworks and contractual obligations to third parties related to privacy, data protection, information security and processing. Failure to comply or the perceived failure to comply with any of these, or if any of these policies or any of our representations, certifications, publications or frameworks are, in whole or part, found or perceived to be inaccurate, incomplete, deceptive, unfair or misrepresentative of our actual practices, could result in reputational harm, result in litigation, cause a material adverse impact to business operations or financial results and otherwise result in other material harm to our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we or our existing or potential future collaborators, manufacturers or service providers fail to comply with healthcare laws and regulations, we or they could be subject to enforcement actions, which could affect our ability to develop, market and sell our product candidates and may harm our reputation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Healthcare providers, physicians and third-party payors, among others, will play a primary role in the prescription and recommendation of any product candidates for which we obtain marketing approval. Our current and future arrangements with third-party payors, providers and customers, among others, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute our product candidates for which we obtain marketing approval. See section titled </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">&#8220;Business - Government Regulation - Other U.S. Healthcare Laws&#8221; in the Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions, and settlements in the healthcare industry. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current of future statures, regulations, agency guidance, or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to use, we may be subject to significant penalties, including administrative, civil, and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment, reputational harm, and curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, defending against any such actions can be costly and time consuming, and may require significant financial and personnel resources. .Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusion from government funded healthcare programs and imprisonment. If any of the above occur, our ability to operate our business and our results of operations could be adversely affected.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If we fail to comply with U.S. and foreign regulatory requirements, regulatory authorities could limit or withdraw any marketing or commercialization approvals we may receive and subject us to other penalties that could materially harm our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Even if we receive marketing and commercialization approval of a product candidate, we will be subject to continuing regulatory requirements, including in relation to adverse patient experiences with the product and clinical results that are reported after a product is made commercially available, both in the United States and any foreign jurisdiction in which we seek regulatory approval. The FDA and other regulatory authorities have significant post- market authority, including the authority to require labeling changes based on new safety information and to require post-market studies or clinical trials to evaluate safety risks related to the use of a product or to require withdrawal of the product candidate from the market. The FDA and other regulatory authorities also have the authority to require a REMS after approval, which may impose further requirements or restrictions on the distribution or use of an approved drug or therapeutic biologic. The manufacturer and manufacturing facilities we use to make a future product, if any, will also be subject to periodic review and inspection by the FDA and other regulatory authorities, including for continued compliance with cGMP and cGTP requirements. The discovery of any new or previously unknown problems with our third-party manufacturers, manufacturing processes or facilities may result in restrictions on the product candidate, manufacturer or facility, including withdrawal of the product candidate from the market. We intend to rely on third-party manufacturers and we will not have control over compliance with applicable rules and regulations by such manufacturers. Any product promotion and advertising will also be subject to regulatory requirements and continuing regulatory review. If we or our existing or future collaborators, manufacturers or service providers fail to comply with applicable continuing regulatory requirements in the U.S. or foreign jurisdictions in which we seek to market our products, we or they may be subject to, among other things, fines, warning letters, holds on clinical trials, delay of approval or refusal by the FDA or other regulatory authorities to approve pending applications or supplements to approved applications, suspension or withdrawal of regulatory approval, product recalls and seizures, administrative detention of products, refusal to permit the import or export of products, operating restrictions, injunction, civil penalties and criminal prosecution.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Even if we are able to commercialize any product candidate, such product candidate may become subject to unfavorable pricing regulations or third-party coverage and reimbursement policies, which would harm our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the United States and markets in other countries, patients generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. Further, due to the COVID-19 pandemic, millions of individuals have lost employer-based insurance coverage, which may adversely affect our ability to commercialize our products. It is unclear what effect, if any, the American Rescue Plan will have on the number of covered individuals. See section titled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Business - Government Regulation - Coverage and Reimbursement&#8221; in the Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Patients who are prescribed medications for the treatment of their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their prescription drugs. Coverage and adequate reimbursement from government healthcare programs, such as Medicare and Medicaid, and private health insurers are critical to new product acceptance. Patients are unlikely to use our future products, if any, unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost. Obtaining coverage and adequate reimbursement for our product candidates may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Similarly, because our product candidates are physician-administered, separate reimbursement for the product itself may or may not be available. Instead, the administering physician may or may not be reimbursed for providing the treatment or procedure in which our product is used.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cost-containment is a priority in the U.S. healthcare industry and elsewhere. As a result, government authorities and other third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors also may request additional clinical evidence beyond the data required to obtain marketing approval, requiring a company to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of its product. Commercial third-party payors often rely upon Medicare coverage policy and </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">payment limitations in setting their reimbursement rates, but also have their own methods and approval process apart from Medicare determinations. Therefore, coverage and reimbursement for pharmaceutical products in the U.S. can differ significantly from payor to payor. We cannot be sure that coverage and adequate reimbursement will be available for any product that we commercialize and, if reimbursement is available, that the level of reimbursement will be adequate. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or are available only at limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, the regulations that govern regulatory approvals, pricing and reimbursement for new drugs and therapeutic biologics vary widely from country to country. Some countries require approval of the sale price of a drug or therapeutic biologic before it can be marketed. In many countries, the pricing review period begins after marketing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a product in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain regulatory approval.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are subject to U.S. and foreign anti-corruption and anti-money laundering laws with respect to our operations and non-compliance with such laws can subject us to criminal or civil liability and harm our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended (the &#8220;FCPA&#8221;), the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act, the USA PATRIOT Act, and possibly other state and national anti-bribery and anti-money laundering laws in countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, third-party intermediaries, joint venture partners and collaborators from authorizing, promising, offering or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We interact with officials and employees of government agencies and government-affiliated hospitals, universities and other organizations. In addition, we may engage third-party intermediaries to promote our clinical research activities abroad or to obtain necessary permits, licenses and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, collaborators and agents, even if we do not explicitly authorize or have actual knowledge of such activities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We adopted a Code of Business Conduct and Ethics and we expect to prepare and implement policies and procedures to ensure compliance with such code. The Code of Business Conduct and Ethics mandates compliance with the FCPA and other anti-corruption laws applicable to our business throughout the world. However, we cannot assure you that our employees and third-party intermediaries will comply with this code or such anti-corruption laws. Noncompliance with anti-corruption and anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage and other collateral consequences. If any subpoenas, investigations or other enforcement actions are launched, or governmental or other sanctions are imposed, or if we do not prevail in any possible civil or criminal litigation, our business, results of operations and financial condition could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#8217;s attention and resources and significant defense and compliance costs and other professional fees. In certain cases, enforcement authorities may even cause us to appoint an independent compliance monitor which can result in added costs and administrative burdens.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Senti and the shares of our common stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our stock price is volatile, and you could lose part of all of your investment.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Similar to the trading prices of the common stock of other biotechnology companies, the trading price of our common stock is subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. The market price for our shares of our Common Stock may be influenced by many </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">factors, including the other risks described in the section of the Quarterly Report entitled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk Factors</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8221; and the following:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our ability to advance our current or potential future product candidates into the clinic;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">results of preclinical studies for our current or potential future product candidates, or those of our competitors or potential future collaborators;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the impact of macroeconomic conditions, including the ongoing COVID-19 pandemic on our business;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">regulatory or legal developments in the United States and other countries, especially changes in laws or regulations applicable to our future products;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our ability to successfully construct and operate our planned cGMP and cGTP facility;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the success of competitive products or technologies;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">introductions and announcements of new products by us, our future commercialization collaborators, or our competitors, and the timing of these introductions or announcements;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">actions taken by regulatory authorities with respect to our future products, clinical trials, manufacturing process or sales and marketing terms;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">actual or anticipated variations in our financial results or those of companies that are perceived to be similar to us;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the success of our efforts to acquire or in-license additional technologies, products or product candidates;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">developments concerning any future collaborations, including, but not limited to, those with any sources of manufacturing supply and future commercialization collaborators;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">market conditions in the pharmaceutical and biotechnology sectors;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">market conditions and sentiment involving companies that have recently completed a business combination with a special purpose acquisition company, or SPAC;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">announcements by us or our competitors of significant acquisitions, strategic alliances, joint ventures or capital commitments;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">developments or disputes concerning patents or other proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our products;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our ability or inability to raise additional capital and the terms on which it is raised;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the recruitment or departure of key personnel;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">changes in the structure of healthcare payment systems;</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations regarding our common stock, other comparable companies or the industry generally;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our failure or the failure of our competitors to meet analysts&#8217; projections or guidance that we or our competitors may give to the market;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">announcement and expectation of additional financing efforts;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">speculation in the press or investment community;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">trading volume of shares of our common stock;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">sales of our common stock by us or our stockholders;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the concentrated ownership of shares of our common stock;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">changes in accounting principles;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">terrorist acts, acts of war or periods of widespread civil unrest;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">natural disasters, public health crises and other calamities; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">general economic, industry and market conditions.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the stock markets in general, and the markets for SPAC post-Merger businesses, pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme volatility, including since the public announcement of the Business Combination Agreement in December 2021. This volatility can often be unrelated to the operating performance of the underlying business. These broad market and industry factors may seriously harm the market price of shares of our common stock, regardless of our operating performance. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#8217;s securities. This type of litigation, if instituted, could result in substantial costs and a diversion of management&#8217;s attention and resources, which would harm our business, operating results, or financial condition.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may incur significant costs from class action litigation due to the expected stock volatility.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our stock price may fluctuate for many reasons, including as a result of public announcements regarding the progress of development efforts for our platform and product candidates, the development efforts of future collaborators or competitors, the addition or departure of key personnel, variations in quarterly operating results and changes in market valuations of biopharmaceutical and biotechnology companies. This risk is especially relevant to us because biopharmaceutical and biotechnology companies have experienced significant stock price volatility in recent years, including since the public announcement of the Business Combination Agreement in December 2021. In addition, recently there has been significant stock price volatility involving the shares of companies that have recently completed a Merger with a SPAC. When the market price of a stock has been volatile as our stock price may be, holders of that stock have occasionally brought securities class action litigation against the company that issued the stock. Additionally, there has recently been a general increase in litigation against companies that have recently completed a Merger with a SPAC alleging fraud and other claims based on inaccurate or misleading disclosures. If any of our stockholders were to bring a lawsuit of this type against us, even if the lawsuit is without </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">merit, we could incur substantial costs defending the lawsuit. The lawsuit could also divert the time and attention of management.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We are an &#8220;emerging growth company&#8221; and it cannot be certain if the reduced disclosure requirements applicable to emerging growth companies will make the shares of our common stock less attractive to investors and may make it more difficult to compare performance with other public companies.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are an emerging growth company as defined in the JOBS Act, and we intend to continue to take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved. Investors may find shares of our common stock less attractive because we will continue to rely on these exemptions. If some investors find our shares of our common stock less attractive as a result, there may be a less active trading market for their common stock, and the stock price may be more volatile.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">An emerging growth company may elect to delay the adoption of new or revised accounting standards. With DYNS making this election, Section 102(b)(2) of the JOBS Act allows us to delay adoption of new or revised accounting standards until those standards apply to non-public business entities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> As a result, the condensed financial statements contained in this Quarterly Report and those that we will file in the future may not be comparable to companies that comply with public business entities revised accounting standards effective dates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">If certain holders of our common stock sell a significant portion of their securities, it may negatively impact the market price of the shares of our common stock and such holders still may receive significant proceeds.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of the date of this Quarterly Report on Form 10-Q, the market price of our common stock is below $10.00 per share, which was the price per share of Class A common stock sold in the initial public offering of our predecessor, DYNS, the per share price of the 5,060,000 shares of our Common Stock sold to certain investors in connection with our PIPE financing and also the per share value of the consideration issued to former stockholders of Senti Sub I, Inc. (formerly Senti Biosciences, Inc.) upon consummation of our Merger. However, certain of our stockholders who hold shares of our common stock that were (i) originally purchased by our predecessor&#8217;s sponsor, Dynamics Sponsor LLC, in a private placement prior to our predecessor&#8217;s initial public offering (the &#8220;Founder Shares&#8221;) or (ii) issued to the Anchor Investors in consideration for their agreement not to redeem their shares of Class A common stock of DYNS in connection with the Merger. In particular, 4,878,972 of the Founder Shares registered for resale in our prospectus dated August 8, 2022 filed pursuant to Rule 424(b)(3) (Registration No. 333-265873), as supplemented from time to time (the &#8220;Prior Resale Prospectus&#8221;), were purchased at an effective price of $0.004 per share, and 871,028 of the shares of our common stock held by the Anchor Investors and registered for resale in the Prior Resale Prospectus were issued solely in consideration for the Anchor Investors&#8217; agreement not to redeem their shares of Class A common stock as described above. Accordingly, holders of these 5,750,000 shares of our common stock could sell their securities at a per share price that is less than $10.00 and still realize a significant return from the sale of those securities that could not be realized by our other stockholders. On </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">May&#160;1, 2023, the closing price of our common stock as reported on the Nasdaq Global Market was $0.98 per share. Based on this closing price, the aggregate sales price of the Founder Shares would be approximately $4.8&#160;million and the aggregate sales price of the shares of our common stock held by the Anchor Investors would be approximately $0.9&#160;million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Sales of a substantial number of shares of our common stock in the public market could cause our stock prices to fall. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales or the perception in the market that the holders of a large number of shares of common stock intend to sell shares, could reduce the market price of our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Shares issued upon the exercise of stock options outstanding under our equity incentive plans or pursuant to future awards granted under those plans will become available for sale in the public market to the extent permitted </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">by the provisions of applicable vesting schedules, any applicable market standoff and lock-up agreements, and Rule 144 and Rule 701 under the Securities Act. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain holders of our common stock have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. We have also filed registration statements on Form S-8 registering shares of common stock issued or reserved for future issuance under our equity compensation plans. Shares registered under a registration statement on Form S-8 can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates. If any of these additional shares are sold, or if it is perceived that they will be sold in the public market, the market price of our common stock could decline.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Future sales and issuances of our common stock or rights to purchase common stock could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Significant additional capital will be needed in the future to continue our planned operations, including further development of our gene circuit platform, preparing IND or equivalent filings, conducting preclinical studies and clinical trials, commercialization efforts, expanded research and development activities and costs associated with operating a public company. To raise capital, we may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner as determined from time to time. If we sell common stock, convertible securities or other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to existing stockholders, and new investors could gain rights, preferences and privileges senior to the holders of shares of our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the Senti Biosciences, Inc. Equity Incentive Plan, our board of directors or compensation committee is authorized to grant stock options to our employees, directors and consultants. Initially, the maximum aggregate number of shares of our common stock that may be issued pursuant to stock awards under the Incentive Plan was 2,492,735 shares of our common stock. Additionally, the number of shares of our common stock reserved for issuance under the Incentive Plan automatically increases on January 1 of each year, beginning on January 1, 2023 and continuing through and including January 1, 2032, by 5% of the total number of shares of our common stock outstanding on December 31 of the preceding calendar year, or a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall. In addition, on August 5, 2022, out board of directors adopted the 2022 Inducement Plan, pursuant to which an aggregate of 2,000,000 shares of our common stock have been reserved for issuance. Our issuance of additional shares of common stock or other equity securities of equal or senior rank would, all else being equal, have the following effects:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the amount of cash available per share, including for payment of dividends in the future, may decrease;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the relative voting strength of each previously outstanding share of common stock would be diminished; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the market price of shares of our common stock may decline.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We must design our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. For example, our directors or executive officers could inadvertently fail to disclose a new relationship or arrangement causing us to fail to make a required related party transaction disclosure. Additionally, controls can be circumvented by the individual acts of some persons, by </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Reports published by analysts, including projections in those reports that differ from our actual results, could adversely affect the price and trading volume of shares of our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We currently expect that securities research analysts will establish and publish their own periodic financial projections for our business. These projections may vary widely and may not accurately predict the results we actually achieve. Our stock price may decline if our actual results do not match the projections of these securities research analysts. Similarly, if one or more of the analysts who write reports on us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price could decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, our stock price or trading volume could decline. While we expect research analyst coverage, if no analysts commence coverage of us, the trading price and volume for shares of our common stock could be adversely affected.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The obligations associated with being a public company will involve significant expenses and will require significant resources and management attention, which may divert from our business operations.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As a public company, we are subject to the reporting requirements of the Exchange Act and the Sarbanes-Oxley Act. The Exchange Act requires the filing of annual, quarterly and current reports with respect to a public company&#8217;s business and financial condition. The Sarbanes-Oxley Act requires, among other things, that a public company establish and maintain effective internal control over financial reporting. As a result, we will incur significant legal, accounting and other expenses that we did not previously incur. Our entire management team and many of our other employees will need to devote substantial time to compliance, and may not effectively or efficiently manage our transition into a public company.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These rules and regulations will result in us incurring substantial legal and financial compliance costs and will make some activities more time-consuming and costly. For example, these rules and regulations will likely make it more difficult and more expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. As a result, it may be difficult for us to attract and retain qualified people to serve on our board of directors, our board committees or as executive officers.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Provisions in our second amended and restated certificate of incorporation (&#8220;Charter&#8221;), our amended and restated bylaws, or Bylaws, and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management, which could depress the trading price of shares of our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our Charter, Bylaws and Delaware law contain provisions that may have the effect of discouraging, delaying or preventing a change in control of us or changes in our management that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. Our Charter and Bylaws include provisions that:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">authorize &#8220;blank check&#8221; preferred stock, which could be issued by our board of directors without stockholder approval and may contain voting, liquidation, dividend and other rights superior to our common stock;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">create a classified board of directors whose members serve staggered three-year terms, such that not all members of the board will be elected at one time;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">specify that special meetings of our stockholders can be called only by our board of directors;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">prohibit stockholder action by written consent;</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">establish an advance notice procedure for stockholder approvals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">specify that no stockholder is permitted to cumulate votes at any election of directors;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">expressly authorize our board of directors to make, alter, amend or repeal our Bylaws; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">require supermajority votes of the holders of our common stock to amend specified provisions of our Charter and Bylaws.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These provisions, alone or together, could delay or prevent hostile takeovers and changes in control or changes in our management. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of shares of our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, because we are incorporated in the State of Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Any provision of our Charter, Bylaws or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for shares of our common stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our Bylaws designate the Court of Chancery of the State of Delaware as the exclusive forum for certain state law litigation that may be initiated by our stockholders and the U.S. federal district courts as the exclusive forum for certain securities law actions, which could limit our stockholders&#8217; ability to litigate disputes with us in a different judicial forum and increase the costs for our stockholders to pursue certain claims against us.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to our Bylaws, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i) any derivative action or proceeding brought on our behalf; (ii) any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or employees to us or our stockholders; (iii) any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware, our Charter or our Bylaws (including their interpretation, validity or enforceability); or (iv) any action asserting a claim governed by the internal affairs doctrine. This exclusive forum provision will not apply to any causes of action arising under the Securities Act or the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. Stockholders cannot waive compliance with the Securities Act, the Exchange Act or any other federal securities laws or the rules and regulations thereunder. Unless we consent in writing to the selection of an alternate forum, the United States federal district courts shall be the sole and exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. In addition, our Bylaws provide that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock is deemed to have notice of and consented to these exclusive forum provisions; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder. The forum selection provisions in our Bylaws may impose additional litigation costs on stockholders in pursuing any such claims and may limit our stockholders&#8217; ability to litigate disputes with us in a judicial forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage the filing of lawsuits against us and our directors, officers and employees, even though an action, if successful, might benefit our stockholders. In addition, while the Delaware Supreme Court and other state courts have upheld the validity of federal forum selection provisions purporting to require claims under the Securities Act be brought in federal court, there is uncertainty as to whether other courts will enforce the federal forum provision. If the federal forum provision is found to be unenforceable, we may incur additional costs associated with resolving such matters. The federal forum provision may also impose additional litigation costs on stockholders who assert that the provision is not enforceable or invalid. The Court of </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chancery of the State of Delaware and the federal district courts of the United States may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our failure to meet the continued listing requirements of Nasdaq could result in a delisting of our securities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If we fail to satisfy the continued listing requirements of Nasdaq such as the corporate governance requirements or the minimum closing bid price requirement, Nasdaq may take steps to delist our securities. Such a delisting would likely have a negative effect on the price of the securities and would impair your ability to sell or purchase the securities when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our securities to become listed again, stabilize the market price or improve the liquidity of our securities, prevent our securities from dropping below the Nasdaq minimum bid price requirement or prevent future non-compliance with Nasdaq&#8217;s listing requirements. Additionally, if our securities are not listed on, or become delisted from, Nasdaq for any reason, and are quoted on the OTC Bulletin Board, an inter-dealer automated quotation system for equity securities that is not a national securities exchange, the liquidity and price of our securities may be more limited than if we were quoted or listed on Nasdaq or another national securities exchange. You may be unable to sell your securities unless a market can be established or sustained.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be investors&#8217; sole source of gain.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. As a result, capital appreciation, if any, of our common stock will be investors&#8217; sole source of gain for the foreseeable future.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be at an increased risk of securities class action litigation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Historically, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we were to be sued, it could result in substantial costs and a diversion of management&#8217;s attention and resources, which could harm our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">General Risk Factors</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Disruptions at the FDA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire, retain or deploy key leadership and other personnel, or otherwise prevent new or modified products from being developed, approved or commercialized in a timely manner or at all, which could negatively impact our business.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, statutory, regulatory and policy changes, the FDA&#8217;s ability to hire and retain key personnel and accept the payment of user fees, and other events that may otherwise affect the FDA&#8217;s ability to perform routine functions. Average review times at the FDA have fluctuated in recent years as a result. In addition, government funding of other government agencies that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies may also slow the time necessary for new drugs and biologics or modifications to approved drugs and biologics to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including for 35 days beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA employees and stop critical activities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since March 2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume pre-pandemic levels of inspection activities, including routine surveillance, bioresearch monitoring and pre-approval inspections. Should the FDA determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the agency has stated that it generally intends to issue, </span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the COVID-19 public health emergency, a number of companies announced receipt of complete response letters due to the FDA&#8217;s inability to complete required inspections for their applications. Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the ongoing COVID-19 pandemic and may experience delays in their regulatory activities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We or the third parties upon whom we depend may be adversely affected by natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our current operations are located in the San Francisco Bay Area. Any unplanned event, such as earthquake, flood, fire, explosion, extreme weather condition, medical epidemics, including any potential effects from the current global spread of COVID-19, power shortage, telecommunication failure or other natural or man-made accidents or incidents that result in us being unable to fully utilize our facilities, or the manufacturing facilities of our third-party contract manufacturers, may have a material adverse effect on our ability to operate our business, particularly on a daily basis and have significant negative consequences on our financial and operating conditions. Loss of access to these facilities may result in increased costs, delays in the development of our product candidates or interruption of our business operations. Natural disasters or pandemics such as the COVID-19 outbreak could further disrupt our operations and have a material adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure, such as our research facilities or the manufacturing facilities of our third-party contract manufacturers, or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible, for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place may prove inadequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business. As part of our risk management policy, we maintain insurance coverage at levels that we believe are appropriate for our business. However, in the event of an accident or incident at these facilities, we cannot assure our investors that the amounts of insurance will be sufficient to satisfy any damages and losses. If our facilities or the manufacturing facilities of our third-party contract manufacturers are unable to operate because of an accident or incident or for any other reason, even for a short period of time, any or all of our research and development programs may be harmed. Any business interruption may have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our quarterly operating results may fluctuate significantly or may fall below the expectations of investors or securities analysts, each of which may cause our stock price to fluctuate or decline.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:</span></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">variations in the level of expense related to the ongoing development of our product candidates or future development programs;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">results of preclinical studies and clinical trials, or the addition or termination of preclinical studies and clinical trials or funding support by us or potential future collaborators;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive under potential future arrangements or the termination or modification of any of our existing or potential future collaboration, licensing or similar arrangements;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">any intellectual property infringement, misappropriation or violation lawsuit or opposition, interference or cancellation proceeding in which we may become involved;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">additions and departures of key personnel;</span></div></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic investments or changes in business strategy;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">if any of our product candidates receives regulatory approval, the terms of such approval and market acceptance and demand for such product candidates;</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">regulatory developments affecting our product candidates or those of our competitors; and</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.310%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.746%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.082%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:87.362%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">changes in general market and economic conditions.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and should not be relied upon as an indication of our future performance.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed confidential information of these third parties or our employees&#8217; former employers, or that we caused an employee to breach the terms of his or her non-competition or non-solicitation agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. If our defenses to these claims fail, in addition to requiring us to pay monetary damages, a court could prohibit us from using technologies or features that are essential to our product candidates, if such technologies or features are found to incorporate or be derived from the trade secrets or other proprietary information of the former employers. Moreover, any such litigation or the threat thereof may adversely affect our reputation, our ability to form strategic alliances or sublicense our rights to collaborators, engage with scientific advisors or hire employees or consultants, each of which would have an adverse effect on our business, results of operations, financial condition and prospects. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span></div><div id="id08c0d7bd703495d970d203330d59b2f_130"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div id="id08c0d7bd703495d970d203330d59b2f_133"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div id="id08c0d7bd703495d970d203330d59b2f_136"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div id="id08c0d7bd703495d970d203330d59b2f_139"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">None.</span></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">103</span></div></div></div><div id="id08c0d7bd703495d970d203330d59b2f_142"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="-sec-extract:summary;margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.880%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:85.279%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Description</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.1*#</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="senti-employmentagreementk.htm">Employee Offer Letter by and between Kanya Rajangam and Senti Biosciences, Inc., dated May 10, 2022.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10.2&#8224;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1854270/000185427023000033/senti123122ex1033bluerocks.htm">Side Letter between BlueRock Therapeutics, LP and Senti Biosciences, Inc., dated February 3, 2023.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31.1*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023033110qex311.htm">Certification of Principal Executive Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">31.2*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023033110qex312.htm">Certification of Principal Financial Officer Pursuant to Securities Exchange Act Rules 13a-14(a) and 15(d)-14(a), as adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32.1**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023033110qex321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">32.2**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a2023033110qex322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.INS*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instance Document &#8211; the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.SCH*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.CAL*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.DEF*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.LAB*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">101.PRE*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The cover page for the Company&#8217;s Quarterly Report on Form 10-Q has been formatted in Inline XBRL and contained in Exhibit 101.</span></td></tr></table></div><div style="margin-bottom:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">___________________</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.910%"><tr><td style="width:1.0%"></td><td style="width:2.824%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.482%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.294%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Filed herewith.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Furnished herewith. This certification will not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing.</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">#</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Indicates a management contract or a compensatory plan, contract or arrangement.</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Portions of this exhibit (indicated by asterisks) have been omitted because the registrant has determined that the information is both not material and is of the type that the registrant treats as private or confidential.</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">104</span></div></div></div><div id="id08c0d7bd703495d970d203330d59b2f_145"></div><hr style="page-break-after:always"/><div style="min-height:72pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%;text-decoration:underline" href="#id08c0d7bd703495d970d203330d59b2f_7">Table of Contents</a></span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">SIGNATURES</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 9th day of May, 2023.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.419%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.938%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.432%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.355%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:33.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date:  May&#160;9, 2023</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">SENTI BIOSCIENCES, INC.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Timothy Lu, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy Lu, M.D., Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer &amp; President</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Deborah Knobelman, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah Knobelman, Ph.D.</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Head of Corporate Development</span></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">105</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>senti-employmentagreementk.htm
<DESCRIPTION>KANYA RAJANGAM OFFER LETTER
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i8ced46a49d004982bc5c04fd82b46788_43"></div><div style="min-height:66.24pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit 10.1</font></div><div style="text-align:right"><font><br></font></div><div id="i8ced46a49d004982bc5c04fd82b46788_1"></div><div style="margin-top:4.35pt;padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">May 10, 2022</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:374.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Kanya Rajangam VIA EMAIL</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Re&#58;&#160;&#160;&#160;&#160;Offer of Employment</font></div><div><font><br></font></div><div style="padding-left:5.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dear Kanya&#58;</font></div><div><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:7.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Senti Biosciences, Inc. (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) is pleased to offer you employment as the Company&#8217;s Chief Medical &#38; Development Officer (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">CMDO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) on the terms and conditions set forth in this letter agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.8pt;text-align:justify;text-indent:35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.&#160;&#160;&#160;&#160;Commencement of Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Your employment with the Company will commence on </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">July 5, 2022 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:7.4pt;text-align:justify;text-indent:35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.&#160;&#160;&#160;&#160;Duties</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. As CMDO, you will be responsible for developing and executing Senti&#8217;s research and development strategy for its NK cell oncology programs, including translational research, clinical research, operations, and development, and clinical strategy, and interfacing with external parties, such as clinical trial sites, KOLs, investors, and partners. You will report to Senti&#8217;s Chief Executive Officer (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">CEO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and be expected to adhere to the general employment policies and practices of the Company that may be in effect from time to time, except that when the terms of this Agreement conflict with the Company&#8217;s general employment policies or practices, this Agreement will control. The Company may change your position, duties, and compensation from time to time at its discretion, subject to the terms and conditions set forth herein, specifically in reference to the terms set forth in Section 7(d). You shall devote your best efforts and full business time, skill and attention to the performance of your duties&#59; provided, however, that you may engage in civic and not-for-profit activities (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">e.g.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, charitable and industry association activities) as long as such activities do not materially interfere with your obligations hereunder. You may also serve as a member of the boards of directors or boards of advisors of outside companies not directly related to the business in which the Company is now involved or becomes involved during the term of your employment provided that these outside commitments do not adversely affect your ability to fulfil your responsibilities to the Company and are agreed to between you and the CEO. The Company acknowledges that you are currently serving and will continue to serve as an independent member of the Board of Directors of Turnstone Biologics.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:78pt;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.&#160;&#160;&#160;&#160;Compensation.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:7.4pt;text-align:justify;text-indent:71.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;Base Salary. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">You will be paid an annual base salary of $490,000, less applicable deductions and withholdings, payable in accordance with the Company&#8217;s payroll practices as may be in effect from time to time. Your base salary shall be reviewed annually by the Company&#8217;s Board of Directors (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) or the Compensation Committee of the Board (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Compensation Committee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), commencing in January 2023.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:7.65pt;text-align:justify;text-indent:71.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;Signing Bonus. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company will pay you a signing bonus of $90,000. This bonus will be paid within ninety (90) days after the Effective Date, less deductions and withholdings, unless you resign your employment with the Company without Good Reason (as</font></div><div style="text-align:justify"><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.24pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4.35pt;padding-left:5.95pt;padding-right:7.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">defined herein) or the Company terminates your employment for Cause during such ninety days period. Although this bonus will be paid within the time period stated in the forgoing sentence, it will not be earned until you have completed twelve (12) months of employment. Therefore, in the event you resign your employment with the Company without Good Reason (as defined herein) or the Company terminates your employment for Cause, in each case after such signing bonus is paid, but before you complete twelve (12) months of employment with the Company, then you will be required to repay, within ninety (90) days after your last day of employment, a pro rata portion of this bonus to the Company equal to (x) the full amount of such signing bonus, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">multiplied by </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(y) a fraction, the numerator of which is the number of days remaining in such 12-month period after the last day of your employment, and the denominator of which is 365. In the event that the Company terminates your employment for any reason other than for Cause after the signing bonus is paid, you will not be required to repay any portion of this signing bonus even if you have not completed twelve (12) months of employment with the Company. For clarity, in the event that Company terminates your employment for any reason other than for Cause before the signing bonus is paid, the signing bonus will be paid within ninety (90) days after the Effective Date.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:7.35pt;text-align:justify;text-indent:71.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;Annual Performance Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Each year, you will be eligible to earn an annual performance bonus with an annual target amount of up to 40% of your annual base salary, less applicable payroll deductions and withholdings (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) (to be prorated for 2022 based on the Effective Date). Whether you receive such a bonus, and the amount of any such bonus, shall be determined by the Board or the Compensation Committee in its sole discretion, and shall be based upon achievement of Company and individual performance objectives, with such goals and the attainment of such goals to be determined by the Company in its sole discretion. No amount of the Annual Bonus is guaranteed, and you must be an employee on the last day of the applicable calendar year in order to earn an Annual Bonus</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Therefore, subject to Section 7 of this Agreement, if your employment is terminated either by you or the Company for any reason prior to the end of the calendar year, you will not have earned the Annual Bonus and no partial or prorated Annual Bonus will be paid. The Annual Bonus, if earned, will be paid following the completion of the applicable bonus year no later than March 15 of such subsequent calendar year.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.65pt;text-align:justify;text-indent:35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.&#160;&#160;&#160;&#160;Benefits. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to any contributions generally required of employees of the Company, commencing on the Effective Date, you shall be entitled to participate in any and all employee benefit plans from time to time in effect for full-time executive employees of the Company. Such participation shall be subject to the terms of the applicable plan documents and generally applicable Company policies. Additional information regarding these benefits is available for your review upon request. The Company may, from time to time, change these benefits in its discretion. In addition, you will be covered by the Company&#8217;s directors and officers insurance to the extent that the Company currently has or in the future obtains such insurance.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;text-align:justify;text-indent:35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.&#160;&#160;&#160;&#160;Equity</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to approval by the Board, the Company will grant you on or as soon as practicable following the closing of the Company&#8217;s business combination with Dynamics Special Purpose Corp. (the &#8220;Business Combination&#8221;), an option to purchase 0.75% of the issued and outstanding shares of the post-Business Combination Company&#8217;s common stock (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Option</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), calculated as of immediately following the closing of the Business Combination, at an exercise price equal to the fair market value per share on the date of the grant, as provided in the Plan (as defined below) and consistent with the requirements for an exemption from the application of Section 409A of the Internal Revenue Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Code</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). You will receive vesting</font></div><div style="text-align:justify"><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.24pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4.35pt;padding-left:5.95pt;padding-right:7.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">credit back to your start date. The Option shall vest over a four-year period, with one quarter (1&#47;4) of the shares subject to the Option vesting on the first anniversary of the Effective Date, and the remaining shares vesting equally over the following thirty-six (36) months of continuous service. The Option shall be issued under and subject to the terms and conditions of the post-Business Combination Company&#8217;s 2022 Equity Incentive Plan (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) then in effect and to the terms of the standard form of incentive stock option agreement.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.4pt;text-align:justify;text-indent:35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.&#160;&#160;&#160;&#160;Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. The Company shall pay or reimburse you for all reasonable business expenses incurred or paid by you in connection with your employment by the Company in accordance with the Company&#8217;s policies in effect from time to time.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:78pt;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.&#160;&#160;&#160;&#160;At Will Employment&#59; Severance Benefits.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.25pt;text-align:justify;text-indent:71.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;At-Will Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Your employment with the Company will be &#8220;at- will.&#8221; This means that either you or Company may terminate your employment at any time, with or without Cause (as defined herein), and with or without advance notice. Upon termination of your employment for any reason, the Company shall pay you all earned but unpaid salary, earned but unpaid Annual Bonus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">attributable to the calendar year prior to the year in which your employment terminates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and all accrued but unused vacation earned by you through and including the employment termination date, subject to required payroll deductions, in accordance with governing law. You will not be eligible to receive any severance benefits, except as expressly provided in this Agreement.</font></div><div><font><br></font></div><div style="margin-top:8.15pt;padding-left:6pt;padding-right:7.55pt;text-align:justify;text-indent:71.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;Termination for Cause&#59; Death&#59; Disability&#59; Resignation Without Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If, at any time, the Company terminates your employment for Cause, or if either party terminates your employment as a result of your death or disability, or if you resign without Good Reason (as defined herein), you will receive the accrued amounts set forth in Section 7(a) and will not be entitled to any other form of compensation from the Company, including any severance benefits.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="margin-top:4.5pt;padding-left:5.95pt;padding-right:7.5pt;text-align:justify;text-indent:71.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;Termination Without Cause or Resignation for Good Reason Outside of Change of Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If at any time outside of a Change of Control Period (as defined below), the Company terminates your employment without Cause or you resign for Good Reason, provided such termination or resignation constitutes a Separation from Service (as defined under Treasury Regulation Section 1.409A-1(h), without regard to any alternative definition thereunder, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Separation from Service</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then subject to your compliance with the terms of this Agreement and subject to the preconditions set forth in Section 7(e), the Company will provide you with the following severance benefits (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Severance Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#58;</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:7.45pt;text-align:justify;text-indent:107.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)&#160;&#160;&#160;&#160;Cash Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You will receive cash severance equal to nine (9) months of your then current base salary. This severance will be paid in equal installments on the Company&#8217;s regular payroll schedule over the 9-month period following your Separation from Service and will be subject to applicable tax withholdings&#59; provided, however, that no payments will be made prior to the 60th day following your Separation from Service (and with the first such payment including any amounts accrued following such Separation from Service).</font></div><div style="text-align:justify"><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.24pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4.35pt;padding-left:5.95pt;padding-right:7.75pt;text-align:justify;text-indent:107.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)&#160;&#160;&#160;&#160;Bonus Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You will receive all earned but unpaid Annual Bonus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">attributable to the calendar year prior to the year in which your employment terminates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For clarity, you will not be entitled to any pro-rated bonus severance for the calendar year in which your employment is terminated.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:7.5pt;text-align:justify;text-indent:107.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)&#160;&#160;&#160;&#160;COBRA Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If you timely elect continued coverage under COBRA, the Company will continue to pay the cost of your health care coverage in effect at the time of your employment termination for a maximum of nine (9) months. The Company&#8217;s obligation to pay these amounts on your behalf will cease if you obtain health care coverage from another source (e.g., a new employer or spouse&#8217;s benefit plan), unless otherwise prohibited by applicable law. Notwithstanding the above, if the Company determines in its sole discretion that it cannot provide these benefits without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof provide to you a taxable monthly payment in an amount equal to the monthly COBRA premium that you would be required to pay to continue your group health coverage in effect on the date of your termination (which amount shall be based on the premium for the first month of COBRA coverage), which payments shall be made on the last day of each month regardless of whether you elect COBRA continuation coverage and shall end on the earlier of (x) the date upon which you obtain other employment or (y) the same date as (when your COBRA began) of the 9th calendar month following your Separation from Service.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify;text-indent:71.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;Termination Without Cause or Resignation for Good Reason During Change of Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If at any time during a Change of Control Period (as defined below), the Company terminates your employment without Cause or you resign for Good Reason, provided such termination or resignation constitutes a Separation from Service, then subject to your compliance with the terms of this Agreement and subject to the preconditions set forth in Section 7(e), the Company will provide you with the following severance benefits&#58;</font></div><div><font><br></font></div><div style="margin-top:7.7pt;padding-left:150pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(i)&#160;&#160;&#160;&#160;Cash Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You will receive cash severance equal to twelve</font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(12) months of your then current base salary, paid in a lump sum, subject to applicable tax withholdings, on the 60th day following your Separation from Service.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify;text-indent:107.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(ii)&#160;&#160;&#160;&#160;Bonus Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. You will receive all earned but unpaid Annual Bonus </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:100%">attributable to the calendar year prior to the year in which your employment terminates</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, and an additional cash severance payment, less applicable deductions and withholdings, equal to the amount of your target annual bonus for the calendar year in which your employment is terminated, paid in a lump on the 60th day following your Separation from Service.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:7.55pt;text-align:justify;text-indent:107.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iii)&#160;&#160;&#160;&#160;COBRA Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. If you timely elect continued coverage under COBRA, the Company will continue to pay the cost of your health care coverage in effect at the time of your employment termination for a maximum of eighteen (18) months. The Company&#8217;s obligation to pay these amounts on your behalf will cease if you obtain health care coverage from another source (e.g., a new employer or spouse&#8217;s benefit plan), unless otherwise prohibited by applicable law. Notwithstanding the above, if the Company determines in its sole discretion that it cannot provide these benefits without potentially violating applicable law (including, without</font></div><div style="text-align:justify"><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.24pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4.35pt;padding-left:5.95pt;padding-right:7.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">limitation, Section 2716 of the Public Health Service Act), the Company shall in lieu thereof provide to you a taxable monthly payment in an amount equal to the monthly COBRA premium that you wouldbe required to pay to continue your group health coverage in effect on the date of your termination (which amount shall be based on the premium for the first month of COBRA coverage), which payments shall be made on the last day of each month regardless of whether you elect COBRA continuation coverage and shall end on the earlier of (x) the date upon which you obtain other employment or (y) the same date as (when your COBRA began) of the eighteenth calendar month following your Separation from Service.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify;text-indent:107.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(iv)&#160;&#160;&#160;&#160;Accelerated Vesting. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">The Company will accelerate the vesting of your time-based equity awards (and the time-based vesting conditions of equity awards which vest by a combination of time-based and performance-based vesting conditions) such that you will be deemed fully vested in all such shares as of your Separation from Service (subject to any applicable performance-based vesting conditions).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify;text-indent:71.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(e)&#160;&#160;&#160;&#160;Conditions to Receipt of Severance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Your receipt of the severance benefits set forth in this Section 7 is conditioned upon&#58; (i) you continuing to comply with your obligations under your Confidential Information and Inventions Agreement&#59; and (ii) you delivering to the Company an effective, general release of claims in favor of the Company substantially in the form attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit A </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Release</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) within the applicable time period set forth therein.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:78pt;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.&#160;&#160;&#160;&#160;Definitions.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:7.45pt;text-align:justify;text-indent:71.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;Cause. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Cause</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean the occurrence of any of the following&#58; (i) your material breach of this Agreement, (ii) any act or omission by you that has a material and adverse effect on the Company&#8217;s business, or on your ability to perform services for the Company, including, without limitation, the commission of any crime (other than minor traffic violations), or (iii) your material misconduct or material neglect of your duties in connection with the business or affairs of the Company, including material breach of company policies&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">that before terminating your employment for Cause, the Company will provide you with 30 days&#8217; advance written notice with the event specifically set forth in the notice and the opportunity to cure the event (if curable).</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;text-align:justify;text-indent:71.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. For purposes of this Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Change of Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall have the meaning set forth in the Plan, provided that such transaction or series of transactions also qualifies as a &#8220;change in control&#8221; event under U.S. Treasury Regulation 1.409A- 3(i)(5). Notwithstanding anything to the foregoing, the consummation of the transactions contemplated by the Business Combination Agreement between Dynamics Special Purchase Corp. Explore Merger Sub, Inc. and the Company shall not constitute a &#8220;Change of Control&#8221; for purposes of this Agreement.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify;text-indent:71.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;Change of Control Period. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Agreement, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Change of Control Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; is defined as the period commencing three (3) months prior to the effective date of a Change of Control and ending on the twelve (12) month anniversary of the effective date of a Change of Control.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:114pt;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(d)&#160;&#160;&#160;&#160;Good Reason. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">For purposes of this Agreement, &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Good Reason</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; shall mean</font></div><div><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.24pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:4.35pt;padding-left:6pt;padding-right:7.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:117%">your resignation because of any of the following actions taken without your consent&#58; (i) the Company&#8217;s material breach of any one or more of the material provisions of this Agreement&#59;</font></div><div style="padding-left:5.95pt;padding-right:7.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii) a material reduction by the Company of your annual base salary, unless such reduction is applied equally, as a percentage of base salary, to all senior executives of the Company&#59; (iii) a material adverse change in your duties, authority, or responsibilities relative to your duties, authority, or responsibilities in effect immediately prior to such reduction (other than a change in title and provided that a change in title, reporting lines or position in connection with a Change of Control will not, in itself, be deemed to be a change in duties, authority or responsibility), except that a change in title from CMDO to Chief Development Officer (or any other title designating a position equivalent to a Chief Development Officer) on its own will not be considered Good Reason&#59; (iv) a material change in the geographic location at which you are required to provide services to the Company&#59; or (v) the failure of an acquiror or successor to assume the terms of this Agreement&#59; provided, however, that any such termination by you shall only be deemed for Good Reason pursuant to this definition if&#58; (1) you give the Company written notice of your intent to terminate for Good Reason within sixty (60) days following the first occurrence of the condition(s) that you believe constitute(s) Good Reason, which notice shall describe such condition(s)&#59; (2) the Company fails to remedy such condition(s) within thirty (30) days following receipt of the written notice (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Cure Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; and (3) you voluntarily terminate your employment within thirty (30) days following the end of the Cure Period.</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:7.5pt;text-align:justify;text-indent:35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.&#160;&#160;&#160;&#160;Section 409A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. It is intended that all of the severance benefits and other payments payable under this letter satisfy, to the greatest extent possible, the exemptions from the application of Code Section 409A provided under Treasury Regulations 1.409A-1(b)(4), 1.409A-1(b)(5) and 1.409A-1(b)(9), and this letter will be construed to the greatest extent possible as consistent with those provisions. For purposes of Code Section 409A (including, without limitation, for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii)), your right to receive any installment payments under this letter (whether severance payments, reimbursements or otherwise) shall be treated as a right to receive a series of separate payments and, accordingly, each installment payment hereunder shall at all times be considered a separate and distinct payment. Notwithstanding any provision to the contrary in this letter, if you are deemed by the Company at the time of your Separation from Service to be a &#8220;specified employee&#8221; for purposes of Code Section 409A(a)(2)(B)(i), and if any of the payments upon Separation from Service set forth herein and&#47;or under any other agreement with the Company are deemed to be &#8220;deferred compensation&#8221;, then to the extent delayed commencement of any portion of such payments is required in order to avoid a prohibited distribution under Code Section 409A(a)(2)(B)(i) and the related adverse taxation under Section 409A, such payments shall notbe provided to you prior to the earliest of</font></div><div style="padding-left:6pt;padding-right:7.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i) the expiration of the six-month period measured from the date of your Separation from Service with the Company, (ii) the date of your death or (iii) such earlier date as permitted under Section 409A without the imposition of adverse taxation. Upon the first business day following the expiration of such applicable Code Section 409A(a)(2)(B)(i) period, all payments deferred pursuant to this paragraph shall be paid in a lump sum to you, and any remaining payments due shall be paid as otherwise provided herein or in the applicable agreement. No interest shall be due on any amounts so deferred.</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="padding-left:78pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.&#160;&#160;&#160;&#160;280G.</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:114pt;text-indent:-36.15pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If any payment or benefit you will or may receive from the Company or</font></div><div><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.24pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="margin-top:4.35pt;padding-left:5.95pt;padding-right:7.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">from another source (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">280G Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) would (i) constitute a &#8220;parachute payment&#8221; within the meaning of Section 280G of Code, and (ii) but for this sentence, be subject to the excise tax imposed by Section 4999 of the Code (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Excise Tax</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), then any such 280G Payment pursuant to this letter agreement (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will be equal to the Reduced Amount. The &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Reduced Amount</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221; will be either (x) the largest portion of the Payment that would result in no portion of the Payment (after reduction) being subject to the Excise Tax or (y) the largest portion, up to and including the total, of the Payment, whichever amount (i.e., the amount determined by clause (x) or by clause (y)), after taking into account all applicable federal, state and local employment taxes, income taxes, and the Excise Tax (all computed at the highest applicable marginal rate), results in your receipt, on an after-tax basis, of the greater economic benefit notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in a Payment is required pursuant to the preceding sentence and the Reduced Amount is determined pursuant to clause (x) of the preceding sentence, the reduction will occur in the manner (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Reduction Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) that results in the greatest economic benefit for you. If more than one method of reduction will result in the same economic benefit, the items so reduced will be reduced pro rata (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Pro Rata Reduction Method</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:5.95pt;text-align:justify;text-indent:71.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding any provision of paragraph (a) to the contrary, if the Reduction Method or the Pro Rata Reduction Method would result in any portion of the Payment being subject to taxes pursuant to Section 409A that would not otherwise be subject to taxes pursuant to Section 409A, then the Reduction Method and&#47;or the Pro Rata Reduction Method, as the case may be, will be modified so as to avoid the imposition of taxes pursuant to Section 409A as follows&#58; (A) as a first priority, the modification will preserve to the greatest extent possible, the greatest economic benefit for you as determined on an after-tax basis&#59; (B) as a second priority, Payments that are contingent on future events (e.g., being terminated without cause), will be reduced (or eliminated) before Payments that are not contingent on future events&#59; and (C) as a third priority, Payments that are &#8220;deferred compensation&#8221; within the meaning of Section 409A of the Code will be reduced (or eliminated) before Payments that are not deferred compensation within the meaning of Section 409A of the Code.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:7.75pt;text-align:justify;text-indent:71.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">If you receive a Payment for which the Reduced Amount was determined pursuant to clause (x) of Section 10(a) and the Internal Revenue Service determines thereafter that some portion of the Payment is subject to the Excise Tax, you agree to promptly return to the Company a sufficient amount of the Payment (after reduction pursuant to clause (x) of Section 10(a)) so that no portion of the remaining Payment is subject to the Excise Tax. For the avoidance of doubt, if the Reduced Amount was determined pursuant to clause (y) of Section 10(a), you will have no obligation to return any portion of the Payment pursuant to the preceding sentence.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.75pt;text-align:justify;text-indent:35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.&#160;&#160;&#160;&#160;Confidentiality Obligations. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">As condition of your employment, you must sign and abide by the Company&#8217;s standard form of Employee Confidential Information and Invention Assignment Agreement, a copy of which is attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:5.95pt;padding-right:7.65pt;text-align:justify;text-indent:35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.&#160;&#160;&#160;&#160;Arbitration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. To ensure the timely and economical resolution of disputes that may arise between you and the Company, both you and the Company mutually agree that pursuant to the Federal Arbitration Act, 9 U.S.C. &#167;1-16, and to the fullest extent permitted by applicable law, you will submit solely to final, binding and confidential arbitration any and all disputes, claims, or causes of action arising from or relating to&#58; the negotiation, execution, interpretation, performance,</font></div><div style="text-align:justify"><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.24pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4.35pt;padding-left:5.95pt;padding-right:7.85pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">breach or enforcement of this letter agreement&#59; or your employment with the Company (including but not limited to all statutory claims)&#59; or the termination of your employment with the Company (including but not limited to all statutory claims). BY AGREEING TO THIS ARBITRATION PROCEDURE, BOTH YOU AND THE COMPANY WAIVE THE RIGHT TO RESOLVE ANY SUCH DISPUTES THROUGH A TRIAL BY JURY OR JUDGE OR THROUGH AN</font></div><div style="margin-top:0.1pt;padding-left:5.95pt;padding-right:7.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">ADMINISTRATIVE PROCEEDING. The Arbitrator will have the sole and exclusive authority to determine whether a dispute, claim or cause of action is subject to arbitration under this section and to determine any procedural questions which grow out of such disputes, claims or causes of action and bear on their final disposition. All claims, disputes, or causes of action under this section, whether by you or the Company, must be brought solely in an individual capacity, and will not be brought as a plaintiff (or claimant) or class member in any purported class or representative proceeding, nor joined or consolidated with the claims of any other person or entity. The Arbitrator may not consolidate the claims of more than one person or entity and may not preside over any form of representative or class proceeding. To the extent that the preceding sentences in this paragraph are found to violate applicable law or are otherwise found unenforceable, any claim(s) alleged or brought on behalf of a class will proceed in a court of law rather than by arbitration. Any arbitration proceeding under this Arbitration section will be presided over by a single arbitrator and conducted by JAMS, Inc. (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">JAMS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) in San Francisco, CA under the then applicable JAMS rules for the resolution of employment disputes (available upon request and also currently available at http&#58;&#47;&#47;www.jamsadr.com&#47;rules-employment-arbitration&#47;). You and the Company both have the right to be represented by legal counsel at any arbitration proceeding, at each party&#8217;s own expense. The Arbitrator will&#58; (a) have the authority to compel adequate discovery for the resolution of the dispute&#59; (b) issue a written arbitration decision, to include the arbitrator&#8217;s essential findings and conclusions and a statement of the award&#59; and (c) be authorized to award any or all remedies that you or the Company would be entitled to seek in a court of law. The Company will pay all JAMS arbitration fees in excess of the amount of court fees that would be required of you if the dispute were decided in a court of law. This section will not apply to any action or claim that cannot be subject to mandatory arbitration as a matter of law, including, without limitation, claims brought pursuant to the California Private Attorneys General Act of 2004, as amended, the California Fair Employment and Housing Act, as amended, and the California Labor Code, as amended, to the extent such claims are not permitted by applicable law to be submitted to mandatory arbitration and such applicable law is not preempted by the Federal Arbitration Act or otherwise invalid (collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Excluded Claims</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). In the event you intend to bring multiple claims, including one of the Excluded Claims listed above, the Excluded Claims may be filed with a court, while any other claims will remain subject to mandatory arbitration. Nothing in this section is intended to prevent either you or the Company from obtaining injunctive relief in court to prevent irreparable harm pending the conclusion of any such arbitration. Any final award in any arbitration proceeding hereunder may be entered as a judgment in the federal and state courts of any competent jurisdiction and enforced accordingly.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:7.5pt;text-align:justify;text-indent:35.85pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.&#160;&#160;&#160;&#160;Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Agreement, including its exhibits, is the complete and exclusive statement of all of the terms and conditions of your employment with the Company, and supersedes and replaces any and all prior agreements or representations with regard to the subject matter hereof, whether written or oral. It is entered into without reliance on any promise or representation other than those expressly contained herein, and it cannot be modified, amended or extended except in a writing signed by you and a duly authorized member of the Board. This Agreement is intended to bind and inure to the benefit of and be enforceable by you and the</font></div><div style="text-align:justify"><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.24pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4.35pt;padding-left:5.95pt;padding-right:7.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Company, and our respective successors, assigns, heirs, executors and administrators, except that you may not assign any of your duties or rights hereunder without the express written consent of the Company. Whenever possible, each provision of this Agreement will be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Agreement is held to be invalid, illegal or unenforceable in any respect under any applicable law or rule in any jurisdiction, such invalidity, illegality or unenforceability will not affect any other provision or any other jurisdiction, but this Agreement will be reformed, construed and enforced as if such invalid, illegal or unenforceable provisions had never been contained herein. This Agreement and the terms of your employment with the Company shall be governed in all aspects by the laws of the State of California.</font></div><div style="margin-top:0.5pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:7.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">This offer is subject to satisfactory proof of your right to work in the United States and satisfactory completion of a Company-required background check. If you agree to the terms and conditions set forth herein, please sign below.</font></div><div style="margin-top:0.05pt"><font><br></font></div><div style="padding-left:6pt;padding-right:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:217%">If you have any questions about this Agreement, please do not hesitate to call me. Best regards,</font></div><div style="padding-left:4.5pt;padding-right:68.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Tim Lu</font></div><div style="margin-top:1.65pt;padding-left:5.95pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Timothy Lu, M.D., Ph.D.</font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Co-founder and Chief Executive Officer</font></div><div><font><br></font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Understood, Accepted and Agreed To&#58;</font></div><div style="padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:47.022%"><tr><td style="width:1.0%"></td><td style="width:52.211%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.285%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#47;s&#47; Kanya Rajangham</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5&#47;10&#47;2022</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Kanya Rajangam</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Date</font></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i8ced46a49d004982bc5c04fd82b46788_50"></div><hr style="page-break-after:always"><div style="min-height:66.24pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.6pt;padding-left:6.55pt;padding-right:6.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT A &#8211; FORM OF RELEASE</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:6.4pt;padding-right:6.4pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(TO BE SIGNED ON OR WITHIN 21 DAYS OF SEPARATION DATE)</font></div><div style="margin-top:0.25pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:7.35pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I understand that my employment with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SENTI BIOSCIENCES, INC. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) has terminated. The Company has agreed that if I sign this Release, the Company will provide me with the benefits set forth in the offer letter agreement (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) between me and the Company. I understand that I am not entitled to such severance benefits unless I sign this Release without revocation. I also understand that, regardless of whether I sign this Release, the Company will pay me all of my accrued salary and vacation through my last day of employment, to which I am entitled by law.</font></div><div style="margin-top:9pt;padding-left:5.95pt;padding-right:7.4pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I hereby generally release the Company and its officers, directors, agents, attorneys, employees, stockholders, parents, subsidiaries, and affiliates from any and all claims, liabilities, demands, causes of action, attorneys&#8217; fees, damages, or obligations of every kind and nature, whether they are now known or unknown, arising at any time prior to the date I sign this Release. This general release includes, but is not limited to&#58; (i) all federal and state statutory and common law claims, including claims for discrimination, harassment, retaliation, attorneys&#8217; fees, or other claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%">ADEA</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the federal Employee Retirement Income Security Act of 1974 (as amended), the California Labor Code (as amended), and the California Fair Employment and Housing Act (as amended)&#59; (ii) claims related to my employment or the termination of my employment&#59; and (iii) claims related to breach of contract, tort, wrongful termination, discrimination, wages or benefits, or claims for any form of equity or compensation.</font></div><div style="margin-top:9pt;padding-left:5.95pt;padding-right:7.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I acknowledge that I am knowingly and voluntarily waiving and releasing any rights I may have under the ADEA. I also acknowledge that the consideration given for the waiver in this paragraph is in addition to anything of value to which I was already entitled. I have been advised by this writing, as required by the ADEA that&#58; (a) my waiver and release do not apply to any claims that may arise after my signing of this Release&#59; (b) I should consult with an attorney prior to executing this Release&#59; (c) I have twenty-one (21) days within which to consider this Release (although I may choose to voluntarily execute this Release earlier)&#59; (d) I have seven (7) days following the execution of this release to revoke the Release&#59; and (e) this Release will not be effective until the eighth day after this Release has been signed by me.</font></div><div><font><br></font></div><div style="padding-left:5.95pt;padding-right:7.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Notwithstanding the release in the preceding paragraphs, I am not releasing&#58; (i) any right of indemnification I may have under contract or law&#59; (ii) any rights that cannot be waived as a matter of law&#59; and (iii) claims for breach of this Release. In addition, I understand that nothing in this Release limits my ability to file a charge or complaint with the Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Occupational Safety and Health Administration, the Securities and Exchange Commission or any other federal, state or local governmental agency or commission (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:112%">Government Agencies</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">&#8221;). I further understand that this Release does not limit my ability to communicate with any Government Agencies or otherwise participate in any investigation or proceeding that may be conducted by any Government Agency, including providing documents or other information, without notice to the Company. While this Release does not limit my right to receive an award for information provided to the Securities and Exchange Commission, I understand and agree that, to maximum extent permitted</font></div><div style="text-align:justify"><font><br></font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:66.24pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:4.3pt;padding-left:6pt;padding-right:7.75pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">by law, I am otherwise waiving any and all rights I may have to individual relief based on any claims that I have released and anyrights I have waived by signing this Release.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:6pt;padding-right:7.55pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">In releasing claims unknown to me at present, I am waiving all rights and benefits under Section 1542 of the California Civil Code, and any law or legal principle of similar effect in any jurisdiction&#58; &#8220;A general release does not extend to claims which the creditor or releasing party does not know or suspect to exist in his favor at the time of executing the release, which if known by him would have materially affected his settlement with the debtor or released party.&#8221;</font></div><div style="margin-top:0.2pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;padding-right:7.65pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">I hereby represent that I have been paid all compensation owed and for all hours worked, I have received all the leave and leave benefits and protections for which I am eligible, and I have not suffered any on- the-job injury for which I have not already filed a workers&#8217; compensation claim.</font></div><div style="margin-top:0.45pt"><font><br></font></div><div style="padding-left:6pt;padding-right:10.3pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">I hereby confirm my obligations under my Confidential Information and Inventions Assignment Agreement with the Company.</font></div><div style="margin-top:0.55pt"><font><br></font></div><div style="padding-left:5.95pt;padding-right:5.45pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">I also agree that I will not voluntarily (except in response to legal compulsion) assist any person in bringing or pursuing any proposed or pending litigation, arbitration, administrative claim or other formal proceeding against the Company, its parent or subsidiary entities, affiliates, officers, directors, employees or agents. I further agree to reasonably cooperate with the Company by voluntarily providing accurate and complete information, in connection with the Company&#8217;s actual or contemplated defense, prosecution, or investigation of any claims or demands by or against third parties, or other matters, arising from events, acts, or failures to act that occurred during the period of my employment by the Company.</font></div><div style="margin-top:0.15pt"><font><br></font></div><div style="padding-left:6pt;padding-right:5.25pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">I hereby agree not to disparage the Company, or its officers, directors, employees, shareholders or agents, in any manner likely to be harmful to them or their business, business reputation, or personal reputation&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">provided, however, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">that I will respond accurately and fully to any question, inquiry or request for information when required by legal process or in connection with a government investigation.</font></div><div style="margin-top:0.3pt"><font><br></font></div><div style="margin-top:0.05pt;padding-left:6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Dated&#58; ________________________________</font></div><div style="text-align:justify"><font><br></font></div><div style="margin-top:0.3pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12.5pt;font-weight:400;line-height:100%">______________________________________</font></div><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:114%">Kanya Rajangam</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i8ced46a49d004982bc5c04fd82b46788_4"></div><hr style="page-break-after:always"><div style="min-height:66.24pt;width:100%"><div><font><br></font></div></div><div style="margin-top:4.6pt;padding-left:163.05pt;padding-right:163.05pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT B</font></div><div style="margin-top:0.1pt"><font><br></font></div><div style="padding-left:6.65pt;padding-right:6.65pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">CONFIDENTIAL INFORMATION AND INVENTION AGREEMENT</font></div><div style="margin-top:0.35pt"><font><br></font></div><div style="padding-left:163.55pt;padding-right:163.55pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(TO BE SENT SEPARATELY)</font></div><div style="height:43.2pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>a2023033110qex311.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i44191718e0754da5bf8c335d9816f880_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Timothy Lu, M.D., Ph.D., certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended March&#160;31, 2023, of Senti Biosciences, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;  May&#160;9, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Timothy Lu, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy Lu, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>a2023033110qex312.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="iac6d5fdb4e0041f2b8cb03e48af57886_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Deborah Knobelman, Ph.D., certify that&#58;</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">I have reviewed this Quarterly Report on Form 10-Q for the quarterly period ended March&#160;31, 2023, of Senti Biosciences, Inc.&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div><font><br></font></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.24pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.67pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.951%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;  May&#160;9, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Deborah Knobelman, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah Knobelman, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Head of Corporate Development</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>a2023033110qex321.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i9222a41171974a22b37f52375f6df560_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Senti Biosciences, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarterly period ended March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date here of (the &#8220;Report&#8221;), I, Timothy Lu, M.D., Ph.D., Chief Executive Officer and President of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.239%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;  May&#160;9, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Timothy Lu, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy Lu, M.D., Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer and President</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Executive Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>a2023033110qex322.htm
<DESCRIPTION>CERTIFICATION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="ia17b21914aa9415aaf15b5ce0a2a5339_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:right"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report of Senti Biosciences, Inc. (the &#8220;Company&#8221;) on Form 10-Q for the quarterly period ended March&#160;31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I, Deborah Knobelman, Ph.D., Chief Financial Officer, Treasurer and Head of Corporate Development of the Company, certify, pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, that to my knowledge&#58;</font></div><div><font><br></font></div><div style="margin-bottom:6pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.380%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:29.829%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.568%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58;  May&#160;9, 2023</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#58;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;  Deborah Knobelman, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deborah Knobelman, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer, Treasurer and Head of Corporate Development</font></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>snti-20230331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7af4709b-ea9b-4a83-bec7-2aee05be3f39,g:bb811bd4-927a-481b-aaf3-dcf961c572fd-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:snti="http://www.sentibio.com/20230331" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sentibio.com/20230331">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="snti-20230331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="snti-20230331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="snti-20230331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="snti-20230331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.sentibio.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>0000002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.sentibio.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" roleURI="http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit">
        <link:definition>0000005 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusiness" roleURI="http://www.sentibio.com/role/OrganizationandDescriptionofBusiness">
        <link:definition>0000007 - Disclosure - Organization and Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.sentibio.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000008 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.sentibio.com/role/FairValueMeasurements">
        <link:definition>0000009 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementinformation" roleURI="http://www.sentibio.com/role/OtherFinancialStatementinformation">
        <link:definition>0000010 - Disclosure - Other Financial Statement information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeases" roleURI="http://www.sentibio.com/role/OperatingLeases">
        <link:definition>0000011 - Disclosure - Operating Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficit" roleURI="http://www.sentibio.com/role/StockholdersEquityDeficit">
        <link:definition>0000012 - Disclosure - Stockholders&#8217; Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenue" roleURI="http://www.sentibio.com/role/Revenue">
        <link:definition>0000013 - Disclosure - Revenue</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.sentibio.com/role/StockBasedCompensation">
        <link:definition>0000014 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTax" roleURI="http://www.sentibio.com/role/IncomeTax">
        <link:definition>0000015 - Disclosure - Income Tax</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.sentibio.com/role/NetLossPerShare">
        <link:definition>0000016 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingencies" roleURI="http://www.sentibio.com/role/CommitmentandContingencies">
        <link:definition>0000017 - Disclosure - Commitment and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedParties" roleURI="http://www.sentibio.com/role/RelatedParties">
        <link:definition>0000018 - Disclosure - Related Parties</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.sentibio.com/role/SubsequentEvents">
        <link:definition>0000019 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.sentibio.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.sentibio.com/role/FairValueMeasurementsTables">
        <link:definition>0000021 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementinformationTables" roleURI="http://www.sentibio.com/role/OtherFinancialStatementinformationTables">
        <link:definition>0000022 - Disclosure - Other Financial Statement information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesTables" roleURI="http://www.sentibio.com/role/OperatingLeasesTables">
        <link:definition>0000023 - Disclosure - Operating Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitTables" roleURI="http://www.sentibio.com/role/StockholdersEquityDeficitTables">
        <link:definition>0000024 - Disclosure - Stockholders&#8217; Equity (Deficit) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.sentibio.com/role/StockBasedCompensationTables">
        <link:definition>0000025 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.sentibio.com/role/NetLossPerShareTables">
        <link:definition>0000026 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandDescriptionofBusinessDetails" roleURI="http://www.sentibio.com/role/OrganizationandDescriptionofBusinessDetails">
        <link:definition>0000027 - Disclosure - Organization and Description of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.sentibio.com/role/SummaryofSignificantAccountingPoliciesDetails">
        <link:definition>0000028 - Disclosure - Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails" roleURI="http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails">
        <link:definition>0000029 - Disclosure - Fair Value Measurements - Summary of the Estimated Fair Value of Cash Equivalents, Restricted Cash, And Short-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails_1" roleURI="http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails_1">
        <link:definition>0000029 - Disclosure - Fair Value Measurements - Summary of the Estimated Fair Value of Cash Equivalents, Restricted Cash, And Short-Term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails" roleURI="http://www.sentibio.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails">
        <link:definition>0000030 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>0000031 - Disclosure - Other Financial Statement information - Schedule of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails" roleURI="http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails">
        <link:definition>0000032 - Disclosure - Other Financial Statement information - Schedule of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementinformationDetails" roleURI="http://www.sentibio.com/role/OtherFinancialStatementinformationDetails">
        <link:definition>0000033 - Disclosure - Other Financial Statement information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails" roleURI="http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails">
        <link:definition>0000034 - Disclosure - Other Financial Statement information - Schedule of Accrued Expenses and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesNarrativeDetails" roleURI="http://www.sentibio.com/role/OperatingLeasesNarrativeDetails">
        <link:definition>0000035 - Disclosure - Operating Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesTotalLeaseCostDetails" roleURI="http://www.sentibio.com/role/OperatingLeasesTotalLeaseCostDetails">
        <link:definition>0000036 - Disclosure - Operating Leases - Total Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesOtherInformationDetails" roleURI="http://www.sentibio.com/role/OperatingLeasesOtherInformationDetails">
        <link:definition>0000037 - Disclosure - Operating Leases - Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails" roleURI="http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails">
        <link:definition>0000038 - Disclosure - Operating Leases - Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitCommonandPreferredStockDetails" roleURI="http://www.sentibio.com/role/StockholdersEquityDeficitCommonandPreferredStockDetails">
        <link:definition>0000039 - Disclosure - Stockholders&#8217; Equity (Deficit) - Common and Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails" roleURI="http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails">
        <link:definition>0000040 - Disclosure - Stockholders&#8217; Equity (Deficit) - Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitCommonStockPurchaseAgreementDetails" roleURI="http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails">
        <link:definition>0000041 - Disclosure - Stockholders&#8217; Equity (Deficit) - Common Stock Purchase Agreement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitContingentEarnoutEquityDetails" roleURI="http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails">
        <link:definition>0000042 - Disclosure - Stockholders&#8217; Equity (Deficit) - Contingent Earnout Equity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails" roleURI="http://www.sentibio.com/role/StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails">
        <link:definition>0000043 - Disclosure - Stockholders&#8217; Equity (Deficit) - Assumptions used in valuation of contingent earnout shares (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueContractRevenueDetails" roleURI="http://www.sentibio.com/role/RevenueContractRevenueDetails">
        <link:definition>0000044 - Disclosure - Revenue - Contract Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueContractRevenueDetails_1" roleURI="http://www.sentibio.com/role/RevenueContractRevenueDetails_1">
        <link:definition>0000044 - Disclosure - Revenue - Contract Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueGrantIncomeDetails" roleURI="http://www.sentibio.com/role/RevenueGrantIncomeDetails">
        <link:definition>0000045 - Disclosure - Revenue - Grant Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueEntitywideinformationDetails" roleURI="http://www.sentibio.com/role/RevenueEntitywideinformationDetails">
        <link:definition>0000046 - Disclosure - Revenue - Entity-wide information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>0000047 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockOptionActivityDetails" roleURI="http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails">
        <link:definition>0000048 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationPerformanceAwardsActivityDetails" roleURI="http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails">
        <link:definition>0000049 - Disclosure - Stock-Based Compensation - Performance Awards Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationRestrictedStockUnitsActivityDetails" roleURI="http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails">
        <link:definition>0000050 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationWeightedAverageAssumptionsDetails" roleURI="http://www.sentibio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails">
        <link:definition>0000051 - Disclosure - Stock-Based Compensation - Weighted Average Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.sentibio.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>0000052 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxDetails" roleURI="http://www.sentibio.com/role/IncomeTaxDetails">
        <link:definition>0000053 - Disclosure - Income Tax (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareBasicandDilutedNetEarningslossPerCommonShareDetails" roleURI="http://www.sentibio.com/role/NetLossPerShareBasicandDilutedNetEarningslossPerCommonShareDetails">
        <link:definition>0000054 - Disclosure - Net Loss Per Share - Basic and Diluted Net Earnings (loss) Per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" roleURI="http://www.sentibio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
        <link:definition>0000055 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentandContingenciesDetails" roleURI="http://www.sentibio.com/role/CommitmentandContingenciesDetails">
        <link:definition>0000056 - Disclosure - Commitment and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RelatedPartiesDetails" roleURI="http://www.sentibio.com/role/RelatedPartiesDetails">
        <link:definition>0000057 - Disclosure - Related Parties (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="snti_A2022StockIncentivePlanMember" abstract="true" name="A2022StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_CommonStockSubjectToRepurchaseValue" abstract="false" name="CommonStockSubjectToRepurchaseValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_TenantImprovementAllowanceUtilized" abstract="false" name="TenantImprovementAllowanceUtilized" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_NumberOfBusinessActivities" abstract="false" name="NumberOfBusinessActivities" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="snti_CGMPFacilityMember" abstract="true" name="CGMPFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" abstract="false" name="ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="snti_ResearchAndDevelopmentExpenseTermOfAgreement" abstract="false" name="ResearchAndDevelopmentExpenseTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="snti_TenantImprovementAllowanceRemainingAmount" abstract="false" name="TenantImprovementAllowanceRemainingAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_OperatingLeaseProceedsPayments" abstract="false" name="OperatingLeaseProceedsPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_ContingentConsiderationTrancheOneMember" abstract="true" name="ContingentConsiderationTrancheOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" abstract="false" name="ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="snti_ContractWithCustomerExtensionOfTermModificationOfContract" abstract="false" name="ContractWithCustomerExtensionOfTermModificationOfContract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="snti_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_CorporateHeadquartersMember" abstract="true" name="CorporateHeadquartersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_MarketAwardsMember" abstract="true" name="MarketAwardsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_RestrictedCashMember" abstract="true" name="RestrictedCashMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_A2022InducementEquityPlanMember" abstract="true" name="A2022InducementEquityPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_EarlyExerciseLiabilityCurrent" abstract="false" name="EarlyExerciseLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="snti_ReverseRecapitalizationContingentConsiderationEquityTerm" abstract="false" name="ReverseRecapitalizationContingentConsiderationEquityTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="snti_ResearchAndDevelopmentArrangementExpectedCosts" abstract="false" name="ResearchAndDevelopmentArrangementExpectedCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_TenantImprovementReimbursements" abstract="false" name="TenantImprovementReimbursements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_SaleOfStockSharesIssuedInTransactionThresholdPercent" abstract="false" name="SaleOfStockSharesIssuedInTransactionThresholdPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" abstract="false" name="BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:decimalItemType"/>
  <xs:element id="snti_SaleOfStockTermOfAgreement" abstract="false" name="SaleOfStockTermOfAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="snti_RevenueFromContractWithCustomerEvaluationPeriod" abstract="false" name="RevenueFromContractWithCustomerEvaluationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm" abstract="false" name="RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="snti_CommonStockPurchaseAgreementMember" abstract="true" name="CommonStockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_NumberOfSeatsOnTheBoardOfDirectors" abstract="false" name="NumberOfSeatsOnTheBoardOfDirectors" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="snti_UnvestedEarlyExercisedOptionsMember" abstract="true" name="UnvestedEarlyExercisedOptionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_SeriesAAndBRedeemableConvertiblePreferredStockMember" abstract="true" name="SeriesAAndBRedeemableConvertiblePreferredStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold" abstract="false" name="SaleOfStockNumberOfSharesIssuedInTransactionThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions" abstract="false" name="ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_NEAMember" abstract="true" name="NEAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_ContingentEarnoutCommonStockMember" abstract="true" name="ContingentEarnoutCommonStockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="snti_GrantAssistancePeriodOfRecognition" abstract="false" name="GrantAssistancePeriodOfRecognition" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsContractualAnnualPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions" abstract="false" name="StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid" abstract="false" name="MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_CustomerBMember" abstract="true" name="CustomerBMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_ContingentConsiderationTrancheTwoMember" abstract="true" name="ContingentConsiderationTrancheTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="snti_AlamedaMember" abstract="true" name="AlamedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_EarningsPerShareBasicAndDilutedEPSAbstract" abstract="true" name="EarningsPerShareBasicAndDilutedEPSAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="snti_A2016StockIncentivePlanMember" abstract="true" name="A2016StockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_ContingentConsiderationTranchesAxis" abstract="true" name="ContingentConsiderationTranchesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="snti_TenantImprovementAllowance" abstract="false" name="TenantImprovementAllowance" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl" abstract="false" name="ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches" abstract="false" name="ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost" abstract="false" name="CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_SaleOfStockMaximumAmountAuthorized" abstract="false" name="SaleOfStockMaximumAmountAuthorized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_May2022NoteMember" abstract="true" name="May2022NoteMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_SaleOfStockIssuanceCosts" abstract="false" name="SaleOfStockIssuanceCosts" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_AccruedProfessionalFeesOtherCurrent" abstract="false" name="AccruedProfessionalFeesOtherCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_CommonStockUnderEquityPlansMember" abstract="true" name="CommonStockUnderEquityPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_SaleOfStockDocumentPreparationFees" abstract="false" name="SaleOfStockDocumentPreparationFees" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_BayerMember" abstract="true" name="BayerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="snti_InterestIncomeAccruedAndNotReceived" abstract="false" name="InterestIncomeAccruedAndNotReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_RevenueFromAndNotFromContractsTextBlock" abstract="false" name="RevenueFromAndNotFromContractsTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="snti_EarlyExerciseLiabilityNoncurrent" abstract="false" name="EarlyExerciseLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_NumberOfVotesPerCommonShare" abstract="false" name="NumberOfVotesPerCommonShare" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="snti_LesseeOperatingLeaseNumberOfRenewalOptions" abstract="false" name="LesseeOperatingLeaseNumberOfRenewalOptions" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="snti_RevenueFromContractWithCustomerTerminationNoticePeriod" abstract="false" name="RevenueFromContractWithCustomerTerminationNoticePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="snti_SeerIncMember" abstract="true" name="SeerIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_RevenueFromAndNotFromContractsAbstract" abstract="true" name="RevenueFromAndNotFromContractsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" abstract="false" name="ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="snti_RelatedPartyMember" abstract="true" name="RelatedPartyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche" abstract="false" name="ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="snti_BlueRockMember" abstract="true" name="BlueRockMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent" abstract="false" name="SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="snti_ComputerEquipmentAndSoftwareMember" abstract="true" name="ComputerEquipmentAndSoftwareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_CustomerAMember" abstract="true" name="CustomerAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="snti_ContingentEarnoutLiabilityMember" abstract="true" name="ContingentEarnoutLiabilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" abstract="false" name="ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="snti_CashAcquiredThroughReverseRecapitalization" abstract="false" name="CashAcquiredThroughReverseRecapitalization" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue" abstract="false" name="CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_ReverseRecapitalizationContingentConsiderationFairValue" abstract="false" name="ReverseRecapitalizationContingentConsiderationFairValue" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_SparkMember" abstract="true" name="SparkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_SaleOfStockDailyAmountToBeSoldThreshold" abstract="false" name="SaleOfStockDailyAmountToBeSoldThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions" abstract="false" name="StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_SaleOfStockDiscountRatePercentage" abstract="false" name="SaleOfStockDiscountRatePercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount" abstract="false" name="RevenueRemainingPerformanceObligationVariableConsiderationAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="snti_ReverseRecapitalizationContingentConsiderationEquityShares" abstract="false" name="ReverseRecapitalizationContingentConsiderationEquityShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="snti_ContingentConsiderationTranchesDomain" abstract="true" name="ContingentConsiderationTranchesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>snti-20230331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7af4709b-ea9b-4a83-bec7-2aee05be3f39,g:bb811bd4-927a-481b-aaf3-dcf961c572fd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="snti-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_bafd94ce-d419-4109-9f62-739739151028" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_80b36788-4e98-47fc-9ce8-b97aade24735" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_bafd94ce-d419-4109-9f62-739739151028" xlink:to="loc_us-gaap_AssetsCurrent_80b36788-4e98-47fc-9ce8-b97aade24735" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_6f8c21a8-4d2b-403b-b1a8-46c80c5072d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_bafd94ce-d419-4109-9f62-739739151028" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_6f8c21a8-4d2b-403b-b1a8-46c80c5072d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_5cf31854-20b5-427f-b7b1-6229effbf754" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_bafd94ce-d419-4109-9f62-739739151028" xlink:to="loc_us-gaap_RestrictedCash_5cf31854-20b5-427f-b7b1-6229effbf754" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a5678067-f9ca-4311-9453-aecc07ae9f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_bafd94ce-d419-4109-9f62-739739151028" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a5678067-f9ca-4311-9453-aecc07ae9f5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_663608bf-91da-4b99-8fa0-b3b11c5d8dab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_bafd94ce-d419-4109-9f62-739739151028" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_663608bf-91da-4b99-8fa0-b3b11c5d8dab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cd7c203e-d3c0-44c6-92fd-9f6653485b00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_dfb09590-4fe6-49fe-bd0c-112c27b38516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cd7c203e-d3c0-44c6-92fd-9f6653485b00" xlink:to="loc_us-gaap_CommonStockValue_dfb09590-4fe6-49fe-bd0c-112c27b38516" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_df834371-5f64-4512-8081-1597a4cd7cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cd7c203e-d3c0-44c6-92fd-9f6653485b00" xlink:to="loc_us-gaap_AdditionalPaidInCapital_df834371-5f64-4512-8081-1597a4cd7cdc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_c5a21672-880c-4387-bf85-e782706eaff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cd7c203e-d3c0-44c6-92fd-9f6653485b00" xlink:to="loc_us-gaap_PreferredStockValue_c5a21672-880c-4387-bf85-e782706eaff7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3a22894e-b01f-400e-9880-c5881c47081c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cd7c203e-d3c0-44c6-92fd-9f6653485b00" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_3a22894e-b01f-400e-9880-c5881c47081c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7ac10d56-cb3b-4a99-b8c8-462d33182752" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_cd7c203e-d3c0-44c6-92fd-9f6653485b00" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_7ac10d56-cb3b-4a99-b8c8-462d33182752" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_736b5a2c-1655-4e64-987d-0bf18d48dd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_449dd8b0-025f-4d22-adb5-1d7ba7c18632" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_736b5a2c-1655-4e64-987d-0bf18d48dd6a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_449dd8b0-025f-4d22-adb5-1d7ba7c18632" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7b971063-06c2-4221-9e69-b9243560568c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_736b5a2c-1655-4e64-987d-0bf18d48dd6a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_7b971063-06c2-4221-9e69-b9243560568c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_690e3984-0719-41b4-bb02-2614f6364c8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_736b5a2c-1655-4e64-987d-0bf18d48dd6a" xlink:to="loc_us-gaap_LiabilitiesCurrent_690e3984-0719-41b4-bb02-2614f6364c8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_c1134fb9-f164-4b96-be38-b7cf795bd746" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_736b5a2c-1655-4e64-987d-0bf18d48dd6a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_c1134fb9-f164-4b96-be38-b7cf795bd746" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_EarlyExerciseLiabilityNoncurrent_ac547773-ecc4-4a26-885c-cfc6d2544958" xlink:href="snti-20230331.xsd#snti_EarlyExerciseLiabilityNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_736b5a2c-1655-4e64-987d-0bf18d48dd6a" xlink:to="loc_snti_EarlyExerciseLiabilityNoncurrent_ac547773-ecc4-4a26-885c-cfc6d2544958" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_f447d3c8-1f20-4567-ad7c-8187fd17a540" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_d1aec466-a1e2-499f-8688-8cf1a0388981" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f447d3c8-1f20-4567-ad7c-8187fd17a540" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_d1aec466-a1e2-499f-8688-8cf1a0388981" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_d9ef8edf-4931-4422-bd72-b3f6694d4c42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f447d3c8-1f20-4567-ad7c-8187fd17a540" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_d9ef8edf-4931-4422-bd72-b3f6694d4c42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3565c7f7-de8c-4e85-a2c8-1260fcb8235b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f447d3c8-1f20-4567-ad7c-8187fd17a540" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3565c7f7-de8c-4e85-a2c8-1260fcb8235b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_43f48995-f985-4de4-8f35-fb03a215677d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f447d3c8-1f20-4567-ad7c-8187fd17a540" xlink:to="loc_us-gaap_AccountsPayableCurrent_43f48995-f985-4de4-8f35-fb03a215677d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_ca7c87fc-4710-4d2b-bd96-5e41e93f68b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f447d3c8-1f20-4567-ad7c-8187fd17a540" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_ca7c87fc-4710-4d2b-bd96-5e41e93f68b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_EarlyExerciseLiabilityCurrent_8f929f24-6509-4228-82ad-6afd721ca7a8" xlink:href="snti-20230331.xsd#snti_EarlyExerciseLiabilityCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f447d3c8-1f20-4567-ad7c-8187fd17a540" xlink:to="loc_snti_EarlyExerciseLiabilityCurrent_8f929f24-6509-4228-82ad-6afd721ca7a8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3027a302-f604-46f5-a353-2811f4521ef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c91f4d59-c09d-40f6-abc7-6022ba77b426" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3027a302-f604-46f5-a353-2811f4521ef3" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c91f4d59-c09d-40f6-abc7-6022ba77b426" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_a9053461-0805-4e39-ba8c-7981da7e92fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3027a302-f604-46f5-a353-2811f4521ef3" xlink:to="loc_us-gaap_ShortTermInvestments_a9053461-0805-4e39-ba8c-7981da7e92fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_abca7c88-f668-4706-aa2f-ebd05c9e9ef5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3027a302-f604-46f5-a353-2811f4521ef3" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_abca7c88-f668-4706-aa2f-ebd05c9e9ef5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_8b9fa246-646d-4267-941b-1b9acdce4c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_3027a302-f604-46f5-a353-2811f4521ef3" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_8b9fa246-646d-4267-941b-1b9acdce4c27" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_6ea6f36c-f71d-4626-a6bf-1b9548f19061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3a6fa40b-cac3-4e6d-9f19-e62e591a1159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6ea6f36c-f71d-4626-a6bf-1b9548f19061" xlink:to="loc_us-gaap_StockholdersEquity_3a6fa40b-cac3-4e6d-9f19-e62e591a1159" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_035bec2b-f5fe-4d7f-9db0-821e59a6a962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6ea6f36c-f71d-4626-a6bf-1b9548f19061" xlink:to="loc_us-gaap_CommitmentsAndContingencies_035bec2b-f5fe-4d7f-9db0-821e59a6a962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_4a02e8b4-849b-47e7-b7a8-2ab647ee600c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_6ea6f36c-f71d-4626-a6bf-1b9548f19061" xlink:to="loc_us-gaap_Liabilities_4a02e8b4-849b-47e7-b7a8-2ab647ee600c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="snti-20230331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_bf69f034-b14d-4a0d-aaad-8aa670f7574a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3ffd217c-6084-44d6-8c9f-75a907963021" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bf69f034-b14d-4a0d-aaad-8aa670f7574a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_3ffd217c-6084-44d6-8c9f-75a907963021" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_7734a09c-1149-45f4-9108-72522764ecea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_bf69f034-b14d-4a0d-aaad-8aa670f7574a" xlink:to="loc_us-gaap_NetIncomeLoss_7734a09c-1149-45f4-9108-72522764ecea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_f0711e6f-a300-4723-9964-988fec745b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5f926404-6279-4d62-89db-8299adff615d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f0711e6f-a300-4723-9964-988fec745b45" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5f926404-6279-4d62-89db-8299adff615d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_66ba0d4a-2c7b-42c6-a9e1-05c1b29f8be1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_f0711e6f-a300-4723-9964-988fec745b45" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_66ba0d4a-2c7b-42c6-a9e1-05c1b29f8be1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_34a66653-5bce-4ecc-b5ca-a9a3394ac235" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_e9e46e30-83c4-4f99-889c-2cbf0f725c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_34a66653-5bce-4ecc-b5ca-a9a3394ac235" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_e9e46e30-83c4-4f99-889c-2cbf0f725c18" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_c35e9aa6-8399-4d02-80fc-6c34d31bdaf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_34a66653-5bce-4ecc-b5ca-a9a3394ac235" xlink:to="loc_us-gaap_OperatingIncomeLoss_c35e9aa6-8399-4d02-80fc-6c34d31bdaf2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9dabbe88-6a67-4c5d-bd4f-051f640144de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_eb7d7fb0-9f7e-497f-8048-a0a4d1bdd5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9dabbe88-6a67-4c5d-bd4f-051f640144de" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_eb7d7fb0-9f7e-497f-8048-a0a4d1bdd5ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5a37a5ed-24a5-4abb-9951-2ad24dbd0668" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9dabbe88-6a67-4c5d-bd4f-051f640144de" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_5a37a5ed-24a5-4abb-9951-2ad24dbd0668" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b304856b-92e7-48a9-9e17-97a388338d9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_9dabbe88-6a67-4c5d-bd4f-051f640144de" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_b304856b-92e7-48a9-9e17-97a388338d9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d291941c-de07-4d8c-8b7e-3aa5d005018a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12e4971d-5f76-45ff-8ebc-f264104e793f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_d291941c-de07-4d8c-8b7e-3aa5d005018a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12e4971d-5f76-45ff-8ebc-f264104e793f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_4deed0fd-3fa5-4cbb-b478-feba1fdbfc2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_d291941c-de07-4d8c-8b7e-3aa5d005018a" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_4deed0fd-3fa5-4cbb-b478-feba1fdbfc2a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_e171f1e5-a663-4851-b7ba-6c373debcc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c759e437-ecfd-4539-8e9d-f694a67eeea4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e171f1e5-a663-4851-b7ba-6c373debcc9b" xlink:to="loc_us-gaap_OperatingExpenses_c759e437-ecfd-4539-8e9d-f694a67eeea4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_17e15e42-28b7-4859-acfd-4471c51cce9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_e171f1e5-a663-4851-b7ba-6c373debcc9b" xlink:to="loc_us-gaap_Revenues_17e15e42-28b7-4859-acfd-4471c51cce9b" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="snti-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a0615f11-ef90-4f43-8bb5-c718d2e12d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_bcb069f6-5f1d-4c70-9894-eb850807f302" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a0615f11-ef90-4f43-8bb5-c718d2e12d4c" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_bcb069f6-5f1d-4c70-9894-eb850807f302" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_8f6d000c-37e2-4982-9b15-611090153d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a0615f11-ef90-4f43-8bb5-c718d2e12d4c" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_8f6d000c-37e2-4982-9b15-611090153d3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9874b6c6-9995-4c74-84d3-552f16a9ecfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_a0615f11-ef90-4f43-8bb5-c718d2e12d4c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_9874b6c6-9995-4c74-84d3-552f16a9ecfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_313ecfcf-c038-42d5-b021-a284f39791f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_65452580-3587-4c77-9f2d-4cca858cb877" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_313ecfcf-c038-42d5-b021-a284f39791f8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_65452580-3587-4c77-9f2d-4cca858cb877" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5f442290-58c4-4bbe-9a08-63256a73385b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_313ecfcf-c038-42d5-b021-a284f39791f8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_5f442290-58c4-4bbe-9a08-63256a73385b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dba84cf4-f54c-4733-9ec6-803eb34f742e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_313ecfcf-c038-42d5-b021-a284f39791f8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_dba84cf4-f54c-4733-9ec6-803eb34f742e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0c55803-d309-487f-8c2d-99a19a4cb4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_6a97b397-0eca-4b2a-982d-edb7e7921716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0c55803-d309-487f-8c2d-99a19a4cb4fb" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_6a97b397-0eca-4b2a-982d-edb7e7921716" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_eaabf007-3d96-4d7f-9670-3846205415e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0c55803-d309-487f-8c2d-99a19a4cb4fb" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_eaabf007-3d96-4d7f-9670-3846205415e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_34094fc1-b327-48d0-887b-f57c6ec8cfba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_d0c55803-d309-487f-8c2d-99a19a4cb4fb" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_34094fc1-b327-48d0-887b-f57c6ec8cfba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d58780b-44f5-4314-9225-51d8dc4c3fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_54d40df6-cbc9-4e97-ae86-60d5dc96b151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d58780b-44f5-4314-9225-51d8dc4c3fbf" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_54d40df6-cbc9-4e97-ae86-60d5dc96b151" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f2fc3ac1-7bdd-436f-9af9-4017daad0351" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d58780b-44f5-4314-9225-51d8dc4c3fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f2fc3ac1-7bdd-436f-9af9-4017daad0351" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6fb3e127-b4bd-4a5d-bbb6-d3a9f5689057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d58780b-44f5-4314-9225-51d8dc4c3fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_6fb3e127-b4bd-4a5d-bbb6-d3a9f5689057" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_199f66d5-3874-4e65-ba6a-6ab33b5458e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d58780b-44f5-4314-9225-51d8dc4c3fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_199f66d5-3874-4e65-ba6a-6ab33b5458e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_113d0206-a2a5-49b5-9fa3-733540a1b873" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d58780b-44f5-4314-9225-51d8dc4c3fbf" xlink:to="loc_us-gaap_NetIncomeLoss_113d0206-a2a5-49b5-9fa3-733540a1b873" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_8ccb1688-3caf-4c51-9eb8-97706d6120a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d58780b-44f5-4314-9225-51d8dc4c3fbf" xlink:to="loc_us-gaap_Depreciation_8ccb1688-3caf-4c51-9eb8-97706d6120a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_InterestIncomeAccruedAndNotReceived_3a991b2b-fcf1-42cf-ab2e-2fa9075aa5af" xlink:href="snti-20230331.xsd#snti_InterestIncomeAccruedAndNotReceived"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d58780b-44f5-4314-9225-51d8dc4c3fbf" xlink:to="loc_snti_InterestIncomeAccruedAndNotReceived_3a991b2b-fcf1-42cf-ab2e-2fa9075aa5af" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_48a6a51e-83fa-4bb4-a0e9-52a902ae9566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d58780b-44f5-4314-9225-51d8dc4c3fbf" xlink:to="loc_us-gaap_ShareBasedCompensation_48a6a51e-83fa-4bb4-a0e9-52a902ae9566" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_56063c67-bad0-4cea-97bb-3fcf417b979b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d58780b-44f5-4314-9225-51d8dc4c3fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_56063c67-bad0-4cea-97bb-3fcf417b979b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6cb9852e-092f-464e-aad1-e1aa93fb8a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d58780b-44f5-4314-9225-51d8dc4c3fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6cb9852e-092f-464e-aad1-e1aa93fb8a1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_31fe3bf9-b695-414f-bb3a-8f416dea079c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d58780b-44f5-4314-9225-51d8dc4c3fbf" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_31fe3bf9-b695-414f-bb3a-8f416dea079c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_b0ec8ddb-fe0a-4683-aae8-0c5427bda381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d58780b-44f5-4314-9225-51d8dc4c3fbf" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_b0ec8ddb-fe0a-4683-aae8-0c5427bda381" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_59507cd6-41e6-4085-b723-40e0bc137eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d58780b-44f5-4314-9225-51d8dc4c3fbf" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_59507cd6-41e6-4085-b723-40e0bc137eff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8e821f6b-a0ee-4ec3-99ea-0da89b08c0f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="14" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_7d58780b-44f5-4314-9225-51d8dc4c3fbf" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_8e821f6b-a0ee-4ec3-99ea-0da89b08c0f8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a00a0a47-d24c-4137-8f9e-0e842ad3a37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_bdca6ac3-cb9e-417a-aa3a-5124002cb46d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a00a0a47-d24c-4137-8f9e-0e842ad3a37b" xlink:to="loc_us-gaap_RestrictedCash_bdca6ac3-cb9e-417a-aa3a-5124002cb46d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bd3dd21c-1977-4ff4-acae-1ff3a784720c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a00a0a47-d24c-4137-8f9e-0e842ad3a37b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_bd3dd21c-1977-4ff4-acae-1ff3a784720c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"/>
  <link:calculationLink xlink:role="http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost_1f3dd422-422f-4475-8aa8-40565c0df422" xlink:href="snti-20230331.xsd#snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_98377292-5ba6-4b63-85bd-ae365b250e8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost_1f3dd422-422f-4475-8aa8-40565c0df422" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_98377292-5ba6-4b63-85bd-ae365b250e8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae437df9-f476-4a94-bdff-d0d33d85285e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost_1f3dd422-422f-4475-8aa8-40565c0df422" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae437df9-f476-4a94-bdff-d0d33d85285e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue_0af449c2-687d-4a46-8f87-55feb140c4d5" xlink:href="snti-20230331.xsd#snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3259ca8b-6307-47e8-a51a-726e096d32d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue_0af449c2-687d-4a46-8f87-55feb140c4d5" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3259ca8b-6307-47e8-a51a-726e096d32d7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75980ef0-f980-40ac-a9d1-018a2f851484" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue_0af449c2-687d-4a46-8f87-55feb140c4d5" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_75980ef0-f980-40ac-a9d1-018a2f851484" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_87c0666e-b774-46ee-9d64-d49fa2397d02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5f0f908f-3010-4e4b-8ac4-97d89402b836" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_87c0666e-b774-46ee-9d64-d49fa2397d02" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_5f0f908f-3010-4e4b-8ac4-97d89402b836" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6a510fcb-6312-40f5-8ac0-b62794b0ce6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_87c0666e-b774-46ee-9d64-d49fa2397d02" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6a510fcb-6312-40f5-8ac0-b62794b0ce6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6e9a8958-9aab-4bab-b80e-fa5188a346f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_87c0666e-b774-46ee-9d64-d49fa2397d02" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_6e9a8958-9aab-4bab-b80e-fa5188a346f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails_1" xlink:type="simple" xlink:href="snti-20230331.xsd#FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails_1"/>
  <link:calculationLink xlink:role="http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost_ed0a04f5-1ca8-4f0d-a0f2-192e92ea0213" xlink:href="snti-20230331.xsd#snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6805c004-6f42-4a05-9350-c6d0cd190682" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost_ed0a04f5-1ca8-4f0d-a0f2-192e92ea0213" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_6805c004-6f42-4a05-9350-c6d0cd190682" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0e84bd7c-4573-4b57-9bd0-9a3ee5479fc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost_ed0a04f5-1ca8-4f0d-a0f2-192e92ea0213" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0e84bd7c-4573-4b57-9bd0-9a3ee5479fc3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue_0fd638b4-b0d2-4f59-bd54-09b993026eab" xlink:href="snti-20230331.xsd#snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost_ed0a04f5-1ca8-4f0d-a0f2-192e92ea0213" xlink:to="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue_0fd638b4-b0d2-4f59-bd54-09b993026eab" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cce77c66-174f-4628-9c6c-de773062d015" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_d7429b1b-a89c-4734-984f-6cf2226dac32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cce77c66-174f-4628-9c6c-de773062d015" xlink:to="loc_us-gaap_DepositsAssetsCurrent_d7429b1b-a89c-4734-984f-6cf2226dac32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_eea9dec6-5d81-4e8d-a50d-11d16f302af0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cce77c66-174f-4628-9c6c-de773062d015" xlink:to="loc_us-gaap_OtherAssetsCurrent_eea9dec6-5d81-4e8d-a50d-11d16f302af0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_7711c105-1eee-4a27-8682-d827c55beba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_cce77c66-174f-4628-9c6c-de773062d015" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_7711c105-1eee-4a27-8682-d827c55beba0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails"/>
  <link:calculationLink xlink:role="http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_5f0200d9-7069-4c3c-9cdb-ef1ae183492c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_13b35f0e-61fe-41a8-a70f-8ea718871923" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5f0200d9-7069-4c3c-9cdb-ef1ae183492c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_13b35f0e-61fe-41a8-a70f-8ea718871923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_eafb0269-3447-46f8-b98c-7257543405f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_5f0200d9-7069-4c3c-9cdb-ef1ae183492c" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_eafb0269-3447-46f8-b98c-7257543405f3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_55b70ba0-4c3d-4596-af4d-330de48df82d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_51ca0dc7-53d6-40a4-b80e-27f5e9f3308d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_55b70ba0-4c3d-4596-af4d-330de48df82d" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_51ca0dc7-53d6-40a4-b80e-27f5e9f3308d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cc8c6e83-83be-46d0-b609-7c156b9b5ef7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_55b70ba0-4c3d-4596-af4d-330de48df82d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cc8c6e83-83be-46d0-b609-7c156b9b5ef7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_AccruedProfessionalFeesOtherCurrent_690897ec-f45c-49f7-af0d-f27015a2745f" xlink:href="snti-20230331.xsd#snti_AccruedProfessionalFeesOtherCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_55b70ba0-4c3d-4596-af4d-330de48df82d" xlink:to="loc_snti_AccruedProfessionalFeesOtherCurrent_690897ec-f45c-49f7-af0d-f27015a2745f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_7c705bd9-cb09-4660-826b-ce948cf8ea22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_55b70ba0-4c3d-4596-af4d-330de48df82d" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_7c705bd9-cb09-4660-826b-ce948cf8ea22" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OperatingLeasesTotalLeaseCostDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#OperatingLeasesTotalLeaseCostDetails"/>
  <link:calculationLink xlink:role="http://www.sentibio.com/role/OperatingLeasesTotalLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_0395f7fb-58f5-4e4a-8611-3e0af384eb64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_5b55e73f-41b4-4f25-b694-f8620be14144" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0395f7fb-58f5-4e4a-8611-3e0af384eb64" xlink:to="loc_us-gaap_VariableLeaseCost_5b55e73f-41b4-4f25-b694-f8620be14144" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c68f678c-eb99-4910-8956-9ca5ba3691a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0395f7fb-58f5-4e4a-8611-3e0af384eb64" xlink:to="loc_us-gaap_OperatingLeaseCost_c68f678c-eb99-4910-8956-9ca5ba3691a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_dd37ec0f-c07a-4349-8fb2-74298e84b6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_0395f7fb-58f5-4e4a-8611-3e0af384eb64" xlink:to="loc_us-gaap_ShortTermLeaseCost_dd37ec0f-c07a-4349-8fb2-74298e84b6cc" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d3a2d14b-c569-4304-9482-cfeb04a32734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f2172e95-61f3-4a0c-afc3-7e5695d0f042" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d3a2d14b-c569-4304-9482-cfeb04a32734" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_f2172e95-61f3-4a0c-afc3-7e5695d0f042" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_fe59cb73-9123-40fa-9013-5cf879ddf6e2" xlink:href="snti-20230331.xsd#snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d3a2d14b-c569-4304-9482-cfeb04a32734" xlink:to="loc_snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_fe59cb73-9123-40fa-9013-5cf879ddf6e2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_67c8402f-a8be-4a56-ab77-c9404aab1c03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d3a2d14b-c569-4304-9482-cfeb04a32734" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_67c8402f-a8be-4a56-ab77-c9404aab1c03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1bea1a99-7aad-46ce-9ccd-7f5acc4b291b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d3a2d14b-c569-4304-9482-cfeb04a32734" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_1bea1a99-7aad-46ce-9ccd-7f5acc4b291b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9cc47e7a-7242-4a4d-ac17-4572ffed47fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d3a2d14b-c569-4304-9482-cfeb04a32734" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_9cc47e7a-7242-4a4d-ac17-4572ffed47fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_74a89203-db14-47a8-b6c1-96c529f01bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d3a2d14b-c569-4304-9482-cfeb04a32734" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_74a89203-db14-47a8-b6c1-96c529f01bcb" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>snti-20230331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7af4709b-ea9b-4a83-bec7-2aee05be3f39,g:bb811bd4-927a-481b-aaf3-dcf961c572fd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.sentibio.com/role/Cover" xlink:type="simple" xlink:href="snti-20230331.xsd#Cover"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/Cover" xlink:type="extended" id="i0e9eddf3027448a6b0f28bb8ef0d3268_Cover">
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a9dbb394-8ea1-48f8-8617-c1bc56905b0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_DocumentType_a9dbb394-8ea1-48f8-8617-c1bc56905b0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_849c6a6e-539b-445d-b526-e31bdc716021" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_DocumentQuarterlyReport_849c6a6e-539b-445d-b526-e31bdc716021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6a33192c-fdaa-4779-afa6-dce593eaced4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_DocumentPeriodEndDate_6a33192c-fdaa-4779-afa6-dce593eaced4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e1ca7c14-4428-4e8b-8fdb-c879279f76c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_DocumentTransitionReport_e1ca7c14-4428-4e8b-8fdb-c879279f76c8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_398013b9-401a-4387-b584-5f5a4cddbbf7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityFileNumber_398013b9-401a-4387-b584-5f5a4cddbbf7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f9766754-d6cb-41f3-9c3e-e81597226078" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityRegistrantName_f9766754-d6cb-41f3-9c3e-e81597226078" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f79b05ed-479a-4f75-8b61-a430a49c40a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f79b05ed-479a-4f75-8b61-a430a49c40a1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_85f363ed-515e-43b4-8a33-f5f83b9c98ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityTaxIdentificationNumber_85f363ed-515e-43b4-8a33-f5f83b9c98ea" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_576e0abc-b71d-4161-9753-d15515fae89d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityAddressAddressLine1_576e0abc-b71d-4161-9753-d15515fae89d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_47611edc-c42b-4ba3-8b83-15cd11bbaf87" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityAddressCityOrTown_47611edc-c42b-4ba3-8b83-15cd11bbaf87" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5cd799aa-f0f0-40b1-a9d5-b68054f3fec8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityAddressStateOrProvince_5cd799aa-f0f0-40b1-a9d5-b68054f3fec8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b6166a32-fe08-4068-890b-804abfaeec78" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityAddressPostalZipCode_b6166a32-fe08-4068-890b-804abfaeec78" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3bf8b5e4-0a6e-4f3d-a6ef-e340c415eed2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_CityAreaCode_3bf8b5e4-0a6e-4f3d-a6ef-e340c415eed2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1b07d1b4-2cd3-4592-88a5-7cfd89c06846" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_LocalPhoneNumber_1b07d1b4-2cd3-4592-88a5-7cfd89c06846" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d9a42f57-c1d8-4163-a795-cf7af3d1919b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_Security12bTitle_d9a42f57-c1d8-4163-a795-cf7af3d1919b" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2e5908df-0146-4b0b-b230-39f8683e9b94" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_TradingSymbol_2e5908df-0146-4b0b-b230-39f8683e9b94" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0e02c08b-c814-46b5-810b-fbd33558d25b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_SecurityExchangeName_0e02c08b-c814-46b5-810b-fbd33558d25b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1cb315a1-d082-4157-b90f-63452cdb359c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityCurrentReportingStatus_1cb315a1-d082-4157-b90f-63452cdb359c" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fcf02086-ad6b-42af-a2f3-d7282d7a65be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityInteractiveDataCurrent_fcf02086-ad6b-42af-a2f3-d7282d7a65be" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b6fc4d12-4e13-43e0-a68d-5706334e0653" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityFilerCategory_b6fc4d12-4e13-43e0-a68d-5706334e0653" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f3dec25f-ec7f-4551-b4d0-cad511ef6221" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntitySmallBusiness_f3dec25f-ec7f-4551-b4d0-cad511ef6221" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_11fa3dd0-080c-4afd-a879-4c331175e3af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityEmergingGrowthCompany_11fa3dd0-080c-4afd-a879-4c331175e3af" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_79663447-e6cf-4769-b53e-c0cbbe68d3fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityExTransitionPeriod_79663447-e6cf-4769-b53e-c0cbbe68d3fc" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_63643758-c430-44a4-bae8-b75bca34686b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityShellCompany_63643758-c430-44a4-bae8-b75bca34686b" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bbf9c9bc-4c9a-4b30-82c4-aa2902af181c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bbf9c9bc-4c9a-4b30-82c4-aa2902af181c" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_50b70602-e9d7-474e-a8d2-6ba659991fd1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityCentralIndexKey_50b70602-e9d7-474e-a8d2-6ba659991fd1" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b6dce8f4-a152-488c-9f54-cf17f3f84804" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_CurrentFiscalYearEndDate_b6dce8f4-a152-488c-9f54-cf17f3f84804" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_260b6d98-213d-4b1d-8068-2ce8e7f4dd69" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_DocumentFiscalYearFocus_260b6d98-213d-4b1d-8068-2ce8e7f4dd69" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b6bdec67-71be-419f-b559-283b3f5f272c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b6bdec67-71be-419f-b559-283b3f5f272c" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a49812c7-bead-4446-9b1a-a211772b887d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_AmendmentFlag_a49812c7-bead-4446-9b1a-a211772b887d" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable_9363bef7-7af2-478f-82d5-4ff75fdcab51" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityAddressesTable_9363bef7-7af2-478f-82d5-4ff75fdcab51" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_550060a9-0de8-46ad-b2af-cb8da2ed1cba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntityAddressesTable_9363bef7-7af2-478f-82d5-4ff75fdcab51" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_550060a9-0de8-46ad-b2af-cb8da2ed1cba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_550060a9-0de8-46ad-b2af-cb8da2ed1cba_default" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_550060a9-0de8-46ad-b2af-cb8da2ed1cba" xlink:to="loc_dei_AddressTypeDomain_550060a9-0de8-46ad-b2af-cb8da2ed1cba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_87e5c40d-2a30-40ea-8771-474decbfa260" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_550060a9-0de8-46ad-b2af-cb8da2ed1cba" xlink:to="loc_dei_AddressTypeDomain_87e5c40d-2a30-40ea-8771-474decbfa260" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_FormerAddressMember_a3166459-0f04-498b-bd67-9ac782e0341c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_FormerAddressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_AddressTypeDomain_87e5c40d-2a30-40ea-8771-474decbfa260" xlink:to="loc_dei_FormerAddressMember_a3166459-0f04-498b-bd67-9ac782e0341c" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="snti-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended" id="ic7536345ed3e4c98aab643bbbfb526c8_CondensedConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_92766994-91c4-44b2-a306-403b00588e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_92766994-91c4-44b2-a306-403b00588e6a" xlink:to="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6babcf80-f7d8-44d6-bf73-61e9be22d4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6babcf80-f7d8-44d6-bf73-61e9be22d4e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9ba3d46f-f6a6-42ac-a7e4-095e1da2a634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9ba3d46f-f6a6-42ac-a7e4-095e1da2a634" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_e16b5bed-a2d4-478d-bc9a-4669463cb0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_ShortTermInvestments_e16b5bed-a2d4-478d-bc9a-4669463cb0a5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_62ed4d07-821f-492c-8ab5-7863c4941c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_62ed4d07-821f-492c-8ab5-7863c4941c02" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5516c473-838b-457b-9975-3f9f319ffe60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_AssetsCurrent_5516c473-838b-457b-9975-3f9f319ffe60" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_8cd7843d-89fd-45fe-9214-4148eafcc145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_RestrictedCash_8cd7843d-89fd-45fe-9214-4148eafcc145" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_256d698d-033a-4510-bf83-98d99347c506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_256d698d-033a-4510-bf83-98d99347c506" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_af90d06d-6d27-4c0a-928d-82f6c9df1291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_af90d06d-6d27-4c0a-928d-82f6c9df1291" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a6b42b06-2ad8-45a3-926b-d2d8bbb8f216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a6b42b06-2ad8-45a3-926b-d2d8bbb8f216" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c58c78d8-169a-49c1-b741-23f3ece9fbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_Assets_c58c78d8-169a-49c1-b741-23f3ece9fbd5" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_92766994-91c4-44b2-a306-403b00588e6a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_16c25d9a-03bd-406b-ba83-662c6f218314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_AccountsPayableCurrent_16c25d9a-03bd-406b-ba83-662c6f218314" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_3e4250d3-a2ee-4286-a875-b24f725d85f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_3e4250d3-a2ee-4286-a875-b24f725d85f0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_EarlyExerciseLiabilityCurrent_f956a477-e651-42e9-8f1e-37b9d60f7a23" xlink:href="snti-20230331.xsd#snti_EarlyExerciseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_snti_EarlyExerciseLiabilityCurrent_f956a477-e651-42e9-8f1e-37b9d60f7a23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_110535b8-f8d3-461d-bb94-a4a8b1c243f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_110535b8-f8d3-461d-bb94-a4a8b1c243f8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2102028d-fcc3-4439-b3d7-fb451af20545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2102028d-fcc3-4439-b3d7-fb451af20545" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a37a300f-4f69-4e01-b529-742057a0c6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a37a300f-4f69-4e01-b529-742057a0c6ec" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_07843cfa-c37e-4d28-8155-82ad541d9b13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_LiabilitiesCurrent_07843cfa-c37e-4d28-8155-82ad541d9b13" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1800ede4-5e16-4a5c-ad96-1635ad8bce0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1800ede4-5e16-4a5c-ad96-1635ad8bce0e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f4b141bb-a55a-48f0-b11e-ef47767d5568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f4b141bb-a55a-48f0-b11e-ef47767d5568" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_6a90d45b-1188-4adb-85a5-e33f6b2933b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_6a90d45b-1188-4adb-85a5-e33f6b2933b0" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_EarlyExerciseLiabilityNoncurrent_3d7e77ce-fc49-4c05-a9f2-a2a1a578e700" xlink:href="snti-20230331.xsd#snti_EarlyExerciseLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_snti_EarlyExerciseLiabilityNoncurrent_3d7e77ce-fc49-4c05-a9f2-a2a1a578e700" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_927025ba-15c7-48d5-ad45-986c86dbffdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_Liabilities_927025ba-15c7-48d5-ad45-986c86dbffdb" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_add0882c-01a4-4638-926a-fb27d5e2fa7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_add0882c-01a4-4638-926a-fb27d5e2fa7c" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a39bd0bc-a0bc-4a8c-8e36-4a73f145c55a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a39bd0bc-a0bc-4a8c-8e36-4a73f145c55a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2683edd9-992d-492e-b369-3f6c11ffed43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a39bd0bc-a0bc-4a8c-8e36-4a73f145c55a" xlink:to="loc_us-gaap_PreferredStockValue_2683edd9-992d-492e-b369-3f6c11ffed43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2f3f35c9-94b7-404c-9674-339013167a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a39bd0bc-a0bc-4a8c-8e36-4a73f145c55a" xlink:to="loc_us-gaap_CommonStockValue_2f3f35c9-94b7-404c-9674-339013167a59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_63bb7e0c-1aad-4a60-a064-086cd05a28f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a39bd0bc-a0bc-4a8c-8e36-4a73f145c55a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_63bb7e0c-1aad-4a60-a064-086cd05a28f0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_44d9f577-d048-4add-adf9-99bb34ac2482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a39bd0bc-a0bc-4a8c-8e36-4a73f145c55a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_44d9f577-d048-4add-adf9-99bb34ac2482" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2b694a63-58e6-4046-81b6-17cd1ed75569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a39bd0bc-a0bc-4a8c-8e36-4a73f145c55a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2b694a63-58e6-4046-81b6-17cd1ed75569" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c18f4e78-b704-425a-b8f1-e4651c6fbf79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a39bd0bc-a0bc-4a8c-8e36-4a73f145c55a" xlink:to="loc_us-gaap_StockholdersEquity_c18f4e78-b704-425a-b8f1-e4651c6fbf79" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e9c630bc-9fd6-456f-b7a3-50472d732751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e9c630bc-9fd6-456f-b7a3-50472d732751" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7796908a-0c23-4dda-ae5f-de8cbc3d6d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_92766994-91c4-44b2-a306-403b00588e6a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7796908a-0c23-4dda-ae5f-de8cbc3d6d1c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_add7bc3f-a229-4b86-b14b-86aa940a58d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_92766994-91c4-44b2-a306-403b00588e6a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_add7bc3f-a229-4b86-b14b-86aa940a58d1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_126af5b4-3430-450b-b01e-81bfddc1d5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_92766994-91c4-44b2-a306-403b00588e6a" xlink:to="loc_us-gaap_StatementTable_126af5b4-3430-450b-b01e-81bfddc1d5e2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e676423e-ac24-4ec5-8945-29f2e05677d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_126af5b4-3430-450b-b01e-81bfddc1d5e2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e676423e-ac24-4ec5-8945-29f2e05677d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_e676423e-ac24-4ec5-8945-29f2e05677d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e676423e-ac24-4ec5-8945-29f2e05677d3" xlink:to="loc_us-gaap_RelatedPartyDomain_e676423e-ac24-4ec5-8945-29f2e05677d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2fc7022e-c455-4afd-9ede-190efb961823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e676423e-ac24-4ec5-8945-29f2e05677d3" xlink:to="loc_us-gaap_RelatedPartyDomain_2fc7022e-c455-4afd-9ede-190efb961823" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RelatedPartyMember_61b69d55-34bb-403c-9971-b4428bd61e42" xlink:href="snti-20230331.xsd#snti_RelatedPartyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_2fc7022e-c455-4afd-9ede-190efb961823" xlink:to="loc_snti_RelatedPartyMember_61b69d55-34bb-403c-9971-b4428bd61e42" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="snti-20230331.xsd#CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended" id="i11f3613f5f5848f4a9d4c1baefa67678_CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_988d949c-dbb0-4e4d-b323-3fff19f5c582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_1bef5bf2-6844-440d-85fa-387b5233536a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_988d949c-dbb0-4e4d-b323-3fff19f5c582" xlink:to="loc_us-gaap_TemporaryEquityAbstract_1bef5bf2-6844-440d-85fa-387b5233536a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_0c914a41-9a28-437b-804e-8196a76ae1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityAbstract_1bef5bf2-6844-440d-85fa-387b5233536a" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_0c914a41-9a28-437b-804e-8196a76ae1e9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6963833e-5ea7-4548-bb51-d27ff7e9a237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityAbstract_1bef5bf2-6844-440d-85fa-387b5233536a" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6963833e-5ea7-4548-bb51-d27ff7e9a237" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_a5d4c465-5fcd-4989-96e3-5451efa99e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b45536d0-4cd5-4290-b627-75b6f6b17552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_988d949c-dbb0-4e4d-b323-3fff19f5c582" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7ae04b2f-477f-4bae-85f5-c28a2763abac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7ae04b2f-477f-4bae-85f5-c28a2763abac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cd9c9bb7-348b-4b51-81c1-202e5c857de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_us-gaap_StockholdersEquity_cd9c9bb7-348b-4b51-81c1-202e5c857de9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e1326fa8-4354-4ca1-86b6-3d8f9ed33135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e1326fa8-4354-4ca1-86b6-3d8f9ed33135" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_30e5dec6-7fda-432c-97ba-fd22513467cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_30e5dec6-7fda-432c-97ba-fd22513467cc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions_a97dba1b-edf5-44f1-9bf9-9366a48d8fe0" xlink:href="snti-20230331.xsd#snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions_a97dba1b-edf5-44f1-9bf9-9366a48d8fe0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions_574764ca-0440-4d0a-aaf2-4e54541ac934" xlink:href="snti-20230331.xsd#snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions_574764ca-0440-4d0a-aaf2-4e54541ac934" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e1c50816-e7b1-4c7f-9f80-efb391fee274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e1c50816-e7b1-4c7f-9f80-efb391fee274" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_19a09848-70fe-46e3-b564-1a83a37f0db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_19a09848-70fe-46e3-b564-1a83a37f0db3" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2805bbda-594f-47a5-8b69-4f927da2db78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_us-gaap_NetIncomeLoss_2805bbda-594f-47a5-8b69-4f927da2db78" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_41d0656c-09de-4714-9845-e18e3e6d985d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3a95faa9-e745-476f-bb5d-15512f73d500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a28b0950-6fcd-4f87-8beb-f76f99aea3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_988d949c-dbb0-4e4d-b323-3fff19f5c582" xlink:to="loc_us-gaap_StatementTable_a28b0950-6fcd-4f87-8beb-f76f99aea3b0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_377b790e-6c6e-4894-8bb4-88e1690fb935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_a28b0950-6fcd-4f87-8beb-f76f99aea3b0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_377b790e-6c6e-4894-8bb4-88e1690fb935" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_377b790e-6c6e-4894-8bb4-88e1690fb935_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_377b790e-6c6e-4894-8bb4-88e1690fb935" xlink:to="loc_us-gaap_EquityComponentDomain_377b790e-6c6e-4894-8bb4-88e1690fb935_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_db35be62-b2eb-406c-8b95-07e0fe48b9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_377b790e-6c6e-4894-8bb4-88e1690fb935" xlink:to="loc_us-gaap_EquityComponentDomain_db35be62-b2eb-406c-8b95-07e0fe48b9fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_219f0bf1-0b74-4cc7-9849-1a118b7b1d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_db35be62-b2eb-406c-8b95-07e0fe48b9fe" xlink:to="loc_us-gaap_CommonStockMember_219f0bf1-0b74-4cc7-9849-1a118b7b1d2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_748f052e-dcda-493a-ace8-e8d8b3902917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_db35be62-b2eb-406c-8b95-07e0fe48b9fe" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_748f052e-dcda-493a-ace8-e8d8b3902917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4f6ac6de-76db-444c-80da-ea6dda910c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_db35be62-b2eb-406c-8b95-07e0fe48b9fe" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4f6ac6de-76db-444c-80da-ea6dda910c5e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_033fe758-ee5e-4712-81ac-4320395d1627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_db35be62-b2eb-406c-8b95-07e0fe48b9fe" xlink:to="loc_us-gaap_RetainedEarningsMember_033fe758-ee5e-4712-81ac-4320395d1627" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails" xlink:type="extended" id="i082a215dfcd54cb1b7bc188c506ed783_FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_27264aac-cf93-48d4-88d6-2ca494bbb428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:to="loc_us-gaap_Cash_27264aac-cf93-48d4-88d6-2ca494bbb428" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e2756c4-c25d-436f-850b-503bfab65bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e2756c4-c25d-436f-850b-503bfab65bdc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_461f6bdc-2203-42b7-94fb-228386b7e51c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_461f6bdc-2203-42b7-94fb-228386b7e51c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5e0f88d3-4778-48c1-877e-ae9063b4202d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5e0f88d3-4778-48c1-877e-ae9063b4202d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7b50b3be-2f10-4c47-84ef-b72d86953c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7b50b3be-2f10-4c47-84ef-b72d86953c87" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_28dc8f71-8970-49e4-9d43-71791cc9f878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_28dc8f71-8970-49e4-9d43-71791cc9f878" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost_a76367ca-4ab4-45fd-a5ed-1163dc376bb8" xlink:href="snti-20230331.xsd#snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:to="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost_a76367ca-4ab4-45fd-a5ed-1163dc376bb8" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue_2ceb1dfe-a6a1-4074-b656-57ee60075bd9" xlink:href="snti-20230331.xsd#snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:to="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue_2ceb1dfe-a6a1-4074-b656-57ee60075bd9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_720a0df2-fc5e-4ba6-bd04-a8c973d78830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_720a0df2-fc5e-4ba6-bd04-a8c973d78830" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fd85d845-98ad-4972-8f67-841c7de60c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_720a0df2-fc5e-4ba6-bd04-a8c973d78830" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fd85d845-98ad-4972-8f67-841c7de60c7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fd85d845-98ad-4972-8f67-841c7de60c7a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fd85d845-98ad-4972-8f67-841c7de60c7a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fd85d845-98ad-4972-8f67-841c7de60c7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9809e512-c72a-4646-a458-4ec048537b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fd85d845-98ad-4972-8f67-841c7de60c7a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9809e512-c72a-4646-a458-4ec048537b8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_72558759-b0e6-41d4-bc9b-33704d91924f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9809e512-c72a-4646-a458-4ec048537b8e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_72558759-b0e6-41d4-bc9b-33704d91924f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_faca2366-0d50-4504-9dbf-072c635f51fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9809e512-c72a-4646-a458-4ec048537b8e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_faca2366-0d50-4504-9dbf-072c635f51fb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_80a87369-753e-449b-bea0-350d4827ffea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_720a0df2-fc5e-4ba6-bd04-a8c973d78830" xlink:to="loc_us-gaap_FinancialInstrumentAxis_80a87369-753e-449b-bea0-350d4827ffea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80a87369-753e-449b-bea0-350d4827ffea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_80a87369-753e-449b-bea0-350d4827ffea" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_80a87369-753e-449b-bea0-350d4827ffea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97d31ac6-83f0-44c6-b89e-8ef3dfb1d291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_80a87369-753e-449b-bea0-350d4827ffea" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97d31ac6-83f0-44c6-b89e-8ef3dfb1d291" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1e191920-2baa-465d-8198-8c1fcd30b5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97d31ac6-83f0-44c6-b89e-8ef3dfb1d291" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1e191920-2baa-465d-8198-8c1fcd30b5c7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_78886e5e-8e69-4abb-bb75-bd90aa947e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97d31ac6-83f0-44c6-b89e-8ef3dfb1d291" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_78886e5e-8e69-4abb-bb75-bd90aa947e58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2d97b702-027d-48af-87be-9d4d274df3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97d31ac6-83f0-44c6-b89e-8ef3dfb1d291" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2d97b702-027d-48af-87be-9d4d274df3db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_626421fc-efa7-45f9-be66-f625863bd1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97d31ac6-83f0-44c6-b89e-8ef3dfb1d291" xlink:to="loc_us-gaap_CommercialPaperMember_626421fc-efa7-45f9-be66-f625863bd1cf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_793b5528-f490-48cf-91e9-9c201911f1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97d31ac6-83f0-44c6-b89e-8ef3dfb1d291" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_793b5528-f490-48cf-91e9-9c201911f1f0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b6db990c-5ed4-45af-9ed4-ec616508169a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_720a0df2-fc5e-4ba6-bd04-a8c973d78830" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b6db990c-5ed4-45af-9ed4-ec616508169a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b6db990c-5ed4-45af-9ed4-ec616508169a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b6db990c-5ed4-45af-9ed4-ec616508169a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b6db990c-5ed4-45af-9ed4-ec616508169a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f4aac716-f0db-4e95-ae2c-f08700c13f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b6db990c-5ed4-45af-9ed4-ec616508169a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f4aac716-f0db-4e95-ae2c-f08700c13f83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_f883afb4-177b-4bdf-9d1f-6c6d0fe9d3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4aac716-f0db-4e95-ae2c-f08700c13f83" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_f883afb4-177b-4bdf-9d1f-6c6d0fe9d3fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RestrictedCashMember_ac0479f6-a208-489c-a43e-f42ebcda7e26" xlink:href="snti-20230331.xsd#snti_RestrictedCashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4aac716-f0db-4e95-ae2c-f08700c13f83" xlink:to="loc_snti_RestrictedCashMember_ac0479f6-a208-489c-a43e-f42ebcda7e26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_2123fc07-dbc8-4f1c-8883-5783482bd2db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4aac716-f0db-4e95-ae2c-f08700c13f83" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_2123fc07-dbc8-4f1c-8883-5783482bd2db" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails" xlink:type="extended" id="id17de7ccc5004080b7bd493859120df0_FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ec940048-6cdf-4867-9fd1-7c2e7491e166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_013a4177-65f6-4698-92e9-9167d7a4fcef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ec940048-6cdf-4867-9fd1-7c2e7491e166" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_013a4177-65f6-4698-92e9-9167d7a4fcef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_917adb72-856e-4a39-8422-8d8fb58bcd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ec940048-6cdf-4867-9fd1-7c2e7491e166" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_917adb72-856e-4a39-8422-8d8fb58bcd4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a6f4a603-cc46-433a-9f63-0291bdf0e4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_042d809b-91c4-407a-9805-9fc6ad19be17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ec940048-6cdf-4867-9fd1-7c2e7491e166" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_042d809b-91c4-407a-9805-9fc6ad19be17" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ad426ef8-356f-417d-9d95-ef2501979631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_042d809b-91c4-407a-9805-9fc6ad19be17" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ad426ef8-356f-417d-9d95-ef2501979631" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad426ef8-356f-417d-9d95-ef2501979631_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ad426ef8-356f-417d-9d95-ef2501979631" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_ad426ef8-356f-417d-9d95-ef2501979631_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9c2af004-46c2-4414-9371-98217096ddff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ad426ef8-356f-417d-9d95-ef2501979631" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9c2af004-46c2-4414-9371-98217096ddff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7a60adfa-4188-4a80-ac08-f734398aa641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9c2af004-46c2-4414-9371-98217096ddff" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7a60adfa-4188-4a80-ac08-f734398aa641" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_62e58912-8156-4e4c-8ab0-aa8ad11c2db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_042d809b-91c4-407a-9805-9fc6ad19be17" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_62e58912-8156-4e4c-8ab0-aa8ad11c2db8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_62e58912-8156-4e4c-8ab0-aa8ad11c2db8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_62e58912-8156-4e4c-8ab0-aa8ad11c2db8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_62e58912-8156-4e4c-8ab0-aa8ad11c2db8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2a010dbb-0ca8-43f5-a233-e53ebdec8bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_62e58912-8156-4e4c-8ab0-aa8ad11c2db8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2a010dbb-0ca8-43f5-a233-e53ebdec8bfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentEarnoutLiabilityMember_44fb84b2-8903-4423-b646-aca4e80779a3" xlink:href="snti-20230331.xsd#snti_ContingentEarnoutLiabilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2a010dbb-0ca8-43f5-a233-e53ebdec8bfb" xlink:to="loc_snti_ContingentEarnoutLiabilityMember_44fb84b2-8903-4423-b646-aca4e80779a3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails" xlink:type="extended" id="ia22e4beb367046099278e5b3b4959f0a_OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_37ab0ad2-15b7-4746-868d-b4d9a5f7fb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c03850da-d64d-4195-805d-c8e15302c2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_37ab0ad2-15b7-4746-868d-b4d9a5f7fb5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c03850da-d64d-4195-805d-c8e15302c2fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_39a020d5-a803-417b-8883-7cbc29f52f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_37ab0ad2-15b7-4746-868d-b4d9a5f7fb5f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_39a020d5-a803-417b-8883-7cbc29f52f83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1cafe3fd-7879-4f1e-9c37-fbad6b1f2ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_37ab0ad2-15b7-4746-868d-b4d9a5f7fb5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1cafe3fd-7879-4f1e-9c37-fbad6b1f2ff5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_250901e9-a456-4a9f-b3d9-3178ed670781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_37ab0ad2-15b7-4746-868d-b4d9a5f7fb5f" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_250901e9-a456-4a9f-b3d9-3178ed670781" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d975c7b-4269-4b4d-a295-0283e98d6c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_250901e9-a456-4a9f-b3d9-3178ed670781" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d975c7b-4269-4b4d-a295-0283e98d6c2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d975c7b-4269-4b4d-a295-0283e98d6c2c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d975c7b-4269-4b4d-a295-0283e98d6c2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8d975c7b-4269-4b4d-a295-0283e98d6c2c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf659f0b-36e0-4808-85cc-b0e6a992910c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d975c7b-4269-4b4d-a295-0283e98d6c2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf659f0b-36e0-4808-85cc-b0e6a992910c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_LaboratoryEquipmentMember_de03a783-e402-4a35-af9a-da34b92c7417" xlink:href="snti-20230331.xsd#snti_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf659f0b-36e0-4808-85cc-b0e6a992910c" xlink:to="loc_snti_LaboratoryEquipmentMember_de03a783-e402-4a35-af9a-da34b92c7417" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8c0300a6-9d47-449f-84fa-e47f4363f961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf659f0b-36e0-4808-85cc-b0e6a992910c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8c0300a6-9d47-449f-84fa-e47f4363f961" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ComputerEquipmentAndSoftwareMember_7fce1a26-9c4c-4290-85ea-1306c8f49be8" xlink:href="snti-20230331.xsd#snti_ComputerEquipmentAndSoftwareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf659f0b-36e0-4808-85cc-b0e6a992910c" xlink:to="loc_snti_ComputerEquipmentAndSoftwareMember_7fce1a26-9c4c-4290-85ea-1306c8f49be8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_4b181fa5-806b-40da-9a12-7f1c86ab8a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf659f0b-36e0-4808-85cc-b0e6a992910c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_4b181fa5-806b-40da-9a12-7f1c86ab8a6a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_2505bb38-7f8f-4ada-8272-e6cd0f406cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf659f0b-36e0-4808-85cc-b0e6a992910c" xlink:to="loc_us-gaap_ConstructionInProgressMember_2505bb38-7f8f-4ada-8272-e6cd0f406cd4" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OperatingLeasesNarrativeDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#OperatingLeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/OperatingLeasesNarrativeDetails" xlink:type="extended" id="i46253942cf59449da0bf94d1e356f3ee_OperatingLeasesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ddf540d-6554-4d29-a4c5-5021122ac6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4d616438-4cb1-4a34-8175-4799597c713a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ddf540d-6554-4d29-a4c5-5021122ac6b2" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4d616438-4cb1-4a34-8175-4799597c713a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0d0e03a6-4968-4a1b-b44c-327e5d865e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ddf540d-6554-4d29-a4c5-5021122ac6b2" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0d0e03a6-4968-4a1b-b44c-327e5d865e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_LesseeOperatingLeaseNumberOfRenewalOptions_0d440c4d-02c7-4e84-b500-6aae808a8770" xlink:href="snti-20230331.xsd#snti_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ddf540d-6554-4d29-a4c5-5021122ac6b2" xlink:to="loc_snti_LesseeOperatingLeaseNumberOfRenewalOptions_0d440c4d-02c7-4e84-b500-6aae808a8770" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_TenantImprovementReimbursements_beaa7dc8-3c8d-4f78-8cd9-29a14f8345fe" xlink:href="snti-20230331.xsd#snti_TenantImprovementReimbursements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ddf540d-6554-4d29-a4c5-5021122ac6b2" xlink:to="loc_snti_TenantImprovementReimbursements_beaa7dc8-3c8d-4f78-8cd9-29a14f8345fe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_TenantImprovementAllowance_4c29e9cb-482d-4078-a883-aaf160044bf4" xlink:href="snti-20230331.xsd#snti_TenantImprovementAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ddf540d-6554-4d29-a4c5-5021122ac6b2" xlink:to="loc_snti_TenantImprovementAllowance_4c29e9cb-482d-4078-a883-aaf160044bf4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_TenantImprovementAllowanceUtilized_fb68c380-95bd-45b9-873f-b403bb39a8ae" xlink:href="snti-20230331.xsd#snti_TenantImprovementAllowanceUtilized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ddf540d-6554-4d29-a4c5-5021122ac6b2" xlink:to="loc_snti_TenantImprovementAllowanceUtilized_fb68c380-95bd-45b9-873f-b403bb39a8ae" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f8a84339-68dd-4992-a5e0-e34ecb806959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ddf540d-6554-4d29-a4c5-5021122ac6b2" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f8a84339-68dd-4992-a5e0-e34ecb806959" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_25ad7bb2-0ad0-4d30-8189-802bd753e490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f8a84339-68dd-4992-a5e0-e34ecb806959" xlink:to="loc_us-gaap_LeaseContractualTermAxis_25ad7bb2-0ad0-4d30-8189-802bd753e490" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_25ad7bb2-0ad0-4d30-8189-802bd753e490_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_25ad7bb2-0ad0-4d30-8189-802bd753e490" xlink:to="loc_us-gaap_LeaseContractualTermDomain_25ad7bb2-0ad0-4d30-8189-802bd753e490_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_c64cae4a-e522-4507-aa1c-754fed69abd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_25ad7bb2-0ad0-4d30-8189-802bd753e490" xlink:to="loc_us-gaap_LeaseContractualTermDomain_c64cae4a-e522-4507-aa1c-754fed69abd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CorporateHeadquartersMember_97aaac18-1219-4009-ab8d-635ade3598a2" xlink:href="snti-20230331.xsd#snti_CorporateHeadquartersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_c64cae4a-e522-4507-aa1c-754fed69abd4" xlink:to="loc_snti_CorporateHeadquartersMember_97aaac18-1219-4009-ab8d-635ade3598a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_AlamedaMember_bbe11fe6-4986-4ceb-bccb-73979dbdb8a0" xlink:href="snti-20230331.xsd#snti_AlamedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_c64cae4a-e522-4507-aa1c-754fed69abd4" xlink:to="loc_snti_AlamedaMember_bbe11fe6-4986-4ceb-bccb-73979dbdb8a0" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails" xlink:type="extended" id="if36a24238a6c427bb5e8691cee8d2be8_StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_71769f6d-ca4e-49bc-a13d-b400263f9d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4259ca78-47b1-4fa0-ad29-c9b9208c5231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_71769f6d-ca4e-49bc-a13d-b400263f9d6c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4259ca78-47b1-4fa0-ad29-c9b9208c5231" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6d790f86-2314-4ec3-a267-871c7df70b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_71769f6d-ca4e-49bc-a13d-b400263f9d6c" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6d790f86-2314-4ec3-a267-871c7df70b23" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a4820be2-2bc1-4534-9741-fa18fe2c5a50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6d790f86-2314-4ec3-a267-871c7df70b23" xlink:to="loc_us-gaap_AwardTypeAxis_a4820be2-2bc1-4534-9741-fa18fe2c5a50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4820be2-2bc1-4534-9741-fa18fe2c5a50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_a4820be2-2bc1-4534-9741-fa18fe2c5a50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_a4820be2-2bc1-4534-9741-fa18fe2c5a50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_a4820be2-2bc1-4534-9741-fa18fe2c5a50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CommonStockPurchaseAgreementMember_6accddc5-0b9b-46a6-883b-6341777e6e00" xlink:href="snti-20230331.xsd#snti_CommonStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:to="loc_snti_CommonStockPurchaseAgreementMember_6accddc5-0b9b-46a6-883b-6341777e6e00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_12a595c7-bccd-4315-9911-2bed399cb8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_12a595c7-bccd-4315-9911-2bed399cb8a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_439f32cc-a367-4780-9102-319412c14186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_439f32cc-a367-4780-9102-319412c14186" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CommonStockUnderEquityPlansMember_aaf4d178-99e9-457e-b133-3dd967d38d2d" xlink:href="snti-20230331.xsd#snti_CommonStockUnderEquityPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:to="loc_snti_CommonStockUnderEquityPlansMember_aaf4d178-99e9-457e-b133-3dd967d38d2d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1981e231-6d8b-4b04-bd11-afd46deb0d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:to="loc_us-gaap_EmployeeStockMember_1981e231-6d8b-4b04-bd11-afd46deb0d58" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentEarnoutCommonStockMember_5db533c2-fcb1-4a4e-852c-af6a8fa297c2" xlink:href="snti-20230331.xsd#snti_ContingentEarnoutCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:to="loc_snti_ContingentEarnoutCommonStockMember_5db533c2-fcb1-4a4e-852c-af6a8fa297c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_a2a89155-5234-4f41-aa18-4abf9d080d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:to="loc_us-gaap_StockCompensationPlanMember_a2a89155-5234-4f41-aa18-4abf9d080d28" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails" xlink:type="extended" id="i99d78ac184ed42d0b1c9d8b5e99f8b23_StockholdersEquityDeficitCommonStockPurchaseAgreementDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockMaximumAmountAuthorized_a0acfaad-b3ec-450c-b4cd-bed6b76f8ed9" xlink:href="snti-20230331.xsd#snti_SaleOfStockMaximumAmountAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockMaximumAmountAuthorized_a0acfaad-b3ec-450c-b4cd-bed6b76f8ed9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockTermOfAgreement_b96516f8-3d10-4554-aeb8-db8788f34d5b" xlink:href="snti-20230331.xsd#snti_SaleOfStockTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockTermOfAgreement_b96516f8-3d10-4554-aeb8-db8788f34d5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold_34e12e6c-9a33-4fa0-ba90-868093a1368d" xlink:href="snti-20230331.xsd#snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold_34e12e6c-9a33-4fa0-ba90-868093a1368d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockSharesIssuedInTransactionThresholdPercent_8a39cd37-9f83-4996-8764-27dcffd4dff9" xlink:href="snti-20230331.xsd#snti_SaleOfStockSharesIssuedInTransactionThresholdPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockSharesIssuedInTransactionThresholdPercent_8a39cd37-9f83-4996-8764-27dcffd4dff9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockDiscountRatePercentage_ecb860e5-bdf7-40f9-b9d9-ca152ce82654" xlink:href="snti-20230331.xsd#snti_SaleOfStockDiscountRatePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockDiscountRatePercentage_ecb860e5-bdf7-40f9-b9d9-ca152ce82654" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent_85b2d6c5-0586-4fe6-850e-6a8d9b3d17cd" xlink:href="snti-20230331.xsd#snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent_85b2d6c5-0586-4fe6-850e-6a8d9b3d17cd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockDailyAmountToBeSoldThreshold_000db20b-debd-4ea1-9f76-86c051df02c0" xlink:href="snti-20230331.xsd#snti_SaleOfStockDailyAmountToBeSoldThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockDailyAmountToBeSoldThreshold_000db20b-debd-4ea1-9f76-86c051df02c0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6a006a4e-ba9f-4083-a5a9-86a67584c32d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6a006a4e-ba9f-4083-a5a9-86a67584c32d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockDocumentPreparationFees_02de2f85-1129-4a94-a998-7020a1d4bc23" xlink:href="snti-20230331.xsd#snti_SaleOfStockDocumentPreparationFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockDocumentPreparationFees_02de2f85-1129-4a94-a998-7020a1d4bc23" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockIssuanceCosts_3bf16d7b-2173-4bd8-8835-e4e4e5e98453" xlink:href="snti-20230331.xsd#snti_SaleOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockIssuanceCosts_3bf16d7b-2173-4bd8-8835-e4e4e5e98453" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_29dc8f4f-529b-423b-b49e-c56527b555b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_29dc8f4f-529b-423b-b49e-c56527b555b2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_59461e4b-ddaf-4690-8c4b-5a85d4d3f1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_59461e4b-ddaf-4690-8c4b-5a85d4d3f1cf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_244bcf7c-4726-4a80-95b0-2556c443ef7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_59461e4b-ddaf-4690-8c4b-5a85d4d3f1cf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_244bcf7c-4726-4a80-95b0-2556c443ef7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_244bcf7c-4726-4a80-95b0-2556c443ef7b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_244bcf7c-4726-4a80-95b0-2556c443ef7b" xlink:to="loc_us-gaap_EquityComponentDomain_244bcf7c-4726-4a80-95b0-2556c443ef7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2e71a651-8439-4705-8506-c06537383ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_244bcf7c-4726-4a80-95b0-2556c443ef7b" xlink:to="loc_us-gaap_EquityComponentDomain_2e71a651-8439-4705-8506-c06537383ac1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1418300e-7a0e-44d4-a2b2-91de37e47fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_2e71a651-8439-4705-8506-c06537383ac1" xlink:to="loc_us-gaap_CommonStockMember_1418300e-7a0e-44d4-a2b2-91de37e47fee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_93a555db-fcc2-4cd2-91f8-9b5c5868bed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_59461e4b-ddaf-4690-8c4b-5a85d4d3f1cf" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_93a555db-fcc2-4cd2-91f8-9b5c5868bed3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_93a555db-fcc2-4cd2-91f8-9b5c5868bed3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_93a555db-fcc2-4cd2-91f8-9b5c5868bed3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_93a555db-fcc2-4cd2-91f8-9b5c5868bed3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78d03b13-ec5f-476a-ab53-ef502d04a585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_93a555db-fcc2-4cd2-91f8-9b5c5868bed3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78d03b13-ec5f-476a-ab53-ef502d04a585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CommonStockPurchaseAgreementMember_53959887-b01c-4d8b-aa47-2d5d99e9f625" xlink:href="snti-20230331.xsd#snti_CommonStockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78d03b13-ec5f-476a-ab53-ef502d04a585" xlink:to="loc_snti_CommonStockPurchaseAgreementMember_53959887-b01c-4d8b-aa47-2d5d99e9f625" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_8f66a63e-165d-4487-9d81-6b36f091459e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_59461e4b-ddaf-4690-8c4b-5a85d4d3f1cf" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_8f66a63e-165d-4487-9d81-6b36f091459e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_8f66a63e-165d-4487-9d81-6b36f091459e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8f66a63e-165d-4487-9d81-6b36f091459e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_8f66a63e-165d-4487-9d81-6b36f091459e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7a0081bc-f6ae-4534-8507-0d29466dbb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8f66a63e-165d-4487-9d81-6b36f091459e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7a0081bc-f6ae-4534-8507-0d29466dbb1b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_54ab3e2d-53a5-4ca6-a65e-a3d7931ff585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7a0081bc-f6ae-4534-8507-0d29466dbb1b" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_54ab3e2d-53a5-4ca6-a65e-a3d7931ff585" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockholdersEquityDeficitContingentEarnoutEquityDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails" xlink:type="extended" id="i08b364ad908c44cb858d05e55165f51b_StockholdersEquityDeficitContingentEarnoutEquityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityShares_5ffb45bf-0627-4568-be2d-0e68b035e224" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityShares_5ffb45bf-0627-4568-be2d-0e68b035e224" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches_9c212143-2547-472d-b204-01924474d30b" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches_9c212143-2547-472d-b204-01924474d30b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche_3ddbfff7-ac7a-4bd3-97f7-5cb4c543dfe9" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche_3ddbfff7-ac7a-4bd3-97f7-5cb4c543dfe9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger_94922fcd-3515-4590-9d7e-f6a3c747b04e" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger_94922fcd-3515-4590-9d7e-f6a3c747b04e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays_ab4e22cb-9568-4f36-ad54-f23b2fd373a7" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays_ab4e22cb-9568-4f36-ad54-f23b2fd373a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays_022ec613-fca8-464c-99cb-29b62ae95d0d" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays_022ec613-fca8-464c-99cb-29b62ae95d0d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityTerm_12642685-fe36-4bc8-aadf-59f73633e276" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityTerm_12642685-fe36-4bc8-aadf-59f73633e276" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl_d0fc41b5-44e8-4b4c-9c9a-57796c804769" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl_d0fc41b5-44e8-4b4c-9c9a-57796c804769" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationFairValue_1b549d25-0a79-45ed-a390-4dee89700803" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationFairValue_1b549d25-0a79-45ed-a390-4dee89700803" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_494b5208-12ae-47a5-89a5-ee960c7193a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_494b5208-12ae-47a5-89a5-ee960c7193a5" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_58286a44-ff4d-420e-a972-09de85e30edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_58286a44-ff4d-420e-a972-09de85e30edd" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c448692e-2fe4-4f91-8b51-c458c8aad784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c448692e-2fe4-4f91-8b51-c458c8aad784" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_2dc94427-b83d-4fef-9b39-e394bb9afd42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_2dc94427-b83d-4fef-9b39-e394bb9afd42" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_2de64884-4f38-4587-bcd3-e7ee25a59f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_2dc94427-b83d-4fef-9b39-e394bb9afd42" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_2de64884-4f38-4587-bcd3-e7ee25a59f6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_2de64884-4f38-4587-bcd3-e7ee25a59f6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_2de64884-4f38-4587-bcd3-e7ee25a59f6f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_2de64884-4f38-4587-bcd3-e7ee25a59f6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_b15a8038-e29c-4295-857b-474e48a7987b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_2de64884-4f38-4587-bcd3-e7ee25a59f6f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_b15a8038-e29c-4295-857b-474e48a7987b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentConsiderationTrancheOneMember_25f58d7b-9696-4600-b1ab-ada47ee7f51d" xlink:href="snti-20230331.xsd#snti_ContingentConsiderationTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b15a8038-e29c-4295-857b-474e48a7987b" xlink:to="loc_snti_ContingentConsiderationTrancheOneMember_25f58d7b-9696-4600-b1ab-ada47ee7f51d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentConsiderationTrancheTwoMember_f59493ee-f746-480e-89ce-a67a3fd7cef6" xlink:href="snti-20230331.xsd#snti_ContingentConsiderationTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b15a8038-e29c-4295-857b-474e48a7987b" xlink:to="loc_snti_ContingentConsiderationTrancheTwoMember_f59493ee-f746-480e-89ce-a67a3fd7cef6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentConsiderationTranchesAxis_f9c73169-c942-4c11-801c-e57a5708dc5d" xlink:href="snti-20230331.xsd#snti_ContingentConsiderationTranchesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_2dc94427-b83d-4fef-9b39-e394bb9afd42" xlink:to="loc_snti_ContingentConsiderationTranchesAxis_f9c73169-c942-4c11-801c-e57a5708dc5d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentConsiderationTranchesDomain_f9c73169-c942-4c11-801c-e57a5708dc5d_default" xlink:href="snti-20230331.xsd#snti_ContingentConsiderationTranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_snti_ContingentConsiderationTranchesAxis_f9c73169-c942-4c11-801c-e57a5708dc5d" xlink:to="loc_snti_ContingentConsiderationTranchesDomain_f9c73169-c942-4c11-801c-e57a5708dc5d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentConsiderationTranchesDomain_880910e2-fd22-46dd-abbd-35d6e8c1fb34" xlink:href="snti-20230331.xsd#snti_ContingentConsiderationTranchesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_snti_ContingentConsiderationTranchesAxis_f9c73169-c942-4c11-801c-e57a5708dc5d" xlink:to="loc_snti_ContingentConsiderationTranchesDomain_880910e2-fd22-46dd-abbd-35d6e8c1fb34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentConsiderationTrancheTwoMember_25f578d1-aa8a-4e5b-b54f-3bb1f58d7187" xlink:href="snti-20230331.xsd#snti_ContingentConsiderationTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_snti_ContingentConsiderationTranchesDomain_880910e2-fd22-46dd-abbd-35d6e8c1fb34" xlink:to="loc_snti_ContingentConsiderationTrancheTwoMember_25f578d1-aa8a-4e5b-b54f-3bb1f58d7187" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails" xlink:type="extended" id="i06331f297fc84745ad3c7e44a017270f_StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_916adfee-b2aa-44cf-9f51-a7950e6dd3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput_012231e0-0b38-4871-8ef8-e0b221b3f821" xlink:href="snti-20230331.xsd#snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_916adfee-b2aa-44cf-9f51-a7950e6dd3ec" xlink:to="loc_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput_012231e0-0b38-4871-8ef8-e0b221b3f821" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_392d36c6-8f58-482b-b0fc-971455d1c956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_916adfee-b2aa-44cf-9f51-a7950e6dd3ec" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_392d36c6-8f58-482b-b0fc-971455d1c956" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_778494c7-d952-4a86-94c7-694005ebcc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_392d36c6-8f58-482b-b0fc-971455d1c956" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_778494c7-d952-4a86-94c7-694005ebcc2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_778494c7-d952-4a86-94c7-694005ebcc2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_778494c7-d952-4a86-94c7-694005ebcc2b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_778494c7-d952-4a86-94c7-694005ebcc2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_31e6552b-c20d-4317-8f46-b55a87887621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_778494c7-d952-4a86-94c7-694005ebcc2b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_31e6552b-c20d-4317-8f46-b55a87887621" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_ec7a6e9a-4b1a-45f9-a9d8-214364e294ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_31e6552b-c20d-4317-8f46-b55a87887621" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_ec7a6e9a-4b1a-45f9-a9d8-214364e294ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_9633c7a7-e911-438e-b9fb-f412e5ced122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_31e6552b-c20d-4317-8f46-b55a87887621" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_9633c7a7-e911-438e-b9fb-f412e5ced122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_4d019948-dfdd-4f50-ae3c-c9985219cd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_31e6552b-c20d-4317-8f46-b55a87887621" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_4d019948-dfdd-4f50-ae3c-c9985219cd14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_2e6018b1-7df8-48be-8f80-f3bf4a9668a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_31e6552b-c20d-4317-8f46-b55a87887621" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_2e6018b1-7df8-48be-8f80-f3bf4a9668a7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_a03cc21b-b823-41a5-ae31-182a62fd43a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_31e6552b-c20d-4317-8f46-b55a87887621" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_a03cc21b-b823-41a5-ae31-182a62fd43a5" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/RevenueContractRevenueDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#RevenueContractRevenueDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/RevenueContractRevenueDetails" xlink:type="extended" id="i290cea810e4349eabdd37725bd5038d4_RevenueContractRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount_dce4c45d-df31-4242-8291-d79d201bc91b" xlink:href="snti-20230331.xsd#snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount_dce4c45d-df31-4242-8291-d79d201bc91b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_808b6970-c271-4441-b53a-d4f4f046c6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_808b6970-c271-4441-b53a-d4f4f046c6a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContractWithCustomerExtensionOfTermModificationOfContract_7bc355e3-9cd2-4d04-bf44-9f077eecae80" xlink:href="snti-20230331.xsd#snti_ContractWithCustomerExtensionOfTermModificationOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_snti_ContractWithCustomerExtensionOfTermModificationOfContract_7bc355e3-9cd2-4d04-bf44-9f077eecae80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_4c6091f9-72c9-4b9b-bc64-e4c07818dc68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_4c6091f9-72c9-4b9b-bc64-e4c07818dc68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_67c960ed-e8ca-461e-bf58-db60aebed4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_67c960ed-e8ca-461e-bf58-db60aebed4fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueFromContractWithCustomerEvaluationPeriod_c9331128-aff5-4eb1-a0cb-9a679e95367a" xlink:href="snti-20230331.xsd#snti_RevenueFromContractWithCustomerEvaluationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_snti_RevenueFromContractWithCustomerEvaluationPeriod_c9331128-aff5-4eb1-a0cb-9a679e95367a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueFromContractWithCustomerTerminationNoticePeriod_9f95d045-ff29-4a1f-aa23-c2a718cf9b89" xlink:href="snti-20230331.xsd#snti_RevenueFromContractWithCustomerTerminationNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_snti_RevenueFromContractWithCustomerTerminationNoticePeriod_9f95d045-ff29-4a1f-aa23-c2a718cf9b89" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1bf42a32-ab0d-48b4-b3ef-7ab3aaf3649c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1bf42a32-ab0d-48b4-b3ef-7ab3aaf3649c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_99c08911-3cc7-473f-ad55-c7f9d43c8e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_99c08911-3cc7-473f-ad55-c7f9d43c8e6d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_420adc94-4284-4d29-9b37-00479e17ca60" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:to="loc_srt_CounterpartyNameAxis_420adc94-4284-4d29-9b37-00479e17ca60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_420adc94-4284-4d29-9b37-00479e17ca60_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_420adc94-4284-4d29-9b37-00479e17ca60" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_420adc94-4284-4d29-9b37-00479e17ca60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a86129a-4078-4659-81a1-5e1c1dd4cff0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_420adc94-4284-4d29-9b37-00479e17ca60" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a86129a-4078-4659-81a1-5e1c1dd4cff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SparkMember_5d8d4573-6d03-4382-9945-4d484ecdee21" xlink:href="snti-20230331.xsd#snti_SparkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a86129a-4078-4659-81a1-5e1c1dd4cff0" xlink:to="loc_snti_SparkMember_5d8d4573-6d03-4382-9945-4d484ecdee21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b8e08353-2ac3-4659-be59-7e9f256003ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:to="loc_srt_ProductOrServiceAxis_b8e08353-2ac3-4659-be59-7e9f256003ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b8e08353-2ac3-4659-be59-7e9f256003ac_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b8e08353-2ac3-4659-be59-7e9f256003ac" xlink:to="loc_srt_ProductsAndServicesDomain_b8e08353-2ac3-4659-be59-7e9f256003ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_939f4ce2-c427-4426-9edc-7cb415ea569a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b8e08353-2ac3-4659-be59-7e9f256003ac" xlink:to="loc_srt_ProductsAndServicesDomain_939f4ce2-c427-4426-9edc-7cb415ea569a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_57e17151-4f92-47af-aa74-aff97726358d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_939f4ce2-c427-4426-9edc-7cb415ea569a" xlink:to="loc_us-gaap_LicenseMember_57e17151-4f92-47af-aa74-aff97726358d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_fa3fbc03-0c98-4f6e-9be4-4ec0c35eba57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_fa3fbc03-0c98-4f6e-9be4-4ec0c35eba57" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_010ef97e-a15b-4fcf-996a-ada8214b0269" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:to="loc_srt_RangeAxis_010ef97e-a15b-4fcf-996a-ada8214b0269" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_010ef97e-a15b-4fcf-996a-ada8214b0269_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_010ef97e-a15b-4fcf-996a-ada8214b0269" xlink:to="loc_srt_RangeMember_010ef97e-a15b-4fcf-996a-ada8214b0269_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5fc2dbd9-f1d5-4e76-becf-764bafe01689" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_010ef97e-a15b-4fcf-996a-ada8214b0269" xlink:to="loc_srt_RangeMember_5fc2dbd9-f1d5-4e76-becf-764bafe01689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_87a96347-4ef1-4571-bf3d-18985c97359e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5fc2dbd9-f1d5-4e76-becf-764bafe01689" xlink:to="loc_srt_MinimumMember_87a96347-4ef1-4571-bf3d-18985c97359e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ce1e9a06-338e-451a-ab20-f3b2fade073f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5fc2dbd9-f1d5-4e76-becf-764bafe01689" xlink:to="loc_srt_MaximumMember_ce1e9a06-338e-451a-ab20-f3b2fade073f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/RevenueContractRevenueDetails_1" xlink:type="simple" xlink:href="snti-20230331.xsd#RevenueContractRevenueDetails_1"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/RevenueContractRevenueDetails_1" xlink:type="extended" id="i5a72d60bbc4e4e3e88f98e23420a5860_RevenueContractRevenueDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount_dce4c45d-df31-4242-8291-d79d201bc91b" xlink:href="snti-20230331.xsd#snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount_dce4c45d-df31-4242-8291-d79d201bc91b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_808b6970-c271-4441-b53a-d4f4f046c6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_808b6970-c271-4441-b53a-d4f4f046c6a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContractWithCustomerExtensionOfTermModificationOfContract_7bc355e3-9cd2-4d04-bf44-9f077eecae80" xlink:href="snti-20230331.xsd#snti_ContractWithCustomerExtensionOfTermModificationOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_snti_ContractWithCustomerExtensionOfTermModificationOfContract_7bc355e3-9cd2-4d04-bf44-9f077eecae80" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_4c6091f9-72c9-4b9b-bc64-e4c07818dc68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_4c6091f9-72c9-4b9b-bc64-e4c07818dc68" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_67c960ed-e8ca-461e-bf58-db60aebed4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_67c960ed-e8ca-461e-bf58-db60aebed4fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueFromContractWithCustomerEvaluationPeriod_c9331128-aff5-4eb1-a0cb-9a679e95367a" xlink:href="snti-20230331.xsd#snti_RevenueFromContractWithCustomerEvaluationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_snti_RevenueFromContractWithCustomerEvaluationPeriod_c9331128-aff5-4eb1-a0cb-9a679e95367a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueFromContractWithCustomerTerminationNoticePeriod_9f95d045-ff29-4a1f-aa23-c2a718cf9b89" xlink:href="snti-20230331.xsd#snti_RevenueFromContractWithCustomerTerminationNoticePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_snti_RevenueFromContractWithCustomerTerminationNoticePeriod_9f95d045-ff29-4a1f-aa23-c2a718cf9b89" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1bf42a32-ab0d-48b4-b3ef-7ab3aaf3649c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1bf42a32-ab0d-48b4-b3ef-7ab3aaf3649c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_99c08911-3cc7-473f-ad55-c7f9d43c8e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_99c08911-3cc7-473f-ad55-c7f9d43c8e6d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_420adc94-4284-4d29-9b37-00479e17ca60" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:to="loc_srt_CounterpartyNameAxis_420adc94-4284-4d29-9b37-00479e17ca60" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_420adc94-4284-4d29-9b37-00479e17ca60_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_420adc94-4284-4d29-9b37-00479e17ca60" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_420adc94-4284-4d29-9b37-00479e17ca60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a86129a-4078-4659-81a1-5e1c1dd4cff0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_420adc94-4284-4d29-9b37-00479e17ca60" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a86129a-4078-4659-81a1-5e1c1dd4cff0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SparkMember_5d8d4573-6d03-4382-9945-4d484ecdee21" xlink:href="snti-20230331.xsd#snti_SparkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a86129a-4078-4659-81a1-5e1c1dd4cff0" xlink:to="loc_snti_SparkMember_5d8d4573-6d03-4382-9945-4d484ecdee21" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b8e08353-2ac3-4659-be59-7e9f256003ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:to="loc_srt_ProductOrServiceAxis_b8e08353-2ac3-4659-be59-7e9f256003ac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b8e08353-2ac3-4659-be59-7e9f256003ac_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_b8e08353-2ac3-4659-be59-7e9f256003ac" xlink:to="loc_srt_ProductsAndServicesDomain_b8e08353-2ac3-4659-be59-7e9f256003ac_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_939f4ce2-c427-4426-9edc-7cb415ea569a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_b8e08353-2ac3-4659-be59-7e9f256003ac" xlink:to="loc_srt_ProductsAndServicesDomain_939f4ce2-c427-4426-9edc-7cb415ea569a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_57e17151-4f92-47af-aa74-aff97726358d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_939f4ce2-c427-4426-9edc-7cb415ea569a" xlink:to="loc_us-gaap_LicenseMember_57e17151-4f92-47af-aa74-aff97726358d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_010ef97e-a15b-4fcf-996a-ada8214b0269" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:to="loc_srt_RangeAxis_010ef97e-a15b-4fcf-996a-ada8214b0269" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_010ef97e-a15b-4fcf-996a-ada8214b0269_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_010ef97e-a15b-4fcf-996a-ada8214b0269" xlink:to="loc_srt_RangeMember_010ef97e-a15b-4fcf-996a-ada8214b0269_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5fc2dbd9-f1d5-4e76-becf-764bafe01689" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_010ef97e-a15b-4fcf-996a-ada8214b0269" xlink:to="loc_srt_RangeMember_5fc2dbd9-f1d5-4e76-becf-764bafe01689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_87a96347-4ef1-4571-bf3d-18985c97359e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5fc2dbd9-f1d5-4e76-becf-764bafe01689" xlink:to="loc_srt_MinimumMember_87a96347-4ef1-4571-bf3d-18985c97359e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ce1e9a06-338e-451a-ab20-f3b2fade073f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_5fc2dbd9-f1d5-4e76-becf-764bafe01689" xlink:to="loc_srt_MaximumMember_ce1e9a06-338e-451a-ab20-f3b2fade073f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/RevenueGrantIncomeDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#RevenueGrantIncomeDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/RevenueGrantIncomeDetails" xlink:type="extended" id="ie3e5bd5c3288498ebab1b4be5184a233_RevenueGrantIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f3fef2cb-2fb5-40c4-b93b-a318c8e71036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_a29fc542-dc20-43b1-b762-9a4c7b629ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f3fef2cb-2fb5-40c4-b93b-a318c8e71036" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_a29fc542-dc20-43b1-b762-9a4c7b629ddf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_GrantAssistancePeriodOfRecognition_e6b1aa8e-590a-4758-9d9c-60dff2be197f" xlink:href="snti-20230331.xsd#snti_GrantAssistancePeriodOfRecognition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f3fef2cb-2fb5-40c4-b93b-a318c8e71036" xlink:to="loc_snti_GrantAssistancePeriodOfRecognition_e6b1aa8e-590a-4758-9d9c-60dff2be197f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7ac93314-4230-4a3f-916e-71dbe4f1ac43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f3fef2cb-2fb5-40c4-b93b-a318c8e71036" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7ac93314-4230-4a3f-916e-71dbe4f1ac43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5e0e9458-ed3f-497e-a817-b1a58648541e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7ac93314-4230-4a3f-916e-71dbe4f1ac43" xlink:to="loc_srt_ProductOrServiceAxis_5e0e9458-ed3f-497e-a817-b1a58648541e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_5e0e9458-ed3f-497e-a817-b1a58648541e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_5e0e9458-ed3f-497e-a817-b1a58648541e" xlink:to="loc_srt_ProductsAndServicesDomain_5e0e9458-ed3f-497e-a817-b1a58648541e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8fbbfa22-5ccb-4459-a725-d183cb148b93" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_5e0e9458-ed3f-497e-a817-b1a58648541e" xlink:to="loc_srt_ProductsAndServicesDomain_8fbbfa22-5ccb-4459-a725-d183cb148b93" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_a0db09c9-a623-4741-9199-b42f87c25fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8fbbfa22-5ccb-4459-a725-d183cb148b93" xlink:to="loc_us-gaap_GrantMember_a0db09c9-a623-4741-9199-b42f87c25fce" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/RevenueEntitywideinformationDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#RevenueEntitywideinformationDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/RevenueEntitywideinformationDetails" xlink:type="extended" id="i73d88fd419c94a239acb4a6a0f8312c7_RevenueEntitywideinformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_87b6346e-3c6b-472f-a8a8-cabab65149e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d6f56f56-30f9-4d5b-bcac-c3cd75c0741d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_87b6346e-3c6b-472f-a8a8-cabab65149e3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d6f56f56-30f9-4d5b-bcac-c3cd75c0741d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_90ebb344-9255-4604-a9dc-2da0e6fc6b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_87b6346e-3c6b-472f-a8a8-cabab65149e3" xlink:to="loc_us-gaap_ConcentrationRiskTable_90ebb344-9255-4604-a9dc-2da0e6fc6b2f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4678e480-ec78-4194-acf5-c26eef1bb21a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_90ebb344-9255-4604-a9dc-2da0e6fc6b2f" xlink:to="loc_srt_MajorCustomersAxis_4678e480-ec78-4194-acf5-c26eef1bb21a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4678e480-ec78-4194-acf5-c26eef1bb21a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_4678e480-ec78-4194-acf5-c26eef1bb21a" xlink:to="loc_srt_NameOfMajorCustomerDomain_4678e480-ec78-4194-acf5-c26eef1bb21a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a9131d49-b45a-4b86-82b0-939fdb502d78" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_4678e480-ec78-4194-acf5-c26eef1bb21a" xlink:to="loc_srt_NameOfMajorCustomerDomain_a9131d49-b45a-4b86-82b0-939fdb502d78" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CustomerAMember_0b8b017a-6433-4aa3-bbf8-fcf9c04f3654" xlink:href="snti-20230331.xsd#snti_CustomerAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a9131d49-b45a-4b86-82b0-939fdb502d78" xlink:to="loc_snti_CustomerAMember_0b8b017a-6433-4aa3-bbf8-fcf9c04f3654" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CustomerBMember_6012eb24-2b36-4b23-8951-03a840ac42f2" xlink:href="snti-20230331.xsd#snti_CustomerBMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_a9131d49-b45a-4b86-82b0-939fdb502d78" xlink:to="loc_snti_CustomerBMember_6012eb24-2b36-4b23-8951-03a840ac42f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb0ebeea-a7a0-435c-b465-60c9c836352a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_90ebb344-9255-4604-a9dc-2da0e6fc6b2f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb0ebeea-a7a0-435c-b465-60c9c836352a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cb0ebeea-a7a0-435c-b465-60c9c836352a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb0ebeea-a7a0-435c-b465-60c9c836352a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_cb0ebeea-a7a0-435c-b465-60c9c836352a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_78751b77-1569-4ef5-907c-38b6516114e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb0ebeea-a7a0-435c-b465-60c9c836352a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_78751b77-1569-4ef5-907c-38b6516114e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_c9c6a371-665d-4448-a1e6-96c412a4e60e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_78751b77-1569-4ef5-907c-38b6516114e1" xlink:to="loc_us-gaap_SalesRevenueNetMember_c9c6a371-665d-4448-a1e6-96c412a4e60e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_44dd0ac2-7eee-4399-8511-7f18b26efc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_90ebb344-9255-4604-a9dc-2da0e6fc6b2f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_44dd0ac2-7eee-4399-8511-7f18b26efc3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_44dd0ac2-7eee-4399-8511-7f18b26efc3b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_44dd0ac2-7eee-4399-8511-7f18b26efc3b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_44dd0ac2-7eee-4399-8511-7f18b26efc3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_72ac2b14-3b56-419d-a7d5-c6af1c7aa173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_44dd0ac2-7eee-4399-8511-7f18b26efc3b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_72ac2b14-3b56-419d-a7d5-c6af1c7aa173" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_46298bad-9117-44da-bc89-ea8898a4c23a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_72ac2b14-3b56-419d-a7d5-c6af1c7aa173" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_46298bad-9117-44da-bc89-ea8898a4c23a" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="i68bf8ee69ad24443a568d946a9c723ab_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ae064d6c-4739-422d-8b20-fc37f9ca7f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ae064d6c-4739-422d-8b20-fc37f9ca7f5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a7097ca4-8966-49be-8d7a-694f2aacfff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a7097ca4-8966-49be-8d7a-694f2aacfff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold_f745e9a5-0222-46f6-8344-b2649a3e37a7" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold_f745e9a5-0222-46f6-8344-b2649a3e37a7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue_09937a22-343e-4de4-9f8a-9e5b9adf8bad" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue_09937a22-343e-4de4-9f8a-9e5b9adf8bad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cfda676c-fa48-4e73-b097-26d62a728bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cfda676c-fa48-4e73-b097-26d62a728bf2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage_54cc60b3-3c26-4975-9361-0106d60638fd" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage_54cc60b3-3c26-4975-9361-0106d60638fd" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_d14a7106-5b3a-4bdd-b3bc-c37ca557ba8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_d14a7106-5b3a-4bdd-b3bc-c37ca557ba8e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_8f683ca1-6bd5-4b6c-bb6c-e6bbeac71178" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_8f683ca1-6bd5-4b6c-bb6c-e6bbeac71178" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares_0904f1ff-4f30-4c9b-82cd-30f4f6c78e3a" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares_0904f1ff-4f30-4c9b-82cd-30f4f6c78e3a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fdf8e415-1880-47b8-950b-742aa231b80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fdf8e415-1880-47b8-950b-742aa231b80e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_674d0aaa-9622-4735-b680-0502eb90aced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_674d0aaa-9622-4735-b680-0502eb90aced" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2a63640b-a128-4159-afe6-18f015ec983c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2a63640b-a128-4159-afe6-18f015ec983c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_249e8cd4-d4a5-4914-8694-457ba2a6cf64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_249e8cd4-d4a5-4914-8694-457ba2a6cf64" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2f4800f4-4254-4d83-97a1-18f3d9e9c2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2f4800f4-4254-4d83-97a1-18f3d9e9c2ee" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_12d2b01d-038b-48f8-b37f-6888cfc95053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_12d2b01d-038b-48f8-b37f-6888cfc95053" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CommonStockSubjectToRepurchaseValue_39fffedd-dd3b-4e62-a478-5c0304965cc8" xlink:href="snti-20230331.xsd#snti_CommonStockSubjectToRepurchaseValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_snti_CommonStockSubjectToRepurchaseValue_39fffedd-dd3b-4e62-a478-5c0304965cc8" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9818281b-4b71-4f97-b8b2-660d809d2fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9818281b-4b71-4f97-b8b2-660d809d2fd3" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_f5465353-a799-4f7f-b1fa-473d28d240a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_f5465353-a799-4f7f-b1fa-473d28d240a0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5dea6907-ff97-45c2-ab2c-2e178793aa0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5dea6907-ff97-45c2-ab2c-2e178793aa0f" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches_05906b21-a1b5-4313-abb7-f24ef3baf50e" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches_05906b21-a1b5-4313-abb7-f24ef3baf50e" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ae44337c-7290-4c25-8db4-be18edd14d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ae44337c-7290-4c25-8db4-be18edd14d6e" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6561da2c-b607-48f2-a2d3-bc13ec81c2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6561da2c-b607-48f2-a2d3-bc13ec81c2ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3b7dcf72-122a-4bf2-922b-69855d09ce0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6561da2c-b607-48f2-a2d3-bc13ec81c2ca" xlink:to="loc_us-gaap_AwardTypeAxis_3b7dcf72-122a-4bf2-922b-69855d09ce0e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b7dcf72-122a-4bf2-922b-69855d09ce0e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3b7dcf72-122a-4bf2-922b-69855d09ce0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3b7dcf72-122a-4bf2-922b-69855d09ce0e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ed8594-09d1-4a1b-8c57-71bf2f1cd4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3b7dcf72-122a-4bf2-922b-69855d09ce0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ed8594-09d1-4a1b-8c57-71bf2f1cd4de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_59b8e572-40f6-4900-a99f-4fa1f1ea888f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ed8594-09d1-4a1b-8c57-71bf2f1cd4de" xlink:to="loc_us-gaap_EmployeeStockOptionMember_59b8e572-40f6-4900-a99f-4fa1f1ea888f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_11e37625-8881-4b65-8299-2155c5f218d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ed8594-09d1-4a1b-8c57-71bf2f1cd4de" xlink:to="loc_us-gaap_EmployeeStockMember_11e37625-8881-4b65-8299-2155c5f218d3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e1bd6e4f-7559-4e7a-b039-fba851bc0eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ed8594-09d1-4a1b-8c57-71bf2f1cd4de" xlink:to="loc_us-gaap_PerformanceSharesMember_e1bd6e4f-7559-4e7a-b039-fba851bc0eff" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_MarketAwardsMember_ca2483fc-4665-4c92-9d15-8f91e9181272" xlink:href="snti-20230331.xsd#snti_MarketAwardsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ed8594-09d1-4a1b-8c57-71bf2f1cd4de" xlink:to="loc_snti_MarketAwardsMember_ca2483fc-4665-4c92-9d15-8f91e9181272" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c65daf55-d9a4-4a4a-9b1d-3aff1cd29cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ed8594-09d1-4a1b-8c57-71bf2f1cd4de" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c65daf55-d9a4-4a4a-9b1d-3aff1cd29cc7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d446ff84-d3df-4734-9403-27c81a6c7f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6561da2c-b607-48f2-a2d3-bc13ec81c2ca" xlink:to="loc_us-gaap_PlanNameAxis_d446ff84-d3df-4734-9403-27c81a6c7f99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d446ff84-d3df-4734-9403-27c81a6c7f99_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d446ff84-d3df-4734-9403-27c81a6c7f99" xlink:to="loc_us-gaap_PlanNameDomain_d446ff84-d3df-4734-9403-27c81a6c7f99_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7385ccf7-0ad5-479b-85dd-44f1928f354e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d446ff84-d3df-4734-9403-27c81a6c7f99" xlink:to="loc_us-gaap_PlanNameDomain_7385ccf7-0ad5-479b-85dd-44f1928f354e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_A2016StockIncentivePlanMember_d86d6c6f-6568-4aa5-81d5-1f7cafa1b3ca" xlink:href="snti-20230331.xsd#snti_A2016StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7385ccf7-0ad5-479b-85dd-44f1928f354e" xlink:to="loc_snti_A2016StockIncentivePlanMember_d86d6c6f-6568-4aa5-81d5-1f7cafa1b3ca" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_A2022StockIncentivePlanMember_054f251d-da61-447d-95a2-59fd38806548" xlink:href="snti-20230331.xsd#snti_A2022StockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7385ccf7-0ad5-479b-85dd-44f1928f354e" xlink:to="loc_snti_A2022StockIncentivePlanMember_054f251d-da61-447d-95a2-59fd38806548" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_A2022InducementEquityPlanMember_326f1d5c-049e-4f4c-99a0-956a84f1cddb" xlink:href="snti-20230331.xsd#snti_A2022InducementEquityPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_7385ccf7-0ad5-479b-85dd-44f1928f354e" xlink:to="loc_snti_A2022InducementEquityPlanMember_326f1d5c-049e-4f4c-99a0-956a84f1cddb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_04dccfc5-b72b-440c-bb97-8d2e8fbd1b3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6561da2c-b607-48f2-a2d3-bc13ec81c2ca" xlink:to="loc_srt_RangeAxis_04dccfc5-b72b-440c-bb97-8d2e8fbd1b3b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_04dccfc5-b72b-440c-bb97-8d2e8fbd1b3b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_04dccfc5-b72b-440c-bb97-8d2e8fbd1b3b" xlink:to="loc_srt_RangeMember_04dccfc5-b72b-440c-bb97-8d2e8fbd1b3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4f52ec0b-ed21-4b69-a897-5bb8c8cc4749" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_04dccfc5-b72b-440c-bb97-8d2e8fbd1b3b" xlink:to="loc_srt_RangeMember_4f52ec0b-ed21-4b69-a897-5bb8c8cc4749" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1830b76a-4671-496c-8705-4de947ead348" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4f52ec0b-ed21-4b69-a897-5bb8c8cc4749" xlink:to="loc_srt_MaximumMember_1830b76a-4671-496c-8705-4de947ead348" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockBasedCompensationPerformanceAwardsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails" xlink:type="extended" id="i74ae614bdb1c415bb34816d816b06de8_StockBasedCompensationPerformanceAwardsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3705d6-b50f-4a0d-ad26-ac8c235d7a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b36c612-7e58-48d2-b8d0-e47d9b2d6554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3705d6-b50f-4a0d-ad26-ac8c235d7a48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b36c612-7e58-48d2-b8d0-e47d9b2d6554" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ff346b1f-ebad-4320-931e-5f30430fff37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b36c612-7e58-48d2-b8d0-e47d9b2d6554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ff346b1f-ebad-4320-931e-5f30430fff37" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_750eed69-34c8-4eb8-a976-47b4ad3f53bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b36c612-7e58-48d2-b8d0-e47d9b2d6554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_750eed69-34c8-4eb8-a976-47b4ad3f53bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d98ee95c-4ba0-40b4-bf34-fa6d8e0a71a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5bfb84f0-1b3b-407a-931c-50830291e3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3705d6-b50f-4a0d-ad26-ac8c235d7a48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5bfb84f0-1b3b-407a-931c-50830291e3a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43ab57ce-f66f-49f5-bfc4-238c8acd69c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3705d6-b50f-4a0d-ad26-ac8c235d7a48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43ab57ce-f66f-49f5-bfc4-238c8acd69c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ba8e6b0f-5176-41ad-af70-cd7c79b755aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43ab57ce-f66f-49f5-bfc4-238c8acd69c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ba8e6b0f-5176-41ad-af70-cd7c79b755aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_cff152c8-8d49-4eb8-b553-e2b9e5f484e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43ab57ce-f66f-49f5-bfc4-238c8acd69c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_cff152c8-8d49-4eb8-b553-e2b9e5f484e1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_21ccb024-ffcc-4f97-a1d1-f0120a7f04a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_18e9c8af-c3ba-4463-a81c-de4827433724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3705d6-b50f-4a0d-ad26-ac8c235d7a48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_18e9c8af-c3ba-4463-a81c-de4827433724" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_439fecac-cac9-4792-abb3-c77c593e4fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3705d6-b50f-4a0d-ad26-ac8c235d7a48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_439fecac-cac9-4792-abb3-c77c593e4fe4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm_d46ffa4d-c75b-4027-b04b-efd3066a03dc" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3705d6-b50f-4a0d-ad26-ac8c235d7a48" xlink:to="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm_d46ffa4d-c75b-4027-b04b-efd3066a03dc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a94192f-c9b9-4e63-beca-9ddc213f25a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3705d6-b50f-4a0d-ad26-ac8c235d7a48" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a94192f-c9b9-4e63-beca-9ddc213f25a3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3f19f061-74f8-4f6b-9fa9-ffa6499d418a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a94192f-c9b9-4e63-beca-9ddc213f25a3" xlink:to="loc_us-gaap_AwardTypeAxis_3f19f061-74f8-4f6b-9fa9-ffa6499d418a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f19f061-74f8-4f6b-9fa9-ffa6499d418a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_3f19f061-74f8-4f6b-9fa9-ffa6499d418a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3f19f061-74f8-4f6b-9fa9-ffa6499d418a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c977addd-d4e6-43be-978f-f0d03400e6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_3f19f061-74f8-4f6b-9fa9-ffa6499d418a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c977addd-d4e6-43be-978f-f0d03400e6ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_04e1a91b-5659-4bcc-ba0f-982d2d0b1493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c977addd-d4e6-43be-978f-f0d03400e6ec" xlink:to="loc_us-gaap_PerformanceSharesMember_04e1a91b-5659-4bcc-ba0f-982d2d0b1493" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockBasedCompensationRestrictedStockUnitsActivityDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended" id="ic016cec8063a4933a22ee07841d2805c_StockBasedCompensationRestrictedStockUnitsActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba19f017-f529-4395-a2d1-c59ded414e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_308f7c0d-aab1-41ba-8057-b2d8bb1c1d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba19f017-f529-4395-a2d1-c59ded414e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_308f7c0d-aab1-41ba-8057-b2d8bb1c1d6c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_619fc277-95a6-4435-80b0-8371209a1780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_308f7c0d-aab1-41ba-8057-b2d8bb1c1d6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_619fc277-95a6-4435-80b0-8371209a1780" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d0a4463b-cb0a-4bfd-ae05-b3e96c00ab4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_308f7c0d-aab1-41ba-8057-b2d8bb1c1d6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d0a4463b-cb0a-4bfd-ae05-b3e96c00ab4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9dbf408c-201f-4cb1-baf1-98652bf0b9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_08c56d3e-cd42-46d1-bb91-0ed5245f1085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba19f017-f529-4395-a2d1-c59ded414e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_08c56d3e-cd42-46d1-bb91-0ed5245f1085" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_26361674-3426-4435-8a78-101c43c657ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_08c56d3e-cd42-46d1-bb91-0ed5245f1085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_26361674-3426-4435-8a78-101c43c657ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a1606608-b9cf-404f-afe4-2aa5e1a71af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_08c56d3e-cd42-46d1-bb91-0ed5245f1085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a1606608-b9cf-404f-afe4-2aa5e1a71af3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4f5c17b4-73f6-4faa-81d8-c1a22dec194d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6a54aaa-7411-4c27-8526-1469f36e2abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba19f017-f529-4395-a2d1-c59ded414e0c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6a54aaa-7411-4c27-8526-1469f36e2abf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d4162508-cd09-48b5-961d-99b9380ecd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6a54aaa-7411-4c27-8526-1469f36e2abf" xlink:to="loc_us-gaap_AwardTypeAxis_d4162508-cd09-48b5-961d-99b9380ecd6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4162508-cd09-48b5-961d-99b9380ecd6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d4162508-cd09-48b5-961d-99b9380ecd6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d4162508-cd09-48b5-961d-99b9380ecd6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33bd077b-17d3-4a22-8735-7641b8e2f7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d4162508-cd09-48b5-961d-99b9380ecd6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33bd077b-17d3-4a22-8735-7641b8e2f7e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7e0b6a85-5d97-4406-b8f9-d5f724ee929d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33bd077b-17d3-4a22-8735-7641b8e2f7e0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7e0b6a85-5d97-4406-b8f9-d5f724ee929d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockBasedCompensationWeightedAverageAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended" id="i9d0617f4e4fe4517b973caf2993966fb_StockBasedCompensationWeightedAverageAssumptionsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91e74cf-b386-4158-8696-d23c3544b32e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1a9d065-cbd1-4445-a84c-1523cf75f456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91e74cf-b386-4158-8696-d23c3544b32e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1a9d065-cbd1-4445-a84c-1523cf75f456" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f9048478-652b-4772-bd97-eb7a6bc237c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91e74cf-b386-4158-8696-d23c3544b32e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f9048478-652b-4772-bd97-eb7a6bc237c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2d2782fc-56c8-4c35-bb8e-a86f6c50e192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91e74cf-b386-4158-8696-d23c3544b32e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2d2782fc-56c8-4c35-bb8e-a86f6c50e192" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0d76eaf9-5f01-4bf5-84a0-c8a2c1659380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91e74cf-b386-4158-8696-d23c3544b32e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0d76eaf9-5f01-4bf5-84a0-c8a2c1659380" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac07ef05-b121-4818-8eed-e1aa70f9f0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91e74cf-b386-4158-8696-d23c3544b32e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac07ef05-b121-4818-8eed-e1aa70f9f0c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ba6fda6c-4b55-440b-bb06-2683b033f6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac07ef05-b121-4818-8eed-e1aa70f9f0c8" xlink:to="loc_us-gaap_AwardTypeAxis_ba6fda6c-4b55-440b-bb06-2683b033f6a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba6fda6c-4b55-440b-bb06-2683b033f6a0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_ba6fda6c-4b55-440b-bb06-2683b033f6a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ba6fda6c-4b55-440b-bb06-2683b033f6a0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee5e3c84-ef06-4b51-a1e3-f0d77069c39e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_ba6fda6c-4b55-440b-bb06-2683b033f6a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee5e3c84-ef06-4b51-a1e3-f0d77069c39e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8b1a69d2-eedd-4094-8777-20d7b3ea2a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee5e3c84-ef06-4b51-a1e3-f0d77069c39e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8b1a69d2-eedd-4094-8777-20d7b3ea2a17" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" id="ia0237594fd2546e2b1f41cfcd24cd9ff_StockBasedCompensationStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_eaa11d1e-c802-40bb-9aaf-88a5391c21c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5931da29-4873-4a49-a46e-d6213f28ee00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_eaa11d1e-c802-40bb-9aaf-88a5391c21c4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5931da29-4873-4a49-a46e-d6213f28ee00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c1c17c43-0e87-4ed7-9420-7990e920be74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_eaa11d1e-c802-40bb-9aaf-88a5391c21c4" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c1c17c43-0e87-4ed7-9420-7990e920be74" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dddf0c68-1c8d-4586-9ba3-77b20b424ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c1c17c43-0e87-4ed7-9420-7990e920be74" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dddf0c68-1c8d-4586-9ba3-77b20b424ec9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_dddf0c68-1c8d-4586-9ba3-77b20b424ec9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dddf0c68-1c8d-4586-9ba3-77b20b424ec9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_dddf0c68-1c8d-4586-9ba3-77b20b424ec9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_df0e998f-14a2-4b95-b7ee-f0f005254ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dddf0c68-1c8d-4586-9ba3-77b20b424ec9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_df0e998f-14a2-4b95-b7ee-f0f005254ceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_25b4ec62-fc3e-4a7e-adda-9bbc2aa97919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_df0e998f-14a2-4b95-b7ee-f0f005254ceb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_25b4ec62-fc3e-4a7e-adda-9bbc2aa97919" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1323a38b-8ed7-4bb5-a858-802a8530b2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_df0e998f-14a2-4b95-b7ee-f0f005254ceb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1323a38b-8ed7-4bb5-a858-802a8530b2c3" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended" id="i7f84a39604e849e882686037bef6460d_NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05d7b2e9-3e2f-47a8-9b8d-f5725b00ab60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7bce0938-3162-44e9-abfe-28be10ee88ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05d7b2e9-3e2f-47a8-9b8d-f5725b00ab60" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7bce0938-3162-44e9-abfe-28be10ee88ae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0547a95d-90c7-43bf-91ae-8e580e69edbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05d7b2e9-3e2f-47a8-9b8d-f5725b00ab60" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0547a95d-90c7-43bf-91ae-8e580e69edbc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f7b2b280-32de-49ca-998b-e79d9a269495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0547a95d-90c7-43bf-91ae-8e580e69edbc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f7b2b280-32de-49ca-998b-e79d9a269495" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7b2b280-32de-49ca-998b-e79d9a269495_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f7b2b280-32de-49ca-998b-e79d9a269495" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f7b2b280-32de-49ca-998b-e79d9a269495_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f432273a-a7b1-4cbe-907a-896f6537d4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f7b2b280-32de-49ca-998b-e79d9a269495" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f432273a-a7b1-4cbe-907a-896f6537d4e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SeriesAAndBRedeemableConvertiblePreferredStockMember_756b481a-1b9a-494d-add7-a0929885da72" xlink:href="snti-20230331.xsd#snti_SeriesAAndBRedeemableConvertiblePreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f432273a-a7b1-4cbe-907a-896f6537d4e8" xlink:to="loc_snti_SeriesAAndBRedeemableConvertiblePreferredStockMember_756b481a-1b9a-494d-add7-a0929885da72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_faad3482-a444-427a-82df-93a697f2a7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f432273a-a7b1-4cbe-907a-896f6537d4e8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_faad3482-a444-427a-82df-93a697f2a7dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_UnvestedEarlyExercisedOptionsMember_516432c5-9cbe-40cc-ba8a-bfd742a25396" xlink:href="snti-20230331.xsd#snti_UnvestedEarlyExercisedOptionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f432273a-a7b1-4cbe-907a-896f6537d4e8" xlink:to="loc_snti_UnvestedEarlyExercisedOptionsMember_516432c5-9cbe-40cc-ba8a-bfd742a25396" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c23bc963-9b5d-4f9e-ba2d-a27af138f611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f432273a-a7b1-4cbe-907a-896f6537d4e8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c23bc963-9b5d-4f9e-ba2d-a27af138f611" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentEarnoutCommonStockMember_99efa435-84e8-4b25-adff-9e646752c775" xlink:href="snti-20230331.xsd#snti_ContingentEarnoutCommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f432273a-a7b1-4cbe-907a-896f6537d4e8" xlink:to="loc_snti_ContingentEarnoutCommonStockMember_99efa435-84e8-4b25-adff-9e646752c775" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#CommitmentandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/CommitmentandContingenciesDetails" xlink:type="extended" id="ia48192eb093649e682e1b538a0c30a9b_CommitmentandContingenciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0f1676a7-8b56-42d9-ae68-4f0d686e8f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0f1676a7-8b56-42d9-ae68-4f0d686e8f07" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_476e6ce4-7ae8-44de-ba04-7cad16f084a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_476e6ce4-7ae8-44de-ba04-7cad16f084a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForConstructionInProcess_5b72d5b6-a83c-4168-be1f-4f3e0d78a9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForConstructionInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_us-gaap_PaymentsForConstructionInProcess_5b72d5b6-a83c-4168-be1f-4f3e0d78a9e4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_73a15950-ac09-41ca-93a2-b4815c06c4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_73a15950-ac09-41ca-93a2-b4815c06c4aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ResearchAndDevelopmentExpenseTermOfAgreement_34336aa0-5dad-4ca4-9b0d-f818634d46bd" xlink:href="snti-20230331.xsd#snti_ResearchAndDevelopmentExpenseTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_snti_ResearchAndDevelopmentExpenseTermOfAgreement_34336aa0-5dad-4ca4-9b0d-f818634d46bd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ResearchAndDevelopmentArrangementExpectedCosts_23a98532-f0f9-4725-ba37-83edaca48a74" xlink:href="snti-20230331.xsd#snti_ResearchAndDevelopmentArrangementExpectedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_snti_ResearchAndDevelopmentArrangementExpectedCosts_23a98532-f0f9-4725-ba37-83edaca48a74" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments_4281effd-f84d-4c36-86ee-ce13743cf36e" xlink:href="snti-20230331.xsd#snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments_4281effd-f84d-4c36-86ee-ce13743cf36e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityShares_9c718dd1-3919-4d61-abf3-1a63ad2e5261" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityShares_9c718dd1-3919-4d61-abf3-1a63ad2e5261" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches_fbde3d70-6ac9-45b0-9f18-3cd48f57cf36" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches_fbde3d70-6ac9-45b0-9f18-3cd48f57cf36" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche_51ef990e-d317-4f83-a246-e5058cce2099" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche_51ef990e-d317-4f83-a246-e5058cce2099" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_255cecba-e828-4590-abbb-725b755f5e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_255cecba-e828-4590-abbb-725b755f5e43" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6d6a9b6c-5fcb-4889-9506-276def715b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_255cecba-e828-4590-abbb-725b755f5e43" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6d6a9b6c-5fcb-4889-9506-276def715b21" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d6a9b6c-5fcb-4889-9506-276def715b21_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6d6a9b6c-5fcb-4889-9506-276def715b21" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_6d6a9b6c-5fcb-4889-9506-276def715b21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3efbc07f-7305-4b23-acf4-c49238ffbcea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6d6a9b6c-5fcb-4889-9506-276def715b21" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3efbc07f-7305-4b23-acf4-c49238ffbcea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CGMPFacilityMember_796bd4ca-fb8a-4a10-ad1e-fafe98c0e444" xlink:href="snti-20230331.xsd#snti_CGMPFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3efbc07f-7305-4b23-acf4-c49238ffbcea" xlink:to="loc_snti_CGMPFacilityMember_796bd4ca-fb8a-4a10-ad1e-fafe98c0e444" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3609879a-0a5f-42f1-a3f1-0a14d5645fa7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_255cecba-e828-4590-abbb-725b755f5e43" xlink:to="loc_srt_CounterpartyNameAxis_3609879a-0a5f-42f1-a3f1-0a14d5645fa7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3609879a-0a5f-42f1-a3f1-0a14d5645fa7_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_3609879a-0a5f-42f1-a3f1-0a14d5645fa7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_3609879a-0a5f-42f1-a3f1-0a14d5645fa7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3085ce9-bcb6-46c9-a974-e624cbd7905d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_3609879a-0a5f-42f1-a3f1-0a14d5645fa7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3085ce9-bcb6-46c9-a974-e624cbd7905d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_BlueRockMember_25bddbee-fac7-4fa2-be66-ebc383501937" xlink:href="snti-20230331.xsd#snti_BlueRockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3085ce9-bcb6-46c9-a974-e624cbd7905d" xlink:to="loc_snti_BlueRockMember_25bddbee-fac7-4fa2-be66-ebc383501937" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_963e9c25-5068-4f69-9cff-3df93a542908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_255cecba-e828-4590-abbb-725b755f5e43" xlink:to="loc_us-gaap_TypeOfArrangementAxis_963e9c25-5068-4f69-9cff-3df93a542908" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_963e9c25-5068-4f69-9cff-3df93a542908_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_963e9c25-5068-4f69-9cff-3df93a542908" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_963e9c25-5068-4f69-9cff-3df93a542908_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02f05003-af68-45a3-a476-dfac8d739f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_963e9c25-5068-4f69-9cff-3df93a542908" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02f05003-af68-45a3-a476-dfac8d739f91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_cf274d17-c850-4076-98cf-676d93898ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02f05003-af68-45a3-a476-dfac8d739f91" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_cf274d17-c850-4076-98cf-676d93898ffd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_734ad946-63c3-4a73-9c2e-74361d2f513c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_255cecba-e828-4590-abbb-725b755f5e43" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_734ad946-63c3-4a73-9c2e-74361d2f513c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_734ad946-63c3-4a73-9c2e-74361d2f513c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_734ad946-63c3-4a73-9c2e-74361d2f513c" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_734ad946-63c3-4a73-9c2e-74361d2f513c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_b9ed4ca7-04a1-46d3-9e01-8456096fcb06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_734ad946-63c3-4a73-9c2e-74361d2f513c" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_b9ed4ca7-04a1-46d3-9e01-8456096fcb06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember_00c3fa9c-cb66-404a-9a47-fef3b042cc51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_b9ed4ca7-04a1-46d3-9e01-8456096fcb06" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementMember_00c3fa9c-cb66-404a-9a47-fef3b042cc51" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/RelatedPartiesDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#RelatedPartiesDetails"/>
  <link:definitionLink xlink:role="http://www.sentibio.com/role/RelatedPartiesDetails" xlink:type="extended" id="if95bd030613d45fd8a312a89a453b485_RelatedPartiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7c5bfbab-3b67-458c-90b5-6eb2b73d2679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_us-gaap_CommonStockSharesIssued_7c5bfbab-3b67-458c-90b5-6eb2b73d2679" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_NumberOfSeatsOnTheBoardOfDirectors_93859dbf-e57a-41bb-9437-f2832cceb553" xlink:href="snti-20230331.xsd#snti_NumberOfSeatsOnTheBoardOfDirectors"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_snti_NumberOfSeatsOnTheBoardOfDirectors_93859dbf-e57a-41bb-9437-f2832cceb553" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6e2b5476-0aa3-48c9-9ff3-428f0ca1088a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6e2b5476-0aa3-48c9-9ff3-428f0ca1088a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_6f2a4141-7ce5-4227-adfa-57698bcbddf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_6f2a4141-7ce5-4227-adfa-57698bcbddf3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_9471c842-ad86-4e43-8ea7-4e971c8672e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_us-gaap_SharePrice_9471c842-ad86-4e43-8ea7-4e971c8672e9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ResearchAndDevelopmentArrangementExpectedCosts_af7d1be5-3126-4ffc-86de-dc056ec6ef46" xlink:href="snti-20230331.xsd#snti_ResearchAndDevelopmentArrangementExpectedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_snti_ResearchAndDevelopmentArrangementExpectedCosts_af7d1be5-3126-4ffc-86de-dc056ec6ef46" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ResearchAndDevelopmentExpenseTermOfAgreement_34a22875-a3b7-43fb-8294-7198aa8e015e" xlink:href="snti-20230331.xsd#snti_ResearchAndDevelopmentExpenseTermOfAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_snti_ResearchAndDevelopmentExpenseTermOfAgreement_34a22875-a3b7-43fb-8294-7198aa8e015e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_b6fc538e-c46f-4386-aafa-0078461a9231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_b6fc538e-c46f-4386-aafa-0078461a9231" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm_f82b035c-f178-4572-9cfe-f1a48d4ab10c" xlink:href="snti-20230331.xsd#snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm_f82b035c-f178-4572-9cfe-f1a48d4ab10c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_31470997-f497-40c2-abde-f17ecb82e4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_31470997-f497-40c2-abde-f17ecb82e4b3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d607717f-5e63-4d63-aaca-c9e719412704" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_31470997-f497-40c2-abde-f17ecb82e4b3" xlink:to="loc_srt_CounterpartyNameAxis_d607717f-5e63-4d63-aaca-c9e719412704" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d607717f-5e63-4d63-aaca-c9e719412704_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_d607717f-5e63-4d63-aaca-c9e719412704" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_d607717f-5e63-4d63-aaca-c9e719412704_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a782fb-0eca-4c4e-bfd5-38c9fb5590c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_d607717f-5e63-4d63-aaca-c9e719412704" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a782fb-0eca-4c4e-bfd5-38c9fb5590c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_NEAMember_ee811a0d-1a86-4084-8875-50e4c4056afb" xlink:href="snti-20230331.xsd#snti_NEAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a782fb-0eca-4c4e-bfd5-38c9fb5590c3" xlink:to="loc_snti_NEAMember_ee811a0d-1a86-4084-8875-50e4c4056afb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_BlueRockMember_fa576e91-579c-4aee-b96b-709d936ef5d9" xlink:href="snti-20230331.xsd#snti_BlueRockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a782fb-0eca-4c4e-bfd5-38c9fb5590c3" xlink:to="loc_snti_BlueRockMember_fa576e91-579c-4aee-b96b-709d936ef5d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_BayerMember_b3aefcab-6105-484a-8cad-e3e88698cf9c" xlink:href="snti-20230331.xsd#snti_BayerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a782fb-0eca-4c4e-bfd5-38c9fb5590c3" xlink:to="loc_snti_BayerMember_b3aefcab-6105-484a-8cad-e3e88698cf9c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SeerIncMember_9090f575-92a8-4fc6-81a4-14aa0f4503f2" xlink:href="snti-20230331.xsd#snti_SeerIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a782fb-0eca-4c4e-bfd5-38c9fb5590c3" xlink:to="loc_snti_SeerIncMember_9090f575-92a8-4fc6-81a4-14aa0f4503f2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_29964035-9255-4e62-86ce-d01314cc2e59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_31470997-f497-40c2-abde-f17ecb82e4b3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_29964035-9255-4e62-86ce-d01314cc2e59" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_29964035-9255-4e62-86ce-d01314cc2e59_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_29964035-9255-4e62-86ce-d01314cc2e59" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_29964035-9255-4e62-86ce-d01314cc2e59_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5094bec2-161a-427c-b577-f3eebdb8053b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_29964035-9255-4e62-86ce-d01314cc2e59" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5094bec2-161a-427c-b577-f3eebdb8053b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_11125d92-afe0-4474-b228-6a7fa2814d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5094bec2-161a-427c-b577-f3eebdb8053b" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_11125d92-afe0-4474-b228-6a7fa2814d48" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_51a0de28-9e04-46e2-b99a-eda6849c65bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_31470997-f497-40c2-abde-f17ecb82e4b3" xlink:to="loc_us-gaap_DebtInstrumentAxis_51a0de28-9e04-46e2-b99a-eda6849c65bb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_51a0de28-9e04-46e2-b99a-eda6849c65bb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_51a0de28-9e04-46e2-b99a-eda6849c65bb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_51a0de28-9e04-46e2-b99a-eda6849c65bb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_14ee8f76-4b47-4ba0-bf2a-5c929bfe9a44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_51a0de28-9e04-46e2-b99a-eda6849c65bb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_14ee8f76-4b47-4ba0-bf2a-5c929bfe9a44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_May2022NoteMember_775c7d05-7471-441d-9fd4-2868182e1811" xlink:href="snti-20230331.xsd#snti_May2022NoteMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_14ee8f76-4b47-4ba0-bf2a-5c929bfe9a44" xlink:to="loc_snti_May2022NoteMember_775c7d05-7471-441d-9fd4-2868182e1811" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1d549d65-88c4-493c-9eb8-da4a382544f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_31470997-f497-40c2-abde-f17ecb82e4b3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1d549d65-88c4-493c-9eb8-da4a382544f2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_1d549d65-88c4-493c-9eb8-da4a382544f2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1d549d65-88c4-493c-9eb8-da4a382544f2" xlink:to="loc_us-gaap_ClassOfStockDomain_1d549d65-88c4-493c-9eb8-da4a382544f2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e5481759-05f1-4773-992c-d250a07f9e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1d549d65-88c4-493c-9eb8-da4a382544f2" xlink:to="loc_us-gaap_ClassOfStockDomain_e5481759-05f1-4773-992c-d250a07f9e50" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_05818ea4-b4d1-433c-b5c0-04cad134fc84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_e5481759-05f1-4773-992c-d250a07f9e50" xlink:to="loc_us-gaap_CommonClassAMember_05818ea4-b4d1-433c-b5c0-04cad134fc84" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>snti-20230331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7af4709b-ea9b-4a83-bec7-2aee05be3f39,g:bb811bd4-927a-481b-aaf3-dcf961c572fd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_aa489f85-494f-4394-ae43-6b4c708b8c9b_terseLabel_en-US" xlink:label="lab_snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Shares Reserved For Future Issuance</link:label>
    <link:label id="lab_snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_label_en-US" xlink:label="lab_snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Shares Reserved For Future Issuance [Table Text Block]</link:label>
    <link:label id="lab_snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_documentation_en-US" xlink:label="lab_snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Shares Reserved For Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:href="snti-20230331.xsd#snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:to="lab_snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e0fa9351-4115-437d-bd32-a9d9bf8ccc44_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_RevenueFromContractWithCustomerTerminationNoticePeriod_549c72cc-670c-48df-a474-43b3ae5544a1_terseLabel_en-US" xlink:label="lab_snti_RevenueFromContractWithCustomerTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement termination advance notice period</link:label>
    <link:label id="lab_snti_RevenueFromContractWithCustomerTerminationNoticePeriod_label_en-US" xlink:label="lab_snti_RevenueFromContractWithCustomerTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Termination Notice, Period</link:label>
    <link:label id="lab_snti_RevenueFromContractWithCustomerTerminationNoticePeriod_documentation_en-US" xlink:label="lab_snti_RevenueFromContractWithCustomerTerminationNoticePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Termination Notice, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueFromContractWithCustomerTerminationNoticePeriod" xlink:href="snti-20230331.xsd#snti_RevenueFromContractWithCustomerTerminationNoticePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_RevenueFromContractWithCustomerTerminationNoticePeriod" xlink:to="lab_snti_RevenueFromContractWithCustomerTerminationNoticePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f4c47330-0c02-49ed-b040-3362ba8b0043_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_13d68474-6ca0-4d06-ba76-0f316d256745_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsAbstract_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract" xlink:to="lab_us-gaap_RelatedPartyTransactionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_LesseeOperatingLeaseNumberOfRenewalOptions_d4b3d729-154c-4945-a342-df35832f4132_terseLabel_en-US" xlink:label="lab_snti_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of renewal options</link:label>
    <link:label id="lab_snti_LesseeOperatingLeaseNumberOfRenewalOptions_label_en-US" xlink:label="lab_snti_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:label id="lab_snti_LesseeOperatingLeaseNumberOfRenewalOptions_documentation_en-US" xlink:label="lab_snti_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Number Of Renewal Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:href="snti-20230331.xsd#snti_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:to="lab_snti_LesseeOperatingLeaseNumberOfRenewalOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_4aaf70da-7ae4-40ad-829e-b981ab5a3a50_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturities of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Maturities, Prepayments and Calls of Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:to="lab_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_284845b7-f500-4bc9-8bcc-3da75eba6a5c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_CustomerAMember_acd0e8e7-12cd-4f97-b8b3-5b318e37033f_terseLabel_en-US" xlink:label="lab_snti_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A</link:label>
    <link:label id="lab_snti_CustomerAMember_label_en-US" xlink:label="lab_snti_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label id="lab_snti_CustomerAMember_documentation_en-US" xlink:label="lab_snti_CustomerAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer A</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CustomerAMember" xlink:href="snti-20230331.xsd#snti_CustomerAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_CustomerAMember" xlink:to="lab_snti_CustomerAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_NumberOfVotesPerCommonShare_14ac8c00-e9fb-4d02-8fc8-ab904abf843b_terseLabel_en-US" xlink:label="lab_snti_NumberOfVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of votes per common stock</link:label>
    <link:label id="lab_snti_NumberOfVotesPerCommonShare_label_en-US" xlink:label="lab_snti_NumberOfVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Votes Per Common Share</link:label>
    <link:label id="lab_snti_NumberOfVotesPerCommonShare_documentation_en-US" xlink:label="lab_snti_NumberOfVotesPerCommonShare" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Votes Per Common Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_NumberOfVotesPerCommonShare" xlink:href="snti-20230331.xsd#snti_NumberOfVotesPerCommonShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_NumberOfVotesPerCommonShare" xlink:to="lab_snti_NumberOfVotesPerCommonShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_3da23023-e8aa-4b30-b8e2-d66a30b5b2f0_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_1c156976-262a-4244-b5ee-911cd3be7261_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_SaleOfStockDiscountRatePercentage_4a4a0768-d49a-479f-b5c3-d96d8540b0bb_terseLabel_en-US" xlink:label="lab_snti_SaleOfStockDiscountRatePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate (in percent)</link:label>
    <link:label id="lab_snti_SaleOfStockDiscountRatePercentage_label_en-US" xlink:label="lab_snti_SaleOfStockDiscountRatePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Discount Rate, Percentage</link:label>
    <link:label id="lab_snti_SaleOfStockDiscountRatePercentage_documentation_en-US" xlink:label="lab_snti_SaleOfStockDiscountRatePercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Discount Rate, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockDiscountRatePercentage" xlink:href="snti-20230331.xsd#snti_SaleOfStockDiscountRatePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_SaleOfStockDiscountRatePercentage" xlink:to="lab_snti_SaleOfStockDiscountRatePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_a7d05653-a757-4bea-b7e5-43be809e96a0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment at cost</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_SparkMember_64f30e9a-e349-45be-91f5-cf5058301325_terseLabel_en-US" xlink:label="lab_snti_SparkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spark</link:label>
    <link:label id="lab_snti_SparkMember_label_en-US" xlink:label="lab_snti_SparkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spark [Member]</link:label>
    <link:label id="lab_snti_SparkMember_documentation_en-US" xlink:label="lab_snti_SparkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Spark</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SparkMember" xlink:href="snti-20230331.xsd#snti_SparkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_SparkMember" xlink:to="lab_snti_SparkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_ba9a13dd-c51d-470a-a8de-ef4d9dbb0b93_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_224ea148-0452-4a45-94ee-8278670584e8_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses incurred from transaction</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:to="lab_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_153d21b8-db6e-4fc6-85c5-ab0d468c2860_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_9cc088dd-2321-4950-98ea-b0a7b9dd4d45_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_be9f5898-924f-4f82-a320-2d4da699a44d_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_SaleOfStockIssuanceCosts_98543797-5dba-44ef-9a42-a95b5bd4c4e2_terseLabel_en-US" xlink:label="lab_snti_SaleOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, issuance costs</link:label>
    <link:label id="lab_snti_SaleOfStockIssuanceCosts_label_en-US" xlink:label="lab_snti_SaleOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Issuance Costs</link:label>
    <link:label id="lab_snti_SaleOfStockIssuanceCosts_documentation_en-US" xlink:label="lab_snti_SaleOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockIssuanceCosts" xlink:href="snti-20230331.xsd#snti_SaleOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_SaleOfStockIssuanceCosts" xlink:to="lab_snti_SaleOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_f76060e7-6e94-4681-b7a6-e50529a6dc62_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_44a121ca-44f7-4176-8bc1-49c2e112133e_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent earnout shares</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Classified as Equity, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:to="lab_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_7e180bce-d62b-4ab2-992a-93bebcacc09c_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_ace4ae5a-35ac-4e62-b6e6-7006aa7a6dcf_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_879eb90c-b7a7-4958-b713-0a5dd4100f34_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_3931eef9-4356-44b5-b87b-0325ab2c40a4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_748be95a-8f2e-418a-8711-076d6473bea6_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_739241fd-f1a7-4c34-bcc8-35d84b93c40b_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_85ef0bd9-4614-448f-ac1a-3c1af6c213e4_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_c9724571-1247-42a6-854b-55ba88ca3812_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_511d457e-67db-4f25-a459-c9e280b35f04_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a8f6eb5f-fff2-4966-bbe9-a4babaa0a90d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_3de455cf-688e-4d0b-b568-eedad9798ff2_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_0a444aa5-6655-4f05-a652-e04dbe91adc9_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_e98d0c5b-49fb-4c05-8021-051095ab0ccd_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6cf25388-629c-48dd-9b1f-4fcef04fcf61_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_c6e1626e-6aef-4920-90cc-f427131f3ae9_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche_c7df5ada-482d-43e7-8668-dfe8713a4169_terseLabel_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contingent earnout shares per tranche (in shares)</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche_label_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Shares per Tranche</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche_documentation_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Shares per Tranche</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche" xlink:to="lab_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_SaleOfStockSharesIssuedInTransactionThresholdPercent_febdda02-1764-4f16-80da-8e09f0c7a317_terseLabel_en-US" xlink:label="lab_snti_SaleOfStockSharesIssuedInTransactionThresholdPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued in transaction, threshold (as a percent)</link:label>
    <link:label id="lab_snti_SaleOfStockSharesIssuedInTransactionThresholdPercent_label_en-US" xlink:label="lab_snti_SaleOfStockSharesIssuedInTransactionThresholdPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Shares Issued In Transaction, Threshold, Percent</link:label>
    <link:label id="lab_snti_SaleOfStockSharesIssuedInTransactionThresholdPercent_documentation_en-US" xlink:label="lab_snti_SaleOfStockSharesIssuedInTransactionThresholdPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Shares Issued In Transaction, Threshold, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockSharesIssuedInTransactionThresholdPercent" xlink:href="snti-20230331.xsd#snti_SaleOfStockSharesIssuedInTransactionThresholdPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_SaleOfStockSharesIssuedInTransactionThresholdPercent" xlink:to="lab_snti_SaleOfStockSharesIssuedInTransactionThresholdPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ComputerEquipmentAndSoftwareMember_f3a18f44-2862-4f2f-bd7e-2308039081b6_terseLabel_en-US" xlink:label="lab_snti_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer equipment and software</link:label>
    <link:label id="lab_snti_ComputerEquipmentAndSoftwareMember_label_en-US" xlink:label="lab_snti_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label id="lab_snti_ComputerEquipmentAndSoftwareMember_documentation_en-US" xlink:label="lab_snti_ComputerEquipmentAndSoftwareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Equipment and Software</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ComputerEquipmentAndSoftwareMember" xlink:href="snti-20230331.xsd#snti_ComputerEquipmentAndSoftwareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ComputerEquipmentAndSoftwareMember" xlink:to="lab_snti_ComputerEquipmentAndSoftwareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ResearchAndDevelopmentExpenseTermOfAgreement_75352260-1c11-4aa6-a8ae-458f8fb535f6_terseLabel_en-US" xlink:label="lab_snti_ResearchAndDevelopmentExpenseTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement (in years)</link:label>
    <link:label id="lab_snti_ResearchAndDevelopmentExpenseTermOfAgreement_label_en-US" xlink:label="lab_snti_ResearchAndDevelopmentExpenseTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Term of Agreement</link:label>
    <link:label id="lab_snti_ResearchAndDevelopmentExpenseTermOfAgreement_documentation_en-US" xlink:label="lab_snti_ResearchAndDevelopmentExpenseTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Term of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ResearchAndDevelopmentExpenseTermOfAgreement" xlink:href="snti-20230331.xsd#snti_ResearchAndDevelopmentExpenseTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ResearchAndDevelopmentExpenseTermOfAgreement" xlink:to="lab_snti_ResearchAndDevelopmentExpenseTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_BlueRockMember_4be88066-31cf-4f92-8d02-54561f8d8398_terseLabel_en-US" xlink:label="lab_snti_BlueRockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BlueRock</link:label>
    <link:label id="lab_snti_BlueRockMember_label_en-US" xlink:label="lab_snti_BlueRockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BlueRock [Member]</link:label>
    <link:label id="lab_snti_BlueRockMember_documentation_en-US" xlink:label="lab_snti_BlueRockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BlueRock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_BlueRockMember" xlink:href="snti-20230331.xsd#snti_BlueRockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_BlueRockMember" xlink:to="lab_snti_BlueRockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_494ea746-cc5f-4464-83e5-8ee7c292efaf_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityTerm_5ea29538-fda5-481a-a30b-c63701190d72_terseLabel_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term (in years)</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityTerm_label_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Term</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityTerm_documentation_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityTerm" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ReverseRecapitalizationContingentConsiderationEquityTerm" xlink:to="lab_snti_ReverseRecapitalizationContingentConsiderationEquityTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_3f740494-62c5-4a60-88c1-179e7dd7c24c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_987808db-e90a-4878-8b41-78da4274118c_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_b5c77514-969c-410f-aaf7-ce0ce161cf18_terseLabel_en-US" xlink:label="lab_snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Four</link:label>
    <link:label id="lab_snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, After Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="snti-20230331.xsd#snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_InterestIncomeAccruedAndNotReceived_663050d5-9fd5-4a4d-b46d-44070466d734_terseLabel_en-US" xlink:label="lab_snti_InterestIncomeAccruedAndNotReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income accrued and not received</link:label>
    <link:label id="lab_snti_InterestIncomeAccruedAndNotReceived_label_en-US" xlink:label="lab_snti_InterestIncomeAccruedAndNotReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Accrued And Not Received</link:label>
    <link:label id="lab_snti_InterestIncomeAccruedAndNotReceived_documentation_en-US" xlink:label="lab_snti_InterestIncomeAccruedAndNotReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Accrued And Not Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_InterestIncomeAccruedAndNotReceived" xlink:href="snti-20230331.xsd#snti_InterestIncomeAccruedAndNotReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_InterestIncomeAccruedAndNotReceived" xlink:to="lab_snti_InterestIncomeAccruedAndNotReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_018f341c-c93e-496b-b7e8-559c9051b411_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting rights (in percent)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_6fc1dda6-abfe-4862-8b6a-9c2635c9dcbe_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_a05eb140-4cf2-4b14-897d-cc73c2a3b66f_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid_9c86d191-d778-4822-8d86-8c7b9c006423_terseLabel_en-US" xlink:label="lab_snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger and related PIPE financing costs included in accounts payable and accrued expenses</link:label>
    <link:label id="lab_snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid_label_en-US" xlink:label="lab_snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger and Related PIPE Financing Costs Incurred But Not Yet Paid</link:label>
    <link:label id="lab_snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Merger and Related PIPE Financing Costs Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid" xlink:href="snti-20230331.xsd#snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid" xlink:to="lab_snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_801761e9-a7d6-4807-b648-d8ad6e362c6d_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_2b34db75-1d59-4edf-aded-6244f8176160_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c9a454d0-bb6b-4079-b4e3-f6b53382e579_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold_724a470e-a1ca-45f2-a782-15b87570af42_terseLabel_en-US" xlink:label="lab_snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued, threshold (in shares)</link:label>
    <link:label id="lab_snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold_label_en-US" xlink:label="lab_snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Shares Issued In Transaction, Threshold</link:label>
    <link:label id="lab_snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold_documentation_en-US" xlink:label="lab_snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Number Of Shares Issued In Transaction, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold" xlink:href="snti-20230331.xsd#snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold" xlink:to="lab_snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_e240214f-c474-4c59-89ed-4e3c2e67b939_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated dividend yield</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedDividendRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="lab_us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40d17b48-596c-4077-8b13-dd18352f9237_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_90b74152-20ca-4f19-8b5d-aaa8c28a09b4_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_aa907d03-d0c3-406d-9c0b-cc7c476ace01_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost not yet recognized, excluding options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_7338ebe1-b8d1-4dbe-8ac9-b70a4cb8ae77_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_9525277a-b134-40d8-95df-5b5c4afdc8f8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023, for the remainder of the year</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_646e1494-5b69-4526-8820-e7a586cf91b9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_af198675-a6a5-4821-9dba-c5f64b438f2f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_c7e4e23d-69f5-4e72-a2bb-6cd22e6c5c5f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_e2ab4e69-6cce-4991-bd38-0ea11bbeec88_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_e7fad880-3417-4db8-8844-99758267baff_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at December 31, 2022, Weighted average remaining contractual life (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a99f61d6-16a2-4e61-9ad2-283c01839794_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at March 31, 2023, Weighted average remaining contractual life (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_1c6c457d-6c29-48ae-bba5-5d6bb4c69e23_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_f3ff5ceb-cc8b-4824-bc60-dab751cbd5cc_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_84364c40-1270-4062-9595-329a4867c94e_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_SaleOfStockMaximumAmountAuthorized_244a616f-e5d0-4381-b59c-21e15561782d_terseLabel_en-US" xlink:label="lab_snti_SaleOfStockMaximumAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum proceeds purchase agreement</link:label>
    <link:label id="lab_snti_SaleOfStockMaximumAmountAuthorized_label_en-US" xlink:label="lab_snti_SaleOfStockMaximumAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Amount Authorized</link:label>
    <link:label id="lab_snti_SaleOfStockMaximumAmountAuthorized_documentation_en-US" xlink:label="lab_snti_SaleOfStockMaximumAmountAuthorized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Maximum Amount Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockMaximumAmountAuthorized" xlink:href="snti-20230331.xsd#snti_SaleOfStockMaximumAmountAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_SaleOfStockMaximumAmountAuthorized" xlink:to="lab_snti_SaleOfStockMaximumAmountAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_afdb75d4-cc20-4bc6-aa0e-a93df04f7403_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c51563cd-0bff-4680-a0d8-8d6f9131f442_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_48c2072a-bb0c-47b7-89b3-c71870ac5656_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_a0436a33-5083-4bd2-861c-b02c6027c0ff_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_77e1b3b0-6b5b-40de-92d2-cc5394751fc4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_1c501c2e-3efd-4ca8-aed9-3cab94803c25_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByLiabilityClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis" xlink:to="lab_us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesTable_21e84a64-183c-42f9-89e5-ec3bc2047fb2_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Table]</link:label>
    <link:label id="lab_dei_EntityAddressesTable_label_en-US" xlink:label="lab_dei_EntityAddressesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesTable" xlink:to="lab_dei_EntityAddressesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_f7a30b86-34aa-4573-9507-4f318e6f58ec_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_e52daa19-bbaf-4005-b9f6-747ac0b99bb0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average remaining lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_dd644764-0419-415e-9078-9e36570ebf13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_38c9c699-1529-46b9-80fe-081babeb65e2_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_75471e6e-9bf6-43ec-8180-9adc87fade32_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_ce625289-6376-4995-9cc1-211b2b67afbc_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_86984815-1fd5-456c-a82c-51ccf28ccfd2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_ffaf71e9-2212-446c-b2d5-e447849793f8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_5776c777-603c-4bc5-9481-cfc2d8c25490_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Property and Equipment, Net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_67ff9fb8-a689-4a89-9b45-8ee9ec8286f8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_95eb5152-373a-4750-98bf-d3efe2559f5b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_d89e52cc-7ae2-4405-aee9-e6d63fd738da_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6f6696a7-5093-415e-9c2e-e1c8f09465ca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_c163399a-f4e4-4ca7-b48c-6002d1c6afdb_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_b432e1c2-493a-412b-b9ff-d2791077f1bc_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm_56415692-c129-45b0-808a-694099c1a892_terseLabel_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable, end of period, weighted average remaining contractual life (in years)</link:label>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm_label_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm_documentation_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:to="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_517ccf4a-bb93-4e00-acb6-5711d07ac8b9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_10636b93-22a0-4d8d-994d-5b2047374197_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_ecf83714-774b-45d1-ac96-ed93eca09212_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_86d1addc-101e-4086-bd60-bcfacc939ded_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_A2022InducementEquityPlanMember_988adf96-2655-4d91-a2f9-32b214602544_terseLabel_en-US" xlink:label="lab_snti_A2022InducementEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Inducement Equity Plan</link:label>
    <link:label id="lab_snti_A2022InducementEquityPlanMember_label_en-US" xlink:label="lab_snti_A2022InducementEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Inducement Equity Plan [Member]</link:label>
    <link:label id="lab_snti_A2022InducementEquityPlanMember_documentation_en-US" xlink:label="lab_snti_A2022InducementEquityPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Inducement Equity Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_A2022InducementEquityPlanMember" xlink:href="snti-20230331.xsd#snti_A2022InducementEquityPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_A2022InducementEquityPlanMember" xlink:to="lab_snti_A2022InducementEquityPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ContingentConsiderationTrancheOneMember_18e1bf99-62a3-438e-9a24-e29d307c9ed3_terseLabel_en-US" xlink:label="lab_snti_ContingentConsiderationTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Tranche One</link:label>
    <link:label id="lab_snti_ContingentConsiderationTrancheOneMember_label_en-US" xlink:label="lab_snti_ContingentConsiderationTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Tranche One [Member]</link:label>
    <link:label id="lab_snti_ContingentConsiderationTrancheOneMember_documentation_en-US" xlink:label="lab_snti_ContingentConsiderationTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Tranche One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentConsiderationTrancheOneMember" xlink:href="snti-20230331.xsd#snti_ContingentConsiderationTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ContingentConsiderationTrancheOneMember" xlink:to="lab_snti_ContingentConsiderationTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityShares_db4527bf-018b-4b60-84c9-ebf835e013c1_terseLabel_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum contingent earnout (in shares)</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityShares_label_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Shares</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityShares_documentation_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityShares" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ReverseRecapitalizationContingentConsiderationEquityShares" xlink:to="lab_snti_ReverseRecapitalizationContingentConsiderationEquityShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_bf01f329-01de-4088-914b-385b3b0f0345_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays_953e3df1-fea7-47c6-bbc6-1482ff056dc0_terseLabel_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of trading days</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays_label_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Trading Days</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays_documentation_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" xlink:to="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_d30a2eab-375b-4294-8486-4e228c667cc0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_9807b51d-275a-4a39-8b48-6db06b728d53_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_246ace54-5ecf-4c7d-8f21-224ea7552eef_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_7d3460b4-b18f-4f7b-8a44-529b9ff25018_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_688ccf07-304a-492c-93e9-1647e24f5165_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_2da807c2-3ed5-4ce5-b8c3-fc2c6f6574eb_terseLabel_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">offering period (in months)</link:label>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_label_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_documentation_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:to="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_5d03d577-6d1a-493b-9413-d730ad009f7d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_cd939cac-4e09-4017-b2b9-3b10be2e2944_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_715c2539-4323-4c66-b1bb-ab9a10b70f91_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ResearchAndDevelopmentArrangementExpectedCosts_c4587c33-ad53-45bd-baf8-b0b0bed7a02e_terseLabel_en-US" xlink:label="lab_snti_ResearchAndDevelopmentArrangementExpectedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected costs and expenses incurred</link:label>
    <link:label id="lab_snti_ResearchAndDevelopmentArrangementExpectedCosts_label_en-US" xlink:label="lab_snti_ResearchAndDevelopmentArrangementExpectedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Expected Costs</link:label>
    <link:label id="lab_snti_ResearchAndDevelopmentArrangementExpectedCosts_documentation_en-US" xlink:label="lab_snti_ResearchAndDevelopmentArrangementExpectedCosts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement, Expected Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ResearchAndDevelopmentArrangementExpectedCosts" xlink:href="snti-20230331.xsd#snti_ResearchAndDevelopmentArrangementExpectedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ResearchAndDevelopmentArrangementExpectedCosts" xlink:to="lab_snti_ResearchAndDevelopmentArrangementExpectedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_95a7de88-57c6-4d09-8ffd-6182712495f7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Contingent Consideration [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionContingentConsiderationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_CGMPFacilityMember_e527df96-7741-41be-b03e-566a3f56cba0_terseLabel_en-US" xlink:label="lab_snti_CGMPFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">cGMP Facility</link:label>
    <link:label id="lab_snti_CGMPFacilityMember_label_en-US" xlink:label="lab_snti_CGMPFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">cGMP Facility [Member]</link:label>
    <link:label id="lab_snti_CGMPFacilityMember_documentation_en-US" xlink:label="lab_snti_CGMPFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">cGMP Facility</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CGMPFacilityMember" xlink:href="snti-20230331.xsd#snti_CGMPFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_CGMPFacilityMember" xlink:to="lab_snti_CGMPFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_33da418d-567f-428d-b2f0-829ecdbc030e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_dcf57a83-8f59-4c0d-8d67-0a1f82f9c774_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_173e7732-47d0-46ad-9bed-bc192c7c6156_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_6f8b7d14-22c1-4cc5-a279-64382dd7d112_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_479dccfd-51d5-4d5f-a52d-84d6310e694f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accrued Expenses and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_37ce8d68-8b8c-46ea-9f5c-587f8d23f220_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_SaleOfStockDailyAmountToBeSoldThreshold_119cd9a6-812f-44c9-b8a6-76459a603c07_terseLabel_en-US" xlink:label="lab_snti_SaleOfStockDailyAmountToBeSoldThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price, threshold</link:label>
    <link:label id="lab_snti_SaleOfStockDailyAmountToBeSoldThreshold_label_en-US" xlink:label="lab_snti_SaleOfStockDailyAmountToBeSoldThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Daily Amount To Be Sold, Threshold</link:label>
    <link:label id="lab_snti_SaleOfStockDailyAmountToBeSoldThreshold_documentation_en-US" xlink:label="lab_snti_SaleOfStockDailyAmountToBeSoldThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Daily Amount To Be Sold, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockDailyAmountToBeSoldThreshold" xlink:href="snti-20230331.xsd#snti_SaleOfStockDailyAmountToBeSoldThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_SaleOfStockDailyAmountToBeSoldThreshold" xlink:to="lab_snti_SaleOfStockDailyAmountToBeSoldThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_A2022StockIncentivePlanMember_228f9119-63d8-46c4-80c2-80e8949f8fd1_terseLabel_en-US" xlink:label="lab_snti_A2022StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Stock Incentive Plan</link:label>
    <link:label id="lab_snti_A2022StockIncentivePlanMember_label_en-US" xlink:label="lab_snti_A2022StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_snti_A2022StockIncentivePlanMember_documentation_en-US" xlink:label="lab_snti_A2022StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_A2022StockIncentivePlanMember" xlink:href="snti-20230331.xsd#snti_A2022StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_A2022StockIncentivePlanMember" xlink:to="lab_snti_A2022StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_c7a59b22-ee9a-43ea-b00f-d2632284d046_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued employee-related expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableLeaseCost_d5cf1882-ea23-459a-9593-9acbbe0846af_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost" xlink:to="lab_us-gaap_VariableLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_341e8238-a740-4f36-9dc7-41b5f8bf6d9a_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_907e8b47-ae40-4810-9aad-9dea6a8c9050_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_133884d7-9dfe-45d5-98c9-85f328ad7ed3_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_22fe55f4-30e5-43c8-a041-e5ee360574f8_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_3c226752-fa68-4594-95a9-835735b3282c_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2460a5cb-a6e6-4d8d-8ebf-cdf3d5094cae_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_d4cbb961-9217-42de-91a6-8c60c2238988_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_affcce8c-ea20-478e-b1da-4ad459ce7aca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_f02b4ec1-d82c-4358-b92b-31607d44cb3a_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_RevenueFromAndNotFromContractsTextBlock_e517ddbf-7c42-4f5b-ba05-288f87b5d7ea_terseLabel_en-US" xlink:label="lab_snti_RevenueFromAndNotFromContractsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_snti_RevenueFromAndNotFromContractsTextBlock_label_en-US" xlink:label="lab_snti_RevenueFromAndNotFromContractsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From and Not From Contracts [Text Block]</link:label>
    <link:label id="lab_snti_RevenueFromAndNotFromContractsTextBlock_documentation_en-US" xlink:label="lab_snti_RevenueFromAndNotFromContractsTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From and Not From Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueFromAndNotFromContractsTextBlock" xlink:href="snti-20230331.xsd#snti_RevenueFromAndNotFromContractsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_RevenueFromAndNotFromContractsTextBlock" xlink:to="lab_snti_RevenueFromAndNotFromContractsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_4d51bff6-a777-4f1d-be3a-c028a5ce09ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_EarlyExerciseLiabilityCurrent_a52841f9-79fb-4b18-90af-7397873647d5_terseLabel_en-US" xlink:label="lab_snti_EarlyExerciseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercise liability, current portion</link:label>
    <link:label id="lab_snti_EarlyExerciseLiabilityCurrent_label_en-US" xlink:label="lab_snti_EarlyExerciseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Exercise Liability, Current</link:label>
    <link:label id="lab_snti_EarlyExerciseLiabilityCurrent_documentation_en-US" xlink:label="lab_snti_EarlyExerciseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Exercise Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_EarlyExerciseLiabilityCurrent" xlink:href="snti-20230331.xsd#snti_EarlyExerciseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_EarlyExerciseLiabilityCurrent" xlink:to="lab_snti_EarlyExerciseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_8ede9365-67d1-4081-82c5-d47611f1a4be_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionLineItems_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems" xlink:to="lab_us-gaap_RelatedPartyTransactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_70fa9a01-97f5-4554-8449-4bc1c2a489a3_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember" xlink:to="lab_us-gaap_ShortTermInvestmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4168e052-66cf-46e4-8eb9-7f84468dbe13_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_a840bff0-17eb-4a98-9339-6028aaf729a8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost not yet recognized, period for recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_264800b7-f714-4bf5-8524-dbc7bd52fd28_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at March 31, 2023, Weighted average remaining contractual life (Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_1f6aa6df-535d-4556-bf91-4f87bcfd4b20_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_938a9134-58c3-4824-9398-2520665802c4_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_us-gaap_SubsequentEventsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_8ceef45b-1a70-4aa0-99c7-92c4df1c3627_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield (in percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_a20bdc72-eae1-41db-a471-8bac724e5c6c_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_CashAcquiredThroughReverseRecapitalization_132ebc96-6f87-41f7-b774-0961524945df_terseLabel_en-US" xlink:label="lab_snti_CashAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash acquired through reverse recapitalization</link:label>
    <link:label id="lab_snti_CashAcquiredThroughReverseRecapitalization_label_en-US" xlink:label="lab_snti_CashAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired Through Reverse Recapitalization</link:label>
    <link:label id="lab_snti_CashAcquiredThroughReverseRecapitalization_documentation_en-US" xlink:label="lab_snti_CashAcquiredThroughReverseRecapitalization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired Through Reverse Recapitalization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CashAcquiredThroughReverseRecapitalization" xlink:href="snti-20230331.xsd#snti_CashAcquiredThroughReverseRecapitalization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_CashAcquiredThroughReverseRecapitalization" xlink:to="lab_snti_CashAcquiredThroughReverseRecapitalization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_24f2c013-8d23-4d5e-8476-e705d844823c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_9b94c781-a82e-4cc3-afda-5eba23778bac_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_MeasurementInputExpectedTermMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputExpectedTermMember" xlink:to="lab_us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_SeerIncMember_7c6bd41e-aa61-47c8-a141-0a6843747923_terseLabel_en-US" xlink:label="lab_snti_SeerIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seer, Inc.</link:label>
    <link:label id="lab_snti_SeerIncMember_label_en-US" xlink:label="lab_snti_SeerIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seer, Inc. [Member]</link:label>
    <link:label id="lab_snti_SeerIncMember_documentation_en-US" xlink:label="lab_snti_SeerIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Seer, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SeerIncMember" xlink:href="snti-20230331.xsd#snti_SeerIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_SeerIncMember" xlink:to="lab_snti_SeerIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_4a6401f1-007b-4f05-9fb1-a85d58c45de5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant income</link:label>
    <link:label id="lab_us-gaap_RevenueNotFromContractWithCustomer_label_en-US" xlink:label="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Not from Contract with Customer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueNotFromContractWithCustomer" xlink:to="lab_us-gaap_RevenueNotFromContractWithCustomer" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_37bf913d-0f66-4322-a1fc-9383095aec50_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue_83a881f2-847c-42f8-88a4-e53f34c357bd_totalLabel_en-US" xlink:label="lab_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and debt securities, available-for-sale, fair value</link:label>
    <link:label id="lab_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue_label_en-US" xlink:label="lab_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Debt Securities, Available-For-Sale, Fair Value</link:label>
    <link:label id="lab_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue_documentation_en-US" xlink:label="lab_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Debt Securities, Available-For-Sale, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue" xlink:href="snti-20230331.xsd#snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue" xlink:to="lab_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_468ed408-66e8-467d-8cdd-e2948b1ebe27_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_e70da54a-1f86-484c-bf2c-e109e2e0c03a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par or stated value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_4dc26300-7678-4667-95c3-5e17103af987_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock subject to repurchase (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_bd6b1238-f7d6-40b7-ad60-f77a4e1c0e52_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_0f04415a-2aa1-4f37-a540-b82435579270_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_1a1ba47c-a8dd-45be-b14e-68cf5e9de1c7_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_19685063-2b59-44c4-ab8a-9ace1d17af48_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_358d5c78-fdd4-44e9-9085-e14537f5a3f3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_ed177a8f-27cf-4927-94ac-e1d05408f129_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions_d84ce873-63c8-42fe-bc04-94c2c2e13a58_terseLabel_en-US" xlink:label="lab_snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of early exercise of common stock options</link:label>
    <link:label id="lab_snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions_label_en-US" xlink:label="lab_snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Vesting Of Early Exercise Of Stock Options</link:label>
    <link:label id="lab_snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions_documentation_en-US" xlink:label="lab_snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Vesting Of Early Exercise Of Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions" xlink:href="snti-20230331.xsd#snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions" xlink:to="lab_snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_12d60a6a-96d5-44fb-9e90-03427a61282a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_8c1990c5-3817-4204-949d-f77139611f04_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">grants in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_2daf71ab-313d-41a8-919a-b6e3e2820f99_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_9a5ea923-e51f-4237-baf9-d4e254eaa1a0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_791d5483-7834-4326-8131-1cc691e62979_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="lab_us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_02c7b6bd-5c34-4604-aefa-79b799a5ffa7_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_87d6964e-045d-451b-8bf5-e7d98d134d6f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_cdfe6312-632b-4c3f-9326-f7bf1f848120_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_64229b74-cf14-47ee-8d3d-6c539c45c7ed_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_e1879c52-6a42-4c35-990d-ee1d7bf0c4fe_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of concentration</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract" xlink:to="lab_us-gaap_SubsequentEventsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_5eb9a75d-9913-4692-9fef-0745356ced93_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_baf99fcc-4585-4bb6-b88a-17d7fcf08a81_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_427df821-5ff4-4217-ba5f-ec02a64c6e6b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_e1ee6fc5-6f35-48b1-b1c1-496d3e5b6b88_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_2e568f6c-dbca-42cc-bf0b-170f48ccf1dc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_e839ba4b-70d6-4b44-bb1e-246afd495d43_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_243fac22-da02-4a98-bc4b-bfa216002ce7_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_5544e825-ec34-46c5-9afe-3d6659fb6302_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_9cc70a21-9517-401f-9048-0a99e984c284_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_0811ceec-d1d9-4699-a300-bb760d2fb87c_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_4a80a033-a675-49e2-84a2-3723985634e6_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses (including prepaid rent)</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_EarningsPerShareBasicAndDilutedEPSAbstract_f688d76a-341b-4d8f-8561-a30071e20c83_terseLabel_en-US" xlink:label="lab_snti_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_snti_EarningsPerShareBasicAndDilutedEPSAbstract_label_en-US" xlink:label="lab_snti_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS [Abstract]</link:label>
    <link:label id="lab_snti_EarningsPerShareBasicAndDilutedEPSAbstract_documentation_en-US" xlink:label="lab_snti_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic and Diluted EPS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:href="snti-20230331.xsd#snti_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:to="lab_snti_EarningsPerShareBasicAndDilutedEPSAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_60a44b17-5c80-4fe7-8d54-1e523f26546e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_299a2032-30fb-482e-a4ea-5ee0c3e9b792_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f04650d0-7fba-4aec-bcd9-641600681867_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_0dd8692e-e40d-4b95-ae8c-e7783380187f_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_2029f3d3-6cdb-4440-b7f4-09d02e6c6513_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_c2951d53-59fb-4fc5-bc35-6ea9f62c3709_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Changes in Fair Value of Level 3 Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_cd090e3f-89cc-48d9-8544-90b5e4dc1b10_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_266e04da-45d3-4eff-8ff3-581d65ce3109_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_75aff90f-17ac-422a-b56e-b7e0a13124f9_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost not yet recognized, options</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_e83307ca-b52a-41d5-a3a7-463ebe16de84_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends declared and paid, common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage_79a65a00-913b-4342-96bd-1f6e6cb8b36c_terseLabel_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual increase in authorized shares, percentage</link:label>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage_label_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Increase In Authorized Shares, Percentage</link:label>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage_documentation_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Increase In Authorized Shares, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage" xlink:to="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_b4b94496-63d7-44d4-928c-3d7ecdfceebe_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_5564ff92-85ce-41f5-90d0-5b438464d5b1_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1cc71210-f439-4765-a479-05e6e6fd15d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_9aa477a5-96fc-49d7-bd07-f290d99f8732_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_36c25746-a686-41b9-882f-03f7726e74b5_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_82211703-04c6-4684-b26b-5f9dec96d9a4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_a54e1bf5-c344-4b3a-8963-bc134f4169df_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration, liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_b132ed9c-bb46-4560-b9e5-3fe4bb0b5838_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_d30cf14d-f002-42ef-a4aa-fcb899d718e5_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and short-term investments</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_8ac4b8ed-e3cc-4886-9d86-d29f1b9a7eee_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable, end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_304f9774-4d85-440e-9860-71afad8d3b5e_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease renewal term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRenewalTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Renewal Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_af327708-3be4-484b-bbf3-728fe303cc66_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount_b4a6b2c3-1a5a-4444-92d0-1219173ecf4e_terseLabel_en-US" xlink:label="lab_snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable consideration</link:label>
    <link:label id="lab_snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount_label_en-US" xlink:label="lab_snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:label id="lab_snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount_documentation_en-US" xlink:label="lab_snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Variable Consideration Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:href="snti-20230331.xsd#snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:to="lab_snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent_ed8164fc-3e78-4c37-8ee9-22e72c04f386_terseLabel_en-US" xlink:label="lab_snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading volume available for purchase, threshold (in percent)</link:label>
    <link:label id="lab_snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent_label_en-US" xlink:label="lab_snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Daily Trading Volume Available For Purchase, Threshold, Percent</link:label>
    <link:label id="lab_snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent_documentation_en-US" xlink:label="lab_snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Daily Trading Volume Available For Purchase, Threshold, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent" xlink:href="snti-20230331.xsd#snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent" xlink:to="lab_snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_09163281-98a6-4cd2-be1e-c59cf6f26479_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_5c53496d-b985-4560-ba14-8135c8c04453_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_3e04fb8f-e7c4-4a47-8715-a59078254cd7_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_6bdc72df-7a3f-4def-afb0-17c93dce161e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Financial Statement information</link:label>
    <link:label id="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Financial Information Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:to="lab_us-gaap_AdditionalFinancialInformationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_5c5ac704-3968-4789-a11b-31c12405296a_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_e8324ee6-4884-402a-b2b3-7aacb62a29ba_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_ea2321b5-ef01-4882-98ea-0f3a59699a9d_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings (accumulated deficit)</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_7e7709d4-74a7-49d1-b5b2-ed1a0ee9f463_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_GrantAssistancePeriodOfRecognition_7c6195bc-070a-4e75-82d7-900b3f0165ab_terseLabel_en-US" xlink:label="lab_snti_GrantAssistancePeriodOfRecognition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Period of recognition of grant (in years)</link:label>
    <link:label id="lab_snti_GrantAssistancePeriodOfRecognition_label_en-US" xlink:label="lab_snti_GrantAssistancePeriodOfRecognition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Assistance, Period Of Recognition</link:label>
    <link:label id="lab_snti_GrantAssistancePeriodOfRecognition_documentation_en-US" xlink:label="lab_snti_GrantAssistancePeriodOfRecognition" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant Assistance, Period Of Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_GrantAssistancePeriodOfRecognition" xlink:href="snti-20230331.xsd#snti_GrantAssistancePeriodOfRecognition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_GrantAssistancePeriodOfRecognition" xlink:to="lab_snti_GrantAssistancePeriodOfRecognition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_53c2e778-2e33-469a-8001-d2c1ca16f728_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_76894d13-09a8-4a6a-8da2-c29c395eff1e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at March 31, 2023 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_1e714676-cda1-4914-98f5-a9493bfa6491_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Parties</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="lab_us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_AccruedProfessionalFeesOtherCurrent_ed454b4b-31c5-4144-9d2f-33d563d0ef1e_terseLabel_en-US" xlink:label="lab_snti_AccruedProfessionalFeesOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional and service fees other</link:label>
    <link:label id="lab_snti_AccruedProfessionalFeesOtherCurrent_label_en-US" xlink:label="lab_snti_AccruedProfessionalFeesOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Other, Current</link:label>
    <link:label id="lab_snti_AccruedProfessionalFeesOtherCurrent_documentation_en-US" xlink:label="lab_snti_AccruedProfessionalFeesOtherCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Other, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_AccruedProfessionalFeesOtherCurrent" xlink:href="snti-20230331.xsd#snti_AccruedProfessionalFeesOtherCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_AccruedProfessionalFeesOtherCurrent" xlink:to="lab_snti_AccruedProfessionalFeesOtherCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_82692761-9cb6-442c-bcc1-ad41e8b7aca6_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InterestIncomeExpenseNonoperatingNet_label_en-US" xlink:label="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income (Expense), Nonoperating, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="lab_us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_c4189672-f404-4277-b403-95e2d4b4da81_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_b1e30a59-f85a-4a5a-8de7-9340dcf14f5b_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Category of Item Purchased [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_adba3dc5-0af6-4383-be32-abdc130a2315_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_817b1827-e4ac-4b1c-9459-43b5ad68d338_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_d0052d6d-d54f-4d5a-810f-db407167e645_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal finance lease payments</link:label>
    <link:label id="lab_us-gaap_FinanceLeasePrincipalPayments_label_en-US" xlink:label="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Principal Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeasePrincipalPayments" xlink:to="lab_us-gaap_FinanceLeasePrincipalPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_31af46b9-957f-4515-a100-d23fe2a54104_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_ced6c0fb-5b0a-4bfc-9167-9ae797a135e0_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_8d89a283-5daa-4369-a64f-e6ce0f5d9d8b_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accrued expenses and other current liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_35268edc-4e5f-40b5-ac5c-44ce0549ffa6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, beginning of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_283fd212-7e8a-4829-a2b2-d1dbbd2d9a70_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_8853c8f7-0487-4c31-9a07-275b36c6aa12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Terms of award (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_03fa49a2-65c3-4117-8722-1255b0acea9d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_7d6e057f-d0b3-4437-a54b-09bcf0e2688b_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_dd4b15aa-5f28-4fce-95f9-bcad87d83c31_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput_f1def92b-d3a8-405a-91ea-45f053fd5e1a_terseLabel_en-US" xlink:label="lab_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement input</link:label>
    <link:label id="lab_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput_label_en-US" xlink:label="lab_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Classified as Equity, Measurement Input</link:label>
    <link:label id="lab_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput_documentation_en-US" xlink:label="lab_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Classified as Equity, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" xlink:href="snti-20230331.xsd#snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" xlink:to="lab_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0be65cc7-4012-4185-943b-a1480c1c3ba3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent earnout liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5b7679ea-a263-4c63-a1ac-90d29194dba5_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent earnout liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_44284551-33fb-49b0-8915-e98f7273cbf7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:label id="lab_dei_EntityAddressesAddressTypeAxis_label_en-US" xlink:label="lab_dei_EntityAddressesAddressTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses, Address Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesAddressTypeAxis" xlink:to="lab_dei_EntityAddressesAddressTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_8bac074e-55a7-4314-81e6-0132d3f66f11_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_a0fe6446-ced9-462f-9fef-ccb078f66dc6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_87cb1142-dbc9-40e7-8488-1ae54aa3be26_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ContingentConsiderationTranchesAxis_cc4f7d71-b069-4199-9cb7-4e1229c21013_terseLabel_en-US" xlink:label="lab_snti_ContingentConsiderationTranchesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Tranches [Axis]</link:label>
    <link:label id="lab_snti_ContingentConsiderationTranchesAxis_label_en-US" xlink:label="lab_snti_ContingentConsiderationTranchesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Tranches [Axis]</link:label>
    <link:label id="lab_snti_ContingentConsiderationTranchesAxis_documentation_en-US" xlink:label="lab_snti_ContingentConsiderationTranchesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentConsiderationTranchesAxis" xlink:href="snti-20230331.xsd#snti_ContingentConsiderationTranchesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ContingentConsiderationTranchesAxis" xlink:to="lab_snti_ContingentConsiderationTranchesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_8fad507b-8bc0-487c-aec4-213784f2bf1e_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_ebb893d5-6e6f-41c4-8649-c7e641688165_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_TenantImprovementAllowanceRemainingAmount_88ddb867-95bd-4e68-97bd-bb25aa3d6fc3_negatedTerseLabel_en-US" xlink:label="lab_snti_TenantImprovementAllowanceRemainingAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance remaining</link:label>
    <link:label id="lab_snti_TenantImprovementAllowanceRemainingAmount_label_en-US" xlink:label="lab_snti_TenantImprovementAllowanceRemainingAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance, Remaining Amount</link:label>
    <link:label id="lab_snti_TenantImprovementAllowanceRemainingAmount_documentation_en-US" xlink:label="lab_snti_TenantImprovementAllowanceRemainingAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance, Remaining Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_TenantImprovementAllowanceRemainingAmount" xlink:href="snti-20230331.xsd#snti_TenantImprovementAllowanceRemainingAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_TenantImprovementAllowanceRemainingAmount" xlink:to="lab_snti_TenantImprovementAllowanceRemainingAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_0097907c-4595-432c-8e84-b849fbc257c0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_a12d1c97-844a-4639-b999-f5a2245d5521_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_AlamedaMember_9f2d8668-1db4-42e5-b370-31012d52f510_terseLabel_en-US" xlink:label="lab_snti_AlamedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda</link:label>
    <link:label id="lab_snti_AlamedaMember_label_en-US" xlink:label="lab_snti_AlamedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda [Member]</link:label>
    <link:label id="lab_snti_AlamedaMember_documentation_en-US" xlink:label="lab_snti_AlamedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Alameda</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_AlamedaMember" xlink:href="snti-20230331.xsd#snti_AlamedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_AlamedaMember" xlink:to="lab_snti_AlamedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_2895fe60-2d55-4bab-af51-b8cbdd12a75b_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recent Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays_6fdcfcab-2cd3-4fc7-9b5f-2bb2fa5e438c_terseLabel_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of consecutive trading days</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays_label_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Consecutive Trading Days</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays_documentation_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Consecutive Trading Days</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" xlink:to="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f4b45e8b-ab0e-4183-8dae-dbf931079128_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_d330a680-8e8d-4060-9bc6-595b2696a915_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_4e6b7db3-b65d-40b9-b85b-016e910e3102_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_feb85290-e5a5-4e37-ad4b-dfb8a0a605f0_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ContingentEarnoutCommonStockMember_aaa20bf6-4b6f-45ab-ad13-e7669fd63c16_terseLabel_en-US" xlink:label="lab_snti_ContingentEarnoutCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent earnout common stock</link:label>
    <link:label id="lab_snti_ContingentEarnoutCommonStockMember_label_en-US" xlink:label="lab_snti_ContingentEarnoutCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Earnout Common Stock [Member]</link:label>
    <link:label id="lab_snti_ContingentEarnoutCommonStockMember_documentation_en-US" xlink:label="lab_snti_ContingentEarnoutCommonStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Earnout Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentEarnoutCommonStockMember" xlink:href="snti-20230331.xsd#snti_ContingentEarnoutCommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ContingentEarnoutCommonStockMember" xlink:to="lab_snti_ContingentEarnoutCommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_080b3c23-b708-4eb4-9b34-c7371a265b4a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_ef18d388-fed4-4c6e-9f1d-c00a49a4cbc8_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Category of Item Purchased [Axis]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Category of Item Purchased [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationFairValue_10853585-9095-4ce6-bb68-e5ff0cb1a81e_terseLabel_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent earnout shares</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationFairValue_label_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Fair Value</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationFairValue_documentation_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationFairValue" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ReverseRecapitalizationContingentConsiderationFairValue" xlink:to="lab_snti_ReverseRecapitalizationContingentConsiderationFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_3689fb1a-abfe-4202-a9fe-38ca70124d98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_7144af88-374b-472a-b1ea-2fa530f9acb8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax provision (benefit)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_260683c2-689e-4395-bee9-ae8eb8252515_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_9d5c8696-8e43-48fe-8896-1920a9879549_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c7f47f92-0f6d-4479-8131-98a14e5d0d3f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AddressTypeDomain_04a102ff-c9b3-473a-a93c-fd7d0360f82f_terseLabel_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:label id="lab_dei_AddressTypeDomain_label_en-US" xlink:label="lab_dei_AddressTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Address Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AddressTypeDomain" xlink:to="lab_dei_AddressTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_72d5f6ca-c7a0-4a78-872f-cc933f6438c5_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets, cumulative catch-up adjustments</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:to="lab_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_74ed6327-f761-45ab-9a02-28c646d4a29c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_f80286c8-c7b5-433d-b361-f700ccd841a5_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_0cf02198-8388-4202-9b2e-b45e32eed962_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_761f5ef0-75f2-4e4b-8b24-c009e7b0cda2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_10627a9d-381c-4e95-a1e9-426bde5ad8f2_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_70b4cfd3-4edf-445e-97ec-84abf2281cdb_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_438ae2da-4356-457e-8dee-804a52ede86d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c790db0d-a883-487f-aaa4-c481a1282692_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7cf0fd42-9de2-4e57-9ea4-0d5d843c16d8_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a765b28f-6763-43dd-b2e4-3b67993ec9e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_A2016StockIncentivePlanMember_e80a5eba-4b09-4b06-ad4d-b1b5908ea199_terseLabel_en-US" xlink:label="lab_snti_A2016StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Incentive Plan</link:label>
    <link:label id="lab_snti_A2016StockIncentivePlanMember_label_en-US" xlink:label="lab_snti_A2016StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_snti_A2016StockIncentivePlanMember_documentation_en-US" xlink:label="lab_snti_A2016StockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2016 Stock Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_A2016StockIncentivePlanMember" xlink:href="snti-20230331.xsd#snti_A2016StockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_A2016StockIncentivePlanMember" xlink:to="lab_snti_A2016StockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_d265e3d9-5030-4452-850c-bacf816a912d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.0001 par value; 500,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; 44,075,194 and 44,062,534 shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_6ef54d3e-3a0c-4484-b858-497048a58649_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_f433366e-a1bf-4739-9db6-ea69c17c09d6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_90974fe9-18e2-4cad-a740-999e06a82d0b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at March 31, 2023, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_670e0ec1-547f-4b67-89fb-abbeb1b157fd_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term lease cost</link:label>
    <link:label id="lab_us-gaap_ShortTermLeaseCost_label_en-US" xlink:label="lab_us-gaap_ShortTermLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermLeaseCost" xlink:to="lab_us-gaap_ShortTermLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_d45d6e28-21e0-474b-b94b-53453a86b770_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_0eca4f7d-fba4-450e-82a0-60e98236bf42_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_adaf78ea-c41c-4d2d-9df7-3fb162643d1e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_99c0c965-ef42-4daa-aa29-775af4848a3e_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash, end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fac5b16e-4a8b-425b-b238-1631371e8097_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0728eefc-3326-409a-9d3a-4c142cffae3b_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_348b9b80-7dc4-499d-b8af-6882565d5cbe_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_668ecf39-f018-4798-96ed-c8c21d02bf73_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current stock price</link:label>
    <link:label id="lab_us-gaap_MeasurementInputSharePriceMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputSharePriceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputSharePriceMember" xlink:to="lab_us-gaap_MeasurementInputSharePriceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_42491265-aefa-44ff-8f95-5b7d29421cdc_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_0b587f28-da4a-4069-b99f-5908c6b544e3_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_e2dba348-1fab-4a4e-a085-ac650062b71f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_177245ff-b822-49ce-9a39-90099ec1b6d4_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_CommonStockSubjectToRepurchaseValue_3b1eee44-b55b-4987-9e9e-09f67a924ec5_terseLabel_en-US" xlink:label="lab_snti_CommonStockSubjectToRepurchaseValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock subject to repurchase</link:label>
    <link:label id="lab_snti_CommonStockSubjectToRepurchaseValue_label_en-US" xlink:label="lab_snti_CommonStockSubjectToRepurchaseValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Subject to Repurchase, Value</link:label>
    <link:label id="lab_snti_CommonStockSubjectToRepurchaseValue_documentation_en-US" xlink:label="lab_snti_CommonStockSubjectToRepurchaseValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Subject to Repurchase, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CommonStockSubjectToRepurchaseValue" xlink:href="snti-20230331.xsd#snti_CommonStockSubjectToRepurchaseValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_CommonStockSubjectToRepurchaseValue" xlink:to="lab_snti_CommonStockSubjectToRepurchaseValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_0915cff8-8f2b-48d2-b37f-18d6452c9b05_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment in accounts payable and accrued expenses</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_5b171ebc-db55-410a-8f99-696b100eceb4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_df9a4032-2b61-4aa8-9e69-689d3104d591_terseLabel_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance lease liabilities, current portion</link:label>
    <link:label id="lab_us-gaap_FinanceLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finance Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinanceLeaseLiabilityCurrent" xlink:to="lab_us-gaap_FinanceLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_09e92a25-fa8e-4b6b-94c8-40f947636c14_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, end of period, weighted average remaining contractual life (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_b36be7b0-cf15-4b35-b939-5f18db7b5c8b_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_ac5607ec-d869-48a5-8cc0-a87c9ab330d5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_97a9bc54-d8b2-4205-b5a9-495c3f7c51d5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_30701c65-8b71-4c82-8a03-cebc1e036c39_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal amount of unsecured convertible promissory note</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_1884e9f0-a7c6-4273-a32b-805d9265eeea_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_4b479526-9bc5-404d-9345-e748c934d089_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ab9dee5a-9037-46c9-92c4-d7fe17d79c2e_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_9707b450-90dd-401b-88aa-0793c52fe066_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment of deferred transaction costs related to Merger</link:label>
    <link:label id="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Merger Related Costs, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:to="lab_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_340eb4c2-d7d5-48d8-bf8a-daa1ffae509e_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_58b2d98b-4c79-4ea4-be29-41674f00845e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments_97721d83-7760-43f9-bd2d-bb8250519cd7_terseLabel_en-US" xlink:label="lab_snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual maintenance payments</link:label>
    <link:label id="lab_snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments_label_en-US" xlink:label="lab_snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Contractual Annual Payments</link:label>
    <link:label id="lab_snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments_documentation_en-US" xlink:label="lab_snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Contractual Annual Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments" xlink:href="snti-20230331.xsd#snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments" xlink:to="lab_snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_0365d4d1-fb34-4150-8167-bc257625ee87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options Additional Disclosures</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_db7ea462-fac6-4683-b2b3-745d624bfcf7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable at March 31, 2023 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_CustomerBMember_1ab1a6f8-a2ad-4ed3-a757-9d77348b34ca_terseLabel_en-US" xlink:label="lab_snti_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:label id="lab_snti_CustomerBMember_label_en-US" xlink:label="lab_snti_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label id="lab_snti_CustomerBMember_documentation_en-US" xlink:label="lab_snti_CustomerBMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer B</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CustomerBMember" xlink:href="snti-20230331.xsd#snti_CustomerBMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_CustomerBMember" xlink:to="lab_snti_CustomerBMember" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue_761590e8-431a-4a1f-acd1-c5c0700d831c_terseLabel_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated fair value of the shares on the date of grant (in percent)</link:label>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue_label_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Exercise Price, Percentage Of Fair Market Value</link:label>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue_documentation_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Exercise Price, Percentage Of Fair Market Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue" xlink:to="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_1cce0182-20b6-43fd-a92a-841b57170964_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of outstanding shares</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_0ac9cb38-3608-4f92-9e0e-d728f409a485_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_37c88e63-dfba-4a34-be64-0026d9358558_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_439a0b96-a319-4db3-b49c-e58b3977db7a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_CommonStockPurchaseAgreementMember_ef3d1aa7-f310-4d8e-a74a-c3078eba3578_terseLabel_en-US" xlink:label="lab_snti_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement</link:label>
    <link:label id="lab_snti_CommonStockPurchaseAgreementMember_label_en-US" xlink:label="lab_snti_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_snti_CommonStockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_snti_CommonStockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Purchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CommonStockPurchaseAgreementMember" xlink:href="snti-20230331.xsd#snti_CommonStockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_CommonStockPurchaseAgreementMember" xlink:to="lab_snti_CommonStockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_bd6f92a5-6434-40f9-9d7f-ca668f90e5f2_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_332148f1-469d-4b16-af52-f0521b76cdea_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at December 31, 2022 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_139d8d99-09ff-42ce-84d2-78fdfb8dba0e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at March 31, 2023 (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_8e8ab3c8-9a58-4724-96a5-ee66a4b24268_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_TenantImprovementAllowanceUtilized_34d3e31a-90a2-4bdd-bb19-501dff33a54f_terseLabel_en-US" xlink:label="lab_snti_TenantImprovementAllowanceUtilized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance utilized</link:label>
    <link:label id="lab_snti_TenantImprovementAllowanceUtilized_label_en-US" xlink:label="lab_snti_TenantImprovementAllowanceUtilized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance Utilized</link:label>
    <link:label id="lab_snti_TenantImprovementAllowanceUtilized_documentation_en-US" xlink:label="lab_snti_TenantImprovementAllowanceUtilized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance Utilized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_TenantImprovementAllowanceUtilized" xlink:href="snti-20230331.xsd#snti_TenantImprovementAllowanceUtilized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_TenantImprovementAllowanceUtilized" xlink:to="lab_snti_TenantImprovementAllowanceUtilized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_37ed8548-6c48-4510-9ece-fac918d6fbc7_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_57d73f28-a03f-42fd-b7f6-8eb79038d4ab_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d02c6b39-f513-496a-8340-0bafd82f6733_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_00b398dc-e9fa-4ae2-a36f-19f131b457b5_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches_85217d46-9909-47d0-bd11-39b96303056c_terseLabel_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches_label_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Tranches</link:label>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches_documentation_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" xlink:to="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_RevenueFromAndNotFromContractsAbstract_label_en-US" xlink:label="lab_snti_RevenueFromAndNotFromContractsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From and Not From Contracts [Abstract]</link:label>
    <link:label id="lab_snti_RevenueFromAndNotFromContractsAbstract_documentation_en-US" xlink:label="lab_snti_RevenueFromAndNotFromContractsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue From and Not From Contracts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueFromAndNotFromContractsAbstract" xlink:href="snti-20230331.xsd#snti_RevenueFromAndNotFromContractsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_RevenueFromAndNotFromContractsAbstract" xlink:to="lab_snti_RevenueFromAndNotFromContractsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_a2c273a0-a9a8-4b85-9239-6d960c26532f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_8025a884-46bf-4e8d-84eb-0de60185bf51_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2495260b-fd21-478c-971a-a8e41bf24a77_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility (in percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_3c996e87-d57a-4322-92b7-8124b702e627_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of common stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_68044842-e4dd-4ffe-974b-bcd43f85ff78_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_f263c855-370e-4b86-a690-3d3e42c8ed4e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_e5dd2a7b-7d3d-4404-927b-86047f96b15b_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_9d132172-53ba-4016-afc7-af88883f64d0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain on investments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_f02dafd9-a143-4060-901a-a10d4adbaa8a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_ccd3cde0-beda-4ed3-899e-682149924442_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent earnout liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_65709126-0610-49ca-8674-464195e82c80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="lab_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_e2bbc76f-3db7-4088-8e62-b4ac1ae8e529_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAbstract_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAbstract" xlink:to="lab_us-gaap_TemporaryEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForConstructionInProcess_f757b7a5-e2df-41dd-9d0a-e06346fc787b_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForConstructionInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction costs</link:label>
    <link:label id="lab_us-gaap_PaymentsForConstructionInProcess_label_en-US" xlink:label="lab_us-gaap_PaymentsForConstructionInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Construction in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForConstructionInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForConstructionInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForConstructionInProcess" xlink:to="lab_us-gaap_PaymentsForConstructionInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_5f65a195-31e4-4cb3-b03b-cdbfe90c1a34_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_43fb8428-14a6-4886-a21a-6da9b3f22e5f_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost_0a6c9336-76ab-4866-8928-be96752f32bb_totalLabel_en-US" xlink:label="lab_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents and debt securities, available-for-sale, adjusted cost</link:label>
    <link:label id="lab_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost_label_en-US" xlink:label="lab_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Debt Securities, Available For-Sale, Amortized Cost</link:label>
    <link:label id="lab_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost_documentation_en-US" xlink:label="lab_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Debt Securities, Available For-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:href="snti-20230331.xsd#snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:to="lab_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3d72c912-856a-4ee4-9443-cee96503315d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrantMember_919ac131-1a29-406b-8cf6-d3e28126fced_terseLabel_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant income</link:label>
    <link:label id="lab_us-gaap_GrantMember_label_en-US" xlink:label="lab_us-gaap_GrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Grant [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrantMember" xlink:to="lab_us-gaap_GrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonClassAMember_8685e70f-2c93-4d42-9b6c-63399cb5f390_terseLabel_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A</link:label>
    <link:label id="lab_us-gaap_CommonClassAMember_label_en-US" xlink:label="lab_us-gaap_CommonClassAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Class A [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonClassAMember" xlink:to="lab_us-gaap_CommonClassAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_8a062adb-4684-4aa5-b762-27c6c996578f_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested early exercised common stock</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_65436be2-2d9f-4ffe-bea8-7b743d83ba12_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_RestrictedCashMember_646e87a2-4ccd-41a1-b961-bedfd06ff070_terseLabel_en-US" xlink:label="lab_snti_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_snti_RestrictedCashMember_label_en-US" xlink:label="lab_snti_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash [Member]</link:label>
    <link:label id="lab_snti_RestrictedCashMember_documentation_en-US" xlink:label="lab_snti_RestrictedCashMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RestrictedCashMember" xlink:href="snti-20230331.xsd#snti_RestrictedCashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_RestrictedCashMember" xlink:to="lab_snti_RestrictedCashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_9b8920d3-301b-4b01-ba66-c5caae5fff4b_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_ace5dbc6-c8c0-4584-9160-73e0eb968456_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_8d524873-99d4-41f8-88ac-3b2a5b2171d8_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized during period previously included in deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_10ffaed0-8b68-4ec9-80cb-fc716ebb80dd_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_504ae8c1-b93f-4256-9e88-f40f3814f9bd_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_811a4d63-f376-467a-9cf5-501066982deb_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_ee0a1d43-fe3b-4513-863c-6c8033e5366d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_7bc507b8-17f6-4b9b-910a-bf0f576e4808_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_OperatingLeaseProceedsPayments_11cdb8b5-e8b4-40d3-b841-9852851dee1b_terseLabel_en-US" xlink:label="lab_snti_OperatingLeaseProceedsPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating cash flows net inflows and (outflows) from operating lease</link:label>
    <link:label id="lab_snti_OperatingLeaseProceedsPayments_label_en-US" xlink:label="lab_snti_OperatingLeaseProceedsPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Proceeds (Payments)</link:label>
    <link:label id="lab_snti_OperatingLeaseProceedsPayments_documentation_en-US" xlink:label="lab_snti_OperatingLeaseProceedsPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Proceeds (Payments)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_OperatingLeaseProceedsPayments" xlink:href="snti-20230331.xsd#snti_OperatingLeaseProceedsPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_OperatingLeaseProceedsPayments" xlink:to="lab_snti_OperatingLeaseProceedsPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_UnvestedEarlyExercisedOptionsMember_4a015725-5292-4c6b-8704-2a486f1a0c0d_terseLabel_en-US" xlink:label="lab_snti_UnvestedEarlyExercisedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested early exercised options</link:label>
    <link:label id="lab_snti_UnvestedEarlyExercisedOptionsMember_label_en-US" xlink:label="lab_snti_UnvestedEarlyExercisedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Early Exercised Options [Member]</link:label>
    <link:label id="lab_snti_UnvestedEarlyExercisedOptionsMember_documentation_en-US" xlink:label="lab_snti_UnvestedEarlyExercisedOptionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unvested Early Exercised Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_UnvestedEarlyExercisedOptionsMember" xlink:href="snti-20230331.xsd#snti_UnvestedEarlyExercisedOptionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_UnvestedEarlyExercisedOptionsMember" xlink:to="lab_snti_UnvestedEarlyExercisedOptionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCash_23e15f85-2efe-431f-878b-e470843f6291_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCash_label_en-US" xlink:label="lab_us-gaap_RestrictedCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCash" xlink:to="lab_us-gaap_RestrictedCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_e9bf4f7e-72f9-42ec-a832-4817779d4dc2_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected timing of satisfaction</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_b4cf69e5-d400-4360-9b27-631884b4bc45_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ffbe69b5-df22-4bce-9a23-b628fafaa817_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_c4fd0ad7-08ba-4207-9ac5-9f8b63391083_terseLabel_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits</link:label>
    <link:label id="lab_us-gaap_DepositsAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DepositsAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deposits Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepositsAssetsCurrent" xlink:to="lab_us-gaap_DepositsAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d7709233-8805-41b6-87b5-feb94e83c185_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at December 31, 2022, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_344c7e2c-943d-4f5e-a171-294d1fa26469_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at March 31, 2023, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_da2f89ae-a2c1-4eb7-bafd-a52f815a7a09_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_9cd6a94c-8fef-4732-8177-3086d63dd870_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_8e0faaf2-c231-4a81-ba5e-ba3f968a3b8d_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_209795ac-a9f6-42e1-93ed-9664f8add1de_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressesLineItems_bb4a9362-a947-4e87-b3fc-157f3a478dc1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
    <link:label id="lab_dei_EntityAddressesLineItems_label_en-US" xlink:label="lab_dei_EntityAddressesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Addresses [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressesLineItems" xlink:to="lab_dei_EntityAddressesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_ce379af2-ce8d-42a7-b387-4b638730b156_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_EarlyExerciseLiabilityNoncurrent_ee2b3019-11e6-4d59-b3d2-634e39989307_terseLabel_en-US" xlink:label="lab_snti_EarlyExerciseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early exercise liability, net of current portion</link:label>
    <link:label id="lab_snti_EarlyExerciseLiabilityNoncurrent_label_en-US" xlink:label="lab_snti_EarlyExerciseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Exercise Liability, Noncurrent</link:label>
    <link:label id="lab_snti_EarlyExerciseLiabilityNoncurrent_documentation_en-US" xlink:label="lab_snti_EarlyExerciseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Early Exercise Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_EarlyExerciseLiabilityNoncurrent" xlink:href="snti-20230331.xsd#snti_EarlyExerciseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_EarlyExerciseLiabilityNoncurrent" xlink:to="lab_snti_EarlyExerciseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_e5fcbe00-87a5-4738-988d-4cd3c1b6b891_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_59a06ec1-fc72-4bb6-abbd-65e3f39c7447_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_32919707-17da-4cb5-9311-4e070a14274f_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_65b78381-1320-4c6d-8b73-d4891837dff5_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected share price volatility</link:label>
    <link:label id="lab_us-gaap_MeasurementInputPriceVolatilityMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="lab_us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_be350973-38c1-43f1-929d-f03d297262e2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion of discount on short-term investments</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_dfa19811-922c-4651-b5dd-1638d1899177_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_e970a8bf-b017-4e08-8154-4055f29d7a36_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury securities</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember" xlink:to="lab_us-gaap_USTreasurySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_eef2f8b7-8064-4dbd-b2de-77595c29a70c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions_36a52622-894b-492b-922b-27c88127fc8a_terseLabel_en-US" xlink:label="lab_snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting of early exercise of common stock options (in shares)</link:label>
    <link:label id="lab_snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions_label_en-US" xlink:label="lab_snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Vesting Of Early Exercise Of Stock Options</link:label>
    <link:label id="lab_snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions_documentation_en-US" xlink:label="lab_snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Vesting Of Early Exercise Of Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions" xlink:href="snti-20230331.xsd#snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions" xlink:to="lab_snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_37640e5f-24ee-4e1a-b51c-d66588e4648e_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2fff427d-cfea-440e-93e3-17d9ba41a802_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate purchase price</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_031f05a3-e492-43d2-9f7c-2652f6dfad14_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_RelatedPartyMember_07e34f7e-ef92-4540-8d3b-99f907e40abd_terseLabel_en-US" xlink:label="lab_snti_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:label id="lab_snti_RelatedPartyMember_label_en-US" xlink:label="lab_snti_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Member]</link:label>
    <link:label id="lab_snti_RelatedPartyMember_documentation_en-US" xlink:label="lab_snti_RelatedPartyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RelatedPartyMember" xlink:href="snti-20230331.xsd#snti_RelatedPartyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_RelatedPartyMember" xlink:to="lab_snti_RelatedPartyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_CommonStockUnderEquityPlansMember_27866795-117f-4d27-83f9-3dbefc6bbdb8_terseLabel_en-US" xlink:label="lab_snti_CommonStockUnderEquityPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Plans</link:label>
    <link:label id="lab_snti_CommonStockUnderEquityPlansMember_label_en-US" xlink:label="lab_snti_CommonStockUnderEquityPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Under Equity Plans [Member]</link:label>
    <link:label id="lab_snti_CommonStockUnderEquityPlansMember_documentation_en-US" xlink:label="lab_snti_CommonStockUnderEquityPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Under Equity Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CommonStockUnderEquityPlansMember" xlink:href="snti-20230331.xsd#snti_CommonStockUnderEquityPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_CommonStockUnderEquityPlansMember" xlink:to="lab_snti_CommonStockUnderEquityPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_CorporateHeadquartersMember_07cb73b2-248b-4ae0-8f6e-881631fe4d53_terseLabel_en-US" xlink:label="lab_snti_CorporateHeadquartersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters</link:label>
    <link:label id="lab_snti_CorporateHeadquartersMember_label_en-US" xlink:label="lab_snti_CorporateHeadquartersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters [Member]</link:label>
    <link:label id="lab_snti_CorporateHeadquartersMember_documentation_en-US" xlink:label="lab_snti_CorporateHeadquartersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Headquarters</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CorporateHeadquartersMember" xlink:href="snti-20230331.xsd#snti_CorporateHeadquartersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_CorporateHeadquartersMember" xlink:to="lab_snti_CorporateHeadquartersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_40ccfd20-8318-4d7a-96e0-4a17ca9a2af9_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_4cb62571-4f9e-4efa-a5d9-518da45dbae1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares outstanding, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_784b933f-aec6-43cd-909e-df628bf0e2c6_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average shares used in computing net loss per share, basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_f134b6e5-7a43-415d-a3f9-dfdd6b6e54cb_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions_722d2a32-dd33-423f-b910-a390d8021b11_terseLabel_en-US" xlink:label="lab_snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables in transit from issuance of common stock upon exercise of stock options</link:label>
    <link:label id="lab_snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions_label_en-US" xlink:label="lab_snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables In Transit From Issuance Of Common Stock Upon Exercise Of Stock Options</link:label>
    <link:label id="lab_snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions_documentation_en-US" xlink:label="lab_snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables In Transit From Issuance Of Common Stock Upon Exercise Of Stock Options</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions" xlink:href="snti-20230331.xsd#snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions" xlink:to="lab_snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_7463a8cf-cc22-41f7-87db-7a35377c9d38_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosures of noncash financing and investing items</link:label>
    <link:label id="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Investing and Financing Items [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="lab_us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_b9ea2c77-d436-4e1b-b440-f69ff6fefd00_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies (Note 11)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_07eb9940-26ed-42b9-8278-cdd2b02285c1_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_06204758-d0f0-4be6-aa02-3445342ed52f_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at December 31, 2022 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_419acebd-8bd0-4ff0-87ab-9f3136f6d36d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding at March 31, 2023 (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_630b3892-3414-4666-ace9-c00fc53a3f46_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_May2022NoteMember_6f9c1ad3-b128-4a46-a338-f38b30d006e1_terseLabel_en-US" xlink:label="lab_snti_May2022NoteMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 Note</link:label>
    <link:label id="lab_snti_May2022NoteMember_label_en-US" xlink:label="lab_snti_May2022NoteMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 Note [Member]</link:label>
    <link:label id="lab_snti_May2022NoteMember_documentation_en-US" xlink:label="lab_snti_May2022NoteMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">May 2022 Note</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_May2022NoteMember" xlink:href="snti-20230331.xsd#snti_May2022NoteMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_May2022NoteMember" xlink:to="lab_snti_May2022NoteMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_e38a32b5-44eb-402a-bfaa-69d94da263ca_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; zero shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ContingentConsiderationTrancheTwoMember_f067a7a2-993a-4255-aae0-89fae277aa42_terseLabel_en-US" xlink:label="lab_snti_ContingentConsiderationTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Tranche Two</link:label>
    <link:label id="lab_snti_ContingentConsiderationTrancheTwoMember_label_en-US" xlink:label="lab_snti_ContingentConsiderationTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Tranche Two [Member]</link:label>
    <link:label id="lab_snti_ContingentConsiderationTrancheTwoMember_documentation_en-US" xlink:label="lab_snti_ContingentConsiderationTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration, Tranche Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentConsiderationTrancheTwoMember" xlink:href="snti-20230331.xsd#snti_ContingentConsiderationTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ContingentConsiderationTrancheTwoMember" xlink:to="lab_snti_ContingentConsiderationTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_cbecc776-95ec-4f7b-8b43-44cdb3dc19ec_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_b8d3af40-9b71-4bb5-b9f4-0eed5b481bcd_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8067fcb4-006c-4ab2-9c7c-5cffe9308dc5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_9ccf0c89-4983-44b1-82b0-3174ade5e53d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of redeemable convertible preferred stock into common stock in connection with the Reverse Recapitalization, net of transaction costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_MarketAwardsMember_c3ae6fc8-4866-4d45-a6e3-7f8cea2fa2b2_terseLabel_en-US" xlink:label="lab_snti_MarketAwardsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Awards</link:label>
    <link:label id="lab_snti_MarketAwardsMember_label_en-US" xlink:label="lab_snti_MarketAwardsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Awards [Member]</link:label>
    <link:label id="lab_snti_MarketAwardsMember_documentation_en-US" xlink:label="lab_snti_MarketAwardsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Market Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_MarketAwardsMember" xlink:href="snti-20230331.xsd#snti_MarketAwardsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_MarketAwardsMember" xlink:to="lab_snti_MarketAwardsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_FormerAddressMember_13bac29a-182c-4e63-9ea5-ac979ee724b2_terseLabel_en-US" xlink:label="lab_dei_FormerAddressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Address</link:label>
    <link:label id="lab_dei_FormerAddressMember_label_en-US" xlink:label="lab_dei_FormerAddressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Former Address [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_FormerAddressMember" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_FormerAddressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_FormerAddressMember" xlink:to="lab_dei_FormerAddressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_9ae80df5-4f11-4a94-9c3b-5387c86278b5_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock reserved for future issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_ff19b1c2-ee81-44f5-bb61-6490e85a0482_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsMember" xlink:to="lab_us-gaap_CashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_NumberOfSeatsOnTheBoardOfDirectors_ecb2b2b5-f232-45f1-a60f-118b60a8436c_terseLabel_en-US" xlink:label="lab_snti_NumberOfSeatsOnTheBoardOfDirectors" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of seats on the board of directors</link:label>
    <link:label id="lab_snti_NumberOfSeatsOnTheBoardOfDirectors_label_en-US" xlink:label="lab_snti_NumberOfSeatsOnTheBoardOfDirectors" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Seats On The Board Of Directors</link:label>
    <link:label id="lab_snti_NumberOfSeatsOnTheBoardOfDirectors_documentation_en-US" xlink:label="lab_snti_NumberOfSeatsOnTheBoardOfDirectors" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Seats On The Board Of Directors</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_NumberOfSeatsOnTheBoardOfDirectors" xlink:href="snti-20230331.xsd#snti_NumberOfSeatsOnTheBoardOfDirectors"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_NumberOfSeatsOnTheBoardOfDirectors" xlink:to="lab_snti_NumberOfSeatsOnTheBoardOfDirectors" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_73e54498-63e1-4748-87ba-7a35185256de_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_139e0288-c60f-4722-ad6a-9a6f46b4bd8e_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_SaleOfStockDocumentPreparationFees_114cb9cf-ef54-4a8d-8c25-92566f72e43a_terseLabel_en-US" xlink:label="lab_snti_SaleOfStockDocumentPreparationFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document preparation fees</link:label>
    <link:label id="lab_snti_SaleOfStockDocumentPreparationFees_label_en-US" xlink:label="lab_snti_SaleOfStockDocumentPreparationFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Document Preparation Fees</link:label>
    <link:label id="lab_snti_SaleOfStockDocumentPreparationFees_documentation_en-US" xlink:label="lab_snti_SaleOfStockDocumentPreparationFees" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Document Preparation Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockDocumentPreparationFees" xlink:href="snti-20230331.xsd#snti_SaleOfStockDocumentPreparationFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_SaleOfStockDocumentPreparationFees" xlink:to="lab_snti_SaleOfStockDocumentPreparationFees" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ContingentEarnoutLiabilityMember_c0e18b31-b57c-4b0e-9369-d3fab9112e73_terseLabel_en-US" xlink:label="lab_snti_ContingentEarnoutLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Earnout Liability</link:label>
    <link:label id="lab_snti_ContingentEarnoutLiabilityMember_label_en-US" xlink:label="lab_snti_ContingentEarnoutLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Earnout Liability [Member]</link:label>
    <link:label id="lab_snti_ContingentEarnoutLiabilityMember_documentation_en-US" xlink:label="lab_snti_ContingentEarnoutLiabilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Earnout Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentEarnoutLiabilityMember" xlink:href="snti-20230331.xsd#snti_ContingentEarnoutLiabilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ContingentEarnoutLiabilityMember" xlink:to="lab_snti_ContingentEarnoutLiabilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_296b00a0-beba-420d-8814-f3b0539c4895_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Current Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger_33a469a6-983d-4a55-8e8a-a847383cd426_terseLabel_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Closing stock price to trigger contingent earnout shares (in dollars per share)</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger_label_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Stock Price Trigger</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger_documentation_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Stock Price Trigger</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" xlink:to="lab_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_86f0c440-aee9-4664-b4dc-16b0279503f1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate (in percent)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_4d57d15e-b422-40bb-81ee-0c2a55d8e0ff_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities, preferred stock and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_63908e47-a8a1-4d03-b618-5c47321bd4fb_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_74e8dbe9-3de9-4573-8dc4-f0f41cad4462_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Cash_9bd3a9f1-8702-4eb0-a50d-431e26687b5b_terseLabel_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_Cash_label_en-US" xlink:label="lab_us-gaap_Cash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Cash" xlink:to="lab_us-gaap_Cash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_7b1a77e2-886b-4979-9fbd-49a26c07f5e1_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_46934427-09c0-46e5-b72a-3bdbd46a2127_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_233ea2ed-cd87-43a5-9e23-bd1017d81419_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_0528475a-ef56-4161-9bb7-e964b6d856f3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0e872f7a-9fec-450f-aba8-3d5b19d1d1e1_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share, diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_41509dc2-0a1b-4c66-9bd1-4972b5fff676_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net loss per share attributable to common stockholders, diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_d1f4e53b-5429-4947-9a61-9cadc3031044_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_7814f201-446a-4df9-88b6-bf8a2e24eff4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_b1270d6e-f3dc-4cfb-bfc0-0ddf012c542f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss on write-off of fixed assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_2b9616fb-903a-4672-9231-e7c41cd30e68_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm_b180e1c7-961f-445b-84a8-ad7b2ee513e7_terseLabel_en-US" xlink:label="lab_snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expenses incurred from transaction, payment term (in years)</link:label>
    <link:label id="lab_snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm_label_en-US" xlink:label="lab_snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party, Payment Term</link:label>
    <link:label id="lab_snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm_documentation_en-US" xlink:label="lab_snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party Transaction, Expenses from Transactions with Related Party, Payment Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm" xlink:href="snti-20230331.xsd#snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm" xlink:to="lab_snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_6471fd50-cbbb-47c3-848e-9dc232fd81fa_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_e14f8087-1fa5-41a2-8ce8-2ae5184f098b_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_BayerMember_0b41b7be-508f-48e8-90df-23dd5c142876_terseLabel_en-US" xlink:label="lab_snti_BayerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer</link:label>
    <link:label id="lab_snti_BayerMember_label_en-US" xlink:label="lab_snti_BayerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer [Member]</link:label>
    <link:label id="lab_snti_BayerMember_documentation_en-US" xlink:label="lab_snti_BayerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bayer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_BayerMember" xlink:href="snti-20230331.xsd#snti_BayerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_BayerMember" xlink:to="lab_snti_BayerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_79b2a60f-efb8-4ed8-8726-390f5ebd6973_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_a6604391-9b82-4c68-9add-fbb2b65021fc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_NumberOfBusinessActivities_f230636e-0d9c-4417-b25f-63440c307cd2_terseLabel_en-US" xlink:label="lab_snti_NumberOfBusinessActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business activities</link:label>
    <link:label id="lab_snti_NumberOfBusinessActivities_label_en-US" xlink:label="lab_snti_NumberOfBusinessActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Business Activities</link:label>
    <link:label id="lab_snti_NumberOfBusinessActivities_documentation_en-US" xlink:label="lab_snti_NumberOfBusinessActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Business Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_NumberOfBusinessActivities" xlink:href="snti-20230331.xsd#snti_NumberOfBusinessActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_NumberOfBusinessActivities" xlink:to="lab_snti_NumberOfBusinessActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_5b6600bc-fb2b-42d1-a4ef-d3daee4d1cc0_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold_8712b202-c5ef-4903-844f-fb3bf891306a_terseLabel_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price of an ISO granted to a stockholder (in percent)</link:label>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold_label_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Stockholder Ownership Percentage, Threshold</link:label>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold_documentation_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Stockholder Ownership Percentage, Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold" xlink:to="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityExTransitionPeriod_1f291fb5-7529-41c6-83d8-5547f7b702a8_terseLabel_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:label id="lab_dei_EntityExTransitionPeriod_label_en-US" xlink:label="lab_dei_EntityExTransitionPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Ex Transition Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityExTransitionPeriod" xlink:to="lab_dei_EntityExTransitionPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_bf0efa03-6f8c-4b04-b5d3-4b9e56564f0f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration received in collaborative development agreement</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_82ae5cc7-393b-49a2-b165-bb656d4d9763_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_9dcc8417-a86a-4ba0-b390-cc1e3c2ac2e1_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_35bff226-801f-4d3f-8a4a-f3239d38d109_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9ef552bb-6885-43a7-a7d9-dd562fefed55_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_ff31cd12-e90b-411a-92a4-c5cf36aadd96_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetGross_155c6cb6-6028-4527-9c60-a58447a8e1f7_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract asset</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetGross_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetGross" xlink:to="lab_us-gaap_ContractWithCustomerAssetGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_44873e7c-1f1e-4bab-9e8a-7d652ef84b65_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment [Table]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentTable_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_TenantImprovementAllowance_20ad7865-a69f-4812-909d-8e9e4068c444_terseLabel_en-US" xlink:label="lab_snti_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance</link:label>
    <link:label id="lab_snti_TenantImprovementAllowance_label_en-US" xlink:label="lab_snti_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance</link:label>
    <link:label id="lab_snti_TenantImprovementAllowance_documentation_en-US" xlink:label="lab_snti_TenantImprovementAllowance" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_TenantImprovementAllowance" xlink:href="snti-20230331.xsd#snti_TenantImprovementAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_TenantImprovementAllowance" xlink:to="lab_snti_TenantImprovementAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_cec377f8-aced-45b8-a683-622b12bea3fe_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_e9ac1297-f413-4867-9c4b-dee0f62ee8dd_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_TenantImprovementReimbursements_40578345-01ba-481e-bbf0-b41e18fda508_terseLabel_en-US" xlink:label="lab_snti_TenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant improvement allowance received</link:label>
    <link:label id="lab_snti_TenantImprovementReimbursements_label_en-US" xlink:label="lab_snti_TenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Reimbursements</link:label>
    <link:label id="lab_snti_TenantImprovementReimbursements_documentation_en-US" xlink:label="lab_snti_TenantImprovementReimbursements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tenant Improvement Reimbursements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_TenantImprovementReimbursements" xlink:href="snti-20230331.xsd#snti_TenantImprovementReimbursements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_TenantImprovementReimbursements" xlink:to="lab_snti_TenantImprovementReimbursements" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ContingentConsiderationTranchesDomain_8f368926-4713-412e-9ba6-315350622599_terseLabel_en-US" xlink:label="lab_snti_ContingentConsiderationTranchesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Tranches [Domain]</link:label>
    <link:label id="lab_snti_ContingentConsiderationTranchesDomain_label_en-US" xlink:label="lab_snti_ContingentConsiderationTranchesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Tranches [Domain]</link:label>
    <link:label id="lab_snti_ContingentConsiderationTranchesDomain_documentation_en-US" xlink:label="lab_snti_ContingentConsiderationTranchesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Tranches [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentConsiderationTranchesDomain" xlink:href="snti-20230331.xsd#snti_ContingentConsiderationTranchesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ContingentConsiderationTranchesDomain" xlink:to="lab_snti_ContingentConsiderationTranchesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_0ce9b15e-2066-4a3a-9581-d81c9beccf15_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_481f6ae9-7953-4afb-a168-f1dbf3175151_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment [Line Items]</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentLineItems_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_7ef2d771-47a0-48f1-9e81-ea24ecdbdd29_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vested and exercisable, end of period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_SeriesAAndBRedeemableConvertiblePreferredStockMember_eb145763-2d3e-4d2b-b228-48b2f73e93c4_terseLabel_en-US" xlink:label="lab_snti_SeriesAAndBRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A and B redeemable convertible preferred stock</link:label>
    <link:label id="lab_snti_SeriesAAndBRedeemableConvertiblePreferredStockMember_label_en-US" xlink:label="lab_snti_SeriesAAndBRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A and B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_snti_SeriesAAndBRedeemableConvertiblePreferredStockMember_documentation_en-US" xlink:label="lab_snti_SeriesAAndBRedeemableConvertiblePreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Series A and B Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SeriesAAndBRedeemableConvertiblePreferredStockMember" xlink:href="snti-20230331.xsd#snti_SeriesAAndBRedeemableConvertiblePreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_SeriesAAndBRedeemableConvertiblePreferredStockMember" xlink:to="lab_snti_SeriesAAndBRedeemableConvertiblePreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_9501acc3-51cd-48b0-a668-31ef45305551_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_36bb6045-7a84-420b-976e-68aa920dbee4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Authorized for issuance under share-based payment arrangement (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches_60ca13e7-3c53-40fb-b667-766675babb28_terseLabel_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of tranches of contingent earnout shares</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches_label_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Number of Tranches</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches_documentation_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration Classified as Equity, Number of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches" xlink:to="lab_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl_b84a36eb-2cd0-477c-98fc-f266026ca394_terseLabel_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Threshold of years for change of control (in years)</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl_label_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Threshold of Years for Change of Control</link:label>
    <link:label id="lab_snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl_documentation_en-US" xlink:label="lab_snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reverse Recapitalization, Contingent Consideration, Equity, Threshold of Years for Change of Control</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl" xlink:to="lab_snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0ce5c6cc-88da-4c18-8cb0-42b4ce27f3bd_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ContractWithCustomerExtensionOfTermModificationOfContract_ea5b98ce-b0a3-402b-a622-d0bbcf0b9979_terseLabel_en-US" xlink:label="lab_snti_ContractWithCustomerExtensionOfTermModificationOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Extension of term of contract (in months)</link:label>
    <link:label id="lab_snti_ContractWithCustomerExtensionOfTermModificationOfContract_label_en-US" xlink:label="lab_snti_ContractWithCustomerExtensionOfTermModificationOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Extension Of Term, Modification Of Contract</link:label>
    <link:label id="lab_snti_ContractWithCustomerExtensionOfTermModificationOfContract_documentation_en-US" xlink:label="lab_snti_ContractWithCustomerExtensionOfTermModificationOfContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Extension Of Term, Modification Of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContractWithCustomerExtensionOfTermModificationOfContract" xlink:href="snti-20230331.xsd#snti_ContractWithCustomerExtensionOfTermModificationOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ContractWithCustomerExtensionOfTermModificationOfContract" xlink:to="lab_snti_ContractWithCustomerExtensionOfTermModificationOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_17b76a6b-34b4-4ee4-b61b-ebb9486d5df8_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_f1f6f038-edc4-48d9-98a2-f6594016be26_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_384932d2-a1e2-443b-a4ff-d096214c331f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_89f25057-338d-48d8-a5e8-a3fe5d30b540_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_2c8cf7cb-bab6-4f1b-8d83-e7acb50836b1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-Average Grant Date Fair Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_43b89b30-c2ad-4fa1-b1f5-cb43f0f9c368_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_LaboratoryEquipmentMember_3ad52d1f-36f7-4765-abbd-bef467c94216_terseLabel_en-US" xlink:label="lab_snti_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_snti_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_snti_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_snti_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_snti_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Laboratory Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_LaboratoryEquipmentMember" xlink:href="snti-20230331.xsd#snti_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_LaboratoryEquipmentMember" xlink:to="lab_snti_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_eaf0e0db-b97d-4317-93e7-e2b4be3016e6_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other accrued expenses</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_54f3ec35-1698-437a-9080-594fa1ce1ed2_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_249a8cf9-a8ba-4227-acb4-80c81d194c3c_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_2270cc72-2a43-40a7-b4d2-47f87b5f0c6e_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued professional and service fees related to facility construction</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_8102eb91-65fe-4364-b537-1cf5260774ae_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_72b347e6-c94c-46be-8c87-1551aab379e2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_48ac1c0b-2bdb-4581-884a-b010f38b1402_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_65a11450-c800-4743-bd33-b5804dc15f81_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_NEAMember_2d7fbdb0-0cab-4d08-8ff4-712f5123b8b2_terseLabel_en-US" xlink:label="lab_snti_NEAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEA</link:label>
    <link:label id="lab_snti_NEAMember_label_en-US" xlink:label="lab_snti_NEAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEA [Member]</link:label>
    <link:label id="lab_snti_NEAMember_documentation_en-US" xlink:label="lab_snti_NEAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NEA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_NEAMember" xlink:href="snti-20230331.xsd#snti_NEAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_NEAMember" xlink:to="lab_snti_NEAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_34148fb0-2c53-4d7d-b989-00307adc8f3b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares_608e818f-d507-4ed2-aae0-66142d5c54eb_terseLabel_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP purchase price of common stock, percent of market price (in percent)</link:label>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares_label_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement, By Share-Based Payment Award, Annual Increase In Shares Authorized, Percentage Of Outstanding Shares</link:label>
    <link:label id="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares_documentation_en-US" xlink:label="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement, By Share-Based Payment Award, Annual Increase In Shares Authorized, Percentage Of Outstanding Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares" xlink:to="lab_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_SaleOfStockTermOfAgreement_8d7de451-7a30-4ffa-b0fd-f8d430978c20_terseLabel_en-US" xlink:label="lab_snti_SaleOfStockTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term of agreement</link:label>
    <link:label id="lab_snti_SaleOfStockTermOfAgreement_label_en-US" xlink:label="lab_snti_SaleOfStockTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Term Of Agreement</link:label>
    <link:label id="lab_snti_SaleOfStockTermOfAgreement_documentation_en-US" xlink:label="lab_snti_SaleOfStockTermOfAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale Of Stock, Term Of Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockTermOfAgreement" xlink:href="snti-20230331.xsd#snti_SaleOfStockTermOfAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_SaleOfStockTermOfAgreement" xlink:to="lab_snti_SaleOfStockTermOfAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_8e6cb016-6ff4-4dc1-9a26-7cd3749c298e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3be30c58-ca58-474c-9349-088f8c4d14d6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_6b3dd0eb-529e-4714-8dad-e54f817b5206_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_716054f1-16e6-4125-b5e3-e3a06c052de6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_feef86b5-8d2d-4083-a4cc-2ba8cc7d4feb_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_7fefaac2-f036-46ea-a002-8cb31ab3952d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term purchase commitment amount</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Purchase Commitment, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_2d059d83-25e5-4fbf-976e-044200f8d679_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0d8949ba-61e4-4689-a1b5-c502255a6520_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ROU assets obtained in exchange for operating lease obligations (including remeasurement of ROU and lease liabilities due to changes in the timing of receipt of lease incentives)</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_b885ebc2-9d5e-4d67-8eab-6649fb96415c_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization and Description of Business</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementMember_ce257d63-4df2-44fd-9acb-592da0e1a706_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentArrangementMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentArrangementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentArrangementMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentArrangementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_5e9a8be0-584c-4004-9c99-e62642bd8891_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_snti_RevenueFromContractWithCustomerEvaluationPeriod_3473ece2-953a-4bc1-af40-e342367a9091_terseLabel_en-US" xlink:label="lab_snti_RevenueFromContractWithCustomerEvaluationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Agreement evaluation period</link:label>
    <link:label id="lab_snti_RevenueFromContractWithCustomerEvaluationPeriod_label_en-US" xlink:label="lab_snti_RevenueFromContractWithCustomerEvaluationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Evaluation Period</link:label>
    <link:label id="lab_snti_RevenueFromContractWithCustomerEvaluationPeriod_documentation_en-US" xlink:label="lab_snti_RevenueFromContractWithCustomerEvaluationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Evaluation Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueFromContractWithCustomerEvaluationPeriod" xlink:href="snti-20230331.xsd#snti_RevenueFromContractWithCustomerEvaluationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_snti_RevenueFromContractWithCustomerEvaluationPeriod" xlink:to="lab_snti_RevenueFromContractWithCustomerEvaluationPeriod" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>snti-20230331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:7af4709b-ea9b-4a83-bec7-2aee05be3f39,g:bb811bd4-927a-481b-aaf3-dcf961c572fd-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.sentibio.com/role/Cover" xlink:type="simple" xlink:href="snti-20230331.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_46bcb2be-a367-4eee-b663-88e2a8df2333" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesTable_9363bef7-7af2-478f-82d5-4ff75fdcab51" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_46bcb2be-a367-4eee-b663-88e2a8df2333" xlink:to="loc_dei_EntityAddressesTable_9363bef7-7af2-478f-82d5-4ff75fdcab51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesAddressTypeAxis_550060a9-0de8-46ad-b2af-cb8da2ed1cba" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesAddressTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_9363bef7-7af2-478f-82d5-4ff75fdcab51" xlink:to="loc_dei_EntityAddressesAddressTypeAxis_550060a9-0de8-46ad-b2af-cb8da2ed1cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AddressTypeDomain_87e5c40d-2a30-40ea-8771-474decbfa260" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AddressTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesAddressTypeAxis_550060a9-0de8-46ad-b2af-cb8da2ed1cba" xlink:to="loc_dei_AddressTypeDomain_87e5c40d-2a30-40ea-8771-474decbfa260" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_FormerAddressMember_a3166459-0f04-498b-bd67-9ac782e0341c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_FormerAddressMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_AddressTypeDomain_87e5c40d-2a30-40ea-8771-474decbfa260" xlink:to="loc_dei_FormerAddressMember_a3166459-0f04-498b-bd67-9ac782e0341c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesTable_9363bef7-7af2-478f-82d5-4ff75fdcab51" xlink:to="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_a9dbb394-8ea1-48f8-8617-c1bc56905b0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_DocumentType_a9dbb394-8ea1-48f8-8617-c1bc56905b0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_849c6a6e-539b-445d-b526-e31bdc716021" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_DocumentQuarterlyReport_849c6a6e-539b-445d-b526-e31bdc716021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_6a33192c-fdaa-4779-afa6-dce593eaced4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_DocumentPeriodEndDate_6a33192c-fdaa-4779-afa6-dce593eaced4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_e1ca7c14-4428-4e8b-8fdb-c879279f76c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_DocumentTransitionReport_e1ca7c14-4428-4e8b-8fdb-c879279f76c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_398013b9-401a-4387-b584-5f5a4cddbbf7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityFileNumber_398013b9-401a-4387-b584-5f5a4cddbbf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_f9766754-d6cb-41f3-9c3e-e81597226078" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityRegistrantName_f9766754-d6cb-41f3-9c3e-e81597226078" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f79b05ed-479a-4f75-8b61-a430a49c40a1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f79b05ed-479a-4f75-8b61-a430a49c40a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_85f363ed-515e-43b4-8a33-f5f83b9c98ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityTaxIdentificationNumber_85f363ed-515e-43b4-8a33-f5f83b9c98ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_576e0abc-b71d-4161-9753-d15515fae89d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityAddressAddressLine1_576e0abc-b71d-4161-9753-d15515fae89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_47611edc-c42b-4ba3-8b83-15cd11bbaf87" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityAddressCityOrTown_47611edc-c42b-4ba3-8b83-15cd11bbaf87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5cd799aa-f0f0-40b1-a9d5-b68054f3fec8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityAddressStateOrProvince_5cd799aa-f0f0-40b1-a9d5-b68054f3fec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_b6166a32-fe08-4068-890b-804abfaeec78" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityAddressPostalZipCode_b6166a32-fe08-4068-890b-804abfaeec78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_3bf8b5e4-0a6e-4f3d-a6ef-e340c415eed2" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_CityAreaCode_3bf8b5e4-0a6e-4f3d-a6ef-e340c415eed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_1b07d1b4-2cd3-4592-88a5-7cfd89c06846" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_LocalPhoneNumber_1b07d1b4-2cd3-4592-88a5-7cfd89c06846" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_d9a42f57-c1d8-4163-a795-cf7af3d1919b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_Security12bTitle_d9a42f57-c1d8-4163-a795-cf7af3d1919b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_2e5908df-0146-4b0b-b230-39f8683e9b94" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_TradingSymbol_2e5908df-0146-4b0b-b230-39f8683e9b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_0e02c08b-c814-46b5-810b-fbd33558d25b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_SecurityExchangeName_0e02c08b-c814-46b5-810b-fbd33558d25b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_1cb315a1-d082-4157-b90f-63452cdb359c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityCurrentReportingStatus_1cb315a1-d082-4157-b90f-63452cdb359c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_fcf02086-ad6b-42af-a2f3-d7282d7a65be" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityInteractiveDataCurrent_fcf02086-ad6b-42af-a2f3-d7282d7a65be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_b6fc4d12-4e13-43e0-a68d-5706334e0653" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityFilerCategory_b6fc4d12-4e13-43e0-a68d-5706334e0653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_f3dec25f-ec7f-4551-b4d0-cad511ef6221" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntitySmallBusiness_f3dec25f-ec7f-4551-b4d0-cad511ef6221" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_11fa3dd0-080c-4afd-a879-4c331175e3af" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityEmergingGrowthCompany_11fa3dd0-080c-4afd-a879-4c331175e3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityExTransitionPeriod_79663447-e6cf-4769-b53e-c0cbbe68d3fc" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityExTransitionPeriod_79663447-e6cf-4769-b53e-c0cbbe68d3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_63643758-c430-44a4-bae8-b75bca34686b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityShellCompany_63643758-c430-44a4-bae8-b75bca34686b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bbf9c9bc-4c9a-4b30-82c4-aa2902af181c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bbf9c9bc-4c9a-4b30-82c4-aa2902af181c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_50b70602-e9d7-474e-a8d2-6ba659991fd1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_EntityCentralIndexKey_50b70602-e9d7-474e-a8d2-6ba659991fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_b6dce8f4-a152-488c-9f54-cf17f3f84804" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_CurrentFiscalYearEndDate_b6dce8f4-a152-488c-9f54-cf17f3f84804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_260b6d98-213d-4b1d-8068-2ce8e7f4dd69" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_DocumentFiscalYearFocus_260b6d98-213d-4b1d-8068-2ce8e7f4dd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_b6bdec67-71be-419f-b559-283b3f5f272c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_DocumentFiscalPeriodFocus_b6bdec67-71be-419f-b559-283b3f5f272c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_a49812c7-bead-4446-9b1a-a211772b887d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityAddressesLineItems_cec51dfc-8672-483e-a3ad-197725520b47" xlink:to="loc_dei_AmendmentFlag_a49812c7-bead-4446-9b1a-a211772b887d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="snti-20230331.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_b004756b-cd34-4dfe-a295-9bb9954e3cf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_126af5b4-3430-450b-b01e-81bfddc1d5e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_b004756b-cd34-4dfe-a295-9bb9954e3cf6" xlink:to="loc_us-gaap_StatementTable_126af5b4-3430-450b-b01e-81bfddc1d5e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e676423e-ac24-4ec5-8945-29f2e05677d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_126af5b4-3430-450b-b01e-81bfddc1d5e2" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e676423e-ac24-4ec5-8945-29f2e05677d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_2fc7022e-c455-4afd-9ede-190efb961823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_e676423e-ac24-4ec5-8945-29f2e05677d3" xlink:to="loc_us-gaap_RelatedPartyDomain_2fc7022e-c455-4afd-9ede-190efb961823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RelatedPartyMember_61b69d55-34bb-403c-9971-b4428bd61e42" xlink:href="snti-20230331.xsd#snti_RelatedPartyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_2fc7022e-c455-4afd-9ede-190efb961823" xlink:to="loc_snti_RelatedPartyMember_61b69d55-34bb-403c-9971-b4428bd61e42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_92766994-91c4-44b2-a306-403b00588e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_126af5b4-3430-450b-b01e-81bfddc1d5e2" xlink:to="loc_us-gaap_StatementLineItems_92766994-91c4-44b2-a306-403b00588e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_92766994-91c4-44b2-a306-403b00588e6a" xlink:to="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6babcf80-f7d8-44d6-bf73-61e9be22d4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_6babcf80-f7d8-44d6-bf73-61e9be22d4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9ba3d46f-f6a6-42ac-a7e4-095e1da2a634" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9ba3d46f-f6a6-42ac-a7e4-095e1da2a634" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_e16b5bed-a2d4-478d-bc9a-4669463cb0a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_ShortTermInvestments_e16b5bed-a2d4-478d-bc9a-4669463cb0a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_62ed4d07-821f-492c-8ab5-7863c4941c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_62ed4d07-821f-492c-8ab5-7863c4941c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5516c473-838b-457b-9975-3f9f319ffe60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_AssetsCurrent_5516c473-838b-457b-9975-3f9f319ffe60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_8cd7843d-89fd-45fe-9214-4148eafcc145" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_RestrictedCash_8cd7843d-89fd-45fe-9214-4148eafcc145" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_256d698d-033a-4510-bf83-98d99347c506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_256d698d-033a-4510-bf83-98d99347c506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_af90d06d-6d27-4c0a-928d-82f6c9df1291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_af90d06d-6d27-4c0a-928d-82f6c9df1291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a6b42b06-2ad8-45a3-926b-d2d8bbb8f216" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a6b42b06-2ad8-45a3-926b-d2d8bbb8f216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_c58c78d8-169a-49c1-b741-23f3ece9fbd5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_12dcc09d-4d08-431f-8336-97b552cede2c" xlink:to="loc_us-gaap_Assets_c58c78d8-169a-49c1-b741-23f3ece9fbd5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_92766994-91c4-44b2-a306-403b00588e6a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_16c25d9a-03bd-406b-ba83-662c6f218314" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_AccountsPayableCurrent_16c25d9a-03bd-406b-ba83-662c6f218314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityCurrent_3e4250d3-a2ee-4286-a875-b24f725d85f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityCurrent_3e4250d3-a2ee-4286-a875-b24f725d85f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_EarlyExerciseLiabilityCurrent_f956a477-e651-42e9-8f1e-37b9d60f7a23" xlink:href="snti-20230331.xsd#snti_EarlyExerciseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_snti_EarlyExerciseLiabilityCurrent_f956a477-e651-42e9-8f1e-37b9d60f7a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_110535b8-f8d3-461d-bb94-a4a8b1c243f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_110535b8-f8d3-461d-bb94-a4a8b1c243f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2102028d-fcc3-4439-b3d7-fb451af20545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_2102028d-fcc3-4439-b3d7-fb451af20545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_a37a300f-4f69-4e01-b529-742057a0c6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_a37a300f-4f69-4e01-b529-742057a0c6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_07843cfa-c37e-4d28-8155-82ad541d9b13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_LiabilitiesCurrent_07843cfa-c37e-4d28-8155-82ad541d9b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1800ede4-5e16-4a5c-ad96-1635ad8bce0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_FinanceLeaseLiabilityNoncurrent_1800ede4-5e16-4a5c-ad96-1635ad8bce0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f4b141bb-a55a-48f0-b11e-ef47767d5568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_f4b141bb-a55a-48f0-b11e-ef47767d5568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_6a90d45b-1188-4adb-85a5-e33f6b2933b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_6a90d45b-1188-4adb-85a5-e33f6b2933b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_EarlyExerciseLiabilityNoncurrent_3d7e77ce-fc49-4c05-a9f2-a2a1a578e700" xlink:href="snti-20230331.xsd#snti_EarlyExerciseLiabilityNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_snti_EarlyExerciseLiabilityNoncurrent_3d7e77ce-fc49-4c05-a9f2-a2a1a578e700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_927025ba-15c7-48d5-ad45-986c86dbffdb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_Liabilities_927025ba-15c7-48d5-ad45-986c86dbffdb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_add0882c-01a4-4638-926a-fb27d5e2fa7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_add0882c-01a4-4638-926a-fb27d5e2fa7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_a39bd0bc-a0bc-4a8c-8e36-4a73f145c55a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_StockholdersEquityAbstract_a39bd0bc-a0bc-4a8c-8e36-4a73f145c55a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_2683edd9-992d-492e-b369-3f6c11ffed43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a39bd0bc-a0bc-4a8c-8e36-4a73f145c55a" xlink:to="loc_us-gaap_PreferredStockValue_2683edd9-992d-492e-b369-3f6c11ffed43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2f3f35c9-94b7-404c-9674-339013167a59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a39bd0bc-a0bc-4a8c-8e36-4a73f145c55a" xlink:to="loc_us-gaap_CommonStockValue_2f3f35c9-94b7-404c-9674-339013167a59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_63bb7e0c-1aad-4a60-a064-086cd05a28f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a39bd0bc-a0bc-4a8c-8e36-4a73f145c55a" xlink:to="loc_us-gaap_AdditionalPaidInCapital_63bb7e0c-1aad-4a60-a064-086cd05a28f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_44d9f577-d048-4add-adf9-99bb34ac2482" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a39bd0bc-a0bc-4a8c-8e36-4a73f145c55a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_44d9f577-d048-4add-adf9-99bb34ac2482" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2b694a63-58e6-4046-81b6-17cd1ed75569" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a39bd0bc-a0bc-4a8c-8e36-4a73f145c55a" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_2b694a63-58e6-4046-81b6-17cd1ed75569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_c18f4e78-b704-425a-b8f1-e4651c6fbf79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_a39bd0bc-a0bc-4a8c-8e36-4a73f145c55a" xlink:to="loc_us-gaap_StockholdersEquity_c18f4e78-b704-425a-b8f1-e4651c6fbf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_e9c630bc-9fd6-456f-b7a3-50472d732751" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4d463c2b-24af-45c0-9d35-7d2569a8da5a" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_e9c630bc-9fd6-456f-b7a3-50472d732751" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7796908a-0c23-4dda-ae5f-de8cbc3d6d1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_92766994-91c4-44b2-a306-403b00588e6a" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7796908a-0c23-4dda-ae5f-de8cbc3d6d1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_add7bc3f-a229-4b86-b14b-86aa940a58d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_92766994-91c4-44b2-a306-403b00588e6a" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_add7bc3f-a229-4b86-b14b-86aa940a58d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="snti-20230331.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_747f0af8-cf9f-40a7-92eb-ff11f69b4542" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_61e54931-3d16-4bfd-aff2-a15f63ac52ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747f0af8-cf9f-40a7-92eb-ff11f69b4542" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_61e54931-3d16-4bfd-aff2-a15f63ac52ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_0207fa27-3615-4f24-b2d3-b47d95174c7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747f0af8-cf9f-40a7-92eb-ff11f69b4542" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_0207fa27-3615-4f24-b2d3-b47d95174c7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_bccb4d0c-e584-4444-a667-e679ed764a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747f0af8-cf9f-40a7-92eb-ff11f69b4542" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_bccb4d0c-e584-4444-a667-e679ed764a05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_f6befdfc-0030-4cdd-af0d-953aa740bb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747f0af8-cf9f-40a7-92eb-ff11f69b4542" xlink:to="loc_us-gaap_PreferredStockSharesIssued_f6befdfc-0030-4cdd-af0d-953aa740bb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d99909fb-e8cd-4047-9dc3-32d4d0bb6b09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747f0af8-cf9f-40a7-92eb-ff11f69b4542" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d99909fb-e8cd-4047-9dc3-32d4d0bb6b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_33dda851-6945-481d-b8d7-d2aa8678c2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747f0af8-cf9f-40a7-92eb-ff11f69b4542" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_33dda851-6945-481d-b8d7-d2aa8678c2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_04d288f3-cc76-4889-a9cd-debe8557d7a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747f0af8-cf9f-40a7-92eb-ff11f69b4542" xlink:to="loc_us-gaap_CommonStockSharesIssued_04d288f3-cc76-4889-a9cd-debe8557d7a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7555316a-3629-4a4a-9f95-2e8df15dcbea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_747f0af8-cf9f-40a7-92eb-ff11f69b4542" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7555316a-3629-4a4a-9f95-2e8df15dcbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="snti-20230331.xsd#CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_f09d1339-aac8-4698-a097-d9942abe78cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_8a2c631e-bf3f-4c7b-b488-3533aff64f44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f09d1339-aac8-4698-a097-d9942abe78cc" xlink:to="loc_us-gaap_RevenuesAbstract_8a2c631e-bf3f-4c7b-b488-3533aff64f44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7779b2f4-0b4d-4b87-9f06-4345161a6ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8a2c631e-bf3f-4c7b-b488-3533aff64f44" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7779b2f4-0b4d-4b87-9f06-4345161a6ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_85ed4765-d594-4387-a60a-99f95e45a454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8a2c631e-bf3f-4c7b-b488-3533aff64f44" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_85ed4765-d594-4387-a60a-99f95e45a454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e01f546f-2b71-405d-966c-048c7fc2d30e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_8a2c631e-bf3f-4c7b-b488-3533aff64f44" xlink:to="loc_us-gaap_Revenues_e01f546f-2b71-405d-966c-048c7fc2d30e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_5a879ee4-91c5-41d9-8219-20ab1cc7cb06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f09d1339-aac8-4698-a097-d9942abe78cc" xlink:to="loc_us-gaap_OperatingExpensesAbstract_5a879ee4-91c5-41d9-8219-20ab1cc7cb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_a2b80416-b11e-47e3-89a6-e19ffce14ca3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5a879ee4-91c5-41d9-8219-20ab1cc7cb06" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_a2b80416-b11e-47e3-89a6-e19ffce14ca3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_7fd4af2c-b32e-4050-a210-42d930a90676" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5a879ee4-91c5-41d9-8219-20ab1cc7cb06" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_7fd4af2c-b32e-4050-a210-42d930a90676" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_c4c06875-ca93-4c36-b513-b5aceeeb10a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_5a879ee4-91c5-41d9-8219-20ab1cc7cb06" xlink:to="loc_us-gaap_OperatingExpenses_c4c06875-ca93-4c36-b513-b5aceeeb10a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7a62cee7-c6ca-4f80-8f8c-788dafa508a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f09d1339-aac8-4698-a097-d9942abe78cc" xlink:to="loc_us-gaap_OperatingIncomeLoss_7a62cee7-c6ca-4f80-8f8c-788dafa508a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0d0e58b8-57d2-4390-83d4-b57e0e0a35f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f09d1339-aac8-4698-a097-d9942abe78cc" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0d0e58b8-57d2-4390-83d4-b57e0e0a35f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_766861b8-c2b9-4c04-8ff8-7194a92b7f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0d0e58b8-57d2-4390-83d4-b57e0e0a35f8" xlink:to="loc_us-gaap_InterestIncomeExpenseNonoperatingNet_766861b8-c2b9-4c04-8ff8-7194a92b7f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3bc78d38-1f6d-48ff-b975-4f75ac9b575a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0d0e58b8-57d2-4390-83d4-b57e0e0a35f8" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3bc78d38-1f6d-48ff-b975-4f75ac9b575a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_44ec8573-575f-4779-94d7-d79cda7ad702" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0d0e58b8-57d2-4390-83d4-b57e0e0a35f8" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_44ec8573-575f-4779-94d7-d79cda7ad702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_6a7def22-38c2-4990-9230-e5be66d298ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_0d0e58b8-57d2-4390-83d4-b57e0e0a35f8" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_6a7def22-38c2-4990-9230-e5be66d298ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d8f874c3-36e3-4d98-be2b-d023f060e461" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f09d1339-aac8-4698-a097-d9942abe78cc" xlink:to="loc_us-gaap_NetIncomeLoss_d8f874c3-36e3-4d98-be2b-d023f060e461" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b7151317-737e-48d2-96dd-dffb18db8cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f09d1339-aac8-4698-a097-d9942abe78cc" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b7151317-737e-48d2-96dd-dffb18db8cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_bcba190a-fbfa-4315-b476-e72e4e14d56a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_b7151317-737e-48d2-96dd-dffb18db8cf0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_bcba190a-fbfa-4315-b476-e72e4e14d56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_73185e2f-8824-4139-8b09-16b5614de92e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f09d1339-aac8-4698-a097-d9942abe78cc" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_73185e2f-8824-4139-8b09-16b5614de92e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_288fe2e3-40f5-4af3-8724-484fda4bfa81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f09d1339-aac8-4698-a097-d9942abe78cc" xlink:to="loc_us-gaap_EarningsPerShareDiluted_288fe2e3-40f5-4af3-8724-484fda4bfa81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c725bd6a-947f-4d16-98da-703d9bb040f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f09d1339-aac8-4698-a097-d9942abe78cc" xlink:to="loc_us-gaap_EarningsPerShareBasic_c725bd6a-947f-4d16-98da-703d9bb040f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e139a1d1-92f8-4c34-847e-7566064f016d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f09d1339-aac8-4698-a097-d9942abe78cc" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_e139a1d1-92f8-4c34-847e-7566064f016d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9fb22d95-a027-4717-b27f-a64133577917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_f09d1339-aac8-4698-a097-d9942abe78cc" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9fb22d95-a027-4717-b27f-a64133577917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="simple" xlink:href="snti-20230331.xsd#CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b11340ff-ea30-4a34-9958-5d3ef56709c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_a28b0950-6fcd-4f87-8beb-f76f99aea3b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b11340ff-ea30-4a34-9958-5d3ef56709c6" xlink:to="loc_us-gaap_StatementTable_a28b0950-6fcd-4f87-8beb-f76f99aea3b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_377b790e-6c6e-4894-8bb4-88e1690fb935" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a28b0950-6fcd-4f87-8beb-f76f99aea3b0" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_377b790e-6c6e-4894-8bb4-88e1690fb935" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_db35be62-b2eb-406c-8b95-07e0fe48b9fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_377b790e-6c6e-4894-8bb4-88e1690fb935" xlink:to="loc_us-gaap_EquityComponentDomain_db35be62-b2eb-406c-8b95-07e0fe48b9fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_219f0bf1-0b74-4cc7-9849-1a118b7b1d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_db35be62-b2eb-406c-8b95-07e0fe48b9fe" xlink:to="loc_us-gaap_CommonStockMember_219f0bf1-0b74-4cc7-9849-1a118b7b1d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_748f052e-dcda-493a-ace8-e8d8b3902917" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_db35be62-b2eb-406c-8b95-07e0fe48b9fe" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_748f052e-dcda-493a-ace8-e8d8b3902917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4f6ac6de-76db-444c-80da-ea6dda910c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_db35be62-b2eb-406c-8b95-07e0fe48b9fe" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_4f6ac6de-76db-444c-80da-ea6dda910c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_033fe758-ee5e-4712-81ac-4320395d1627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_db35be62-b2eb-406c-8b95-07e0fe48b9fe" xlink:to="loc_us-gaap_RetainedEarningsMember_033fe758-ee5e-4712-81ac-4320395d1627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_988d949c-dbb0-4e4d-b323-3fff19f5c582" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_a28b0950-6fcd-4f87-8beb-f76f99aea3b0" xlink:to="loc_us-gaap_StatementLineItems_988d949c-dbb0-4e4d-b323-3fff19f5c582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityAbstract_1bef5bf2-6844-440d-85fa-387b5233536a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_988d949c-dbb0-4e4d-b323-3fff19f5c582" xlink:to="loc_us-gaap_TemporaryEquityAbstract_1bef5bf2-6844-440d-85fa-387b5233536a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_0c914a41-9a28-437b-804e-8196a76ae1e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_1bef5bf2-6844-440d-85fa-387b5233536a" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_0c914a41-9a28-437b-804e-8196a76ae1e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6963833e-5ea7-4548-bb51-d27ff7e9a237" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_1bef5bf2-6844-440d-85fa-387b5233536a" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_6963833e-5ea7-4548-bb51-d27ff7e9a237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_a5d4c465-5fcd-4989-96e3-5451efa99e11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_1bef5bf2-6844-440d-85fa-387b5233536a" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_a5d4c465-5fcd-4989-96e3-5451efa99e11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b45536d0-4cd5-4290-b627-75b6f6b17552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityAbstract_1bef5bf2-6844-440d-85fa-387b5233536a" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_b45536d0-4cd5-4290-b627-75b6f6b17552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_988d949c-dbb0-4e4d-b323-3fff19f5c582" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_7ae04b2f-477f-4bae-85f5-c28a2763abac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_7ae04b2f-477f-4bae-85f5-c28a2763abac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_cd9c9bb7-348b-4b51-81c1-202e5c857de9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_us-gaap_StockholdersEquity_cd9c9bb7-348b-4b51-81c1-202e5c857de9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e1326fa8-4354-4ca1-86b6-3d8f9ed33135" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e1326fa8-4354-4ca1-86b6-3d8f9ed33135" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_30e5dec6-7fda-432c-97ba-fd22513467cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_30e5dec6-7fda-432c-97ba-fd22513467cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions_a97dba1b-edf5-44f1-9bf9-9366a48d8fe0" xlink:href="snti-20230331.xsd#snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions_a97dba1b-edf5-44f1-9bf9-9366a48d8fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions_574764ca-0440-4d0a-aaf2-4e54541ac934" xlink:href="snti-20230331.xsd#snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions_574764ca-0440-4d0a-aaf2-4e54541ac934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e1c50816-e7b1-4c7f-9f80-efb391fee274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_e1c50816-e7b1-4c7f-9f80-efb391fee274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_19a09848-70fe-46e3-b564-1a83a37f0db3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_19a09848-70fe-46e3-b564-1a83a37f0db3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2805bbda-594f-47a5-8b69-4f927da2db78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_us-gaap_NetIncomeLoss_2805bbda-594f-47a5-8b69-4f927da2db78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_41d0656c-09de-4714-9845-e18e3e6d985d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_41d0656c-09de-4714-9845-e18e3e6d985d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3a95faa9-e745-476f-bb5d-15512f73d500" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_048c4eac-fa1f-4f78-8663-6aafd15e8688" xlink:to="loc_us-gaap_StockholdersEquity_3a95faa9-e745-476f-bb5d-15512f73d500" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="snti-20230331.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_28edb6bc-0353-49b0-87c4-52347ec23411" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_24e1d627-0cd8-403b-9113-47eb25dc17f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28edb6bc-0353-49b0-87c4-52347ec23411" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_24e1d627-0cd8-403b-9113-47eb25dc17f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_89a3e54d-7cda-48e7-aa9f-01eb36d554aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_24e1d627-0cd8-403b-9113-47eb25dc17f7" xlink:to="loc_us-gaap_NetIncomeLoss_89a3e54d-7cda-48e7-aa9f-01eb36d554aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dd400e8-f8b2-4efd-bf14-b29b9b093bed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_24e1d627-0cd8-403b-9113-47eb25dc17f7" xlink:to="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dd400e8-f8b2-4efd-bf14-b29b9b093bed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_b0ece542-af47-4dad-bf4b-1357b817e59b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dd400e8-f8b2-4efd-bf14-b29b9b093bed" xlink:to="loc_us-gaap_Depreciation_b0ece542-af47-4dad-bf4b-1357b817e59b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4b094b4e-fe12-4d72-b8b6-47f5899b59f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dd400e8-f8b2-4efd-bf14-b29b9b093bed" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4b094b4e-fe12-4d72-b8b6-47f5899b59f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_04ab176b-c4d5-4b1c-8db1-b8e8bd65115a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dd400e8-f8b2-4efd-bf14-b29b9b093bed" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_04ab176b-c4d5-4b1c-8db1-b8e8bd65115a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_35a49a45-6089-42d4-b225-449ab0fc8650" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dd400e8-f8b2-4efd-bf14-b29b9b093bed" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_35a49a45-6089-42d4-b225-449ab0fc8650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_24da719c-8294-47d4-a633-f1c6d4d77a64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dd400e8-f8b2-4efd-bf14-b29b9b093bed" xlink:to="loc_us-gaap_ShareBasedCompensation_24da719c-8294-47d4-a633-f1c6d4d77a64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_375a363d-1208-4b97-9eaa-1818e5344f58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dd400e8-f8b2-4efd-bf14-b29b9b093bed" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_375a363d-1208-4b97-9eaa-1818e5344f58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_InterestIncomeAccruedAndNotReceived_fb82250a-b8da-403f-88d0-d767ee2b8876" xlink:href="snti-20230331.xsd#snti_InterestIncomeAccruedAndNotReceived"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_7dd400e8-f8b2-4efd-bf14-b29b9b093bed" xlink:to="loc_snti_InterestIncomeAccruedAndNotReceived_fb82250a-b8da-403f-88d0-d767ee2b8876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_e10ace96-6601-49f0-a3f3-4f93a2f53568" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingAssetsAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_24e1d627-0cd8-403b-9113-47eb25dc17f7" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_e10ace96-6601-49f0-a3f3-4f93a2f53568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4f9dee74-513e-4aa3-a194-19b90b888c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_e10ace96-6601-49f0-a3f3-4f93a2f53568" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4f9dee74-513e-4aa3-a194-19b90b888c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_15558250-5b4c-4e84-b7c0-85433ea4fcd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_e10ace96-6601-49f0-a3f3-4f93a2f53568" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_15558250-5b4c-4e84-b7c0-85433ea4fcd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_91955870-8a66-47a8-8713-b46fe17e9019" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_e10ace96-6601-49f0-a3f3-4f93a2f53568" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_91955870-8a66-47a8-8713-b46fe17e9019" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_bf106211-b3d6-47d1-9051-7c4ac586636d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_e10ace96-6601-49f0-a3f3-4f93a2f53568" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_bf106211-b3d6-47d1-9051-7c4ac586636d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_816437cc-91db-425a-9538-ce16546b2655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_e10ace96-6601-49f0-a3f3-4f93a2f53568" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_816437cc-91db-425a-9538-ce16546b2655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0da3d075-dab9-4fe9-9e09-111b1ebab6be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract_e10ace96-6601-49f0-a3f3-4f93a2f53568" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_0da3d075-dab9-4fe9-9e09-111b1ebab6be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_347b3941-3a7d-4f0c-8e29-4357c3054f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_24e1d627-0cd8-403b-9113-47eb25dc17f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_347b3941-3a7d-4f0c-8e29-4357c3054f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bf8590c6-effe-4d20-a081-07d31b79382c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28edb6bc-0353-49b0-87c4-52347ec23411" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bf8590c6-effe-4d20-a081-07d31b79382c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_3c951619-65e4-41a7-b0f7-93c5d7ba21f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireShortTermInvestments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bf8590c6-effe-4d20-a081-07d31b79382c" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_3c951619-65e4-41a7-b0f7-93c5d7ba21f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_71f403c1-b1e7-4e33-a2c3-04287f2b43b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bf8590c6-effe-4d20-a081-07d31b79382c" xlink:to="loc_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments_71f403c1-b1e7-4e33-a2c3-04287f2b43b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bbcb710b-41e0-42dd-a7df-5ab995e4d830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bf8590c6-effe-4d20-a081-07d31b79382c" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bbcb710b-41e0-42dd-a7df-5ab995e4d830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5e4a120c-987a-4ef4-8d5b-90309f758321" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_bf8590c6-effe-4d20-a081-07d31b79382c" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_5e4a120c-987a-4ef4-8d5b-90309f758321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8522eca4-0b17-4253-ba3b-7dcf9f4f95f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28edb6bc-0353-49b0-87c4-52347ec23411" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8522eca4-0b17-4253-ba3b-7dcf9f4f95f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_1213bee4-8d10-4db0-8066-4c0c0052b459" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8522eca4-0b17-4253-ba3b-7dcf9f4f95f1" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_1213bee4-8d10-4db0-8066-4c0c0052b459" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinanceLeasePrincipalPayments_90021438-d020-472f-ae96-4ca33ba8611e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinanceLeasePrincipalPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8522eca4-0b17-4253-ba3b-7dcf9f4f95f1" xlink:to="loc_us-gaap_FinanceLeasePrincipalPayments_90021438-d020-472f-ae96-4ca33ba8611e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_2c8b6641-179e-4f22-924f-ad05a29e042d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8522eca4-0b17-4253-ba3b-7dcf9f4f95f1" xlink:to="loc_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities_2c8b6641-179e-4f22-924f-ad05a29e042d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44515f93-b5bf-4495-98cf-f4175f6b0679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_8522eca4-0b17-4253-ba3b-7dcf9f4f95f1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_44515f93-b5bf-4495-98cf-f4175f6b0679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c003b147-58c7-4d9f-a14c-7ffad9ae675f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28edb6bc-0353-49b0-87c4-52347ec23411" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_c003b147-58c7-4d9f-a14c-7ffad9ae675f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d591e1b6-063d-4c1e-927f-17760e2f11a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28edb6bc-0353-49b0-87c4-52347ec23411" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d591e1b6-063d-4c1e-927f-17760e2f11a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c05c3b11-04ea-4947-9f6c-a3444f872060" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28edb6bc-0353-49b0-87c4-52347ec23411" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c05c3b11-04ea-4947-9f6c-a3444f872060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ef1d76b5-5530-4968-aa07-6a63cc1dc8b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28edb6bc-0353-49b0-87c4-52347ec23411" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ef1d76b5-5530-4968-aa07-6a63cc1dc8b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a19895ea-777d-4c98-ad68-8f701e004d0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ef1d76b5-5530-4968-aa07-6a63cc1dc8b0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_a19895ea-777d-4c98-ad68-8f701e004d0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCash_3b985daa-6634-4031-a3c9-770630ba9ab1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCash"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ef1d76b5-5530-4968-aa07-6a63cc1dc8b0" xlink:to="loc_us-gaap_RestrictedCash_3b985daa-6634-4031-a3c9-770630ba9ab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7f251b3b-dd97-4bfe-9abe-79a8a3c4819f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_ef1d76b5-5530-4968-aa07-6a63cc1dc8b0" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7f251b3b-dd97-4bfe-9abe-79a8a3c4819f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0dc2f82b-3535-4f86-bcd6-6c0706848cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_28edb6bc-0353-49b0-87c4-52347ec23411" xlink:to="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0dc2f82b-3535-4f86-bcd6-6c0706848cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_03a341c4-35ac-4585-9cd5-6f3f1b0027bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0dc2f82b-3535-4f86-bcd6-6c0706848cca" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_03a341c4-35ac-4585-9cd5-6f3f1b0027bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid_09a5a8cf-82c2-49c6-930b-3ae0a7d108dd" xlink:href="snti-20230331.xsd#snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0dc2f82b-3535-4f86-bcd6-6c0706848cca" xlink:to="loc_snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid_09a5a8cf-82c2-49c6-930b-3ae0a7d108dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions_7f70843a-1ab6-4eaf-bc4a-d410eca5f09e" xlink:href="snti-20230331.xsd#snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashInvestingAndFinancingItemsAbstract_0dc2f82b-3535-4f86-bcd6-6c0706848cca" xlink:to="loc_snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions_7f70843a-1ab6-4eaf-bc4a-d410eca5f09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OrganizationandDescriptionofBusiness" xlink:type="simple" xlink:href="snti-20230331.xsd#OrganizationandDescriptionofBusiness"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/OrganizationandDescriptionofBusiness" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4c3ea433-b056-4be7-b8e8-399e0b9aba50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_c8ddd8b8-9c65-41db-ba3c-4f6056a20f16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4c3ea433-b056-4be7-b8e8-399e0b9aba50" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_c8ddd8b8-9c65-41db-ba3c-4f6056a20f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="snti-20230331.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_fd6cedcc-986b-4c08-bd1c-d54742e0899a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_57b301ce-046d-4f44-81c1-f3a8dafbdb66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_fd6cedcc-986b-4c08-bd1c-d54742e0899a" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_57b301ce-046d-4f44-81c1-f3a8dafbdb66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="snti-20230331.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_127c3888-2dad-4619-818b-5811b322a5eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_e0c7f0e4-ca11-4243-b36f-f0bd69b567b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_127c3888-2dad-4619-818b-5811b322a5eb" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_e0c7f0e4-ca11-4243-b36f-f0bd69b567b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OtherFinancialStatementinformation" xlink:type="simple" xlink:href="snti-20230331.xsd#OtherFinancialStatementinformation"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/OtherFinancialStatementinformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ab2dbe07-9f8b-4c31-9c77-b3bb75370223" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1fb261d1-f65c-4412-b38e-b7d9fd93e53e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalFinancialInformationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_ab2dbe07-9f8b-4c31-9c77-b3bb75370223" xlink:to="loc_us-gaap_AdditionalFinancialInformationDisclosureTextBlock_1fb261d1-f65c-4412-b38e-b7d9fd93e53e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OperatingLeases" xlink:type="simple" xlink:href="snti-20230331.xsd#OperatingLeases"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/OperatingLeases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_38bb4d93-54a1-4476-853d-186f0eca8c75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_e44f7d73-9c7f-4150-813c-b32515ff2202" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_38bb4d93-54a1-4476-853d-186f0eca8c75" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_e44f7d73-9c7f-4150-813c-b32515ff2202" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockholdersEquityDeficit" xlink:type="simple" xlink:href="snti-20230331.xsd#StockholdersEquityDeficit"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/StockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e1f20f24-f9ca-4acf-a8ae-17466bc498b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_431fd8c8-ce6f-41f0-bcf6-8e672c9b5d62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e1f20f24-f9ca-4acf-a8ae-17466bc498b9" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_431fd8c8-ce6f-41f0-bcf6-8e672c9b5d62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/Revenue" xlink:type="simple" xlink:href="snti-20230331.xsd#Revenue"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/Revenue" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueFromAndNotFromContractsAbstract_54ed6a79-9179-4b5a-89c3-5d430e6a05af" xlink:href="snti-20230331.xsd#snti_RevenueFromAndNotFromContractsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueFromAndNotFromContractsTextBlock_292c2458-bf7a-49f6-88c8-b32ba27533aa" xlink:href="snti-20230331.xsd#snti_RevenueFromAndNotFromContractsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_snti_RevenueFromAndNotFromContractsAbstract_54ed6a79-9179-4b5a-89c3-5d430e6a05af" xlink:to="loc_snti_RevenueFromAndNotFromContractsTextBlock_292c2458-bf7a-49f6-88c8-b32ba27533aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="snti-20230331.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38ca738e-5700-4c95-a239-deaff63157e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e1d016d9-9f58-42df-995d-ec9482cfbf74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38ca738e-5700-4c95-a239-deaff63157e7" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_e1d016d9-9f58-42df-995d-ec9482cfbf74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/IncomeTax" xlink:type="simple" xlink:href="snti-20230331.xsd#IncomeTax"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/IncomeTax" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_02236f3e-a903-4f42-866e-b2c60d3b7869" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_02a4d7c5-cc31-48d1-9cd9-f2ce3d68a950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_02236f3e-a903-4f42-866e-b2c60d3b7869" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_02a4d7c5-cc31-48d1-9cd9-f2ce3d68a950" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/NetLossPerShare" xlink:type="simple" xlink:href="snti-20230331.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_7927da56-06ef-459f-9c49-faffd6faea5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_169ff18b-100c-4deb-9249-e54be0bce8f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_7927da56-06ef-459f-9c49-faffd6faea5a" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_169ff18b-100c-4deb-9249-e54be0bce8f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/CommitmentandContingencies" xlink:type="simple" xlink:href="snti-20230331.xsd#CommitmentandContingencies"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/CommitmentandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8acbafaa-35d4-423c-96b4-4197c22cea27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4d787c46-64de-4745-9b13-2a97a2c510a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_8acbafaa-35d4-423c-96b4-4197c22cea27" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_4d787c46-64de-4745-9b13-2a97a2c510a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/RelatedParties" xlink:type="simple" xlink:href="snti-20230331.xsd#RelatedParties"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/RelatedParties" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_c046c0f3-3f8c-4cdf-82ba-80e0554383b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5156bda7-f152-42ea-8833-7b381a5df187" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_c046c0f3-3f8c-4cdf-82ba-80e0554383b9" xlink:to="loc_us-gaap_RelatedPartyTransactionsDisclosureTextBlock_5156bda7-f152-42ea-8833-7b381a5df187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/SubsequentEvents" xlink:type="simple" xlink:href="snti-20230331.xsd#SubsequentEvents"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsAbstract_15d9c051-e47b-446a-922f-4c56a31a5e94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_9d4066a9-a1eb-4e46-a4a4-001d6cec9508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_15d9c051-e47b-446a-922f-4c56a31a5e94" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_9d4066a9-a1eb-4e46-a4a4-001d6cec9508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="snti-20230331.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_c7424a9b-dc85-407e-8474-e25aedb85000" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f323eeea-6688-4163-813d-507807446a78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7424a9b-dc85-407e-8474-e25aedb85000" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_f323eeea-6688-4163-813d-507807446a78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f9690a14-daf3-45dc-8450-776d0051e5fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7424a9b-dc85-407e-8474-e25aedb85000" xlink:to="loc_us-gaap_UseOfEstimates_f9690a14-daf3-45dc-8450-776d0051e5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_851f411f-6c15-43c7-bd6e-40e8fd2e8c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_c7424a9b-dc85-407e-8474-e25aedb85000" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_851f411f-6c15-43c7-bd6e-40e8fd2e8c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="snti-20230331.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9f87ed5f-b9bd-450f-b24a-0f022a7e2c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_36b088a1-d090-49dd-9629-da1943d96195" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9f87ed5f-b9bd-450f-b24a-0f022a7e2c02" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_36b088a1-d090-49dd-9629-da1943d96195" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_fb4fdb65-32de-41cd-88c1-e237a1d93790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9f87ed5f-b9bd-450f-b24a-0f022a7e2c02" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_fb4fdb65-32de-41cd-88c1-e237a1d93790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OtherFinancialStatementinformationTables" xlink:type="simple" xlink:href="snti-20230331.xsd#OtherFinancialStatementinformationTables"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/OtherFinancialStatementinformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d897e553-57ff-4025-9f7c-8d9630411a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_cc497b61-d14d-4049-bf25-f53e0cad04fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d897e553-57ff-4025-9f7c-8d9630411a9a" xlink:to="loc_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock_cc497b61-d14d-4049-bf25-f53e0cad04fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_8da5b5fc-26e4-4f30-995b-f62c1bfaa7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d897e553-57ff-4025-9f7c-8d9630411a9a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_8da5b5fc-26e4-4f30-995b-f62c1bfaa7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_bc759e48-50d1-4c07-9f0b-1c74fc45647b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_d897e553-57ff-4025-9f7c-8d9630411a9a" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_bc759e48-50d1-4c07-9f0b-1c74fc45647b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OperatingLeasesTables" xlink:type="simple" xlink:href="snti-20230331.xsd#OperatingLeasesTables"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/OperatingLeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6c2b02a3-8c1e-4640-a606-42451047d833" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_65ecda3f-262b-4f14-9b1f-2aed1af3738c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6c2b02a3-8c1e-4640-a606-42451047d833" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_65ecda3f-262b-4f14-9b1f-2aed1af3738c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_31666628-636b-4963-8211-ebf560991288" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6c2b02a3-8c1e-4640-a606-42451047d833" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_31666628-636b-4963-8211-ebf560991288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockholdersEquityDeficitTables" xlink:type="simple" xlink:href="snti-20230331.xsd#StockholdersEquityDeficitTables"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/StockholdersEquityDeficitTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_daa32034-f7c1-4bb6-9835-377df4dd1fe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_e3812e7f-15db-4210-a478-a67333412eed" xlink:href="snti-20230331.xsd#snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_daa32034-f7c1-4bb6-9835-377df4dd1fe6" xlink:to="loc_snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock_e3812e7f-15db-4210-a478-a67333412eed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_b4715426-7056-465d-9ae9-003aadf170e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_daa32034-f7c1-4bb6-9835-377df4dd1fe6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_b4715426-7056-465d-9ae9-003aadf170e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="snti-20230331.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f196b4f-64be-4550-a1a4-8e265f40effb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e1ee5b74-bb2d-4d98-9c76-2899a83a0c9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f196b4f-64be-4550-a1a4-8e265f40effb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_e1ee5b74-bb2d-4d98-9c76-2899a83a0c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_14b766ef-622b-4572-91fd-df7bfba5469c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f196b4f-64be-4550-a1a4-8e265f40effb" xlink:to="loc_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock_14b766ef-622b-4572-91fd-df7bfba5469c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a68e48c3-7cf5-4089-bd06-7a88819d3333" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f196b4f-64be-4550-a1a4-8e265f40effb" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_a68e48c3-7cf5-4089-bd06-7a88819d3333" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bd348366-9598-4c3f-bc8b-3509392afc8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7f196b4f-64be-4550-a1a4-8e265f40effb" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_bd348366-9598-4c3f-bc8b-3509392afc8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="snti-20230331.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_32e316b4-e105-4bec-93c3-ade6ab067892" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_436c39b9-e8eb-4394-b036-c54e403cb9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_32e316b4-e105-4bec-93c3-ade6ab067892" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_436c39b9-e8eb-4394-b036-c54e403cb9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_de4d68cc-2a39-4b41-97b2-e9fe65df4081" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_32e316b4-e105-4bec-93c3-ade6ab067892" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_de4d68cc-2a39-4b41-97b2-e9fe65df4081" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#OrganizationandDescriptionofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/OrganizationandDescriptionofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_340ec721-3e08-49df-a359-d99de7b3a522" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CashAcquiredThroughReverseRecapitalization_d9be7a25-4909-4717-ab00-a299f0bc3595" xlink:href="snti-20230331.xsd#snti_CashAcquiredThroughReverseRecapitalization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_340ec721-3e08-49df-a359-d99de7b3a522" xlink:to="loc_snti_CashAcquiredThroughReverseRecapitalization_d9be7a25-4909-4717-ab00-a299f0bc3595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab6b1120-dadd-497a-867b-f4e81d08a355" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_340ec721-3e08-49df-a359-d99de7b3a522" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_ab6b1120-dadd-497a-867b-f4e81d08a355" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_20345d2b-ab8b-4ece-8402-946c0b78e80a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_340ec721-3e08-49df-a359-d99de7b3a522" xlink:to="loc_us-gaap_NetIncomeLoss_20345d2b-ab8b-4ece-8402-946c0b78e80a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_5014f3e9-f107-4a5d-abb6-1364f5bff167" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_340ec721-3e08-49df-a359-d99de7b3a522" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestments_5014f3e9-f107-4a5d-abb6-1364f5bff167" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#SummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/SummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_ce7a8943-f43a-4520-b430-d433dbfd05b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_NumberOfBusinessActivities_11fff937-798f-4cb0-92b3-dcd6fab8df87" xlink:href="snti-20230331.xsd#snti_NumberOfBusinessActivities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce7a8943-f43a-4520-b430-d433dbfd05b9" xlink:to="loc_snti_NumberOfBusinessActivities_11fff937-798f-4cb0-92b3-dcd6fab8df87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_832e720d-e96f-41f1-8374-afe1bcb87696" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_ce7a8943-f43a-4520-b430-d433dbfd05b9" xlink:to="loc_us-gaap_NumberOfReportableSegments_832e720d-e96f-41f1-8374-afe1bcb87696" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_4c4a8050-d478-4ee9-9ab4-64c5764b5b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_720a0df2-fc5e-4ba6-bd04-a8c973d78830" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_4c4a8050-d478-4ee9-9ab4-64c5764b5b01" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_720a0df2-fc5e-4ba6-bd04-a8c973d78830" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fd85d845-98ad-4972-8f67-841c7de60c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_720a0df2-fc5e-4ba6-bd04-a8c973d78830" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fd85d845-98ad-4972-8f67-841c7de60c7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9809e512-c72a-4646-a458-4ec048537b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_fd85d845-98ad-4972-8f67-841c7de60c7a" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9809e512-c72a-4646-a458-4ec048537b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_72558759-b0e6-41d4-bc9b-33704d91924f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9809e512-c72a-4646-a458-4ec048537b8e" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_72558759-b0e6-41d4-bc9b-33704d91924f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_faca2366-0d50-4504-9dbf-072c635f51fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9809e512-c72a-4646-a458-4ec048537b8e" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_faca2366-0d50-4504-9dbf-072c635f51fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_80a87369-753e-449b-bea0-350d4827ffea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_720a0df2-fc5e-4ba6-bd04-a8c973d78830" xlink:to="loc_us-gaap_FinancialInstrumentAxis_80a87369-753e-449b-bea0-350d4827ffea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97d31ac6-83f0-44c6-b89e-8ef3dfb1d291" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_80a87369-753e-449b-bea0-350d4827ffea" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97d31ac6-83f0-44c6-b89e-8ef3dfb1d291" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_1e191920-2baa-465d-8198-8c1fcd30b5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97d31ac6-83f0-44c6-b89e-8ef3dfb1d291" xlink:to="loc_us-gaap_MoneyMarketFundsMember_1e191920-2baa-465d-8198-8c1fcd30b5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_78886e5e-8e69-4abb-bb75-bd90aa947e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97d31ac6-83f0-44c6-b89e-8ef3dfb1d291" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_78886e5e-8e69-4abb-bb75-bd90aa947e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2d97b702-027d-48af-87be-9d4d274df3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97d31ac6-83f0-44c6-b89e-8ef3dfb1d291" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_2d97b702-027d-48af-87be-9d4d274df3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_626421fc-efa7-45f9-be66-f625863bd1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97d31ac6-83f0-44c6-b89e-8ef3dfb1d291" xlink:to="loc_us-gaap_CommercialPaperMember_626421fc-efa7-45f9-be66-f625863bd1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_793b5528-f490-48cf-91e9-9c201911f1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_97d31ac6-83f0-44c6-b89e-8ef3dfb1d291" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_793b5528-f490-48cf-91e9-9c201911f1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_b6db990c-5ed4-45af-9ed4-ec616508169a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_720a0df2-fc5e-4ba6-bd04-a8c973d78830" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_b6db990c-5ed4-45af-9ed4-ec616508169a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f4aac716-f0db-4e95-ae2c-f08700c13f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_b6db990c-5ed4-45af-9ed4-ec616508169a" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f4aac716-f0db-4e95-ae2c-f08700c13f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsMember_f883afb4-177b-4bdf-9d1f-6c6d0fe9d3fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4aac716-f0db-4e95-ae2c-f08700c13f83" xlink:to="loc_us-gaap_CashAndCashEquivalentsMember_f883afb4-177b-4bdf-9d1f-6c6d0fe9d3fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RestrictedCashMember_ac0479f6-a208-489c-a43e-f42ebcda7e26" xlink:href="snti-20230331.xsd#snti_RestrictedCashMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4aac716-f0db-4e95-ae2c-f08700c13f83" xlink:to="loc_snti_RestrictedCashMember_ac0479f6-a208-489c-a43e-f42ebcda7e26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_2123fc07-dbc8-4f1c-8883-5783482bd2db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermInvestmentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f4aac716-f0db-4e95-ae2c-f08700c13f83" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_2123fc07-dbc8-4f1c-8883-5783482bd2db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_720a0df2-fc5e-4ba6-bd04-a8c973d78830" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Cash_27264aac-cf93-48d4-88d6-2ca494bbb428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Cash"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:to="loc_us-gaap_Cash_27264aac-cf93-48d4-88d6-2ca494bbb428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e2756c4-c25d-436f-850b-503bfab65bdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_8e2756c4-c25d-436f-850b-503bfab65bdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_461f6bdc-2203-42b7-94fb-228386b7e51c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_461f6bdc-2203-42b7-94fb-228386b7e51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5e0f88d3-4778-48c1-877e-ae9063b4202d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_5e0f88d3-4778-48c1-877e-ae9063b4202d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7b50b3be-2f10-4c47-84ef-b72d86953c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7b50b3be-2f10-4c47-84ef-b72d86953c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_28dc8f71-8970-49e4-9d43-71791cc9f878" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_28dc8f71-8970-49e4-9d43-71791cc9f878" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost_a76367ca-4ab4-45fd-a5ed-1163dc376bb8" xlink:href="snti-20230331.xsd#snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:to="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost_a76367ca-4ab4-45fd-a5ed-1163dc376bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue_2ceb1dfe-a6a1-4074-b656-57ee60075bd9" xlink:href="snti-20230331.xsd#snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_6d32d7df-efcf-4057-9954-e35d6398b31a" xlink:to="loc_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue_2ceb1dfe-a6a1-4074-b656-57ee60075bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails_1" xlink:type="simple" xlink:href="snti-20230331.xsd#FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails_1"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sentibio.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_b12ae057-6a32-4867-9ccb-639f5001b11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_042d809b-91c4-407a-9805-9fc6ad19be17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_b12ae057-6a32-4867-9ccb-639f5001b11c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_042d809b-91c4-407a-9805-9fc6ad19be17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ad426ef8-356f-417d-9d95-ef2501979631" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_042d809b-91c4-407a-9805-9fc6ad19be17" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ad426ef8-356f-417d-9d95-ef2501979631" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9c2af004-46c2-4414-9371-98217096ddff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_ad426ef8-356f-417d-9d95-ef2501979631" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9c2af004-46c2-4414-9371-98217096ddff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_7a60adfa-4188-4a80-ac08-f734398aa641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9c2af004-46c2-4414-9371-98217096ddff" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_7a60adfa-4188-4a80-ac08-f734398aa641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByLiabilityClassAxis_62e58912-8156-4e4c-8ab0-aa8ad11c2db8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByLiabilityClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_042d809b-91c4-407a-9805-9fc6ad19be17" xlink:to="loc_us-gaap_FairValueByLiabilityClassAxis_62e58912-8156-4e4c-8ab0-aa8ad11c2db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2a010dbb-0ca8-43f5-a233-e53ebdec8bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByLiabilityClassAxis_62e58912-8156-4e4c-8ab0-aa8ad11c2db8" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2a010dbb-0ca8-43f5-a233-e53ebdec8bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentEarnoutLiabilityMember_44fb84b2-8903-4423-b646-aca4e80779a3" xlink:href="snti-20230331.xsd#snti_ContingentEarnoutLiabilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_2a010dbb-0ca8-43f5-a233-e53ebdec8bfb" xlink:to="loc_snti_ContingentEarnoutLiabilityMember_44fb84b2-8903-4423-b646-aca4e80779a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ec940048-6cdf-4867-9fd1-7c2e7491e166" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_042d809b-91c4-407a-9805-9fc6ad19be17" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ec940048-6cdf-4867-9fd1-7c2e7491e166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_013a4177-65f6-4698-92e9-9167d7a4fcef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ec940048-6cdf-4867-9fd1-7c2e7491e166" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_013a4177-65f6-4698-92e9-9167d7a4fcef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_917adb72-856e-4a39-8422-8d8fb58bcd4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ec940048-6cdf-4867-9fd1-7c2e7491e166" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_917adb72-856e-4a39-8422-8d8fb58bcd4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a6f4a603-cc46-433a-9f63-0291bdf0e4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_ec940048-6cdf-4867-9fd1-7c2e7491e166" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_a6f4a603-cc46-433a-9f63-0291bdf0e4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e0fb1be-364d-437e-91dc-40a1ddb72c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_d9a0a786-77b3-4ec1-880e-d48e4bb2f2c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e0fb1be-364d-437e-91dc-40a1ddb72c3b" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_d9a0a786-77b3-4ec1-880e-d48e4bb2f2c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepositsAssetsCurrent_164d684f-89f3-4ade-b688-b26c25e74576" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepositsAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e0fb1be-364d-437e-91dc-40a1ddb72c3b" xlink:to="loc_us-gaap_DepositsAssetsCurrent_164d684f-89f3-4ade-b688-b26c25e74576" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_256d8522-0e13-41c1-b391-e1e2c0b5171c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e0fb1be-364d-437e-91dc-40a1ddb72c3b" xlink:to="loc_us-gaap_OtherAssetsCurrent_256d8522-0e13-41c1-b391-e1e2c0b5171c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8c0f7554-b0be-4881-a4b3-099a5cfb0f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9e0fb1be-364d-437e-91dc-40a1ddb72c3b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_8c0f7554-b0be-4881-a4b3-099a5cfb0f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12fa08f1-9b3a-44e3-8fdc-bc4ed728dd64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_250901e9-a456-4a9f-b3d9-3178ed670781" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_12fa08f1-9b3a-44e3-8fdc-bc4ed728dd64" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_250901e9-a456-4a9f-b3d9-3178ed670781" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d975c7b-4269-4b4d-a295-0283e98d6c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_250901e9-a456-4a9f-b3d9-3178ed670781" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d975c7b-4269-4b4d-a295-0283e98d6c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf659f0b-36e0-4808-85cc-b0e6a992910c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8d975c7b-4269-4b4d-a295-0283e98d6c2c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf659f0b-36e0-4808-85cc-b0e6a992910c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_LaboratoryEquipmentMember_de03a783-e402-4a35-af9a-da34b92c7417" xlink:href="snti-20230331.xsd#snti_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf659f0b-36e0-4808-85cc-b0e6a992910c" xlink:to="loc_snti_LaboratoryEquipmentMember_de03a783-e402-4a35-af9a-da34b92c7417" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_8c0300a6-9d47-449f-84fa-e47f4363f961" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf659f0b-36e0-4808-85cc-b0e6a992910c" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_8c0300a6-9d47-449f-84fa-e47f4363f961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ComputerEquipmentAndSoftwareMember_7fce1a26-9c4c-4290-85ea-1306c8f49be8" xlink:href="snti-20230331.xsd#snti_ComputerEquipmentAndSoftwareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf659f0b-36e0-4808-85cc-b0e6a992910c" xlink:to="loc_snti_ComputerEquipmentAndSoftwareMember_7fce1a26-9c4c-4290-85ea-1306c8f49be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_4b181fa5-806b-40da-9a12-7f1c86ab8a6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf659f0b-36e0-4808-85cc-b0e6a992910c" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_4b181fa5-806b-40da-9a12-7f1c86ab8a6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_2505bb38-7f8f-4ada-8272-e6cd0f406cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_cf659f0b-36e0-4808-85cc-b0e6a992910c" xlink:to="loc_us-gaap_ConstructionInProgressMember_2505bb38-7f8f-4ada-8272-e6cd0f406cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_37ab0ad2-15b7-4746-868d-b4d9a5f7fb5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_250901e9-a456-4a9f-b3d9-3178ed670781" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_37ab0ad2-15b7-4746-868d-b4d9a5f7fb5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_c03850da-d64d-4195-805d-c8e15302c2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_37ab0ad2-15b7-4746-868d-b4d9a5f7fb5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_c03850da-d64d-4195-805d-c8e15302c2fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_39a020d5-a803-417b-8883-7cbc29f52f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_37ab0ad2-15b7-4746-868d-b4d9a5f7fb5f" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_39a020d5-a803-417b-8883-7cbc29f52f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1cafe3fd-7879-4f1e-9c37-fbad6b1f2ff5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_37ab0ad2-15b7-4746-868d-b4d9a5f7fb5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1cafe3fd-7879-4f1e-9c37-fbad6b1f2ff5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OtherFinancialStatementinformationDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#OtherFinancialStatementinformationDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/OtherFinancialStatementinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b0e7a425-aa08-4f91-b46f-3e93d82a17f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_07bc2661-f53f-47df-aae7-2a71e86e984c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b0e7a425-aa08-4f91-b46f-3e93d82a17f9" xlink:to="loc_us-gaap_Depreciation_07bc2661-f53f-47df-aae7-2a71e86e984c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35f3e1a5-1242-4c76-8348-46501dcc6341" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_06e32e42-3c7b-40c0-b11e-8176dc2b9afb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35f3e1a5-1242-4c76-8348-46501dcc6341" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_06e32e42-3c7b-40c0-b11e-8176dc2b9afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7c702dc2-20fc-4fa7-8508-a18d29df8213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35f3e1a5-1242-4c76-8348-46501dcc6341" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_7c702dc2-20fc-4fa7-8508-a18d29df8213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_AccruedProfessionalFeesOtherCurrent_db76def7-7e18-4168-a8d0-fc53b0c43aef" xlink:href="snti-20230331.xsd#snti_AccruedProfessionalFeesOtherCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35f3e1a5-1242-4c76-8348-46501dcc6341" xlink:to="loc_snti_AccruedProfessionalFeesOtherCurrent_db76def7-7e18-4168-a8d0-fc53b0c43aef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_53cc52d8-8b11-451c-91c2-2e4e75860794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35f3e1a5-1242-4c76-8348-46501dcc6341" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_53cc52d8-8b11-451c-91c2-2e4e75860794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_c5cb337f-3f51-476b-a995-3e1850c1c8c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_35f3e1a5-1242-4c76-8348-46501dcc6341" xlink:to="loc_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent_c5cb337f-3f51-476b-a995-3e1850c1c8c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OperatingLeasesNarrativeDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#OperatingLeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/OperatingLeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_be32c730-cfd9-4de4-90b2-dc20ca19d84e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_f8a84339-68dd-4992-a5e0-e34ecb806959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_be32c730-cfd9-4de4-90b2-dc20ca19d84e" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_f8a84339-68dd-4992-a5e0-e34ecb806959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_25ad7bb2-0ad0-4d30-8189-802bd753e490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f8a84339-68dd-4992-a5e0-e34ecb806959" xlink:to="loc_us-gaap_LeaseContractualTermAxis_25ad7bb2-0ad0-4d30-8189-802bd753e490" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_c64cae4a-e522-4507-aa1c-754fed69abd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_25ad7bb2-0ad0-4d30-8189-802bd753e490" xlink:to="loc_us-gaap_LeaseContractualTermDomain_c64cae4a-e522-4507-aa1c-754fed69abd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CorporateHeadquartersMember_97aaac18-1219-4009-ab8d-635ade3598a2" xlink:href="snti-20230331.xsd#snti_CorporateHeadquartersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_c64cae4a-e522-4507-aa1c-754fed69abd4" xlink:to="loc_snti_CorporateHeadquartersMember_97aaac18-1219-4009-ab8d-635ade3598a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_AlamedaMember_bbe11fe6-4986-4ceb-bccb-73979dbdb8a0" xlink:href="snti-20230331.xsd#snti_AlamedaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_c64cae4a-e522-4507-aa1c-754fed69abd4" xlink:to="loc_snti_AlamedaMember_bbe11fe6-4986-4ceb-bccb-73979dbdb8a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ddf540d-6554-4d29-a4c5-5021122ac6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_f8a84339-68dd-4992-a5e0-e34ecb806959" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ddf540d-6554-4d29-a4c5-5021122ac6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4d616438-4cb1-4a34-8175-4799597c713a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ddf540d-6554-4d29-a4c5-5021122ac6b2" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_4d616438-4cb1-4a34-8175-4799597c713a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0d0e03a6-4968-4a1b-b44c-327e5d865e91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ddf540d-6554-4d29-a4c5-5021122ac6b2" xlink:to="loc_us-gaap_LesseeOperatingLeaseRenewalTerm_0d0e03a6-4968-4a1b-b44c-327e5d865e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_LesseeOperatingLeaseNumberOfRenewalOptions_0d440c4d-02c7-4e84-b500-6aae808a8770" xlink:href="snti-20230331.xsd#snti_LesseeOperatingLeaseNumberOfRenewalOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ddf540d-6554-4d29-a4c5-5021122ac6b2" xlink:to="loc_snti_LesseeOperatingLeaseNumberOfRenewalOptions_0d440c4d-02c7-4e84-b500-6aae808a8770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_TenantImprovementReimbursements_beaa7dc8-3c8d-4f78-8cd9-29a14f8345fe" xlink:href="snti-20230331.xsd#snti_TenantImprovementReimbursements"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ddf540d-6554-4d29-a4c5-5021122ac6b2" xlink:to="loc_snti_TenantImprovementReimbursements_beaa7dc8-3c8d-4f78-8cd9-29a14f8345fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_TenantImprovementAllowance_4c29e9cb-482d-4078-a883-aaf160044bf4" xlink:href="snti-20230331.xsd#snti_TenantImprovementAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ddf540d-6554-4d29-a4c5-5021122ac6b2" xlink:to="loc_snti_TenantImprovementAllowance_4c29e9cb-482d-4078-a883-aaf160044bf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_TenantImprovementAllowanceUtilized_fb68c380-95bd-45b9-873f-b403bb39a8ae" xlink:href="snti-20230331.xsd#snti_TenantImprovementAllowanceUtilized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_1ddf540d-6554-4d29-a4c5-5021122ac6b2" xlink:to="loc_snti_TenantImprovementAllowanceUtilized_fb68c380-95bd-45b9-873f-b403bb39a8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OperatingLeasesTotalLeaseCostDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#OperatingLeasesTotalLeaseCostDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/OperatingLeasesTotalLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_445906f9-8410-4d74-8e44-24559c2b78ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_5d80149e-0733-4e58-bef8-48aa0445c838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_445906f9-8410-4d74-8e44-24559c2b78ba" xlink:to="loc_us-gaap_OperatingLeaseCost_5d80149e-0733-4e58-bef8-48aa0445c838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermLeaseCost_d55e6ec9-cfa5-4c68-9526-c5ecc3aae26e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermLeaseCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_445906f9-8410-4d74-8e44-24559c2b78ba" xlink:to="loc_us-gaap_ShortTermLeaseCost_d55e6ec9-cfa5-4c68-9526-c5ecc3aae26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableLeaseCost_722d2377-9c0e-49af-88ba-6df0da6b76e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableLeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_445906f9-8410-4d74-8e44-24559c2b78ba" xlink:to="loc_us-gaap_VariableLeaseCost_722d2377-9c0e-49af-88ba-6df0da6b76e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_302be454-6a3f-4ab4-a8ca-783c1a6c0e74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_445906f9-8410-4d74-8e44-24559c2b78ba" xlink:to="loc_us-gaap_LeaseCost_302be454-6a3f-4ab4-a8ca-783c1a6c0e74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OperatingLeasesOtherInformationDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#OperatingLeasesOtherInformationDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/OperatingLeasesOtherInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_1321a6d1-7db1-4612-aea0-e509f0704e62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_OperatingLeaseProceedsPayments_d396b0bf-f5f7-4490-9502-51fb5a95cb00" xlink:href="snti-20230331.xsd#snti_OperatingLeaseProceedsPayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1321a6d1-7db1-4612-aea0-e509f0704e62" xlink:to="loc_snti_OperatingLeaseProceedsPayments_d396b0bf-f5f7-4490-9502-51fb5a95cb00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_aa08f733-7fed-494f-9326-6c53d1efa39e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1321a6d1-7db1-4612-aea0-e509f0704e62" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_aa08f733-7fed-494f-9326-6c53d1efa39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_64ef8f4b-e5cc-433a-a85a-12d13723424f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1321a6d1-7db1-4612-aea0-e509f0704e62" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_64ef8f4b-e5cc-433a-a85a-12d13723424f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_51cc8155-9ddc-468e-a1de-f23de15fd87e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_1321a6d1-7db1-4612-aea0-e509f0704e62" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_51cc8155-9ddc-468e-a1de-f23de15fd87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a3cce64d-f4bb-4544-b20b-d6186ba99aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_26283f9c-c50b-486e-9d82-e731f9b228b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a3cce64d-f4bb-4544-b20b-d6186ba99aa7" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_26283f9c-c50b-486e-9d82-e731f9b228b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f7f22143-394d-4cdd-9d44-b8eb6aeb2a16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_26283f9c-c50b-486e-9d82-e731f9b228b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_f7f22143-394d-4cdd-9d44-b8eb6aeb2a16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_428d7f73-604d-4f36-a8e3-4af2e8a18535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_26283f9c-c50b-486e-9d82-e731f9b228b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_428d7f73-604d-4f36-a8e3-4af2e8a18535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ebf0aaf0-b94b-4a8f-9c93-e66999ceee34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_26283f9c-c50b-486e-9d82-e731f9b228b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_ebf0aaf0-b94b-4a8f-9c93-e66999ceee34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f754a839-bda8-4888-a2fc-869877d7252e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_26283f9c-c50b-486e-9d82-e731f9b228b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_f754a839-bda8-4888-a2fc-869877d7252e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1c523a57-0474-45e3-99a6-badba8edc62e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_26283f9c-c50b-486e-9d82-e731f9b228b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_1c523a57-0474-45e3-99a6-badba8edc62e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_dea64c4c-f6c3-4d02-8f60-90c13e3834ce" xlink:href="snti-20230331.xsd#snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_26283f9c-c50b-486e-9d82-e731f9b228b8" xlink:to="loc_snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour_dea64c4c-f6c3-4d02-8f60-90c13e3834ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c76d6059-21dc-4c1c-bd65-4d278c3331e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_26283f9c-c50b-486e-9d82-e731f9b228b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_c76d6059-21dc-4c1c-bd65-4d278c3331e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_befe781e-2500-4b9a-b0aa-86e4a487c065" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_26283f9c-c50b-486e-9d82-e731f9b228b8" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_befe781e-2500-4b9a-b0aa-86e4a487c065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_TenantImprovementAllowanceRemainingAmount_2a7247b8-9b1c-4b16-8ae3-b0d8d83fe9f7" xlink:href="snti-20230331.xsd#snti_TenantImprovementAllowanceRemainingAmount"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_26283f9c-c50b-486e-9d82-e731f9b228b8" xlink:to="loc_snti_TenantImprovementAllowanceRemainingAmount_2a7247b8-9b1c-4b16-8ae3-b0d8d83fe9f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_714ec18e-0a21-4ae5-99cf-4763047c3ace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_26283f9c-c50b-486e-9d82-e731f9b228b8" xlink:to="loc_us-gaap_OperatingLeaseLiability_714ec18e-0a21-4ae5-99cf-4763047c3ace" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockholdersEquityDeficitCommonandPreferredStockDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockholdersEquityDeficitCommonandPreferredStockDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/StockholdersEquityDeficitCommonandPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_25490bf7-81ec-4ff0-89a4-ffc43fef494d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_NumberOfVotesPerCommonShare_8bbe1a73-ab46-476c-a27a-22693b642b35" xlink:href="snti-20230331.xsd#snti_NumberOfVotesPerCommonShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_25490bf7-81ec-4ff0-89a4-ffc43fef494d" xlink:to="loc_snti_NumberOfVotesPerCommonShare_8bbe1a73-ab46-476c-a27a-22693b642b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_01785864-9718-49d7-9617-8cda2493d5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_25490bf7-81ec-4ff0-89a4-ffc43fef494d" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_01785864-9718-49d7-9617-8cda2493d5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_f6465a68-2fc4-4b04-b0b0-0c5ab8b030a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_25490bf7-81ec-4ff0-89a4-ffc43fef494d" xlink:to="loc_us-gaap_DividendsCommonStockCash_f6465a68-2fc4-4b04-b0b0-0c5ab8b030a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_57340317-41d0-4db7-9d18-f0d21b0a0293" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_25490bf7-81ec-4ff0-89a4-ffc43fef494d" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_57340317-41d0-4db7-9d18-f0d21b0a0293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_fbd7e0b9-cc27-4aa7-b04f-4a65bcf9da49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_25490bf7-81ec-4ff0-89a4-ffc43fef494d" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_fbd7e0b9-cc27-4aa7-b04f-4a65bcf9da49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_17fe5c62-9c38-4fbf-a0cf-f4a01a1b5f48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_25490bf7-81ec-4ff0-89a4-ffc43fef494d" xlink:to="loc_us-gaap_PreferredStockSharesIssued_17fe5c62-9c38-4fbf-a0cf-f4a01a1b5f48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_965875f9-5409-4968-a50f-de53da3a985d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_bc5f44e2-e06b-4b14-ad98-06b096faf93c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_965875f9-5409-4968-a50f-de53da3a985d" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_bc5f44e2-e06b-4b14-ad98-06b096faf93c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_ad555ac0-7954-4070-baf6-b0ba88a0b827" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_965875f9-5409-4968-a50f-de53da3a985d" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_ad555ac0-7954-4070-baf6-b0ba88a0b827" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_6d790f86-2314-4ec3-a267-871c7df70b23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_965875f9-5409-4968-a50f-de53da3a985d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_6d790f86-2314-4ec3-a267-871c7df70b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_a4820be2-2bc1-4534-9741-fa18fe2c5a50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6d790f86-2314-4ec3-a267-871c7df70b23" xlink:to="loc_us-gaap_AwardTypeAxis_a4820be2-2bc1-4534-9741-fa18fe2c5a50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_a4820be2-2bc1-4534-9741-fa18fe2c5a50" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CommonStockPurchaseAgreementMember_6accddc5-0b9b-46a6-883b-6341777e6e00" xlink:href="snti-20230331.xsd#snti_CommonStockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:to="loc_snti_CommonStockPurchaseAgreementMember_6accddc5-0b9b-46a6-883b-6341777e6e00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_12a595c7-bccd-4315-9911-2bed399cb8a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:to="loc_us-gaap_EmployeeStockOptionMember_12a595c7-bccd-4315-9911-2bed399cb8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_439f32cc-a367-4780-9102-319412c14186" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_439f32cc-a367-4780-9102-319412c14186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CommonStockUnderEquityPlansMember_aaf4d178-99e9-457e-b133-3dd967d38d2d" xlink:href="snti-20230331.xsd#snti_CommonStockUnderEquityPlansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:to="loc_snti_CommonStockUnderEquityPlansMember_aaf4d178-99e9-457e-b133-3dd967d38d2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_1981e231-6d8b-4b04-bd11-afd46deb0d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:to="loc_us-gaap_EmployeeStockMember_1981e231-6d8b-4b04-bd11-afd46deb0d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentEarnoutCommonStockMember_5db533c2-fcb1-4a4e-852c-af6a8fa297c2" xlink:href="snti-20230331.xsd#snti_ContingentEarnoutCommonStockMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:to="loc_snti_ContingentEarnoutCommonStockMember_5db533c2-fcb1-4a4e-852c-af6a8fa297c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_a2a89155-5234-4f41-aa18-4abf9d080d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7deb0879-309c-4f6d-8f9f-0fea293c855b" xlink:to="loc_us-gaap_StockCompensationPlanMember_a2a89155-5234-4f41-aa18-4abf9d080d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_71769f6d-ca4e-49bc-a13d-b400263f9d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_6d790f86-2314-4ec3-a267-871c7df70b23" xlink:to="loc_us-gaap_ClassOfStockLineItems_71769f6d-ca4e-49bc-a13d-b400263f9d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4259ca78-47b1-4fa0-ad29-c9b9208c5231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_71769f6d-ca4e-49bc-a13d-b400263f9d6c" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_4259ca78-47b1-4fa0-ad29-c9b9208c5231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_ae33ab3f-68fd-4e56-ba63-fc462476cef3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_59461e4b-ddaf-4690-8c4b-5a85d4d3f1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_ae33ab3f-68fd-4e56-ba63-fc462476cef3" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_59461e4b-ddaf-4690-8c4b-5a85d4d3f1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_244bcf7c-4726-4a80-95b0-2556c443ef7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_59461e4b-ddaf-4690-8c4b-5a85d4d3f1cf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_244bcf7c-4726-4a80-95b0-2556c443ef7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_2e71a651-8439-4705-8506-c06537383ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_244bcf7c-4726-4a80-95b0-2556c443ef7b" xlink:to="loc_us-gaap_EquityComponentDomain_2e71a651-8439-4705-8506-c06537383ac1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_1418300e-7a0e-44d4-a2b2-91de37e47fee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_2e71a651-8439-4705-8506-c06537383ac1" xlink:to="loc_us-gaap_CommonStockMember_1418300e-7a0e-44d4-a2b2-91de37e47fee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_93a555db-fcc2-4cd2-91f8-9b5c5868bed3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_59461e4b-ddaf-4690-8c4b-5a85d4d3f1cf" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_93a555db-fcc2-4cd2-91f8-9b5c5868bed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78d03b13-ec5f-476a-ab53-ef502d04a585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_93a555db-fcc2-4cd2-91f8-9b5c5868bed3" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78d03b13-ec5f-476a-ab53-ef502d04a585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CommonStockPurchaseAgreementMember_53959887-b01c-4d8b-aa47-2d5d99e9f625" xlink:href="snti-20230331.xsd#snti_CommonStockPurchaseAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_78d03b13-ec5f-476a-ab53-ef502d04a585" xlink:to="loc_snti_CommonStockPurchaseAgreementMember_53959887-b01c-4d8b-aa47-2d5d99e9f625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_8f66a63e-165d-4487-9d81-6b36f091459e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_59461e4b-ddaf-4690-8c4b-5a85d4d3f1cf" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_8f66a63e-165d-4487-9d81-6b36f091459e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7a0081bc-f6ae-4534-8507-0d29466dbb1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_8f66a63e-165d-4487-9d81-6b36f091459e" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7a0081bc-f6ae-4534-8507-0d29466dbb1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_54ab3e2d-53a5-4ca6-a65e-a3d7931ff585" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_7a0081bc-f6ae-4534-8507-0d29466dbb1b" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_54ab3e2d-53a5-4ca6-a65e-a3d7931ff585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_59461e4b-ddaf-4690-8c4b-5a85d4d3f1cf" xlink:to="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockMaximumAmountAuthorized_a0acfaad-b3ec-450c-b4cd-bed6b76f8ed9" xlink:href="snti-20230331.xsd#snti_SaleOfStockMaximumAmountAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockMaximumAmountAuthorized_a0acfaad-b3ec-450c-b4cd-bed6b76f8ed9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockTermOfAgreement_b96516f8-3d10-4554-aeb8-db8788f34d5b" xlink:href="snti-20230331.xsd#snti_SaleOfStockTermOfAgreement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockTermOfAgreement_b96516f8-3d10-4554-aeb8-db8788f34d5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold_34e12e6c-9a33-4fa0-ba90-868093a1368d" xlink:href="snti-20230331.xsd#snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold_34e12e6c-9a33-4fa0-ba90-868093a1368d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockSharesIssuedInTransactionThresholdPercent_8a39cd37-9f83-4996-8764-27dcffd4dff9" xlink:href="snti-20230331.xsd#snti_SaleOfStockSharesIssuedInTransactionThresholdPercent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockSharesIssuedInTransactionThresholdPercent_8a39cd37-9f83-4996-8764-27dcffd4dff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockDiscountRatePercentage_ecb860e5-bdf7-40f9-b9d9-ca152ce82654" xlink:href="snti-20230331.xsd#snti_SaleOfStockDiscountRatePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockDiscountRatePercentage_ecb860e5-bdf7-40f9-b9d9-ca152ce82654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent_85b2d6c5-0586-4fe6-850e-6a8d9b3d17cd" xlink:href="snti-20230331.xsd#snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent_85b2d6c5-0586-4fe6-850e-6a8d9b3d17cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockDailyAmountToBeSoldThreshold_000db20b-debd-4ea1-9f76-86c051df02c0" xlink:href="snti-20230331.xsd#snti_SaleOfStockDailyAmountToBeSoldThreshold"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockDailyAmountToBeSoldThreshold_000db20b-debd-4ea1-9f76-86c051df02c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6a006a4e-ba9f-4083-a5a9-86a67584c32d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_6a006a4e-ba9f-4083-a5a9-86a67584c32d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockDocumentPreparationFees_02de2f85-1129-4a94-a998-7020a1d4bc23" xlink:href="snti-20230331.xsd#snti_SaleOfStockDocumentPreparationFees"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockDocumentPreparationFees_02de2f85-1129-4a94-a998-7020a1d4bc23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SaleOfStockIssuanceCosts_3bf16d7b-2173-4bd8-8835-e4e4e5e98453" xlink:href="snti-20230331.xsd#snti_SaleOfStockIssuanceCosts"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_snti_SaleOfStockIssuanceCosts_3bf16d7b-2173-4bd8-8835-e4e4e5e98453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_29dc8f4f-529b-423b-b49e-c56527b555b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d014ccf5-8cdb-499a-a4a8-a8f9e63dc0e3" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_29dc8f4f-529b-423b-b49e-c56527b555b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockholdersEquityDeficitContingentEarnoutEquityDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_31d71eb6-781e-434a-8aa4-3b32f4bc05d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_2dc94427-b83d-4fef-9b39-e394bb9afd42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_31d71eb6-781e-434a-8aa4-3b32f4bc05d1" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_2dc94427-b83d-4fef-9b39-e394bb9afd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_2de64884-4f38-4587-bcd3-e7ee25a59f6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_2dc94427-b83d-4fef-9b39-e394bb9afd42" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_2de64884-4f38-4587-bcd3-e7ee25a59f6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_b15a8038-e29c-4295-857b-474e48a7987b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_2de64884-4f38-4587-bcd3-e7ee25a59f6f" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_b15a8038-e29c-4295-857b-474e48a7987b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentConsiderationTrancheOneMember_25f58d7b-9696-4600-b1ab-ada47ee7f51d" xlink:href="snti-20230331.xsd#snti_ContingentConsiderationTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b15a8038-e29c-4295-857b-474e48a7987b" xlink:to="loc_snti_ContingentConsiderationTrancheOneMember_25f58d7b-9696-4600-b1ab-ada47ee7f51d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentConsiderationTrancheTwoMember_f59493ee-f746-480e-89ce-a67a3fd7cef6" xlink:href="snti-20230331.xsd#snti_ContingentConsiderationTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_b15a8038-e29c-4295-857b-474e48a7987b" xlink:to="loc_snti_ContingentConsiderationTrancheTwoMember_f59493ee-f746-480e-89ce-a67a3fd7cef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentConsiderationTranchesAxis_f9c73169-c942-4c11-801c-e57a5708dc5d" xlink:href="snti-20230331.xsd#snti_ContingentConsiderationTranchesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_2dc94427-b83d-4fef-9b39-e394bb9afd42" xlink:to="loc_snti_ContingentConsiderationTranchesAxis_f9c73169-c942-4c11-801c-e57a5708dc5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentConsiderationTranchesDomain_880910e2-fd22-46dd-abbd-35d6e8c1fb34" xlink:href="snti-20230331.xsd#snti_ContingentConsiderationTranchesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_snti_ContingentConsiderationTranchesAxis_f9c73169-c942-4c11-801c-e57a5708dc5d" xlink:to="loc_snti_ContingentConsiderationTranchesDomain_880910e2-fd22-46dd-abbd-35d6e8c1fb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentConsiderationTrancheTwoMember_25f578d1-aa8a-4e5b-b54f-3bb1f58d7187" xlink:href="snti-20230331.xsd#snti_ContingentConsiderationTrancheTwoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_snti_ContingentConsiderationTranchesDomain_880910e2-fd22-46dd-abbd-35d6e8c1fb34" xlink:to="loc_snti_ContingentConsiderationTrancheTwoMember_25f578d1-aa8a-4e5b-b54f-3bb1f58d7187" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionContingentConsiderationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable_2dc94427-b83d-4fef-9b39-e394bb9afd42" xlink:to="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityShares_5ffb45bf-0627-4568-be2d-0e68b035e224" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityShares_5ffb45bf-0627-4568-be2d-0e68b035e224" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches_9c212143-2547-472d-b204-01924474d30b" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches_9c212143-2547-472d-b204-01924474d30b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche_3ddbfff7-ac7a-4bd3-97f7-5cb4c543dfe9" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche_3ddbfff7-ac7a-4bd3-97f7-5cb4c543dfe9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger_94922fcd-3515-4590-9d7e-f6a3c747b04e" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger_94922fcd-3515-4590-9d7e-f6a3c747b04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays_ab4e22cb-9568-4f36-ad54-f23b2fd373a7" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays_ab4e22cb-9568-4f36-ad54-f23b2fd373a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays_022ec613-fca8-464c-99cb-29b62ae95d0d" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays_022ec613-fca8-464c-99cb-29b62ae95d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityTerm_12642685-fe36-4bc8-aadf-59f73633e276" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityTerm"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityTerm_12642685-fe36-4bc8-aadf-59f73633e276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl_d0fc41b5-44e8-4b4c-9c9a-57796c804769" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl_d0fc41b5-44e8-4b4c-9c9a-57796c804769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationFairValue_1b549d25-0a79-45ed-a390-4dee89700803" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationFairValue"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationFairValue_1b549d25-0a79-45ed-a390-4dee89700803" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_494b5208-12ae-47a5-89a5-ee960c7193a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_494b5208-12ae-47a5-89a5-ee960c7193a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_58286a44-ff4d-420e-a972-09de85e30edd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure_58286a44-ff4d-420e-a972-09de85e30edd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c448692e-2fe4-4f91-8b51-c458c8aad784" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionContingentConsiderationLineItems_03fb7a6f-847c-4d5d-b35a-bab6686dcd60" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c448692e-2fe4-4f91-8b51-c458c8aad784" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_e7997ab6-0315-4be1-8189-af69c46cc4bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_392d36c6-8f58-482b-b0fc-971455d1c956" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_e7997ab6-0315-4be1-8189-af69c46cc4bd" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_392d36c6-8f58-482b-b0fc-971455d1c956" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_778494c7-d952-4a86-94c7-694005ebcc2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_392d36c6-8f58-482b-b0fc-971455d1c956" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_778494c7-d952-4a86-94c7-694005ebcc2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_31e6552b-c20d-4317-8f46-b55a87887621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_778494c7-d952-4a86-94c7-694005ebcc2b" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_31e6552b-c20d-4317-8f46-b55a87887621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputSharePriceMember_ec7a6e9a-4b1a-45f9-a9d8-214364e294ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputSharePriceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_31e6552b-c20d-4317-8f46-b55a87887621" xlink:to="loc_us-gaap_MeasurementInputSharePriceMember_ec7a6e9a-4b1a-45f9-a9d8-214364e294ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputPriceVolatilityMember_9633c7a7-e911-438e-b9fb-f412e5ced122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_31e6552b-c20d-4317-8f46-b55a87887621" xlink:to="loc_us-gaap_MeasurementInputPriceVolatilityMember_9633c7a7-e911-438e-b9fb-f412e5ced122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_4d019948-dfdd-4f50-ae3c-c9985219cd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_31e6552b-c20d-4317-8f46-b55a87887621" xlink:to="loc_us-gaap_MeasurementInputRiskFreeInterestRateMember_4d019948-dfdd-4f50-ae3c-c9985219cd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedDividendRateMember_2e6018b1-7df8-48be-8f80-f3bf4a9668a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedDividendRateMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_31e6552b-c20d-4317-8f46-b55a87887621" xlink:to="loc_us-gaap_MeasurementInputExpectedDividendRateMember_2e6018b1-7df8-48be-8f80-f3bf4a9668a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputExpectedTermMember_a03cc21b-b823-41a5-ae31-182a62fd43a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputExpectedTermMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_31e6552b-c20d-4317-8f46-b55a87887621" xlink:to="loc_us-gaap_MeasurementInputExpectedTermMember_a03cc21b-b823-41a5-ae31-182a62fd43a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_916adfee-b2aa-44cf-9f51-a7950e6dd3ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_392d36c6-8f58-482b-b0fc-971455d1c956" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_916adfee-b2aa-44cf-9f51-a7950e6dd3ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput_012231e0-0b38-4871-8ef8-e0b221b3f821" xlink:href="snti-20230331.xsd#snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_916adfee-b2aa-44cf-9f51-a7950e6dd3ec" xlink:to="loc_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput_012231e0-0b38-4871-8ef8-e0b221b3f821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/RevenueContractRevenueDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#RevenueContractRevenueDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/RevenueContractRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueFromAndNotFromContractsAbstract_d15cffe2-84c8-4d74-8fe4-d8785436ff2b" xlink:href="snti-20230331.xsd#snti_RevenueFromAndNotFromContractsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_snti_RevenueFromAndNotFromContractsAbstract_d15cffe2-84c8-4d74-8fe4-d8785436ff2b" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_420adc94-4284-4d29-9b37-00479e17ca60" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:to="loc_srt_CounterpartyNameAxis_420adc94-4284-4d29-9b37-00479e17ca60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a86129a-4078-4659-81a1-5e1c1dd4cff0" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_420adc94-4284-4d29-9b37-00479e17ca60" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a86129a-4078-4659-81a1-5e1c1dd4cff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SparkMember_5d8d4573-6d03-4382-9945-4d484ecdee21" xlink:href="snti-20230331.xsd#snti_SparkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4a86129a-4078-4659-81a1-5e1c1dd4cff0" xlink:to="loc_snti_SparkMember_5d8d4573-6d03-4382-9945-4d484ecdee21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_b8e08353-2ac3-4659-be59-7e9f256003ac" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:to="loc_srt_ProductOrServiceAxis_b8e08353-2ac3-4659-be59-7e9f256003ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_939f4ce2-c427-4426-9edc-7cb415ea569a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_b8e08353-2ac3-4659-be59-7e9f256003ac" xlink:to="loc_srt_ProductsAndServicesDomain_939f4ce2-c427-4426-9edc-7cb415ea569a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_57e17151-4f92-47af-aa74-aff97726358d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_939f4ce2-c427-4426-9edc-7cb415ea569a" xlink:to="loc_us-gaap_LicenseMember_57e17151-4f92-47af-aa74-aff97726358d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_fa3fbc03-0c98-4f6e-9be4-4ec0c35eba57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_fa3fbc03-0c98-4f6e-9be4-4ec0c35eba57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_010ef97e-a15b-4fcf-996a-ada8214b0269" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:to="loc_srt_RangeAxis_010ef97e-a15b-4fcf-996a-ada8214b0269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_5fc2dbd9-f1d5-4e76-becf-764bafe01689" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_010ef97e-a15b-4fcf-996a-ada8214b0269" xlink:to="loc_srt_RangeMember_5fc2dbd9-f1d5-4e76-becf-764bafe01689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_87a96347-4ef1-4571-bf3d-18985c97359e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5fc2dbd9-f1d5-4e76-becf-764bafe01689" xlink:to="loc_srt_MinimumMember_87a96347-4ef1-4571-bf3d-18985c97359e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ce1e9a06-338e-451a-ab20-f3b2fade073f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_5fc2dbd9-f1d5-4e76-becf-764bafe01689" xlink:to="loc_srt_MaximumMember_ce1e9a06-338e-451a-ab20-f3b2fade073f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_bd129cb6-0336-4cf7-a701-c06f55554c5a" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount_dce4c45d-df31-4242-8291-d79d201bc91b" xlink:href="snti-20230331.xsd#snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount_dce4c45d-df31-4242-8291-d79d201bc91b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_808b6970-c271-4441-b53a-d4f4f046c6a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_808b6970-c271-4441-b53a-d4f4f046c6a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContractWithCustomerExtensionOfTermModificationOfContract_7bc355e3-9cd2-4d04-bf44-9f077eecae80" xlink:href="snti-20230331.xsd#snti_ContractWithCustomerExtensionOfTermModificationOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_snti_ContractWithCustomerExtensionOfTermModificationOfContract_7bc355e3-9cd2-4d04-bf44-9f077eecae80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_4c6091f9-72c9-4b9b-bc64-e4c07818dc68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract_4c6091f9-72c9-4b9b-bc64-e4c07818dc68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_67c960ed-e8ca-461e-bf58-db60aebed4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_67c960ed-e8ca-461e-bf58-db60aebed4fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueFromContractWithCustomerEvaluationPeriod_c9331128-aff5-4eb1-a0cb-9a679e95367a" xlink:href="snti-20230331.xsd#snti_RevenueFromContractWithCustomerEvaluationPeriod"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_snti_RevenueFromContractWithCustomerEvaluationPeriod_c9331128-aff5-4eb1-a0cb-9a679e95367a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueFromContractWithCustomerTerminationNoticePeriod_9f95d045-ff29-4a1f-aa23-c2a718cf9b89" xlink:href="snti-20230331.xsd#snti_RevenueFromContractWithCustomerTerminationNoticePeriod"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_snti_RevenueFromContractWithCustomerTerminationNoticePeriod_9f95d045-ff29-4a1f-aa23-c2a718cf9b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1bf42a32-ab0d-48b4-b3ef-7ab3aaf3649c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_1bf42a32-ab0d-48b4-b3ef-7ab3aaf3649c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetGross_99c08911-3cc7-473f-ad55-c7f9d43c8e6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetGross"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_e064754c-5a17-490f-aa7a-5ae9befc6575" xlink:to="loc_us-gaap_ContractWithCustomerAssetGross_99c08911-3cc7-473f-ad55-c7f9d43c8e6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/RevenueContractRevenueDetails_1" xlink:type="simple" xlink:href="snti-20230331.xsd#RevenueContractRevenueDetails_1"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/RevenueContractRevenueDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.sentibio.com/role/RevenueGrantIncomeDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#RevenueGrantIncomeDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/RevenueGrantIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueFromAndNotFromContractsAbstract_6dbe78b9-38b9-4a76-adb3-9568e407a750" xlink:href="snti-20230331.xsd#snti_RevenueFromAndNotFromContractsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_7ac93314-4230-4a3f-916e-71dbe4f1ac43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_snti_RevenueFromAndNotFromContractsAbstract_6dbe78b9-38b9-4a76-adb3-9568e407a750" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_7ac93314-4230-4a3f-916e-71dbe4f1ac43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_5e0e9458-ed3f-497e-a817-b1a58648541e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7ac93314-4230-4a3f-916e-71dbe4f1ac43" xlink:to="loc_srt_ProductOrServiceAxis_5e0e9458-ed3f-497e-a817-b1a58648541e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8fbbfa22-5ccb-4459-a725-d183cb148b93" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_5e0e9458-ed3f-497e-a817-b1a58648541e" xlink:to="loc_srt_ProductsAndServicesDomain_8fbbfa22-5ccb-4459-a725-d183cb148b93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrantMember_a0db09c9-a623-4741-9199-b42f87c25fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8fbbfa22-5ccb-4459-a725-d183cb148b93" xlink:to="loc_us-gaap_GrantMember_a0db09c9-a623-4741-9199-b42f87c25fce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_f3fef2cb-2fb5-40c4-b93b-a318c8e71036" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_7ac93314-4230-4a3f-916e-71dbe4f1ac43" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_f3fef2cb-2fb5-40c4-b93b-a318c8e71036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueNotFromContractWithCustomer_a29fc542-dc20-43b1-b762-9a4c7b629ddf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f3fef2cb-2fb5-40c4-b93b-a318c8e71036" xlink:to="loc_us-gaap_RevenueNotFromContractWithCustomer_a29fc542-dc20-43b1-b762-9a4c7b629ddf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_GrantAssistancePeriodOfRecognition_e6b1aa8e-590a-4758-9d9c-60dff2be197f" xlink:href="snti-20230331.xsd#snti_GrantAssistancePeriodOfRecognition"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_f3fef2cb-2fb5-40c4-b93b-a318c8e71036" xlink:to="loc_snti_GrantAssistancePeriodOfRecognition_e6b1aa8e-590a-4758-9d9c-60dff2be197f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/RevenueEntitywideinformationDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#RevenueEntitywideinformationDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/RevenueEntitywideinformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_snti_RevenueFromAndNotFromContractsAbstract_80cb4612-d6f1-43b7-b2cb-1b34311a34e7" xlink:href="snti-20230331.xsd#snti_RevenueFromAndNotFromContractsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_90ebb344-9255-4604-a9dc-2da0e6fc6b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_snti_RevenueFromAndNotFromContractsAbstract_80cb4612-d6f1-43b7-b2cb-1b34311a34e7" xlink:to="loc_us-gaap_ConcentrationRiskTable_90ebb344-9255-4604-a9dc-2da0e6fc6b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4678e480-ec78-4194-acf5-c26eef1bb21a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_90ebb344-9255-4604-a9dc-2da0e6fc6b2f" xlink:to="loc_srt_MajorCustomersAxis_4678e480-ec78-4194-acf5-c26eef1bb21a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_a9131d49-b45a-4b86-82b0-939fdb502d78" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_4678e480-ec78-4194-acf5-c26eef1bb21a" xlink:to="loc_srt_NameOfMajorCustomerDomain_a9131d49-b45a-4b86-82b0-939fdb502d78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CustomerAMember_0b8b017a-6433-4aa3-bbf8-fcf9c04f3654" xlink:href="snti-20230331.xsd#snti_CustomerAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a9131d49-b45a-4b86-82b0-939fdb502d78" xlink:to="loc_snti_CustomerAMember_0b8b017a-6433-4aa3-bbf8-fcf9c04f3654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CustomerBMember_6012eb24-2b36-4b23-8951-03a840ac42f2" xlink:href="snti-20230331.xsd#snti_CustomerBMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_a9131d49-b45a-4b86-82b0-939fdb502d78" xlink:to="loc_snti_CustomerBMember_6012eb24-2b36-4b23-8951-03a840ac42f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb0ebeea-a7a0-435c-b465-60c9c836352a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_90ebb344-9255-4604-a9dc-2da0e6fc6b2f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb0ebeea-a7a0-435c-b465-60c9c836352a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_78751b77-1569-4ef5-907c-38b6516114e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_cb0ebeea-a7a0-435c-b465-60c9c836352a" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_78751b77-1569-4ef5-907c-38b6516114e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_c9c6a371-665d-4448-a1e6-96c412a4e60e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_78751b77-1569-4ef5-907c-38b6516114e1" xlink:to="loc_us-gaap_SalesRevenueNetMember_c9c6a371-665d-4448-a1e6-96c412a4e60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_44dd0ac2-7eee-4399-8511-7f18b26efc3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_90ebb344-9255-4604-a9dc-2da0e6fc6b2f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_44dd0ac2-7eee-4399-8511-7f18b26efc3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_72ac2b14-3b56-419d-a7d5-c6af1c7aa173" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_44dd0ac2-7eee-4399-8511-7f18b26efc3b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_72ac2b14-3b56-419d-a7d5-c6af1c7aa173" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_46298bad-9117-44da-bc89-ea8898a4c23a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_72ac2b14-3b56-419d-a7d5-c6af1c7aa173" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_46298bad-9117-44da-bc89-ea8898a4c23a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_87b6346e-3c6b-472f-a8a8-cabab65149e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_90ebb344-9255-4604-a9dc-2da0e6fc6b2f" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_87b6346e-3c6b-472f-a8a8-cabab65149e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_d6f56f56-30f9-4d5b-bcac-c3cd75c0741d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_87b6346e-3c6b-472f-a8a8-cabab65149e3" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_d6f56f56-30f9-4d5b-bcac-c3cd75c0741d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ba948ff-d5ab-4528-ba69-5fa423a32f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6561da2c-b607-48f2-a2d3-bc13ec81c2ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9ba948ff-d5ab-4528-ba69-5fa423a32f9e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6561da2c-b607-48f2-a2d3-bc13ec81c2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3b7dcf72-122a-4bf2-922b-69855d09ce0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6561da2c-b607-48f2-a2d3-bc13ec81c2ca" xlink:to="loc_us-gaap_AwardTypeAxis_3b7dcf72-122a-4bf2-922b-69855d09ce0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ed8594-09d1-4a1b-8c57-71bf2f1cd4de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3b7dcf72-122a-4bf2-922b-69855d09ce0e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ed8594-09d1-4a1b-8c57-71bf2f1cd4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_59b8e572-40f6-4900-a99f-4fa1f1ea888f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ed8594-09d1-4a1b-8c57-71bf2f1cd4de" xlink:to="loc_us-gaap_EmployeeStockOptionMember_59b8e572-40f6-4900-a99f-4fa1f1ea888f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_11e37625-8881-4b65-8299-2155c5f218d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ed8594-09d1-4a1b-8c57-71bf2f1cd4de" xlink:to="loc_us-gaap_EmployeeStockMember_11e37625-8881-4b65-8299-2155c5f218d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e1bd6e4f-7559-4e7a-b039-fba851bc0eff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ed8594-09d1-4a1b-8c57-71bf2f1cd4de" xlink:to="loc_us-gaap_PerformanceSharesMember_e1bd6e4f-7559-4e7a-b039-fba851bc0eff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_MarketAwardsMember_ca2483fc-4665-4c92-9d15-8f91e9181272" xlink:href="snti-20230331.xsd#snti_MarketAwardsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ed8594-09d1-4a1b-8c57-71bf2f1cd4de" xlink:to="loc_snti_MarketAwardsMember_ca2483fc-4665-4c92-9d15-8f91e9181272" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c65daf55-d9a4-4a4a-9b1d-3aff1cd29cc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_65ed8594-09d1-4a1b-8c57-71bf2f1cd4de" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c65daf55-d9a4-4a4a-9b1d-3aff1cd29cc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d446ff84-d3df-4734-9403-27c81a6c7f99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6561da2c-b607-48f2-a2d3-bc13ec81c2ca" xlink:to="loc_us-gaap_PlanNameAxis_d446ff84-d3df-4734-9403-27c81a6c7f99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_7385ccf7-0ad5-479b-85dd-44f1928f354e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d446ff84-d3df-4734-9403-27c81a6c7f99" xlink:to="loc_us-gaap_PlanNameDomain_7385ccf7-0ad5-479b-85dd-44f1928f354e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_A2016StockIncentivePlanMember_d86d6c6f-6568-4aa5-81d5-1f7cafa1b3ca" xlink:href="snti-20230331.xsd#snti_A2016StockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7385ccf7-0ad5-479b-85dd-44f1928f354e" xlink:to="loc_snti_A2016StockIncentivePlanMember_d86d6c6f-6568-4aa5-81d5-1f7cafa1b3ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_A2022StockIncentivePlanMember_054f251d-da61-447d-95a2-59fd38806548" xlink:href="snti-20230331.xsd#snti_A2022StockIncentivePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7385ccf7-0ad5-479b-85dd-44f1928f354e" xlink:to="loc_snti_A2022StockIncentivePlanMember_054f251d-da61-447d-95a2-59fd38806548" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_A2022InducementEquityPlanMember_326f1d5c-049e-4f4c-99a0-956a84f1cddb" xlink:href="snti-20230331.xsd#snti_A2022InducementEquityPlanMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_7385ccf7-0ad5-479b-85dd-44f1928f354e" xlink:to="loc_snti_A2022InducementEquityPlanMember_326f1d5c-049e-4f4c-99a0-956a84f1cddb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_04dccfc5-b72b-440c-bb97-8d2e8fbd1b3b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6561da2c-b607-48f2-a2d3-bc13ec81c2ca" xlink:to="loc_srt_RangeAxis_04dccfc5-b72b-440c-bb97-8d2e8fbd1b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4f52ec0b-ed21-4b69-a897-5bb8c8cc4749" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_04dccfc5-b72b-440c-bb97-8d2e8fbd1b3b" xlink:to="loc_srt_RangeMember_4f52ec0b-ed21-4b69-a897-5bb8c8cc4749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1830b76a-4671-496c-8705-4de947ead348" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4f52ec0b-ed21-4b69-a897-5bb8c8cc4749" xlink:to="loc_srt_MaximumMember_1830b76a-4671-496c-8705-4de947ead348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6561da2c-b607-48f2-a2d3-bc13ec81c2ca" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ae064d6c-4739-422d-8b20-fc37f9ca7f5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_ae064d6c-4739-422d-8b20-fc37f9ca7f5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a7097ca4-8966-49be-8d7a-694f2aacfff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a7097ca4-8966-49be-8d7a-694f2aacfff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold_f745e9a5-0222-46f6-8344-b2649a3e37a7" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold_f745e9a5-0222-46f6-8344-b2649a3e37a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue_09937a22-343e-4de4-9f8a-9e5b9adf8bad" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue_09937a22-343e-4de4-9f8a-9e5b9adf8bad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cfda676c-fa48-4e73-b097-26d62a728bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_cfda676c-fa48-4e73-b097-26d62a728bf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage_54cc60b3-3c26-4975-9361-0106d60638fd" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage_54cc60b3-3c26-4975-9361-0106d60638fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_d14a7106-5b3a-4bdd-b3bc-c37ca557ba8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_d14a7106-5b3a-4bdd-b3bc-c37ca557ba8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_8f683ca1-6bd5-4b6c-bb6c-e6bbeac71178" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod_8f683ca1-6bd5-4b6c-bb6c-e6bbeac71178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares_0904f1ff-4f30-4c9b-82cd-30f4f6c78e3a" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares_0904f1ff-4f30-4c9b-82cd-30f4f6c78e3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fdf8e415-1880-47b8-950b-742aa231b80e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fdf8e415-1880-47b8-950b-742aa231b80e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_674d0aaa-9622-4735-b680-0502eb90aced" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_674d0aaa-9622-4735-b680-0502eb90aced" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2a63640b-a128-4159-afe6-18f015ec983c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_2a63640b-a128-4159-afe6-18f015ec983c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_249e8cd4-d4a5-4914-8694-457ba2a6cf64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_249e8cd4-d4a5-4914-8694-457ba2a6cf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2f4800f4-4254-4d83-97a1-18f3d9e9c2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_2f4800f4-4254-4d83-97a1-18f3d9e9c2ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_12d2b01d-038b-48f8-b37f-6888cfc95053" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_12d2b01d-038b-48f8-b37f-6888cfc95053" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CommonStockSubjectToRepurchaseValue_39fffedd-dd3b-4e62-a478-5c0304965cc8" xlink:href="snti-20230331.xsd#snti_CommonStockSubjectToRepurchaseValue"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_snti_CommonStockSubjectToRepurchaseValue_39fffedd-dd3b-4e62-a478-5c0304965cc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9818281b-4b71-4f97-b8b2-660d809d2fd3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_9818281b-4b71-4f97-b8b2-660d809d2fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_f5465353-a799-4f7f-b1fa-473d28d240a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward_f5465353-a799-4f7f-b1fa-473d28d240a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5dea6907-ff97-45c2-ab2c-2e178793aa0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5dea6907-ff97-45c2-ab2c-2e178793aa0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches_05906b21-a1b5-4313-abb7-f24ef3baf50e" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches_05906b21-a1b5-4313-abb7-f24ef3baf50e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ae44337c-7290-4c25-8db4-be18edd14d6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b03c5b11-f5cc-46e3-8d98-ac7a737e11d6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_ae44337c-7290-4c25-8db4-be18edd14d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockBasedCompensationStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce3c2954-7372-4f7e-baeb-0b69e8c0bed4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee69f3f6-ceac-4826-a143-745486f99586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce3c2954-7372-4f7e-baeb-0b69e8c0bed4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee69f3f6-ceac-4826-a143-745486f99586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6acea0c9-29e4-4f55-bf75-0dc60207d6a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee69f3f6-ceac-4826-a143-745486f99586" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6acea0c9-29e4-4f55-bf75-0dc60207d6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0cd8dcd8-94bc-4ab4-86f2-cbcd9ed68364" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee69f3f6-ceac-4826-a143-745486f99586" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_0cd8dcd8-94bc-4ab4-86f2-cbcd9ed68364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_74181a27-ca5a-4598-bd49-341a6b3ba095" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee69f3f6-ceac-4826-a143-745486f99586" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_74181a27-ca5a-4598-bd49-341a6b3ba095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_85690f37-b099-44ff-ae0e-4040947cd7e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee69f3f6-ceac-4826-a143-745486f99586" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_85690f37-b099-44ff-ae0e-4040947cd7e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_cec596cd-802e-4bc3-8f6b-0820ed501ba5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ee69f3f6-ceac-4826-a143-745486f99586" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_cec596cd-802e-4bc3-8f6b-0820ed501ba5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e63d9503-e9d5-4697-ad57-f8b00712a641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce3c2954-7372-4f7e-baeb-0b69e8c0bed4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e63d9503-e9d5-4697-ad57-f8b00712a641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_db7838d3-ab58-438e-9f73-cec7ce30fca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e63d9503-e9d5-4697-ad57-f8b00712a641" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_db7838d3-ab58-438e-9f73-cec7ce30fca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_77ef13aa-f615-49cf-b41a-141c664cf226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e63d9503-e9d5-4697-ad57-f8b00712a641" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_77ef13aa-f615-49cf-b41a-141c664cf226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f406b823-c6a3-410d-821c-a33e110fd66e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e63d9503-e9d5-4697-ad57-f8b00712a641" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_f406b823-c6a3-410d-821c-a33e110fd66e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5b86b528-1fd4-477d-b5d8-9d46cc28664e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e63d9503-e9d5-4697-ad57-f8b00712a641" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_5b86b528-1fd4-477d-b5d8-9d46cc28664e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_75b6c55c-2ea2-49b8-a707-e18197b9b40a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e63d9503-e9d5-4697-ad57-f8b00712a641" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_75b6c55c-2ea2-49b8-a707-e18197b9b40a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1a3f0377-180b-4fba-b567-129eb16b2f57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce3c2954-7372-4f7e-baeb-0b69e8c0bed4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1a3f0377-180b-4fba-b567-129eb16b2f57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a684283d-7abc-4f3f-8cd6-7d9589f33105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1a3f0377-180b-4fba-b567-129eb16b2f57" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_a684283d-7abc-4f3f-8cd6-7d9589f33105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fcf69b41-4b8b-4ca6-bd95-f396df64a446" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1a3f0377-180b-4fba-b567-129eb16b2f57" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_fcf69b41-4b8b-4ca6-bd95-f396df64a446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5af7aec2-24d1-44c7-8ce2-f665f4fcdb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1a3f0377-180b-4fba-b567-129eb16b2f57" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_5af7aec2-24d1-44c7-8ce2-f665f4fcdb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_836694a2-7719-4d51-ab71-560a17a3a819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1a3f0377-180b-4fba-b567-129eb16b2f57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_836694a2-7719-4d51-ab71-560a17a3a819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3731ab09-a53f-4df1-aa61-17d03f634b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1a3f0377-180b-4fba-b567-129eb16b2f57" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_3731ab09-a53f-4df1-aa61-17d03f634b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1375460e-8564-4675-9590-80369f152b1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_1a3f0377-180b-4fba-b567-129eb16b2f57" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_1375460e-8564-4675-9590-80369f152b1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockBasedCompensationPerformanceAwardsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a5bbe61-b4ef-4d08-9f87-87a23f66f21e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a94192f-c9b9-4e63-beca-9ddc213f25a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8a5bbe61-b4ef-4d08-9f87-87a23f66f21e" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a94192f-c9b9-4e63-beca-9ddc213f25a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_3f19f061-74f8-4f6b-9fa9-ffa6499d418a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a94192f-c9b9-4e63-beca-9ddc213f25a3" xlink:to="loc_us-gaap_AwardTypeAxis_3f19f061-74f8-4f6b-9fa9-ffa6499d418a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c977addd-d4e6-43be-978f-f0d03400e6ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_3f19f061-74f8-4f6b-9fa9-ffa6499d418a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c977addd-d4e6-43be-978f-f0d03400e6ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_04e1a91b-5659-4bcc-ba0f-982d2d0b1493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c977addd-d4e6-43be-978f-f0d03400e6ec" xlink:to="loc_us-gaap_PerformanceSharesMember_04e1a91b-5659-4bcc-ba0f-982d2d0b1493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3705d6-b50f-4a0d-ad26-ac8c235d7a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4a94192f-c9b9-4e63-beca-9ddc213f25a3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3705d6-b50f-4a0d-ad26-ac8c235d7a48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b36c612-7e58-48d2-b8d0-e47d9b2d6554" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3705d6-b50f-4a0d-ad26-ac8c235d7a48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b36c612-7e58-48d2-b8d0-e47d9b2d6554" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ff346b1f-ebad-4320-931e-5f30430fff37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b36c612-7e58-48d2-b8d0-e47d9b2d6554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ff346b1f-ebad-4320-931e-5f30430fff37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_750eed69-34c8-4eb8-a976-47b4ad3f53bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b36c612-7e58-48d2-b8d0-e47d9b2d6554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_750eed69-34c8-4eb8-a976-47b4ad3f53bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d98ee95c-4ba0-40b4-bf34-fa6d8e0a71a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_8b36c612-7e58-48d2-b8d0-e47d9b2d6554" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d98ee95c-4ba0-40b4-bf34-fa6d8e0a71a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5bfb84f0-1b3b-407a-931c-50830291e3a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3705d6-b50f-4a0d-ad26-ac8c235d7a48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_5bfb84f0-1b3b-407a-931c-50830291e3a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43ab57ce-f66f-49f5-bfc4-238c8acd69c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3705d6-b50f-4a0d-ad26-ac8c235d7a48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43ab57ce-f66f-49f5-bfc4-238c8acd69c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ba8e6b0f-5176-41ad-af70-cd7c79b755aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43ab57ce-f66f-49f5-bfc4-238c8acd69c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_ba8e6b0f-5176-41ad-af70-cd7c79b755aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_cff152c8-8d49-4eb8-b553-e2b9e5f484e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43ab57ce-f66f-49f5-bfc4-238c8acd69c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_cff152c8-8d49-4eb8-b553-e2b9e5f484e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_21ccb024-ffcc-4f97-a1d1-f0120a7f04a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_43ab57ce-f66f-49f5-bfc4-238c8acd69c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_21ccb024-ffcc-4f97-a1d1-f0120a7f04a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_18e9c8af-c3ba-4463-a81c-de4827433724" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3705d6-b50f-4a0d-ad26-ac8c235d7a48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_18e9c8af-c3ba-4463-a81c-de4827433724" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_439fecac-cac9-4792-abb3-c77c593e4fe4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3705d6-b50f-4a0d-ad26-ac8c235d7a48" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_439fecac-cac9-4792-abb3-c77c593e4fe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm_d46ffa4d-c75b-4027-b04b-efd3066a03dc" xlink:href="snti-20230331.xsd#snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cf3705d6-b50f-4a0d-ad26-ac8c235d7a48" xlink:to="loc_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm_d46ffa4d-c75b-4027-b04b-efd3066a03dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockBasedCompensationRestrictedStockUnitsActivityDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1cb904cb-d5e9-410c-b8e8-36e9c6174532" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6a54aaa-7411-4c27-8526-1469f36e2abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1cb904cb-d5e9-410c-b8e8-36e9c6174532" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6a54aaa-7411-4c27-8526-1469f36e2abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d4162508-cd09-48b5-961d-99b9380ecd6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6a54aaa-7411-4c27-8526-1469f36e2abf" xlink:to="loc_us-gaap_AwardTypeAxis_d4162508-cd09-48b5-961d-99b9380ecd6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33bd077b-17d3-4a22-8735-7641b8e2f7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d4162508-cd09-48b5-961d-99b9380ecd6a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33bd077b-17d3-4a22-8735-7641b8e2f7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7e0b6a85-5d97-4406-b8f9-d5f724ee929d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_33bd077b-17d3-4a22-8735-7641b8e2f7e0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7e0b6a85-5d97-4406-b8f9-d5f724ee929d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba19f017-f529-4395-a2d1-c59ded414e0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d6a54aaa-7411-4c27-8526-1469f36e2abf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba19f017-f529-4395-a2d1-c59ded414e0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_308f7c0d-aab1-41ba-8057-b2d8bb1c1d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba19f017-f529-4395-a2d1-c59ded414e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_308f7c0d-aab1-41ba-8057-b2d8bb1c1d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_619fc277-95a6-4435-80b0-8371209a1780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_308f7c0d-aab1-41ba-8057-b2d8bb1c1d6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_619fc277-95a6-4435-80b0-8371209a1780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d0a4463b-cb0a-4bfd-ae05-b3e96c00ab4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_308f7c0d-aab1-41ba-8057-b2d8bb1c1d6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_d0a4463b-cb0a-4bfd-ae05-b3e96c00ab4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9dbf408c-201f-4cb1-baf1-98652bf0b9c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_308f7c0d-aab1-41ba-8057-b2d8bb1c1d6c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_9dbf408c-201f-4cb1-baf1-98652bf0b9c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_08c56d3e-cd42-46d1-bb91-0ed5245f1085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_ba19f017-f529-4395-a2d1-c59ded414e0c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_08c56d3e-cd42-46d1-bb91-0ed5245f1085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_26361674-3426-4435-8a78-101c43c657ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_08c56d3e-cd42-46d1-bb91-0ed5245f1085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_26361674-3426-4435-8a78-101c43c657ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a1606608-b9cf-404f-afe4-2aa5e1a71af3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_08c56d3e-cd42-46d1-bb91-0ed5245f1085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_a1606608-b9cf-404f-afe4-2aa5e1a71af3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4f5c17b4-73f6-4faa-81d8-c1a22dec194d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_08c56d3e-cd42-46d1-bb91-0ed5245f1085" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_4f5c17b4-73f6-4faa-81d8-c1a22dec194d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockBasedCompensationWeightedAverageAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11c3f005-56d7-4b42-a681-37e906964daa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac07ef05-b121-4818-8eed-e1aa70f9f0c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_11c3f005-56d7-4b42-a681-37e906964daa" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac07ef05-b121-4818-8eed-e1aa70f9f0c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_ba6fda6c-4b55-440b-bb06-2683b033f6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac07ef05-b121-4818-8eed-e1aa70f9f0c8" xlink:to="loc_us-gaap_AwardTypeAxis_ba6fda6c-4b55-440b-bb06-2683b033f6a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee5e3c84-ef06-4b51-a1e3-f0d77069c39e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_ba6fda6c-4b55-440b-bb06-2683b033f6a0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee5e3c84-ef06-4b51-a1e3-f0d77069c39e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8b1a69d2-eedd-4094-8777-20d7b3ea2a17" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ee5e3c84-ef06-4b51-a1e3-f0d77069c39e" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8b1a69d2-eedd-4094-8777-20d7b3ea2a17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91e74cf-b386-4158-8696-d23c3544b32e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ac07ef05-b121-4818-8eed-e1aa70f9f0c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91e74cf-b386-4158-8696-d23c3544b32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1a9d065-cbd1-4445-a84c-1523cf75f456" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91e74cf-b386-4158-8696-d23c3544b32e" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e1a9d065-cbd1-4445-a84c-1523cf75f456" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f9048478-652b-4772-bd97-eb7a6bc237c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91e74cf-b386-4158-8696-d23c3544b32e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_f9048478-652b-4772-bd97-eb7a6bc237c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2d2782fc-56c8-4c35-bb8e-a86f6c50e192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91e74cf-b386-4158-8696-d23c3544b32e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2d2782fc-56c8-4c35-bb8e-a86f6c50e192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0d76eaf9-5f01-4bf5-84a0-c8a2c1659380" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f91e74cf-b386-4158-8696-d23c3544b32e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_0d76eaf9-5f01-4bf5-84a0-c8a2c1659380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#StockBasedCompensationStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1b4a11c2-af21-451c-98fc-d79eda70147d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c1c17c43-0e87-4ed7-9420-7990e920be74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1b4a11c2-af21-451c-98fc-d79eda70147d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c1c17c43-0e87-4ed7-9420-7990e920be74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_dddf0c68-1c8d-4586-9ba3-77b20b424ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c1c17c43-0e87-4ed7-9420-7990e920be74" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_dddf0c68-1c8d-4586-9ba3-77b20b424ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_df0e998f-14a2-4b95-b7ee-f0f005254ceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_dddf0c68-1c8d-4586-9ba3-77b20b424ec9" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_df0e998f-14a2-4b95-b7ee-f0f005254ceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_25b4ec62-fc3e-4a7e-adda-9bbc2aa97919" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_df0e998f-14a2-4b95-b7ee-f0f005254ceb" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_25b4ec62-fc3e-4a7e-adda-9bbc2aa97919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1323a38b-8ed7-4bb5-a858-802a8530b2c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_df0e998f-14a2-4b95-b7ee-f0f005254ceb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1323a38b-8ed7-4bb5-a858-802a8530b2c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_eaa11d1e-c802-40bb-9aaf-88a5391c21c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c1c17c43-0e87-4ed7-9420-7990e920be74" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_eaa11d1e-c802-40bb-9aaf-88a5391c21c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_5931da29-4873-4a49-a46e-d6213f28ee00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_eaa11d1e-c802-40bb-9aaf-88a5391c21c4" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_5931da29-4873-4a49-a46e-d6213f28ee00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/IncomeTaxDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#IncomeTaxDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/IncomeTaxDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_06661117-30a7-4642-b0a0-10d1dc88bca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_1ab67f9d-538a-4e0e-8c19-2fff69e0cdd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_06661117-30a7-4642-b0a0-10d1dc88bca0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_1ab67f9d-538a-4e0e-8c19-2fff69e0cdd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/NetLossPerShareBasicandDilutedNetEarningslossPerCommonShareDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#NetLossPerShareBasicandDilutedNetEarningslossPerCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/NetLossPerShareBasicandDilutedNetEarningslossPerCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c6902e28-e603-4a50-854f-4895454ce65c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_46a439de-8d67-4edb-b36c-a72eec87aab2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c6902e28-e603-4a50-854f-4895454ce65c" xlink:to="loc_us-gaap_NetIncomeLoss_46a439de-8d67-4edb-b36c-a72eec87aab2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d9bfac29-062c-4135-ab82-890def7a98a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c6902e28-e603-4a50-854f-4895454ce65c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d9bfac29-062c-4135-ab82-890def7a98a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7382a07f-0864-41a8-a5eb-de6edf809254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c6902e28-e603-4a50-854f-4895454ce65c" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7382a07f-0864-41a8-a5eb-de6edf809254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_EarningsPerShareBasicAndDilutedEPSAbstract_15bbb50b-9fe1-481d-b014-7215d9293f0b" xlink:href="snti-20230331.xsd#snti_EarningsPerShareBasicAndDilutedEPSAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c6902e28-e603-4a50-854f-4895454ce65c" xlink:to="loc_snti_EarningsPerShareBasicAndDilutedEPSAbstract_15bbb50b-9fe1-481d-b014-7215d9293f0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_58d86822-973b-49f7-a485-6489c51e6b97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_snti_EarningsPerShareBasicAndDilutedEPSAbstract_15bbb50b-9fe1-481d-b014-7215d9293f0b" xlink:to="loc_us-gaap_EarningsPerShareDiluted_58d86822-973b-49f7-a485-6489c51e6b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ab297cfd-05f7-4be9-8274-7b259fc8d7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_snti_EarningsPerShareBasicAndDilutedEPSAbstract_15bbb50b-9fe1-481d-b014-7215d9293f0b" xlink:to="loc_us-gaap_EarningsPerShareBasic_ab297cfd-05f7-4be9-8274-7b259fc8d7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f3ef0be8-445a-4ce3-b48f-c095f68293a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0547a95d-90c7-43bf-91ae-8e580e69edbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f3ef0be8-445a-4ce3-b48f-c095f68293a4" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0547a95d-90c7-43bf-91ae-8e580e69edbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f7b2b280-32de-49ca-998b-e79d9a269495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0547a95d-90c7-43bf-91ae-8e580e69edbc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f7b2b280-32de-49ca-998b-e79d9a269495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f432273a-a7b1-4cbe-907a-896f6537d4e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_f7b2b280-32de-49ca-998b-e79d9a269495" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f432273a-a7b1-4cbe-907a-896f6537d4e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SeriesAAndBRedeemableConvertiblePreferredStockMember_756b481a-1b9a-494d-add7-a0929885da72" xlink:href="snti-20230331.xsd#snti_SeriesAAndBRedeemableConvertiblePreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f432273a-a7b1-4cbe-907a-896f6537d4e8" xlink:to="loc_snti_SeriesAAndBRedeemableConvertiblePreferredStockMember_756b481a-1b9a-494d-add7-a0929885da72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_faad3482-a444-427a-82df-93a697f2a7dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f432273a-a7b1-4cbe-907a-896f6537d4e8" xlink:to="loc_us-gaap_EmployeeStockOptionMember_faad3482-a444-427a-82df-93a697f2a7dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_UnvestedEarlyExercisedOptionsMember_516432c5-9cbe-40cc-ba8a-bfd742a25396" xlink:href="snti-20230331.xsd#snti_UnvestedEarlyExercisedOptionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f432273a-a7b1-4cbe-907a-896f6537d4e8" xlink:to="loc_snti_UnvestedEarlyExercisedOptionsMember_516432c5-9cbe-40cc-ba8a-bfd742a25396" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_c23bc963-9b5d-4f9e-ba2d-a27af138f611" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f432273a-a7b1-4cbe-907a-896f6537d4e8" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_c23bc963-9b5d-4f9e-ba2d-a27af138f611" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ContingentEarnoutCommonStockMember_99efa435-84e8-4b25-adff-9e646752c775" xlink:href="snti-20230331.xsd#snti_ContingentEarnoutCommonStockMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_f432273a-a7b1-4cbe-907a-896f6537d4e8" xlink:to="loc_snti_ContingentEarnoutCommonStockMember_99efa435-84e8-4b25-adff-9e646752c775" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05d7b2e9-3e2f-47a8-9b8d-f5725b00ab60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_0547a95d-90c7-43bf-91ae-8e580e69edbc" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05d7b2e9-3e2f-47a8-9b8d-f5725b00ab60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7bce0938-3162-44e9-abfe-28be10ee88ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_05d7b2e9-3e2f-47a8-9b8d-f5725b00ab60" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_7bce0938-3162-44e9-abfe-28be10ee88ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/CommitmentandContingenciesDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#CommitmentandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/CommitmentandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_592e9773-277f-451b-b485-88ce311081ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentTable_255cecba-e828-4590-abbb-725b755f5e43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_592e9773-277f-451b-b485-88ce311081ad" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentTable_255cecba-e828-4590-abbb-725b755f5e43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6d6a9b6c-5fcb-4889-9506-276def715b21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_255cecba-e828-4590-abbb-725b755f5e43" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6d6a9b6c-5fcb-4889-9506-276def715b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3efbc07f-7305-4b23-acf4-c49238ffbcea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_6d6a9b6c-5fcb-4889-9506-276def715b21" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3efbc07f-7305-4b23-acf4-c49238ffbcea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CGMPFacilityMember_796bd4ca-fb8a-4a10-ad1e-fafe98c0e444" xlink:href="snti-20230331.xsd#snti_CGMPFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3efbc07f-7305-4b23-acf4-c49238ffbcea" xlink:to="loc_snti_CGMPFacilityMember_796bd4ca-fb8a-4a10-ad1e-fafe98c0e444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_3609879a-0a5f-42f1-a3f1-0a14d5645fa7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_255cecba-e828-4590-abbb-725b755f5e43" xlink:to="loc_srt_CounterpartyNameAxis_3609879a-0a5f-42f1-a3f1-0a14d5645fa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3085ce9-bcb6-46c9-a974-e624cbd7905d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_3609879a-0a5f-42f1-a3f1-0a14d5645fa7" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3085ce9-bcb6-46c9-a974-e624cbd7905d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_BlueRockMember_25bddbee-fac7-4fa2-be66-ebc383501937" xlink:href="snti-20230331.xsd#snti_BlueRockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e3085ce9-bcb6-46c9-a974-e624cbd7905d" xlink:to="loc_snti_BlueRockMember_25bddbee-fac7-4fa2-be66-ebc383501937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_963e9c25-5068-4f69-9cff-3df93a542908" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_255cecba-e828-4590-abbb-725b755f5e43" xlink:to="loc_us-gaap_TypeOfArrangementAxis_963e9c25-5068-4f69-9cff-3df93a542908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02f05003-af68-45a3-a476-dfac8d739f91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_963e9c25-5068-4f69-9cff-3df93a542908" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02f05003-af68-45a3-a476-dfac8d739f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_cf274d17-c850-4076-98cf-676d93898ffd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02f05003-af68-45a3-a476-dfac8d739f91" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_cf274d17-c850-4076-98cf-676d93898ffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_734ad946-63c3-4a73-9c2e-74361d2f513c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_255cecba-e828-4590-abbb-725b755f5e43" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_734ad946-63c3-4a73-9c2e-74361d2f513c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_b9ed4ca7-04a1-46d3-9e01-8456096fcb06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis_734ad946-63c3-4a73-9c2e-74361d2f513c" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_b9ed4ca7-04a1-46d3-9e01-8456096fcb06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentArrangementMember_00c3fa9c-cb66-404a-9a47-fef3b042cc51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain_b9ed4ca7-04a1-46d3-9e01-8456096fcb06" xlink:to="loc_us-gaap_ResearchAndDevelopmentArrangementMember_00c3fa9c-cb66-404a-9a47-fef3b042cc51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentTable_255cecba-e828-4590-abbb-725b755f5e43" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0f1676a7-8b56-42d9-ae68-4f0d686e8f07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_0f1676a7-8b56-42d9-ae68-4f0d686e8f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_476e6ce4-7ae8-44de-ba04-7cad16f084a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_476e6ce4-7ae8-44de-ba04-7cad16f084a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForConstructionInProcess_5b72d5b6-a83c-4168-be1f-4f3e0d78a9e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForConstructionInProcess"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_us-gaap_PaymentsForConstructionInProcess_5b72d5b6-a83c-4168-be1f-4f3e0d78a9e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_73a15950-ac09-41ca-93a2-b4815c06c4aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermPurchaseCommitmentAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_73a15950-ac09-41ca-93a2-b4815c06c4aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ResearchAndDevelopmentExpenseTermOfAgreement_34336aa0-5dad-4ca4-9b0d-f818634d46bd" xlink:href="snti-20230331.xsd#snti_ResearchAndDevelopmentExpenseTermOfAgreement"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_snti_ResearchAndDevelopmentExpenseTermOfAgreement_34336aa0-5dad-4ca4-9b0d-f818634d46bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ResearchAndDevelopmentArrangementExpectedCosts_23a98532-f0f9-4725-ba37-83edaca48a74" xlink:href="snti-20230331.xsd#snti_ResearchAndDevelopmentArrangementExpectedCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_snti_ResearchAndDevelopmentArrangementExpectedCosts_23a98532-f0f9-4725-ba37-83edaca48a74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments_4281effd-f84d-4c36-86ee-ce13743cf36e" xlink:href="snti-20230331.xsd#snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments_4281effd-f84d-4c36-86ee-ce13743cf36e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityShares_9c718dd1-3919-4d61-abf3-1a63ad2e5261" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityShares"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityShares_9c718dd1-3919-4d61-abf3-1a63ad2e5261" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches_fbde3d70-6ac9-45b0-9f18-3cd48f57cf36" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches_fbde3d70-6ac9-45b0-9f18-3cd48f57cf36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche_51ef990e-d317-4f83-a246-e5058cce2099" xlink:href="snti-20230331.xsd#snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentLineItems_87376e77-0a8b-4050-b1b1-f2f301e543b4" xlink:to="loc_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche_51ef990e-d317-4f83-a246-e5058cce2099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.sentibio.com/role/RelatedPartiesDetails" xlink:type="simple" xlink:href="snti-20230331.xsd#RelatedPartiesDetails"/>
  <link:presentationLink xlink:role="http://www.sentibio.com/role/RelatedPartiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsAbstract_0ce65edb-bc7b-46d3-b894-8b505247c968" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_31470997-f497-40c2-abde-f17ecb82e4b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsAbstract_0ce65edb-bc7b-46d3-b894-8b505247c968" xlink:to="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_31470997-f497-40c2-abde-f17ecb82e4b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_d607717f-5e63-4d63-aaca-c9e719412704" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_31470997-f497-40c2-abde-f17ecb82e4b3" xlink:to="loc_srt_CounterpartyNameAxis_d607717f-5e63-4d63-aaca-c9e719412704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a782fb-0eca-4c4e-bfd5-38c9fb5590c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_d607717f-5e63-4d63-aaca-c9e719412704" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a782fb-0eca-4c4e-bfd5-38c9fb5590c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_NEAMember_ee811a0d-1a86-4084-8875-50e4c4056afb" xlink:href="snti-20230331.xsd#snti_NEAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a782fb-0eca-4c4e-bfd5-38c9fb5590c3" xlink:to="loc_snti_NEAMember_ee811a0d-1a86-4084-8875-50e4c4056afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_BlueRockMember_fa576e91-579c-4aee-b96b-709d936ef5d9" xlink:href="snti-20230331.xsd#snti_BlueRockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a782fb-0eca-4c4e-bfd5-38c9fb5590c3" xlink:to="loc_snti_BlueRockMember_fa576e91-579c-4aee-b96b-709d936ef5d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_BayerMember_b3aefcab-6105-484a-8cad-e3e88698cf9c" xlink:href="snti-20230331.xsd#snti_BayerMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a782fb-0eca-4c4e-bfd5-38c9fb5590c3" xlink:to="loc_snti_BayerMember_b3aefcab-6105-484a-8cad-e3e88698cf9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_SeerIncMember_9090f575-92a8-4fc6-81a4-14aa0f4503f2" xlink:href="snti-20230331.xsd#snti_SeerIncMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_07a782fb-0eca-4c4e-bfd5-38c9fb5590c3" xlink:to="loc_snti_SeerIncMember_9090f575-92a8-4fc6-81a4-14aa0f4503f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_29964035-9255-4e62-86ce-d01314cc2e59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_31470997-f497-40c2-abde-f17ecb82e4b3" xlink:to="loc_us-gaap_TypeOfArrangementAxis_29964035-9255-4e62-86ce-d01314cc2e59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5094bec2-161a-427c-b577-f3eebdb8053b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_29964035-9255-4e62-86ce-d01314cc2e59" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5094bec2-161a-427c-b577-f3eebdb8053b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_11125d92-afe0-4474-b228-6a7fa2814d48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_5094bec2-161a-427c-b577-f3eebdb8053b" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_11125d92-afe0-4474-b228-6a7fa2814d48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_51a0de28-9e04-46e2-b99a-eda6849c65bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_31470997-f497-40c2-abde-f17ecb82e4b3" xlink:to="loc_us-gaap_DebtInstrumentAxis_51a0de28-9e04-46e2-b99a-eda6849c65bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_14ee8f76-4b47-4ba0-bf2a-5c929bfe9a44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_51a0de28-9e04-46e2-b99a-eda6849c65bb" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_14ee8f76-4b47-4ba0-bf2a-5c929bfe9a44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_May2022NoteMember_775c7d05-7471-441d-9fd4-2868182e1811" xlink:href="snti-20230331.xsd#snti_May2022NoteMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_14ee8f76-4b47-4ba0-bf2a-5c929bfe9a44" xlink:to="loc_snti_May2022NoteMember_775c7d05-7471-441d-9fd4-2868182e1811" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1d549d65-88c4-493c-9eb8-da4a382544f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_31470997-f497-40c2-abde-f17ecb82e4b3" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1d549d65-88c4-493c-9eb8-da4a382544f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_e5481759-05f1-4773-992c-d250a07f9e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1d549d65-88c4-493c-9eb8-da4a382544f2" xlink:to="loc_us-gaap_ClassOfStockDomain_e5481759-05f1-4773-992c-d250a07f9e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonClassAMember_05818ea4-b4d1-433c-b5c0-04cad134fc84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonClassAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_e5481759-05f1-4773-992c-d250a07f9e50" xlink:to="loc_us-gaap_CommonClassAMember_05818ea4-b4d1-433c-b5c0-04cad134fc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_31470997-f497-40c2-abde-f17ecb82e4b3" xlink:to="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_7c5bfbab-3b67-458c-90b5-6eb2b73d2679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_us-gaap_CommonStockSharesIssued_7c5bfbab-3b67-458c-90b5-6eb2b73d2679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_NumberOfSeatsOnTheBoardOfDirectors_93859dbf-e57a-41bb-9437-f2832cceb553" xlink:href="snti-20230331.xsd#snti_NumberOfSeatsOnTheBoardOfDirectors"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_snti_NumberOfSeatsOnTheBoardOfDirectors_93859dbf-e57a-41bb-9437-f2832cceb553" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6e2b5476-0aa3-48c9-9ff3-428f0ca1088a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6e2b5476-0aa3-48c9-9ff3-428f0ca1088a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_6f2a4141-7ce5-4227-adfa-57698bcbddf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_6f2a4141-7ce5-4227-adfa-57698bcbddf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_9471c842-ad86-4e43-8ea7-4e971c8672e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_us-gaap_SharePrice_9471c842-ad86-4e43-8ea7-4e971c8672e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ResearchAndDevelopmentArrangementExpectedCosts_af7d1be5-3126-4ffc-86de-dc056ec6ef46" xlink:href="snti-20230331.xsd#snti_ResearchAndDevelopmentArrangementExpectedCosts"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_snti_ResearchAndDevelopmentArrangementExpectedCosts_af7d1be5-3126-4ffc-86de-dc056ec6ef46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_ResearchAndDevelopmentExpenseTermOfAgreement_34a22875-a3b7-43fb-8294-7198aa8e015e" xlink:href="snti-20230331.xsd#snti_ResearchAndDevelopmentExpenseTermOfAgreement"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_snti_ResearchAndDevelopmentExpenseTermOfAgreement_34a22875-a3b7-43fb-8294-7198aa8e015e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_b6fc538e-c46f-4386-aafa-0078461a9231" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty_b6fc538e-c46f-4386-aafa-0078461a9231" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm_f82b035c-f178-4572-9cfe-f1a48d4ab10c" xlink:href="snti-20230331.xsd#snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionLineItems_1ba3796e-2e13-4cee-b002-779c47022f0c" xlink:to="loc_snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm_f82b035c-f178-4572-9cfe-f1a48d4ab10c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748152355344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>May 01, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 31,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40440<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Senti Biosciences, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">86-2437900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2 Corporate Drive, First Floor<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">239-2030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SNTI<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,168,034<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001854270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember', window );">Former Address</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressesLineItems', window );"><strong>Entity Addresses [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">2875 El Camino Real<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Redwood City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94061<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressesAddressTypeAxis=dei_FormerAddressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748150814928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 31,600<span></span>
</td>
<td class="nump">$ 57,621<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">791<span></span>
</td>
<td class="nump">626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">44,506<span></span>
</td>
<td class="nump">40,942<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,614<span></span>
</td>
<td class="nump">3,390<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">80,511<span></span>
</td>
<td class="nump">102,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">3,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">58,987<span></span>
</td>
<td class="nump">56,136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">17,905<span></span>
</td>
<td class="nump">18,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">471<span></span>
</td>
<td class="nump">293<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">161,425<span></span>
</td>
<td class="nump">180,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,582<span></span>
</td>
<td class="nump">2,267<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_EarlyExerciseLiabilityCurrent', window );">Early exercise liability, current portion</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">407<span></span>
</td>
<td class="nump">799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">7,591<span></span>
</td>
<td class="nump">12,864<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities</a></td>
<td class="nump">2,056<span></span>
</td>
<td class="nump">1,988<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">12,866<span></span>
</td>
<td class="nump">18,053<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">35,866<span></span>
</td>
<td class="nump">35,103<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent earnout liability</a></td>
<td class="nump">168<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_EarlyExerciseLiabilityNoncurrent', window );">Early exercise liability, net of current portion</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">49,085<span></span>
</td>
<td class="nump">53,529<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 11)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; zero shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 500,000,000 shares authorized at March&#160;31, 2023 and December&#160;31, 2022; 44,075,194 and 44,062,534 shares issued and outstanding at March&#160;31, 2023 and December&#160;31, 2022, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">304,341<span></span>
</td>
<td class="nump">300,544<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(192,008)<span></span>
</td>
<td class="num">(173,286)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">112,340<span></span>
</td>
<td class="nump">127,263<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, preferred stock and stockholders&#8217; equity</a></td>
<td class="nump">$ 161,425<span></span>
</td>
<td class="nump">$ 180,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=snti_RelatedPartyMember', window );">Related Party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Stockholders&#8217; Equity (Deficit)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityCurrent', window );">Finance lease liabilities, current portion</a></td>
<td class="nump">$ 95<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeaseLiabilityNoncurrent', window );">Finance lease liabilities, net of current portion</a></td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_EarlyExerciseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Early Exercise Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_EarlyExerciseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_EarlyExerciseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Early Exercise Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_EarlyExerciseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=snti_RelatedPartyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=snti_RelatedPartyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748152281744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">44,075,194<span></span>
</td>
<td class="nump">44,062,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">44,075,194<span></span>
</td>
<td class="nump">44,062,534<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748156283248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Contract revenue</a></td>
<td class="nump">$ 1,036<span></span>
</td>
<td class="nump">$ 854<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant income</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">250<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">1,286<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">11,318<span></span>
</td>
<td class="nump">7,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">9,802<span></span>
</td>
<td class="nump">5,259<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">21,120<span></span>
</td>
<td class="nump">12,862<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(19,834)<span></span>
</td>
<td class="num">(11,758)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent earnout liability</a></td>
<td class="nump">59<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense)</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(54)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">1,112<span></span>
</td>
<td class="num">(50)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(18,722)<span></span>
</td>
<td class="num">(11,808)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Unrealized gain on investments</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (18,720)<span></span>
</td>
<td class="num">$ (11,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share, diluted (in dollars per share)</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (3.72)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share, basic (in dollars per share)</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (3.72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted (in shares)</a></td>
<td class="nump">44,070,974<span></span>
</td>
<td class="nump">3,171,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic (in shares)</a></td>
<td class="nump">44,070,974<span></span>
</td>
<td class="nump">3,171,254<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748156242528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#8217; Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Other Comprehensive Income</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">19,517,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 171,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="nump">19,517,988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="nump">$ 171,833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,972,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="num">(111,457)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3,619<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (115,076)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of options of common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172,606<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of common stock options</a></td>
<td class="nump">422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions', window );">Vesting of early exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions', window );">Vesting of early exercise of common stock options</a></td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(11,808)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,808)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,288,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2022</a></td>
<td class="num">$ (121,807)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,077<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(126,884)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="nump">44,062,534<span></span>
</td>
<td class="nump">44,062,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 127,263<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">300,544<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(173,286)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions', window );">Vesting of early exercise of common stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions', window );">Vesting of early exercise of common stock options</a></td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">3,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,763<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Unrealized gain on investments</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,722)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,722)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Mar. 31, 2023</a></td>
<td class="nump">44,075,194<span></span>
</td>
<td class="nump">44,075,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Mar. 31, 2023</a></td>
<td class="nump">$ 112,340<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 304,341<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">$ (192,008)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Vesting Of Early Exercise Of Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Value, Vesting Of Early Exercise Of Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748150950256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Net Cash Provided by (Used in) Operating Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,722)<span></span>
</td>
<td class="num">$ (11,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">467<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of operating lease right-of-use assets</a></td>
<td class="nump">462<span></span>
</td>
<td class="nump">770<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Accretion of discount on short-term investments</a></td>
<td class="num">(572)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent earnout liability</a></td>
<td class="num">(59)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">3,763<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on write-off of fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_InterestIncomeAccruedAndNotReceived', window );">Interest income accrued and not received</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract', window );"><strong>Changes in assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(135)<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(402)<span></span>
</td>
<td class="num">(381)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">280<span></span>
</td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="num">(1,846)<span></span>
</td>
<td class="num">(1,413)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(392)<span></span>
</td>
<td class="num">(453)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">882<span></span>
</td>
<td class="nump">2,424<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash from operating activities</a></td>
<td class="num">(16,304)<span></span>
</td>
<td class="num">(10,059)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(17,990)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments', window );">Maturities of short-term investments</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(6,507)<span></span>
</td>
<td class="num">(7,380)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash from investing activities</a></td>
<td class="num">(9,497)<span></span>
</td>
<td class="num">(7,380)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Principal finance lease payments</a></td>
<td class="num">(35)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities', window );">Payment of deferred transaction costs related to Merger</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(595)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash from financing activities</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(455)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net decrease in cash and cash equivalents</a></td>
<td class="num">(25,836)<span></span>
</td>
<td class="num">(17,894)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, beginning of period</a></td>
<td class="nump">60,987<span></span>
</td>
<td class="nump">59,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash, end of period</a></td>
<td class="nump">35,151<span></span>
</td>
<td class="nump">41,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">31,600<span></span>
</td>
<td class="nump">38,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCash', window );">Restricted cash</a></td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">3,257<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents and restricted cash</a></td>
<td class="nump">35,151<span></span>
</td>
<td class="nump">41,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of noncash financing and investing items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">4,758<span></span>
</td>
<td class="nump">8,920<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid', window );">Merger and related PIPE financing costs included in accounts payable and accrued expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions', window );">Receivables in transit from issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_InterestIncomeAccruedAndNotReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Interest Income Accrued And Not Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_InterestIncomeAccruedAndNotReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Merger and Related PIPE Financing Costs Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Receivables In Transit From Issuance Of Common Stock Upon Exercise Of Stock Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for financing costs associated with business combinations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748153922224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Organization and Description of Business</a></td>
<td class="text">Organization and Description of Business<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Senti Biosciences, Inc. and its subsidiaries (the &#8220;Company&#8221; or &#8220;Senti&#8221;), is a biotechnology company that was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti has built a synthetic biology platform that enables it to program next-generation cell and gene therapies with what the Company refers to as &#8220;gene circuits.&#8221; These gene circuits, which are created from novel and proprietary combinations of DNA sequences, reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. The Company is headquartered in South San Francisco, California.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 8, 2022 (the &#8220;Closing Date&#8221;), Dynamics Special Purpose Acquisition Corp. (&#8220;Dynamics&#8221; or &#8220;DYNS&#8221;) consummated a merger pursuant to which Explore Merger Sub, Inc. (&#8220;Merger Sub&#8221;), a Delaware corporation and wholly owned subsidiary of Dynamics, merged with and into Senti Sub I, Inc., formerly named Senti Biosciences, Inc. (&#8220;Legacy Senti&#8221;), with Legacy Senti surviving as a wholly-owned subsidiary of Dynamics (such transactions, the &#8220;Merger,&#8221; and, collectively with the other transactions described in the merger agreement (as defined below, the &#8220;Reverse Recapitalization&#8221;)). As a result of the Merger, Dynamics was renamed Senti Biosciences, Inc.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity and Going Concern</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company were unable to continue as a going concern.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has devoted substantially all of its efforts to organizing and staffing, business planning, raising capital, and conducting preclinical studies and has not realized substantial revenues from its planned principal operations.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> To date, the Company raised aggregate gross proceeds of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$298.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> from the Merger and PIPE Financing, the issuance of shares of our redeemable convertible preferred stock, the issuance of convertible notes and, to a less extent, through collaboration agreements and government grants.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At March&#160;31, 2023 and December&#160;31, 2022, the Company had an accumulated deficit of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$192.0 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$173.3 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, respectively. The Company&#8217;s net losses were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$18.7 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$11.8 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for the three months ended March&#160;31, 2023 and 2022, respectively. Substantially all of the Company&#8217;s net losses resulted from costs incurred in connection with the Company&#8217;s research and development programs and from general and administrative costs associated with the Company&#8217;s operations. The Company expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future as the Company advances its</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> preclinical activities and clinical trials for its product candidates in development</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023 and December&#160;31, 2022, the Company had cash, cash equivalents and short-term investments of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$76.1&#160;million and $98.6 million, respectively. As of May&#160;9, 2023, the issuance date of the condensed consolidated financial statements as of for the three months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">March&#160;31, 2023, there is uncertainty about whether the Company&#8217;s combined cash, cash equivalents, and short-term investments will be sufficient to fund operations, including clinical trial expenses and capital expenditure requirements, beyond twelve months from the issuance date of these financial statements and therefore the Company concluded that substantial doubt existed about the Company&#8217;s ability to continue as a going concern.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s continued existence is dependent upon management&#8217;s ability to raise capital and develop profitable op</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">erations. Management is devoting substantially all of its efforts to developing its business and raising capital and there can be no assurance that the Company&#8217;s efforts will be successful. No assurance can be given that management&#8217;s actions will result in profitable operations or the meeting of ongoing liquidity needs.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI https://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748152339712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) and the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and as amended by Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The condensed consolidated financial statements include the accounts of Senti Biosciences, Inc., and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. We have one business activity and operate in one reportable segment.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related price information to give effect to the exchange ratio established in the Merger Agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the valuation of stock-based awards, the accrual for research and development expenses, the valuation of contingent earnout, the valuation of convertible notes, the valuation of common and redeemable convertible preferred stock, the valuation of preferred stock tranche liability, standalone selling price (&#8220;SSP&#8221;) and the determination of the incremental borrowing rate. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Unaudited Interim Condensed Consolidated Financial Statements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying interim condensed consolidated financial statements and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared on the same basis as the audited financial statements, and in management&#8217;s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Company&#8217;s financial position as of March&#160;31, 2023 and its results of operations for the three months ended March&#160;31, 2023 and 2022, and cash flows for the three months ended March&#160;31, 2023 and 2022. The results of operations for the three months ended March&#160;31, 2023 are not necessarily indicative of the results to be expected for the year ended December&#160;31, 2023 or any other period. The December&#160;31, 2022 year-end condensed consolidated balance sheet was derived from audited annual financial statements but does not include all disclosures from the annual financial statements.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2022 and the related notes included in the Company&#8217;s Form 10-K, filed with the SEC on March&#160;22, 2023, which provides a more complete discussion of the Company&#8217;s accounting policies and certain other information. There have been no material changes to the Company&#8217;s significant accounting policies as of and for the three months ended March&#160;31, 2023, as compared to the significant accounting policies described in the Company&#8217;s audited annual consolidated financial statements as of and for the year ended December&#160;31, 2022, except as discussed below.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company believes that the impact of recently issued accounting standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748236803552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize the estimated value of cash equivalents and restricted cash (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.167%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted cash</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,105&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35,105&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,554&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,503&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44,506&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,506&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,657&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.167%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted cash</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40,942&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,929&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,621&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,366&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,942&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No securities have contractual maturities of longer than one year. There were no transfers between Levels 1, 2, or 3 for any of the periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748153193680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Statement information<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock', window );">Other Financial Statement information</a></td>
<td class="text">Other Financial Statement information<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses (including prepaid rent)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,390&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment, Net</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment at cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,406&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,122&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,986)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,987&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,136&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Depreciation totaled $0.5&#160;million and $0.2&#160;million for the three months ended March 31, 2023 and 2022, respectively. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Accrued Expenses and Other Liabilities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional and service fees related to facility construction</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional and service fees other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,591&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalFinancialInformationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalFinancialInformationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748152999744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Operating Leases</a></td>
<td class="text">Leases<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s operating leases are primarily for its corporate headquarters located in South San Francisco, California (&#8220;HQ lease&#8221;) and for additional office and laboratory space located in Alameda, California (&#8220;Alameda lease&#8221;) that commenced on July 30, 2021, and is expected to be placed into service in June 2023. The corporate headquarters lease has an initial term of eight years expiring in 2027, with an option to renew for an additional eight years unless canceled by either party thereafter. The Alameda lease has an initial term of eleven years expiring in 2032, with an option to renew the lease for up to two additional terms of five years. The exercise of these renewal options is not recognized as part of the ROU assets and lease liabilities, as the Company did not conclude, at the commencement date of the leases, that the exercise of renewal options or termination options was reasonably certain. The Alameda lease provides for a tenant improvement allowance of up to $17.5&#160;million for the costs relating to the design, permitting and construction of the improvements, to be disbursed by the landlord no later than December 31, 2023. The Company is deemed to be the accounting owner of the tenant improvements primarily because the Company is the principal in the construction and design of the assets, is responsible for costs overruns and retains substantially all economic benefits from the leasehold improvements over their economic lives</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Accordingly, the tenant improvement allowance is considered an incentive and was deducted from the initial measurement of the ROU asset and lease liability. The Company estimated the timing of tenant improvement reimbursements at the lease commencement date and upon receipt of the cash incentives, the Company recognized the cash received as an increase in the lease liability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of total lease costs and other information for the period relating to the Company&#8217;s operating leases is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows net inflows and (outflows) from operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for operating lease obligations (including remeasurement of ROU and lease liabilities due to changes in the timing of receipt of lease incentives)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended March 31, 2023 and 2022, the Company received $1.0 million and $2.5 million, respectively, of the $17.5&#160;million tenant improvement allowance. Through March&#160;31, 2023, the Company utilized $15.1 million of the tenant improvement allowance inception-to-date. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2023 and 2022, amounts disclosed for ROU assets obtained in exchange for lease obligations include amounts added to the carrying amount of ROU assets resulting from lease modifications and reassessments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of the Company&#8217;s lease liabilities as of March&#160;31, 2023, were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.721%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023, for the remainder of the year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,637)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant improvement allowance remaining</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748236722592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity (Deficit)</a></td>
<td class="text">Stockholders&#8217; Equity (Deficit)<div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Common Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Holders of common stock are entitled to one vote per share, and to receive dividends and, upon liquidation or dissolution, are entitled to receive all assets available for distribution to stockholders. The holders have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such shares. Common stock is subordinate to the preferred stock with respect to dividend rights and rights upon liquidation, winding up, and dissolution of the Company; although, no preferred stock is outstanding as of March&#160;31, 2023 and December&#160;31, 2022. Through March&#160;31, 2023, no cash dividends have been declared or paid.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At March&#160;31, 2023 and December&#160;31, 2022, the Company was authorized to issue 500,000,000 shares of common stock, all at a par value of $0.0001 per share, and had reserved the following shares for future issuance:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Purchase Agreement</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,327,049</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,327,049</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options issued and outstanding </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,792,908</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,875,675</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs issued and outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,322</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,948</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock shares available for future issuance under equity plans </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299,266</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,948,472</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock shares available for future issuance under the 2022 Employee Stock Purchase Plan (the "ESPP") </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923,307</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481,627</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earnout common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested early exercised common stock </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,840</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,500</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,823,692</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,186,271</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Preferred Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the close of the Merger, the Company&#8217;s Amended and Restated Certificate of Incorporation provides the Company&#8217;s board of directors with the authority to issue $0.0001 par value preferred stock in one or more series and to establish from time to time the number of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating, optional, special and other rights shall be stated and expressed in such resolutions. There were </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">10,000,000 shares designated as preferred stock and none were outstanding as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Common Stock Purchase Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August 31, 2022, the Company entered into a Common Stock Purchase Agreement and a Registration Rights Agreement (collectively referred to as the &#8220;Purchase Agreement&#8221;) with Chardan Capital Markets LLC (&#8220;Chardan&#8221;). Pursuant to the Purchase Agreement, the Company has the right, in its sole discretion, to sell to Chardan up to the lesser of (i) $50.0 million of newly issued shares of the Company&#8217;s common stock, and (ii) the Exchange Cap (as defined below) (subject to certain conditions and limitations), from time to time during the 36-month term of the Purchase Agreement. Under the applicable NASDAQ rules, the Company may not issue to Chardan under the Purchase Agreement more than 8,727,049 shares of common stock, which number of shares is equal to 19.99% of the common shares outstanding immediately prior to the execution of the Purchase Agreement unless certain exceptions are met (the &#8220;Exchange Cap&#8221;). The purchase price of the shares of common stock will be determined by reference to the Volume Weighted Average Price (&#8220;VWAP&#8221;) of the common stock during the applicable purchase date, less a fixed 3% discount to such VWAP. However, the total shares to be purchased on any day may not exceed 20% of the trading volume, and the total purchase price on any day may not exceed $3.0 million. As consideration for Chardan&#8217;s commitment to purchase shares of common stock at the Company&#8217;s direction upon the terms and subject to the conditions set forth in the Purchase Agreement, upon execution of the Purchase Agreement, the Company issued 100,000 shares of its common stock to Chardan and paid a $0.4 million document preparation fee. Upon execution of the Purchase Agreement, the Company recognized an expense of $0.7 million within general and administrative expenses in the Company&#8217;s Condensed Consolidated Statements of Operations and Comprehensive Loss for the Chardan related costs and legal fees incurred in connection with the agreement.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Other than the issuance of the commitment shares of the Company&#8217;s common stock to Chardan, the Company issued 300,000 Class A common stock shares up until December&#160;31, 2022 aggregating to net proceeds of $0.7 million, under the Purchase Agreement. There were no shares issued within three months ended March 31, 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Contingent Earnout Equity</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the closing of the Merger, former holders of Legacy Senti common stock and preferred stock may receive up to 2,000,000 additional shares of the Company&#8217;s common stock in the aggregate, in two equal tranches of 1,000,000 shares of common stock per tranche. The first and second tranches are issuable if the closing volume weighted average price (&#8220;VWAP&#8221;) per share of common stock quoted on the Nasdaq (or the exchange on which the shares of common stock are then listed) is greater or equal to $15.00 and $20.00, respectively over any <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNTE5OA_43c54c31-da11-473c-9a9b-97c930e0d994">twenty</span> trading days within any thirty-day trading period. The first and second tranche term is <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NTIxMA_4c4a7b87-cc7a-4ee5-be63-48c4f60a7afc">two</span> and three years, respectively, from the closing of the Merger. If there is a change of control within the three-year following the closing of the Merger that results in a per share price equal to or in excess of the $15.00 and $20.00 share price milestones not previously met, then Company shall issue the earnout shares to the holders of Legacy Senti common stock and preferred stock.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The estimated fair value of the total Contingent Earnout Shares at the Closing on June 8, 2022, was $9.8&#160;million based on a Monte Carlo simulation valuation model. Of this amount, $9.7&#160;million was accounted for as a Contingent Earnout Liability because the triggering events that determine the number of Contingent Earnout Shares required to be issued include events that are not solely indexed to the common stock of the Company. The remaining balance of  $0.1&#160;million relates to holders of Legacy Senti common stock that are subject to repurchase were accounted for as stock-based compensation expense and recorded as an expense, as there was no remaining service period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Contingent Earnout Liability was remeasured to fair value as of March&#160;31, 2023, resulting in the recording of a non-cash gain of $0.1&#160;million for the three months ended March&#160;31, 2023, classified within change in fair value of contingent earnout liability in the condensed consolidated statements of operations and comprehensive loss.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assumptions used in the valuation are described below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current stock price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748236719072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_RevenueFromAndNotFromContractsAbstract', window );"><strong>Revenue From and Not From Contracts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_RevenueFromAndNotFromContractsTextBlock', window );">Revenue</a></td>
<td class="text">Revenue<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s revenue consists of amounts received related to research services provided to customers.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Contract Revenue</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In April 2021, the Company entered into a research collaboration and license agreement with Spark Therapeutics, Inc. (&#8220;Spark&#8221;). Under the agreement, the Company will be responsible for a research program, which includes designing, building and testing five cell type specific-synthetic promoters for use in developing certain gene therapies using the Company&#8217;s proprietary technology. The Company received an upfront payment from Spark of $3.0 million and Spark is obligated to reimburse the Company for costs and expenses incurred for the research program. The Company expected to complete the research program over a two-year period. In December 2022, the Company amended the research collaboration and license agreement to allow for an increase in budget and a two-month extension of the research program. As there were no changes to performance obligations and the services to be provided are not distinct from those already transferred, the transactions was accounted for as a contract modification and a cumulative catch-up of $(0.7) million was recognized in December 2022. As of March&#160;31, 2023 and December&#160;31, 2022, there was a total of $0.4 million and $0.8 million, respectively, remaining of the upfront payment to be recognized over the remaining period of the research program.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company assessed this agreement in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Revenue Recognition </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(&#8220;ASC 606&#8221;) and concluded that the contract counterparty, Spark, is a customer. The Company identified only one combined performance obligation in the agreement, which is to perform research services, the related joint research plan and committees for the five specified promoters. The Company determined that the research activities for each of the five promoters are not distinct given there is one single research plan that is performed by the same research team and research results for one promoter may provide insights for other promoters. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Pursuant to the agreement, once the research program is completed and the Company delivers a data package to Spark, Spark has 24 months (the &#8220;Evaluation Period&#8221;) to determine whether Spark will exercise its options to obtain field-limited, royalty-bearing licenses to develop, manufacture and commercialize promoters corresponding to each of the five specified promoters being researched. For each licensed promoter option that is exercised, the Company is eligible to receive a license fee, potential research, development and commercial milestone payments and royalties on product sales. Spark may generally terminate the agreement upon 90 days prior written notice or 180 days prior written notice if the licensed promoter is in clinical trials or is being commercialized at the time of termination.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company evaluated Spark&#8217;s optional rights to license, develop, manufacture and commercialize each of the promoter profiles to determine whether they provide Spark with any material rights to purchase the promoter licenses at an incremental discount.  The Company&#8217;s proprietary technology used to develop the promoters is in the early stages of development, so technological feasibility and probability of developing a product is highly uncertain. As a result, determining the SSP for the optional rights is subject to significant judgment. Given the subjectivity associated with determining the SSP for the right to a future license related to unproven technology at contract inception, the Company also evaluated whether the contract consideration associated with the research services represents the SSP for those services. The Company determined the transaction price, inclusive of the upfront payment and reimbursement of costs and expenses incurred for the research program, is commensurate with SSP for the research being conducted given the specialized nature and reliance on proprietary technology. Based on the Company&#8217;s assessment of the optional consideration and the qualitative factors of feasibility and probability of development combined with the quantitative assessment that research services are priced at their SSP, the Company </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">concluded that the license option does not provide Spark with an incremental discount and therefore does not constitute a material right. The transaction price associated with the research services in this agreement consists of the fixed upfront amount of $3.0 million and variable consideration.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For Spark collaboration agreement, the Company will recognize the transaction price as research and development services are provided, using a cost-based input method to measure the progress toward completion of its performance obligation and to calculate the corresponding amount of revenue to recognize each period. The Company believes that the cost-based input method is the best measure of progress because other measurements would not reflect how the Company transfers the control related to the performance obligation to our customers. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March 31, 2023 and 2022, the Company recorded revenue, which was previously included in deferred revenue at the beginning of each period, of $0.4 million and $0.4 million, respectively. Contract asset balances related to unbilled revenue for our collaboration agreements were zero as of March 31, 2023 and 2022, and are presented within prepaid expenses and other current assets on the condensed consolidated balance sheets. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Grant Income</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2021, the Small Business Innovation Research (&#8220;SBIR&#8221;) awarded the Company a grant in the amount of $2.0 million over two years subject to meeting certain terms and conditions. The purpose of the grant is to support the further development of SENTI-202 for acute myeloid leukemia towards clinical development. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Grant income was recognized when qualified research and development costs were incurred and the Company obtained reasonable assurance that the terms and conditions of the grant were met.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Entity-wide information</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the three months ended March 31, 2023, Customers A and B accounted for 81% and 19%, respectively, of revenue. During the three months ended March 31, 2022, Customers A and B accounted for 77% and 23%, respectively, of revenue.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">All revenues were generated in the United States for the three months ended March 31, 2023 and 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_RevenueFromAndNotFromContractsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From and Not From Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_RevenueFromAndNotFromContractsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_RevenueFromAndNotFromContractsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue From and Not From Contracts</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_RevenueFromAndNotFromContractsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748152999744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text">Stock-Based Compensation<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2016 Stock Incentive Plan (as Amended and Restated)</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s 2016 Stock Incentive Plan (the &#8220;2016 Plan&#8221;) provides for the grant of incentive stock options, non-qualified stock options and restricted stock awards to employees, directors, and consultants of the Company. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock options granted under the 2016 Plan generally vest over four years and expire no later than ten years after the grant date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the Merger, the 2016 Plan was terminated. No additional stock awards will be granted under the 2016 Plan. All awards previously granted and outstanding as of the effective date of the Merger, were adjusted to reflect the impact of the Merger, but otherwise remain in effect pursuant to their original terms. The shares underlying any award granted under the 2016 Plan that are forfeited back to or repurchased or reacquired by the Company, will revert to and again become available for issuance under the 2022 Plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022 Stock Incentive Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June&#160;8, 2022, upon the Merger, the Company adopted a 2022 Stock Incentive Plan (the &#8220;2022 Plan&#8221;). The 2022 Plan provides for the grant of incentive stock options to employees, and for the grant of non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The exercise price of an option granted under the 2022 Plan shall not be less than the fair market value of a common stock share on the date of grant. With respect to a 10% stockholder, the exercise price of an option granted shall not be less than 110% of the fair value of the common stock share on the date of grant.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock options granted under the 2022 Plan generally vest over four years and expire no later than ten years after the grant date.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company initially reserved 2,492,735 shares of common stock for issuance under the 2022 Plan. On the first day of each year commencing January 1, 2023, the 2022 Plan will automatically increase by 5% of the outstanding number of shares of common stock of the Company on the last day of the preceding calendar year or such lesser number of shares as approved by the Company&#8217;s Board of Directors prior to the effective date of the annual increase. In addition, the shares underlying any award granted under the 2016 Plan that are forfeited back to or repurchased or reacquired by the Company, will revert to and again become available for issuance under the 2022 Plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the total number of shares of common stock available for issuance under the 2022 Plan is 2,168,837.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022 Inducement Equity Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On August&#160;5, 2022, the Company adopted a 2022 Inducement Equity Plan (the &#8220;2022 Inducement Plan&#8221;). The 2022 Plan provides for the grant of non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to persons not previously an employee of the Company and its affiliates. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The exercise price of an option granted under the 2022 Inducement Plan shall not be less than the fair market value of a common stock share on the date of grant.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Stock options granted under the 2022 Inducement Plan generally vest over four years and expire no later than ten years after the grant date. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company initially reserved 2,000,000 shares of common stock for issuance under the 2022 Inducement Plan.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the total number of shares of common stock available for issuance under the 2022 Inducement Plan is 1,130,429.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">2022 Employee Stock Purchase Plan</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June&#160;8, 2022, upon the Merger, the Company adopted a 2022 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;). The ESPP allows eligible employees to purchase shares of the Company's common stock at a price equal to 85% of the lower of the fair market values of the stock on the first day of an offering or on the date of purchase. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s ESPP operates with rolling offering periods, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">which are generally 24 months.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company initially reserved 592,584 shares of common stock for issuance under the ESPP. On the first day of each year commencing January 1, 2023, the 2022 Plan will automatically increase by 1% of the outstanding number of shares of common stock of the Company on the last day of the preceding calendar year or such lesser number of shares as approved by the Company&#8217;s Board of Directors prior to the effective date of the annual increase.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the total number of shares of common stock available for issuance under the ESPP is 923,307.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Stock options</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity and related information under all equity plans, excluding performance and market awards:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,191,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,177,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of stock options granted during the three months ended March 31, 2023 and 2022 were $1.30 and none, respectively. The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2023 and 2022 were none and $1.2 million, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the unrecognized stock-based compensation expense related to stock options was approximately $9.5&#160;million, expected to be recognized over a weighted-average period of 2.8 years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Early Exercise of Stock Options into Restricted Stock</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For the three months ended March 31, 2023 and 2022, the Company issued zero shares of common stock upon exercise of unvested stock options. As of March&#160;31, 2023 and December&#160;31, 2022, 92,840 and 105,500 shares were held by employees subject to repurchase at an aggregate price of $0.2 million and $0.3 million, respectively.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Performance Awards</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Merger, on December 19, 2021, Legacy Senti approved 8,400,892 performance award options to existing employees that vest contingent upon the satisfaction of both a four-year service condition and a performance condition tied to the consummation of the Merger. The awards and the associated recognition of stock-based compensation were contingent on the Merger being consummated. As of the approval date of the performance awards, Legacy Senti did not have sufficient common stock available for issuance. Upon the Merger, the Company increased the number of shares authorized and 6,796,074 awards were granted on June&#160;8, 2022. Refer to Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stockholders&#8217; Equity (Deficit),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for further details of the shares of common stock authorized.</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,368,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,299,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,586&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The were no performance based options granted or exercised during the three months ended March 31, 2023 and 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the unrecognized stock-based compensation expense related to performance based options was approximately $10.4&#160;million, expected to be recognized over a weighted-average period of 1.8 years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Market</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Awards </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In connection with the Business Combination Agreement with DYNS, on December 19, 2021, Legacy Senti approved 605,451 market award options to its co-founder and Chief Executive Officer, Dr. Timothy Lu, that vest contingent upon the satisfaction of all three of the following conditions: a service condition, a performance condition tied to the consummation of the Merger, and market conditions. The market condition is achieved in four tranches, where 25% of the options will vest when the trading price of the Company&#8217;s stock is above various thresholds of price per share. The award and the associated recognition of stock-based compensation were contingent on the Merger being consummated. The estimated fair value of the market awards at the grant date was based on a Monte Carlo simulation valuation model. As of the approval date, Legacy Senti did not have sufficient common stock available for issuance to allow for exercise of the stock options. Upon the Merger, the Company increased the number of shares authorized and 315,748 awards were granted on June&#160;8, 2022. Refer to Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Stockholders&#8217; Equity (Deficit),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for further details of the shares of common stock authorized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The were no market based options granted or exercised during the three months ended March 31, 2023 and 2022. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the unrecognized stock-based compensation expense related to market based options was approximately $0.6&#160;million, expected to be recognized over a weighted-average period of 1.1 years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Restricted Stock Units </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Company&#8217;s restricted stock units activity and related information under all equity plans:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,626)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, the unrecognized stock-based compensation expense related to restricted stock units was approximately $0.7&#160;million, expected to be recognized over a weighted-average period of 1.5 years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock-Based Compensation Expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In determining the fair value of the stock-based awards, the Company uses the assumptions below for the Black-Scholes option pricing model, which are subjective and generally require significant judgment.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Fair Value of Common Stock </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;The fair value of the shares of common stock has historically been determined by the Company&#8217;s board of directors as there was no public market for the common stock. The board of directors determined the fair value of the common stock by considering a number of objective and subjective factors, including: third-party valuations of the Company&#8217;s common stock, the valuation of comparable companies, the Company&#8217;s operating and financial performance, and general and industry-specific economic outlook, amongst other factors. As of the closing of the Merger and going forward, the fair value of common stock will be based on the publicly traded market value.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Expected Term</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#8212; The expected term represents the period that the Company&#8217;s stock options are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and the end of the contractual term). The expected term for the ESPP purchase rights is the length of the purchase period.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Volatility</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#8212; The expected volatility is based on the average historical volatility of comparable publicly-traded peer companies, over a period equal to the expected term of the stock option grants, as the Company was not publicly traded prior to the Merger and does not have a trading history for its common stock for a sufficient period of time subsequent to the Merger. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Risk-free Rate</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#8212; The risk-free rate assumption is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Dividends</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#8212; The Company has never paid dividends on its common stock and does not anticipate paying dividends on common stock. Therefore, the Company uses an expected dividend yield of zero.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The assumptions used to determine the grant date fair value of non-market based, stock options granted were as follows, presented on a weighted-average basis:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total stock-based compensation expense was as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:71.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748153206928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax</a></td>
<td class="text">Income TaxNo provision for income taxes was recorded for the three months ended March 31, 2023 and 2022, respectively. Deferred tax assets generated from the Company&#8217;s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized due to the Company&#8217;s cumulative losses generated to date.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748152971904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of net loss available to common stockholders and the number of shares in the calculation of basic and diluted loss per share is as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:67.760%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.829%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,722)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,808)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in computing net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,070,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,171,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.72)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following potential common stock securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive (on an as-converted basis):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.810%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.805%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A and B redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,517,988</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,792,908</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,814,742</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested early exercised options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,840</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,850</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earnout common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,274,070</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,662,580</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748153868752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the ordinary course of business, the Company enters into contractual agreements with third parties that include non-cancelable payment obligations, for which the Company is liable in future periods. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On June 3, 2021, the Company entered into a lease agreement for a new cGMP facility in Alameda, California to support planned initial clinical trials for our product candidates. Refer to Note 5, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Operating Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, for further details of the leases. The lease will expire in 2032 with future undiscounted operating lease payments of $46.0 million over an initial lease period of eleven years.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2021, the Company began construction of the cGMP facility. As of March&#160;31, 2023 the Company paid $37.5 million in construction costs of the $42.2 million purchase commitment. The agreements with the construction company provide for termination following a certain period after notice. Upon termination, the Company will be responsible for payment for work performed to date. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2021, the Company entered into a three-year collaboration and option agreement with BlueRock Therapeutics LP (&#8220;BlueRock&#8221;) under which the Company granted BlueRock an option to acquire an exclusive or non-exclusive license to develop, manufacture and commercialize cell therapy products. Refer to Note 12, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Related Parties</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, for further details of the related parties. In consideration for the option, the Company is responsible for up to $10.0 million in costs and expenses incurred over the three-year term.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023, purchase commitments related to sponsored research agreements amounted to approximately $0.8 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has entered into license agreements under which they are obligated to make annual maintenance payments of $0.1 million and specified milestone and royalty payments. Future milestone and royalty payments under these agreements are not considered contractual obligations since the payments under these agreements are contingent upon future events, such as the Company&#8217;s achievement of specified development, regulatory, and sales milestones, or generating product sales. As of March&#160;31, 2023, the Company is unable to estimate the timing or likelihood of achieving these milestones or generating future product sales.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Following the Closing, former holders of Legacy Senti common stock and preferred stock may receive up to 2,000,000 additional shares of the Company&#8217;s common stock in the aggregate, in two equal tranches of 1,000,000 shares of common stock per tranche. Refer to Note 6, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Stockholders&#8217; Equity (Deficit),</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> for further details of the contingent earnout liability.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legal Proceedings</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is subject to claims and assessments from time to time in the ordinary course of business but does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company&#8217;s financial position, results of operations, or cash flows.</span></div>IndemnificationIn the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions and has never accrued any liabilities related to such obligations in its condensed consolidated financial statements. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#8217; and officers&#8217; insurance.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748155330272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Parties</a></td>
<td class="text">Related Parties<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NEA</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">NEA held 4,429,725 and 4,429,725 shares, respectively, of common stock as of March&#160;31, 2023 and December&#160;31, 2022, respectively. NEA held one of the seven seats on the Company&#8217;s Board of Directors as of March&#160;31, 2023 and December&#160;31, 2022.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer Healthcare LLC</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 19, 2022, Legacy Senti issued to Bayer a $5.2&#160;million unsecured convertible promissory note. On June 8, 2022, the May 2022 Note was automatically cancelled and exchanged for 517,500 shares of Class A Common Stock at a price of $10.00 per share.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On May 21, 2021, the Company entered into a collaboration and option agreement (&#8220;BlueRock Agreement&#8221;) with BlueRock, a wholly-owned subsidiary of Bayer, pursuant to which the Company granted to BlueRock an option (&#8220;BlueRock Option&#8221;), on a collaboration program-by-collaboration program basis, to obtain an exclusive or non-exclusive license to develop, manufacture and commercialize cell therapy products that contain cells of specified types and which incorporate an option gene circuit from such collaboration program or a closely related derivative gene circuit. The Company is responsible for up to $10 million in costs and expenses incurred in connection with the research plan and related activities to be conducted over a term of three years as specified in the collaboration and option agreement. If the Company and BlueRock agree to add new research activities to the research plan, then BlueRock will be obligated to reimburse the Company for the costs and expenses incurred that, together with costs and expenses incurred under the initial research plan, exceed $10 million.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company concluded that the Agreement is not within the scope of ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, because the Company did not receive any consideration and therefore, is not exposed to both significant risks and rewards for the arrangement. The Company also determined that the agreement is also not currently within the scope of ASC 606 because the BlueRock Agreement does not currently meet the criteria of a contract with a customer, and will not be within the scope of ASC 606 until any consideration is paid. Potential future milestone payments and royalties are subject to BlueRock&#8217;s exercise of the BlueRock Option and execution of a commercial license agreement by both parties. Under the BlueRock Agreement, the specific financial terms for milestone payments and royalties will be negotiated and agreed to only after the option is exercised. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March&#160;31, 2023 and December&#160;31, 2022, Bayer held 5,878,488 and 5,878,488 shares, respectively, of the Company&#8217;s common stock. As of March&#160;31, 2023 and December&#160;31, 2022, Bayer held one of the seven seats on the Board of Directors of the Company. Bayer&#8217;s parent company is Bayer AG, which served as the lead investor in our Series B financing through its Leaps by Bayer unit. Accordingly, Bayer is considered a related party.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Seer, Inc.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In January 2023, the Company received lab automation equipment purchased from Seer, Inc. (&#8220;Seer&#8221;) (NASDAQ: SEER). Omid Farokhzad, a member of the Company&#8217;s board of directors is the Chief Executive Officer </span></div>for Seer. The consideration of $200,000, plus interest, will be paid over a two-year period, and title will transfer to the Company upon final payment. The transaction was classified as a finance lease<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI https://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748153090256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text">Subsequent EventsOn April 26, 2023, Mr. David R. Epstein, informed the board of directors (the &#8220;Board&#8221;) of the Company of his intention to resign as a director, effective as of the close of business on June 16, 2023. Mr. Epstein has resigned in order to minimize potential conflict or the appearance of conflict with his role as Chief Executive Officer of Seagen, Inc. (an oncology company) rather than because of any disagreement relating to any of Senti&#8217;s operations, policies or practices.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI https://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748154331408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;) and the rules and regulations of the Securities and Exchange Commission (&#8220;SEC&#8221;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#8220;ASC&#8221;) and as amended by Accounting Standards Updates (&#8220;ASU&#8221;) of the Financial Accounting Standards Board (&#8220;FASB&#8221;). The condensed consolidated financial statements include the accounts of Senti Biosciences, Inc., and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. We have one business activity and operate in one reportable segment.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related price information to give effect to the exchange ratio established in the Merger Agreement.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the valuation of stock-based awards, the accrual for research and development expenses, the valuation of contingent earnout, the valuation of convertible notes, the valuation of common and redeemable convertible preferred stock, the valuation of preferred stock tranche liability, standalone selling price (&#8220;SSP&#8221;) and the determination of the incremental borrowing rate. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Standards</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Recent Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company believes that the impact of recently issued accounting standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748153181040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash, Cash Equivalents and Investments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following tables summarize the estimated value of cash equivalents and restricted cash (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.167%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted cash</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,105&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">35,105&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,554&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,380&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">11,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,382&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,744&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">13,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,746&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">17,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,381&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,998&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,503&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">44,506&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,506&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79,657&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,600&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,551&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,506&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.307%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.159%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.167%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Gain</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Restricted cash</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Short-term investments</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42,046&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">45,412&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">42,046&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,366&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,866&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">14,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. agency securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">3,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial Paper</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">28,122&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">22,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">7,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">1,992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56,516&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">(4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">56,517&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">15,575&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">40,942&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,928&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101,929&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,621&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,366&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,942&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Fair Value of Level 3 Financial Instruments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table presents a summary of the changes in the fair value of the Company&#8217;s Level 3 financial instruments (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:85.438%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.721%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contingent Earnout Liability</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(227)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value included in other income (expense)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair value as of March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(168)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748154576896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Statement information (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Prepaid Expenses and Other Current Assets</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Prepaid expenses and other current assets consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses (including prepaid rent)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,871&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deposits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,300&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,418&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total prepaid expenses and other current assets</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,614&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,390&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment, Net</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Property and equipment, net consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lab equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,474&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,265&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,869&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Computer equipment and software</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">389&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,347&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,273&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment at cost</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,406&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,122&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,419)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,986)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,987&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,136&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses and Other Liabilities</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Accrued expenses and other liabilities consisted of the following (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional and service fees related to facility construction</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,990&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,342&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued employee-related expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,799&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued professional and service fees other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,749&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other accrued expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,591&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,864&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748153229360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A summary of total lease costs and other information for the period relating to the Company&#8217;s operating leases is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,326&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Variable lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,584&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,500&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating cash flows net inflows and (outflows) from operating lease</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,874</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ROU assets obtained in exchange for operating lease obligations (including remeasurement of ROU and lease liabilities due to changes in the timing of receipt of lease incentives)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average remaining lease term</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 years</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Maturities of the Company&#8217;s lease liabilities as of March&#160;31, 2023, were as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:86.079%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.721%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023, for the remainder of the year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,307&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,712&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,769&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,384&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total undiscounted lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,904&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,637)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tenant improvement allowance remaining</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,345)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total lease liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,922&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748152993296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock', window );">Schedule Of Shares Reserved For Future Issuance</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At March&#160;31, 2023 and December&#160;31, 2022, the Company was authorized to issue 500,000,000 shares of common stock, all at a par value of $0.0001 per share, and had reserved the following shares for future issuance:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:72.617%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common Stock Purchase Agreement</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,327,049</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,327,049</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock options issued and outstanding </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,792,908</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,875,675</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs issued and outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,322</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,948</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock shares available for future issuance under equity plans </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,299,266</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,948,472</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock shares available for future issuance under the 2022 Employee Stock Purchase Plan (the "ESPP") </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">923,307</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">481,627</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earnout common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000,000</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000,000</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested early exercised common stock </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,840</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,500</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,823,692</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,186,271</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Business Acquisitions by Acquisition, Contingent Consideration</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Assumptions used in the valuation are described below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">March 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current stock price</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.18</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.41</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected share price volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Shares Reserved For Future Issuance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748152279904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-Based Payment Arrangement, Option, Activity</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s stock option activity and related information under all equity plans, excluding performance and market awards:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,191,426&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,189,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(203,367)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,177,759&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972,055&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.97&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock', window );">Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:45.053%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.723%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average<br/>Remaining Contractual Life (Years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate Intrinsic Value (in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,368,501&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.92&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(69,100)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,299,401&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.92&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vested and exercisable at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334,586&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.92&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following table summarizes the Company&#8217;s restricted stock units activity and related information under all equity plans:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Restricted Stock Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant Date Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at December&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447,948&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59,626)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outstanding at March&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,322&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The assumptions used to determine the grant date fair value of non-market based, stock options granted were as follows, presented on a weighted-average basis:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:71.976%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.720%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.722%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dividend yield</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-Based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Total stock-based compensation expense was as follows (in thousands):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"><tr><td style="width:1.0%"/><td style="width:71.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.804%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">524&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,763&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">661&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748152993168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Mar. 31, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Earnings Per Share, Basic and Diluted</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of net loss available to common stockholders and the number of shares in the calculation of basic and diluted loss per share is as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"><tr><td style="width:1.0%"/><td style="width:67.760%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.827%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.442%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.829%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18,722)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,808)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average shares used in computing net loss per share, basic and diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,070,974&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,171,254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss per share attributable to common stockholders, basic and diluted</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.42)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.72)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The following potential common stock securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive (on an as-converted basis):</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.810%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.803%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.805%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Series A and B redeemable convertible preferred stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,517,988</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options to purchase common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,792,908</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,814,742</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested early exercised options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,840</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">329,850</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units outstanding</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">388,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent earnout common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,000,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,274,070</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,662,580</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748155236656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Description of Business (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_CashAcquiredThroughReverseRecapitalization', window );">Cash acquired through reverse recapitalization</a></td>
<td class="nump">$ 298,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings (accumulated deficit)</a></td>
<td class="num">(192,008)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (173,286)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">18,722<span></span>
</td>
<td class="nump">$ 11,808<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents, and short-term investments</a></td>
<td class="nump">$ 76,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 98,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_CashAcquiredThroughReverseRecapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Acquired Through Reverse Recapitalization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_CashAcquiredThroughReverseRecapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748153047808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>reportableSegment </div>
<div>businessActivitiy</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_NumberOfBusinessActivities', window );">Number of business activities | businessActivitiy</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments | reportableSegment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_NumberOfBusinessActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Business Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_NumberOfBusinessActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748146474176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of the Estimated Fair Value of Cash Equivalents, Restricted Cash, And Short-Term Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="nump">$ 35,151<span></span>
</td>
<td class="nump">$ 60,987<span></span>
</td>
<td class="nump">$ 41,397<span></span>
</td>
<td class="nump">$ 59,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost', window );">Cash and cash equivalents and debt securities, available-for-sale, adjusted cost</a></td>
<td class="nump">79,654<span></span>
</td>
<td class="nump">101,928<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue', window );">Cash and cash equivalents and debt securities, available-for-sale, fair value</a></td>
<td class="nump">79,657<span></span>
</td>
<td class="nump">101,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue', window );">Cash and cash equivalents and debt securities, available-for-sale, fair value</a></td>
<td class="nump">31,600<span></span>
</td>
<td class="nump">57,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=snti_RestrictedCashMember', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue', window );">Cash and cash equivalents and debt securities, available-for-sale, fair value</a></td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">3,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue', window );">Cash and cash equivalents and debt securities, available-for-sale, fair value</a></td>
<td class="nump">44,506<span></span>
</td>
<td class="nump">40,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="nump">35,105<span></span>
</td>
<td class="nump">45,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="nump">31,554<span></span>
</td>
<td class="nump">42,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">3,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="nump">35,105<span></span>
</td>
<td class="nump">45,412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="nump">31,554<span></span>
</td>
<td class="nump">42,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds | Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="nump">3,551<span></span>
</td>
<td class="nump">3,366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money market funds | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">44,503<span></span>
</td>
<td class="nump">56,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">44,506<span></span>
</td>
<td class="nump">56,517<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">15,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">44,506<span></span>
</td>
<td class="nump">40,942<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Treasury securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">11,380<span></span>
</td>
<td class="nump">14,866<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">11,382<span></span>
</td>
<td class="nump">14,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Treasury securities | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Treasury securities | Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Treasury securities | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">11,382<span></span>
</td>
<td class="nump">14,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">13,744<span></span>
</td>
<td class="nump">5,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">13,746<span></span>
</td>
<td class="nump">5,938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. agency securities | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. agency securities | Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. agency securities | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">13,746<span></span>
</td>
<td class="nump">1,955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">17,381<span></span>
</td>
<td class="nump">28,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">17,381<span></span>
</td>
<td class="nump">28,122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial Paper | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial Paper | Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Commercial Paper | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">17,381<span></span>
</td>
<td class="nump">22,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">1,998<span></span>
</td>
<td class="nump">7,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">1,997<span></span>
</td>
<td class="nump">7,590<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities | Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,598<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities | Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Corporate debt securities | Short-term investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-Sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Estimated Fair Value</a></td>
<td class="nump">$ 1,997<span></span>
</td>
<td class="nump">$ 1,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Debt Securities, Available For-Sale, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Debt Securities, Available-For-Sale, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=snti_RestrictedCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=snti_RestrictedCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748156223264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Financial Instruments (Details) - Fair Value, Inputs, Level 3 - Contingent Earnout Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="num">$ (227)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value</a></td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="num">$ (168)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=snti_ContingentEarnoutLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=snti_ContingentEarnoutLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748155324880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Statement information - Schedule of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses (including prepaid rent)</a></td>
<td class="nump">$ 2,202<span></span>
</td>
<td class="nump">$ 1,871<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">1,418<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 3,614<span></span>
</td>
<td class="nump">$ 3,390<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126905020&amp;loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748155299248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Statement information - Schedule of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment at cost</a></td>
<td class="nump">$ 62,406<span></span>
</td>
<td class="nump">$ 59,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(3,419)<span></span>
</td>
<td class="num">(2,986)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">58,987<span></span>
</td>
<td class="nump">56,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=snti_LaboratoryEquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment at cost</a></td>
<td class="nump">8,474<span></span>
</td>
<td class="nump">8,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment at cost</a></td>
<td class="nump">1,869<span></span>
</td>
<td class="nump">1,869<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=snti_ComputerEquipmentAndSoftwareMember', window );">Computer equipment and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment at cost</a></td>
<td class="nump">390<span></span>
</td>
<td class="nump">389<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment at cost</a></td>
<td class="nump">326<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment at cost</a></td>
<td class="nump">$ 51,347<span></span>
</td>
<td class="nump">$ 48,273<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=snti_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=snti_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=snti_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=snti_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748153066576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Financial Statement information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">$ 467<span></span>
</td>
<td class="nump">$ 240<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748152265088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Financial Statement information - Schedule of Accrued Expenses and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional and service fees related to facility construction</a></td>
<td class="nump">$ 3,990<span></span>
</td>
<td class="nump">$ 7,342<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee-related expenses</a></td>
<td class="nump">1,799<span></span>
</td>
<td class="nump">3,743<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_AccruedProfessionalFeesOtherCurrent', window );">Accrued professional and service fees other</a></td>
<td class="nump">1,749<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent', window );">Total accrued expenses and other current liabilities</a></td>
<td class="nump">$ 7,591<span></span>
</td>
<td class="nump">$ 12,864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_AccruedProfessionalFeesOtherCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued Professional Fees, Other, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_AccruedProfessionalFeesOtherCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748155373552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">20 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>tradingDay</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=snti_CorporateHeadquartersMember', window );">Corporate Headquarters</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=snti_AlamedaMember', window );">Alameda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lease term</a></td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease renewal term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_LesseeOperatingLeaseNumberOfRenewalOptions', window );">Number of renewal options | tradingDay</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_TenantImprovementReimbursements', window );">Tenant improvement allowance received</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_TenantImprovementAllowance', window );">Tenant improvement allowance</a></td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_TenantImprovementAllowanceUtilized', window );">Tenant improvement allowance utilized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_LesseeOperatingLeaseNumberOfRenewalOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Number Of Renewal Options</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_LesseeOperatingLeaseNumberOfRenewalOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_TenantImprovementAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant Improvement Allowance</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_TenantImprovementAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_TenantImprovementAllowanceUtilized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant Improvement Allowance Utilized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_TenantImprovementAllowanceUtilized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_TenantImprovementReimbursements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant Improvement Reimbursements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_TenantImprovementReimbursements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=snti_CorporateHeadquartersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=snti_CorporateHeadquartersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=snti_AlamedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=snti_AlamedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748154223232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Total Lease Cost (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 1,309<span></span>
</td>
<td class="nump">$ 1,326<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">31<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">244<span></span>
</td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 1,584<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748154220544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Operating Leases - Other Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_OperatingLeaseProceedsPayments', window );">Operating cash flows net inflows and (outflows) from operating lease</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 1,874<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for operating lease obligations (including remeasurement of ROU and lease liabilities due to changes in the timing of receipt of lease incentives)</a></td>
<td class="num">$ (51)<span></span>
</td>
<td class="nump">$ 239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">7 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average discount rate</a></td>
<td class="nump">9.10%<span></span>
</td>
<td class="nump">9.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_OperatingLeaseProceedsPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Proceeds (Payments)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_OperatingLeaseProceedsPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748156105088">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Operating Leases - Maturities of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Jun. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2023, for the remainder of the year</a></td>
<td class="nump">$ 5,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2024</a></td>
<td class="nump">7,254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2025</a></td>
<td class="nump">7,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2026</a></td>
<td class="nump">7,712<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2027</a></td>
<td class="nump">5,769<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">24,384<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">57,904<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(17,637)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_TenantImprovementAllowanceRemainingAmount', window );">Tenant improvement allowance remaining</a></td>
<td class="num">(2,345)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total lease liabilities</a></td>
<td class="nump">$ 37,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Liability, to be Paid, After Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_TenantImprovementAllowanceRemainingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tenant Improvement Allowance, Remaining Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_TenantImprovementAllowanceRemainingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748152081008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) - Common and Preferred Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_NumberOfVotesPerCommonShare', window );">Number of votes per common stock | vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends declared and paid, common stock | $</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_NumberOfVotesPerCommonShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Votes Per Common Share</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_NumberOfVotesPerCommonShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748150990384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) - Common Stock Reserved for Future Issuance (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par or stated value (in dollars per share)</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">26,823,692<span></span>
</td>
<td class="nump">24,186,271<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=snti_CommonStockPurchaseAgreementMember', window );">Common Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">8,327,049<span></span>
</td>
<td class="nump">8,327,049<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">11,792,908<span></span>
</td>
<td class="nump">9,875,675<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">388,322<span></span>
</td>
<td class="nump">447,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=snti_CommonStockUnderEquityPlansMember', window );">Equity Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">3,299,266<span></span>
</td>
<td class="nump">2,948,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">923,307<span></span>
</td>
<td class="nump">481,627<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=snti_ContingentEarnoutCommonStockMember', window );">Contingent earnout common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember', window );">Unvested early exercised common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for future issuance (in shares)</a></td>
<td class="nump">92,840<span></span>
</td>
<td class="nump">105,500<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=snti_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=snti_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=snti_CommonStockUnderEquityPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=snti_CommonStockUnderEquityPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=snti_ContingentEarnoutCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=snti_ContingentEarnoutCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748156460112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) - Common Stock Purchase Agreement (Details) - Common Stock - Common Stock Purchase Agreement - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2022</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_SaleOfStockMaximumAmountAuthorized', window );">Maximum proceeds purchase agreement</a></td>
<td class="nump">$ 50.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_SaleOfStockTermOfAgreement', window );">Term of agreement</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold', window );">Number of shares issued, threshold (in shares)</a></td>
<td class="nump">8,727,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_SaleOfStockSharesIssuedInTransactionThresholdPercent', window );">Shares issued in transaction, threshold (as a percent)</a></td>
<td class="nump">19.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent', window );">Trading volume available for purchase, threshold (in percent)</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_SaleOfStockDailyAmountToBeSoldThreshold', window );">Purchase price, threshold</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued (in shares)</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_SaleOfStockDocumentPreparationFees', window );">Document preparation fees</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_SaleOfStockIssuanceCosts', window );">Sale of stock, issuance costs</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_SaleOfStockDiscountRatePercentage', window );">Discount rate (in percent)</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_SaleOfStockDailyAmountToBeSoldThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Daily Amount To Be Sold, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_SaleOfStockDailyAmountToBeSoldThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Daily Trading Volume Available For Purchase, Threshold, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_SaleOfStockDiscountRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Discount Rate, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_SaleOfStockDiscountRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_SaleOfStockDocumentPreparationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Document Preparation Fees</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_SaleOfStockDocumentPreparationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_SaleOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Issuance Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_SaleOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_SaleOfStockMaximumAmountAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Amount Authorized</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_SaleOfStockMaximumAmountAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Number Of Shares Issued In Transaction, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_SaleOfStockSharesIssuedInTransactionThresholdPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Shares Issued In Transaction, Threshold, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_SaleOfStockSharesIssuedInTransactionThresholdPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_SaleOfStockTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Term Of Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_SaleOfStockTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=snti_CommonStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=snti_CommonStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748150296976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) - Contingent Earnout Equity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 08, 2022 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ReverseRecapitalizationContingentConsiderationEquityShares', window );">Maximum contingent earnout (in shares) | shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches', window );">Number of tranches of contingent earnout shares | tranche</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche', window );">Number of contingent earnout shares per tranche (in shares) | shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays', window );">Number of trading days</a></td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays', window );">Number of consecutive trading days</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl', window );">Threshold of years for change of control (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ReverseRecapitalizationContingentConsiderationFairValue', window );">Fair value of contingent earnout shares</a></td>
<td class="nump">$ 9,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration, liability</a></td>
<td class="nump">9,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure', window );">Fair value of contingent earnout shares</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent earnout liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 59<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ContingentConsiderationTranchesAxis=snti_ContingentConsiderationTrancheTwoMember', window );">Contingent Consideration, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger', window );">Closing stock price to trigger contingent earnout shares (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 20.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=snti_ContingentConsiderationTrancheOneMember', window );">Contingent Consideration, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger', window );">Closing stock price to trigger contingent earnout shares (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ReverseRecapitalizationContingentConsiderationEquityTerm', window );">Term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContingentConsiderationByTypeAxis=snti_ContingentConsiderationTrancheTwoMember', window );">Contingent Consideration, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems', window );"><strong>Business Acquisition, Contingent Consideration [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ReverseRecapitalizationContingentConsiderationEquityTerm', window );">Term (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Stock Price Trigger</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Consecutive Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Trading Days</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Contingent Consideration Classified as Equity, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ReverseRecapitalizationContingentConsiderationEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Contingent Consideration, Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ReverseRecapitalizationContingentConsiderationEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Contingent Consideration, Equity, Shares per Tranche</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ReverseRecapitalizationContingentConsiderationEquityTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Contingent Consideration, Equity, Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ReverseRecapitalizationContingentConsiderationEquityTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Contingent Consideration, Equity, Threshold of Years for Change of Control</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ReverseRecapitalizationContingentConsiderationFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Contingent Consideration, Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ReverseRecapitalizationContingentConsiderationFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionContingentConsiderationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionContingentConsiderationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of contingent consideration in a business combination that is classified in shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ContingentConsiderationTranchesAxis=snti_ContingentConsiderationTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ContingentConsiderationTranchesAxis=snti_ContingentConsiderationTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=snti_ContingentConsiderationTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=snti_ContingentConsiderationTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=snti_ContingentConsiderationTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=snti_ContingentConsiderationTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748150813568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Deficit) - Assumptions used in valuation of contingent earnout shares (Details)<br></strong></div></th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>Years </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 08, 2022 </div>
<div>Years </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember', window );">Current stock price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput', window );">Measurement input | $ / shares</a></td>
<td class="nump">1.41<span></span>
</td>
<td class="nump">1.18<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember', window );">Expected share price volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.850<span></span>
</td>
<td class="nump">0.950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember', window );">Risk-free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.043<span></span>
</td>
<td class="nump">0.041<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember', window );">Estimated dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput', window );">Measurement input</a></td>
<td class="nump">0.000<span></span>
</td>
<td class="nump">0.000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember', window );">Expected term (years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput', window );">Measurement input | Years</a></td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Contingent Consideration Classified as Equity, Measurement Input</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748154985936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Contract Revenue (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized during period previously included in deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetGross', window );">Contract asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=snti_SparkMember', window );">Spark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_RevenueFromContractWithCustomerEvaluationPeriod', window );">Agreement evaluation period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=snti_SparkMember', window );">Spark | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_RevenueFromContractWithCustomerTerminationNoticePeriod', window );">Agreement termination advance notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=snti_SparkMember', window );">Spark | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_RevenueFromContractWithCustomerTerminationNoticePeriod', window );">Agreement termination advance notice period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=snti_SparkMember', window );">Spark | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount', window );">Variable consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ContractWithCustomerExtensionOfTermModificationOfContract', window );">Extension of term of contract (in months)</a></td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract', window );">Contract assets, cumulative catch-up adjustments</a></td>
<td class="num">$ (700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Consideration received in collaborative development agreement</a></td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=snti_SparkMember', window );">Spark | License | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-05-01</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Expected timing of satisfaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ContractWithCustomerExtensionOfTermModificationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Extension Of Term, Modification Of Contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ContractWithCustomerExtensionOfTermModificationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_RevenueFromContractWithCustomerEvaluationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from Contract with Customer, Evaluation Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_RevenueFromContractWithCustomerEvaluationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_RevenueFromContractWithCustomerTerminationNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue from Contract with Customer, Termination Notice, Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_RevenueFromContractWithCustomerTerminationNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Variable Consideration Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=snti_SparkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=snti_SparkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-05-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2021-05-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748156163328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Grant Income (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant income</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Grant income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_GrantAssistancePeriodOfRecognition', window );">Period of recognition of grant (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_GrantAssistancePeriodOfRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Grant Assistance, Period Of Recognition</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_GrantAssistancePeriodOfRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748154231904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue - Entity-wide information (Details) - Revenue Benchmark - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=snti_CustomerAMember', window );">Customer A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration</a></td>
<td class="nump">81.00%<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=snti_CustomerBMember', window );">Customer B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of concentration</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=snti_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=snti_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=snti_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=snti_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748151064272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 05, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 08, 2022 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 19, 2021 </div>
<div>tranche </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Cost not yet recognized, options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=snti_A2016StockIncentivePlanMember', window );">2016 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Issued in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Common stock subject to repurchase (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">92,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_CommonStockSubjectToRepurchaseValue', window );">Common stock subject to repurchase | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=snti_A2022StockIncentivePlanMember', window );">2022 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold', window );">Exercise price of an ISO granted to a stockholder (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized for issuance under share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,492,735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,168,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage', window );">Annual increase in authorized shares, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=snti_A2022StockIncentivePlanMember', window );">2022 Stock Incentive Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue', window );">Estimated fair value of the shares on the date of grant (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=snti_A2022InducementEquityPlanMember', window );">2022 Inducement Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized for issuance under share-based payment arrangement (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,130,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Cost not yet recognized, period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | 2016 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | 2022 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options | 2022 Inducement Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period (in years)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">Employee Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Authorized for issuance under share-based payment arrangement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">592,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">923,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod', window );">offering period (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares', window );">ESPP purchase price of common stock, percent of market price (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Cost not yet recognized, period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">grants in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,796,074<span></span>
</td>
<td class="nump">8,400,892<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward', window );">Terms of award (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">four<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Cost not yet recognized, excluding options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=snti_MarketAwardsMember', window );">Market Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Cost not yet recognized, period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">grants in period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,748<span></span>
</td>
<td class="nump">605,451<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Cost not yet recognized, excluding options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Cost not yet recognized, period for recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Cost not yet recognized, excluding options | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_CommonStockSubjectToRepurchaseValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common Stock Subject to Repurchase, Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_CommonStockSubjectToRepurchaseValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Increase In Authorized Shares, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement, By Share-Based Payment Award, Annual Increase In Shares Authorized, Percentage Of Outstanding Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Exercise Price, Percentage Of Fair Market Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Stockholder Ownership Percentage, Threshold</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of terms of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=snti_A2016StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=snti_A2016StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=snti_A2022StockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=snti_A2022StockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=snti_A2022InducementEquityPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=snti_A2022InducementEquityPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=snti_MarketAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=snti_MarketAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748152086208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at December 31, 2022 (in shares)</a></td>
<td class="nump">4,191,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,189,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(203,367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at March 31, 2023 (in shares)</a></td>
<td class="nump">6,177,759<span></span>
</td>
<td class="nump">4,191,426<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and exercisable at March 31, 2023 (in shares)</a></td>
<td class="nump">972,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at December 31, 2022 (in dollars per share)</a></td>
<td class="nump">$ 3.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">1.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">3.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at March 31, 2023 (in dollars per share)</a></td>
<td class="nump">2.69<span></span>
</td>
<td class="nump">$ 3.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Vested and exercisable at March 31, 2023 (in shares)</a></td>
<td class="nump">$ 3.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Stock Options Additional Disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at December 31, 2022, Weighted average remaining contractual life (Years)</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding at March 31, 2023, Weighted average remaining contractual life (Years)</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable at March 31, 2023, Weighted average remaining contractual life (Years)</a></td>
<td class="text">7 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at December 31, 2022, aggregate intrinsic value</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at March 31, 2023, aggregate intrinsic value</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested and exercisable at March 31, 2023, aggregate intrinsic value</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748150989232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Performance Awards Activity (Details) - Performance Shares - $ / shares<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning of period (in shares)</a></td>
<td class="nump">5,368,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(69,100)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, end of period (in shares)</a></td>
<td class="nump">5,299,401<span></span>
</td>
<td class="nump">5,368,501<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested and exercisable, end of period (in shares)</a></td>
<td class="nump">334,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning of period (in dollars per share)</a></td>
<td class="nump">$ 9.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">9.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, end of period (in dollars per share)</a></td>
<td class="nump">9.92<span></span>
</td>
<td class="nump">$ 9.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested and exercisable, end of period (in dollars per share)</a></td>
<td class="nump">$ 9.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding, end of period, weighted average remaining contractual life (in years)</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">9 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm', window );">Vested and exercisable, end of period, weighted average remaining contractual life (in years)</a></td>
<td class="text">7 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Exercisable, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748156476112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Restricted Stock Units Activity (Details) - Restricted Stock Units (RSUs)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Mar. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Number of Restricted Stock Units</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning of period (in shares) | shares</a></td>
<td class="nump">447,948<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(59,626)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, end of period (in shares) | shares</a></td>
<td class="nump">388,322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, beginning of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">2.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Outstanding, end of period (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748154674768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Weighted Average Assumptions (Details) - Options<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility (in percent)</a></td>
<td class="nump">82.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate (in percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield (in percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748150834112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 3,763<span></span>
</td>
<td class="nump">$ 661<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,239<span></span>
</td>
<td class="nump">458<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 524<span></span>
</td>
<td class="nump">$ 203<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748154320208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Tax (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax provision (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748147337344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Basic and Diluted Net Earnings (loss) Per Common Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (18,722)<span></span>
</td>
<td class="num">$ (11,808)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares used in computing net loss per share, basic (in shares)</a></td>
<td class="nump">44,070,974<span></span>
</td>
<td class="nump">3,171,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares used in computing net loss per share, diluted (in shares)</a></td>
<td class="nump">44,070,974<span></span>
</td>
<td class="nump">3,171,254<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_EarningsPerShareBasicAndDilutedEPSAbstract', window );"><strong>Earnings Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share attributable to common stockholders, diluted (in shares)</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (3.72)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share attributable to common stockholders, basic (in shares)</a></td>
<td class="num">$ (0.42)<span></span>
</td>
<td class="num">$ (3.72)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_EarningsPerShareBasicAndDilutedEPSAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Earnings Per Share, Basic and Diluted EPS</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_EarningsPerShareBasicAndDilutedEPSAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748151036352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2023</div></th>
<th class="th"><div>Mar. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">14,274,070<span></span>
</td>
<td class="nump">21,662,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=snti_SeriesAAndBRedeemableConvertiblePreferredStockMember', window );">Series A and B redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">19,517,988<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">11,792,908<span></span>
</td>
<td class="nump">1,814,742<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=snti_UnvestedEarlyExercisedOptionsMember', window );">Unvested early exercised options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">92,840<span></span>
</td>
<td class="nump">329,850<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">388,322<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=snti_ContingentEarnoutCommonStockMember', window );">Contingent earnout common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=snti_SeriesAAndBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=snti_SeriesAAndBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=snti_UnvestedEarlyExercisedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=snti_UnvestedEarlyExercisedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=snti_ContingentEarnoutCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=snti_ContingentEarnoutCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748150766320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 08, 2022 </div>
<div>tranche </div>
<div>shares</div>
</th>
<th class="th">
<div>May 21, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 03, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 57,904<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments', window );">Annual maintenance payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ReverseRecapitalizationContingentConsiderationEquityShares', window );">Maximum contingent earnout (in shares) | shares</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches', window );">Number of tranches of contingent earnout shares | tranche</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche', window );">Number of contingent earnout shares per tranche (in shares) | shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=snti_BlueRockMember', window );">BlueRock | Research and Development Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term purchase commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=snti_BlueRockMember', window );">BlueRock | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ResearchAndDevelopmentExpenseTermOfAgreement', window );">Term of agreement (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ResearchAndDevelopmentArrangementExpectedCosts', window );">Expected costs and expenses incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=snti_CGMPFacilityMember', window );">cGMP Facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long-Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForConstructionInProcess', window );">Construction costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term purchase commitment amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Contractual Annual Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ResearchAndDevelopmentArrangementExpectedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Expected Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ResearchAndDevelopmentArrangementExpectedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ResearchAndDevelopmentExpenseTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expense, Term of Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ResearchAndDevelopmentExpenseTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Contingent Consideration Classified as Equity, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ReverseRecapitalizationContingentConsiderationEquityShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Contingent Consideration, Equity, Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ReverseRecapitalizationContingentConsiderationEquityShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reverse Recapitalization, Contingent Consideration, Equity, Shares per Tranche</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForConstructionInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForConstructionInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=snti_BlueRockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=snti_BlueRockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis=us-gaap_ResearchAndDevelopmentArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=snti_CGMPFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=snti_CGMPFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.1</span><table class="report" border="0" cellspacing="2" id="idm139748150364352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Parties (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 08, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 21, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2023 </div>
<div>tradingDay </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>tradingDay </div>
<div>shares</div>
</th>
<th class="th">
<div>May 19, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,075,194<span></span>
</td>
<td class="nump">44,062,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_NumberOfSeatsOnTheBoardOfDirectors', window );">Number of seats on the board of directors | tradingDay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember', window );">Common Class A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of redeemable convertible preferred stock into common stock in connection with the Reverse Recapitalization, net of transaction costs (in shares)</a></td>
<td class="nump">517,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Common stock share price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=snti_May2022NoteMember', window );">May 2022 Note</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Principal amount of unsecured convertible promissory note | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=snti_NEAMember', window );">NEA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,429,725<span></span>
</td>
<td class="nump">4,429,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_NumberOfSeatsOnTheBoardOfDirectors', window );">Number of seats on the board of directors | tradingDay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=snti_BlueRockMember', window );">BlueRock | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ResearchAndDevelopmentArrangementExpectedCosts', window );">Expected costs and expenses incurred | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_ResearchAndDevelopmentExpenseTermOfAgreement', window );">Term of agreement (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=snti_BayerMember', window );">Bayer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,878,488<span></span>
</td>
<td class="nump">5,878,488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_NumberOfSeatsOnTheBoardOfDirectors', window );">Number of seats on the board of directors | tradingDay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=snti_SeerIncMember', window );">Seer, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty', window );">Expenses incurred from transaction | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm', window );">Expenses incurred from transaction, payment term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_NumberOfSeatsOnTheBoardOfDirectors">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Seats On The Board Of Directors</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_NumberOfSeatsOnTheBoardOfDirectors</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Related Party Transaction, Expenses from Transactions with Related Party, Payment Term</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ResearchAndDevelopmentArrangementExpectedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Expected Costs</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ResearchAndDevelopmentArrangementExpectedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_snti_ResearchAndDevelopmentExpenseTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and Development Expense, Term of Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">snti_ResearchAndDevelopmentExpenseTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>snti_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=snti_May2022NoteMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=snti_May2022NoteMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=snti_NEAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=snti_NEAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=snti_BlueRockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=snti_BlueRockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=snti_BayerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=snti_BayerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=snti_SeerIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=snti_SeerIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>snti-20230331_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:snti="http://www.sentibio.com/20230331"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="snti-20230331.xsd" xlink:type="simple"/>
    <context id="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i839f745b74bd42b2b4ae2745233146b4_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:EntityAddressesAddressTypeAxis">dei:FormerAddressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5a1e89939cfa42e790464e0d1aafd27c_I20230501">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
        </entity>
        <period>
            <instant>2023-05-01</instant>
        </period>
    </context>
    <context id="i2db00a77192f4255a898540eac49878e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5bdb6a23de54461f88fa0cf0fb407155_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie93d0f28fa434fdd8b2c267c63e09208_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">snti:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i5b11b2dbf83b49388972be2c36307328_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">snti:RelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i81b11644709349c9bc306b63606105cc_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i4e8c2a57c818445b8ad0d8224990f182_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i28bc0e58798a48d59cce5700cab14713_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i5910a2afac7e44af947c9bd551313533_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia327828af3c64db9a9c8cc328000bcb5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i78a270744c2d4a1f98a4a39f1d1043d3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="id81fb690a0ac44c7b7413c241996b920_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6e696449bb8f473ba9b98e6d54a4196f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6a290377bb464be7a1011652879be414_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic47933b228a74660947c56c9928b9097_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i83c0f0002c6640cf8e492cd72f557b7f_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i521e15cacfab469899d7fc2c91390f18_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id07031ea08724f1eb814c4d290dec411_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="id453bf1b5a4b44eb97fecc35ef14b460_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i81684dd89952407fad1331a3c1ba7940_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ia120b6b0d53947b9858a5dbe0b78569f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if1f5158cc8cb4ef09ae38b5dc0f801bf_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if4026bb920b246c6ab69bb9a495e015c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5ec8395b47bf40878513f3f1f51bfab2_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2611a18b085f44fa80ee121714ee9959_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i6c7cf871f8f445ce8ffd3b796c78114b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i72961400d84f441aa4a9de049fb9ea0f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if20ddea8370b47e2a8d0cc41b5712871_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3400e851c0774865aacdc65833967f02_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id70d23838a974b229e80c5c9278df638_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iaa14ff1d6afd4a6aaad076de554b3054_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ia1507455ae4545acb5c5e77c20ccf10c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id5a57a126aad418cab737f9098520762_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i78139b1e342f47d9b902943821cf2036_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if4705a76340e438cbf1fd59d574befef_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4a0a24d2beff407985996abce370fac1_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic853c11d285841a9a58448f68290872e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i54edccfe021d431689266dad3928a2bf_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic621dc1a5dd1488e9267eea6f23d8049_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3e4f2aae937b4d63890360a721452a0a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i38ec92e6b86d4514acf595c514672dce_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i07bc91a53f5a459baf1197c27ade6ed2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib1249a7ce3f54ef5bb8002ca6d310e15_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i04e58e5594694539a02749f71be310dd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i806026a6a971437f8a3ed419e043f3f8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0599314ad55c451a80b55746b2dc9bfd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id7093d18319c4542a600a6987750ebc6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i56248ee32fc0485f8d3c8bad91562cee_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0e20fb37f0c44033bc88e5d7cdb0ff33_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie612beff75d94ee5b9518fe9ad917d8c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9a0ba519d4ef4fc6aeabfe9afc583b1a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ibcdf00099f6948e394392540bc14975f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i182e6b0e83c74e2e91736e7bb9c35972_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i201af4811a374b0d85692aa3b41f79b5_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i3359592a1b094bac8319cc1e2408c43f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic3c09c639dac47edb944ea9ecf3b0299_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ic8d224f088f74ed28515d75a9ea6d258_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i31c096de9b294cce82f4eddee4fe3e1a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i613e04533fcc42e9b6435b116c5cf0be_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i66db0287b069499789e51d16f875e403_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1967ceac06c041718a989a37273e427a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iecaecf3f762f4965b2caf2cdaec72352_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i8df3f77390c94af5886983ba9c67ce4c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i738f1818b2ee440b81ae9395474ef8a6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i77067e3a647e4bcf86bbaa6aecc10bc6_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6d690099dd934e29ab16020f70f61c81_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i04776ba3407e4211bf944ba32f788c04_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0c53dece0f4746dca63507589ca1b33f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ic975f5329514459cb776591a8393e656_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i341995b37eeb4178a439a3e4c98245c3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4c01bb3709c34dd49620a247ad1fbc01_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i230fd69e00ae4f99b1e3a2d854b95850_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5289294e32684de3b46e5ac39b5c1c4c_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibb5bf968a6f341f1a417ef865d2b0373_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8cf2e03c3b7044dd8f4d13d428853cad_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i0493e8bc17624187bbe1a3959ac97b33_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i45596385065544378327410d696e5e0f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iae83b8ab01644353acb71b4d4fcf3c2b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i5a9825b53292444882e4b80aee4ca647_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ibba6c7e42d174d4dad4f3aa9b26cc841_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i86691c0476ba404f814077f7c6873c81_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id7dddc4574d1483ca39ac475a557c315_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i2ed753b6656243da8485cb9941f77565_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i031d672c83f54e5596727cbdebf7ddce_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i369efc411a944e0ab23af95aeaed1da3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iaf727ea3cbd14cc599d0b296bd695c30_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id2dd1486f0094652a61e2542b663d473_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="iac83004296dc489eb73145ef1a50ed6f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i652407f4e1424c81a265a8aeb53e2c9f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="icb62e4f0d0f34a19a5af68bf3ca4be90_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i758da6ca9a82424fbac7ce29a91ab127_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3913e52d42bd4b0584295d1000454575_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">snti:RestrictedCashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib4bf17ca1c12485a95f53564217086b7_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i057bc7826d4b4c84aacdd029762ebfee_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">snti:ContingentEarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="idc3b98e8794d4db98f8a5bec44536adc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">snti:ContingentEarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0d7515206e374c2f8b3ba0988b6e7cc6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">snti:ContingentEarnoutLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i84c054ca47f34f0fb57a2cc22fa7ebb3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">snti:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ib151b972fd8f4cd79d899cda2eeb31e2_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">snti:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3df465c4a0264659996eb97c82a869a6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9622647ee0c949e0a3c0188f49fed90f_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i6a54633d73574574bcdce66f8f30a522_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">snti:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i092aed2ed1dc43bba672fdbaa11ea98d_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">snti:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ie51e5a8e9f5f4b7a82df0ce23e6b0e47_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i2de56f4fdc344660850e0c6380cf9deb_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i55a0a250ecba480e9d2984321a23058c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ie5a7787f606c4694a34c9edafbf1c9a3_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i13c2b1f5934440b19195e3dc99ca0b84_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">snti:CorporateHeadquartersMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iffa91051becf44e9bef166d4fa25aabf_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">snti:AlamedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if0a2f740c54a4460bdf1870465e2fd28_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">snti:AlamedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i13d4209f114b48ae802f8c70848bac8d_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">snti:AlamedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i5a99c95357954ece87322f3f9568adc0_D20210730-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">snti:AlamedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-30</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i81d4d8a5f9114d1886175ca8b72ce10a_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7840bf286e7b4bce9183521fe23e6524_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="id20463a91ddd421ea41fcb5abe035d56_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6e6ef9d05bdb4e6ab4465b3414f327a9_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i16305f4a1b8449d1a35861d9aa0fc5c8_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i9ee3457100c84c3d87184e1e135ba640_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i47d461e06c0441f3bf66aa005d566b32_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:CommonStockUnderEquityPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i52cce8c44b9b4333a95f74f60f360543_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:CommonStockUnderEquityPlansMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1cabf5a80a1a48298b9edf643135beb0_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i0381c522846d4ca6a0f0602fe5c59dc0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i4027bdb9ad2f4e6c85d6878c9bb667fc_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:ContingentEarnoutCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="id5f4bb6471d7488ba9e91594b407b669_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:ContingentEarnoutCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i066bdaf0f5a0401387fa517ed3d8324c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i190ad14af5cf48d182dd17a670b1c6b0_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">snti:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-31</startDate>
            <endDate>2022-08-31</endDate>
        </period>
    </context>
    <context id="i2695814ca4b34861bbd946616eacf91a_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">snti:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="i3301414885c64fcb913d8ab29a5a4c1d_I20220831">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">snti:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-31</instant>
        </period>
    </context>
    <context id="iaf30c96ccd494c5792c0230ca1a3d6db_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">snti:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i29d9a37c9c3b447eb4fb6ec96fa1dd2b_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">snti:CommonStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i2cf3659743e3408a95f042ce0308c736_D20220608-20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
        </entity>
        <period>
            <startDate>2022-06-08</startDate>
            <endDate>2022-06-08</endDate>
        </period>
    </context>
    <context id="ic402157e4d8841ffabfdea65ced1a7b6_I20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="ic0e7bfd5199240fe911cf1a70a64d6a8_I20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">snti:ContingentConsiderationTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="i3a8876a6338d4250b6c025cf2cd85bf7_I20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="snti:ContingentConsiderationTranchesAxis">snti:ContingentConsiderationTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="i73952d58d72347dd9b9031f6d875bf3d_D20220608-20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">snti:ContingentConsiderationTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-08</startDate>
            <endDate>2022-06-08</endDate>
        </period>
    </context>
    <context id="i987337493e8f4d6b95c95a50303ac90b_D20220608-20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">snti:ContingentConsiderationTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-08</startDate>
            <endDate>2022-06-08</endDate>
        </period>
    </context>
    <context id="i478aae25e06348e2896c5435db3def08_I20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="i1d50e05b3f964b1e8bd1212007d0f5b2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i4303eca5071e4e959e6a005f6949bbc0_I20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="i585e64a0dde84731b30a56a965b3502e_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i22fe4e8df6ab4d1dab35a6b9027729c0_I20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="i4dfd924deef14485b70ba9b749718b18_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="iebf31f1f016a4897aeecc0db5ee0375f_I20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="i743280c266ac4be9bba0b85a394d535f_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i6c5f60d8079a4c929fb01b0c4238eb77_I20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="i74c815e4a7ff416083bff82a684e4da6_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if7e5dfb75c5345e0908face1c31bf68c_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SparkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i928b078b707f45d4ab1ac6398e73bf1b_I20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SparkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2021-05-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i766f28525f3748399d68ffe1034f13d1_D20221201-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SparkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9b3c57ec032744ba8f6125f37486a864_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SparkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i27014437a0604c6493a324456d9bebc5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SparkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="if8ecffc42af64ac98c375ec96588e97e_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SparkMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="ieb49597653b64cf59b45a61e885d9cab_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SparkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="id4caf954de824dcfa399375ed1463740_D20210401-20210430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SparkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="i27aef62b1f3e4bffb3dd2df12b5856fe_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i71c1a8f9ff524518959d9a765706749d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie8b4557210454abca1e04086bd66db43_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">snti:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="icaa788b9dd8d4c5989a84143f00ba716_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">snti:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i39380c3017c0443ea9d9f875c6d12c89_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">snti:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="id0b118498cc947c4a737ef007df909ed_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">snti:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3e7073ad95d14237a686257c1f249847_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2016StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i8bbb2d044d4540fba0cfd4b952348522_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i109dbba609114d389a60bbd41cab5bfc_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i0157834a97314a79aab287cf1bcc1d2d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i3d089448db5c47ac864b335700ebdf6c_I20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="i1fdc25c4786948e396c80e21496eaec2_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i65140541deed4a8a9d94a28b4b349127_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022InducementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i93b6fc338c6a44bfac709886289913e3_D20220805-20220805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022InducementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-08-05</startDate>
            <endDate>2022-08-05</endDate>
        </period>
    </context>
    <context id="i84ff68234e48415aabc730672a424709_I20220805">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022InducementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-08-05</instant>
        </period>
    </context>
    <context id="i3b946e4dc38a43f985ff9ce7ef855a78_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2022InducementEquityPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifb4c537cd827433eb1fd0857cc6e392f_D20220608-20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-08</startDate>
            <endDate>2022-06-08</endDate>
        </period>
    </context>
    <context id="i7ab0adeec3bc495a85352b6cd04f0ea6_I20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="i921a457818234d30b26fac9b4d02f4a7_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="ie25bf12b097d4142a80c4443e8e34b7c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia6f53a18a05e4e3e9c95c5959b5464af_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2016StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i09e65d7dd7ff4a518134d5af6af7496b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2016StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="iecb98f68e3f54315adf9e9038dadf418_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2016StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i6cba8c98475b4484aa393d6615db82dd_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2016StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="ifc61cf9dbb914210b3fe39d9d8805450_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">snti:A2016StockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i09d1b2b0e78f4a2a9de67b5ef64622f8_D20211219-20211219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-19</startDate>
            <endDate>2021-12-19</endDate>
        </period>
    </context>
    <context id="i55f59dff27474019a6a976d08d32c7a5_D20220608-20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-08</startDate>
            <endDate>2022-06-08</endDate>
        </period>
    </context>
    <context id="i5aee551dc4424308a0cbe423b5aa00f5_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i3f3e04de252e4ab9ad665ce2c64c8f64_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i787b64c59226487c91cbebde035a735d_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="if95b9a3a21314a64be95e971b65657ab_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i148f91500cfa448b90c1ca1b3fe51ddd_D20211219-20211219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:MarketAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-19</startDate>
            <endDate>2021-12-19</endDate>
        </period>
    </context>
    <context id="i342ee2fd8d6845069313253e24f45e30_I20211219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:MarketAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-19</instant>
        </period>
    </context>
    <context id="i1d8a71f2d75d44fd822915e608589a18_D20220608-20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:MarketAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-08</startDate>
            <endDate>2022-06-08</endDate>
        </period>
    </context>
    <context id="id4e222fd06584beba7f3df061459dfd0_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:MarketAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ifb827c206b774ff486fdcdc6ed921a68_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:MarketAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic26e10f702604471b0ad4cc00f011d6c_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">snti:MarketAwardsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i24a619ba2bc2425c8c531466ceb3022f_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ib140873ca1da43bab9fd62b4810057e8_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i6537e1d4905e4ed2b36a8e22e7ed2fde_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="iba81969c6f8347389b8d4c2ac513fd4e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i3f71e36b64d04c6589346f18f9cf047d_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i1dfd433797ae4a47a3afcd51ca0bd98b_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ie599948bb538493ca54ae5c945c4b314_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">snti:SeriesAAndBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="if2546b82138745239b77f03d5bb97902_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">snti:SeriesAAndBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i8ce095b293ee421697f3e146ad0f8453_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="ia1ba20d9c2a54249ad151ad0d937ed15_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="ic1c8a87aa2e340119590adac4cec8f56_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">snti:UnvestedEarlyExercisedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i9531c149469c43a9ac1f3916d2cb652f_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">snti:UnvestedEarlyExercisedOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i0c36144fc5464645b44250cb81efdb06_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i7307cc0c5600489eb471edc1bd0b09e3_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i45a6fb8c66694eb9a022dbc503607f1c_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">snti:ContingentEarnoutCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i162569ca541746a58397f1201089485e_D20220101-20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">snti:ContingentEarnoutCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="i43648233679b4319915d781e0fdea7bf_I20210603">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
        </entity>
        <period>
            <instant>2021-06-03</instant>
        </period>
    </context>
    <context id="i082b5a0a6bc54f70b3e73ff4d25c3e03_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">snti:CGMPFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i591e3e2787ef4aa3b0dde7a4158d5d4e_D20210521-20210521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:BlueRockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-21</startDate>
            <endDate>2021-05-21</endDate>
        </period>
    </context>
    <context id="i9ddb97ef409844f1b6d57e39963c1d3d_I20210521">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:BlueRockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-21</instant>
        </period>
    </context>
    <context id="id747b950a62d4ac19aee5dcc6cf15399_D20230101-20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:BlueRockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis">us-gaap:ResearchAndDevelopmentArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-03-31</endDate>
        </period>
    </context>
    <context id="i5f79f3be18db4668bcb3b5370e9cecd3_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:NEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i7c26ec28b64d45bc9036cc8d57f2140b_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:NEAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="i1f7c274bcbdf4ef58b92b5848babde15_I20220519">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">snti:May2022NoteMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-05-19</instant>
        </period>
    </context>
    <context id="ib7a73372076e4e89a384e72fe0e3c45e_D20220608-20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-06-08</startDate>
            <endDate>2022-06-08</endDate>
        </period>
    </context>
    <context id="i057310d2a92b4448be2ea0e4a9991828_I20220608">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonClassAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-08</instant>
        </period>
    </context>
    <context id="ie37202655afe400799f589b98e2e9296_I20230331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-31</instant>
        </period>
    </context>
    <context id="i1fc3f895e15c4c5e96890aa6215ca746_I20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:BayerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="ib8899c630b094438a9d71777a8d3774a_D20230101-20230131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001854270</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">snti:SeerIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-01-31</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="businessactivitiy">
        <measure>snti:businessActivitiy</measure>
    </unit>
    <unit id="reportablesegment">
        <measure>snti:reportableSegment</measure>
    </unit>
    <unit id="tradingday">
        <measure>snti:tradingDay</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="vote">
        <measure>snti:vote</measure>
    </unit>
    <unit id="tranche">
        <measure>snti:tranche</measure>
    </unit>
    <unit id="years">
        <measure>snti:Years</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80L2ZyYWc6MmFlZTUwYjA5NzhmNGNjM2IxODk0YWZkZWMyNTg1NzQvdGFibGU6NDZhNmZmYTlhOWVjNGNlODljYjM1ZWJiNzMwOGZlYzYvdGFibGVyYW5nZTo0NmE2ZmZhOWE5ZWM0Y2U4OWNiMzVlYmI3MzA4ZmVjNl8yLTItMS0xLTEzMDc4Mw_4bbf7482-d3ed-4b2e-9eee-fb22c3723041">0001854270</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80L2ZyYWc6MmFlZTUwYjA5NzhmNGNjM2IxODk0YWZkZWMyNTg1NzQvdGFibGU6NDZhNmZmYTlhOWVjNGNlODljYjM1ZWJiNzMwOGZlYzYvdGFibGVyYW5nZTo0NmE2ZmZhOWE5ZWM0Y2U4OWNiMzVlYmI3MzA4ZmVjNl8zLTItMS0xLTEzMDc4Mw_d8c1c19a-d8d6-42c7-8c6e-40dcd8ccd9b2">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80L2ZyYWc6MmFlZTUwYjA5NzhmNGNjM2IxODk0YWZkZWMyNTg1NzQvdGFibGU6NDZhNmZmYTlhOWVjNGNlODljYjM1ZWJiNzMwOGZlYzYvdGFibGVyYW5nZTo0NmE2ZmZhOWE5ZWM0Y2U4OWNiMzVlYmI3MzA4ZmVjNl80LTItMS0xLTEzMDc4Mw_f4df1221-fbfc-48fe-b7fc-d0fa2afbad42">2023</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80L2ZyYWc6MmFlZTUwYjA5NzhmNGNjM2IxODk0YWZkZWMyNTg1NzQvdGFibGU6NDZhNmZmYTlhOWVjNGNlODljYjM1ZWJiNzMwOGZlYzYvdGFibGVyYW5nZTo0NmE2ZmZhOWE5ZWM0Y2U4OWNiMzVlYmI3MzA4ZmVjNl81LTItMS0xLTEzMDc4Mw_a8e0c684-dada-4436-aeec-a2e4cd092653">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80L2ZyYWc6MmFlZTUwYjA5NzhmNGNjM2IxODk0YWZkZWMyNTg1NzQvdGFibGU6NDZhNmZmYTlhOWVjNGNlODljYjM1ZWJiNzMwOGZlYzYvdGFibGVyYW5nZTo0NmE2ZmZhOWE5ZWM0Y2U4OWNiMzVlYmI3MzA4ZmVjNl82LTItMS0xLTEzMDc4Mw_575d84aa-ae16-4f30-967a-b3bf2763b38e">false</dei:AmendmentFlag>
    <snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays
      contextRef="i2cf3659743e3408a95f042ce0308c736_D20220608-20220608"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNTE5OA_43c54c31-da11-473c-9a9b-97c930e0d994">P20D</snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays>
    <snti:ReverseRecapitalizationContingentConsiderationEquityTerm
      contextRef="i73952d58d72347dd9b9031f6d875bf3d_D20220608-20220608"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NTIxMA_4c4a7b87-cc7a-4ee5-be63-48c4f60a7afc">P2Y0M0D</snti:ReverseRecapitalizationContingentConsiderationEquityTerm>
    <dei:DocumentType
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6MThmMTBjZWQ4OWE3NDA3YWE5YzliYjNmZTMxZGQ3NGEvdGFibGVyYW5nZToxOGYxMGNlZDg5YTc0MDdhYTljOWJiM2ZlMzFkZDc0YV8wLTAtMS0xLTEzMDc4My90ZXh0cmVnaW9uOjcyMmY0MWIwNjUxZDQ2NzhiYWE2MzAyMDc3MzQxNTRiXzk_b87463f8-f2c7-43a2-a4f7-83cb93e3e804">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6NjA1NTY5ZjgxYzEyNDBjOWFjOGRkZGZlY2EzZjFlYmEvdGFibGVyYW5nZTo2MDU1NjlmODFjMTI0MGM5YWM4ZGRkZmVjYTNmMWViYV8xLTAtMS0xLTEzMDc4Mw_2e1f839f-b312-41d1-b47d-34dc3716e97a">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6NjA1NTY5ZjgxYzEyNDBjOWFjOGRkZGZlY2EzZjFlYmEvdGFibGVyYW5nZTo2MDU1NjlmODFjMTI0MGM5YWM4ZGRkZmVjYTNmMWViYV8yLTEtMS0xLTEzMDc4My90ZXh0cmVnaW9uOjI1YTk4ODE5M2ZkMTRiNWFhYmVhNGZmODk4NWJmNDU4XzM1_ccfca7e1-b240-4418-93d0-8ba6a308164a">2023-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6NjA1NTY5ZjgxYzEyNDBjOWFjOGRkZGZlY2EzZjFlYmEvdGFibGVyYW5nZTo2MDU1NjlmODFjMTI0MGM5YWM4ZGRkZmVjYTNmMWViYV8zLTAtMS0xLTEzMDc4Mw_e12d965e-287f-4ecc-8835-d55f0eb17935">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMjk3_095685de-f492-4016-b833-cf8c0294dfaf">001-40440</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMjk4_c7bdbec9-890a-48d8-a566-6050eccb3931">Senti Biosciences, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6MTM4NzFiM2I5OTIyNDhhZWE2YWNhMzc4YjA3NDM5MDYvdGFibGVyYW5nZToxMzg3MWIzYjk5MjI0OGFlYTZhY2EzNzhiMDc0MzkwNl8wLTAtMS0xLTEzMDc4Mw_78b4cd7a-7a37-42e7-8f0c-510cfc43448c">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6MTM4NzFiM2I5OTIyNDhhZWE2YWNhMzc4YjA3NDM5MDYvdGFibGVyYW5nZToxMzg3MWIzYjk5MjI0OGFlYTZhY2EzNzhiMDc0MzkwNl8wLTItMS0xLTEzMDc4Mw_e1217af3-64d2-4b34-a5c8-beec5f252ae8">86-2437900</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzA1_d97f8539-6a82-4da7-9f29-9b2d26b1900b">2 Corporate Drive, First Floor</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzAw_aa0bcee3-6082-4201-a760-f23eda838230">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzAx_a01be5e4-0653-4a71-ab74-802271144130">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8zNTM_5887e94f-3fe5-43a8-bae4-c3e577b066a0">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzA2_b118cfe9-cbe6-432e-901b-e36de22a9407">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzAz_a740de6e-b863-4b75-a1e8-6b50e770ad6e">239-2030</dei:LocalPhoneNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i839f745b74bd42b2b4ae2745233146b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMjk1_4268c8e3-a2c4-4dd2-a554-133405781634">2875 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i839f745b74bd42b2b4ae2745233146b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzA3_1fac5021-cda8-4075-bf1d-4f18ee4147e9">Redwood City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i839f745b74bd42b2b4ae2745233146b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMjk2_f56da2a0-0dea-41de-a27d-87ebde2a11d8">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i839f745b74bd42b2b4ae2745233146b4_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF81NDY_89910846-8048-4795-b018-0c7dae9c9d37">94061</dei:EntityAddressPostalZipCode>
    <dei:Security12bTitle
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6ZTBiYjdjMzRhMGM4NGI3ZmI4ZDg0MTZhZDdjNTRjOTkvdGFibGVyYW5nZTplMGJiN2MzNGEwYzg0YjdmYjhkODQxNmFkN2M1NGM5OV8xLTAtMS0xLTEzMDc4Mw_aa3e9123-733a-43be-b34b-58cbf0f9fe28">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6ZTBiYjdjMzRhMGM4NGI3ZmI4ZDg0MTZhZDdjNTRjOTkvdGFibGVyYW5nZTplMGJiN2MzNGEwYzg0YjdmYjhkODQxNmFkN2M1NGM5OV8xLTItMS0xLTEzMDc4Mw_51b92ea2-98ea-448a-b7df-9ed740586f80">SNTI</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6ZTBiYjdjMzRhMGM4NGI3ZmI4ZDg0MTZhZDdjNTRjOTkvdGFibGVyYW5nZTplMGJiN2MzNGEwYzg0YjdmYjhkODQxNmFkN2M1NGM5OV8xLTQtMS0xLTEzMDc4Mw_02851960-6727-4a7a-a0a0-72b1f15db744">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzA4_073780fe-7739-4a17-8101-969ea97d810c">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMjk0_2c9cde58-294d-4cf1-af25-273a453042bc">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6MGU0MjVkNDNkMWY1NDk0OWIxNGUxOTMxNGJjMzMzNDEvdGFibGVyYW5nZTowZTQyNWQ0M2QxZjU0OTQ5YjE0ZTE5MzE0YmMzMzM0MV8xLTAtMS0xLTEzMDc4Mw_556688c0-c07e-402d-b047-331b77a7b438">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6MGU0MjVkNDNkMWY1NDk0OWIxNGUxOTMxNGJjMzMzNDEvdGFibGVyYW5nZTowZTQyNWQ0M2QxZjU0OTQ5YjE0ZTE5MzE0YmMzMzM0MV8xLTMtMS0xLTEzMDc4Mw_e066fb52-f5b0-431d-b558-4d223b1f85a3">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGFibGU6MGU0MjVkNDNkMWY1NDk0OWIxNGUxOTMxNGJjMzMzNDEvdGFibGVyYW5nZTowZTQyNWQ0M2QxZjU0OTQ5YjE0ZTE5MzE0YmMzMzM0MV8yLTMtMS0xLTEzMDc4Mw_cc978c67-1ca6-44dc-909d-390245f785dd">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzA5_170f9b35-8a30-4c2b-89c0-ee4e1e07e4f9">true</dei:EntityExTransitionPeriod>
    <dei:EntityShellCompany
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMzA0_f231734c-4075-470e-90a0-b38f088e5ea4">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i5a1e89939cfa42e790464e0d1aafd27c_I20230501"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xL2ZyYWc6ZDM0YjhkMGY1MzBiNGFiMThjNzIzZDgxZTQwZTFiNmQvdGV4dHJlZ2lvbjpkMzRiOGQwZjUzMGI0YWIxOGM3MjNkODFlNDBlMWI2ZF8yMTky_eab774f3-1430-4e21-a618-f2ddcfb7741a"
      unitRef="shares">44168034</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfNC0xLTEtMS0xMzA3ODM_ca5e63d0-a82e-481f-bfb7-f57e0d8aaff0"
      unitRef="usd">31600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfNC0zLTEtMS0xMzA3ODM_8fb61176-ed21-441c-be46-b5eca64b770c"
      unitRef="usd">57621000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfNS0xLTEtMS0xMzA3ODM_fbf380b8-2555-44fc-9ad8-7547989a6bdb"
      unitRef="usd">791000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfNS0zLTEtMS0xMzA3ODM_aaddf1f1-4bc3-48d7-a591-df614e5473a7"
      unitRef="usd">626000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfNi0xLTEtMS0xMzA3ODM_bb48551f-db03-4369-85c8-1c60f3076bf8"
      unitRef="usd">44506000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfNi0zLTEtMS0xMzA3ODM_450b4b12-7f3d-4e02-80c8-2c57025da40e"
      unitRef="usd">40942000</us-gaap:ShortTermInvestments>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfNy0xLTEtMS0xMzA3ODM_9077dd0d-a655-4e42-89e6-06fd1a7286dc"
      unitRef="usd">3614000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfNy0zLTEtMS0xMzA3ODM_80cca51d-9c6c-409a-b2d3-04c1fadaab5b"
      unitRef="usd">3390000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfOC0xLTEtMS0xMzA3ODM_51f801d3-e569-43f2-9d68-b2ac8e1d76f4"
      unitRef="usd">80511000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfOC0zLTEtMS0xMzA3ODM_3ef9ed74-3da4-4cfd-9e56-bd3c13100e10"
      unitRef="usd">102579000</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCash
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfOS0xLTEtMS0xMzA3ODM_93c92854-2e14-4f02-9b9a-8faaf927fff0"
      unitRef="usd">3551000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfOS0zLTEtMS0xMzA3ODM_3e59ec70-7971-4ed8-89cc-c07b28346855"
      unitRef="usd">3366000</us-gaap:RestrictedCash>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTAtMS0xLTEtMTMwNzgz_2b38fc5d-4ab0-403b-ad41-bc82a9a4ea23"
      unitRef="usd">58987000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTAtMy0xLTEtMTMwNzgz_fa9aaa20-ab96-413f-ad77-5bb62c4240dc"
      unitRef="usd">56136000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTEtMS0xLTEtMTMwNzgz_fe1d26f5-d059-49c5-9c83-e376bc216b90"
      unitRef="usd">17905000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTEtMy0xLTEtMTMwNzgz_840fffc9-199a-44e0-b9b2-5f54b944546a"
      unitRef="usd">18418000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTItMS0xLTEtMTMwNzgz_47a3372c-b217-475e-b152-fd84cd453b29"
      unitRef="usd">471000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTItMy0xLTEtMTMwNzgz_2948b36c-854d-4a23-96b6-52d15d996652"
      unitRef="usd">293000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTMtMS0xLTEtMTMwNzgz_186831ff-08f8-423a-99b8-45a0bb1bdcc9"
      unitRef="usd">161425000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTMtMy0xLTEtMTMwNzgz_5f99e36b-3e5d-442a-b99b-1ffa15eec6cf"
      unitRef="usd">180792000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTYtMS0xLTEtMTMwNzgz_7fe4cf79-3042-4892-8af3-d3573a7d3b89"
      unitRef="usd">2582000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTYtMy0xLTEtMTMwNzgz_c527a421-e627-4874-be18-280506587a6a"
      unitRef="usd">2267000</us-gaap:AccountsPayableCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="ie93d0f28fa434fdd8b2c267c63e09208_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTctMS0xLTEtMTM3Njcy_f77db9f9-fa87-49d1-88b2-3a5c93026c74"
      unitRef="usd">95000</us-gaap:FinanceLeaseLiabilityCurrent>
    <us-gaap:FinanceLeaseLiabilityCurrent
      contextRef="i5b11b2dbf83b49388972be2c36307328_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTctMy0xLTEtMTM3Njcy_627f0f91-aa8d-4e8d-bef3-d8f3c889a4b0"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityCurrent>
    <snti:EarlyExerciseLiabilityCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTctMS0xLTEtMTMwNzgz_e145495b-fe9c-4036-8cc7-2eaffc3400ce"
      unitRef="usd">135000</snti:EarlyExerciseLiabilityCurrent>
    <snti:EarlyExerciseLiabilityCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTctMy0xLTEtMTMwNzgz_5af0ae16-f1f5-4256-a771-538fc5f222bb"
      unitRef="usd">135000</snti:EarlyExerciseLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTktMS0xLTEtMTMwNzgz_2a9029bc-05e3-4de2-a6ef-80ac28a7e84c"
      unitRef="usd">407000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMTktMy0xLTEtMTMwNzgz_2322430d-33f4-4680-9a47-676708e15fed"
      unitRef="usd">799000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjAtMS0xLTEtMTMwNzgz_b44a3a8c-36e9-4c16-91df-07bcc543857f"
      unitRef="usd">7591000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjAtMy0xLTEtMTMwNzgz_6997476e-b3fa-47c0-bdd7-b9631d0ec0f4"
      unitRef="usd">12864000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjEtMS0xLTEtMTMwNzgz_8d88f537-6eb9-443e-ad9d-fe5c4c018d5e"
      unitRef="usd">2056000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjEtMy0xLTEtMTMwNzgz_cf99c223-73f1-4abf-9ab4-767fbdde5a17"
      unitRef="usd">1988000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjItMS0xLTEtMTMwNzgz_ddf9f1c9-74ec-4b63-9a00-bc5dda78cd08"
      unitRef="usd">12866000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjItMy0xLTEtMTMwNzgz_e727611e-08ca-43d8-908e-d6bb5718cc85"
      unitRef="usd">18053000</us-gaap:LiabilitiesCurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="ie93d0f28fa434fdd8b2c267c63e09208_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjQtMS0xLTEtMTM3Njc4_3058cdb6-957c-4aee-a591-861b9f2a85bf"
      unitRef="usd">73000</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:FinanceLeaseLiabilityNoncurrent
      contextRef="i5b11b2dbf83b49388972be2c36307328_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjQtMy0xLTEtMTM3Njc4_474869f2-e7f8-4d71-8347-f8fcc7cf7d12"
      unitRef="usd">0</us-gaap:FinanceLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjMtMS0xLTEtMTMwNzgz_e231ca23-490d-49bd-9854-d47bbf22221f"
      unitRef="usd">35866000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjMtMy0xLTEtMTMwNzgz_f3698e68-d924-4937-96de-e0106f538686"
      unitRef="usd">35103000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjQtMS0xLTEtMTMwNzgz_31984982-c619-41d6-8237-b05f4454847d"
      unitRef="usd">168000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjQtMy0xLTEtMTMwNzgz_0e80b1d4-47de-48d7-bdcd-abc74ecea592"
      unitRef="usd">227000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <snti:EarlyExerciseLiabilityNoncurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjUtMS0xLTEtMTMwNzgz_d4fc8c39-7216-487f-b92b-6e1af8dbe960"
      unitRef="usd">112000</snti:EarlyExerciseLiabilityNoncurrent>
    <snti:EarlyExerciseLiabilityNoncurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjUtMy0xLTEtMTMwNzgz_4e19c33f-d211-4231-94c1-094b4759ea28"
      unitRef="usd">146000</snti:EarlyExerciseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjctMS0xLTEtMTMwNzgz_b59c843b-1cad-4792-9272-3fbc52556b6c"
      unitRef="usd">49085000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjctMy0xLTEtMTMwNzgz_ee06fc20-d567-47e8-90f7-4885bf1c8ccf"
      unitRef="usd">53529000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjgtMS0xLTEtMTMwNzgz_2575610e-c255-4b9b-895f-542f9398d99a"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMjgtMy0xLTEtMTMwNzgz_d7f01959-6f22-46a4-9e57-01971add4a9f"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMC0xLTEtMTMwNzgzL3RleHRyZWdpb246NjA1ODg3NmUzMjdjNGE2MDk5MmJjZjliODY5YTNmNzBfMjE_46dd7eb1-8454-4b9e-8687-ad614e5cadd1"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMC0xLTEtMTMwNzgzL3RleHRyZWdpb246NjA1ODg3NmUzMjdjNGE2MDk5MmJjZjliODY5YTNmNzBfMjE_80a251bb-69c3-40f4-b8d9-3143c7a1c859"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMC0xLTEtMTMwNzgzL3RleHRyZWdpb246NjA1ODg3NmUzMjdjNGE2MDk5MmJjZjliODY5YTNmNzBfMzU_1ae03aeb-cf40-4dbb-8b92-315e741378fb"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMC0xLTEtMTMwNzgzL3RleHRyZWdpb246NjA1ODg3NmUzMjdjNGE2MDk5MmJjZjliODY5YTNmNzBfMzU_c151700f-a09f-4b9c-a616-9f3741f9f663"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMC0xLTEtMTMwNzgzL3RleHRyZWdpb246NjA1ODg3NmUzMjdjNGE2MDk5MmJjZjliODY5YTNmNzBfNzg_408466dd-a356-456d-8f13-3ec70f2f6148"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMC0xLTEtMTMwNzgzL3RleHRyZWdpb246NjA1ODg3NmUzMjdjNGE2MDk5MmJjZjliODY5YTNmNzBfNzg_56cb8f3e-26dc-4ee5-b816-016a5c74d6f5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMC0xLTEtMTMwNzgzL3RleHRyZWdpb246NjA1ODg3NmUzMjdjNGE2MDk5MmJjZjliODY5YTNmNzBfNzg_851e37c7-2582-4392-9f49-62d4e849a6a9"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMC0xLTEtMTMwNzgzL3RleHRyZWdpb246NjA1ODg3NmUzMjdjNGE2MDk5MmJjZjliODY5YTNmNzBfNzg_c3d8dc32-1cf8-4535-9b58-7deb3baa8cfe"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMS0xLTEtMTMwNzgz_5178f703-96f6-4355-8bb1-a21da53b3674"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzEtMy0xLTEtMTMwNzgz_ff6ebe90-a650-4fb4-a820-9e8822848287"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMC0xLTEtMTMwNzgzL3RleHRyZWdpb246Yzc0NGMwYzc0MzQ1NGVhZGI2ZGIwMTAwZWJmZGRkZWNfMTg_10a5fd8e-b521-4701-ae82-ac9ae0c4ec90"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMC0xLTEtMTMwNzgzL3RleHRyZWdpb246Yzc0NGMwYzc0MzQ1NGVhZGI2ZGIwMTAwZWJmZGRkZWNfMTg_999b0d92-0ece-4709-ac2a-f5c40fb983b5"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMC0xLTEtMTMwNzgzL3RleHRyZWdpb246Yzc0NGMwYzc0MzQ1NGVhZGI2ZGIwMTAwZWJmZGRkZWNfMzI_b4d0a300-cfe6-4d53-8cde-336f78bc4ac3"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMC0xLTEtMTMwNzgzL3RleHRyZWdpb246Yzc0NGMwYzc0MzQ1NGVhZGI2ZGIwMTAwZWJmZGRkZWNfMzI_fd2c793b-219a-47ac-81fc-e06a29cd4351"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMC0xLTEtMTMwNzgzL3RleHRyZWdpb246Yzc0NGMwYzc0MzQ1NGVhZGI2ZGIwMTAwZWJmZGRkZWNfNzQ_151cbf6d-f3bc-477c-b775-c5bc183f7e53"
      unitRef="shares">44075194</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMC0xLTEtMTMwNzgzL3RleHRyZWdpb246Yzc0NGMwYzc0MzQ1NGVhZGI2ZGIwMTAwZWJmZGRkZWNfNzQ_396fb435-4719-4f54-b620-5c524bcdecf2"
      unitRef="shares">44075194</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMC0xLTEtMTMwNzgzL3RleHRyZWdpb246Yzc0NGMwYzc0MzQ1NGVhZGI2ZGIwMTAwZWJmZGRkZWNfODE_474f3d32-fbe3-4e33-a804-f6b4c749ddb3"
      unitRef="shares">44062534</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMC0xLTEtMTMwNzgzL3RleHRyZWdpb246Yzc0NGMwYzc0MzQ1NGVhZGI2ZGIwMTAwZWJmZGRkZWNfODE_d32b2ff7-cb63-4175-affd-7df54db19f24"
      unitRef="shares">44062534</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMS0xLTEtMTMwNzgz_1b674d3d-a5f7-4e71-a18b-e59c77369d4d"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzItMy0xLTEtMTMwNzgz_18317fe3-0f95-4c87-a9f8-08e9f26ef2ac"
      unitRef="usd">4000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzMtMS0xLTEtMTMwNzgz_6ef9925a-41e4-4068-b9ad-53fcb74bb4cb"
      unitRef="usd">304341000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzMtMy0xLTEtMTMwNzgz_3d6ac4a5-24e3-4474-a81f-1a7d37f6a835"
      unitRef="usd">300544000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzQtMS0xLTEtMTMwNzgz_bb1c9f3c-f0e5-4d9e-9a4e-6bed38992e68"
      unitRef="usd">3000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzQtMy0xLTEtMTMwNzgz_5f6cda5d-c42b-4e9c-ab95-83e7355c7b7f"
      unitRef="usd">1000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzUtMS0xLTEtMTMwNzgz_e79f5732-5b40-40bf-9d92-1aec0ce22fef"
      unitRef="usd">-192008000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzUtMy0xLTEtMTMwNzgz_b6a3f725-df8b-49ed-9305-f4769da1a859"
      unitRef="usd">-173286000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzYtMS0xLTEtMTMwNzgz_0dab6424-f4a7-45ba-9baa-e3b6f85ea585"
      unitRef="usd">112340000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzYtMy0xLTEtMTMwNzgz_c9f4f3a0-ba1f-4b7c-934a-102f2d8dd5f7"
      unitRef="usd">127263000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzctMS0xLTEtMTMwNzgz_ad5d4060-5aea-4bbf-b0ac-c8383451a22d"
      unitRef="usd">161425000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xNi9mcmFnOmU2YTA3ODcyMGEwZjQ5ZDNhM2E4Y2FmNjRjMTRmZmJiL3RhYmxlOmViZWJlMGVjMWUzMTQ4NTZhY2QzN2RjYzAxNzFhODkzL3RhYmxlcmFuZ2U6ZWJlYmUwZWMxZTMxNDg1NmFjZDM3ZGNjMDE3MWE4OTNfMzctMy0xLTEtMTMwNzgz_c486fa98-b502-44d6-a9df-9c602d44d927"
      unitRef="usd">180792000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMy0xLTEtMS0xMzA3ODM_cae3b20d-725f-4841-a60c-e75d26d8ee70"
      unitRef="usd">1036000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMy0zLTEtMS0xMzA3ODM_5277609e-7b22-4ee0-bb11-c79be6892e53"
      unitRef="usd">854000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfNC0xLTEtMS0xMzA3ODM_e95ff1ce-6c4f-428e-9769-80668814b67d"
      unitRef="usd">250000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfNC0zLTEtMS0xMzA3ODM_320be741-fc7e-41bf-8aca-fc02e39999ec"
      unitRef="usd">250000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:Revenues
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfNS0xLTEtMS0xMzA3ODM_756f9706-eb71-4f2e-b090-e51b14efd14e"
      unitRef="usd">1286000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfNS0zLTEtMS0xMzA3ODM_166165dc-a796-4d59-9833-b1a94c908a9a"
      unitRef="usd">1104000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfOC0xLTEtMS0xMzA3ODM_6f325d22-f3d0-4815-9c32-8ddb6d42feff"
      unitRef="usd">11318000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfOC0zLTEtMS0xMzA3ODM_9f92404d-ab44-4c15-9203-36b0ee91d6c2"
      unitRef="usd">7603000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfOS0xLTEtMS0xMzA3ODM_d582358d-a42c-45e1-bf20-823a8cc20f39"
      unitRef="usd">9802000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfOS0zLTEtMS0xMzA3ODM_50bba16b-9c32-4107-8a18-5b1912b5641d"
      unitRef="usd">5259000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTAtMS0xLTEtMTMwNzgz_5bc04af8-a906-4a7d-9114-3f5b8a5a8843"
      unitRef="usd">21120000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTAtMy0xLTEtMTMwNzgz_1b700bcb-14ae-4f07-83cb-0f5560e6b477"
      unitRef="usd">12862000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTEtMS0xLTEtMTMwNzgz_52943476-8605-4f76-9764-34491bfae42e"
      unitRef="usd">-19834000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTEtMy0xLTEtMTMwNzgz_9571cceb-8931-4da0-b0cc-a367b1603cea"
      unitRef="usd">-11758000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTQtMS0xLTEtMTMwNzgz_8545aefd-1059-4290-b477-cbba53d77aca"
      unitRef="usd">1061000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTQtMy0xLTEtMTMwNzgz_3a19b28c-fbfb-4553-837f-bc8023013d14"
      unitRef="usd">4000</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTUtMS0xLTEtMTMwNzgz_bb828665-f221-4b7d-b772-ab8415b9c123"
      unitRef="usd">-59000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTUtMy0xLTEtMTMwNzgz_b6b3f0ca-c750-45cf-be88-e16e2bbf4ab1"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTktMS0xLTEtMTMwNzgz_0c6596b3-4b7e-47a9-a046-98bce6b0a03c"
      unitRef="usd">-8000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMTktMy0xLTEtMTMwNzgz_34d72a14-aa07-4731-ab24-3c7648ad5068"
      unitRef="usd">-54000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjAtMS0xLTEtMTMwNzgz_a97cc60f-74ca-4e78-8dda-9e1ee6ce451e"
      unitRef="usd">1112000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjAtMy0xLTEtMTMwNzgz_b7efe616-b45a-478a-8c40-f2965baa8cce"
      unitRef="usd">-50000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjEtMS0xLTEtMTMwNzgz_dada71f3-ed65-49fb-b83a-dc958ecd5dc1"
      unitRef="usd">-18722000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjEtMy0xLTEtMTMwNzgz_6e34f3d1-9ea3-4217-bb77-7ba38a8dc085"
      unitRef="usd">-11808000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjQtMS0xLTEtMTMwNzgz_1f8b34c9-b62e-4a76-95c6-c9f56311a1b7"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjQtMy0xLTEtMTMwNzgz_2b473f4b-4ad9-459b-b16c-e0d0f9f56037"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjUtMS0xLTEtMTMwNzgz_1512d639-d74c-45ba-95a1-a7ea8e8f7a56"
      unitRef="usd">-18720000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjUtMy0xLTEtMTMwNzgz_77d60d48-11ca-4063-9066-049591d196dd"
      unitRef="usd">-11808000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjYtMS0xLTEtMTMwNzgz_79d88443-fb76-487f-94c6-cba8d5cbf6b6"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjYtMS0xLTEtMTMwNzgz_d24e9fcf-6a78-4cdf-8254-1ade9bbc33db"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjYtMy0xLTEtMTMwNzgz_2a110e56-2b5a-4656-aa82-824d1daf6643"
      unitRef="usdPerShare">-3.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjYtMy0xLTEtMTMwNzgz_5e0a2780-02d6-4402-90b5-e5db275c7d1c"
      unitRef="usdPerShare">-3.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjctMS0xLTEtMTMwNzgz_229eac0d-2652-4932-907a-a70fb7651127"
      unitRef="shares">44070974</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjctMS0xLTEtMTMwNzgz_d3f1bd7b-6c53-45fe-9d24-2b766edf6be8"
      unitRef="shares">44070974</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjctMy0xLTEtMTMwNzgz_2f184849-e80c-4509-9b60-f894e04b226c"
      unitRef="shares">3171254</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8xOS9mcmFnOmQ1NjBlNDllNGRhMDRlMDI4YmMyZTVjNDdlYjIxMjY2L3RhYmxlOjI4MWQ3YmRlN2U2YzRkY2Y4NjdmMjQ4MWZkN2Y1Zjc3L3RhYmxlcmFuZ2U6MjgxZDdiZGU3ZTZjNGRjZjg2N2YyNDgxZmQ3ZjVmNzdfMjctMy0xLTEtMTMwNzgz_5a8fa117-bfed-4cf8-b2e1-cad78032bfd8"
      unitRef="shares">3171254</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i4e8c2a57c818445b8ad0d8224990f182_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfMi0xLTEtMS0xMzA3ODM_ca59f377-899e-4b52-a972-7909d7c5295a"
      unitRef="shares">19517988</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i4e8c2a57c818445b8ad0d8224990f182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfMi0zLTEtMS0xMzA3ODM_7f32b3bb-51a9-4eec-ac93-74a36d48c1fa"
      unitRef="usd">171833000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i28bc0e58798a48d59cce5700cab14713_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfMi02LTEtMS0xMzA3ODM_667f3c41-c06d-4d8e-8112-caacb23cb4fb"
      unitRef="shares">2972409</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i28bc0e58798a48d59cce5700cab14713_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfMi04LTEtMS0xMzA3ODM_933e41ca-175f-4e3b-873c-7a0a25aff560"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5910a2afac7e44af947c9bd551313533_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfMi0xMC0xLTEtMTMwNzgz_260af3e5-b163-48eb-9461-e68d42293eec"
      unitRef="usd">3619000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia327828af3c64db9a9c8cc328000bcb5_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfMi0xMi0xLTEtMTM4MjM1_6d4d9d67-a8f8-46fa-95f0-ae715ff07097"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i78a270744c2d4a1f98a4a39f1d1043d3_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfMi0xMi0xLTEtMTMwNzgz_963a793c-8ee7-44a7-95df-83ad1ba92805"
      unitRef="usd">-115076000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4e8c2a57c818445b8ad0d8224990f182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfMi0xNi0xLTEtMTMwNzgz_ca972155-5c3a-4c51-9146-d05fd0f6f38b"
      unitRef="usd">-111457000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="id81fb690a0ac44c7b7413c241996b920_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNC02LTEtMS0xMzA3ODM_0c46c578-f34f-4b28-b3d2-5cfb35ecd593"
      unitRef="shares">172606</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i6e696449bb8f473ba9b98e6d54a4196f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNC0xMC0xLTEtMTMwNzgz_599a2ff9-27de-47d3-a997-f16773286648"
      unitRef="usd">422000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNC0xNi0xLTEtMTMwNzgz_f0f1dd1a-4f32-48c2-9782-822e30bfec65"
      unitRef="usd">422000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <snti:StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions
      contextRef="id81fb690a0ac44c7b7413c241996b920_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNC02LTEtMS0xMzgwNDI_44a674f7-5f35-41e1-9995-4d6b26afb6e1"
      unitRef="shares">143524</snti:StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions>
    <snti:StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions
      contextRef="i6e696449bb8f473ba9b98e6d54a4196f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNi0xMC0xLTEtMTMwNzgz_9d00ea4f-18bf-4894-ad0d-0af3533f303b"
      unitRef="usd">375000</snti:StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions>
    <snti:StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNC0xNi0xLTEtMTM4MDQy_c919c9ae-c2c3-46ba-ac9c-48baa5297fab"
      unitRef="usd">375000</snti:StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6e696449bb8f473ba9b98e6d54a4196f_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNy0xMC0xLTEtMTMwNzgz_3a347b61-d9c2-4235-8f5f-4384b8813f32"
      unitRef="usd">661000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNy0xNi0xLTEtMTMwNzgz_bb0188cd-9333-40ab-b135-93eb42de83df"
      unitRef="usd">661000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="i6a290377bb464be7a1011652879be414_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOC0xMi0xLTEtMTMwNzgz_370acdcd-11d4-4042-939d-21606c559701"
      unitRef="usd">-11808000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOC0xNi0xLTEtMTMwNzgz_84918021-f76c-456a-8dbf-3f146d154433"
      unitRef="usd">-11808000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="ic47933b228a74660947c56c9928b9097_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOS0xLTEtMS0xMzA3ODM_4c4d9f4f-dfad-4a33-833f-d8931f813747"
      unitRef="shares">19517988</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="ic47933b228a74660947c56c9928b9097_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOS0zLTEtMS0xMzA3ODM_9d9d3b8a-4f6c-458b-b904-4223531af992"
      unitRef="usd">171833000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i83c0f0002c6640cf8e492cd72f557b7f_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOS02LTEtMS0xMzA3ODM_79533c32-14ae-4488-8147-b3117e143161"
      unitRef="shares">3288539</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i83c0f0002c6640cf8e492cd72f557b7f_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOS04LTEtMS0xMzA3ODM_e4034571-9471-4e88-ab0d-2895863ea634"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i521e15cacfab469899d7fc2c91390f18_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOS0xMC0xLTEtMTMwNzgz_aabc3607-f9fb-4297-be87-39791f021db0"
      unitRef="usd">5077000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id07031ea08724f1eb814c4d290dec411_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfNy0xMi0xLTEtMTM5MzM0_96c0b5ce-b332-4614-8a63-4c1b4376e336"
      unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id453bf1b5a4b44eb97fecc35ef14b460_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOS0xMi0xLTEtMTMwNzgz_6abc5f5d-698d-4ab5-a8d6-335ac85a9892"
      unitRef="usd">-126884000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic47933b228a74660947c56c9928b9097_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjRkMzYxOWM1Y2FlYjQ0MDc4ZDEzNTM3ZDRhNzA3NjBjL3RhYmxlcmFuZ2U6NGQzNjE5YzVjYWViNDQwNzhkMTM1MzdkNGE3MDc2MGNfOS0xNi0xLTEtMTMwNzgz_545ea259-ef6e-49cf-87a5-5adbf28ac69c"
      unitRef="usd">-121807000</us-gaap:StockholdersEquity>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfMi0xLTEtMS0xMzA3ODM_d56e3bc1-9d90-403a-837c-9effb42de9e7"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfMi0zLTEtMS0xMzA3ODM_46f1b5f5-4461-40f5-813e-5469cd658654"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i81684dd89952407fad1331a3c1ba7940_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfMi02LTEtMS0xMzA3ODM_f39231dc-2e73-457e-9664-08022bb2ca7f"
      unitRef="shares">44062534</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i81684dd89952407fad1331a3c1ba7940_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfMi04LTEtMS0xMzA3ODM_a7f42828-8a9a-4c3d-8702-2e2a8c9aafa3"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia120b6b0d53947b9858a5dbe0b78569f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfMi0xMC0xLTEtMTMwNzgz_cd64d3b6-27de-4754-bbcc-b4eeb367acfa"
      unitRef="usd">300544000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if1f5158cc8cb4ef09ae38b5dc0f801bf_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfMi0xMi0xLTEtMTM4NTM4_f8f25427-17db-455e-af75-ec90c1f21a51"
      unitRef="usd">1000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if4026bb920b246c6ab69bb9a495e015c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfMi0xMi0xLTEtMTMwNzgz_4e8cfc1c-3eae-417e-ab11-fc8b47862d70"
      unitRef="usd">-173286000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfMi0xNi0xLTEtMTMwNzgz_c920cdef-a9ae-4019-84f0-7e36829f2a05"
      unitRef="usd">127263000</us-gaap:StockholdersEquity>
    <snti:StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions
      contextRef="i5ec8395b47bf40878513f3f1f51bfab2_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNC02LTEtMS0xMzA3ODM_2dfd0f61-65a4-4674-b3cd-eb78078dd802"
      unitRef="shares">12660</snti:StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions>
    <snti:StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions
      contextRef="i2611a18b085f44fa80ee121714ee9959_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNC0xMC0xLTEtMTMwNzgz_ceb72f16-2216-49a8-aebf-5829bfb9c74c"
      unitRef="usd">34000</snti:StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions>
    <snti:StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNC0xNi0xLTEtMTMwNzgz_28e72fdb-e5ac-481c-a0e3-77cc238c673e"
      unitRef="usd">34000</snti:StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i2611a18b085f44fa80ee121714ee9959_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNi0xMC0xLTEtMTMwNzgz_f3cebb6b-6098-4984-b2fe-35ff325c066b"
      unitRef="usd">3763000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNi0xNi0xLTEtMTMwNzgz_6bb18f75-359d-4281-a81c-ca521ae7ec4e"
      unitRef="usd">3763000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i6c7cf871f8f445ce8ffd3b796c78114b_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNy0xMi0xLTEtMTM4NzU3_299ab8b1-91b5-4ae8-9c1b-3908851f7c5b"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNy0xNi0xLTEtMTM5MzYw_a1b04332-3dfd-4ff5-b5f4-148479be2a5a"
      unitRef="usd">2000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:NetIncomeLoss
      contextRef="i72961400d84f441aa4a9de049fb9ea0f_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNy0xMi0xLTEtMTMwNzgz_f12a87d0-e4e9-4398-b05e-a558d6c04910"
      unitRef="usd">-18722000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfNy0xNi0xLTEtMTMwNzgz_6dec4281-e189-4f4c-81a9-278b497f8cdc"
      unitRef="usd">-18722000</us-gaap:NetIncomeLoss>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfOC0xLTEtMS0xMzA3ODM_e2275e9c-bdad-4c72-b3a6-ed60cca12ae0"
      unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfOC0zLTEtMS0xMzA3ODM_2a9237a2-5b84-4e7f-bd04-844abdd27786"
      unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if20ddea8370b47e2a8d0cc41b5712871_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfOC02LTEtMS0xMzA3ODM_a507779c-54af-4b2a-a233-e8156856dc29"
      unitRef="shares">44075194</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if20ddea8370b47e2a8d0cc41b5712871_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfOC04LTEtMS0xMzA3ODM_eb04596e-4d48-4cc2-8584-0f9153211aaa"
      unitRef="usd">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3400e851c0774865aacdc65833967f02_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfOC0xMC0xLTEtMTMwNzgz_b914dbd0-4894-4145-93ad-a6d36becb7da"
      unitRef="usd">304341000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="id70d23838a974b229e80c5c9278df638_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfOS0xMi0xLTEtMTM4NTM4_5c9a18e8-2d76-4af1-96db-8e058f556107"
      unitRef="usd">3000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iaa14ff1d6afd4a6aaad076de554b3054_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfOC0xMi0xLTEtMTMwNzgz_1e7d669c-99b7-4d45-8a33-3cdfd1004062"
      unitRef="usd">-192008000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yMi9mcmFnOjlmYjBlYTdmMzQwMjQ0ODA4YTRiMDcxYjZhMzJjZmUyL3RhYmxlOjY1OTdmMDBkMWI2YjRmMmI4ZDQ4MmIyMWU3ZTQ2MTk4L3RhYmxlcmFuZ2U6NjU5N2YwMGQxYjZiNGYyYjhkNDgyYjIxZTdlNDYxOThfOC0xNi0xLTEtMTMwNzgz_e8f9ecfd-0575-4326-aab8-3d8f06643cc8"
      unitRef="usd">112340000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMy0xLTEtMS0xMzA3ODM_5bca2960-979c-4a52-9968-bfa5c1c15326"
      unitRef="usd">-18722000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMy0zLTEtMS0xMzA3ODM_65f8da88-11ff-467a-8f70-016bc9239826"
      unitRef="usd">-11808000</us-gaap:NetIncomeLoss>
    <us-gaap:Depreciation
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNS0xLTEtMS0xMzA3ODM_1a6a13b7-a486-48bb-900d-a2698106673d"
      unitRef="usd">467000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNS0zLTEtMS0xMzA3ODM_890d4df1-5547-4b19-a397-ecbd1ff1010f"
      unitRef="usd">240000</us-gaap:Depreciation>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNi0xLTEtMS0xMzA3ODM_f00e9031-8f5e-4a7f-8fbb-9742b00e6be4"
      unitRef="usd">462000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNi0zLTEtMS0xMzA3ODM_5c1f0425-4acd-4de7-a54d-95cafb3369b8"
      unitRef="usd">770000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNy0xLTEtMS0xMzA3ODM_ffb4bd4e-df5d-46a6-b7ce-529c4ce86f54"
      unitRef="usd">572000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNy0zLTEtMS0xMzA3ODM_5b504f7a-4923-4f28-bd08-e6af721a852b"
      unitRef="usd">0</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfOS0xLTEtMS0xMzA3ODM_593b6b6a-19b5-4bf3-a214-8f80b24990af"
      unitRef="usd">-59000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfOS0zLTEtMS0xMzA3ODM_74853b97-a3b1-45ca-bf83-7309a65403bd"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ShareBasedCompensation
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTEtMS0xLTEtMTMwNzgz_50332f0d-72b0-4b2f-a936-bb000a9bdfde"
      unitRef="usd">3763000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTEtMy0xLTEtMTMwNzgz_c9d706e8-b051-4286-bfa8-95eff017a7d6"
      unitRef="usd">661000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTItMS0xLTEtMTMwNzgz_4ad85e74-f9ad-4d85-b322-bd1797a0c0da"
      unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTItMy0xLTEtMTMwNzgz_c35a1b8e-60b9-4c79-be26-1e2d6531c4fb"
      unitRef="usd">-12000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <snti:InterestIncomeAccruedAndNotReceived
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTMtMS0xLTEtMTQ0NDY1_e300a33d-8628-41f8-959f-62a089e54aee"
      unitRef="usd">-30000</snti:InterestIncomeAccruedAndNotReceived>
    <snti:InterestIncomeAccruedAndNotReceived
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTMtMy0xLTEtMTQ0NDY1_f7242b65-0fc2-43a2-bdb6-44deaa1c312e"
      unitRef="usd">0</snti:InterestIncomeAccruedAndNotReceived>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTYtMS0xLTEtMTMwNzgz_f1b35cd3-e9d6-40b2-bbd2-4b47766f0125"
      unitRef="usd">135000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTYtMy0xLTEtMTMwNzgz_554fa748-69e4-48c9-84a0-a01795312da0"
      unitRef="usd">-53000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTctMS0xLTEtMTMwNzgz_42b23c8f-2b7f-4eca-99e9-a69df5042991"
      unitRef="usd">402000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTctMy0xLTEtMTMwNzgz_9371c594-57fd-46b7-bcd5-f0dce90e732f"
      unitRef="usd">381000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTgtMS0xLTEtMTMwNzgz_4d2edab2-7001-408d-89e3-c8c483f9407f"
      unitRef="usd">280000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTgtMy0xLTEtMTMwNzgz_82c85045-8239-49f0-ba4e-67ba62234e1f"
      unitRef="usd">-164000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTktMS0xLTEtMTMwNzgz_d77bfedd-401f-48d3-bed8-0bc806f3ecfa"
      unitRef="usd">-1846000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMTktMy0xLTEtMTMwNzgz_cfbbea0b-2ef2-499d-8374-7152a3c53277"
      unitRef="usd">-1413000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjAtMS0xLTEtMTMwNzgz_0c0e423c-f4fd-4ad5-91b3-2459c368cc87"
      unitRef="usd">-392000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjAtMy0xLTEtMTMwNzgz_37bc1068-f222-4b1e-a3c3-239569e344c2"
      unitRef="usd">-453000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjEtMS0xLTEtMTMwNzgz_5273565c-3567-4f20-a523-c119a2df5dbc"
      unitRef="usd">882000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjEtMy0xLTEtMTMwNzgz_49d8effb-e6a8-4a94-b571-57d03feefb92"
      unitRef="usd">2424000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjItMS0xLTEtMTMwNzgz_8ed3bcd4-331d-470e-870a-37e315a7162c"
      unitRef="usd">-16304000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjItMy0xLTEtMTMwNzgz_48093626-7ab3-454b-9ece-32a8b43eaab3"
      unitRef="usd">-10059000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjQtMS0xLTEtMTMwNzgz_f1a30ed0-cb35-4af0-8791-bd1a33a905b3"
      unitRef="usd">17990000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjQtMy0xLTEtMTMwNzgz_c0717fe9-c3d6-47a2-93ac-4e94676bfc1e"
      unitRef="usd">0</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjUtMS0xLTEtMTMwNzgz_c7816c58-5dc4-4d3c-a958-12a9685ddab0"
      unitRef="usd">15000000</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjUtMy0xLTEtMTMwNzgz_9b005799-84cd-4d6c-a790-70e1f81dd4ef"
      unitRef="usd">0</us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjctMS0xLTEtMTMwNzgz_48365d37-3a67-4437-8944-d4326cb3df32"
      unitRef="usd">6507000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjctMy0xLTEtMTMwNzgz_8225bf3f-15de-434c-8e22-91c479017652"
      unitRef="usd">7380000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjktMS0xLTEtMTMwNzgz_1acaf024-1661-4081-9eb5-584231a8a61a"
      unitRef="usd">-9497000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMjktMy0xLTEtMTMwNzgz_6304fb40-4934-4886-af66-cfa09b4f9b5e"
      unitRef="usd">-7380000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzItMS0xLTEtMTMwNzgz_7308f09f-a235-4e67-acf0-f28c75e54433"
      unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzItMy0xLTEtMTMwNzgz_883fe413-4f39-4506-810c-1ef2a840a6df"
      unitRef="usd">140000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzctMS0xLTEtMTQ0NTE0_ec810cfb-0c51-4dbb-8f9e-88721abb55a9"
      unitRef="usd">35000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzctMy0xLTEtMTQ0NTE0_edc43069-cc0d-4dab-905e-67038b81c693"
      unitRef="usd">0</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzctMS0xLTEtMTMwNzgz_63f838d6-c666-45a1-be8a-a91bd39c42c7"
      unitRef="usd">0</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzctMy0xLTEtMTMwNzgz_d0a234c7-d777-4e5c-b2db-b22ca4e7454f"
      unitRef="usd">595000</us-gaap:PaymentsOfMergerRelatedCostsFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzgtMS0xLTEtMTMwNzgz_d5474e1d-d546-4f4c-96b2-6a581d464cf7"
      unitRef="usd">-35000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzgtMy0xLTEtMTMwNzgz_45ad2b5d-ebab-425d-8697-01bcf16af81d"
      unitRef="usd">-455000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzktMS0xLTEtMTMwNzgz_00cf3663-6f60-414e-9a01-3c5a7e80c4e1"
      unitRef="usd">-25836000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfMzktMy0xLTEtMTMwNzgz_362f965d-01d9-4f20-bce3-97e996a07bee"
      unitRef="usd">-17894000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDAtMS0xLTEtMTMwNzgz_aba0060e-08e6-4505-a508-fb22c28ba330"
      unitRef="usd">60987000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4e8c2a57c818445b8ad0d8224990f182_I20211231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDAtMy0xLTEtMTMwNzgz_87c826cc-45b5-4943-80dd-7d67022ddf6a"
      unitRef="usd">59291000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDEtMS0xLTEtMTMwNzgz_61b92bbb-9c7c-445e-998f-9fb2b6d07e1c"
      unitRef="usd">35151000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic47933b228a74660947c56c9928b9097_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDEtMy0xLTEtMTMwNzgz_17f5c3a4-ad68-4a2f-8af6-dfb9b67dfada"
      unitRef="usd">41397000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDQtMS0xLTEtMTMwNzgz_637429b2-d889-43f1-b60e-61efae3fffef"
      unitRef="usd">31600000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic47933b228a74660947c56c9928b9097_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDQtMy0xLTEtMTMwNzgz_97392fc2-2088-454f-9b43-be04323b9a30"
      unitRef="usd">38140000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCash
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDUtMS0xLTEtMTMwNzgz_637fe490-a2e5-4459-a899-2c967c0b4d77"
      unitRef="usd">3551000</us-gaap:RestrictedCash>
    <us-gaap:RestrictedCash
      contextRef="ic47933b228a74660947c56c9928b9097_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDUtMy0xLTEtMTMwNzgz_e20f4f80-f1ee-4bb6-8b31-7587419d3a2b"
      unitRef="usd">3257000</us-gaap:RestrictedCash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDYtMS0xLTEtMTMwNzgz_0f237789-d9d0-48b1-90bb-278b3682f84e"
      unitRef="usd">35151000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic47933b228a74660947c56c9928b9097_I20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNDYtMy0xLTEtMTMwNzgz_785836ef-f51a-4641-a7f1-69f50e26d6fd"
      unitRef="usd">41397000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNTEtMS0xLTEtMTMwNzgz_6b4ea0d8-ffdd-40fa-9ca0-df2555b8e0fe"
      unitRef="usd">4758000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNTEtMy0xLTEtMTMwNzgz_583375d2-0806-4c4b-b926-24babb862a76"
      unitRef="usd">8920000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <snti:MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNTQtMS0xLTEtMTMwNzgz_bc3bccb4-a499-4e5f-840d-8cba27fbfda6"
      unitRef="usd">0</snti:MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid>
    <snti:MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNTQtMy0xLTEtMTMwNzgz_2b7e2a93-352f-460c-ab19-8552c0713822"
      unitRef="usd">2462000</snti:MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid>
    <snti:ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNTYtMS0xLTEtMTMwNzgz_3e64e07b-d133-4b3f-8eee-48eb8ec6a75a"
      unitRef="usd">0</snti:ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions>
    <snti:ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8yNS9mcmFnOjI3N2EzMzI2YTJjNzQ4NTQ4Yjg5OGYzYmE4N2M4Mzg2L3RhYmxlOmZjNTY3NDFmNmY2YTQ1ZjM4MGZkMmVlZTEyZWFlM2MxL3RhYmxlcmFuZ2U6ZmM1Njc0MWY2ZjZhNDVmMzgwZmQyZWVlMTJlYWUzYzFfNTYtMy0xLTEtMTMwNzgz_d64568f3-a0d4-4070-85c9-c117792ace42"
      unitRef="usd">306000</snti:ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zMS9mcmFnOmNjMTY4MjNhMDU2NzRiMWViNDdmNTdkZTcxYmEzYWFjL3RleHRyZWdpb246Y2MxNjgyM2EwNTY3NGIxZWI0N2Y1N2RlNzFiYTNhYWNfMzM5Mw_80bb2af6-9cab-4f93-81d9-edac413afbbd">Organization and Description of Business&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Senti Biosciences, Inc. and its subsidiaries (the &#x201c;Company&#x201d; or &#x201c;Senti&#x201d;), is a biotechnology company that was founded to create a new generation of smarter medicines that outmaneuver complex diseases using novel and unprecedented approaches. Senti has built a synthetic biology platform that enables it to program next-generation cell and gene therapies with what the Company refers to as &#x201c;gene circuits.&#x201d; These gene circuits, which are created from novel and proprietary combinations of DNA sequences, reprogram cells with biological logic to sense inputs, compute decisions and respond to their cellular environments. The Company is headquartered in South San Francisco, California.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On June 8, 2022 (the &#x201c;Closing Date&#x201d;), Dynamics Special Purpose Acquisition Corp. (&#x201c;Dynamics&#x201d; or &#x201c;DYNS&#x201d;) consummated a merger pursuant to which Explore Merger Sub, Inc. (&#x201c;Merger Sub&#x201d;), a Delaware corporation and wholly owned subsidiary of Dynamics, merged with and into Senti Sub I, Inc., formerly named Senti Biosciences, Inc. (&#x201c;Legacy Senti&#x201d;), with Legacy Senti surviving as a wholly-owned subsidiary of Dynamics (such transactions, the &#x201c;Merger,&#x201d; and, collectively with the other transactions described in the merger agreement (as defined below, the &#x201c;Reverse Recapitalization&#x201d;)). As a result of the Merger, Dynamics was renamed Senti Biosciences, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity and Going Concern&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;These consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) assuming the Company will continue as a going concern. The going concern assumption contemplates the realization of assets and satisfaction of liabilities in the normal course of business. The consolidated financial statements do not include any adjustments to the carrying amounts and classification of assets, liabilities, and reported expenses that may be necessary if the Company were unable to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has devoted substantially all of its efforts to organizing and staffing, business planning, raising capital, and conducting preclinical studies and has not realized substantial revenues from its planned principal operations.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; To date, the Company raised aggregate gross proceeds of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$298.8 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; from the Merger and PIPE Financing, the issuance of shares of our redeemable convertible preferred stock, the issuance of convertible notes and, to a less extent, through collaboration agreements and government grants.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At March&#160;31, 2023 and December&#160;31, 2022, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$192.0 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$173.3 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, respectively. The Company&#x2019;s net losses were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$18.7 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$11.8 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; for the three months ended March&#160;31, 2023 and 2022, respectively. Substantially all of the Company&#x2019;s net losses resulted from costs incurred in connection with the Company&#x2019;s research and development programs and from general and administrative costs associated with the Company&#x2019;s operations. The Company expects to incur substantial operating losses and negative cash flows from operations for the foreseeable future as the Company advances its&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; preclinical activities and clinical trials for its product candidates in development&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, the Company had cash, cash equivalents and short-term investments of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$76.1&#160;million and $98.6 million, respectively. As of May&#160;9, 2023, the issuance date of the condensed consolidated financial statements as of for the three months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;March&#160;31, 2023, there is uncertainty about whether the Company&#x2019;s combined cash, cash equivalents, and short-term investments will be sufficient to fund operations, including clinical trial expenses and capital expenditure requirements, beyond twelve months from the issuance date of these financial statements and therefore the Company concluded that substantial doubt existed about the Company&#x2019;s ability to continue as a going concern.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s continued existence is dependent upon management&#x2019;s ability to raise capital and develop profitable op&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;erations. Management is devoting substantially all of its efforts to developing its business and raising capital and there can be no assurance that the Company&#x2019;s efforts will be successful. No assurance can be given that management&#x2019;s actions will result in profitable operations or the meeting of ongoing liquidity needs.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <snti:CashAcquiredThroughReverseRecapitalization
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zMS9mcmFnOmNjMTY4MjNhMDU2NzRiMWViNDdmNTdkZTcxYmEzYWFjL3RleHRyZWdpb246Y2MxNjgyM2EwNTY3NGIxZWI0N2Y1N2RlNzFiYTNhYWNfMjE5OTAyMzI2MzM1MQ_c0c0bf70-b7eb-44d9-9285-1efadea936a0"
      unitRef="usd">298800000</snti:CashAcquiredThroughReverseRecapitalization>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zMS9mcmFnOmNjMTY4MjNhMDU2NzRiMWViNDdmNTdkZTcxYmEzYWFjL3RleHRyZWdpb246Y2MxNjgyM2EwNTY3NGIxZWI0N2Y1N2RlNzFiYTNhYWNfMjAxNw_6cd49b96-bc5c-49ab-857d-202b1f77605c"
      unitRef="usd">-192000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zMS9mcmFnOmNjMTY4MjNhMDU2NzRiMWViNDdmNTdkZTcxYmEzYWFjL3RleHRyZWdpb246Y2MxNjgyM2EwNTY3NGIxZWI0N2Y1N2RlNzFiYTNhYWNfMjAyNA_2eeb832d-2036-4338-9314-7a086e95ad82"
      unitRef="usd">-173300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:NetIncomeLoss
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zMS9mcmFnOmNjMTY4MjNhMDU2NzRiMWViNDdmNTdkZTcxYmEzYWFjL3RleHRyZWdpb246Y2MxNjgyM2EwNTY3NGIxZWI0N2Y1N2RlNzFiYTNhYWNfMjA3Mg_89de034c-6312-4b96-b43e-2a99a77b1b8c"
      unitRef="usd">-18700000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zMS9mcmFnOmNjMTY4MjNhMDU2NzRiMWViNDdmNTdkZTcxYmEzYWFjL3RleHRyZWdpb246Y2MxNjgyM2EwNTY3NGIxZWI0N2Y1N2RlNzFiYTNhYWNfMjA3OQ_a47d6e68-f7e4-4d1d-964c-ac4e4f4be745"
      unitRef="usd">-11800000</us-gaap:NetIncomeLoss>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zMS9mcmFnOmNjMTY4MjNhMDU2NzRiMWViNDdmNTdkZTcxYmEzYWFjL3RleHRyZWdpb246Y2MxNjgyM2EwNTY3NGIxZWI0N2Y1N2RlNzFiYTNhYWNfMjY2OA_a06b2c55-f3f4-47b5-bcd5-05911e215fe6"
      unitRef="usd">76100000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zMS9mcmFnOmNjMTY4MjNhMDU2NzRiMWViNDdmNTdkZTcxYmEzYWFjL3RleHRyZWdpb246Y2MxNjgyM2EwNTY3NGIxZWI0N2Y1N2RlNzFiYTNhYWNfNjU5NzA2OTc3MjI1Mg_737f0dbf-468b-459a-80bc-1380043751dc"
      unitRef="usd">98600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zNC9mcmFnOjVlMzhiZjFmZmQ1ZDQwOTI5NmY2YzZhN2ZhOGU3MTU2L3RleHRyZWdpb246NWUzOGJmMWZmZDVkNDA5Mjk2ZjZjNmE3ZmE4ZTcxNTZfNjUwNQ_9ca7266e-2072-4eac-a03c-698001ce3608">Summary of Significant Accounting Policies&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) and the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and as amended by Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The condensed consolidated financial statements include the accounts of Senti Biosciences, Inc., and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. We have one business activity and operate in one reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related price information to give effect to the exchange ratio established in the Merger Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the valuation of stock-based awards, the accrual for research and development expenses, the valuation of contingent earnout, the valuation of convertible notes, the valuation of common and redeemable convertible preferred stock, the valuation of preferred stock tranche liability, standalone selling price (&#x201c;SSP&#x201d;) and the determination of the incremental borrowing rate. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Unaudited Interim Condensed Consolidated Financial Statements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying interim condensed consolidated financial statements and the related footnote disclosures are unaudited. These unaudited interim financial statements have been prepared on the same basis as the audited financial statements, and in management&#x2019;s opinion, include all adjustments, consisting of only normal recurring adjustments, necessary for the fair statement of the Company&#x2019;s financial position as of March&#160;31, 2023 and its results of operations for the three months ended March&#160;31, 2023 and 2022, and cash flows for the three months ended March&#160;31, 2023 and 2022. The results of operations for the three months ended March&#160;31, 2023 are not necessarily indicative of the results to be expected for the year ended December&#160;31, 2023 or any other period. The December&#160;31, 2022 year-end condensed consolidated balance sheet was derived from audited annual financial statements but does not include all disclosures from the annual financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December&#160;31, 2022 and the related notes included in the Company&#x2019;s Form 10-K, filed with the SEC on March&#160;22, 2023, which provides a more complete discussion of the Company&#x2019;s accounting policies and certain other information. There have been no material changes to the Company&#x2019;s significant accounting policies as of and for the three months ended March&#160;31, 2023, as compared to the significant accounting policies described in the Company&#x2019;s audited annual consolidated financial statements as of and for the year ended December&#160;31, 2022, except as discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company believes that the impact of recently issued accounting standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zNC9mcmFnOjVlMzhiZjFmZmQ1ZDQwOTI5NmY2YzZhN2ZhOGU3MTU2L3RleHRyZWdpb246NWUzOGJmMWZmZDVkNDA5Mjk2ZjZjNmE3ZmE4ZTcxNTZfNjUwMg_c43bf8f5-1801-4b0e-be14-333902c31de7">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The accompanying condensed consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#x201c;U.S. GAAP&#x201d;) and the rules and regulations of the Securities and Exchange Commission (&#x201c;SEC&#x201d;). Any reference in these notes to applicable guidance is meant to refer to the authoritative U.S. GAAP as found in the Accounting Standards Codification (&#x201c;ASC&#x201d;) and as amended by Accounting Standards Updates (&#x201c;ASU&#x201d;) of the Financial Accounting Standards Board (&#x201c;FASB&#x201d;). The condensed consolidated financial statements include the accounts of Senti Biosciences, Inc., and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. We have one business activity and operate in one reportable segment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Unless otherwise noted, the Company has retroactively adjusted all common and preferred share and related price information to give effect to the exchange ratio established in the Merger Agreement.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <snti:NumberOfBusinessActivities
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zNC9mcmFnOjVlMzhiZjFmZmQ1ZDQwOTI5NmY2YzZhN2ZhOGU3MTU2L3RleHRyZWdpb246NWUzOGJmMWZmZDVkNDA5Mjk2ZjZjNmE3ZmE4ZTcxNTZfODQx_e0040d51-7cf0-4ba0-84cb-ad4dd4ed7b66"
      unitRef="businessactivitiy">1</snti:NumberOfBusinessActivities>
    <us-gaap:NumberOfReportableSegments
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zNC9mcmFnOjVlMzhiZjFmZmQ1ZDQwOTI5NmY2YzZhN2ZhOGU3MTU2L3RleHRyZWdpb246NWUzOGJmMWZmZDVkNDA5Mjk2ZjZjNmE3ZmE4ZTcxNTZfODc3_38fb26b4-2395-4c1f-b56c-a4f42b269968"
      unitRef="reportablesegment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:UseOfEstimates
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zNC9mcmFnOjVlMzhiZjFmZmQ1ZDQwOTI5NmY2YzZhN2ZhOGU3MTU2L3RleHRyZWdpb246NWUzOGJmMWZmZDVkNDA5Mjk2ZjZjNmE3ZmE4ZTcxNTZfNjUwNw_41452d54-9d0b-4808-895e-ed8ec464408e">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the valuation of stock-based awards, the accrual for research and development expenses, the valuation of contingent earnout, the valuation of convertible notes, the valuation of common and redeemable convertible preferred stock, the valuation of preferred stock tranche liability, standalone selling price (&#x201c;SSP&#x201d;) and the determination of the incremental borrowing rate. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could differ from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zNC9mcmFnOjVlMzhiZjFmZmQ1ZDQwOTI5NmY2YzZhN2ZhOGU3MTU2L3RleHRyZWdpb246NWUzOGJmMWZmZDVkNDA5Mjk2ZjZjNmE3ZmE4ZTcxNTZfNjUwNA_9ab5f135-2062-4c44-a9f4-1ab0e2137eea">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Recent Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company believes that the impact of recently issued accounting standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RleHRyZWdpb246OTk4ZTQzN2QzZWQ2NDFhNzllY2QyYTM3Y2ZkYmJiNmRfMTIwOQ_d6411ee5-25e8-408d-a40e-043a48004777">Fair Value Measurements&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables summarize the estimated value of cash equivalents and restricted cash (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;35,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;35,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;17,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;44,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;42,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;42,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;14,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;14,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;14,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;28,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;28,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;56,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;56,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;40,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;No securities have contractual maturities of longer than one year. There were no transfers between Levels 1, 2, or 3 for any of the periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RleHRyZWdpb246OTk4ZTQzN2QzZWQ2NDFhNzllY2QyYTM3Y2ZkYmJiNmRfMTIxMA_8c78c01e-2d29-4123-8587-e64439c02e4a">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following tables summarize the estimated value of cash equivalents and restricted cash (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;35,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;35,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;11,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,382&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,744&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;13,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,746&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;17,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,381&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,998&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,997&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;44,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;79,657&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31,600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:1pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.159%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.167%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="39" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Gain&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Unrealized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Short-term investments&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;42,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;45,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;42,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;14,866&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;14,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;14,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;3,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial Paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;28,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;28,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;22,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;7,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;1,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;56,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;56,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;15,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;40,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,928&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,621&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,942&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:Cash
      contextRef="ia1507455ae4545acb5c5e77c20ccf10c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMi0xLTEtMS0xNDE1MDk_e793df43-f68c-4252-af14-3dc2b56770fa"
      unitRef="usd">46000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="ia1507455ae4545acb5c5e77c20ccf10c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMi03LTEtMS0xNDU5MTU_8b5a533c-5910-4617-9f96-d8fc08582c21"
      unitRef="usd">46000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="id5a57a126aad418cab737f9098520762_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMi05LTEtMS0xNDE1MjA_402a071e-db5d-46fd-bc07-2738ffe7f0f0"
      unitRef="usd">46000</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="i78139b1e342f47d9b902943821cf2036_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMi0xMS0xLTEtMTQxNTIw_c5829d76-60d1-4ebe-8b74-ac4661a534ad"
      unitRef="usd">0</us-gaap:Cash>
    <us-gaap:Cash
      contextRef="if4705a76340e438cbf1fd59d574befef_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMi0xMy0xLTEtMTQxNTIw_64d673d0-e270-45bf-8797-40f5411c2bfc"
      unitRef="usd">0</us-gaap:Cash>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4a0a24d2beff407985996abce370fac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMy0xLTEtMS0xNDEzMDM_4a6527cc-3382-4fe5-b288-a89719b1a25c"
      unitRef="usd">35105000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4a0a24d2beff407985996abce370fac1_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNC03LTEtMS0xNDU5MjE_090cc618-2257-4d17-aad6-5c8d0d47d258"
      unitRef="usd">35105000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic853c11d285841a9a58448f68290872e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMy05LTEtMS0xNDEzMTU_8cba1c9c-dc7a-4975-90dd-2e0a19c31474"
      unitRef="usd">31554000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i54edccfe021d431689266dad3928a2bf_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMy0xMS0xLTEtMTQxMzE1_e7f70959-2a92-4bcd-a186-d1ecae3ce7d4"
      unitRef="usd">3551000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic621dc1a5dd1488e9267eea6f23d8049_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNC0xMy0xLTEtMTQ1OTIx_573f5d34-2cfb-4e60-bb5b-f1127e808c5c"
      unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia1507455ae4545acb5c5e77c20ccf10c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNS0xLTEtMS0xNDU5MTU_693be55b-375f-47e1-8ee9-9ed7daed6a4a"
      unitRef="usd">35105000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia1507455ae4545acb5c5e77c20ccf10c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNS03LTEtMS0xNDU5MTU_d0138086-0a48-4f29-ba64-265ed0414797"
      unitRef="usd">35105000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="id5a57a126aad418cab737f9098520762_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNS05LTEtMS0xNDU5MTU_039bf6f9-27f1-4e96-8028-36b859e5fcf1"
      unitRef="usd">31554000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i78139b1e342f47d9b902943821cf2036_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNS0xMS0xLTEtMTQ1OTE1_bd47c50d-1de9-4287-9edc-914c95be26a1"
      unitRef="usd">3551000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if4705a76340e438cbf1fd59d574befef_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNS0xMy0xLTEtMTQ1OTE1_d9991b67-686a-45d1-884a-011c26cf5b50"
      unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3e4f2aae937b4d63890360a721452a0a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNi0xLTEtMS0xNDEzNDg_1ca0ea65-7e48-43c8-aa59-8de6ea317a1a"
      unitRef="usd">11380000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i3e4f2aae937b4d63890360a721452a0a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNi0zLTEtMS0xNDEzNDg_a1fcba30-8048-4f9d-914f-71b122d07e44"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3e4f2aae937b4d63890360a721452a0a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNi01LTEtMS0xNDEzNDg_9180acd6-5250-432e-8cb9-919adbf52e46"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3e4f2aae937b4d63890360a721452a0a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNy03LTEtMS0xNDU5MTU_17be97c9-8f31-4225-abfd-4ce8bd3acc55"
      unitRef="usd">11382000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i38ec92e6b86d4514acf595c514672dce_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNi05LTEtMS0xNDEzNTY_c4c8eb7d-c992-4d7f-9fa8-2e0cb3fe8497"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i07bc91a53f5a459baf1197c27ade6ed2_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNi0xMS0xLTEtMTQxMzU2_f545a1c9-7516-4156-909a-c298bf935699"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib1249a7ce3f54ef5bb8002ca6d310e15_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNi0xMy0xLTEtMTQxMzU2_e69cc028-8cf8-45d2-82c8-1fddc46676d3"
      unitRef="usd">11382000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i04e58e5594694539a02749f71be310dd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNy0xLTEtMS0xNDEzNDg_dc9c23a6-b3ac-4b1b-95aa-e7b6d5bb7f7a"
      unitRef="usd">13744000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i04e58e5594694539a02749f71be310dd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNy0zLTEtMS0xNDEzNDg_775cc10e-6035-4c96-9873-c3e618655b83"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i04e58e5594694539a02749f71be310dd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNy01LTEtMS0xNDEzNDg_0931e8bb-3058-4c79-abb7-43f5a1b15dae"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i04e58e5594694539a02749f71be310dd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOC03LTEtMS0xNDU5MTU_d38371ee-2763-426b-aaaf-9fa366f1f688"
      unitRef="usd">13746000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i806026a6a971437f8a3ed419e043f3f8_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNy05LTEtMS0xNDEzNTY_8b3660c2-e82e-4c19-bf1a-0e9f0c9251e4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0599314ad55c451a80b55746b2dc9bfd_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNy0xMS0xLTEtMTQxMzU2_56ab0974-78d8-4450-bb9c-a7e5ec6edfc1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7093d18319c4542a600a6987750ebc6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfNy0xMy0xLTEtMTQxMzU2_c57756a0-5d64-487a-81f9-70523fed70ab"
      unitRef="usd">13746000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i56248ee32fc0485f8d3c8bad91562cee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOC0xLTEtMS0xNDEzNDg_bef50f71-fb54-4a51-9284-ef2333511ed5"
      unitRef="usd">17381000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i56248ee32fc0485f8d3c8bad91562cee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOC0zLTEtMS0xNDEzNDg_10f150e1-4197-4d38-8d8d-347dea3fa84a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i56248ee32fc0485f8d3c8bad91562cee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOC01LTEtMS0xNDEzNDg_8f2a0d69-10eb-4df1-a0a8-7be6080dbb8a"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i56248ee32fc0485f8d3c8bad91562cee_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOS03LTEtMS0xNDU5MTU_235ce73b-2462-4372-8799-91516d8680cb"
      unitRef="usd">17381000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0e20fb37f0c44033bc88e5d7cdb0ff33_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOC05LTEtMS0xNDEzNTY_b2652ae6-e138-46d9-bfaf-127717cdcb19"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie612beff75d94ee5b9518fe9ad917d8c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOC0xMS0xLTEtMTQxMzU2_87caa5bf-5607-47c2-8bd6-7214185665f8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9a0ba519d4ef4fc6aeabfe9afc583b1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOC0xMy0xLTEtMTQxMzU2_4e86d962-7d5e-4549-968e-b65d5ca93918"
      unitRef="usd">17381000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ibcdf00099f6948e394392540bc14975f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOS0xLTEtMS0xNDEzNDg_7ec0ca1c-e66c-4b62-8269-00788c05401f"
      unitRef="usd">1998000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ibcdf00099f6948e394392540bc14975f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOS0zLTEtMS0xNDEzNDg_95571804-5dd8-4f8f-b8e4-4257d2787107"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ibcdf00099f6948e394392540bc14975f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOS01LTEtMS0xNDEzNDg_cb68f95b-6725-4f92-bff1-4d45790fa6ba"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibcdf00099f6948e394392540bc14975f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTAtNy0xLTEtMTQ1OTE1_c267f25a-c858-4832-b086-6fb2fe81a590"
      unitRef="usd">1997000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i182e6b0e83c74e2e91736e7bb9c35972_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOS05LTEtMS0xNDEzNTY_b8370cb2-4317-4f9e-a6da-87440c705778"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i201af4811a374b0d85692aa3b41f79b5_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOS0xMS0xLTEtMTQxMzU2_472b9126-c1b4-4552-a854-004be5fcf11a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3359592a1b094bac8319cc1e2408c43f_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfOS0xMy0xLTEtMTQxMzU2_97b32122-518b-4ff3-bbd5-6261605609ab"
      unitRef="usd">1997000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic3c09c639dac47edb944ea9ecf3b0299_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTEtMS0xLTEtMTQ1OTE1_8f06717e-c126-4ba0-a481-de424a2b26a2"
      unitRef="usd">44503000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic3c09c639dac47edb944ea9ecf3b0299_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTEtMy0xLTEtMTQ1OTE1_7d68d4e8-b853-43d2-891a-a2e9f7caa596"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic3c09c639dac47edb944ea9ecf3b0299_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTEtNS0xLTEtMTQ1OTE1_8399d340-c78c-448a-ba25-06ff19d574d3"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic3c09c639dac47edb944ea9ecf3b0299_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTEtNy0xLTEtMTQ1OTE1_d3762056-94a3-446c-adc7-fe6f932cdd7e"
      unitRef="usd">44506000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic8d224f088f74ed28515d75a9ea6d258_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTEtOS0xLTEtMTQ1OTE1_3cd6dd85-5fa4-4d75-b5ce-21461158e79f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i31c096de9b294cce82f4eddee4fe3e1a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTEtMTEtMS0xLTE0NTkxNQ_e3723bdc-fb76-40aa-8890-0f15094944cf"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i613e04533fcc42e9b6435b116c5cf0be_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTEtMTMtMS0xLTE0NTkxNQ_7a58bdd5-f68c-41a1-b79c-c4cba229417e"
      unitRef="usd">44506000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTItMS0xLTEtMTQ1OTE1_985d9baa-8821-4ae3-b329-068457bee797"
      unitRef="usd">79654000</snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTItMy0xLTEtMTQ1OTIx_8da525fb-3184-4035-bff7-2cb3b107b39e"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTItNS0xLTEtMTQ1OTIx_da4e7d37-cddc-4199-8f85-83cf49648077"
      unitRef="usd">2000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTItNy0xLTEtMTQ1OTE1_0070e338-5e49-49f6-8df2-82a0fd51a104"
      unitRef="usd">79657000</snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue>
    <snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue
      contextRef="i66db0287b069499789e51d16f875e403_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTItOS0xLTEtMTQ1OTE1_5be53b93-95ee-4261-bb69-0d3fab971291"
      unitRef="usd">31600000</snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue>
    <snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue
      contextRef="i1967ceac06c041718a989a37273e427a_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTItMTEtMS0xLTE0NTkxNQ_85ff2e31-ba64-475c-80fc-bb7fbca7406a"
      unitRef="usd">3551000</snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue>
    <snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue
      contextRef="iecaecf3f762f4965b2caf2cdaec72352_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOjE2N2JmMTE0MzQ5ZDQ2ZTM5NGM2ZTU0ZTI1Mzk0NmNhL3RhYmxlcmFuZ2U6MTY3YmYxMTQzNDlkNDZlMzk0YzZlNTRlMjUzOTQ2Y2FfMTItMTMtMS0xLTE0NTkxNQ_d63d7906-298b-4165-b992-fba972c53db3"
      unitRef="usd">44506000</snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8df3f77390c94af5886983ba9c67ce4c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMy0xLTEtMS0xNDEyMDU_78304ebc-23bc-4c73-831b-361be88524d9"
      unitRef="usd">45412000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i8df3f77390c94af5886983ba9c67ce4c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNC03LTEtMS0xNDU5MjU_2004f53d-9bf6-49b2-a438-981278c5263f"
      unitRef="usd">45412000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i738f1818b2ee440b81ae9395474ef8a6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMy05LTEtMS0xNDEyNTQ_0efc09a4-ad34-4450-9e25-743cd720ca28"
      unitRef="usd">42046000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i77067e3a647e4bcf86bbaa6aecc10bc6_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMy0xMS0xLTEtMTQxMjU0_4298537f-a455-4ac8-aef6-026128a022b2"
      unitRef="usd">3366000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6d690099dd934e29ab16020f70f61c81_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMy0xMy0xLTEtMTQxMjU0_b36b03b8-2d61-403f-b5fe-93fd4081a0a4"
      unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i04776ba3407e4211bf944ba32f788c04_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNS0xLTEtMS0xNDU5MjU_ec704813-75a3-4629-b2c9-eaf79cd63753"
      unitRef="usd">45412000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i04776ba3407e4211bf944ba32f788c04_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNS03LTEtMS0xNDU5MjU_789300b3-28ec-46e2-8771-a7630ca00ea1"
      unitRef="usd">45412000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0c53dece0f4746dca63507589ca1b33f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNS05LTEtMS0xNDU5MjU_b2c6b2e7-5f2c-4a02-b707-cbabe6c3fd08"
      unitRef="usd">42046000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic975f5329514459cb776591a8393e656_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNS0xMS0xLTEtMTQ1OTI1_8ebccc20-5d7b-4ef7-9370-37ce6e5d8543"
      unitRef="usd">3366000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i341995b37eeb4178a439a3e4c98245c3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNS0xMy0xLTEtMTQ1OTI1_9727837d-3260-43fe-8cb2-323a9c72a2ec"
      unitRef="usd">0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i4c01bb3709c34dd49620a247ad1fbc01_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNi0xLTEtMS0xNDEyNTI_8b472114-6925-490f-9d95-5637426ca1a4"
      unitRef="usd">14866000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i4c01bb3709c34dd49620a247ad1fbc01_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNi0zLTEtMS0xNDEyNTI_058cc2df-c2d5-4da1-9deb-d20bfe9998bf"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i4c01bb3709c34dd49620a247ad1fbc01_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNi01LTEtMS0xNDEyNTI_1fff7be4-211e-48c3-a3b9-826c0a7832df"
      unitRef="usd">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4c01bb3709c34dd49620a247ad1fbc01_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNy03LTEtMS0xNDU5MjU_81465a10-f537-463e-86b4-9d4ab80879d8"
      unitRef="usd">14867000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i230fd69e00ae4f99b1e3a2d854b95850_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNi05LTEtMS0xNDEyNTU_f720e723-c03d-4911-a05a-d923a76200e1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5289294e32684de3b46e5ac39b5c1c4c_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNi0xMS0xLTEtMTQxMjU1_eb35d1ac-4d47-464d-918c-c79fa929410f"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibb5bf968a6f341f1a417ef865d2b0373_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNi0xMy0xLTEtMTQxMjU1_15e4f214-039e-439f-a50f-3d97f331c715"
      unitRef="usd">14867000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8cf2e03c3b7044dd8f4d13d428853cad_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNy0xLTEtMS0xNDEyNTI_b2f27b51-ca0c-4671-8501-e08812180b2b"
      unitRef="usd">5938000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8cf2e03c3b7044dd8f4d13d428853cad_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNy0zLTEtMS0xNDEyNTI_bf1a026e-7ee2-4a37-956b-6affd25de6c9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8cf2e03c3b7044dd8f4d13d428853cad_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNy01LTEtMS0xNDEyNTI_a01b086c-65c0-48ea-99f2-d3b0c3f3fda6"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8cf2e03c3b7044dd8f4d13d428853cad_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOC03LTEtMS0xNDU5MjU_9dddc4d8-83a0-44da-afe6-7c8cb1aad981"
      unitRef="usd">5938000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i0493e8bc17624187bbe1a3959ac97b33_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNy05LTEtMS0xNDEyNTU_3fedcb6c-700c-4af0-b328-afe28665c1d5"
      unitRef="usd">3983000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i45596385065544378327410d696e5e0f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNy0xMS0xLTEtMTQxMjU1_dc548ac4-1347-4c5e-a9ed-87909f703170"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iae83b8ab01644353acb71b4d4fcf3c2b_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfNy0xMy0xLTEtMTQxMjU1_ef45723a-b2e7-4459-bc3f-efaa5bea07df"
      unitRef="usd">1955000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5a9825b53292444882e4b80aee4ca647_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOC0xLTEtMS0xNDEyNTI_085c7339-b917-468a-ba17-5bf92db75870"
      unitRef="usd">28122000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5a9825b53292444882e4b80aee4ca647_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOC0zLTEtMS0xNDEyNTI_2370f587-8ec0-4d48-96fe-3c13a94bd0dc"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5a9825b53292444882e4b80aee4ca647_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOC01LTEtMS0xNDEyNTI_d069d743-64fb-41e0-824c-636ceca94c68"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5a9825b53292444882e4b80aee4ca647_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOS03LTEtMS0xNDU5MjU_80f0a9ef-ab85-47fd-b214-cd7d4485fd2a"
      unitRef="usd">28122000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibba6c7e42d174d4dad4f3aa9b26cc841_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOC05LTEtMS0xNDEyNTU_86765c7a-71bb-4794-a9d3-1771e3354f0d"
      unitRef="usd">5994000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i86691c0476ba404f814077f7c6873c81_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOC0xMS0xLTEtMTQxMjU1_d6334333-6d7a-4263-a822-eef75bfa44e7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id7dddc4574d1483ca39ac475a557c315_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOC0xMy0xLTEtMTQxMjU1_007b2804-263f-435d-afe1-319b6635dc22"
      unitRef="usd">22128000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i2ed753b6656243da8485cb9941f77565_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOS0xLTEtMS0xNDEyNTI_0d368525-7c76-460e-91a1-26d33fc1a365"
      unitRef="usd">7590000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i2ed753b6656243da8485cb9941f77565_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOS0zLTEtMS0xNDEyNTI_5834d85f-7a24-4b94-83ec-edbda19e7102"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i2ed753b6656243da8485cb9941f77565_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOS01LTEtMS0xNDEyNTI_bd4fbf94-7454-4ca2-831b-62f0a82fcca0"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i2ed753b6656243da8485cb9941f77565_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTAtNy0xLTEtMTQ1OTI1_0dbac4d0-8e23-4682-a02a-e5ed8da66d24"
      unitRef="usd">7590000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i031d672c83f54e5596727cbdebf7ddce_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOS05LTEtMS0xNDEyNTU_b405b914-4e79-4b47-855c-2055db7de9ff"
      unitRef="usd">5598000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i369efc411a944e0ab23af95aeaed1da3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOS0xMS0xLTEtMTQxMjU1_6720f62c-70c6-445d-a4c2-f8a1362a0b5e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaf727ea3cbd14cc599d0b296bd695c30_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfOS0xMy0xLTEtMTQxMjU1_8c9cb1a9-0058-44a7-971e-ae49d038274f"
      unitRef="usd">1992000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="id2dd1486f0094652a61e2542b663d473_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTEtMS0xLTEtMTQ1OTI1_7453da90-dbe5-4656-9c9a-3aa12f6d4421"
      unitRef="usd">56516000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="id2dd1486f0094652a61e2542b663d473_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTEtMy0xLTEtMTQ1OTI1_3404b28d-8fff-4b8e-a994-750710e97a63"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="id2dd1486f0094652a61e2542b663d473_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTEtNS0xLTEtMTQ1OTI1_6985d11a-fc69-4975-ac67-94fdd9540bd1"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id2dd1486f0094652a61e2542b663d473_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTEtNy0xLTEtMTQ1OTI1_1c84ceb0-7aba-4f10-bd5e-25ce7807a974"
      unitRef="usd">56517000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iac83004296dc489eb73145ef1a50ed6f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTEtOS0xLTEtMTQ1OTI1_411964b7-e98d-43c1-b88d-66f175169767"
      unitRef="usd">15575000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i652407f4e1424c81a265a8aeb53e2c9f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTEtMTEtMS0xLTE0NTkyNQ_8b9e1c41-6b2c-4147-8f5d-9ada6852ee5e"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icb62e4f0d0f34a19a5af68bf3ca4be90_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTEtMTMtMS0xLTE0NTkyNQ_bfca7d0d-2e95-4777-8ee9-d01986ba29ff"
      unitRef="usd">40942000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTItMS0xLTEtMTQ1OTI1_22752595-148b-4195-b09e-11f9586e3f6d"
      unitRef="usd">101928000</snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTItMy0xLTEtMTQ1OTI1_45902db8-72d4-4134-8780-42aa0d9c39c0"
      unitRef="usd">5000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTItNS0xLTEtMTQ1OTI1_766d4baa-190d-4470-86e3-47d4f1cfd69a"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTItNy0xLTEtMTQ1OTI1_74642b94-c9fb-4c68-8e9f-559f6e37c01e"
      unitRef="usd">101929000</snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue>
    <snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue
      contextRef="i758da6ca9a82424fbac7ce29a91ab127_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTItOS0xLTEtMTQ1OTI1_03e5651c-f767-4180-8051-5aa4a475831c"
      unitRef="usd">57621000</snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue>
    <snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue
      contextRef="i3913e52d42bd4b0584295d1000454575_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTItMTEtMS0xLTE0NTkyNQ_e32d999e-c7a0-43bf-bf6c-f7a22b136e08"
      unitRef="usd">3366000</snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue>
    <snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue
      contextRef="ib4bf17ca1c12485a95f53564217086b7_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80MC9mcmFnOjk5OGU0MzdkM2VkNjQxYTc5ZWNkMmEzN2NmZGJiYjZkL3RhYmxlOmY2YTU1MzBlNmJkYTRjYzNhZWZiZDBkZTY0NTc1ZTRhL3RhYmxlcmFuZ2U6ZjZhNTUzMGU2YmRhNGNjM2FlZmJkMGRlNjQ1NzVlNGFfMTItMTMtMS0xLTE0NTkyNQ_d8129b31-1781-4a9b-a27a-f6098f234f5c"
      unitRef="usd">40942000</snti:CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zODYvZnJhZzpjMGFhODNlMjQ3ZTM0ZTYwYTcyZjI5MmJhMDU2YTI2Zi90ZXh0cmVnaW9uOmMwYWE4M2UyNDdlMzRlNjBhNzJmMjkyYmEwNTZhMjZmXzExNTQ0ODcyMDkzMjYx_67891004-3985-48e9-aaba-799245f4eee4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table presents a summary of the changes in the fair value of the Company&#x2019;s Level 3 financial instruments (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:85.438%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contingent Earnout Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(227)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value included in other income (expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair value as of March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i057bc7826d4b4c84aacdd029762ebfee_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zODYvZnJhZzpjMGFhODNlMjQ3ZTM0ZTYwYTcyZjI5MmJhMDU2YTI2Zi90YWJsZTowNTIzM2FjMDBlNmQ0MTQ3OGJhMjU0MDM4YWYxNzY5NC90YWJsZXJhbmdlOjA1MjMzYWMwMGU2ZDQxNDc4YmEyNTQwMzhhZjE3Njk0XzEtMi0xLTEtMTQxMTI3_03cfd33f-8870-43de-a171-6ba4555d52d4"
      unitRef="usd">227000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="idc3b98e8794d4db98f8a5bec44536adc_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zODYvZnJhZzpjMGFhODNlMjQ3ZTM0ZTYwYTcyZjI5MmJhMDU2YTI2Zi90YWJsZTowNTIzM2FjMDBlNmQ0MTQ3OGJhMjU0MDM4YWYxNzY5NC90YWJsZXJhbmdlOjA1MjMzYWMwMGU2ZDQxNDc4YmEyNTQwMzhhZjE3Njk0XzMtMi0xLTEtMTQxMTI3_eb6e2647-e83e-4c05-82fe-766dd5b05c7c"
      unitRef="usd">59000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i0d7515206e374c2f8b3ba0988b6e7cc6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl8zODYvZnJhZzpjMGFhODNlMjQ3ZTM0ZTYwYTcyZjI5MmJhMDU2YTI2Zi90YWJsZTowNTIzM2FjMDBlNmQ0MTQ3OGJhMjU0MDM4YWYxNzY5NC90YWJsZXJhbmdlOjA1MjMzYWMwMGU2ZDQxNDc4YmEyNTQwMzhhZjE3Njk0XzQtMi0xLTEtMTQyMTU3_50f8bbde-42ab-46b1-bf06-aabcaac43474"
      unitRef="usd">168000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:AdditionalFinancialInformationDisclosureTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RleHRyZWdpb246MDA3ZTc2MTFjNGEzNDc4MDkyMDViYjA1ZDRlMzVkMjNfNDk2_d7db5650-2c22-4482-9774-6f0e85aeb6f1">Other Financial Statement information&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses (including prepaid rent)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Depreciation totaled $0.5&#160;million and $0.2&#160;million for the three months ended March 31, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Accrued Expenses and Other Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued expenses and other liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional and service fees related to facility construction&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued employee-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional and service fees other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AdditionalFinancialInformationDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RleHRyZWdpb246MDA3ZTc2MTFjNGEzNDc4MDkyMDViYjA1ZDRlMzVkMjNfNDk3_22d132b9-2257-4eca-a27c-9cc73dea0654">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prepaid expenses (including prepaid rent)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;101&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total prepaid expenses and other current assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmU2NGQ2NDhkNjQ2NzQ1NzRhZTc2Zjg5OWI3NmFhYjFmL3RhYmxlcmFuZ2U6ZTY0ZDY0OGQ2NDY3NDU3NGFlNzZmODk5Yjc2YWFiMWZfMi0xLTEtMS0xMzA3ODM_ca789ad6-1f39-4261-82f0-0455598032be"
      unitRef="usd">2202000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmU2NGQ2NDhkNjQ2NzQ1NzRhZTc2Zjg5OWI3NmFhYjFmL3RhYmxlcmFuZ2U6ZTY0ZDY0OGQ2NDY3NDU3NGFlNzZmODk5Yjc2YWFiMWZfMi0zLTEtMS0xMzA3ODM_753ebcf5-4386-4693-ade6-f768d932f024"
      unitRef="usd">1871000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmU2NGQ2NDhkNjQ2NzQ1NzRhZTc2Zjg5OWI3NmFhYjFmL3RhYmxlcmFuZ2U6ZTY0ZDY0OGQ2NDY3NDU3NGFlNzZmODk5Yjc2YWFiMWZfMy0xLTEtMS0xMzA3ODM_825c6732-558e-41e0-a525-5b7d363589ce"
      unitRef="usd">1300000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:DepositsAssetsCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmU2NGQ2NDhkNjQ2NzQ1NzRhZTc2Zjg5OWI3NmFhYjFmL3RhYmxlcmFuZ2U6ZTY0ZDY0OGQ2NDY3NDU3NGFlNzZmODk5Yjc2YWFiMWZfMy0zLTEtMS0xMzA3ODM_754d9825-3de0-47df-a0d0-8c2112367272"
      unitRef="usd">1418000</us-gaap:DepositsAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmU2NGQ2NDhkNjQ2NzQ1NzRhZTc2Zjg5OWI3NmFhYjFmL3RhYmxlcmFuZ2U6ZTY0ZDY0OGQ2NDY3NDU3NGFlNzZmODk5Yjc2YWFiMWZfNS0xLTEtMS0xMzA3ODM_ac1664ad-dab2-4385-8bf1-e7b99ac21bde"
      unitRef="usd">112000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmU2NGQ2NDhkNjQ2NzQ1NzRhZTc2Zjg5OWI3NmFhYjFmL3RhYmxlcmFuZ2U6ZTY0ZDY0OGQ2NDY3NDU3NGFlNzZmODk5Yjc2YWFiMWZfNS0zLTEtMS0xMzA3ODM_7255a441-c6b6-44cb-bd24-60159b9102fb"
      unitRef="usd">101000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmU2NGQ2NDhkNjQ2NzQ1NzRhZTc2Zjg5OWI3NmFhYjFmL3RhYmxlcmFuZ2U6ZTY0ZDY0OGQ2NDY3NDU3NGFlNzZmODk5Yjc2YWFiMWZfNi0xLTEtMS0xMzA3ODM_accec37b-da13-440a-b96e-015021874e61"
      unitRef="usd">3614000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmU2NGQ2NDhkNjQ2NzQ1NzRhZTc2Zjg5OWI3NmFhYjFmL3RhYmxlcmFuZ2U6ZTY0ZDY0OGQ2NDY3NDU3NGFlNzZmODk5Yjc2YWFiMWZfNi0zLTEtMS0xMzA3ODM_70f86676-13b8-4204-8ef1-699a956a4cec"
      unitRef="usd">3390000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RleHRyZWdpb246MDA3ZTc2MTFjNGEzNDc4MDkyMDViYjA1ZDRlMzVkMjNfNDk4_438bb0ab-1755-47b1-bb09-7ff344fd8bbe">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lab equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,474&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,869&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Computer equipment and software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;389&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and fixtures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,273&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment at cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,419)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,986)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i84c054ca47f34f0fb57a2cc22fa7ebb3_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfMi0xLTEtMS0xMzA3ODM_ceebfd9b-ad18-4dab-a4fc-0c8eb020c1d0"
      unitRef="usd">8474000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib151b972fd8f4cd79d899cda2eeb31e2_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfMi0zLTEtMS0xMzA3ODM_4a09bc09-5559-4cc0-b4ea-b0af1ae35725"
      unitRef="usd">8265000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i3df465c4a0264659996eb97c82a869a6_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfMy0xLTEtMS0xMzA3ODM_3079ddf9-6672-4f97-9bdf-daa654366e4a"
      unitRef="usd">1869000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9622647ee0c949e0a3c0188f49fed90f_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfMy0zLTEtMS0xMzA3ODM_395f6bd5-87b0-4ed9-8c38-20c2d252c68d"
      unitRef="usd">1869000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6a54633d73574574bcdce66f8f30a522_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfNC0xLTEtMS0xMzA3ODM_d97cf308-9262-4573-9272-dd20f676d10e"
      unitRef="usd">390000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i092aed2ed1dc43bba672fdbaa11ea98d_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfNC0zLTEtMS0xMzA3ODM_ea8580de-1828-4604-a145-8bdf2f69d604"
      unitRef="usd">389000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie51e5a8e9f5f4b7a82df0ce23e6b0e47_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfNS0xLTEtMS0xMzA3ODM_aadac17f-44aa-4f57-844e-82eaa36ecb09"
      unitRef="usd">326000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2de56f4fdc344660850e0c6380cf9deb_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfNS0zLTEtMS0xMzA3ODM_c4d2af3d-8739-4b9f-818e-484d918aded6"
      unitRef="usd">326000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i55a0a250ecba480e9d2984321a23058c_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfNi0xLTEtMS0xMzA3ODM_f0915ecc-ffeb-493e-b9f2-b2b811bdfd4f"
      unitRef="usd">51347000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ie5a7787f606c4694a34c9edafbf1c9a3_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfNi0zLTEtMS0xMzA3ODM_83600048-4b93-4735-9bfe-93d4d34fa209"
      unitRef="usd">48273000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfNy0xLTEtMS0xMzA3ODM_72a44c47-c3be-47cd-a5b9-16d1a0b93d81"
      unitRef="usd">62406000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfNy0zLTEtMS0xMzA3ODM_610e1736-98be-4e9d-9622-317b9f22b97c"
      unitRef="usd">59122000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfOC0xLTEtMS0xMzA3ODM_7cb1867e-a51c-4790-8ff8-6486327b2420"
      unitRef="usd">3419000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfOC0zLTEtMS0xMzA3ODM_40cb39fd-33c9-49a7-b44d-530700b6046f"
      unitRef="usd">2986000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfOS0xLTEtMS0xMzA3ODM_513d352f-83a9-4198-8dac-bf32ce791c7b"
      unitRef="usd">58987000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOjRmZTU2M2Q5ZTdhMzQwOGZhMzg4ZTNjNWViZTNjMzg1L3RhYmxlcmFuZ2U6NGZlNTYzZDllN2EzNDA4ZmEzODhlM2M1ZWJlM2MzODVfOS0zLTEtMS0xMzA3ODM_ba2e971a-adb5-4178-8871-48fb40f0a212"
      unitRef="usd">56136000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RleHRyZWdpb246MDA3ZTc2MTFjNGEzNDc4MDkyMDViYjA1ZDRlMzVkMjNfMzM3_20b60795-db2c-4780-afe6-8d34125e2a09"
      unitRef="usd">500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RleHRyZWdpb246MDA3ZTc2MTFjNGEzNDc4MDkyMDViYjA1ZDRlMzVkMjNfMzQ0_49be05ce-c734-4a51-90d8-b11da58b3699"
      unitRef="usd">200000</us-gaap:Depreciation>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RleHRyZWdpb246MDA3ZTc2MTFjNGEzNDc4MDkyMDViYjA1ZDRlMzVkMjNfNDk1_eba77bd5-6821-42e5-a36f-ec86b6252918">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Accrued expenses and other liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional and service fees related to facility construction&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,342&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued employee-related expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accrued professional and service fees other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accrued expenses and other current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,864&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfMi0xLTEtMS0xMzA3ODM_7e2ea589-ff2c-4239-b7cc-87fd444feaa0"
      unitRef="usd">3990000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfMi0zLTEtMS0xMzA3ODM_9992951f-85d3-479e-9f35-56d689416885"
      unitRef="usd">7342000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfMy0xLTEtMS0xNDEwNTM_51696754-a545-43be-8ba1-7d8b845dae44"
      unitRef="usd">1799000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfMy0zLTEtMS0xNDEwNTM_557b97d4-b942-47aa-841f-d57eedfd80f0"
      unitRef="usd">3743000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <snti:AccruedProfessionalFeesOtherCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfMy0xLTEtMS0xMzA3ODM_c885e878-95f4-4f9c-be82-5a8b221de871"
      unitRef="usd">1749000</snti:AccruedProfessionalFeesOtherCurrent>
    <snti:AccruedProfessionalFeesOtherCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfMy0zLTEtMS0xMzA3ODM_730ed523-f9a5-4401-a305-63d6803c8d84"
      unitRef="usd">1750000</snti:AccruedProfessionalFeesOtherCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfNS0xLTEtMS0xMzA3ODM_b54f12fb-76cb-409f-be68-5e12db5db468"
      unitRef="usd">53000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfNS0zLTEtMS0xMzA3ODM_b6271ff5-18cf-4a51-aac7-79ab9eaa4350"
      unitRef="usd">29000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfNi0xLTEtMS0xMzA3ODM_726915cf-c34b-4b0d-ac2b-524f9bf7ad6f"
      unitRef="usd">7591000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80Ni9mcmFnOjAwN2U3NjExYzRhMzQ3ODA5MjA1YmIwNWQ0ZTM1ZDIzL3RhYmxlOmE2N2ZlYWZjY2I1ZTQ4OTM4ZTdmZTI2OTU2ZDUzNTI4L3RhYmxlcmFuZ2U6YTY3ZmVhZmNjYjVlNDg5MzhlN2ZlMjY5NTZkNTM1MjhfNi0zLTEtMS0xMzA3ODM_07b58988-6f94-4107-828f-007ab2a5d19e"
      unitRef="usd">12864000</us-gaap:AccountsPayableAndOtherAccruedLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfMjI5OQ_84465294-5c67-42b7-939f-c95c745908f2">Leases&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s operating leases are primarily for its corporate headquarters located in South San Francisco, California (&#x201c;HQ lease&#x201d;) and for additional office and laboratory space located in Alameda, California (&#x201c;Alameda lease&#x201d;) that commenced on July 30, 2021, and is expected to be placed into service in June 2023. The corporate headquarters lease has an initial term of eight years expiring in 2027, with an option to renew for an additional eight years unless canceled by either party thereafter. The Alameda lease has an initial term of eleven years expiring in 2032, with an option to renew the lease for up to two additional terms of five years. The exercise of these renewal options is not recognized as part of the ROU assets and lease liabilities, as the Company did not conclude, at the commencement date of the leases, that the exercise of renewal options or termination options was reasonably certain. The Alameda lease provides for a tenant improvement allowance of up to $17.5&#160;million for the costs relating to the design, permitting and construction of the improvements, to be disbursed by the landlord no later than December 31, 2023. The Company is deemed to be the accounting owner of the tenant improvements primarily because the Company is the principal in the construction and design of the assets, is responsible for costs overruns and retains substantially all economic benefits from the leasehold improvements over their economic lives&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Accordingly, the tenant improvement allowance is considered an incentive and was deducted from the initial measurement of the ROU asset and lease liability. The Company estimated the timing of tenant improvement reimbursements at the lease commencement date and upon receipt of the cash incentives, the Company recognized the cash received as an increase in the lease liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of total lease costs and other information for the period relating to the Company&#x2019;s operating leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows net inflows and (outflows) from operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,874&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for operating lease obligations (including remeasurement of ROU and lease liabilities due to changes in the timing of receipt of lease incentives)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the three months ended March 31, 2023 and 2022, the Company received $1.0 million and $2.5 million, respectively, of the $17.5&#160;million tenant improvement allowance. Through March&#160;31, 2023, the Company utilized $15.1 million of the tenant improvement allowance inception-to-date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March 31, 2023 and 2022, amounts disclosed for ROU assets obtained in exchange for lease obligations include amounts added to the carrying amount of ROU assets resulting from lease modifications and reassessments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maturities of the Company&#x2019;s lease liabilities as of March&#160;31, 2023, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023, for the remainder of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tenant improvement allowance remaining&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i13c2b1f5934440b19195e3dc99ca0b84_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfMzQz_7c4d12f0-d30f-45b9-8e4f-4fa884d75767">P8Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i13c2b1f5934440b19195e3dc99ca0b84_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfNDA2_7703b1f6-fa32-4f4c-ac05-9f39d521bcbf">P8Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="iffa91051becf44e9bef166d4fa25aabf_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfNDk0_a8255312-59c5-4547-94fc-b302eb88ffea">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <snti:LesseeOperatingLeaseNumberOfRenewalOptions
      contextRef="if0a2f740c54a4460bdf1870465e2fd28_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfNTU5_f8a57f8f-63c2-41dd-8ba7-7a32080542a2"
      unitRef="tradingday">2</snti:LesseeOperatingLeaseNumberOfRenewalOptions>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="iffa91051becf44e9bef166d4fa25aabf_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfNTgy_e7da9500-530c-419e-8e4f-9efdc3d85644">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <snti:TenantImprovementAllowance
      contextRef="iffa91051becf44e9bef166d4fa25aabf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfOTE5_427a9513-af06-49c1-b87e-2dbfc0fa11a6"
      unitRef="usd">17500000</snti:TenantImprovementAllowance>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfMjMwMA_fd6c971f-cae2-4483-8fb0-20c60685f03e">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;A summary of total lease costs and other information for the period relating to the Company&#x2019;s operating leases is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Variable lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating cash flows net inflows and (outflows) from operating lease&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,874&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ROU assets obtained in exchange for operating lease obligations (including remeasurement of ROU and lease liabilities due to changes in the timing of receipt of lease incentives)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 13pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average remaining lease term&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.0 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjM1NDI1Yjk5NTRhYTQwOThiYzlmYjhhZTc4MWFmZDQyL3RhYmxlcmFuZ2U6MzU0MjViOTk1NGFhNDA5OGJjOWZiOGFlNzgxYWZkNDJfMi0xLTEtMS0xMzA3ODM_abd0ac36-cdd2-4a1c-9954-7205ebd1fcfc"
      unitRef="usd">1309000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjM1NDI1Yjk5NTRhYTQwOThiYzlmYjhhZTc4MWFmZDQyL3RhYmxlcmFuZ2U6MzU0MjViOTk1NGFhNDA5OGJjOWZiOGFlNzgxYWZkNDJfMi0zLTEtMS0xMzA3ODM_8d433d12-011c-46ef-837a-0c51a1a496b2"
      unitRef="usd">1326000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjM1NDI1Yjk5NTRhYTQwOThiYzlmYjhhZTc4MWFmZDQyL3RhYmxlcmFuZ2U6MzU0MjViOTk1NGFhNDA5OGJjOWZiOGFlNzgxYWZkNDJfMy0xLTEtMS0xMzA3ODM_ab088dac-5b39-46bf-bbb8-43ca9b3b2731"
      unitRef="usd">31000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjM1NDI1Yjk5NTRhYTQwOThiYzlmYjhhZTc4MWFmZDQyL3RhYmxlcmFuZ2U6MzU0MjViOTk1NGFhNDA5OGJjOWZiOGFlNzgxYWZkNDJfMy0zLTEtMS0xMzA3ODM_b98c21c0-3243-45b6-9191-bcaba01e1890"
      unitRef="usd">2000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjM1NDI1Yjk5NTRhYTQwOThiYzlmYjhhZTc4MWFmZDQyL3RhYmxlcmFuZ2U6MzU0MjViOTk1NGFhNDA5OGJjOWZiOGFlNzgxYWZkNDJfNC0xLTEtMS0xMzA3ODM_8dbe8b9f-d91c-4db5-ab42-c21d0bf77d00"
      unitRef="usd">244000</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjM1NDI1Yjk5NTRhYTQwOThiYzlmYjhhZTc4MWFmZDQyL3RhYmxlcmFuZ2U6MzU0MjViOTk1NGFhNDA5OGJjOWZiOGFlNzgxYWZkNDJfNC0zLTEtMS0xMzA3ODM_f51552f3-13fe-450c-96e7-0a10be79b25e"
      unitRef="usd">172000</us-gaap:VariableLeaseCost>
    <us-gaap:LeaseCost
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjM1NDI1Yjk5NTRhYTQwOThiYzlmYjhhZTc4MWFmZDQyL3RhYmxlcmFuZ2U6MzU0MjViOTk1NGFhNDA5OGJjOWZiOGFlNzgxYWZkNDJfNS0xLTEtMS0xMzA3ODM_7be0277c-7272-45b9-87dc-157bd93ca755"
      unitRef="usd">1584000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjM1NDI1Yjk5NTRhYTQwOThiYzlmYjhhZTc4MWFmZDQyL3RhYmxlcmFuZ2U6MzU0MjViOTk1NGFhNDA5OGJjOWZiOGFlNzgxYWZkNDJfNS0zLTEtMS0xMzA3ODM_91f58105-cf74-470e-ad95-8d0790e976a2"
      unitRef="usd">1500000</us-gaap:LeaseCost>
    <snti:OperatingLeaseProceedsPayments
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjY4OTRmZTlkODE2YzQzMTU5YzhhMzBmYTc1MjFkMzA3L3RhYmxlcmFuZ2U6Njg5NGZlOWQ4MTZjNDMxNTljOGEzMGZhNzUyMWQzMDdfMy0xLTEtMS0xMzA3ODM_0e810c07-a31f-4cba-9186-812e88b86810"
      unitRef="usd">37000</snti:OperatingLeaseProceedsPayments>
    <snti:OperatingLeaseProceedsPayments
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjY4OTRmZTlkODE2YzQzMTU5YzhhMzBmYTc1MjFkMzA3L3RhYmxlcmFuZ2U6Njg5NGZlOWQ4MTZjNDMxNTljOGEzMGZhNzUyMWQzMDdfMy0zLTEtMS0xMzA3ODM_50050e47-6327-44a2-9e02-696b6ade049f"
      unitRef="usd">1874000</snti:OperatingLeaseProceedsPayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjY4OTRmZTlkODE2YzQzMTU5YzhhMzBmYTc1MjFkMzA3L3RhYmxlcmFuZ2U6Njg5NGZlOWQ4MTZjNDMxNTljOGEzMGZhNzUyMWQzMDdfNC0xLTEtMS0xMzA3ODM_a8063246-2890-481b-a7a7-cba728ba3a59"
      unitRef="usd">-51000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjY4OTRmZTlkODE2YzQzMTU5YzhhMzBmYTc1MjFkMzA3L3RhYmxlcmFuZ2U6Njg5NGZlOWQ4MTZjNDMxNTljOGEzMGZhNzUyMWQzMDdfNC0zLTEtMS0xMzA3ODM_647e5ff6-4e16-43a0-8760-5afb4bcb4b72"
      unitRef="usd">239000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjY4OTRmZTlkODE2YzQzMTU5YzhhMzBmYTc1MjFkMzA3L3RhYmxlcmFuZ2U6Njg5NGZlOWQ4MTZjNDMxNTljOGEzMGZhNzUyMWQzMDdfNS0xLTEtMS0xMzA3ODM_13e635b9-149d-4d2e-b5cc-080f45fb85d1">P8Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ic47933b228a74660947c56c9928b9097_I20220331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjY4OTRmZTlkODE2YzQzMTU5YzhhMzBmYTc1MjFkMzA3L3RhYmxlcmFuZ2U6Njg5NGZlOWQ4MTZjNDMxNTljOGEzMGZhNzUyMWQzMDdfNS0zLTEtMS0xMzA3ODM_d55883a7-d790-40d1-b573-d506ed685940">P7Y10M24D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjY4OTRmZTlkODE2YzQzMTU5YzhhMzBmYTc1MjFkMzA3L3RhYmxlcmFuZ2U6Njg5NGZlOWQ4MTZjNDMxNTljOGEzMGZhNzUyMWQzMDdfNi0xLTEtMS0xMzA3ODM_303229b3-4627-42e6-b08f-13215baaccce"
      unitRef="number">0.091</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ic47933b228a74660947c56c9928b9097_I20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjY4OTRmZTlkODE2YzQzMTU5YzhhMzBmYTc1MjFkMzA3L3RhYmxlcmFuZ2U6Njg5NGZlOWQ4MTZjNDMxNTljOGEzMGZhNzUyMWQzMDdfNi0zLTEtMS0xMzA3ODM_892a3179-fd60-497e-b813-525d1493adf0"
      unitRef="number">0.091</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <snti:TenantImprovementReimbursements
      contextRef="if0a2f740c54a4460bdf1870465e2fd28_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfNzE0NjgyNTU4Mjk1Mg_5df71c39-11ea-4a6c-b71a-714ea620cefd"
      unitRef="usd">1000000</snti:TenantImprovementReimbursements>
    <snti:TenantImprovementReimbursements
      contextRef="i13d4209f114b48ae802f8c70848bac8d_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfNzE0NjgyNTU4Mjk2OA_fdd989be-c710-4ea4-9333-c1b1552dbd39"
      unitRef="usd">2500000</snti:TenantImprovementReimbursements>
    <snti:TenantImprovementAllowance
      contextRef="iffa91051becf44e9bef166d4fa25aabf_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfNzE0NjgyNTU4MzAyMQ_427a9513-af06-49c1-b87e-2dbfc0fa11a6"
      unitRef="usd">17500000</snti:TenantImprovementAllowance>
    <snti:TenantImprovementAllowanceUtilized
      contextRef="i5a99c95357954ece87322f3f9568adc0_D20210730-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfNzE0NjgyNTU4MzEyOA_2d472a9a-69a5-48d0-afe9-e99606dec7d0"
      unitRef="usd">15100000</snti:TenantImprovementAllowanceUtilized>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RleHRyZWdpb246MzU0MjFmNTRhYTgyNDI4MDkyMzlmYWMxZWUyNDA5NzFfMjI5OA_89594aac-e349-4d0d-93cd-15375b82e014">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Maturities of the Company&#x2019;s lease liabilities as of March&#160;31, 2023, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.079%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.721%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2023, for the remainder of the year&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,712&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,384&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tenant improvement allowance remaining&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,345)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfMC0xLTEtMS0xMzA3ODM_892f7268-a210-4929-af5e-ee7454e07780"
      unitRef="usd">5307000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfMS0xLTEtMS0xMzA3ODM_a37c23ec-eadc-44b4-883e-5d26c0d1be7c"
      unitRef="usd">7254000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfMi0xLTEtMS0xMzA3ODM_8239dce6-d82b-47c4-bb27-c0f5e881c1ca"
      unitRef="usd">7478000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfMy0xLTEtMS0xMzA3ODM_feda0600-7cbf-4a37-8a87-7d5aea940874"
      unitRef="usd">7712000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfNC0xLTEtMS0xMzA3ODM_866a879f-9b22-4424-8fdd-5f8046a3393c"
      unitRef="usd">5769000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <snti:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfNS0xLTEtMS0xMzA3ODM_9c26e630-b30c-4252-82e6-7a1cc0d67d23"
      unitRef="usd">24384000</snti:LesseeOperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfNi0xLTEtMS0xMzA3ODM_8671f35c-aab8-4faf-a0f8-d74ee5797b29"
      unitRef="usd">57904000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfNy0xLTEtMS0xMzA3ODM_2ac03d6a-a9a4-45e8-afcc-4aae5f542139"
      unitRef="usd">17637000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <snti:TenantImprovementAllowanceRemainingAmount
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfOC0xLTEtMS0xMzA3ODM_a9a97169-2bd1-424c-9477-eb33a36863df"
      unitRef="usd">2345000</snti:TenantImprovementAllowanceRemainingAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl80OS9mcmFnOjM1NDIxZjU0YWE4MjQyODA5MjM5ZmFjMWVlMjQwOTcxL3RhYmxlOjRjOGVjNjNmN2EzOTQzNDc5MzkyYjYxZTFhN2Y2MDVkL3RhYmxlcmFuZ2U6NGM4ZWM2M2Y3YTM5NDM0NzkzOTJiNjFlMWE3ZjYwNWRfOS0xLTEtMS0xMzA3ODM_9130de8a-9a24-4e32-a1e9-1591c14b05cd"
      unitRef="usd">37922000</us-gaap:OperatingLeaseLiability>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNjY0OQ_4f83abfd-595a-4c22-9c01-c19350cea875">Stockholders&#x2019; Equity (Deficit)&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Holders of common stock are entitled to one vote per share, and to receive dividends and, upon liquidation or dissolution, are entitled to receive all assets available for distribution to stockholders. The holders have no preemptive or other subscription rights, and there are no redemption or sinking fund provisions with respect to such shares. Common stock is subordinate to the preferred stock with respect to dividend rights and rights upon liquidation, winding up, and dissolution of the Company; although, no preferred stock is outstanding as of March&#160;31, 2023 and December&#160;31, 2022. Through March&#160;31, 2023, no cash dividends have been declared or paid.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At March&#160;31, 2023 and December&#160;31, 2022, the Company was authorized to issue 500,000,000 shares of common stock, all at a par value of $0.0001 per share, and had reserved the following shares for future issuance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock Purchase Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,327,049&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,327,049&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options issued and outstanding &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,792,908&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,875,675&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,322&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,948&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock shares available for future issuance under equity plans &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299,266&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,948,472&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock shares available for future issuance under the 2022 Employee Stock Purchase Plan (the "ESPP") &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923,307&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481,627&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earnout common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested early exercised common stock &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,840&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,500&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,823,692&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,186,271&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the close of the Merger, the Company&#x2019;s Amended and Restated Certificate of Incorporation provides the Company&#x2019;s board of directors with the authority to issue $0.0001 par value preferred stock in one or more series and to establish from time to time the number of shares to be included in each such series, by adopting a resolution and filing a certification of designations. Voting powers, designations, powers, preferences and relative, participating, optional, special and other rights shall be stated and expressed in such resolutions. There were &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;10,000,000 shares designated as preferred stock and none were outstanding as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Common Stock Purchase Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August 31, 2022, the Company entered into a Common Stock Purchase Agreement and a Registration Rights Agreement (collectively referred to as the &#x201c;Purchase Agreement&#x201d;) with Chardan Capital Markets LLC (&#x201c;Chardan&#x201d;). Pursuant to the Purchase Agreement, the Company has the right, in its sole discretion, to sell to Chardan up to the lesser of (i) $50.0 million of newly issued shares of the Company&#x2019;s common stock, and (ii) the Exchange Cap (as defined below) (subject to certain conditions and limitations), from time to time during the 36-month term of the Purchase Agreement. Under the applicable NASDAQ rules, the Company may not issue to Chardan under the Purchase Agreement more than 8,727,049 shares of common stock, which number of shares is equal to 19.99% of the common shares outstanding immediately prior to the execution of the Purchase Agreement unless certain exceptions are met (the &#x201c;Exchange Cap&#x201d;). The purchase price of the shares of common stock will be determined by reference to the Volume Weighted Average Price (&#x201c;VWAP&#x201d;) of the common stock during the applicable purchase date, less a fixed 3% discount to such VWAP. However, the total shares to be purchased on any day may not exceed 20% of the trading volume, and the total purchase price on any day may not exceed $3.0 million. As consideration for Chardan&#x2019;s commitment to purchase shares of common stock at the Company&#x2019;s direction upon the terms and subject to the conditions set forth in the Purchase Agreement, upon execution of the Purchase Agreement, the Company issued 100,000 shares of its common stock to Chardan and paid a $0.4 million document preparation fee. Upon execution of the Purchase Agreement, the Company recognized an expense of $0.7 million within general and administrative expenses in the Company&#x2019;s Condensed Consolidated Statements of Operations and Comprehensive Loss for the Chardan related costs and legal fees incurred in connection with the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Other than the issuance of the commitment shares of the Company&#x2019;s common stock to Chardan, the Company issued 300,000 Class A common stock shares up until December&#160;31, 2022 aggregating to net proceeds of $0.7 million, under the Purchase Agreement. There were no shares issued within three months ended March 31, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Contingent Earnout Equity&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Following the closing of the Merger, former holders of Legacy Senti common stock and preferred stock may receive up to 2,000,000 additional shares of the Company&#x2019;s common stock in the aggregate, in two equal tranches of 1,000,000 shares of common stock per tranche. The first and second tranches are issuable if the closing volume weighted average price (&#x201c;VWAP&#x201d;) per share of common stock quoted on the Nasdaq (or the exchange on which the shares of common stock are then listed) is greater or equal to $15.00 and $20.00, respectively over any &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNTE5OA_43c54c31-da11-473c-9a9b-97c930e0d994"&gt;twenty&lt;/span&gt; trading days within any thirty-day trading period. The first and second tranche term is &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NTIxMA_4c4a7b87-cc7a-4ee5-be63-48c4f60a7afc"&gt;two&lt;/span&gt; and three years, respectively, from the closing of the Merger. If there is a change of control within the three-year following the closing of the Merger that results in a per share price equal to or in excess of the $15.00 and $20.00 share price milestones not previously met, then Company shall issue the earnout shares to the holders of Legacy Senti common stock and preferred stock.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The estimated fair value of the total Contingent Earnout Shares at the Closing on June 8, 2022, was $9.8&#160;million based on a Monte Carlo simulation valuation model. Of this amount, $9.7&#160;million was accounted for as a Contingent Earnout Liability because the triggering events that determine the number of Contingent Earnout Shares required to be issued include events that are not solely indexed to the common stock of the Company. The remaining balance of  $0.1&#160;million relates to holders of Legacy Senti common stock that are subject to repurchase were accounted for as stock-based compensation expense and recorded as an expense, as there was no remaining service period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Contingent Earnout Liability was remeasured to fair value as of March&#160;31, 2023, resulting in the recording of a non-cash gain of $0.1&#160;million for the three months ended March&#160;31, 2023, classified within change in fair value of contingent earnout liability in the condensed consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Assumptions used in the valuation are described below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current stock price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected share price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <snti:NumberOfVotesPerCommonShare
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNjM3_e20538da-45fe-4a89-9a4c-febfe82ca462"
      unitRef="vote">1</snti:NumberOfVotesPerCommonShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjc0ODc3OTA4MDEwNA_602415b9-2c29-44b3-a0bf-dc0f3085ae1d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjc0ODc3OTA4MDEwNA_e9792861-a8cf-4c02-aacd-0083f86fa5f7"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:DividendsCommonStockCash
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMTEzNA_d254e9e8-a430-42f1-9a42-6da6215ecf6c"
      unitRef="usd">0</us-gaap:DividendsCommonStockCash>
    <snti:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNjY1NQ_4ee35c2e-7726-40f9-b582-9ee4887209d9">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;At March&#160;31, 2023 and December&#160;31, 2022, the Company was authorized to issue 500,000,000 shares of common stock, all at a par value of $0.0001 per share, and had reserved the following shares for future issuance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:72.617%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common Stock Purchase Agreement&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,327,049&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,327,049&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock options issued and outstanding &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,792,908&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,875,675&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs issued and outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,322&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,948&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock shares available for future issuance under equity plans &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,299,266&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,948,472&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Common stock shares available for future issuance under the 2022 Employee Stock Purchase Plan (the "ESPP") &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;923,307&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;481,627&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earnout common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000,000&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested early exercised common stock &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,840&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105,500&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,823,692&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,186,271&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</snti:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMTIzMA_b4d0a300-cfe6-4d53-8cde-336f78bc4ac3"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMTIzMA_fd2c793b-219a-47ac-81fc-e06a29cd4351"
      unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMTI5OQ_10a5fd8e-b521-4701-ae82-ac9ae0c4ec90"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMTI5OQ_999b0d92-0ece-4709-ac2a-f5c40fb983b5"
      unitRef="usdPerShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i81d4d8a5f9114d1886175ca8b72ce10a_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfMy0xLTEtMS0xMzA3ODM_0659b5c0-e61e-41ff-920b-5b99343edd1c"
      unitRef="shares">8327049</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i7840bf286e7b4bce9183521fe23e6524_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfMy0zLTEtMS0xMzA3ODM_2a9f308e-9551-432d-b7fa-5f194ba27da2"
      unitRef="shares">8327049</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id20463a91ddd421ea41fcb5abe035d56_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfNC0xLTEtMS0xMzA3ODM_68d14bb0-3be4-4683-a18d-c5f5813f253b"
      unitRef="shares">11792908</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i6e6ef9d05bdb4e6ab4465b3414f327a9_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfNC0zLTEtMS0xMzA3ODM_27b57b43-1628-452d-879d-eb1a6edf9737"
      unitRef="shares">9875675</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i16305f4a1b8449d1a35861d9aa0fc5c8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfNS0xLTEtMS0xMzA3ODM_1e8954ea-e072-4eee-bbd4-204d2fc88e67"
      unitRef="shares">388322</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i9ee3457100c84c3d87184e1e135ba640_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfNS0zLTEtMS0xMzA3ODM_512c6bd3-91a5-4d8c-8d19-569a7b2f858d"
      unitRef="shares">447948</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i47d461e06c0441f3bf66aa005d566b32_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfNi0xLTEtMS0xMzA3ODM_2050c2a2-20b3-4631-af77-9ed6a40ea5af"
      unitRef="shares">3299266</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i52cce8c44b9b4333a95f74f60f360543_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfNi0zLTEtMS0xMzA3ODM_f0e98af2-f76e-461e-afa0-e45183e6ed65"
      unitRef="shares">2948472</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i1cabf5a80a1a48298b9edf643135beb0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfNy0xLTEtMS0xMzA3ODM_7f7940bf-ae2f-41d3-ab84-11729c252e92"
      unitRef="shares">923307</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i0381c522846d4ca6a0f0602fe5c59dc0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfNy0zLTEtMS0xMzA3ODM_5b551e2e-882e-47f6-9a30-81a03b9a6afe"
      unitRef="shares">481627</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i4027bdb9ad2f4e6c85d6878c9bb667fc_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfOC0xLTEtMS0xNDQ5MjI_8052f32d-9d19-46e0-bc27-9e73f5a7fbb7"
      unitRef="shares">2000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="id5f4bb6471d7488ba9e91594b407b669_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfOC0zLTEtMS0xNDQ5MjI_b53984fb-0578-4ecf-a49e-6d08bd64439a"
      unitRef="shares">2000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i066bdaf0f5a0401387fa517ed3d8324c_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfOC0xLTEtMS0xMzA3ODM_f50013b2-db98-45ab-b07a-c4d5f4058c40"
      unitRef="shares">92840</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i190ad14af5cf48d182dd17a670b1c6b0_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfOC0zLTEtMS0xMzA3ODM_723737c4-df09-4d81-a174-3981e0d043c6"
      unitRef="shares">105500</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfOS0xLTEtMS0xMzA3ODM_2f74db74-e977-4e20-9887-b964348e0a89"
      unitRef="shares">26823692</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOmVjM2QyZWY4YmI4YTQ0NmViNDM3MjQ2MjkyNjUxNzMyL3RhYmxlcmFuZ2U6ZWMzZDJlZjhiYjhhNDQ2ZWI0MzcyNDYyOTI2NTE3MzJfOS0zLTEtMS0xMzA3ODM_0663a4d6-9615-41e5-8eae-a0c20970a4ce"
      unitRef="shares">24186271</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMTkzNA_46dd7eb1-8454-4b9e-8687-ad614e5cadd1"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMTkzNA_80a251bb-69c3-40f4-b8d9-3143c7a1c859"
      unitRef="usdPerShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjMyMQ_1ae03aeb-cf40-4dbb-8b92-315e741378fb"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjMyMQ_c151700f-a09f-4b9c-a616-9f3741f9f663"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NDQwNw_408466dd-a356-456d-8f13-3ec70f2f6148"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NDQwNw_56cb8f3e-26dc-4ee5-b816-016a5c74d6f5"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NDQwNw_851e37c7-2582-4392-9f49-62d4e849a6a9"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NDQwNw_c3d8dc32-1cf8-4535-9b58-7deb3baa8cfe"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <snti:SaleOfStockMaximumAmountAuthorized
      contextRef="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjc3Mw_b15e2565-717c-4986-a8ef-e61c9f3df83c"
      unitRef="usd">50000000</snti:SaleOfStockMaximumAmountAuthorized>
    <snti:SaleOfStockTermOfAgreement
      contextRef="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjk1Mw_0ae3abfc-301a-493d-85ff-ceac34530690">P36M</snti:SaleOfStockTermOfAgreement>
    <snti:SaleOfStockNumberOfSharesIssuedInTransactionThreshold
      contextRef="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMzEwNQ_a55938c1-63ac-46ad-9ddc-2218eb624b45"
      unitRef="shares">8727049</snti:SaleOfStockNumberOfSharesIssuedInTransactionThreshold>
    <snti:SaleOfStockSharesIssuedInTransactionThresholdPercent
      contextRef="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMzE2Nw_0e21faf4-1821-47eb-97e6-520d266a4e7c"
      unitRef="number">0.1999</snti:SaleOfStockSharesIssuedInTransactionThresholdPercent>
    <snti:SaleOfStockDiscountRatePercentage
      contextRef="i2695814ca4b34861bbd946616eacf91a_I20220831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMzUxNw_a9388494-341c-463b-92fa-b5f50a2d9164"
      unitRef="number">0.03</snti:SaleOfStockDiscountRatePercentage>
    <snti:SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent
      contextRef="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMzYxMQ_b2de3f3c-66b1-4b9d-820c-b67eebef87a7"
      unitRef="number">0.20</snti:SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent>
    <snti:SaleOfStockDailyAmountToBeSoldThreshold
      contextRef="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMzY5Mg_75c3b9f4-2399-488e-95e9-3a45c019bfa1"
      unitRef="usd">3000000</snti:SaleOfStockDailyAmountToBeSoldThreshold>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMzk0Mw_eaecc037-7325-453f-b15f-3484155c0ac6"
      unitRef="shares">100000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <snti:SaleOfStockDocumentPreparationFees
      contextRef="i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMzk5NQ_6ee582a2-bc80-4392-b847-13c95b07e636"
      unitRef="usd">400000</snti:SaleOfStockDocumentPreparationFees>
    <snti:SaleOfStockIssuanceCosts
      contextRef="i3301414885c64fcb913d8ab29a5a4c1d_I20220831"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNDA2MQ_0185c08a-363d-4cfa-b05c-99da6d66988a"
      unitRef="usd">700000</snti:SaleOfStockIssuanceCosts>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="iaf30c96ccd494c5792c0230ca1a3d6db_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NDQzOQ_43f80abf-6fc8-4d1b-9d35-94e82d7f57c4"
      unitRef="shares">300000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="iaf30c96ccd494c5792c0230ca1a3d6db_D20220101-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NDYwMA_b32c179d-8414-469e-b40d-d1e956d67c75"
      unitRef="usd">700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="i29d9a37c9c3b447eb4fb6ec96fa1dd2b_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NDY2Mg_77a777ef-e23c-4222-a431-250d5b6a0b07"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <snti:ReverseRecapitalizationContingentConsiderationEquityShares
      contextRef="i2cf3659743e3408a95f042ce0308c736_D20220608-20220608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNDc5Ng_7bd49395-58cb-4457-8c3f-64ec7d2dd357"
      unitRef="shares">2000000</snti:ReverseRecapitalizationContingentConsiderationEquityShares>
    <snti:ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches
      contextRef="ic402157e4d8841ffabfdea65ced1a7b6_I20220608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NTIwNA_907f1e1d-d663-49ae-b3a0-20de11f1af43"
      unitRef="tranche">2</snti:ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches>
    <snti:ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche
      contextRef="i2cf3659743e3408a95f042ce0308c736_D20220608-20220608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNDg4OQ_d07f892f-81b1-48e5-9d7a-d320d8af9553"
      unitRef="shares">1000000</snti:ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche>
    <snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger
      contextRef="ic0e7bfd5199240fe911cf1a70a64d6a8_I20220608"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNTE2NQ_b8a6732c-d055-4917-999f-659e094fada4"
      unitRef="usdPerShare">15.00</snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger>
    <snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger
      contextRef="i3a8876a6338d4250b6c025cf2cd85bf7_I20220608"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNTE3Mg_ecea7e00-a68e-42ba-88dc-d262e4e60a47"
      unitRef="usdPerShare">20.00</snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger>
    <snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays
      contextRef="i2cf3659743e3408a95f042ce0308c736_D20220608-20220608"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNjY1Ng_ea196930-2f17-469f-9af8-c083715ba54e">P30D</snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays>
    <snti:ReverseRecapitalizationContingentConsiderationEquityTerm
      contextRef="i987337493e8f4d6b95c95a50303ac90b_D20220608-20220608"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NTIxNQ_7d51b4a4-bbea-459a-af6d-7c0b92e1f1d3">P3Y</snti:ReverseRecapitalizationContingentConsiderationEquityTerm>
    <snti:ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl
      contextRef="i2cf3659743e3408a95f042ce0308c736_D20220608-20220608"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNjY1Nw_86e0a29d-af52-4c66-af6c-4bfe54529993">P3Y</snti:ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl>
    <snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger
      contextRef="ic0e7bfd5199240fe911cf1a70a64d6a8_I20220608"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNTQ5Mg_b8a6732c-d055-4917-999f-659e094fada4"
      unitRef="usdPerShare">15.00</snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger>
    <snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger
      contextRef="i3a8876a6338d4250b6c025cf2cd85bf7_I20220608"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNTQ5OQ_ecea7e00-a68e-42ba-88dc-d262e4e60a47"
      unitRef="usdPerShare">20.00</snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger>
    <snti:ReverseRecapitalizationContingentConsiderationFairValue
      contextRef="ic402157e4d8841ffabfdea65ced1a7b6_I20220608"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NTI1NQ_dde17d2c-60d2-491f-a6d3-a2c0428ad509"
      unitRef="usd">9800000</snti:ReverseRecapitalizationContingentConsiderationFairValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ic402157e4d8841ffabfdea65ced1a7b6_I20220608"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NTI2Mg_b5b9d4e5-ec7d-41f0-949c-2b9ea6b45c5c"
      unitRef="usd">9700000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure
      contextRef="ic402157e4d8841ffabfdea65ced1a7b6_I20220608"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfMjE5OTAyMzI2NTI2OA_2f385032-2d33-48b8-8b3c-b4a5d03e1d4d"
      unitRef="usd">100000</us-gaap:ContingentConsiderationClassifiedAsEquityFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNjQxMA_5a00fa44-37fb-46cb-bd32-16fcfd3dbf34"
      unitRef="usd">-100000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RleHRyZWdpb246ZThjZDk3N2QyMzcyNDllNWExNDRhNDhiYTFlYjRiNWNfNjY1Mw_c8959904-2f9e-44c2-b78e-b3cf3e85db68">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Assumptions used in the valuation are described below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current stock price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.18&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.41&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected share price volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;85.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput
      contextRef="i478aae25e06348e2896c5435db3def08_I20220608"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfMi0yLTEtMS0xMzA3ODM_a802abc1-947b-42c5-aab2-8181d4a0354e"
      unitRef="usdPerShare">1.18</snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput>
    <snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput
      contextRef="i1d50e05b3f964b1e8bd1212007d0f5b2_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfMi00LTEtMS0xMzA3ODM_5a095fde-6596-48b5-bc64-921c9e0d9bcf"
      unitRef="usdPerShare">1.41</snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput>
    <snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput
      contextRef="i4303eca5071e4e959e6a005f6949bbc0_I20220608"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfMy0yLTEtMS0xMzA3ODM_499154b7-b79b-4a6b-ba92-1e736a8fc6ac"
      unitRef="number">0.950</snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput>
    <snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput
      contextRef="i585e64a0dde84731b30a56a965b3502e_I20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfMy00LTEtMS0xMzA3ODM_b47bea94-4be5-4872-8def-a50352f62d39"
      unitRef="number">0.850</snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput>
    <snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput
      contextRef="i22fe4e8df6ab4d1dab35a6b9027729c0_I20220608"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfNC0yLTEtMS0xMzA3ODM_23cfa9b5-922f-4412-ba46-9deef61c0148"
      unitRef="number">0.041</snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput>
    <snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput
      contextRef="i4dfd924deef14485b70ba9b749718b18_I20230331"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfNC00LTEtMS0xMzA3ODM_07a71812-3b60-4e8c-8073-1b4fcb1a4598"
      unitRef="number">0.043</snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput>
    <snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput
      contextRef="iebf31f1f016a4897aeecc0db5ee0375f_I20220608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfNS0yLTEtMS0xMzA3ODM_2cc028df-9b41-44ba-a345-7d61455914b5"
      unitRef="number">0.000</snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput>
    <snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput
      contextRef="i743280c266ac4be9bba0b85a394d535f_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfNS00LTEtMS0xMzA3ODM_399ca1d8-201e-4e8f-8710-5e91b8a70594"
      unitRef="number">0.000</snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput>
    <snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput
      contextRef="i6c5f60d8079a4c929fb01b0c4238eb77_I20220608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfNi0yLTEtMS0xMzA3ODM_567f0328-6cfb-42a7-969a-457a2e23bbc2"
      unitRef="years">2.2</snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput>
    <snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput
      contextRef="i74c815e4a7ff416083bff82a684e4da6_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81NS9mcmFnOmU4Y2Q5NzdkMjM3MjQ5ZTVhMTQ0YTQ4YmExZWI0YjVjL3RhYmxlOjU5ZWFmMzMyZWNlYTQ2OWRiYzUyNTBlZmUxY2M3MzNlL3RhYmxlcmFuZ2U6NTllYWYzMzJlY2VhNDY5ZGJjNTI1MGVmZTFjYzczM2VfNi00LTEtMS0xMzA3ODM_2cde6f16-97ef-4939-9911-611d8690b8e8"
      unitRef="years">2.4</snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput>
    <snti:RevenueFromAndNotFromContractsTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjgyMw_5d6fcbf2-1c03-48f8-894b-0a1286c7b926">Revenue&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s revenue consists of amounts received related to research services provided to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Contract Revenue&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In April 2021, the Company entered into a research collaboration and license agreement with Spark Therapeutics, Inc. (&#x201c;Spark&#x201d;). Under the agreement, the Company will be responsible for a research program, which includes designing, building and testing five cell type specific-synthetic promoters for use in developing certain gene therapies using the Company&#x2019;s proprietary technology. The Company received an upfront payment from Spark of $3.0 million and Spark is obligated to reimburse the Company for costs and expenses incurred for the research program. The Company expected to complete the research program over a two-year period. In December 2022, the Company amended the research collaboration and license agreement to allow for an increase in budget and a two-month extension of the research program. As there were no changes to performance obligations and the services to be provided are not distinct from those already transferred, the transactions was accounted for as a contract modification and a cumulative catch-up of $(0.7) million was recognized in December 2022. As of March&#160;31, 2023 and December&#160;31, 2022, there was a total of $0.4 million and $0.8 million, respectively, remaining of the upfront payment to be recognized over the remaining period of the research program.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company assessed this agreement in accordance with ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Revenue Recognition &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;(&#x201c;ASC 606&#x201d;) and concluded that the contract counterparty, Spark, is a customer. The Company identified only one combined performance obligation in the agreement, which is to perform research services, the related joint research plan and committees for the five specified promoters. The Company determined that the research activities for each of the five promoters are not distinct given there is one single research plan that is performed by the same research team and research results for one promoter may provide insights for other promoters. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Pursuant to the agreement, once the research program is completed and the Company delivers a data package to Spark, Spark has 24 months (the &#x201c;Evaluation Period&#x201d;) to determine whether Spark will exercise its options to obtain field-limited, royalty-bearing licenses to develop, manufacture and commercialize promoters corresponding to each of the five specified promoters being researched. For each licensed promoter option that is exercised, the Company is eligible to receive a license fee, potential research, development and commercial milestone payments and royalties on product sales. Spark may generally terminate the agreement upon 90 days prior written notice or 180 days prior written notice if the licensed promoter is in clinical trials or is being commercialized at the time of termination.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company evaluated Spark&#x2019;s optional rights to license, develop, manufacture and commercialize each of the promoter profiles to determine whether they provide Spark with any material rights to purchase the promoter licenses at an incremental discount.  The Company&#x2019;s proprietary technology used to develop the promoters is in the early stages of development, so technological feasibility and probability of developing a product is highly uncertain. As a result, determining the SSP for the optional rights is subject to significant judgment. Given the subjectivity associated with determining the SSP for the right to a future license related to unproven technology at contract inception, the Company also evaluated whether the contract consideration associated with the research services represents the SSP for those services. The Company determined the transaction price, inclusive of the upfront payment and reimbursement of costs and expenses incurred for the research program, is commensurate with SSP for the research being conducted given the specialized nature and reliance on proprietary technology. Based on the Company&#x2019;s assessment of the optional consideration and the qualitative factors of feasibility and probability of development combined with the quantitative assessment that research services are priced at their SSP, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;concluded that the license option does not provide Spark with an incremental discount and therefore does not constitute a material right. The transaction price associated with the research services in this agreement consists of the fixed upfront amount of $3.0 million and variable consideration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For Spark collaboration agreement, the Company will recognize the transaction price as research and development services are provided, using a cost-based input method to measure the progress toward completion of its performance obligation and to calculate the corresponding amount of revenue to recognize each period. The Company believes that the cost-based input method is the best measure of progress because other measurements would not reflect how the Company transfers the control related to the performance obligation to our customers. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the three months ended March 31, 2023 and 2022, the Company recorded revenue, which was previously included in deferred revenue at the beginning of each period, of $0.4 million and $0.4 million, respectively. Contract asset balances related to unbilled revenue for our collaboration agreements were zero as of March 31, 2023 and 2022, and are presented within prepaid expenses and other current assets on the condensed consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Grant Income&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In 2021, the Small Business Innovation Research (&#x201c;SBIR&#x201d;) awarded the Company a grant in the amount of $2.0 million over two years subject to meeting certain terms and conditions. The purpose of the grant is to support the further development of SENTI-202 for acute myeloid leukemia towards clinical development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Grant income was recognized when qualified research and development costs were incurred and the Company obtained reasonable assurance that the terms and conditions of the grant were met.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Entity-wide information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the three months ended March 31, 2023, Customers A and B accounted for 81% and 19%, respectively, of revenue. During the three months ended March 31, 2022, Customers A and B accounted for 77% and 23%, respectively, of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;All revenues were generated in the United States for the three months ended March 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</snti:RevenueFromAndNotFromContractsTextBlock>
    <snti:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="if7e5dfb75c5345e0908face1c31bf68c_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfMTU3Ng_dff3842e-f81b-412a-b6c3-d0a0bb76001c"
      unitRef="usd">3000000</snti:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i928b078b707f45d4ab1ac6398e73bf1b_I20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfMjc0ODc3OTA3ODU2OA_e197f646-c5ee-42bb-99e2-058745be2c9c">P2Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <snti:ContractWithCustomerExtensionOfTermModificationOfContract
      contextRef="i766f28525f3748399d68ffe1034f13d1_D20221201-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfMjc0ODc3OTA3ODU2OQ_7747e6f1-7f1b-45c9-8808-a087da9faf24">P2M</snti:ContractWithCustomerExtensionOfTermModificationOfContract>
    <us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract
      contextRef="i766f28525f3748399d68ffe1034f13d1_D20221201-20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU5NzA2OTc3NDI2Nw_fdf918d4-ef2d-4933-a3e1-aa25a1a9026a"
      unitRef="usd">-700000</us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i9b3c57ec032744ba8f6125f37486a864_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU5NzA2OTc3NDMyNg_3fcb9d90-afc0-4870-b7b5-9b4f3fce9d02"
      unitRef="usd">400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i27014437a0604c6493a324456d9bebc5_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU5NzA2OTc3NDMyMg_60dad0fb-db53-4744-947c-524c45f91d8f"
      unitRef="usd">800000</us-gaap:RevenueRemainingPerformanceObligation>
    <snti:RevenueFromContractWithCustomerEvaluationPeriod
      contextRef="if8ecffc42af64ac98c375ec96588e97e_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfMjUyMA_2f097596-3f94-425b-a0fd-a43ad6f9ba73">P24M</snti:RevenueFromContractWithCustomerEvaluationPeriod>
    <snti:RevenueFromContractWithCustomerTerminationNoticePeriod
      contextRef="ieb49597653b64cf59b45a61e885d9cab_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfMzAzMw_0605d425-848d-4426-a62e-5491ac8d8aa4">P90D</snti:RevenueFromContractWithCustomerTerminationNoticePeriod>
    <snti:RevenueFromContractWithCustomerTerminationNoticePeriod
      contextRef="id4caf954de824dcfa399375ed1463740_D20210401-20210430"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfMzA2NQ_78513dfc-367d-48ab-a5f1-753ab28b2f56">P180D</snti:RevenueFromContractWithCustomerTerminationNoticePeriod>
    <snti:RevenueRemainingPerformanceObligationVariableConsiderationAmount
      contextRef="if7e5dfb75c5345e0908face1c31bf68c_I20210430"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNDgwMw_dff3842e-f81b-412a-b6c3-d0a0bb76001c"
      unitRef="usd">3000000</snti:RevenueRemainingPerformanceObligationVariableConsiderationAmount>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU5NzA2OTc3NDM0OQ_d5b18a71-2a30-4c31-b626-e9b147015927"
      unitRef="usd">400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU5NzA2OTc3NDM1Ng_b202b396-a307-44d8-b6eb-c7e189262aff"
      unitRef="usd">400000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerAssetGross
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU5NzA2OTc3NDUyMQ_5007b975-7dbf-4d1e-a9a6-d75f20435c47"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetGross>
    <us-gaap:ContractWithCustomerAssetGross
      contextRef="ic47933b228a74660947c56c9928b9097_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU5NzA2OTc3NDUyMQ_549e212e-94b5-4a76-81f8-97f093fa11ae"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetGross>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="i27aef62b1f3e4bffb3dd2df12b5856fe_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjAyNA_2871b74f-4753-47ea-961a-8099713cf0b2"
      unitRef="usd">2000000</us-gaap:RevenueNotFromContractWithCustomer>
    <snti:GrantAssistancePeriodOfRecognition
      contextRef="i71c1a8f9ff524518959d9a765706749d_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjAzMg_443677d7-ab5a-4fca-8eb5-ad2f1da2495b">P2Y</snti:GrantAssistancePeriodOfRecognition>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie8b4557210454abca1e04086bd66db43_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjQ3Ng_885b5b4c-df2f-476a-ae5f-775d4bfb59d2"
      unitRef="number">0.81</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="icaa788b9dd8d4c5989a84143f00ba716_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjQ4Mw_e506202b-d238-414e-8bf1-74a38082abcd"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i39380c3017c0443ea9d9f875c6d12c89_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU2MA_40f669f6-c744-4d02-8b17-a83fdaab1fd9"
      unitRef="number">0.77</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id0b118498cc947c4a737ef007df909ed_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl81OC9mcmFnOjkwYzNlZjZjODY3YjQzZTdhYTk0NDAyNWJmNTc4NjZmL3RleHRyZWdpb246OTBjM2VmNmM4NjdiNDNlN2FhOTQ0MDI1YmY1Nzg2NmZfNjU2Nw_cd27dfa3-4fda-461f-b2c4-6932abeb8bcc"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfOTE2Nw_07015c72-bdeb-4748-a227-24f16630afbe">Stock-Based Compensation&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2016 Stock Incentive Plan (as Amended and Restated)&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s 2016 Stock Incentive Plan (the &#x201c;2016 Plan&#x201d;) provides for the grant of incentive stock options, non-qualified stock options and restricted stock awards to employees, directors, and consultants of the Company. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock options granted under the 2016 Plan generally vest over four years and expire no later than ten years after the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Following the Merger, the 2016 Plan was terminated. No additional stock awards will be granted under the 2016 Plan. All awards previously granted and outstanding as of the effective date of the Merger, were adjusted to reflect the impact of the Merger, but otherwise remain in effect pursuant to their original terms. The shares underlying any award granted under the 2016 Plan that are forfeited back to or repurchased or reacquired by the Company, will revert to and again become available for issuance under the 2022 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On June&#160;8, 2022, upon the Merger, the Company adopted a 2022 Stock Incentive Plan (the &#x201c;2022 Plan&#x201d;). The 2022 Plan provides for the grant of incentive stock options to employees, and for the grant of non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to employees, directors and consultants. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The exercise price of an option granted under the 2022 Plan shall not be less than the fair market value of a common stock share on the date of grant. With respect to a 10% stockholder, the exercise price of an option granted shall not be less than 110% of the fair value of the common stock share on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock options granted under the 2022 Plan generally vest over four years and expire no later than ten years after the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company initially reserved 2,492,735 shares of common stock for issuance under the 2022 Plan. On the first day of each year commencing January 1, 2023, the 2022 Plan will automatically increase by 5% of the outstanding number of shares of common stock of the Company on the last day of the preceding calendar year or such lesser number of shares as approved by the Company&#x2019;s Board of Directors prior to the effective date of the annual increase. In addition, the shares underlying any award granted under the 2016 Plan that are forfeited back to or repurchased or reacquired by the Company, will revert to and again become available for issuance under the 2022 Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023, the total number of shares of common stock available for issuance under the 2022 Plan is 2,168,837.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022 Inducement Equity Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On August&#160;5, 2022, the Company adopted a 2022 Inducement Equity Plan (the &#x201c;2022 Inducement Plan&#x201d;). The 2022 Plan provides for the grant of non-statutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, performance awards and other forms of awards to persons not previously an employee of the Company and its affiliates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The exercise price of an option granted under the 2022 Inducement Plan shall not be less than the fair market value of a common stock share on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Stock options granted under the 2022 Inducement Plan generally vest over four years and expire no later than ten years after the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company initially reserved 2,000,000 shares of common stock for issuance under the 2022 Inducement Plan.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023, the total number of shares of common stock available for issuance under the 2022 Inducement Plan is 1,130,429.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;2022 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On June&#160;8, 2022, upon the Merger, the Company adopted a 2022 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;). The ESPP allows eligible employees to purchase shares of the Company's common stock at a price equal to 85% of the lower of the fair market values of the stock on the first day of an offering or on the date of purchase. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company&#x2019;s ESPP operates with rolling offering periods, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;which are generally 24 months.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company initially reserved 592,584 shares of common stock for issuance under the ESPP. On the first day of each year commencing January 1, 2023, the 2022 Plan will automatically increase by 1% of the outstanding number of shares of common stock of the Company on the last day of the preceding calendar year or such lesser number of shares as approved by the Company&#x2019;s Board of Directors prior to the effective date of the annual increase.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023, the total number of shares of common stock available for issuance under the ESPP is 923,307.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Stock options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity and related information under all equity plans, excluding performance and market awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,191,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,177,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;972,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of stock options granted during the three months ended March 31, 2023 and 2022 were $1.30 and none, respectively. The aggregate intrinsic value of stock options exercised during the three months ended March 31, 2023 and 2022 were none and $1.2 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023, the unrecognized stock-based compensation expense related to stock options was approximately $9.5&#160;million, expected to be recognized over a weighted-average period of 2.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Early Exercise of Stock Options into Restricted Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;For the three months ended March 31, 2023 and 2022, the Company issued zero shares of common stock upon exercise of unvested stock options. As of March&#160;31, 2023 and December&#160;31, 2022, 92,840 and 105,500 shares were held by employees subject to repurchase at an aggregate price of $0.2 million and $0.3 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Performance Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the Merger, on December 19, 2021, Legacy Senti approved 8,400,892 performance award options to existing employees that vest contingent upon the satisfaction of both a four-year service condition and a performance condition tied to the consummation of the Merger. The awards and the associated recognition of stock-based compensation were contingent on the Merger being consummated. As of the approval date of the performance awards, Legacy Senti did not have sufficient common stock available for issuance. Upon the Merger, the Company increased the number of shares authorized and 6,796,074 awards were granted on June&#160;8, 2022. Refer to Note 6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Stockholders&#x2019; Equity (Deficit),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for further details of the shares of common stock authorized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,368,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,299,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The were no performance based options granted or exercised during the three months ended March 31, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023, the unrecognized stock-based compensation expense related to performance based options was approximately $10.4&#160;million, expected to be recognized over a weighted-average period of 1.8 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Market&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Awards &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In connection with the Business Combination Agreement with DYNS, on December 19, 2021, Legacy Senti approved 605,451 market award options to its co-founder and Chief Executive Officer, Dr. Timothy Lu, that vest contingent upon the satisfaction of all three of the following conditions: a service condition, a performance condition tied to the consummation of the Merger, and market conditions. The market condition is achieved in four tranches, where 25% of the options will vest when the trading price of the Company&#x2019;s stock is above various thresholds of price per share. The award and the associated recognition of stock-based compensation were contingent on the Merger being consummated. The estimated fair value of the market awards at the grant date was based on a Monte Carlo simulation valuation model. As of the approval date, Legacy Senti did not have sufficient common stock available for issuance to allow for exercise of the stock options. Upon the Merger, the Company increased the number of shares authorized and 315,748 awards were granted on June&#160;8, 2022. Refer to Note 6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Stockholders&#x2019; Equity (Deficit),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; for further details of the shares of common stock authorized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The were no market based options granted or exercised during the three months ended March 31, 2023 and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023, the unrecognized stock-based compensation expense related to market based options was approximately $0.6&#160;million, expected to be recognized over a weighted-average period of 1.1 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Restricted Stock Units &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the Company&#x2019;s restricted stock units activity and related information under all equity plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023, the unrecognized stock-based compensation expense related to restricted stock units was approximately $0.7&#160;million, expected to be recognized over a weighted-average period of 1.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In determining the fair value of the stock-based awards, the Company uses the assumptions below for the Black-Scholes option pricing model, which are subjective and generally require significant judgment.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Fair Value of Common Stock &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;The fair value of the shares of common stock has historically been determined by the Company&#x2019;s board of directors as there was no public market for the common stock. The board of directors determined the fair value of the common stock by considering a number of objective and subjective factors, including: third-party valuations of the Company&#x2019;s common stock, the valuation of comparable companies, the Company&#x2019;s operating and financial performance, and general and industry-specific economic outlook, amongst other factors. As of the closing of the Merger and going forward, the fair value of common stock will be based on the publicly traded market value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Expected Term&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#x2014; The expected term represents the period that the Company&#x2019;s stock options are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;and the end of the contractual term). The expected term for the ESPP purchase rights is the length of the purchase period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Volatility&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#x2014; The expected volatility is based on the average historical volatility of comparable publicly-traded peer companies, over a period equal to the expected term of the stock option grants, as the Company was not publicly traded prior to the Merger and does not have a trading history for its common stock for a sufficient period of time subsequent to the Merger. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Risk-free Rate&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#x2014; The risk-free rate assumption is based on the U.S. Treasury zero-coupon issues in effect at the time of grant for periods corresponding with the expected term of the option.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Dividends&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#x2014; The Company has never paid dividends on its common stock and does not anticipate paying dividends on common stock. Therefore, the Company uses an expected dividend yield of zero.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The assumptions used to determine the grant date fair value of non-market based, stock options granted were as follows, presented on a weighted-average basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total stock-based compensation expense was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i3e7073ad95d14237a686257c1f249847_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NTU4Ng_9a5b1100-2a51-4cd2-af51-27fbdabcac0b">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i3e7073ad95d14237a686257c1f249847_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NTU5Ng_778fc677-59c7-49c5-ad79-09c3392cbb10">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold
      contextRef="i8bbb2d044d4540fba0cfd4b952348522_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3MjIwNQ_cb6c4c5b-b7b3-4e46-af20-b7cbdce83bff"
      unitRef="number">0.10</snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold>
    <snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue
      contextRef="i109dbba609114d389a60bbd41cab5bfc_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3MjIxOA_a04deef1-1041-4457-b194-f66bee7a9ad0"
      unitRef="number">1.10</snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i0157834a97314a79aab287cf1bcc1d2d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3MzA0NQ_7c77c6e8-0140-4118-9ed1-e21174d1e505">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i0157834a97314a79aab287cf1bcc1d2d_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3MzA1MQ_6e6107f5-f277-4744-b80c-b79894f940fa">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i3d089448db5c47ac864b335700ebdf6c_I20220608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3MzAzMQ_a471808b-96d7-414a-bbc6-51fabb3b9a49"
      unitRef="shares">2492735</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage
      contextRef="i8bbb2d044d4540fba0cfd4b952348522_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3MzA1OQ_624ec41a-17f2-4807-a5b9-94f407f793cf"
      unitRef="number">0.05</snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i1fdc25c4786948e396c80e21496eaec2_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxNjE0NA_42660eac-3877-42de-800c-6804a7d146b3"
      unitRef="shares">2168837</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i65140541deed4a8a9d94a28b4b349127_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3NTQwNQ_33a4c901-2e54-4419-8071-c523f194141e">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i93b6fc338c6a44bfac709886289913e3_D20220805-20220805"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3NTM2NQ_bfe7bac7-e819-4550-bba5-33c29467f46b">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i84ff68234e48415aabc730672a424709_I20220805"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI3NTM3Mg_96047995-b5a2-4da7-8348-7a61079622bc"
      unitRef="shares">2000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i3b946e4dc38a43f985ff9ce7ef855a78_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxNjE1MQ_4186e849-b920-4790-83fa-7136878f2732"
      unitRef="shares">1130429</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="ifb4c537cd827433eb1fd0857cc6e392f_D20220608-20220608"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4Mzk3Mg_b00795fc-dce5-446e-a0f8-7045db23019d"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod
      contextRef="ifb4c537cd827433eb1fd0857cc6e392f_D20220608-20220608"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4Mzk4Nw_ec5ec3ae-9d7e-4560-8da3-28e85bca310c">P24M</snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i7ab0adeec3bc495a85352b6cd04f0ea6_I20220608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NDAwMw_c447af32-ced6-40d8-9b73-6d471d1dcef0"
      unitRef="shares">592584</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares
      contextRef="ifb4c537cd827433eb1fd0857cc6e392f_D20220608-20220608"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NDAwNw_33bbb499-aa3a-4555-8117-9d43a6dfb969"
      unitRef="number">0.01</snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i1cabf5a80a1a48298b9edf643135beb0_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxNjE1Nw_d321e922-751e-434a-a4a3-8b107df715aa"
      unitRef="shares">923307</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfOTE2NQ_2c79bc9d-61a4-4e1b-9dfb-606c94342d81">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the Company&#x2019;s stock option activity and related information under all equity plans, excluding performance and market awards:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,191,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,189,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(203,367)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,177,759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.69&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;972,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.97&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfMS0xLTEtMS0xMzA3ODM_cd98e0d9-ff9e-487e-984d-cb85ebbcd332"
      unitRef="shares">4191426</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfMS0zLTEtMS0xMzA3ODM_5e7c460f-8a8c-4245-aa99-8f0959151f60"
      unitRef="usdPerShare">3.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i921a457818234d30b26fac9b4d02f4a7_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfMS01LTEtMS0xMzA3ODM_92186b3d-ff6a-4d73-aa4d-b3ac2677b7a2">P9Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfMS03LTEtMS0xMzA3ODM_43ded0e0-1441-4ed8-a481-f2a1f7db5cd6"
      unitRef="usd">6000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfMi0xLTEtMS0xMzA3ODM_dda03bed-1b1f-4650-9168-a6ed24168474"
      unitRef="shares">2189700</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfMi0zLTEtMS0xMzA3ODM_865978bf-e41b-4fb0-8a06-1afa891ffe61"
      unitRef="usdPerShare">1.81</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNC0xLTEtMS0xMzA3ODM_df91b106-20e3-4106-a93c-54752daee5d6"
      unitRef="shares">203367</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNC0zLTEtMS0xMzA3ODM_f750652b-d9b3-4d42-aa55-f5554b34380c"
      unitRef="usdPerShare">3.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNS0xLTEtMS0xMzA3ODM_00ec04a4-47a1-4566-8d46-4e9e067b55b6"
      unitRef="shares">6177759</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNS0zLTEtMS0xMzA3ODM_144bec4a-617b-43b0-9ad1-0b89ab6375fb"
      unitRef="usdPerShare">2.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNS01LTEtMS0xMzA3ODM_66daa9e0-ba38-442a-a826-593e6f8eba25">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNS03LTEtMS0xMzA3ODM_7a8559eb-3ab8-4af1-a98a-e020ff124054"
      unitRef="usd">5000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNi0xLTEtMS0xMzA3ODM_a5802338-133e-4e84-8dec-2e442c6b7fa4"
      unitRef="shares">972055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNi0zLTEtMS0xMzA3ODM_64430257-1074-4aa8-bf2d-7016e138a117"
      unitRef="usdPerShare">3.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNi01LTEtMS0xMzA3ODM_92606c13-f6a4-45a4-9ae5-f56550d95bf8">P7Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjNiMDVkNmZhMDRmZjQxY2Q4MWVkZmI3MGI2YjE0MjAxL3RhYmxlcmFuZ2U6M2IwNWQ2ZmEwNGZmNDFjZDgxZWRmYjcwYjZiMTQyMDFfNi03LTEtMS0xMzA3ODM_bd8322b3-f782-4983-ad34-5855aa8da181"
      unitRef="usd">5000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NTc0MA_f9928e92-8019-4e13-8c0e-02db75544b21"
      unitRef="usdPerShare">1.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NjAyMA_86a0fd76-90e2-48e9-a68d-585d32b0ef99"
      unitRef="usdPerShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NjA5Mw_5c76eba1-9ee6-45a4-90b8-3cd5d067e05f"
      unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NjA4OQ_bc96afe7-2b21-4153-9af3-1b7c19a634c5"
      unitRef="usd">1200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzI4NjE5OA_4d4f32c9-6520-4cfe-8a64-654d93fa1a9b"
      unitRef="usd">9500000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie25bf12b097d4142a80c4443e8e34b7c_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzMwNjAzMg_e22ece62-bc0b-4733-9a7c-1020ac244c6e">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="ia6f53a18a05e4e3e9c95c5959b5464af_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjg5MQ_19d75fa1-f22b-4cd6-a4f7-fe5d33066351"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="i09e65d7dd7ff4a518134d5af6af7496b_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjg5MQ_511a993c-c1d3-415f-b20b-0e311e564bda"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="ia6f53a18a05e4e3e9c95c5959b5464af_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjk5Nw_830c5468-2112-4d67-b4f8-3d6bb01f84d7"
      unitRef="shares">92840</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
      contextRef="iecb98f68e3f54315adf9e9038dadf418_D20220101-20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMzAwNA_64ca0751-37dc-4cf1-b7fe-326d10cf141f"
      unitRef="shares">105500</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
    <snti:CommonStockSubjectToRepurchaseValue
      contextRef="i6cba8c98475b4484aa393d6615db82dd_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMzA4NA_7cbdff1e-d175-4f73-b2f9-aca3d0fc545f"
      unitRef="usd">200000</snti:CommonStockSubjectToRepurchaseValue>
    <snti:CommonStockSubjectToRepurchaseValue
      contextRef="ifc61cf9dbb914210b3fe39d9d8805450_I20221231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMzA5MQ_e304a149-c2ed-4b49-b765-be80c9efe411"
      unitRef="usd">300000</snti:CommonStockSubjectToRepurchaseValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i09d1b2b0e78f4a2a9de67b5ef64622f8_D20211219-20211219"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMzIwMw_3be3dae6-a6dc-4085-8d61-09fdddffb27c"
      unitRef="shares">8400892</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward
      contextRef="i09d1b2b0e78f4a2a9de67b5ef64622f8_D20211219-20211219"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMzMwMA_ebcd9a99-261e-469a-ba4c-3b5aefd67c40">four</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i55f59dff27474019a6a976d08d32c7a5_D20220608-20220608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMzcxMw_cd32a3f7-a4ff-49a4-afc4-81d955d98632"
      unitRef="shares">6796074</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfOTE2OA_51ff319d-fe22-4fbb-bdf5-a4b696c6dc9e">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:45.053%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;br/&gt;Remaining Contractual Life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate Intrinsic Value (in thousands)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,368,501&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(69,100)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,299,401&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Vested and exercisable at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.92&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following table summarizes the Company&#x2019;s restricted stock units activity and related information under all equity plans:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Number of Restricted Stock Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant Date Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at December&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59,626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Outstanding at March&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i5aee551dc4424308a0cbe423b5aa00f5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfMS0xLTEtMS0xMzA3ODM_600c2843-e09f-4c72-a152-fa8c312021a7"
      unitRef="shares">5368501</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i5aee551dc4424308a0cbe423b5aa00f5_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfMS0zLTEtMS0xMzA3ODM_d43c1592-8235-4617-b5c9-46283a317536"
      unitRef="usdPerShare">9.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="i3f3e04de252e4ab9ad665ce2c64c8f64_D20220101-20221231"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfMS01LTEtMS0xMzA3ODM_b78cd495-fd08-4476-a366-3e24201c7b1e">P9Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfNC0xLTEtMS0xMzA3ODM_7e0fa9b1-6c37-4c36-afe7-a118df3dae8d"
      unitRef="shares">69100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfNC0zLTEtMS0xMzA3ODM_27d6a236-f8c5-4297-93bb-9844ecd4acc9"
      unitRef="usdPerShare">9.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i787b64c59226487c91cbebde035a735d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfNS0xLTEtMS0xMzA3ODM_de52e281-5fa4-4544-8874-89811e600044"
      unitRef="shares">5299401</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i787b64c59226487c91cbebde035a735d_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfNS0zLTEtMS0xMzA3ODM_f4801345-3183-4be6-8377-982712e30143"
      unitRef="usdPerShare">9.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfNS01LTEtMS0xMzA3ODM_58e078d7-9b5e-4e0c-8292-aa788f902dd1">P8Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfNi0xLTEtMS0xMzA3ODM_4165220e-8333-4bd8-a91f-e82d63b20289"
      unitRef="shares">334586</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfNi0zLTEtMS0xMzA3ODM_ab23f3a1-27bf-4dc4-b22e-d88ae7204e5e"
      unitRef="usdPerShare">9.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm
      contextRef="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjVlYjgwMTFkZmVmZTQwZmRiMjViNGNjNzZhY2E4Y2VkL3RhYmxlcmFuZ2U6NWViODAxMWRmZWZlNDBmZGIyNWI0Y2M3NmFjYThjZWRfNi01LTEtMS0xMzA3ODM_2b38f4cd-63d4-4503-9ffa-d5f66d3157ef">P7Y1M6D</snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="if95b9a3a21314a64be95e971b65657ab_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxMjE1Nw_2643f510-b6d2-47f4-bcf9-d3f2d45e20ae"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxMjE1Nw_285f8641-2bd3-481f-aa7b-09d71ed70146"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i787b64c59226487c91cbebde035a735d_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxMjc0Mg_f11becb2-25d3-4669-9de4-4f87367d749c"
      unitRef="usd">10400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMjE5OTAyMzMwNjA0Mg_1d675ebb-ef4f-4bdd-a717-6cf430ec4028">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i148f91500cfa448b90c1ca1b3fe51ddd_D20211219-20211219"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfMzk4MQ_00e178a9-1545-4d57-b529-1ae3aa4c4828"
      unitRef="shares">605451</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches
      contextRef="i342ee2fd8d6845069313253e24f45e30_I20211219"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNDI5MA_58b4961b-61c6-4b1e-8439-d5417637098c"
      unitRef="tranche">4</snti:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i148f91500cfa448b90c1ca1b3fe51ddd_D20211219-20211219"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNDMwOQ_41f36743-fe04-43a1-9ffe-3f0fcdceb090"
      unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i1d8a71f2d75d44fd822915e608589a18_D20220608-20220608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNDc2NQ_d0dacccc-b78d-4a6e-8a09-e42963bae62f"
      unitRef="shares">315748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="id4e222fd06584beba7f3df061459dfd0_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxMzAwMA_86092817-83ea-4564-8623-dfd7ee070f1c"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ifb827c206b774ff486fdcdc6ed921a68_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxMzAwMA_ffcd3293-f743-44c6-8c37-81114ea16693"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="ic26e10f702604471b0ad4cc00f011d6c_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxMzAwOA_b02d788e-75d6-455c-a848-9d26aedc1ce4"
      unitRef="usd">600000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="id4e222fd06584beba7f3df061459dfd0_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxMzAxNQ_d3c07f59-788b-474c-b085-9c11bc23adc9">P1Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i9ee3457100c84c3d87184e1e135ba640_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjYzNjgxYTFhODUzYTQzYWViNWM2ZTE2NWE5OTBmYmFmL3RhYmxlcmFuZ2U6NjM2ODFhMWE4NTNhNDNhZWI1YzZlMTY1YTk5MGZiYWZfMS0yLTEtMS0xNDM1Nzg_5123fb85-807b-4800-9a55-98bd4a3ac530"
      unitRef="shares">447948</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i9ee3457100c84c3d87184e1e135ba640_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjYzNjgxYTFhODUzYTQzYWViNWM2ZTE2NWE5OTBmYmFmL3RhYmxlcmFuZ2U6NjM2ODFhMWE4NTNhNDNhZWI1YzZlMTY1YTk5MGZiYWZfMS00LTEtMS0xNDM1Nzg_57ea9ee5-bb27-43ef-9124-3a05dca03f51"
      unitRef="usdPerShare">2.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="i24a619ba2bc2425c8c531466ceb3022f_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjYzNjgxYTFhODUzYTQzYWViNWM2ZTE2NWE5OTBmYmFmL3RhYmxlcmFuZ2U6NjM2ODFhMWE4NTNhNDNhZWI1YzZlMTY1YTk5MGZiYWZfNC0yLTEtMS0xNDM1Nzg_c1f09dfd-b2fb-4bc3-a3c2-85f367061148"
      unitRef="shares">59626</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="i24a619ba2bc2425c8c531466ceb3022f_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjYzNjgxYTFhODUzYTQzYWViNWM2ZTE2NWE5OTBmYmFmL3RhYmxlcmFuZ2U6NjM2ODFhMWE4NTNhNDNhZWI1YzZlMTY1YTk5MGZiYWZfNC00LTEtMS0xNDM1Nzg_aa7cfff5-ff02-4e20-8070-1cb30112c067"
      unitRef="usdPerShare">2.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i16305f4a1b8449d1a35861d9aa0fc5c8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjYzNjgxYTFhODUzYTQzYWViNWM2ZTE2NWE5OTBmYmFmL3RhYmxlcmFuZ2U6NjM2ODFhMWE4NTNhNDNhZWI1YzZlMTY1YTk5MGZiYWZfNS0yLTEtMS0xNDM1Nzg_bc00839e-cc09-48c4-ba19-df73e08fdf85"
      unitRef="shares">388322</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i16305f4a1b8449d1a35861d9aa0fc5c8_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjYzNjgxYTFhODUzYTQzYWViNWM2ZTE2NWE5OTBmYmFmL3RhYmxlcmFuZ2U6NjM2ODFhMWE4NTNhNDNhZWI1YzZlMTY1YTk5MGZiYWZfNS00LTEtMS0xNDM1Nzg_f8f0ff57-a2e6-42f8-8a9d-70a4c478efd8"
      unitRef="usdPerShare">2.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="i16305f4a1b8449d1a35861d9aa0fc5c8_I20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxNTQ5NQ_967d936d-41d9-4034-be1c-8521f0936047"
      unitRef="usd">700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i24a619ba2bc2425c8c531466ceb3022f_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfNzE0NjgyNTYxNTUwMA_42a092f8-7263-426c-ba8c-ddd5700e207c">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfOTE2OQ_7671b3f5-3c4d-42a0-bed3-e188d49dda70">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The assumptions used to determine the grant date fair value of non-market based, stock options granted were as follows, presented on a weighted-average basis:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.976%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.720%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.722%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected term (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie25bf12b097d4142a80c4443e8e34b7c_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOmY4ZGQxYmFlNTA1YjQ2NjliM2Y2ZTVmZThjNjgwZDlhL3RhYmxlcmFuZ2U6ZjhkZDFiYWU1MDViNDY2OWIzZjZlNWZlOGM2ODBkOWFfMi0xLTEtMS0xMzA3ODM_d45a69c2-440f-4c2e-be16-8aa03208433b">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie25bf12b097d4142a80c4443e8e34b7c_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOmY4ZGQxYmFlNTA1YjQ2NjliM2Y2ZTVmZThjNjgwZDlhL3RhYmxlcmFuZ2U6ZjhkZDFiYWU1MDViNDY2OWIzZjZlNWZlOGM2ODBkOWFfMy0xLTEtMS0xMzA3ODM_b906d875-8278-417b-829a-8f9484d86cca"
      unitRef="number">0.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ib140873ca1da43bab9fd62b4810057e8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOmY4ZGQxYmFlNTA1YjQ2NjliM2Y2ZTVmZThjNjgwZDlhL3RhYmxlcmFuZ2U6ZjhkZDFiYWU1MDViNDY2OWIzZjZlNWZlOGM2ODBkOWFfMy0zLTEtMS0xMzA3ODM_152b8dbb-3d20-4f4b-8e6b-f821abfd5735"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie25bf12b097d4142a80c4443e8e34b7c_D20230101-20230331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOmY4ZGQxYmFlNTA1YjQ2NjliM2Y2ZTVmZThjNjgwZDlhL3RhYmxlcmFuZ2U6ZjhkZDFiYWU1MDViNDY2OWIzZjZlNWZlOGM2ODBkOWFfNC0xLTEtMS0xMzA3ODM_f9713d49-77f5-45dd-9d13-a8d5b126a9f2"
      unitRef="number">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ib140873ca1da43bab9fd62b4810057e8_D20220101-20220331"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOmY4ZGQxYmFlNTA1YjQ2NjliM2Y2ZTVmZThjNjgwZDlhL3RhYmxlcmFuZ2U6ZjhkZDFiYWU1MDViNDY2OWIzZjZlNWZlOGM2ODBkOWFfNC0zLTEtMS0xMzA3ODM_b491e3e1-0d80-4846-9401-c3c5ce3ac2eb"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie25bf12b097d4142a80c4443e8e34b7c_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOmY4ZGQxYmFlNTA1YjQ2NjliM2Y2ZTVmZThjNjgwZDlhL3RhYmxlcmFuZ2U6ZjhkZDFiYWU1MDViNDY2OWIzZjZlNWZlOGM2ODBkOWFfNS0xLTEtMS0xMzA3ODM_38d32cf7-c5de-4dc3-af2d-44b6abe69971"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ib140873ca1da43bab9fd62b4810057e8_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOmY4ZGQxYmFlNTA1YjQ2NjliM2Y2ZTVmZThjNjgwZDlhL3RhYmxlcmFuZ2U6ZjhkZDFiYWU1MDViNDY2OWIzZjZlNWZlOGM2ODBkOWFfNS0zLTEtMS0xMzA3ODM_5f0f5c4b-ac19-467c-94c4-8ac372d27546"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RleHRyZWdpb246ZjVhMmFjMjQ2MTEzNDExMWE5YThjYmFhZjM1ZTI2MjBfOTE2Ng_de5e4d2f-cf4e-49ac-a343-31d5d8bba438">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Total stock-based compensation expense was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.358%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;661&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6537e1d4905e4ed2b36a8e22e7ed2fde_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjFlY2QyNDg3NzJiNDRjNWM5ZjBkMWMxNmIyNGE4NDA1L3RhYmxlcmFuZ2U6MWVjZDI0ODc3MmI0NGM1YzlmMGQxYzE2YjI0YTg0MDVfMi0xLTEtMS0xMzA3ODM_3088c69b-287f-41aa-bc6e-cb50926ab0a6"
      unitRef="usd">3239000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="iba81969c6f8347389b8d4c2ac513fd4e_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjFlY2QyNDg3NzJiNDRjNWM5ZjBkMWMxNmIyNGE4NDA1L3RhYmxlcmFuZ2U6MWVjZDI0ODc3MmI0NGM1YzlmMGQxYzE2YjI0YTg0MDVfMi0zLTEtMS0xMzA3ODM_0f79cb6d-d920-4f74-8b5e-cb67df1efeaa"
      unitRef="usd">458000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3f71e36b64d04c6589346f18f9cf047d_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjFlY2QyNDg3NzJiNDRjNWM5ZjBkMWMxNmIyNGE4NDA1L3RhYmxlcmFuZ2U6MWVjZDI0ODc3MmI0NGM1YzlmMGQxYzE2YjI0YTg0MDVfMy0xLTEtMS0xMzA3ODM_f30496bf-db5c-4353-b66f-8a0bf11d8ff9"
      unitRef="usd">524000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i1dfd433797ae4a47a3afcd51ca0bd98b_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjFlY2QyNDg3NzJiNDRjNWM5ZjBkMWMxNmIyNGE4NDA1L3RhYmxlcmFuZ2U6MWVjZDI0ODc3MmI0NGM1YzlmMGQxYzE2YjI0YTg0MDVfMy0zLTEtMS0xMzA3ODM_6faba0a6-aeff-499a-9a8f-83a1e95b24cf"
      unitRef="usd">203000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjFlY2QyNDg3NzJiNDRjNWM5ZjBkMWMxNmIyNGE4NDA1L3RhYmxlcmFuZ2U6MWVjZDI0ODc3MmI0NGM1YzlmMGQxYzE2YjI0YTg0MDVfNC0xLTEtMS0xMzA3ODM_b7a1923e-378a-4453-bac4-41b32a41655f"
      unitRef="usd">3763000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82MS9mcmFnOmY1YTJhYzI0NjExMzQxMTFhOWE4Y2JhYWYzNWUyNjIwL3RhYmxlOjFlY2QyNDg3NzJiNDRjNWM5ZjBkMWMxNmIyNGE4NDA1L3RhYmxlcmFuZ2U6MWVjZDI0ODc3MmI0NGM1YzlmMGQxYzE2YjI0YTg0MDVfNC0zLTEtMS0xMzA3ODM_97fd6b2f-dcdf-4296-a232-b50ace9aa44a"
      unitRef="usd">661000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82NC9mcmFnOjcwNzExMGY2MDg4YzQyYTM4MGU0Y2QyNWQ2ZmI1ZTQ0L3RleHRyZWdpb246NzA3MTEwZjYwODhjNDJhMzgwZTRjZDI1ZDZmYjVlNDRfNzgy_c680e620-82f7-43f5-b33d-0cfb0b002f37">Income TaxNo provision for income taxes was recorded for the three months ended March 31, 2023 and 2022, respectively. Deferred tax assets generated from the Company&#x2019;s net operating losses have been fully reserved, as the Company believes it is not more likely than not that the benefit will be realized due to the Company&#x2019;s cumulative losses generated to date.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82NC9mcmFnOjcwNzExMGY2MDg4YzQyYTM4MGU0Y2QyNWQ2ZmI1ZTQ0L3RleHRyZWdpb246NzA3MTEwZjYwODhjNDJhMzgwZTRjZDI1ZDZmYjVlNDRfMjA_04184775-3b03-407c-a270-cc2a076f2a38"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82NC9mcmFnOjcwNzExMGY2MDg4YzQyYTM4MGU0Y2QyNWQ2ZmI1ZTQ0L3RleHRyZWdpb246NzA3MTEwZjYwODhjNDJhMzgwZTRjZDI1ZDZmYjVlNDRfMjA_c4783ebe-93fd-41b6-bd38-55f3b06dacbf"
      unitRef="usd">0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RleHRyZWdpb246MmE4ZGIxOTFhMzcwNDFiNWE0N2Q2ZDc5ZjNlYmFmOWJfNDQ0_f739ce78-b853-4615-8700-8d300d8b7e42">Net Loss Per Share &lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of net loss available to common stockholders and the number of shares in the calculation of basic and diluted loss per share is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,070,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,171,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following potential common stock securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive (on an as-converted basis):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A and B redeemable convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,517,988&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,792,908&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,814,742&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested early exercised options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,840&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329,850&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earnout common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,274,070&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,662,580&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RleHRyZWdpb246MmE4ZGIxOTFhMzcwNDFiNWE0N2Q2ZDc5ZjNlYmFmOWJfNDQ1_13b298af-8c69-4720-8f65-43ccecf5f6eb">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of net loss available to common stockholders and the number of shares in the calculation of basic and diluted loss per share is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.839%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.760%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.442%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.829%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18,722)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,808)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average shares used in computing net loss per share, basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,070,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,171,254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net loss per share attributable to common stockholders, basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.42)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfMi0yLTEtMS0xMzA3ODM_e284c972-3a52-45e7-bc8f-7f616648fce8"
      unitRef="usd">-18722000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfMi00LTEtMS0xMzA3ODM_9fe71981-c9f0-487d-a2f8-cbfddc208d70"
      unitRef="usd">-11808000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfNC0yLTEtMS0xMzA3ODM_229eac0d-2652-4932-907a-a70fb7651127"
      unitRef="shares">44070974</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfNC0yLTEtMS0xMzA3ODM_d3f1bd7b-6c53-45fe-9d24-2b766edf6be8"
      unitRef="shares">44070974</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfNC00LTEtMS0xMzA3ODM_2f184849-e80c-4509-9b60-f894e04b226c"
      unitRef="shares">3171254</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfNC00LTEtMS0xMzA3ODM_5a8fa117-bfed-4cf8-b2e1-cad78032bfd8"
      unitRef="shares">3171254</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfNS0yLTEtMS0xMzA3ODM_5192c1a8-3411-4d4d-a482-c378af344cf2"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfNS0yLTEtMS0xMzA3ODM_d65c3847-0461-4227-a032-9dcff39af108"
      unitRef="usdPerShare">-0.42</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfNS00LTEtMS0xMzA3ODM_4f6f224c-b669-4f1f-a11d-d037c0646838"
      unitRef="usdPerShare">-3.72</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjZhMGQzMDdlNzQ1MzQ2Y2NhNDhkZDQ1MGI5MDE3MWM2L3RhYmxlcmFuZ2U6NmEwZDMwN2U3NDUzNDZjY2E0OGRkNDUwYjkwMTcxYzZfNS00LTEtMS0xMzA3ODM_b1e08cc9-3641-4a68-afc4-7efa366023cf"
      unitRef="usdPerShare">-3.72</us-gaap:EarningsPerShareBasic>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RleHRyZWdpb246MmE4ZGIxOTFhMzcwNDFiNWE0N2Q2ZDc5ZjNlYmFmOWJfNDQ2_0274fc40-8037-4cdd-bca4-cac6f471c5d7">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The following potential common stock securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the periods presented because including them would have been anti-dilutive (on an as-converted basis):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.810%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.805%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Three Months Ended March 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Series A and B redeemable convertible preferred stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,517,988&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options to purchase common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,792,908&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,814,742&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unvested early exercised options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;92,840&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;329,850&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;388,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent earnout common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,000,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,274,070&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,662,580&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie599948bb538493ca54ae5c945c4b314_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfMi0xLTEtMS0xMzA3ODM_4b76a9e6-4a83-4546-8bf8-7b95c15e88c2"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if2546b82138745239b77f03d5bb97902_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfMi0zLTEtMS0xMzA3ODM_9aa381f0-242c-49c9-9f10-3de38fe5200a"
      unitRef="shares">19517988</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i8ce095b293ee421697f3e146ad0f8453_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfMy0xLTEtMS0xMzA3ODM_913c65b2-8402-436e-8e77-c78940baed75"
      unitRef="shares">11792908</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia1ba20d9c2a54249ad151ad0d937ed15_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfMy0zLTEtMS0xMzA3ODM_b9c1972a-ee86-49df-add0-72e0acf534df"
      unitRef="shares">1814742</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ic1c8a87aa2e340119590adac4cec8f56_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfNC0xLTEtMS0xMzA3ODM_e7d87177-8313-4b42-9a2a-23b62a026d81"
      unitRef="shares">92840</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i9531c149469c43a9ac1f3916d2cb652f_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfNC0zLTEtMS0xMzA3ODM_a99309a8-7541-4fbc-9f90-551078c22960"
      unitRef="shares">329850</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0c36144fc5464645b44250cb81efdb06_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfNS0xLTEtMS0xNDAyNDM_f63f9288-ab86-442f-8126-a1412f26181b"
      unitRef="shares">388322</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i7307cc0c5600489eb471edc1bd0b09e3_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfNS0zLTEtMS0xNDAyNDM_066ff632-10d6-4a02-8b25-6b17a16c4dce"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i45a6fb8c66694eb9a022dbc503607f1c_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfNS0xLTEtMS0xMzA3ODM_a5c7a589-bffb-4dee-9592-aa43a08e5b4c"
      unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i162569ca541746a58397f1201089485e_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfNS0zLTEtMS0xMzA3ODM_ca83d7fd-d226-4dbb-ab2a-bf4e6339fb85"
      unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfNi0xLTEtMS0xMzA3ODM_4a25e8ec-e44a-493b-89ec-29b84c55c1e4"
      unitRef="shares">14274070</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i81b11644709349c9bc306b63606105cc_D20220101-20220331"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl82Ny9mcmFnOjJhOGRiMTkxYTM3MDQxYjVhNDdkNmQ3OWYzZWJhZjliL3RhYmxlOjI4OGZjMjNiOGQ2MzQ3OTZhZWU0MTQ4NTMxNzc4ZGZmL3RhYmxlcmFuZ2U6Mjg4ZmMyM2I4ZDYzNDc5NmFlZTQxNDg1MzE3NzhkZmZfNi0zLTEtMS0xMzA3ODM_7808bd88-74e2-4424-a182-68477aa08d7a"
      unitRef="shares">21662580</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfNDAxNg_3005a833-697b-4e97-b8f8-971f7823000b">Commitments and Contingencies &lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In the ordinary course of business, the Company enters into contractual agreements with third parties that include non-cancelable payment obligations, for which the Company is liable in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On June 3, 2021, the Company entered into a lease agreement for a new cGMP facility in Alameda, California to support planned initial clinical trials for our product candidates. Refer to Note 5, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Operating Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, for further details of the leases. The lease will expire in 2032 with future undiscounted operating lease payments of $46.0 million over an initial lease period of eleven years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In 2021, the Company began construction of the cGMP facility. As of March&#160;31, 2023 the Company paid $37.5 million in construction costs of the $42.2 million purchase commitment. The agreements with the construction company provide for termination following a certain period after notice. Upon termination, the Company will be responsible for payment for work performed to date. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In 2021, the Company entered into a three-year collaboration and option agreement with BlueRock Therapeutics LP (&#x201c;BlueRock&#x201d;) under which the Company granted BlueRock an option to acquire an exclusive or non-exclusive license to develop, manufacture and commercialize cell therapy products. Refer to Note 12, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Related Parties&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, for further details of the related parties. In consideration for the option, the Company is responsible for up to $10.0 million in costs and expenses incurred over the three-year term.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023, purchase commitments related to sponsored research agreements amounted to approximately $0.8 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company has entered into license agreements under which they are obligated to make annual maintenance payments of $0.1 million and specified milestone and royalty payments. Future milestone and royalty payments under these agreements are not considered contractual obligations since the payments under these agreements are contingent upon future events, such as the Company&#x2019;s achievement of specified development, regulatory, and sales milestones, or generating product sales. As of March&#160;31, 2023, the Company is unable to estimate the timing or likelihood of achieving these milestones or generating future product sales.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Following the Closing, former holders of Legacy Senti common stock and preferred stock may receive up to 2,000,000 additional shares of the Company&#x2019;s common stock in the aggregate, in two equal tranches of 1,000,000 shares of common stock per tranche. Refer to Note 6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Stockholders&#x2019; Equity (Deficit),&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; for further details of the contingent earnout liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company is subject to claims and assessments from time to time in the ordinary course of business but does not believe that any such matters, individually or in the aggregate, will have a material adverse effect on the Company&#x2019;s financial position, results of operations, or cash flows.&lt;/span&gt;&lt;/div&gt;IndemnificationIn the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions and has never accrued any liabilities related to such obligations in its condensed consolidated financial statements. The Company has also entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#x2019; and officers&#x2019; insurance.</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i43648233679b4319915d781e0fdea7bf_I20210603"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfNTU3_89f48965-2fce-43bf-9518-015e6000df3e"
      unitRef="usd">46000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i43648233679b4319915d781e0fdea7bf_I20210603"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfNTky_7720cbf6-d5b8-41f7-a200-5d00ad2f3694">P11Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:PaymentsForConstructionInProcess
      contextRef="i082b5a0a6bc54f70b3e73ff4d25c3e03_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfNjg0_0b54346b-761e-4de2-8141-24ebf2750c79"
      unitRef="usd">37500000</us-gaap:PaymentsForConstructionInProcess>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="i082b5a0a6bc54f70b3e73ff4d25c3e03_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfNzE2_b182a72a-9eb4-4d20-847b-8571612a91df"
      unitRef="usd">42200000</us-gaap:LongTermPurchaseCommitmentAmount>
    <snti:ResearchAndDevelopmentExpenseTermOfAgreement
      contextRef="i591e3e2787ef4aa3b0dde7a4158d5d4e_D20210521-20210521"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfNDAxNA_6039d384-1978-4030-b2f2-f88a538834a3">P3Y</snti:ResearchAndDevelopmentExpenseTermOfAgreement>
    <snti:ResearchAndDevelopmentArrangementExpectedCosts
      contextRef="i9ddb97ef409844f1b6d57e39963c1d3d_I20210521"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfMTM3Nw_ce65cafd-7645-445d-9e2d-afcefe083d41"
      unitRef="usd">10000000</snti:ResearchAndDevelopmentArrangementExpectedCosts>
    <snti:ResearchAndDevelopmentExpenseTermOfAgreement
      contextRef="i591e3e2787ef4aa3b0dde7a4158d5d4e_D20210521-20210521"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfNDAxNQ_1d157912-003a-4f50-b5de-c2c989c4d079">P3Y</snti:ResearchAndDevelopmentExpenseTermOfAgreement>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="id747b950a62d4ac19aee5dcc6cf15399_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfMTUzMg_890489d4-650f-43d0-aef4-977e89ff178a"
      unitRef="usd">800000</us-gaap:LongTermPurchaseCommitmentAmount>
    <snti:CollaborativeArrangementRightsAndObligationsContractualAnnualPayments
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfMTY1NA_ea9bad2a-7b4c-4484-a257-93ea299798a4"
      unitRef="usd">100000</snti:CollaborativeArrangementRightsAndObligationsContractualAnnualPayments>
    <snti:ReverseRecapitalizationContingentConsiderationEquityShares
      contextRef="i2cf3659743e3408a95f042ce0308c736_D20220608-20220608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfMjI0Nw_7bd49395-58cb-4457-8c3f-64ec7d2dd357"
      unitRef="shares">2000000</snti:ReverseRecapitalizationContingentConsiderationEquityShares>
    <snti:ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches
      contextRef="ic402157e4d8841ffabfdea65ced1a7b6_I20220608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfMjc0ODc3OTA3MzU0NQ_eb8229b2-302b-473e-931a-59b2f57131dd"
      unitRef="tranche">2</snti:ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches>
    <snti:ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche
      contextRef="i2cf3659743e3408a95f042ce0308c736_D20220608-20220608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83MC9mcmFnOjA3MmQwZDNlYzhlYjQ3MDRhNThlNmZiZjUwZDQ2NGE5L3RleHRyZWdpb246MDcyZDBkM2VjOGViNDcwNGE1OGU2ZmJmNTBkNDY0YTlfMjM0MA_d07f892f-81b1-48e5-9d7a-d320d8af9553"
      unitRef="shares">1000000</snti:ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfNDM0Nw_9c799759-83cb-4fed-9f59-7cdaaa504aff">Related Parties&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;NEA&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;NEA held 4,429,725 and 4,429,725 shares, respectively, of common stock as of March&#160;31, 2023 and December&#160;31, 2022, respectively. NEA held one of the seven seats on the Company&#x2019;s Board of Directors as of March&#160;31, 2023 and December&#160;31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Bayer Healthcare LLC&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On May 19, 2022, Legacy Senti issued to Bayer a $5.2&#160;million unsecured convertible promissory note. On June 8, 2022, the May 2022 Note was automatically cancelled and exchanged for 517,500 shares of Class A Common Stock at a price of $10.00 per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On May 21, 2021, the Company entered into a collaboration and option agreement (&#x201c;BlueRock Agreement&#x201d;) with BlueRock, a wholly-owned subsidiary of Bayer, pursuant to which the Company granted to BlueRock an option (&#x201c;BlueRock Option&#x201d;), on a collaboration program-by-collaboration program basis, to obtain an exclusive or non-exclusive license to develop, manufacture and commercialize cell therapy products that contain cells of specified types and which incorporate an option gene circuit from such collaboration program or a closely related derivative gene circuit. The Company is responsible for up to $10 million in costs and expenses incurred in connection with the research plan and related activities to be conducted over a term of three years as specified in the collaboration and option agreement. If the Company and BlueRock agree to add new research activities to the research plan, then BlueRock will be obligated to reimburse the Company for the costs and expenses incurred that, together with costs and expenses incurred under the initial research plan, exceed $10 million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company concluded that the Agreement is not within the scope of ASC 808, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%"&gt;Collaborative Arrangements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, because the Company did not receive any consideration and therefore, is not exposed to both significant risks and rewards for the arrangement. The Company also determined that the agreement is also not currently within the scope of ASC 606 because the BlueRock Agreement does not currently meet the criteria of a contract with a customer, and will not be within the scope of ASC 606 until any consideration is paid. Potential future milestone payments and royalties are subject to BlueRock&#x2019;s exercise of the BlueRock Option and execution of a commercial license agreement by both parties. Under the BlueRock Agreement, the specific financial terms for milestone payments and royalties will be negotiated and agreed to only after the option is exercised. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;As of March&#160;31, 2023 and December&#160;31, 2022, Bayer held 5,878,488 and 5,878,488 shares, respectively, of the Company&#x2019;s common stock. As of March&#160;31, 2023 and December&#160;31, 2022, Bayer held one of the seven seats on the Board of Directors of the Company. Bayer&#x2019;s parent company is Bayer AG, which served as the lead investor in our Series B financing through its Leaps by Bayer unit. Accordingly, Bayer is considered a related party.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%"&gt;Seer, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In January 2023, the Company received lab automation equipment purchased from Seer, Inc. (&#x201c;Seer&#x201d;) (NASDAQ: SEER). Omid Farokhzad, a member of the Company&#x2019;s board of directors is the Chief Executive Officer &lt;/span&gt;&lt;/div&gt;for Seer. The consideration of $200,000, plus interest, will be paid over a two-year period, and title will transfer to the Company upon final payment. The transaction was classified as a finance lease</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5f79f3be18db4668bcb3b5370e9cecd3_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMTI5OQ_3eb9fb80-37c9-461b-821a-e68964fce6ef"
      unitRef="shares">4429725</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7c26ec28b64d45bc9036cc8d57f2140b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfNjU5NzA2OTc3MTUwMw_4cc6a4cc-426b-4cd5-ac94-2a957a9d856f"
      unitRef="shares">4429725</us-gaap:CommonStockSharesIssued>
    <snti:NumberOfSeatsOnTheBoardOfDirectors
      contextRef="i7c26ec28b64d45bc9036cc8d57f2140b_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMTU5OA_341338dd-5da7-4d9b-8cc6-c851026b9b88"
      unitRef="tradingday">1</snti:NumberOfSeatsOnTheBoardOfDirectors>
    <snti:NumberOfSeatsOnTheBoardOfDirectors
      contextRef="i5f79f3be18db4668bcb3b5370e9cecd3_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMTU5OA_a29f9903-81fe-4be7-8033-14746dbeb121"
      unitRef="tradingday">1</snti:NumberOfSeatsOnTheBoardOfDirectors>
    <snti:NumberOfSeatsOnTheBoardOfDirectors
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMTYwOA_cb536151-3fc3-4ab3-88d3-686f2d120523"
      unitRef="tradingday">7</snti:NumberOfSeatsOnTheBoardOfDirectors>
    <snti:NumberOfSeatsOnTheBoardOfDirectors
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMTYwOA_f3146a5c-9017-4f01-a8c7-0d1e7b8ebd91"
      unitRef="tradingday">7</snti:NumberOfSeatsOnTheBoardOfDirectors>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i1f7c274bcbdf4ef58b92b5848babde15_I20220519"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMTczOQ_9a74abd2-2b14-403f-8cd7-c8aa4ee33354"
      unitRef="usd">5200000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="ib7a73372076e4e89a384e72fe0e3c45e_D20220608-20220608"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMTg2Mg_91d8cc98-8b27-45ac-923d-fdf1e048deab"
      unitRef="shares">517500</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:SharePrice
      contextRef="i057310d2a92b4448be2ea0e4a9991828_I20220608"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMTkxMA_6801a393-009b-4aea-a3df-1c6e3505035c"
      unitRef="usdPerShare">10.00</us-gaap:SharePrice>
    <snti:ResearchAndDevelopmentArrangementExpectedCosts
      contextRef="i9ddb97ef409844f1b6d57e39963c1d3d_I20210521"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMjYzNw_a469580a-4d44-4608-9c2f-50d25950bc81"
      unitRef="usd">10000000</snti:ResearchAndDevelopmentArrangementExpectedCosts>
    <snti:ResearchAndDevelopmentExpenseTermOfAgreement
      contextRef="i591e3e2787ef4aa3b0dde7a4158d5d4e_D20210521-20210521"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMjc2Mg_be1fb0af-682a-4663-a2f7-068f7f18b0ab">P3Y</snti:ResearchAndDevelopmentExpenseTermOfAgreement>
    <snti:ResearchAndDevelopmentArrangementExpectedCosts
      contextRef="i9ddb97ef409844f1b6d57e39963c1d3d_I20210521"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMzA4OQ_a469580a-4d44-4608-9c2f-50d25950bc81"
      unitRef="usd">10000000</snti:ResearchAndDevelopmentArrangementExpectedCosts>
    <us-gaap:CommonStockSharesIssued
      contextRef="ie37202655afe400799f589b98e2e9296_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMzk3NA_3cbe7986-8067-422a-98ef-22e29e23a9a9"
      unitRef="shares">5878488</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i1fc3f895e15c4c5e96890aa6215ca746_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfNjU5NzA2OTc3MTY5OA_64ed8f40-790c-45c3-bb69-f9bd9a75d512"
      unitRef="shares">5878488</us-gaap:CommonStockSharesIssued>
    <snti:NumberOfSeatsOnTheBoardOfDirectors
      contextRef="ie37202655afe400799f589b98e2e9296_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfNDEwNg_835898bb-ec3e-4f7c-bea3-c5d76ad31887"
      unitRef="tradingday">1</snti:NumberOfSeatsOnTheBoardOfDirectors>
    <snti:NumberOfSeatsOnTheBoardOfDirectors
      contextRef="i1fc3f895e15c4c5e96890aa6215ca746_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfNDEwNg_bfd1ea42-e1a5-46da-86ea-87a26084f726"
      unitRef="tradingday">1</snti:NumberOfSeatsOnTheBoardOfDirectors>
    <snti:NumberOfSeatsOnTheBoardOfDirectors
      contextRef="i5bdb6a23de54461f88fa0cf0fb407155_I20221231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfNDExNg_30818b7f-95c2-4dee-b927-15c0503af23f"
      unitRef="tradingday">7</snti:NumberOfSeatsOnTheBoardOfDirectors>
    <snti:NumberOfSeatsOnTheBoardOfDirectors
      contextRef="i2db00a77192f4255a898540eac49878e_I20230331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfNDExNg_5d17851e-f1d2-4ba6-bb18-8e0aa55cf7cd"
      unitRef="tradingday">7</snti:NumberOfSeatsOnTheBoardOfDirectors>
    <us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty
      contextRef="ib8899c630b094438a9d71777a8d3774a_D20230101-20230131"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMjc0ODc3OTA3ODUxMQ_04c71340-77e7-42ae-9e3e-c251df567a50"
      unitRef="usd">200000</us-gaap:RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty>
    <snti:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm
      contextRef="ib8899c630b094438a9d71777a8d3774a_D20230101-20230131"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83My9mcmFnOjM2ZDI4NTliMmFjNjQyNDQ4Yjc5ZWY3YTc4MDc2Y2M3L3RleHRyZWdpb246MzZkMjg1OWIyYWM2NDI0NDhiNzllZjdhNzgwNzZjYzdfMjc0ODc3OTA3ODUyOQ_e14f67e0-4c53-461f-a462-0830d4a6a0c7">P2Y</snti:RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331"
      id="id3VybDovL2RvY3MudjEvZG9jOmQwOGMwZDdiZDcwMzQ5NWQ5NzBkMjAzMzMwZDU5YjJmL3NlYzpkMDhjMGQ3YmQ3MDM0OTVkOTcwZDIwMzMzMGQ1OWIyZl83Ni9mcmFnOmE4ZmJiMTg3MWI3NjRkNGNiYmZiMmEyYThlNGY1MmI0L3RleHRyZWdpb246YThmYmIxODcxYjc2NGQ0Y2JiZmIyYTJhOGU0ZjUyYjRfMjk2_07bbabab-cc54-4661-8a97-4cf4657baca5">Subsequent EventsOn April 26, 2023, Mr. David R. Epstein, informed the board of directors (the &#x201c;Board&#x201d;) of the Company of his intention to resign as a director, effective as of the close of business on June 16, 2023. Mr. Epstein has resigned in order to minimize potential conflict or the appearance of conflict with his role as Chief Executive Officer of Seagen, Inc. (an oncology company) rather than because of any disagreement relating to any of Senti&#x2019;s operations, policies or practices.</us-gaap:SubsequentEventsTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MZ$5WO192'2@F"[T MJQ2Q50)0^OA01#": 318073 +M!1CN0D1?DI60;RE>
M_=B8-5TUPR[4FDG=2J34B &=G/"1A8A$*!C!=AB1%+I1QSO4L1?U%Z%H_@R
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MZ0Q&]=@UH,.RN4F]YG6UIO_*FE^)ZJ' NT ^]H,.^'0__(8F#=QOPUUPWZ3
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M8R:- ;Q?":$/-^8#]0'A_#]02P,$%     @ _("I5C9V_1GS!@  *S4  !@
M  !X;"]W;W)K<VAE971S+W-H965T-2YX;6R]6UUSFT84_2L[2B:-9^J(73Z5
MV)I)))CFH:W'3M*'3A^P6%M,@%5A93O]]=U%6&AAM8+TIB\22/>>N]RS7_<
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M\;KW'C5V/6XT@H)EN4['+M38=:K;2&-RCGVQ_S]RSX.T&@"Q_\>['@2R"E^
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M-F4O-=;L*@=4O7(["]6A70==:NF17^3,&.B-RF=DHP,82DQ*/7C"!EDD=!Q
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MLSG<M:KFIJ45NUWP9SO6D,03]]BS:E3;-74*@JQM:%_#F/A/IY"20]/D#5J
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MV7PHP"V,7LE4JL\T-P::I$S82PB6?:S-B*)6%."D([2$VN5 A[FFH5Q+VW-
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M("O@W5CNZ7$7'<A0Z%:GJ&/P'@[+9S!I>!J3$S21W5KMN"3<+%LQXEPT$Z(
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M ((?T/A0)$J72GML=IB6PNS[R,T4URGM224PVBIM-C*%C(-[FX1KTJ;)I1V
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M,G$WT80DM\L$$4,95:=!;R!6W)OY: P/P5.&D\$G1C I^*=1E.[_-T7Y^KC
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M<P/8T5M[]X5CU'=W;9LJ$#!A[.\JUX>0C*F&:NA59C<VTEM^VK\3O.Q.N@9
MO6 RL-'6[0R#84WG>.>7*F6$KZF&*6>_N@Y)?:YC/I$UXK)BU_<Z=<38$.J$
M_4,A=-4 N@M+_G%$C726N8=:3 ::; O7*J.Z4S8*IOT():*-N*8V6UVH)L$
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M2*&X-BU]=NJ.X^1E0RW\".+#K?CA^^]>+1:S-[U >IV_^9%Y1L?J=^UEHMZ
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M>]4/ H1V]1_<S]@D9:2N<RN3 7TL9*Z7WM5,B,22]*O_]DR*AR@*AVAPZ:W
M(! [GS)9;ZH-D(V/JAS:0F-D([!H57#T:?#3T*TD("1O(SZZ(;/HKE!+9<D.
M.'LTK:7F5L3R#=B6&SVRA"MCBF!WR$IG6JA6,N P!HZ&R;&+PG3GF@?&KM-E
MEJF#OIMO?,/J<%^^RM?$1_%\V49=KC5ZCJ$26V>3EV<CX?,%-K]$UZ1+X\I%
M7$'38X4[/WD6P/?2@4'="RL8_HIP^1=02P,$%     @ _("I5E--?4D+!P
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M3=SW)MID?>CKO=?"W.*OU_\P6\RW^>*6^IDN0OUUDU-*3]HLUFR!527FRGH
M%$GU)^*3R88G,4H%F75IT55O[-K M&^67N5*.M07-=,:=@.YMK-!YIH+DTH/
MG!LOL]0=VR8FK4"ZT='4QJWC$!N*KY0DK8%TXP$N[].8X49GJYB=#LJLRT)
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M&4[N?8]L3CB)X&C-#(3CL&Y'++B@GVV+'^=F3J#*R'WM1OP1-7"Q',C>TCI
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M=R-7"]'IBC=X(T%U=<WDTR568K?T0F__XI9O2VU>C%>+EFWQ#O7G]D;2TWA
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M&>U\]ND<-E+4+TM&-.+,<IEF"=Q>?Z;Z*:3^B+6F+93(\ ;P,2]9LT7;GI<
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M?-,@R9PC!FDZ"L=I]M+97BK?<"%=*;XF&EHJ,0W8)70C.9%+0C8>AVPX!.9
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M)C:2!RF_V,FO^<(+K$/ (3.6@>)K"RO@W!*A&U];3J\S:8&'XSW[!Q<[QO)
M-:PD_\QR4RR\F4=R6-.:FSNY^P7:>":6+Y-<NR?9M7L#CV2U-K)LP>A!R43S
MIM]:'0X R-,/B%I ]!@P?@(P:@&CYP+&+6#LE&E"<3JDU-!DKN2.*+L;V>S
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MN9\T$R,KU[$?I,'^[X8%7NE V0WX?2VEV4^L@>Z2F/P'4$L#!!0    ( /R
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M=:K/O*]5VU:;W3]OR^*JK/N [N_75=4>?IAW_,>J_K;;Q_E_ %!+ P04
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M/3DCN;J>9O7&JM)/D+FR-(_\,J<? &IG0/<+I>QFXPC:7TKR!U!+ P04
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MA;X3Z\]0Z^D9O%04RC[)VOG&F#%=*BW*.ACMDG'WIL]U';8"$*<](*P#PMV
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M,99+NF[O#"TJVS!G0F/[M<L<!R1(XX#G<R'TQC )FI&;_ %02P,$%     @
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M+3<W!"\)4P'R_(I2\;JC/H$TG[QF_P!02P,$%     @ _("I5CS\&8IG!
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MSMS>-Q$9^[T4T4!B+43C&M'8B.A/8*E:9D8@9@E_@E*]E?O6DM'U4E #B;5
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M9.597=D0-->G5QLJ!$WU90PX J8,Y/,MI>+84!W4)Z;+_P!02P,$%     @
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M54&^7U,J]@^J@?( ?OD?4$L#!!0    ( /R J59A-I1QO ,  &L1   9
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MQI'8Z9QQ6$JB=D5!Y?,<<G&8.;YS;%BQ3:9-@QM')=W  ^BOY5)BS6U84E8
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M-I'5+5Y5M"CM1?@H-&:Z+6;X\ %I K!_+80^5LP S5,J_@U02P,$%     @
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MB'$BX^D#'\S^^A=S9/RM37%(F(>$423,1\(8"*;(R]G+R]'19[^7XYS03/#
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M5A/JL4)I'I1&H30?2F,HFBHSZ;2:>JN59GD8!472J_[Y/]\OZB%"<\6[<HV
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M8%Y_!7(+0?K;+SB)?N_2=R&P5VI[K=J>#SW]LM%*4YXSOKI""U@QSLW0JJ]
M,I&C#XPW=^UCER-J]+Y#MUEMF_;C9-B/\#C<'FKTLCA38[_5V/=J-"EI"4S#
M_XKIOQ%SG8QP%!UI\9YVII:DU9*<'B_@^>F12MY&BHQ&O3>1ZMAW%-%7Q <M
M\8&7^#=0-@*&.H(GD!E3=%' #VH8O.$6Q[W^,#F2X&5R9H"&K<ZA-WU\=]\V
MR*^G6Y#F6XT^U6H!S27+H$O5\)+)Y$)@K[2/6NVCGT\FN2@**I5=JD/=&>GZ
MH.%!I$<W(W(49R^;,[7B:/]QCWX@K9PFJX'$Q"_,?_*YR@[*%OPS2>9$J?@T
MJ=@?Z=<2R%X"N5"Z.5$-.>5"^DF=&[=]Y8*]I8(G;E=HU^0E1)N\),$V(O;]
MS$P])TW)OZ$%*M@2G%N>P3BEVQ5^$L/:%"6H='5B9XGIAQC5$#Z?[.L;["]P
M3KH(%W6/G\^@<0^NW6/<E-/G;B==M&8*#]J8$N3*=7?*B-MP77<T[6K;04Y=
MWQ3NM]?MIRG836I7J("E,8UN!N:#+.N.KIYH4;FF:"&T:;'<<&VZ8)!V@WF^
M%$*_3.P!;5^=_@=02P,$%     @ _("I5C*_++[N @  S@@  !D   !X;"]W
M;W)K<VAE971S+W-H965T-3 N>&ULM99M;YLP$,>_RHE-4RLU@4 >NP0I:==M
M+[I5B=J^=N 2K(+-;).TTC[\;$-HII*H:[4WX*>[^]T?V\=XR\6#3! 5/&8I
MDQ,G42H_=UT9)9@1V>8Y,CVSXB(C2G?%VI6Y0!);HRQU?<_KNQFAS G'=NQ&
MA&->J)0RO!$@BRPCXFF&*=].G(ZS&YC3=:+,@!N.<[+&!:K;_$;HGEM[B6F&
M3%+.0.!JXDP[Y[..9PSLBCN*6[G7!I/*DO,'T_D>3QS/$&&*D3(NB'YM\ +3
MU'C2'+\JITX=TQCNMW?>KVSR.IDED7C!TWL:JV3B#!V(<46*5,WY]AM6"?6,
MOXBGTCYA6ZWU'(@*J7A6&6N"C++R31XK(?8, O^ @5\9^):[#&0I+XDBX5CP
M+0BS6GLS#9NJM=9PE)FOLE!"SU)MI\*%XM%#:Z;SBN&"9_IC2V+E:L$<I1(T
M4GK&KH);1I6$J=&1JB<XN41%:"I/#Z\]F2]NY>G859K4Q'.CBFI64OD'J *X
MYDPE$KZP&.._[5V=89VFOTMSYA]U>$U$&X+.&?B>'\!'<$$F1*"L7D<B!+60
M@8T0'(CPH\B6*("O#FC1)$+IL=OLT9S'<YF3"">./G 2Q0:=\-.'3M_[?(2W
M6_-VCWD/?Q9**L)BRM9GL,0U94PW#7^.@O(83BBKU#F%WXTZE4F487HVC+D#
M-F&W.QAUAV-WTX#7J_%Z1_'TD5LA-1J^EJ/W@J/5&_7]?C-'O^;HOUXF9/$;
M!.J_  N&P\#WF\$&-=C@Z'Z[M_<-QJWI!H6^/^&K($R!O@00K@@5<$?2 IMX
M!O]AUPUKZN'[=UW,TY0(:89*68V^SV>V*:<RZG!/8[_=:Q9X5*.._F$'OH&I
M=-_Q7P/5\9[O:^\]&_(-G%7 X^*Y>R4F0[&VA51"Q NFRFI3C];%>EJ6J.?E
M9:77=['^[A)27&E3KSW01T.4Q;/L*)[;@K7D2I<_VTST#P<*LT#/KSA7NXX)
M4/_"A'\ 4$L#!!0    ( /R J58",S%^W (  "D(   9    >&PO=V]R:W-H
M965T<R]S:&5E=#4Q+GAM;*U6;6_:,!#^*U8F3:VTDI#PTG40"6BG55HUU&KK
MAVD?3'(0"R?.;$/*O]_9A@RJ-*VF?2'V^>[Q\YSM.T:5D&N5 6CRE/-"C;U,
MZ_+*]U6204Y51Y10X,I2R)QJG,J5KTH)-+5!.??#(!CX.66%%X^L;2[CD=AH
MS@J82Z(V>4[E;@I<5&.OZQT,]VR5:6/PXU%)5_  ^GLYESCS:Y24Y5 H)@HB
M83GV)MVKV=#X6X<?#"IU-"9&R4*(M9G<IF,O,(2 0Z(- L7/%F; N0%"&K_W
MF%Z]I0D\'A_0/UOMJ&5!%<P$?V2ISL;>I4=26-(-U_>B^@)[/7V#EPBN["^I
MG._PHT>2C=(BWP<C@YP5[DN?]GDX"D"<YH!P'Q ^#^B]$!#M R(KU#&SLJZI
MIO%(BHI(XXUH9F!S8Z-1#2O,*3YHB:L,XW3\H$6ROIAB(E(R$SE>#D5M?B_(
MHTT!VB=;D'BB9*+PK$NSJLC9-6C*N#I'QV_.-O(U$C*P?K+??.HV#U_8/")W
MHM"9(C=%"NEIO(]":C7A0<TT; 6\H[)#HNX'$@9AU,!G]O;PL(5.5"<WLGC1
M2\G-J(2FY$ZDI,4*\#5HLMB18[\YW5GSI*(R)3^_(B2YU9"K7TWY=?OWFO<W
M%>!*E32!L8=/7('<@A>_?]<=!)^:DO.?P$Y2U:M3U6M#CV^>2GS8J%^#S,D9
M*\@.J%3G3:+;D08NLDE@:^ _"NS7 OMO$[@5'"\!9WIG998@$SSO1J$.L>O>
MKJG'VSCH7.+-W!ZK:O*J74ZX#FJN@U:N]TRM+Y82@+ "SP.4)I)J>)6O0^T&
M)WR#J/^,\.#-A(<UX6$KX6NV92D4*=DQX.FK/(=M!!S'5A?'T3^JNCG(E6U&
MBB1B4VA7LFIKW>\FMLP_LT^Q#[JV]1?&-5$L2"N&U9;#$B&#SA#/6KK&Y"9:
ME+:V+X3&3F&'&?9RD,8!UY="Z,/$;%#_.XC_ %!+ P04    " #\@*E68D=#
M"2 #  "V"P  &0   'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6S%5FUOVC 0
M_BM65DV=U#8A@0 =1"JTVRJM$BKM]F':!Y,<Q&H29[:!=K]^9R>D0 -:):I^
M(7ZY>_S<<V=SO247#S(&4.0Q33+9MV*E\G/;EF$,*95G/(<,=Z9<I%3A5,QL
MF0N@D7%*$]MU'-].*<NLH&?61B+H\;E*6 8C0>0\3:EX&D#"EWVK8:T6;MDL
M5GK!#GHYG<$8U'T^$CBS*Y2(I9!)QC,B8-JW+AKGPX:C'8S%#P9+N38F.I0)
MYP]Z<AWU+4<S@@1"I2$H?A8PA"312,CC3PEJ56=JQ_7Q"OV+"1Z#F5 )0Y[\
M9)&*^U;'(A%,Z3Q1MWSY#<J 6AHOY(DTOV19VCH6">=2\;1T1@8IRXHO?2R%
M6'- G'H'MW1PMQV:.QR\TL$S@1;,3%B75-&@)_B2"&V-:'I@M#'>& W+=!K'
M2N N0S\5C!4/'TX'*$1$ACS%ZI#4Z'M*=FY=/>HQD.-+4)0E\A,:WX\OR?'1
M)W)$6$;N8CZ7-(MDSU;(49]DAR6?0<''W<''(S<\4[$D5UD$T::_C;%5 ;JK
M  ?N7L ;*LZ(US@AKN-Z-7R&_^_N[J'C57I[!L_;I7=,!92BCN@37@A%+H2@
MV0ST^&0E;D10/S*D.5,T87\A.B$7*9^C]:_O"$FN%:3R=YV^Q?G-^O/UJW N
M<QI"W\)K+T$LP H^?FCXSN<Z<0X$MB%5LY*JN0\]N.,8.I&F"B=&L'"]"J$0
MJDZ" M<WN/H=6P1>V\?D+]9#>VGD^XW*9H-QJV+<VLOX*V0@D+-.'8WPMC*I
M!-7O5!W+O5BO3=2!P#;"]JNP_7>N:?^04AT(;$.J=B55^XUJNL!MK=>TZW6W
M:OJE4;/5J:_I3L6XLY?Q+6I 11B;W$6PP#_^7&>UCN->I->FZ4!@&T%WJZ"[
M[US1W4-*=2"P#:D:SG,'X;Q139? ZV]PRVUNU72-D>MX6T5MKW5 *8B9:0PE
M$L%<%+U"M5HUGQ>FY=I:'^BFU'16SS!%1XN=P(QEDB0P14CGK(W73!1-8C%1
M/#=]UH0K[-K,,,;&&H0VP/TIYVHUT0=4K7KP#U!+ P04    " #\@*E6B?C%
MD$,"  "1!0  &0   'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6RME-N.TS 0
MAE_%"@AU)5BG22FH))%Z +$7*U5;%BX0%VXR::QU[&"[37E[?$A#=Y4M7'#3
M^##_Y_E=SR2MD ^J M#H6#.NTJ#2NIEAK/(*:J*N10/<[)1"UD2;J=QAU4@@
MA1/5#$=A.,4UH3S($K>VEEDB]II1#FN)U+ZNB?RU ";:-!@'IX4[NJNT7<!9
MTI =;$#?-VMI9KBG%+0&KJC@2$*9!O/Q;#FQ\2[@*X56G8V1=;(5XL%.;HHT
M"&U"P"#7ED#,YP!+8,R"3!H_.V;0'VF%Y^,3_9/S;KQLB8*E8-]HH:LT>!^@
M DJR9_I.M)^A\_/6\G+!E/M%K8^-XP#E>Z5%W8E-!C7E_DN.W3V<"0QG6!!U
M@NBI8/*,(.X$L3/J,W.V5D23+)&B1=)&&YH=N+MQ:N.&<OLO;K0TN]3H=';#
M<U$#^D*.:+0"32A35^@-NM^LT.CE58*U.<-&XKSC+3PO>H87HUO!=:701UY
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M*;9+57?S0%/U6OC]63*N2 8+I/0Z$9:-K/J7:J!%85N N=#84-C'%%L^D"8
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M7US__<4 H\\:4O5/&\M%%(/V*.QE<:NV-(*I8VX#!7('SNSGG_#(^ZV-HI[
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MSPG7!=3O+XS)W8VNH/R/"^-_ 5!+ P04    " #\@*E6G^V.T P'  #H/0
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MA!%(6  )"X%@ECRFM3RFK[1LF$+*!A+F0\(()"R A(5 ,$LVLUHVLP.C2O[
M1+&[UI.&8#'3^_W[E*&HN* 2<ZS[73*A+Y;+"[T14EPW:!8<9FND _)JD_V8
MJ'4Q&]TR S>?$=TDBJ;)O]2T.$,Y4Z9#U=)IQ*6>QPZL568OQNBQ-QT/!O9
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M\HOBF^*MUGNN%,^*PS6C,1.F@;Z^Y%P]?S$=U"]WS_\#4$L#!!0    ( /R
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MX$0&*&> <BS+A4S,!\OCYB3Z<H\T2:(HCK$9G4R<#B;8O,4Q_+C5,&_ P/)
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M4$L! A0#%     @ _("I5DP,C+GO    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ _("I5IE<G",0!@  G"<
M !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " #\@*E6*ETIT8<&  !X)0  &               @($."   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ _("I5M;?V,7K!@  %B
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M965T-BYX;6Q02P$"% ,4    " #\@*E6?<N1"!8)  "W%@  &
M    @(%>+0  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M_("I5N."H)L9"   8Q8  !@              ("!JC8  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( /R J598[ \R6@0  %D+   8
M          " @?D^  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    " #\@*E6_Z_2XB@$  !+"@  &0              @(&)0P  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( /R J58".CFI0P<  "42
M   9              " @>A'  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ _("I5E8>+!1$"P  S1T  !D              ("!8D\
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #\@*E6ZZK6
MM-X*  "U'0  &0              @('=6@  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( /R J5:_15LCNPX  &HT   9
M  " @?)E  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M_("I5DE+)]"P @  ]P4  !D              ("!Y'0  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    " #\@*E6Z!$_3-L#  "B"   &0
M            @('+=P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( /R J59(<AXDRP8  %$0   9              " @=U[  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ _("I5E--?4D+!P
M(!$  !D              ("!WX(  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    " #\@*E6OE"99PH#  "*!@  &0              @($A
MB@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( /R J594
MX\/[&P8  '$/   9              " @6*-  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ _("I5@%#*@N^!   Q0P  !D
M     ("!M),  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( /R J5;N0WH5$P0  'X)   9              "
M@1:K  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ _("I
M5D'^-8Y/ P  , H  !D              ("!8*\  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    " #\@*E6YO?^+54"  ![!0  &0
M        @('FL@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( /R J59;+>_/>PX  ,NS   9              " @7*U  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ _("I5M',"8G& @  7@8
M !D              ("!),0  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    " #\@*E6L^)Z)<D"  !J!P  &0              @($AQP
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( /R J5:9U0$M
M_0,  ! 4   9              " @2'*  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ _("I5B>:6VQP @  W 4  !D
M ("!5<X  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " #\
M@*E6VA%;9@X#  !P"   &0              @('\T   >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( /R J59+=&A)+00  *X9   9
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M970S.2YX;6Q02P$"% ,4    " #\@*E6/PK_Q;8$  #^&@  &0
M    @($"Y@  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M /R J58\_!F*9P0  #T5   9              " @>_J  !X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ _("I5KN1!A,H!0  C!\  !D
M             ("!C>\  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    " #\@*E683:4<;P#  !K$0  &0              @('L]   >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( /R J587^EMKBP4
M -HE   9              " @=_X  !X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ _("I5M+TM'+E @  P@L  !D              ("!
MH?X  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " #\@*E6
MA$/9UK$"  !6"0  &0              @(&] 0$ >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    ( /R J5;W_S%1XPL  *V$   9
M      " @:4$ 0!X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ _("I5A_V'#>8!   VA4  !D              ("!OQ ! 'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " #\@*E6F<LA3[,#  !C#P
M&0              @(&.%0$ >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    ( /R J58RORR^[@(  ,X(   9              " @7@9 0!X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ _("I5@(S,7[<
M @  *0@  !D              ("!G1P! 'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    " #\@*E68D=#"2 #  "V"P  &0
M@(&P'P$ >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( /R
MJ5:)^,600P(  )$%   9              " @0<C 0!X;"]W;W)K<VAE971S
M+W-H965T-3,N>&UL4$L! A0#%     @ _("I5BM9+"8Z P  4 H  !D
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M<R\N<F5L<U!+ 0(4 Q0    ( /R J59@H6;*H00   4F   /
M  "  4@^ 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    " #\@*E6\R"+>>D!
M   2(@  &@              @ $60P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    " #\@*E6LFA)V-4!  "_(0  $P
M@ $W10$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     00!! +X1   ]1P$
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>223</ContextCount>
  <ElementCount>293</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>73</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Disclosure - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/OrganizationandDescriptionofBusiness</Role>
      <ShortName>Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Disclosure - Other Financial Statement information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/OtherFinancialStatementinformation</Role>
      <ShortName>Other Financial Statement information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Operating Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/OperatingLeases</Role>
      <ShortName>Operating Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Stockholders??? Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/StockholdersEquityDeficit</Role>
      <ShortName>Stockholders??? Equity (Deficit)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/Revenue</Role>
      <ShortName>Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Income Tax</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/IncomeTax</Role>
      <ShortName>Income Tax</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Commitment and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/CommitmentandContingencies</Role>
      <ShortName>Commitment and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Related Parties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/RelatedParties</Role>
      <ShortName>Related Parties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/FairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Other Financial Statement information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/OtherFinancialStatementinformationTables</Role>
      <ShortName>Other Financial Statement information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/OtherFinancialStatementinformation</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Operating Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/OperatingLeasesTables</Role>
      <ShortName>Operating Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/OperatingLeases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - Stockholders??? Equity (Deficit) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/StockholdersEquityDeficitTables</Role>
      <ShortName>Stockholders??? Equity (Deficit) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/StockholdersEquityDeficit</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/NetLossPerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Organization and Description of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/OrganizationandDescriptionofBusinessDetails</Role>
      <ShortName>Organization and Description of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/OrganizationandDescriptionofBusiness</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/SummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/SummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Fair Value Measurements - Summary of the Estimated Fair Value of Cash Equivalents, Restricted Cash, And Short-Term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of the Estimated Fair Value of Cash Equivalents, Restricted Cash, And Short-Term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Financial Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Financial Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Other Financial Statement information - Schedule of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Other Financial Statement information - Schedule of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Other Financial Statement information - Schedule of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails</Role>
      <ShortName>Other Financial Statement information - Schedule of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Other Financial Statement information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/OtherFinancialStatementinformationDetails</Role>
      <ShortName>Other Financial Statement information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/OtherFinancialStatementinformationTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Other Financial Statement information - Schedule of Accrued Expenses and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails</Role>
      <ShortName>Other Financial Statement information - Schedule of Accrued Expenses and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Operating Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/OperatingLeasesNarrativeDetails</Role>
      <ShortName>Operating Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Operating Leases - Total Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/OperatingLeasesTotalLeaseCostDetails</Role>
      <ShortName>Operating Leases - Total Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Operating Leases - Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/OperatingLeasesOtherInformationDetails</Role>
      <ShortName>Operating Leases - Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Operating Leases - Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Operating Leases - Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Stockholders??? Equity (Deficit) - Common and Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/StockholdersEquityDeficitCommonandPreferredStockDetails</Role>
      <ShortName>Stockholders??? Equity (Deficit) - Common and Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Stockholders??? Equity (Deficit) - Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails</Role>
      <ShortName>Stockholders??? Equity (Deficit) - Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Stockholders??? Equity (Deficit) - Common Stock Purchase Agreement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails</Role>
      <ShortName>Stockholders??? Equity (Deficit) - Common Stock Purchase Agreement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Stockholders??? Equity (Deficit) - Contingent Earnout Equity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails</Role>
      <ShortName>Stockholders??? Equity (Deficit) - Contingent Earnout Equity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Stockholders??? Equity (Deficit) - Assumptions used in valuation of contingent earnout shares (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails</Role>
      <ShortName>Stockholders??? Equity (Deficit) - Assumptions used in valuation of contingent earnout shares (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/StockholdersEquityDeficitTables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Revenue - Contract Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/RevenueContractRevenueDetails</Role>
      <ShortName>Revenue - Contract Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Revenue - Grant Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/RevenueGrantIncomeDetails</Role>
      <ShortName>Revenue - Grant Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Revenue - Entity-wide information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/RevenueEntitywideinformationDetails</Role>
      <ShortName>Revenue - Entity-wide information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Stock-Based Compensation - Performance Awards Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Performance Awards Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Restricted Stock Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Stock-Based Compensation - Weighted Average Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Weighted Average Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/IncomeTaxDetails</Role>
      <ShortName>Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/IncomeTax</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Net Loss Per Share - Basic and Diluted Net Earnings (loss) Per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/NetLossPerShareBasicandDilutedNetEarningslossPerCommonShareDetails</Role>
      <ShortName>Net Loss Per Share - Basic and Diluted Net Earnings (loss) Per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Commitment and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/CommitmentandContingenciesDetails</Role>
      <ShortName>Commitment and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/CommitmentandContingencies</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="snti-20230331.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Related Parties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sentibio.com/role/RelatedPartiesDetails</Role>
      <ShortName>Related Parties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sentibio.com/role/RelatedParties</ParentRole>
      <Position>57</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty in us-gaap/2022 used in 1 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. snti-20230331.htm 4</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 2 fact(s) appearing in ix:hidden were eligible for transformation: snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays, snti:ReverseRecapitalizationContingentConsiderationEquityTerm -  snti-20230331.htm 4</Log>
    <Log type="Warning">[dqc-0015-Negative-Values] Fact us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability has a value of -51000 which is less than zero. This element should not have a negative value. The preparer should consider if the value is input correctly for this assertion and, after considering the appropriateness of the input, if incorrect, input the amount as a positive (i.e., absolute) value and provide a negated label. The properties of this us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability fact are: Context: i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331, Unit: usd, Rule Element Id: 7062. snti-20230331.htm 4</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-Q" original="snti-20230331.htm">snti-20230331.htm</File>
    <File>a2023033110qex311.htm</File>
    <File>a2023033110qex312.htm</File>
    <File>a2023033110qex321.htm</File>
    <File>a2023033110qex322.htm</File>
    <File>senti-employmentagreementk.htm</File>
    <File>snti-20230331.xsd</File>
    <File>snti-20230331_cal.xml</File>
    <File>snti-20230331_def.xml</File>
    <File>snti-20230331_lab.xml</File>
    <File>snti-20230331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="581">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="34">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>76
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "snti-20230331.htm": {
   "axisCustom": 1,
   "axisStandard": 27,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 581,
    "http://xbrl.sec.gov/dei/2022": 34
   },
   "contextCount": 223,
   "dts": {
    "calculationLink": {
     "local": [
      "snti-20230331_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "snti-20230331_def.xml"
     ]
    },
    "inline": {
     "local": [
      "snti-20230331.htm"
     ]
    },
    "labelLink": {
     "local": [
      "snti-20230331_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "snti-20230331_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "snti-20230331.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 487,
   "entityCount": 1,
   "hidden": {
    "http://www.sentibio.com/20230331": 2,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 7
   },
   "keyCustom": 59,
   "keyStandard": 234,
   "memberCustom": 27,
   "memberStandard": 41,
   "nsprefix": "snti",
   "nsuri": "http://www.sentibio.com/20230331",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.sentibio.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000010 - Disclosure - Other Financial Statement information",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.sentibio.com/role/OtherFinancialStatementinformation",
     "shortName": "Other Financial Statement information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Operating Leases",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.sentibio.com/role/OperatingLeases",
     "shortName": "Operating Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Stockholders\u2019 Equity (Deficit)",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.sentibio.com/role/StockholdersEquityDeficit",
     "shortName": "Stockholders\u2019 Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "snti:RevenueFromAndNotFromContractsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Revenue",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.sentibio.com/role/Revenue",
     "shortName": "Revenue",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "snti:RevenueFromAndNotFromContractsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.sentibio.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Income Tax",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.sentibio.com/role/IncomeTax",
     "shortName": "Income Tax",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Net Loss Per Share",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.sentibio.com/role/NetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Commitment and Contingencies",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.sentibio.com/role/CommitmentandContingencies",
     "shortName": "Commitment and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Related Parties",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.sentibio.com/role/RelatedParties",
     "shortName": "Related Parties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Subsequent Events",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.sentibio.com/role/SubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000002 - Statement - Condensed Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i5bdb6a23de54461f88fa0cf0fb407155_I20221231",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "20",
     "role": "http://www.sentibio.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "21",
     "role": "http://www.sentibio.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Other Financial Statement information (Tables)",
     "menuCat": "Tables",
     "order": "22",
     "role": "http://www.sentibio.com/role/OtherFinancialStatementinformationTables",
     "shortName": "Other Financial Statement information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Operating Leases (Tables)",
     "menuCat": "Tables",
     "order": "23",
     "role": "http://www.sentibio.com/role/OperatingLeasesTables",
     "shortName": "Operating Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "snti:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - Stockholders\u2019 Equity (Deficit) (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.sentibio.com/role/StockholdersEquityDeficitTables",
     "shortName": "Stockholders\u2019 Equity (Deficit) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "snti:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.sentibio.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Net Loss Per Share (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.sentibio.com/role/NetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "snti:CashAcquiredThroughReverseRecapitalization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Organization and Description of Business (Details)",
     "menuCat": "Details",
     "order": "27",
     "role": "http://www.sentibio.com/role/OrganizationandDescriptionofBusinessDetails",
     "shortName": "Organization and Description of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "snti:CashAcquiredThroughReverseRecapitalization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "snti:NumberOfBusinessActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "businessactivitiy",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Summary of Significant Accounting Policies (Details)",
     "menuCat": "Details",
     "order": "28",
     "role": "http://www.sentibio.com/role/SummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "snti:NumberOfBusinessActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "businessactivitiy",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Fair Value Measurements - Summary of the Estimated Fair Value of Cash Equivalents, Restricted Cash, And Short-Term Investments (Details)",
     "menuCat": "Details",
     "order": "29",
     "role": "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails",
     "shortName": "Fair Value Measurements - Summary of the Estimated Fair Value of Cash Equivalents, Restricted Cash, And Short-Term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i057bc7826d4b4c84aacdd029762ebfee_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Financial Instruments (Details)",
     "menuCat": "Details",
     "order": "30",
     "role": "http://www.sentibio.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails",
     "shortName": "Fair Value Measurements - Summary of Changes in Fair Value of Level 3 Financial Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i057bc7826d4b4c84aacdd029762ebfee_I20221231",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Other Financial Statement information - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "menuCat": "Details",
     "order": "31",
     "role": "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails",
     "shortName": "Other Financial Statement information - Schedule of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Other Financial Statement information - Schedule of Property and Equipment, Net (Details)",
     "menuCat": "Details",
     "order": "32",
     "role": "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails",
     "shortName": "Other Financial Statement information - Schedule of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Other Financial Statement information (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.sentibio.com/role/OtherFinancialStatementinformationDetails",
     "shortName": "Other Financial Statement information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Other Financial Statement information - Schedule of Accrued Expenses and Other Liabilities (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails",
     "shortName": "Other Financial Statement information - Schedule of Accrued Expenses and Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i43648233679b4319915d781e0fdea7bf_I20210603",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseTermOfContract",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Operating Leases - Narrative (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.sentibio.com/role/OperatingLeasesNarrativeDetails",
     "shortName": "Operating Leases - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "if0a2f740c54a4460bdf1870465e2fd28_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "snti:LesseeOperatingLeaseNumberOfRenewalOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "tradingday",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Operating Leases - Total Lease Cost (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.sentibio.com/role/OperatingLeasesTotalLeaseCostDetails",
     "shortName": "Operating Leases - Total Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "snti:OperatingLeaseProceedsPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Operating Leases - Other Information (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.sentibio.com/role/OperatingLeasesOtherInformationDetails",
     "shortName": "Operating Leases - Other Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "snti:OperatingLeaseProceedsPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Operating Leases - Maturities of Operating Lease Liabilities (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails",
     "shortName": "Operating Leases - Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "snti:NumberOfVotesPerCommonShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Stockholders\u2019 Equity (Deficit) - Common and Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.sentibio.com/role/StockholdersEquityDeficitCommonandPreferredStockDetails",
     "shortName": "Stockholders\u2019 Equity (Deficit) - Common and Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "snti:NumberOfVotesPerCommonShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "vote",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Stockholders\u2019 Equity (Deficit) - Common Stock Reserved for Future Issuance (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails",
     "shortName": "Stockholders\u2019 Equity (Deficit) - Common Stock Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "snti:ScheduleOfSharesReservedForFutureIssuanceTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "snti:SaleOfStockMaximumAmountAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Stockholders\u2019 Equity (Deficit) - Common Stock Purchase Agreement (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails",
     "shortName": "Stockholders\u2019 Equity (Deficit) - Common Stock Purchase Agreement (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i8140f7ff276b4342b7efa96f0f710dba_D20220831-20220831",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "snti:SaleOfStockMaximumAmountAuthorized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2cf3659743e3408a95f042ce0308c736_D20220608-20220608",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "snti:ReverseRecapitalizationContingentConsiderationEquityShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Stockholders\u2019 Equity (Deficit) - Contingent Earnout Equity (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails",
     "shortName": "Stockholders\u2019 Equity (Deficit) - Contingent Earnout Equity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2cf3659743e3408a95f042ce0308c736_D20220608-20220608",
      "decimals": null,
      "lang": "en-US",
      "name": "snti:ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i1d50e05b3f964b1e8bd1212007d0f5b2_I20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Stockholders\u2019 Equity (Deficit) - Assumptions used in valuation of contingent earnout shares (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.sentibio.com/role/StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails",
     "shortName": "Stockholders\u2019 Equity (Deficit) - Assumptions used in valuation of contingent earnout shares (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i1d50e05b3f964b1e8bd1212007d0f5b2_I20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "snti:BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Revenue - Contract Revenue (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.sentibio.com/role/RevenueContractRevenueDetails",
     "shortName": "Revenue - Contract Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiabilityRevenueRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Revenue - Grant Income (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.sentibio.com/role/RevenueGrantIncomeDetails",
     "shortName": "Revenue - Grant Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i27aef62b1f3e4bffb3dd2df12b5856fe_D20210101-20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "ie8b4557210454abca1e04086bd66db43_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Revenue - Entity-wide information (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.sentibio.com/role/RevenueEntitywideinformationDetails",
     "shortName": "Revenue - Entity-wide information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "ie8b4557210454abca1e04086bd66db43_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i5bdb6a23de54461f88fa0cf0fb407155_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Stock-Based Compensation - Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i5aee551dc4424308a0cbe423b5aa00f5_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Stock-Based Compensation - Performance Awards Activity (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails",
     "shortName": "Stock-Based Compensation - Performance Awards Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "idf1fbc37b9e248a9bdc03ecf2ef35943_D20230101-20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i4e8c2a57c818445b8ad0d8224990f182_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
     "shortName": "Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders\u2019 Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i4e8c2a57c818445b8ad0d8224990f182_I20211231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TemporaryEquitySharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i9ee3457100c84c3d87184e1e135ba640_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Stock-Based Compensation - Restricted Stock Units Activity (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
     "shortName": "Stock-Based Compensation - Restricted Stock Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i9ee3457100c84c3d87184e1e135ba640_I20221231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "ie25bf12b097d4142a80c4443e8e34b7c_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Stock-Based Compensation - Weighted Average Assumptions (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.sentibio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Weighted Average Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "ie25bf12b097d4142a80c4443e8e34b7c_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.sentibio.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Income Tax (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.sentibio.com/role/IncomeTaxDetails",
     "shortName": "Income Tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Net Loss Per Share - Basic and Diluted Net Earnings (loss) Per Common Share (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.sentibio.com/role/NetLossPerShareBasicandDilutedNetEarningslossPerCommonShareDetails",
     "shortName": "Net Loss Per Share - Basic and Diluted Net Earnings (loss) Per Common Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.sentibio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
     "shortName": "Net Loss Per Share - Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Commitment and Contingencies (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.sentibio.com/role/CommitmentandContingenciesDetails",
     "shortName": "Commitment and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-5",
      "lang": "en-US",
      "name": "snti:CollaborativeArrangementRightsAndObligationsContractualAnnualPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Related Parties (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.sentibio.com/role/RelatedPartiesDetails",
     "shortName": "Related Parties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "snti:NumberOfSeatsOnTheBoardOfDirectors",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i2db00a77192f4255a898540eac49878e_I20230331",
      "decimals": "INF",
      "lang": "en-US",
      "name": "snti:NumberOfSeatsOnTheBoardOfDirectors",
      "reportCount": 1,
      "unique": true,
      "unitRef": "tradingday",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000007 - Disclosure - Organization and Description of Business",
     "menuCat": "Notes",
     "order": "7",
     "role": "http://www.sentibio.com/role/OrganizationandDescriptionofBusiness",
     "shortName": "Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000008 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.sentibio.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000009 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.sentibio.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "snti-20230331.htm",
      "contextRef": "i82036898b3e742c0b370c00d7e9c1445_D20230101-20230331",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 73,
   "tag": {
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]",
        "terseLabel": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r517"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]",
        "terseLabel": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Addresses [Line Items]",
        "terseLabel": "Entity Addresses [Line Items]"
       }
      }
     },
     "localname": "EntityAddressesLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesTable": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container of address information for the entity",
        "label": "Entity Addresses [Table]",
        "terseLabel": "Entity Addresses [Table]"
       }
      }
     },
     "localname": "EntityAddressesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_FormerAddressMember": {
     "auth_ref": [
      "r518",
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former address for entity",
        "label": "Former Address [Member]",
        "terseLabel": "Former Address"
       }
      }
     },
     "localname": "FormerAddressMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.sentibio.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "snti_A2016StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2016 Stock Incentive Plan",
        "label": "2016 Stock Incentive Plan [Member]",
        "terseLabel": "2016 Stock Incentive Plan"
       }
      }
     },
     "localname": "A2016StockIncentivePlanMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_A2022InducementEquityPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Inducement Equity Plan",
        "label": "2022 Inducement Equity Plan [Member]",
        "terseLabel": "2022 Inducement Equity Plan"
       }
      }
     },
     "localname": "A2022InducementEquityPlanMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_A2022StockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Stock Incentive Plan",
        "label": "2022 Stock Incentive Plan [Member]",
        "terseLabel": "2022 Stock Incentive Plan"
       }
      }
     },
     "localname": "A2022StockIncentivePlanMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_AccruedProfessionalFeesOtherCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Professional Fees, Other, Current",
        "label": "Accrued Professional Fees, Other, Current",
        "terseLabel": "Accrued professional and service fees other"
       }
      }
     },
     "localname": "AccruedProfessionalFeesOtherCurrent",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_AlamedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alameda",
        "label": "Alameda [Member]",
        "terseLabel": "Alameda"
       }
      }
     },
     "localname": "AlamedaMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_BayerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bayer",
        "label": "Bayer [Member]",
        "terseLabel": "Bayer"
       }
      }
     },
     "localname": "BayerMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_BlueRockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BlueRock",
        "label": "BlueRock [Member]",
        "terseLabel": "BlueRock"
       }
      }
     },
     "localname": "BlueRockMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails",
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Contingent Consideration Classified as Equity, Measurement Input",
        "label": "Business Combination, Contingent Consideration Classified as Equity, Measurement Input",
        "terseLabel": "Measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationClassifiedAsEquityMeasurementInput",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "snti_CGMPFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "cGMP Facility",
        "label": "cGMP Facility [Member]",
        "terseLabel": "cGMP Facility"
       }
      }
     },
     "localname": "CGMPFacilityMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_CashAcquiredThroughReverseRecapitalization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Acquired Through Reverse Recapitalization",
        "label": "Cash Acquired Through Reverse Recapitalization",
        "terseLabel": "Cash acquired through reverse recapitalization"
       }
      }
     },
     "localname": "CashAcquiredThroughReverseRecapitalization",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Debt Securities, Available For-Sale, Amortized Cost",
        "label": "Cash, Cash Equivalents, Restricted Cash And Debt Securities, Available For-Sale, Amortized Cost",
        "totalLabel": "Cash and cash equivalents and debt securities, available-for-sale, adjusted cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails_1": {
       "order": 3.0,
       "parentTag": "snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Debt Securities, Available-For-Sale, Fair Value",
        "label": "Cash, Cash Equivalents, Restricted Cash And Debt Securities, Available-For-Sale, Fair Value",
        "totalLabel": "Cash and cash equivalents and debt securities, available-for-sale, fair value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_CollaborativeArrangementRightsAndObligationsContractualAnnualPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Contractual Annual Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Contractual Annual Payments",
        "terseLabel": "Annual maintenance payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsContractualAnnualPayments",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_CommonStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Purchase Agreement",
        "label": "Common Stock Purchase Agreement [Member]",
        "terseLabel": "Common Stock Purchase Agreement"
       }
      }
     },
     "localname": "CommonStockPurchaseAgreementMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_CommonStockSubjectToRepurchaseValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Subject to Repurchase, Value",
        "label": "Common Stock Subject to Repurchase, Value",
        "terseLabel": "Common stock subject to repurchase"
       }
      }
     },
     "localname": "CommonStockSubjectToRepurchaseValue",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_CommonStockUnderEquityPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Under Equity Plans",
        "label": "Common Stock Under Equity Plans [Member]",
        "terseLabel": "Equity Plans"
       }
      }
     },
     "localname": "CommonStockUnderEquityPlansMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Computer Equipment and Software",
        "label": "Computer Equipment and Software [Member]",
        "terseLabel": "Computer equipment and software"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_ContingentConsiderationTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration, Tranche One",
        "label": "Contingent Consideration, Tranche One [Member]",
        "terseLabel": "Contingent Consideration, Tranche One"
       }
      }
     },
     "localname": "ContingentConsiderationTrancheOneMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_ContingentConsiderationTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration, Tranche Two",
        "label": "Contingent Consideration, Tranche Two [Member]",
        "terseLabel": "Contingent Consideration, Tranche Two"
       }
      }
     },
     "localname": "ContingentConsiderationTrancheTwoMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_ContingentConsiderationTranchesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Tranches",
        "label": "Contingent Consideration Tranches [Axis]",
        "terseLabel": "Contingent Consideration Tranches [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationTranchesAxis",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "snti_ContingentConsiderationTranchesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Tranches [Domain]",
        "label": "Contingent Consideration Tranches [Domain]",
        "terseLabel": "Contingent Consideration Tranches [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTranchesDomain",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_ContingentEarnoutCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Earnout Common Stock",
        "label": "Contingent Earnout Common Stock [Member]",
        "terseLabel": "Contingent earnout common stock"
       }
      }
     },
     "localname": "ContingentEarnoutCommonStockMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_ContingentEarnoutLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Earnout Liability",
        "label": "Contingent Earnout Liability [Member]",
        "terseLabel": "Contingent Earnout Liability"
       }
      }
     },
     "localname": "ContingentEarnoutLiabilityMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_ContractWithCustomerExtensionOfTermModificationOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Extension Of Term, Modification Of Contract",
        "label": "Contract With Customer, Extension Of Term, Modification Of Contract",
        "terseLabel": "Extension of term of contract (in months)"
       }
      }
     },
     "localname": "ContractWithCustomerExtensionOfTermModificationOfContract",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snti_CorporateHeadquartersMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Headquarters",
        "label": "Corporate Headquarters [Member]",
        "terseLabel": "Corporate Headquarters"
       }
      }
     },
     "localname": "CorporateHeadquartersMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer A",
        "label": "Customer A [Member]",
        "terseLabel": "Customer A"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/RevenueEntitywideinformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customer B",
        "label": "Customer B [Member]",
        "terseLabel": "Customer B"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/RevenueEntitywideinformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_EarlyExerciseLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early Exercise Liability, Current",
        "label": "Early Exercise Liability, Current",
        "terseLabel": "Early exercise liability, current portion"
       }
      }
     },
     "localname": "EarlyExerciseLiabilityCurrent",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_EarlyExerciseLiabilityNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Early Exercise Liability, Noncurrent",
        "label": "Early Exercise Liability, Noncurrent",
        "terseLabel": "Early exercise liability, net of current portion"
       }
      }
     },
     "localname": "EarlyExerciseLiabilityNoncurrent",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_EarningsPerShareBasicAndDilutedEPSAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Earnings Per Share, Basic and Diluted EPS",
        "label": "Earnings Per Share, Basic and Diluted EPS [Abstract]",
        "terseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDilutedEPSAbstract",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/NetLossPerShareBasicandDilutedNetEarningslossPerCommonShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "snti_GrantAssistancePeriodOfRecognition": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant Assistance, Period Of Recognition",
        "label": "Grant Assistance, Period Of Recognition",
        "terseLabel": "Period of recognition of grant (in years)"
       }
      }
     },
     "localname": "GrantAssistancePeriodOfRecognition",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/RevenueGrantIncomeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snti_InterestIncomeAccruedAndNotReceived": {
     "auth_ref": [],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Income Accrued And Not Received",
        "label": "Interest Income Accrued And Not Received",
        "terseLabel": "Interest income accrued and not received"
       }
      }
     },
     "localname": "InterestIncomeAccruedAndNotReceived",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Lab equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_LesseeOperatingLeaseLiabilityToBePaidAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Liability, to be Paid, After Year Four",
        "label": "Lessee, Operating Lease, Liability, to be Paid, After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityToBePaidAfterYearFour",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_LesseeOperatingLeaseNumberOfRenewalOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee, Operating Lease, Number Of Renewal Options",
        "label": "Lessee, Operating Lease, Number Of Renewal Options",
        "terseLabel": "Number of renewal options"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNumberOfRenewalOptions",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "snti_MarketAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Market Awards",
        "label": "Market Awards [Member]",
        "terseLabel": "Market Awards"
       }
      }
     },
     "localname": "MarketAwardsMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_May2022NoteMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "May 2022 Note",
        "label": "May 2022 Note [Member]",
        "terseLabel": "May 2022 Note"
       }
      }
     },
     "localname": "May2022NoteMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger and Related PIPE Financing Costs Incurred But Not Yet Paid",
        "label": "Merger and Related PIPE Financing Costs Incurred But Not Yet Paid",
        "terseLabel": "Merger and related PIPE financing costs included in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "MergerAndRelatedPIPEFinancingCostsIncurredButNotYetPaid",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_NEAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "NEA",
        "label": "NEA [Member]",
        "terseLabel": "NEA"
       }
      }
     },
     "localname": "NEAMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_NumberOfBusinessActivities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Business Activities",
        "label": "Number of Business Activities",
        "terseLabel": "Number of business activities"
       }
      }
     },
     "localname": "NumberOfBusinessActivities",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "snti_NumberOfSeatsOnTheBoardOfDirectors": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Seats On The Board Of Directors",
        "label": "Number of Seats On The Board Of Directors",
        "terseLabel": "Number of seats on the board of directors"
       }
      }
     },
     "localname": "NumberOfSeatsOnTheBoardOfDirectors",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "snti_NumberOfVotesPerCommonShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Votes Per Common Share",
        "label": "Number Of Votes Per Common Share",
        "terseLabel": "Number of votes per common stock"
       }
      }
     },
     "localname": "NumberOfVotesPerCommonShare",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonandPreferredStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "snti_OperatingLeaseProceedsPayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Proceeds (Payments)",
        "label": "Operating Lease, Proceeds (Payments)",
        "terseLabel": "Operating cash flows net inflows and (outflows) from operating lease"
       }
      }
     },
     "localname": "OperatingLeaseProceedsPayments",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Receivables In Transit From Issuance Of Common Stock Upon Exercise Of Stock Options",
        "label": "Receivables In Transit From Issuance Of Common Stock Upon Exercise Of Stock Options",
        "terseLabel": "Receivables in transit from issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "ReceivablesInTransitFromIssuanceOfCommonStockUponExerciseOfStockOptions",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_RelatedPartyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party",
        "label": "Related Party [Member]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related Party Transaction, Expenses from Transactions with Related Party, Payment Term",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party, Payment Term",
        "terseLabel": "Expenses incurred from transaction, payment term (in years)"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedPartyPaymentTerm",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snti_ResearchAndDevelopmentArrangementExpectedCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Arrangement, Expected Costs",
        "label": "Research and Development Arrangement, Expected Costs",
        "terseLabel": "Expected costs and expenses incurred"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementExpectedCosts",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails",
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_ResearchAndDevelopmentExpenseTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and Development Expense, Term of Agreement",
        "label": "Research and Development Expense, Term of Agreement",
        "terseLabel": "Term of agreement (in years)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseTermOfAgreement",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails",
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snti_RestrictedCashMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted Cash",
        "label": "Restricted Cash [Member]",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_RevenueFromAndNotFromContractsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From and Not From Contracts",
        "label": "Revenue From and Not From Contracts [Abstract]"
       }
      }
     },
     "localname": "RevenueFromAndNotFromContractsAbstract",
     "nsuri": "http://www.sentibio.com/20230331",
     "xbrltype": "stringItemType"
    },
    "snti_RevenueFromAndNotFromContractsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue From and Not From Contracts",
        "label": "Revenue From and Not From Contracts [Text Block]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromAndNotFromContractsTextBlock",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/Revenue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "snti_RevenueFromContractWithCustomerEvaluationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from Contract with Customer, Evaluation Period",
        "label": "Revenue from Contract with Customer, Evaluation Period",
        "terseLabel": "Agreement evaluation period"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerEvaluationPeriod",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snti_RevenueFromContractWithCustomerTerminationNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from Contract with Customer, Termination Notice, Period",
        "label": "Revenue from Contract with Customer, Termination Notice, Period",
        "terseLabel": "Agreement termination advance notice period"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTerminationNoticePeriod",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snti_RevenueRemainingPerformanceObligationVariableConsiderationAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "label": "Revenue, Remaining Performance Obligation, Variable Consideration Amount",
        "terseLabel": "Variable consideration"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationVariableConsiderationAmount",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Stock Price Trigger",
        "label": "Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Stock Price Trigger",
        "terseLabel": "Closing stock price to trigger contingent earnout shares (in dollars per share)"
       }
      }
     },
     "localname": "ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodStockPriceTrigger",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Consecutive Trading Days",
        "label": "Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Consecutive Trading Days",
        "terseLabel": "Number of consecutive trading days"
       }
      }
     },
     "localname": "ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdConsecutiveTradingDays",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snti_ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Trading Days",
        "label": "Reverse Recapitalization, Contingent Consideration, Equity, Earnout Period, Threshold Trading Days",
        "terseLabel": "Number of trading days"
       }
      }
     },
     "localname": "ReverseRecapitalizationContingentConsiderationEquityEarnoutPeriodThresholdTradingDays",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snti_ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse Recapitalization, Contingent Consideration Classified as Equity, Number of Tranches",
        "label": "Reverse Recapitalization, Contingent Consideration, Equity, Number of Tranches",
        "terseLabel": "Number of tranches of contingent earnout shares"
       }
      }
     },
     "localname": "ReverseRecapitalizationContingentConsiderationEquityNumberOfTranches",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails",
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "snti_ReverseRecapitalizationContingentConsiderationEquityShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse Recapitalization, Contingent Consideration, Equity, Shares",
        "label": "Reverse Recapitalization, Contingent Consideration, Equity, Shares",
        "terseLabel": "Maximum contingent earnout (in shares)"
       }
      }
     },
     "localname": "ReverseRecapitalizationContingentConsiderationEquityShares",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails",
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "snti_ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse Recapitalization, Contingent Consideration, Equity, Shares per Tranche",
        "label": "Reverse Recapitalization, Contingent Consideration, Equity, Shares per Tranche",
        "terseLabel": "Number of contingent earnout shares per tranche (in shares)"
       }
      }
     },
     "localname": "ReverseRecapitalizationContingentConsiderationEquitySharesPerTranche",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails",
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "snti_ReverseRecapitalizationContingentConsiderationEquityTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse Recapitalization, Contingent Consideration, Equity, Term",
        "label": "Reverse Recapitalization, Contingent Consideration, Equity, Term",
        "terseLabel": "Term (in years)"
       }
      }
     },
     "localname": "ReverseRecapitalizationContingentConsiderationEquityTerm",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snti_ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse Recapitalization, Contingent Consideration, Equity, Threshold of Years for Change of Control",
        "label": "Reverse Recapitalization, Contingent Consideration, Equity, Threshold of Years for Change of Control",
        "terseLabel": "Threshold of years for change of control (in years)"
       }
      }
     },
     "localname": "ReverseRecapitalizationContingentConsiderationEquityThresholdOfYearsForChangeOfControl",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snti_ReverseRecapitalizationContingentConsiderationFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reverse Recapitalization, Contingent Consideration, Fair Value",
        "label": "Reverse Recapitalization, Contingent Consideration, Fair Value",
        "terseLabel": "Fair value of contingent earnout shares"
       }
      }
     },
     "localname": "ReverseRecapitalizationContingentConsiderationFairValue",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_SaleOfStockDailyAmountToBeSoldThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of Stock, Daily Amount To Be Sold, Threshold",
        "label": "Sale of Stock, Daily Amount To Be Sold, Threshold",
        "terseLabel": "Purchase price, threshold"
       }
      }
     },
     "localname": "SaleOfStockDailyAmountToBeSoldThreshold",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Daily Trading Volume Available For Purchase, Threshold, Percent",
        "label": "Sale Of Stock, Daily Trading Volume Available For Purchase, Threshold, Percent",
        "terseLabel": "Trading volume available for purchase, threshold (in percent)"
       }
      }
     },
     "localname": "SaleOfStockDailyTradingVolumeAvailableForPurchaseThresholdPercent",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "snti_SaleOfStockDiscountRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Discount Rate, Percentage",
        "label": "Sale Of Stock, Discount Rate, Percentage",
        "terseLabel": "Discount rate (in percent)"
       }
      }
     },
     "localname": "SaleOfStockDiscountRatePercentage",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "snti_SaleOfStockDocumentPreparationFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Document Preparation Fees",
        "label": "Sale Of Stock, Document Preparation Fees",
        "terseLabel": "Document preparation fees"
       }
      }
     },
     "localname": "SaleOfStockDocumentPreparationFees",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_SaleOfStockIssuanceCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Issuance Costs",
        "label": "Sale Of Stock, Issuance Costs",
        "terseLabel": "Sale of stock, issuance costs"
       }
      }
     },
     "localname": "SaleOfStockIssuanceCosts",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_SaleOfStockMaximumAmountAuthorized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Maximum Amount Authorized",
        "label": "Sale Of Stock, Maximum Amount Authorized",
        "terseLabel": "Maximum proceeds purchase agreement"
       }
      }
     },
     "localname": "SaleOfStockMaximumAmountAuthorized",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_SaleOfStockNumberOfSharesIssuedInTransactionThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Number Of Shares Issued In Transaction, Threshold",
        "label": "Sale Of Stock, Number Of Shares Issued In Transaction, Threshold",
        "terseLabel": "Number of shares issued, threshold (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransactionThreshold",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "snti_SaleOfStockSharesIssuedInTransactionThresholdPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Shares Issued In Transaction, Threshold, Percent",
        "label": "Sale Of Stock, Shares Issued In Transaction, Threshold, Percent",
        "terseLabel": "Shares issued in transaction, threshold (as a percent)"
       }
      }
     },
     "localname": "SaleOfStockSharesIssuedInTransactionThresholdPercent",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "snti_SaleOfStockTermOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale Of Stock, Term Of Agreement",
        "label": "Sale Of Stock, Term Of Agreement",
        "terseLabel": "Term of agreement"
       }
      }
     },
     "localname": "SaleOfStockTermOfAgreement",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snti_ScheduleOfSharesReservedForFutureIssuanceTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Shares Reserved For Future Issuance",
        "label": "Schedule Of Shares Reserved For Future Issuance [Table Text Block]",
        "terseLabel": "Schedule Of Shares Reserved For Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfSharesReservedForFutureIssuanceTableTextBlock",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "snti_SeerIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Seer, Inc.",
        "label": "Seer, Inc. [Member]",
        "terseLabel": "Seer, Inc."
       }
      }
     },
     "localname": "SeerIncMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_SeriesAAndBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series A and B Redeemable Convertible Preferred Stock",
        "label": "Series A and B Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series A and B redeemable convertible preferred stock"
       }
      }
     },
     "localname": "SeriesAAndBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Increase In Authorized Shares, Percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Annual Increase In Authorized Shares, Percentage",
        "terseLabel": "Annual increase in authorized shares, percentage"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInAuthorizedSharesPercentage",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement, By Share-Based Payment Award, Annual Increase In Shares Authorized, Percentage Of Outstanding Shares",
        "label": "Share-Based Compensation Arrangement, By Share-Based Payment Award, Annual Increase In Shares Authorized, Percentage Of Outstanding Shares",
        "terseLabel": "ESPP purchase price of common stock, percent of market price (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInSharesAuthorizedPercentageOfOutstandingShares",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Tranches",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Number Of Tranches",
        "terseLabel": "Number of tranches"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsNumberOfTranches",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Exercisable, Weighted Average Remaining Contractual Term",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Vested And Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable, end of period, weighted average remaining contractual life (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Exercise Price, Percentage Of Fair Market Value",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Exercise Price, Percentage Of Fair Market Value",
        "terseLabel": "Estimated fair value of the shares on the date of grant (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardExercisePricePercentageOfFairMarketValue",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "label": "Share-Based Compensation Arrangement By Share-based Payment Award, Offering Period",
        "terseLabel": "offering period (in months)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOfferingPeriod",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "snti_ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Stockholder Ownership Percentage, Threshold",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Stockholder Ownership Percentage, Threshold",
        "terseLabel": "Exercise price of an ISO granted to a stockholder (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardStockholderOwnershipPercentageThreshold",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "snti_SparkMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Spark",
        "label": "Spark [Member]",
        "terseLabel": "Spark"
       }
      }
     },
     "localname": "SparkMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "snti_StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Shares, Vesting Of Early Exercise Of Stock Options",
        "label": "Stock Issued During Period, Shares, Vesting Of Early Exercise Of Stock Options",
        "terseLabel": "Vesting of early exercise of common stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesVestingOfEarlyExerciseOfStockOptions",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "snti_StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Issued During Period, Value, Vesting Of Early Exercise Of Stock Options",
        "label": "Stock Issued During Period, Value, Vesting Of Early Exercise Of Stock Options",
        "terseLabel": "Vesting of early exercise of common stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueVestingOfEarlyExerciseOfStockOptions",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_TenantImprovementAllowance": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant Improvement Allowance",
        "label": "Tenant Improvement Allowance",
        "terseLabel": "Tenant improvement allowance"
       }
      }
     },
     "localname": "TenantImprovementAllowance",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_TenantImprovementAllowanceRemainingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant Improvement Allowance, Remaining Amount",
        "label": "Tenant Improvement Allowance, Remaining Amount",
        "negatedTerseLabel": "Tenant improvement allowance remaining"
       }
      }
     },
     "localname": "TenantImprovementAllowanceRemainingAmount",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_TenantImprovementAllowanceUtilized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant Improvement Allowance Utilized",
        "label": "Tenant Improvement Allowance Utilized",
        "terseLabel": "Tenant improvement allowance utilized"
       }
      }
     },
     "localname": "TenantImprovementAllowanceUtilized",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_TenantImprovementReimbursements": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tenant Improvement Reimbursements",
        "label": "Tenant Improvement Reimbursements",
        "terseLabel": "Tenant improvement allowance received"
       }
      }
     },
     "localname": "TenantImprovementReimbursements",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "snti_UnvestedEarlyExercisedOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Early Exercised Options",
        "label": "Unvested Early Exercised Options [Member]",
        "terseLabel": "Unvested early exercised options"
       }
      }
     },
     "localname": "UnvestedEarlyExercisedOptionsMember",
     "nsuri": "http://www.sentibio.com/20230331",
     "presentation": [
      "http://www.sentibio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r168",
      "r169",
      "r260",
      "r276",
      "r480",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails",
      "http://www.sentibio.com/role/RelatedPartiesDetails",
      "http://www.sentibio.com/role/RevenueContractRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r218",
      "r497",
      "r558",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueEntitywideinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r307",
      "r436",
      "r460",
      "r475",
      "r476",
      "r493",
      "r505",
      "r512",
      "r555",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails",
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r307",
      "r436",
      "r460",
      "r475",
      "r476",
      "r493",
      "r505",
      "r512",
      "r555",
      "r600",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r218",
      "r497",
      "r558",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueEntitywideinformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r216",
      "r438",
      "r495",
      "r511",
      "r550",
      "r551",
      "r558",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails",
      "http://www.sentibio.com/role/RevenueGrantIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r216",
      "r438",
      "r495",
      "r511",
      "r550",
      "r551",
      "r558",
      "r610"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails",
      "http://www.sentibio.com/role/RevenueGrantIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r299",
      "r307",
      "r334",
      "r335",
      "r336",
      "r412",
      "r436",
      "r460",
      "r475",
      "r476",
      "r493",
      "r505",
      "r512",
      "r549",
      "r555",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails",
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r244",
      "r245",
      "r246",
      "r247",
      "r299",
      "r307",
      "r334",
      "r335",
      "r336",
      "r412",
      "r436",
      "r460",
      "r475",
      "r476",
      "r493",
      "r505",
      "r512",
      "r549",
      "r555",
      "r601",
      "r602",
      "r603",
      "r604",
      "r605"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails",
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r168",
      "r169",
      "r260",
      "r276",
      "r481",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails",
      "http://www.sentibio.com/role/RelatedPartiesDetails",
      "http://www.sentibio.com/role/RevenueContractRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.",
        "label": "Accounts Payable and Other Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses and other current liabilities",
        "totalLabel": "Total accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r12",
      "r510"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r219",
      "r220"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedTerseLabel": "Accretion of discount on short-term investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees, Current",
        "terseLabel": "Accrued professional and service fees related to facility construction"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r64",
      "r138"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedTerseLabel": "Less: accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r23",
      "r24",
      "r144",
      "r456",
      "r465",
      "r466"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r21",
      "r24",
      "r98",
      "r397",
      "r461",
      "r462",
      "r527",
      "r528",
      "r529",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Other Comprehensive Income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement.",
        "label": "Additional Financial Information Disclosure [Text Block]",
        "terseLabel": "Other Financial Statement information"
       }
      }
     },
     "localname": "AdditionalFinancialInformationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r7",
      "r510"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r343",
      "r344",
      "r345",
      "r537",
      "r538",
      "r539",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r91",
      "r92",
      "r309"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r338"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails",
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r115",
      "r125",
      "r140",
      "r165",
      "r207",
      "r210",
      "r214",
      "r227",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r362",
      "r364",
      "r375",
      "r510",
      "r553",
      "r554",
      "r598"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r134",
      "r147",
      "r165",
      "r227",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r362",
      "r364",
      "r375",
      "r510",
      "r553",
      "r554",
      "r598"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      },
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails_1": {
       "order": 1.0,
       "parentTag": "snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      },
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails_1": {
       "order": 2.0,
       "parentTag": "snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r223",
      "r234"
     ],
     "calculation": {
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "totalLabel": "Adjusted Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r59",
      "r222",
      "r234",
      "r451"
     ],
     "calculation": {
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Estimated Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails",
      "http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://www.sentibio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionContingentConsiderationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition, Contingent Consideration [Line Items]",
        "terseLabel": "Business Acquisition, Contingent Consideration [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionContingentConsiderationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r361",
      "r531"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "negatedTerseLabel": "Change in fair value of contingent earnout liability",
        "terseLabel": "Change in fair value of contingent earnout liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r94",
      "r95",
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration, liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r94",
      "r96"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent earnout liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r0",
      "r46",
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "terseLabel": "Organization and Description of Business"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OrganizationandDescriptionofBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r42",
      "r43",
      "r44"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property and equipment in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r468",
      "r469",
      "r510",
      "r524"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r41",
      "r136",
      "r478"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-Term Investments",
        "terseLabel": "Cash, cash equivalents, and short-term investments"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r36",
      "r41",
      "r45"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "snti_CashCashEquivalentsRestrictedCashAndDebtSecuritiesAvailableForSaleFairValue",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash, end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash, beginning of period",
        "terseLabel": "Cash, cash equivalents, and restricted cash",
        "totalLabel": "Total cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r36",
      "r109"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net decrease in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r165",
      "r186",
      "r187",
      "r189",
      "r191",
      "r198",
      "r199",
      "r227",
      "r248",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r274",
      "r275",
      "r278",
      "r282",
      "r289",
      "r375",
      "r477",
      "r523",
      "r534",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails",
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r17",
      "r121",
      "r129"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 11)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r66",
      "r242",
      "r243",
      "r474",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonClassAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Classification of common stock representing ownership interest in a corporation.",
        "label": "Common Class A [Member]",
        "terseLabel": "Common Class A"
       }
      }
     },
     "localname": "CommonClassAMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Common stock reserved for future issuance (in shares)"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r537",
      "r538",
      "r589"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par or stated value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r6",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r6",
      "r510"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.0001 par value; 500,000,000 shares authorized at March\u00a031, 2023 and December\u00a031, 2022; 44,075,194 and 44,062,534 shares issued and outstanding at March\u00a031, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r25",
      "r153",
      "r155",
      "r160",
      "r452",
      "r457"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r51",
      "r52",
      "r106",
      "r107",
      "r218",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueEntitywideinformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r51",
      "r52",
      "r106",
      "r107",
      "r218",
      "r467",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueEntitywideinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r51",
      "r52",
      "r106",
      "r107",
      "r218",
      "r473",
      "r613"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueEntitywideinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueEntitywideinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r51",
      "r52",
      "r106",
      "r107",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of concentration"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueEntitywideinformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r49",
      "r51",
      "r52",
      "r53",
      "r106",
      "r108",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueEntitywideinformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r51",
      "r52",
      "r106",
      "r107",
      "r218",
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueEntitywideinformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationClassifiedAsEquityFairValueDisclosure": {
     "auth_ref": [
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of contingent consideration in a business combination that is classified in shareholders' equity.",
        "label": "Contingent Consideration Classified as Equity, Fair Value Disclosure",
        "terseLabel": "Fair value of contingent earnout shares"
       }
      }
     },
     "localname": "ContingentConsiderationClassifiedAsEquityFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract": {
     "auth_ref": [
      "r494"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract",
        "terseLabel": "Contract assets, cumulative catch-up adjustments"
       }
      }
     },
     "localname": "ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetGross": {
     "auth_ref": [
      "r221",
      "r231",
      "r556",
      "r557"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration in exchange for good or service transferred to customer, when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, before Allowance for Credit Loss",
        "terseLabel": "Contract asset"
       }
      }
     },
     "localname": "ContractWithCustomerAssetGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r291",
      "r292",
      "r297"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r298"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "terseLabel": "Revenue recognized during period previously included in deferred revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r502",
      "r504",
      "r612"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r50",
      "r218"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueEntitywideinformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r1",
      "r2",
      "r3",
      "r116",
      "r117",
      "r123",
      "r170",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r382",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r110",
      "r111",
      "r257",
      "r382",
      "r489",
      "r490"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Principal amount of unsecured convertible promissory note"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r16",
      "r170",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r382",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "terseLabel": "Debt Securities, Available-for-Sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepositsAssetsCurrent": {
     "auth_ref": [
      "r525"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.",
        "label": "Deposits Assets, Current",
        "terseLabel": "Deposits"
       }
      }
     },
     "localname": "DepositsAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r39",
      "r62"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.sentibio.com/role/OtherFinancialStatementinformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails",
      "http://www.sentibio.com/role/RevenueGrantIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r296",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails",
      "http://www.sentibio.com/role/RevenueGrantIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r311",
      "r339",
      "r340",
      "r342",
      "r346",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "terseLabel": "Cash dividends declared and paid, common stock"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonandPreferredStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r161",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r184",
      "r186",
      "r189",
      "r190",
      "r191",
      "r195",
      "r369",
      "r370",
      "r453",
      "r458",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net loss per share, basic (in dollars per share)",
        "verboseLabel": "Net loss per share attributable to common stockholders, basic (in shares)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.sentibio.com/role/NetLossPerShareBasicandDilutedNetEarningslossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r161",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r186",
      "r189",
      "r190",
      "r191",
      "r195",
      "r369",
      "r370",
      "r453",
      "r458",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net loss per share, diluted (in dollars per share)",
        "verboseLabel": "Net loss per share attributable to common stockholders, diluted (in shares)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.sentibio.com/role/NetLossPerShareBasicandDilutedNetEarningslossPerCommonShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r192",
      "r193",
      "r194",
      "r196"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/NetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued employee-related expenses"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Cost not yet recognized, period for recognition (in years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r587"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Cost not yet recognized, excluding options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r587"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Cost not yet recognized, options"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "Employee Stock"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sentibio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r71",
      "r132",
      "r156",
      "r157",
      "r158",
      "r171",
      "r172",
      "r173",
      "r175",
      "r181",
      "r183",
      "r197",
      "r228",
      "r290",
      "r343",
      "r344",
      "r345",
      "r351",
      "r352",
      "r368",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r397",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r265",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r371",
      "r409",
      "r410",
      "r411",
      "r489",
      "r490",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails",
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r104",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]",
        "terseLabel": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r265",
      "r300",
      "r305",
      "r371",
      "r409",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r265",
      "r300",
      "r305",
      "r371",
      "r410",
      "r489",
      "r490",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r265",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r371",
      "r411",
      "r489",
      "r490",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r103",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r103",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Changes in Fair Value of Level 3 Financial Instruments"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r373"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in fair value"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "negatedPeriodEndLabel": "Ending balance",
        "negatedPeriodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r265",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r409",
      "r410",
      "r411",
      "r489",
      "r490",
      "r502",
      "r503",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryofChangesinFairValueofLevel3FinancialInstrumentsDetails",
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeaseLiabilityCurrent": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as current.",
        "label": "Finance Lease, Liability, Current",
        "terseLabel": "Finance lease liabilities, current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.",
        "label": "Finance Lease, Liability, Noncurrent",
        "terseLabel": "Finance lease liabilities, net of current portion"
       }
      }
     },
     "localname": "FinanceLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r385",
      "r390"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease, Principal Payments",
        "negatedTerseLabel": "Principal finance lease payments"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r224",
      "r225",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r235",
      "r236",
      "r237",
      "r273",
      "r287",
      "r366",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r487",
      "r545",
      "r546",
      "r547",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r39"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedTerseLabel": "Loss on write-off of fixed assets"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant income"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueGrantIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r240",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r166",
      "r348",
      "r349",
      "r350",
      "r353",
      "r355",
      "r357",
      "r358",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Tax"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/IncomeTax"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r167",
      "r182",
      "r183",
      "r206",
      "r347",
      "r354",
      "r356",
      "r459"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax provision (benefit)"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/IncomeTaxDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r531"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r437",
      "r531"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Assets [Abstract]",
        "terseLabel": "Changes in assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r531",
      "r594"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedTerseLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest Income (Expense), Nonoperating, Net",
        "terseLabel": "Interest income, net"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r593"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r394",
      "r509"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OperatingLeasesTotalLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesTotalLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r595"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r596"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Lessee, Operating Lease, Liability, Maturity"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "terseLabel": "Total undiscounted lease payments",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails",
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r395"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r596"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "terseLabel": "2023, for the remainder of the year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r395"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedTerseLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r592"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease, term of contract",
        "verboseLabel": "Lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails",
      "http://www.sentibio.com/role/OperatingLeasesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r13",
      "r165",
      "r227",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r363",
      "r364",
      "r365",
      "r375",
      "r485",
      "r553",
      "r598",
      "r599"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r11",
      "r118",
      "r127",
      "r510",
      "r536",
      "r548",
      "r591"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, preferred stock and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r15",
      "r135",
      "r165",
      "r227",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r363",
      "r364",
      "r365",
      "r375",
      "r510",
      "r553",
      "r598",
      "r599"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.",
        "label": "Long-Term Purchase Commitment, Amount",
        "terseLabel": "Long-term purchase commitment amount"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of items purchased under a long-term purchase commitment.",
        "label": "Category of Item Purchased [Axis]",
        "terseLabel": "Category of Item Purchased [Axis]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentByCategoryOfItemPurchasedAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General description of the goods or services to be purchased from the counterparty to the long-term purchase commitment.",
        "label": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]",
        "terseLabel": "Long-Term Purchase Commitment, Category of Item Purchased [Domain]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentCategoryOfItemPurchasedDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Long-Term Purchase Commitment [Line Items]",
        "terseLabel": "Long-Term Purchase Commitment [Line Items]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.",
        "label": "Long-Term Purchase Commitment [Table]",
        "terseLabel": "Long-Term Purchase Commitment [Table]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]",
        "terseLabel": "Estimated dividend yield"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]",
        "terseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]",
        "terseLabel": "Expected share price volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price [Member]",
        "terseLabel": "Current stock price"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitAssumptionsusedinvaluationofcontingentearnoutsharesDetails",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r162"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r162"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r36",
      "r37",
      "r40"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r26",
      "r40",
      "r122",
      "r130",
      "r133",
      "r152",
      "r154",
      "r158",
      "r165",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r182",
      "r183",
      "r188",
      "r207",
      "r209",
      "r213",
      "r215",
      "r227",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r370",
      "r375",
      "r486",
      "r553"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "negatedTerseLabel": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.sentibio.com/role/NetLossPerShareBasicandDilutedNetEarningslossPerCommonShareDetails",
      "http://www.sentibio.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosures of noncash financing and investing items"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/SummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r207",
      "r209",
      "r213",
      "r215",
      "r486"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r387",
      "r509"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OperatingLeasesTotalLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesTotalLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r384"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Total lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesMaturitiesofOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r532"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r393",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesOtherInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r392",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted-average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesOtherInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other accrued expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofAccruedExpensesandOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r146",
      "r510"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r139"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r148",
      "r149",
      "r150"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "terseLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "auth_ref": [
      "r148",
      "r149",
      "r151"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax",
        "terseLabel": "Unrealized gain on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense)"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForConstructionInProcess": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from construction costs to date on capital projects that have not been completed and assets being constructed that are not ready to be placed into service.",
        "label": "Payments for Construction in Process",
        "terseLabel": "Construction costs"
       }
      }
     },
     "localname": "PaymentsForConstructionInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for financing costs associated with business combinations.",
        "label": "Payments of Merger Related Costs, Financing Activities",
        "negatedTerseLabel": "Payment of deferred transaction costs related to Merger"
       }
      }
     },
     "localname": "PaymentsOfMergerRelatedCostsFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedTerseLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-Term Investments",
        "negatedTerseLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r5",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonandPreferredStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r5",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonandPreferredStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r5",
      "r510"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized at March\u00a031, 2023 and December\u00a031, 2022; zero shares issued and outstanding at March\u00a031, 2023 and December\u00a031, 2022, respectively"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r526"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r145",
      "r238",
      "r239",
      "r479"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid expenses (including prepaid rent)"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments": {
     "auth_ref": [
      "r31",
      "r33"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Maturities, Prepayments and Calls of Short-Term Investments",
        "terseLabel": "Maturities of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r34",
      "r89"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails",
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r63",
      "r137"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment at cost"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r65",
      "r128",
      "r455",
      "r510"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r63"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails",
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r306",
      "r400",
      "r401"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expenses recognized resulting from transactions (excluding transactions that are eliminated in consolidated or combined financial statements) with related party.",
        "label": "Related Party Transaction, Expenses from Transactions with Related Party",
        "terseLabel": "Expenses incurred from transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionExpensesFromTransactionsWithRelatedParty",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r306",
      "r400",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r445",
      "r446",
      "r447",
      "r448",
      "r449",
      "r450",
      "r597"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r398",
      "r399",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Parties"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RelatedParties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual obligation to provide funding of research and development costs over periods that initially exceed one year or the normal operating cycle, if longer.",
        "label": "Research and Development Arrangement [Member]",
        "terseLabel": "Research and Development Arrangement"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r93",
      "r131",
      "r606"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCash": {
     "auth_ref": [
      "r524",
      "r533",
      "r607",
      "r609"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails",
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r78",
      "r126",
      "r464",
      "r466",
      "r510"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings (accumulated deficit)",
        "verboseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sentibio.com/role/OrganizationandDescriptionofBusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r132",
      "r171",
      "r172",
      "r173",
      "r175",
      "r181",
      "r183",
      "r228",
      "r343",
      "r344",
      "r345",
      "r351",
      "r352",
      "r368",
      "r461",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r204",
      "r205",
      "r208",
      "r211",
      "r212",
      "r216",
      "r217",
      "r218",
      "r295",
      "r296",
      "r438"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Contract revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "auth_ref": [
      "r530"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue that is not accounted for under Topic 606.",
        "label": "Revenue Not from Contract with Customer",
        "terseLabel": "Grant income"
       }
      }
     },
     "localname": "RevenueNotFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.sentibio.com/role/RevenueGrantIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r293"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Consideration received in collaborative development agreement"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Expected timing of satisfaction"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueContractRevenueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r159",
      "r165",
      "r204",
      "r205",
      "r208",
      "r211",
      "r212",
      "r216",
      "r217",
      "r218",
      "r227",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r375",
      "r454",
      "r553"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r391",
      "r509"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets obtained in exchange for operating lease obligations (including remeasurement of ROU and lease liabilities due to changes in the timing of receipt of lease incentives)"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Aggregate purchase price"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of shares issued (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r218",
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Revenue Benchmark"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RevenueEntitywideinformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.",
        "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Accrued Expenses and Other Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/NetLossPerShareAntidilutiveSecuritiesExcludedfromComputationofEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-Sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information about a contingent payment arrangement including the terms that will result in payment and the accounting treatment that will be followed if such contingency occurs, including the potential impact on earnings per share if the contingency is to be settled in shares of common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitContingentEarnoutEquityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Investments"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r541"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/NetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r87",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amounts of other current assets.",
        "label": "Schedule of Other Current Assets [Table Text Block]",
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "ScheduleOfOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.",
        "label": "Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]",
        "terseLabel": "Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option"
       }
      }
     },
     "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OtherFinancialStatementinformationScheduleofPropertyandEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r113",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r308",
      "r310",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails",
      "http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://www.sentibio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r81",
      "r83",
      "r84"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Share-Based Payment Arrangement, Option, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r68",
      "r69",
      "r70",
      "r72",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r141",
      "r142",
      "r143",
      "r198",
      "r274",
      "r275",
      "r276",
      "r278",
      "r282",
      "r287",
      "r289",
      "r493",
      "r523",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule of Stock by Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails",
      "http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails",
      "http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "grants in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Outstanding, end of period (in shares)",
        "periodStartLabel": "Outstanding, beginning of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails",
      "http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Number of Options",
        "verboseLabel": "Number of Restricted Stock Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails",
      "http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Outstanding, end of period (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails",
      "http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price",
        "verboseLabel": "Weighted-Average Grant Date Fair Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails",
      "http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Outstanding, end of period, weighted average remaining contractual life (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "terseLabel": "Vested and exercisable, end of period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested and exercisable, end of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate (in percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails",
      "http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://www.sentibio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Authorized for issuance under share-based payment arrangement (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Stock Options Additional Disclosures"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Vested and exercisable at March 31, 2023 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Vested and exercisable at March 31, 2023 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value of options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding at December 31, 2022, aggregate intrinsic value",
        "verboseLabel": "Outstanding at March 31, 2023, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at March 31, 2023 (in shares)",
        "periodStartLabel": "Outstanding at December 31, 2022 (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r315",
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at March 31, 2023 (in dollars per share)",
        "periodStartLabel": "Outstanding at December 31, 2022 (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted-Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period",
        "terseLabel": "Issued in period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Terms of Award",
        "terseLabel": "Terms of award (in years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardTermsOfAward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails",
      "http://www.sentibio.com/role/StockBasedCompensationPerformanceAwardsActivityDetails",
      "http://www.sentibio.com/role/StockBasedCompensationRestrictedStockUnitsActivityDetails",
      "http://www.sentibio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Common stock share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting rights (in percent)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "terseLabel": "Expiration period (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationWeightedAverageAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Vested and exercisable at March 31, 2023, aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and exercisable at March 31, 2023, Weighted average remaining contractual life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r85"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding at December 31, 2022, Weighted average remaining contractual life (Years)",
        "verboseLabel": "Outstanding at March 31, 2023, Weighted average remaining contractual life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "terseLabel": "Percent of outstanding shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r119",
      "r120",
      "r124",
      "r525"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-Term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r470",
      "r471",
      "r472",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-Term Investments [Member]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r388",
      "r509"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OperatingLeasesTotalLeaseCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-Term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesTotalLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r46",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r141",
      "r142",
      "r143",
      "r165",
      "r186",
      "r187",
      "r189",
      "r191",
      "r198",
      "r199",
      "r227",
      "r248",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256",
      "r274",
      "r275",
      "r278",
      "r282",
      "r289",
      "r375",
      "r477",
      "r523",
      "r534",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r20",
      "r71",
      "r132",
      "r156",
      "r157",
      "r158",
      "r171",
      "r172",
      "r173",
      "r175",
      "r181",
      "r183",
      "r197",
      "r228",
      "r290",
      "r343",
      "r344",
      "r345",
      "r351",
      "r352",
      "r368",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r397",
      "r461",
      "r462",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit",
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r171",
      "r172",
      "r173",
      "r197",
      "r438"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-Based Payment Arrangement [Member]",
        "terseLabel": "Unvested early exercised common stock"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockReservedforFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r19",
      "r71",
      "r72",
      "r78",
      "r267"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock in connection with the Reverse Recapitalization, net of transaction costs (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r5",
      "r6",
      "r71",
      "r78",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "terseLabel": "Exercise of options of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r71",
      "r78"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of common stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r6",
      "r9",
      "r10",
      "r58",
      "r510",
      "r536",
      "r548",
      "r591"
     ],
     "calculation": {
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r164",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r288",
      "r290",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Stockholders\u2019 Equity (Deficit)"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficit"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r404",
      "r405"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/SubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockholdersEquityDeficitCommonStockPurchaseAgreementDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Temporary Equity [Abstract]",
        "terseLabel": "Temporary Equity [Abstract]"
       }
      }
     },
     "localname": "TemporaryEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r248",
      "r250",
      "r251",
      "r252",
      "r255",
      "r256"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofRedeemableConvertiblePreferredStockandStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r224",
      "r225",
      "r273",
      "r287",
      "r366",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r431",
      "r432",
      "r433",
      "r434",
      "r435",
      "r545",
      "r546",
      "r547",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r588"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CommitmentandContingenciesDetails",
      "http://www.sentibio.com/role/RelatedPartiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r483",
      "r502",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. agency securities"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r483",
      "r502",
      "r504",
      "r608"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "U.S. Treasury securities"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/FairValueMeasurementsSummaryoftheEstimatedFairValueofCashEquivalentsRestrictedCashAndShortTermInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r54",
      "r55",
      "r56",
      "r200",
      "r201",
      "r202",
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r389",
      "r509"
     ],
     "calculation": {
      "http://www.sentibio.com/role/OperatingLeasesTotalLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/OperatingLeasesTotalLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r185",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares used in computing net loss per share, diluted (in shares)",
        "verboseLabel": "Weighted-average shares outstanding, diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.sentibio.com/role/NetLossPerShareBasicandDilutedNetEarningslossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).",
        "label": "Weighted Average Number of Shares, Common Stock Subject to Repurchase or Cancellation",
        "terseLabel": "Common stock subject to repurchase (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r184",
      "r191"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding, basic (in shares)",
        "verboseLabel": "Weighted-average shares used in computing net loss per share, basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.sentibio.com/role/CondensedConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.sentibio.com/role/NetLossPerShareBasicandDilutedNetEarningslossPerCommonShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "https://asc.fasb.org/topic&trid=2122745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "https://asc.fasb.org/topic&trid=2122774",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2646-109256",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r514": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r515": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r516": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r517": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r518": {
   "Name": "Form 10-Q",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r519": {
   "Name": "Form 8-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r521": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r522": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "https://asc.fasb.org/topic&trid=2134479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r614": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r615": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r616": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r617": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r618": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r619": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "https://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21553-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21484-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21488-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "c",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>77
<FILENAME>0001854270-23-000064-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001854270-23-000064-xbrl.zip
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M*4^\TW>?D5P"=,@* SQ+-P4:PO(&C:=TIG(_^'<$KX-Q,M=&VR9VX4R)SK<
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M%^P0W#,2O/8.?7T!_&7"7R3[&GVO&[3J#,K-'D+,NSV=FO=B^W*1]%\DDKS
MJI43 P\62D5P)<6W!ID-S(2;8H;50"/:U&2298#+T!B2(=Y5B1!73;,JX04I
M8OT>!5(S%IMJ@ER+K$X(@871Z*QN5!:--;[1[)MJNJZAL3C#2D=AMKIBFOW$
M#J3(+&.;T,^$I$Q:B$!&RHJ%FYL>Y569D57("Q-'LZAWO6A@_'IGN@;&)%NW
M;9-G-?ER(+;=>BA6:(ZB&\UKLFU(CJ*W:7[+#O;N)[NV=R_M(;'!KNT'W>\2
M^[#*CA_\>&-;MM?>>Y18Q\2WCC'"6&$JO6D$C1M%(?3+<_ V):%&36^(FTC6
M(#:>9VHQ^3+"G67Z&^#4L*IGAFX],MSXH%I'YFE.F\^7>[U^#H</5M?;^;?=
M<K53C>^-P(.P/T< MK=:G5YEKG#?L'8M.H],^2>$Z<>RKJNK$F6(O%")C%/0
M<>S]2K#\%Y#XE>+]J*^1_Z/__=$W$D.N4%O\"#QV3B3'6:[$8>X6**]OX^"8
M6>F.L?SJ:6$IZK/24+*,:(&WS@\O:X@9MMS+)62&A62A;B_YQI'C^EJ??IIS
MV/U_ %!+ P04    " #\@*E6I0 H_#X%   Q%@  %0   &$R,#(S,#,S,3$P
M<65X,S(R+FAT;>U8;6_;-A#^OE]Q=; T!:QW.XEE-X!C.VBP-DYC%5T_#;1$
M640E4J7H.-ZOWY&RG?>T*=HE'18$AJ0['N^>YUXH]5X,QX/HT^D(,E7D</KA
M\.WQ !J6XWP,!HXSC(;P)GKW%EJVZT$D":^88H*3W'%&)PUH9$J5H>,L%@M[
M$=A"SISHS-&F6DXN1$7M1"6-@YY^@K^4) >_]5Y8%@Q%/"\H5Q!+2A1-8%XQ
M/H./":T^@V6MM :B7$HVRQ3XKA_ 1R$_LW-2RQ53.3U8V^DY]7W/,9OTIB)9
M'O02=@XL>=U@Q-N;^E[':Q'2:7EM0E*O/6W'U"4^:0=!YR\/G710O5Y3J65.
M7S<*QJV,ZOW#/;]4W05+5!9ZKOM[P^@=]%+!%6XF<7%]6=NX94G1"V61G,UX
M:.)IU$O7XECD0H9;KOGK:HF5DH+ER_!EQ I:P0E=P)DH"'_9K) #JZ*2I;5B
MQ?ZFZ!.Z9VX7*W_13LXX7?OO^=KIT47&IDQ!X-O^=8^_[NL=8=Z]*$8ZJ'RB
M" >CL^CXZ'C0CX[')YC.9Y,/_9,(HO&S]]S;AP_VQ![8,!D-C/=>T':?O=O]
M"?2'X]-H-/RET%YCW'%W87P$T9L13/IGA_V3T<0:__EV] GZ@TA+?->]72H/
M5<3/CJ=U9SS''&+!.8UU=X8%4QFHC,+[.9$(<KZ$,UH*J4"D,$'<&1PR4<6,
M\IA633CFL0T[>L'VUK[ON]V!*$K"E^;.Z[X"M'DD9 &>:[V'5$AC_,O&>(E.
MBP0H3["3OR,RSK:WO%VW&WA-T[F;0"I(68[2C6L3&L\E#A/$@/ $1A=Q1OB,
M8L\O"E95.@S\UYH)#@C(J*3H_%4GZY#6/F(431C2J9 D@S^XF-(<46W":68/
M[28,,D93.&*<\)B1',9IRF(JFSC4**GFDDKCQAN<'AJD@9!H7&\\I.<T%Z49
M5BC0^Z_0:0(:4"S%BW(NJSE!#27@LI U"'M=7<8& )*(4H^ZJ\JUBL["E>T)
MD5/":66-+W*ZA'YL=M59V$0Y,8N*)7SF8H%PSNCV5GN_^Z@$W4PW(F<XX*9"
M*5&$NYAF)4D2G,)63E,5!OJ)*5>&M'(56MY^^?,'U]WI[=GK,/[]W:_#XKEV
M6\,0(5>KFDKG.=9 C$F1ZVS>9+BD7^9,4ITY55UX=75ZP0[!DI+@M7>25QOB
M+^MA4PLK]KU.T*HSJ# EAIQWNCI=[^7V^3+I/TLF&<>F5A!##_9117!E@D\-
M,VN:"3.]3M)*,]K48I+G@,O0&6PI*"B1XJII5J6;5H,&$W-J-AT&M>9YG1 "
M^Z;9L[K16337^$2KKYOMJL7&XAP;80+3Y177[$<.*$6F.5U#CPTSH=)"!G)2
M5C1<7W035I4Y68:,&QS-HN[UIH'X=<]U#XQ)OIKJ)L]J\>5YV7;K,[-"=U2R
MWGDEMHW(4<EMF=^R@_W[Q:[MW2M[T&S'WO<[WV7VX2WW_."'.]O"--W=_R:S
MCL&WQAAIK#"57C>"QHVF$/KE!7CKEE"SI@OB)I,UB8VG.=28?!EB99GY!GBH
M6-9'BDY]HKCQOK5"YG%!F[>;>Z-^BH /E]?'^=?#<G50C>]%X$':GP* [:W6
M7K<ROW#O8>X:/-^8\X_ Z<>JKMJK$F6(NE")G"6@@>S^2KS\)ZCXE0#_$:\K
M_Y/S_>08BR%3N%O\#73MG$J&1)7(U"5GFJ!^'(LYOF_SV9K"5[=I<<S9ZHYC
M_-6/CZ6H/[V&DN9X:#RGMSY'7K8<<SAS+Y>0*?:=N;J]Y"M?,%>_]<=4\UGW
MX!]02P,$%     @ _("I5O.<D;R&-0  (3(! !X   !S96YT:2UE;7!L;WEM
M96YT86=R965M96YT:RYH=&WM?6ESVT:VZ/?W*W"=-W.E*HH6M7K)I$J6E%@S
MMN62E,G+IZDFT!01@P O%DF\O_Z=K1<LE&A',N$93]7$-DDTND^???WQOT[.
MCZ]^_W@:3,M9$GS\]<V[L^/@V=;SY[_M'C]_?G)U$KR]>O\NV!MNCX*K7*5%
M7,99JI+GST\_/ N>3<MR_NKY\]O;V^'M[C#+KY]?73S'I?:>)UE6Z&%41L]^
M^A$_@?]J%?WT?W[\KZVMX"0+JYE.RR#,M2IU%%1%G%X'OT6Z^!1L;<FOCK/Y
M(H^OIV6PL[VS&_R6Y9_B&\7?EW&9Z)_,.C\^YW__^)Q>\N,XBQ8__1C%-T$<
M_>U9_"+4T=Z!VGL9;6_OO7RQ,P[WP^V]201_VSLX?/'B7WN[L,OG\'M^J"@7
MB?[;LUF<;DTU;N#5P<%P9V]>OKZ-HW+Z:K2]_9=G]-.??IQD:0DOS.%Y_BLO
MTUJLU'?EEDKBZ_05G>D9/VJ^#K,DRU_]L$W_>XW?;$W4+$X6K_[[*I[I(OB@
M;X.+;*;2_QX4< ];A<[C"?^PB/]7PYY@>_3/6][R(:R3Q*DV1^!-G]Y-XW%<
M!J/MX:B^XX?WVG',U4$\ZH2PRJ\!R&4V?[4WW-V'$\Q5% $J;"5Z E"?/SZ8
M=AI@VNL$TWNU ! -$/%VEH+)VSU <_X F.2AV@'WAR_]0Q.P7^T>[@U?[*_M
MZ/]0Z4(%%^H/E5ZK6?#/LZ/@]/W1V;O5P+"S_^5P>/(#=Y/$A?[K#_LO7O_U
MA]'!=L=_SR<3G0?9)#B=S9-LP>RF<:B^'KC[AD^TR@.Z9CKX%YVF=NG;+<KM
M1.S#X0%^Z'&7/ZJBC">+-<'A$JXR#M[$61'&.@UU,0C.TG 8;)13'?SUAQ<[
M.]L6.$^T/UKQ55P".,(54/4XF\WAWIYX4_<"C> R>KT9Q$4P3[0J0'J7&= '
M4LDBJP)MR21018"@E%WCDZ/#UT5P/(WU)'BOHSA4"0!Z]\7KX$3?Z"2;TV-
M<7$(JVWT\P[>GYSWX@*RE*!;ZGQ6!"J-@C!+(]+/BJ#093#)\G(:Q/@KN*M$
ME_#+0%WG6A.4^XOE1V:/?0#S<#46^$5B[Z"#1;[HY)#\49Q& )57N_M?1S_H
MOIW1<)FD!#J?(1\E].H4F.NXR&'P>U;E/ENZC8$N/,8$'R0)4 _O'NGJZ^RW
M&[Y_KY)%L,^JYU?:2#?@^LL@3D'8A&5\HX,3L![[R24>QQ8X'.[UG1_L+.4'
M)U49ZV*]M'\$Z@8([ &I)D3G8QWDNIB#E(S'B48I&42L?* + N6HOM,A;!W^
M11JBU5O@,="<PRG]*/(4EJ+, 0^O%[187,+V_Q&$&MZ5I7A2^&*>9]>YFH&&
M&:=A4N$-!R7Z4Q+%#A6[^" (X1RD&;F/LKG.Z8>P0./E_(%]QFR%/XY3D/D3
M%>+KB.L!UN@<7S=7.5[.("@J/%#A5BCS&->)2_SV'^?O:,\WNBBS7-Z.SZ8Z
M+XBS,E!S/0=M Q7!.LA8U3ME@ *]]ERU.^V'9H= !C35=W-@<ZQ?JVBJ<XU_
M0ZY\K0'^<$N>4)MG<$:X4;ZA7 %_!(L&Q; OZ<JI*H.96N#RH!EJ8J3!),]F
M00E'H?7ASP&\.]3SDG]_.]6^JDE+@D9IU314/"?P]K9DM7APWX:!9NQ^!\VE
M132G99XEP^#*.PJ>(IRJ]%HC;<,:&3LG!T%4,6JS3CR;Z[0@XFF?,X#3(;U&
M<1'FFI\NJO$?"!0!]0/J-=Y*C$_!5<43)""0W@#97(,]1.I$;9V:7GZ)0@RV
M=;@1;3(M%5-X'JD[*^548R \O"9XAG<QJ9"'H;]4%X5<5O$)H83?*E#R4UI4
M7@N, YX%U$3%9L)K,GS ]G_Y&AG331SI:!!,LUO@*OF [QS9)4)8I]?JFG E
MC&_BD%Z29D  6;X%STYBL/)0%,>X9+"Q+GKN)B@]O!ZNDZ 'B* Y;!<%#?/C
M".1WO@"&6V1AS%CIX+>)C#C)4 P5PI@=;*,, 0^7 I@4"YHA=T>V0'1'=YN-
M04U@44&X68&*D#-RX76JI,@ "7-@Q? *%<ST;,S>+426<:;RB @\BG- 3N#X
M2)WN8Q7=Q 5].@FRJBP <XC"5(H[Q.WQ@["Y7"=*>!<M;3 6,.EV&H=U!3S&
MAV]1SF3)#3R$+]6PL"[<9U&5D]046K+8[+,4069&8?AEH?UMSN(2?V9!":<!
M*:9ALXKY(*VGQG$2EPO<.-#:)$[X8ZLSX+=X6CF8.0)1'UP%&=AT[+$N;S5P
M3B0E_)9^?7I>YV(J_ 0G3W1TC4L:RL.%PBH'!H*@Q/LRNHGEAW%:$6]QEYDB
M>FG@=J@4-F[V#5XA_N/$7>PDN*KR%.1ZJM$)!GI*'!8KFKNC5>W=!_R$A];<
M%5UV:_? 7_QK*[.[]QFW5I"L"*0_XPO_$CO@<+1..V!#;2Z#W1L%A'BI$I4O
MAFLU:7_WC("YBB,D&I6F%6@F8]QC07M$TOB_>R^W!["909 @UU+S.8@<XN/
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MMJ5]:[XH>RS;[=QZ>W_6W]:+&S2%9#/7NLG&<-J,XRQ0,_(-UA+R,";0,7U
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MY 'L#B;4C, ]CY#A">U<E4 6$N@RN"?$JHFZ03VE/J[4MZ$LMII)X_%$')F
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M=13VXZ\/LR7YVU(K . P%0&G[WY?7@S0%T[S?)Q%"_AC6LZ2G_X_4$L#!!0
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M/"NCB3_V/QOJH"80 AM\]$(<(T!:YP$A/ AI+-66O%K4*6O5BFI5<-@*10S
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MG--."Q0(\(XS0%4PP$BB@;.*26\=<Q9%0B6; D\RJKG=UMJ0J5QVH.9D*D/
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M=B79UO#"^.(PE#C=/[R1[VCQ?DR8.L/Y8^#<3GH<&"NO+70 <X8!523!N=!
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M0 H'BAG34DE&H=>6QK5<^A+2'Y&WE"&])I ^I3,E1T9A8PQ05D1<I\P#I60
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M*KV1WG(MF%[CADX9QM85QA;*/Q<&8QFNYH.KB:95G#(N P$:.@HH%#"R3:N
M14@(A;7U-%+.*.H:055).'\=).V)_[KVUZW_C3_&7WVAB]-V=YSC<OO6UD=]
M+E[.U,H[ODOA^[9]V/@02VGL9[X,35[$T:1SH8UN;Q"_3Q<I0!EIYL"?%KK3
MN-1%V4AS<.8CC8PVZ5*\,J%UMTRH*F.@H_!GO+P_B"^4C=\VKV5S?XI&PQ X
MCORR%TTORO-=&4YM?_7OO[7=X&P,$+<^50GA';SYB#9Q!,/![(^,9#'ZI%JN
M.!Z<?'9W<F[_3..OP 1*&WF:<0)&R&-.">@2L!'HF#(X?,9R8_RAL^L\M$M]
MZH$IO/X"=(@/^$YWONFK_L:O=V<F3LMM,=R?P9FS$L)"9F4B52?.2B6<B-F]
MHBS2\BZ:KR_257%,NC9C:9P5:47Z/S^7CXA&5@;\H_GLI,6LK#:BMV8:QEU]
MY:^BK]-F8V/K:*]UO-_X;?_P:&=_K[6S=]1L[+=V9IMX7<;=*C%MT$OS/P*N
MG=O ]?LU<!U= ]<CQ?,Z<#+],7\9=O70M>,3_6L!H]_Z7U/\NC4-H1Z\W:V5
M;]Z[/Q[S(JU[S&"6+P><H!-M-D:<MC6\B+>P"_#%[V[0_S;LQV_M]W=]WQ;M
MDH9N=]UONM_N'X8/15RCNX,2L8[CM_[6B5SU=:GICX,Q-;UHG1\<G]"#\];9
MP>Y?N/7C8_O@G[_;K5UWT3IV7SX=V^^1GOXX^>?W\T@S._[_?8P4TET:3/E)
MI)ZM\].K [SWK:2J?^Q___3//FSA$]3"'SNM'[^W3XY;9R?_M$+\=G;P[;.$
MQN!4]T[9U%0L* )D:F+AG;84$1V,&;D8[>[0N^T4B@A&&H:0,TQ8FAQF KTT
MU'F"L'16;33BI.O+!&_%,"Y*A\6I[K9_5!7%TJ;N+:$DS!_+:LQ=1SIQ3_?C
M>Z-A5#<JI?73H3S&M$?=V9%<@CU,ISE'\?O;C=_:O;YM^^A7]>.RT;6;59;M
MH-_H#TV_[=JZ:,?O_"52S$:*3&#X?J>BI>5?Z'VC5XS?*.\X>OE?S48[$M:&
M:4>4MV?=^%"G5XT1HXV$50\:WW2_$9(?4/5Y3PUE!I'?-KKQ^4Y]UQ?7Y>#Z
M<1(C2#4NO&O;)+;J!KWA(,Z"'T:/H+QSQW]/2<2^S"E-\DV\^:OOE(\T[%X6
MT;-,LQZ_3U]>%CUM(V_>;%03<19'8X;MSB".H'_5C<\;O8PT_'+@EY$ I[!8
M]<6^.XKW#M+ XYTB&[^(XXYRO35PZSO55Z?7$D<O]&6:RV_MP5GC6[I/FM31
M;#8B<?%%N1S&@8PFM/R@;1=V& 6R.9[PXY+MWWFO&>_7MF>E@U#-HZLBT#?/
MGQ)LHR@'NBC%8.+B6OK):7YW6]N-OO_O<*0&A1\_4GJ$T8"KF4B.5Z/\-XVT
MGU;MZ(Y<#M,0D@@BXR\]^WYYZ]&!V^BCEQ*.C]LNRGL..[J(L_BU7?2ZE4.2
MGNIZ+J+FG'GM_CLLQ5YE:AQ%:9\UCJ*=1#<STH*^[34;.W$-BV+IMO5LNE-;
M SSL-OX]C$*4S48*B]RUL4ZOU-_=*,H;B]J]B@M.V_8;1Y>^)$8?AD7TN'QC
MV_YWV*X\KSB)Q>5FXY?1C<8?F;36W9/6T?C6I<<XO+@H%4='.RLS:2Z'10JY
ME$I>Z=?>]\LX-[XQ2K4Y&IH1:(R_[N:-FU'KB+T=_:W4S3BV$6LOE>/;6:_3
MN6KTOG7C]UX#SE6IDZ.!-ZO1N$H+JR, <3R5T<;O:>Q70VB68>OH!UR5J[)K
MS,*W\5#_XT^UO6K< ZWR6VZ_%8=5?&U_+<\?)$"KA@P>&G+CE_XP3E:Y%51%
M1.)WWQ)N-4G-L4CB,R7CZ71\:ESJXP.4@T@?Z"74N'.C:%UI'3.54:1K1L+2
MIX4O.7+C%YVNBFY_O,;X3N_;G2__Z"-<1I7YZ&V53SA:),=3\*_-QG9ZSFBW
MP\XXNC 2^"T-3.!=^ =GNI86.3,0,YTT_J<=#2N2]^I<PA^]I ;12;&^Z-;R
M\7X65:K"1 \'A^)2^-5'S?'=N&CX2UW<I,H5KMS.+/7SK\VCS=$ZG6PXONTO
M2_BH4NK23,4%)][\,BV5O_RQO?WA7]&$(LRDMVXO?=_:<:$<T[W*RDY[5;Y>
M.=/5XG#GI>I&%9LK:?Q%6J%+8N"C7EYK==+?>*D?57_HQQ?[8131CF]UVMJT
M.V6OX+$Y==/F5QK.L*BV9LV(*5:C^/GLN5Z*UHVS#!OI ;4['_8'U=O5.MBP
MHXIO#7U1)2"6Y4\[<:SM$!?9NV-OWA[HN-U&!-+!K23%BIE<Z*LHN4A%HA7V
M$RRUP]VICLMII$)EY"-QK@<F?27U^_I!STH0_-H;C%!Z$->Q=J6H4=GBS":*
MZT-<,RJ9]"I_87S,+%X?HG1/F]?B3Q2P;,@6^9%NEXOS"$ K@:3HZ]".U-[;
M.+J2*_4'T??WE7C3F))J5/IY=V#QQ:\^2J(_RAP8C+[0N[$5Q6O2$:F*M5U+
MY_8\STSE6)8 &L>]1K*,YEUF&Z<KX<)I7*%.$\6/8TSS6?2L]ZXDH-.>9EF#
M_I\E;MBS.SM=Y:GWQ-PBPAZ?1<&=GHU6Y_N+\^.2J_A;"R><[['#X^VKM*,6
M1X(._OQLHSA,$! 8X0V@U"F@L&0@%9]U7BO"-=S8PDIN3AXD:D3EZL1?ZFE:
M)2S<4+$24,KT]NO<O,KJ;N<<]<_TZ#!M7,TBPKC($$OHCTI=;J.EWR]+SS,M
M\F42TN1=;E\\VH=*C#5YJHU.0L9H'A'YTP=+'2ZYK#;7/'],3"L0/(T>:5$Z
M?1$'](-[47,O-*\NI>U!XT 7]JS: "6H].S(*/YD_87QQ9VW\%VD/-,N[>]%
M!C6\&%8G&!*1M^W!*H'D$PLGL9E]BS_Z@4[>S)XNT@+<W[Z9G]UJ>C(^3L?'
M[>^M;Y^Y=509Q8&QS *JM &2"9=6*(."$!PRN[$5I;4Y>6"IWIB8[&I5K.*)
M36JS5;R 55RUMC]C[XTD.)D!X8 2(H$BB *AH>1>,>TD3OVSR299+:MHEB'7
M<2SI3F"U3"T4[Z,7X@>-3B3A*1J=/,)5,:(%\.\9UM3R@_VN[5WX_\1IR88S
MPW#(P>EGJ9R'A%K "<* E@L+)1Y@K51<]0TR,BTG<G.R5%2M[6:E5I/GIEQF
M0WBF(1S^^5E3X;CG$@3A*: ..:!XM(O(<ST-U$2(8M$0T.JYFKVB=$NB/^=]
MXR)^X*R?VOE&=V26=U/Y,G<7GJ-I8;?!PZM1M>LPWKV\/J]='C=+$=IH!%U?
M6<?U)LG]VZ5$BS3,<F#.Q\'TJF)"HUW-R@\MOV 4OJY.?;N+=K?='Q1EJN/H
MNW6_W[/MTA.;^7VWHG)W=C%39-96T<7R$>Z$^T8?ZIZ.GSP-H9OB8^67EX6O
M.KUOHW#@S5=<"R?^&Y_3E^Y\&*9J$"F(>]N;U.YK<N'3-G7_-7'M3CPT&<#7
M*N!>1;Q'KP^*."O5TY6QSZ*7HJEQ(KJN#+:7\?E;PJREY:Q5**.,&STWFO%
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MWQU;5[Q4FBG277QWJRC5,[X[I83W0!R1Q$P@[@WH%5HQY%F41$LAG ;^P8I
M/S.!_NT92?24\ZY(]"(2/>.DPX:1J)U## O0*+PRR,+IC'@V A%'1+ 1SND9
MB?Y'$>85%.9%/7,/)<O%//#0LKP[7<@UIUPSS12)$5$E&>)4.F2MK:SY3,I$
MDM1ZS+F7U8FP2/4*<FZ-):;22FL4X4PE;5D,G)B( =59TL6.OX("W3B=]<QI
M!W*+/451TPB',S'()6(1CB9A;Z@@D:]B<;<BT<O6HH4!GL9M$,)S0:S&3@A
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M,L$()"13G$IO28YM(7Q=+TT)?*:J7I'N)4CW:^KI^WA2?38MU5AH[VE("/X
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MJQ/F@7K12Y>$^',\>1:0V#/E@)$1!HB/+7)&1@2 CRG1BD=)<E%K26;;9CU
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M;9A;B-*K,O[,'-HA]P<;YB+1=G W)]P2G:S/&F)FE89.U9-E*5VB;Z@,-(5
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M]);.[\;*)TSINQDRU4:#E*R5]"^E]B]_"]9DG\Q:6L>#+/K_S_5#E=3&5@&
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M521&)<DE\B(6V$\'[DBD" NMN'"1>E/!EB]'&VZ@XT$'3;H3*Z3):;J$<RU
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MFP!&[FBQO<O2O_H1GV.<Z/W,II0MS56,$VC1R3E,-;%^SH5'UP9E0>ICQ6P
MO48X9<I*+:E0GB0*)A]7-Q#_EZ)]6L9L#P8962R+^M\N%J3_=C["\L_?%5;I
MDX<F?' ]L7OR1NP?;%_L?MWA>P=_\;VC0V,%V.(8(VH%01R,1603O*(JN9"C
M,:"^-[92SOTOC^O6;4"="OLM:^=,/_;JIN;[(A%W/8FX>1)YDQ=['9[!FCZ
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M-K.^N6!HSP]B><+\;F\R!+OV#NQX=-P?E%S+[1U+(9(P("JHXHKCG&^U1LF
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MJDU_H.T3([Y.P.5,Z"8;"L1 1!^BOW&[\@>>W;5SD30<%QD<:@8FVI0DL+G
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M NE8Q%UEM/XHSX%2=B12_\ARX?CLR#WY]-WF$0*!&;KMTU!W/#/204\1G8-
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M#L''!,8"8P+;=X[%T*"Y)?H42G0\'ZA$$VM4JF<\&44BX:P^@1(BYSH602V
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MSB*$7<J0-QS*S9[OF^Y8'N%8UCB I60N/4@A0-65R@IG4MQK)@*2#1%6$^5
MU0?/IP7K3O6A3W4TPK0M;7'7MSK.[H@>\(C LP05AP%</(\Y<#PJ*$HF*FC7
MJX73:L%R<82I0I^L<ZL($C7&DGXBF"R#9))+KQ0CPZP<1A3WB0!SXVOPD^JR
MW5'! U(!H;(C.AY+U5"@'N$2OG?=!NWTY9,>&"9 8#()1G2P#1&9@-R\),-.
ML+;EA, E$,Y'W5\CP]X\QZ=72LDR62>?X?5%:;THYP*^FJ.+.:R+X.I#<3%4
M3&3F0)$U#!S1^&.%*=5;$+&+#4(4N$V,.8X=B3R6+U+U;KG(TBL\HD2DH_8T
MCAD(*K6&\9@KFD)]*1+ "V'7(HE-9QH20IP.DU2D16WASG=GM^79R?!*S;<8
M\@O!TY1B<SZ1?5AFB-3[)M2B$7B,979?G;M%;>-\X#5QH'GH3.0X%&#$T3*A
M80<#.4?C:LVB4D0VC+KB6@3[*L)LV %1I1[AG3/CXGY-!&+T05KD7*5VZFFL
MPQ;J&'$IU>!%FBX:I%7999D20#\<?RP3 939.:O+UZ9@K02F+E ^2NVJ$C*J
MJ[?:1:2Z6ERAAT44;S&,)?(IJGFHN!*\EM?5B<A>2V2M3#G/LA%'-=\I)L#)
MN!^2W)J[TSWM9,D!J%X/4ZDG+0S%9>>%Q*['.Z5\NM15BHK"EX8-B<$M3&/%
MZ":6^))?LL07=[#,#A ZL:S]1=(7.11P?*ORXS?,L7+;G&/UF>.-EE9K4M+.
MY/CM\/.ND*#'*::2(]JAREW&-!CLL807W"DM(5W&,G,3:!.Y$3L9(@86PC'T
MU(^.82)AJ'22>44X1E7'8 OU%H/?HJF;),^%(%(CN4?RA!#196B^+HA%N8Q,
M1)$\RF1_!YD\+(/L>#5;-05:$[B2B[ -<[\WOW'&3*+R@0$'OD^K#!U*0+*,
MX53F&2KOWLT35%()3)E>C;523J ,>*,-TBMD3"4V12Z5K.1!_JW?!  =_>3P
M9B$P$&])-@>JSU-<E,B0.*Z.9UF"6?@JMPH^VL\3;*^'H\/L\ VP32)^)Z^Q
M92J_VIDO8U&").H_\@5\3"25C,MH.-:RB;.3&9HET5QP/)S)0*51X9%C&$%,
M^N9-Q[A]DL\3Z6'GT9LMVW;44\%S/)81TO><-)4E+,WR?![_A\>!^4I[3-QN
M9<7XBLPJ?% X'<P<ECT[XB2#G_Y7YOOB!(&^G=O+M*#-,@TS=M-QF;"PLB"B
MG2FE6S;!/DNG(L_[DJ/<:>6*;KH]JV4E81[-.%4ZG!<B:;'L#BGC"ZHY<0X,
MKIK+J/2;,<J=,BE5U/I@AK?<EJI@ +]60F>L>@EFE$Z%+I!?%%!QN22<*LI8
M_K$LLY3H)/*Z%=%\A46'<TT42Y?=<"0#BWZ>HG<E&$VJD64^'R$NQDQ&*Q7D
MJ[RDQ2_EN]BI!4VZ6MYE>4"5^:=V4]U;,CX1XDSJEU+2JJ2[^C@9E_EGO+SN
M%OQ=UB7EA2@<B(OA4DQ8I,X7PJE9##BHP-6R85IFX%Y5^E==>*^_R!;WJ4B2
M0FMC-K'HS82I_XUM:)#H<DN_I0Y#>54MTN+[\BUEV$GE2)9P=KM%YW(1\R@;
M+*1RMY4$0=I:FY/12!6X)AVC?&[]H7?Y<6\MN\N/Z_+C6IT?UP9)O%J(?:Z+
MJ%H\H!+,.R67A3SXO$[JRJ!F*9\G60)+2(8S:>HU<NQ*+8_5?YB<-5,5-]>F
MB:RW(E3U^.M-E5QWL7&;NZ_19)C..-=+*[U4GHWH"ADJ1)[RJ0BT;RQJKD0&
M/#8"TV7-,\:U80!U-55J;"2-\E6B(H]<R*3,M<H^5E@N^9ON_!_V[O/FUNOE
M(?4T97:GF>P]6HQ0SN=+?-YE;#W\R97]P97/C8X=^KX;,5?)QI4;7CJ$8D 1
M\"\O%[BL8ZK""\C)A4RE7;S&+C/&Q&#B)J/CW8>D@'G&50\# AE&@>=-[AO7
MF0LZ55QVT8:\%P=;):*(2VT^+A%;ZV]*@-2R"D("K[*&R.K=23]H^D%>89:H
M0%J53R3+NO% WEQ?%-:E$MRKS"42.J2,/,6<[V3<L2S+;*).@7V/0=R?G&T0
MCHEFY9U<;XZ P@622 4_DF1,%PW4YN,IA"EY7R?F@-A :9%791?PW' &OAG>
M7S>FL>0TU'R.<E@9)1+C*$ 1<8$U+\%IO++2;\+AE5];N):7U^[+]Z"]FF4K
M$\+BC,@4"%2?):271./&C4T4^B-"3X]K*TM7>$/+"Y,1+QAT.INHHP+AC^^'
MCVF6YGFCG%AM\;X$B>K58K-EXE(#S:>!>I7S-2X>@H7=\FQD597("U&STZO.
M[N!!)#O)1$@8\GS%1:.@CQ759'.6*;&DJJ=5ZM 42"TJIB)Z@DWI%RRLAE]>
M*Q'G0WG1*4'$,J'Z&P'].>+D'2K5UZ4I*K2MNBLAC(PZUU>W0C55IB#8&XDL
MO06N:Y1>"=S583GS$M]$VIOIKT25\\^_4<\$*"V>!@-?%_%H&DRUY,XJU48\
M=ZU/U(R$5"\L%7FME')5\> DF7!QP5V"V==94J*3K.?[>?6B&$JE??=D<@8I
MI4$IG'(.QP1O!V$R[Z'2SDN3VT6Q%B\:."MAL>8 M7^(*R/0!O#E_,]-:_MD
MV%BR;'51@+T1='%--<GYZ_*'-T /<!*SU\E83%U\Z4US.+ SW@#%3)$%U#V!
MV%OYYWEH?<^0X?5I!O]CY9O5G_?$G_X]9<M_\_R]P%S_9V//O.7?'.=VW[QN
MLJ:]%QCV+DW6W718H DDK_]Z9;\JGRNI8YR*T'\+GORWH*YLW5>4C?S:T$S!
M!->,?N.CX=*CUN07/KQ\8[;('Y(U[EOB!#==EPC^.Q,E[<>I*&D_Q.0D<>54
ME;570N09'-'\427@IND$6UJI[#O<ZS<[=7B8 +G! =V\VA>U9=:#TW3')T]U
MZ$M6E3CT5:U4N_VY[?[L'&]$A/Z\R-)BS'2UH91R'L>+AZ2)?XWF:6'\K!E6
M#)<MW(<YO)M]!G%Z'TO7[OH[T 'X2BON.#?1'S?MWR*G;+/OAK:"1<2FMVF/
M_[6X35LML;ZT#$=MU=J<7F $$C;N+JLL&6B+U78T]U)ISNKY8=@VFGL&BBT6
M_W>=]=$Z,C\L0\B-R_SR7O96ZFEA%]8:<M9V.[E2;+2/M^R>9]A;\M9JNGE0
M>?ZR#\GJ!8'7MD-Z!@)PM9)HM0"438(E?DJ5I_(09OE&++6IN=1&EG+#;>5>
M^^S89WY(9L]W_+8=TC.0>SMH^)W@-7]GWVUOWYE.VPR'[H@6I)QOMNV(GH&,
MVT';3I29/T6(5=U,S).6-986F.(A;B<VN[=XIF&R>]F:ELL?LV>;MXSIWL?V
MM#P6W#''2V8._Q;QL=;R1DO5^K]%:N"SR+RL)[EFV-P.$X&'979S!?4T2AD?
MBKX-9<Y\,>(9IN:7K6074V07 $Q6XI2('/OUA<;SZUV%O"MSCB6 7M6N&"=1
M*[A1_5!5Q]F1>H5,%Z8(I385;24X=H1**B1F[.J4$3IK ('-^P3C#&4R/8S5
MR*UNP"VJ:=9F4^Y.Q&=I"7"%N=;I4*"I)*,)9EU?ETA>)@OO:1^7\?FQ&G35
MEQ3\1@E&A'W2%G+.99JR@!:3K7P7>L:)U>8+R^W5"LR9!(C#8RXQ=K%?]&\%
ML%K,FVHN%6KLU_98E#RH<\%!4NQ6.=/*?M58=?%SG%Z)]XANA_ -^-,<;U?A
M&HFB%@4P)F ?RP8B8XXDB(!Z MH..W).):#=-:7OUQ+FGO;?-7RXLF*E[)BR
M-F^]@SNY!N[$Z>!..KB35L.=/!%G-%"5%KI*R$*8:WHPK6FKA="AJ/DV 3FO
M&P@*LVL,\DT3#15E/5T=R&L'J\/.UB.M;=4K!Q0:ZEG8=@1KS;!V3P%F(NBO
MU):5U90E^4]YIM7#9?UV';VZJG[I6ED]8-WPF%](:+(T$XB&> 0Y_EX"\@E8
MNW5X"G7H5(40K9!VECZ.9=V_K.9?U4P6#!O$K976-Q:O<<)4'1ZI6E1K @J@
MLG(59*\8Z_H636NF2B*8@< EF(E?Y^W[2MNS0PIY0.I3=%"EM^8)$Z:LJ))&
M\9\E7* _8R$W-AM&<',%H2BDT_*)1K)K\F7""OP$G;B+.E+H(J5U+4T>]\C!
MEP:[572[+J)1,A6UMD?]@V:5+W(KMB'()"!GFG'A]M8>$9T1U&!86TR2(2@G
MT?<ZC43QN-37I0=4-K=1$JWR4W/E&\D>8V2!I,1;P/0K<C1%E "2[O/<DU\L
M#$Y%MS(U).NHZ6&[GTBIGV,\(<VEJ!!HX7NG>]I[;-D@D/"PCGR_!L8)1U=6
MDK\_V*\*R2LH]WI;I&(Z2#-I!C9 "+2<IA,NZ5"$94J;J2F5.@)X%''"QQE8
MC!)XN<1R+B()N%&/%76'\N"'@KZ QK)THJ?%5,N$?5>'SRW/I3N$!VTN1!A8
MRAA(%"G7PL"%WP5 !)S&,AH*K2'N8Q<7T'.E526%8IFZ75.K);)F:85W(O#1
M#_K=@(]0J\U6-V63$?=2V;T[KIJ :'0 _@X?7ZP ^5@>"/OKX,_%1(L2T8V'
MKG+CL*$%PK!5R/OHI2FJ$[V5REZ@$QA:M>H1O5CP_F&48FO0!.Q_$7.(R)0.
M^+S3>T=4CT=4%]A:!J\\!V2LS]M*L45;5P3BNI-X2!\YQ8")8A$$JQ7N,7:&
MQ\O)M3<U> VU BJL.ZH'/*IB')/+5/JLX%5<ZTU@F +AQ2I8S(Q?)C"UE0[E
M8D^U/)GR[B0?WJT0;1%E)+2\:'UW\L_1@6Z&&LR4@>*E@B<OA=6T*@^@?*P[
MK@?%FQ71GU(:KH)WPTB/B'&7('/ST _:Q@I->F4J1<7'5TG.M1'GHAE7,F];
MCFB;:314T'7"W23BAA\&'N%]4R;C2 +KK2.$1^!;M'S!<KF0-W=K4V0FZ1 ,
MF[)O2Y$P@6J7=XUO'P&M]B8%*6]=P0:=9%RFEX!=0^;N >*58@J/@ W=04#
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MK\7K@&C?7"5L.E"1L_JW%"T9\Z^0*$^'Q73]5]90X>T\N'L]1,MO[D[]O[B
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M2 MI2,+2"04MQ033B-U<MW%(:L YTLW <6VOM'/S(OH![@UN#06.0TMUF(Q
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M,L()D"Z .)RZ Z0XXPKT<T^0"V=BBW%&TL9/ZX>&H7=0UK"-.<5]11>OA^]
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M@+J#U5"@'?A&!=0L1P*O:LBG7 &;23C ^8KS-!V7X+,5IB)B$Y:'@YW[Y'F
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M2@&A;"7XJXOD'SLYV?27WO&(:JJH[TVJKW5CL7+X[YNZ^8!7A']OQ2L 8_0
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MRJ20T5^J-^-9_TE;PA83[ (!)@([:]-(%&7BAJX"(\4>B\&Q69HU6XV9VU.
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MU713BFJN(^&^R/VB2<854U)3.S8>(RX"? SX_9X35VC+9QH1[L%I=]"3?D?
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MD2-=\21./MQH'6QEBB4LO>B-R3X0&YZX<#:8H.:4&F8 ]J3GRS4&,UI*W<>
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M&<@QBW)>KWJ\B:3Q,?% Z3A_O<(GX+(&@6INMP%-EZZ6RN,$FWBB <FUZ)]
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M#ZTSKZQ)$COKLKZYI]'FB8B!'ZBT:$]+/X5BLBT?PUIN]4KX,#GT5<W.>(T
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M7JY7N*#3>W"GI4$F]D%C6?@=SZ'&VQ,%6^A&.Q=:(H-\Y$=_4R,GLY"Q:>!
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MHGX/^7U<.%^!M<%@R79BB8LUB+_ ]>QJ>-9H=*+1B48G&IT3/!IDO+!(-39
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M\M]1PQZBN+!/*+M\KGMR#4-(=[B\Z%64-[!_UV3[9)QN.,&;[V\O4(0O'#R
M="W"TY1WHJ(V,5 D #D<SJ500+/S5<0S#Z'Q/35!0*Y,VEO5B<G,,9O.YC*>
MO=O5G\0W?:BD&)*^7#695GB;%!G2W,)ZP@C%DJ,ME"N/,^F)H]-B"X\*!5.X
MHK@+[G!@7XA.@@/*^(RP ?*@4(U,9RM+*88B/M_L9T=D_ R(J!ZT1(M;[TL
M0.2ER'KLJR.-#>VF]J%19$9FRB=3:<,6;"M]G2K"[:7204W>6"+"R4N7QW9@
M- \*&WSB].%J&Q? 46B& +!R=?&[KCR&"?^NY7I(;FYIRT:(*7<:5LV=+%0)
M6(*7X+ 8<-D!F(E[@U=%NXJ(E/6PO:O.-B+PZ!Q"I<@#+?RG76#)"(3QGGG(
MNI(AF" L3PA[RON6E6F CO&8%D'-$@47@_UES,;U)08(L0.QH1,=\Q-.Z1 0
M(;Y4A! 2YK2=0M!["/]L&,=:=F "BT-9<,4JF-X-PM<04_&X^DDI*$CA!<D.
M%=RCGE:45G]D%; 3%V4-G8FQM;)K-P,7%?5B91CR8!0Y4N6*16$JB*)3-G13
MIS&Z"P45KQXJ2A8EZ0'MI$B!#8CK>7C[FDJ/6=B4C;?NK^E"Q2KS?;#LXX;U
ML*]/O8L7N"J#!^UE\<?)EZT8LY')TMAVY4-NHR'$3_<59473A\03\+5D<<;%
MC+A2UNHVC,U=>,:P"X+#)K "Z=X%[@:FAQMRLR=XQIP6LJI=2/1$.[P&0$I\
M/<9<1Q?R%9[:7U3]*5@3\7T%#S]V<.)Y0V-V9&H(%,@%8,F*5LQ^SIX[)8<
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M1(&*; <*NE0G@8A$0(A@.9X<X2NGJ,KHN"75,$U+2^,G%\QEMG/O?%^W!TP
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M0=S7A\I+)/N^K'3+67.$&1@Q7SJX.H_N"(DSR2UVOJ&-(+ ]LT6V5WA8T![
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MG'/#\R6#%)UIG4;9XY(643\[G.W52GB.U-E L]2L+T),1FGAQ9H/:"KX4KK
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M&G;/[=X-U-\\M9I;)3<T*REY1HX\,67LQ*HYGP%E>Q1R0PD3)E(3Y$VF/4W
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M(8DP3N-.6Z5%P\TG9' 9X_",-RJ4!/Q8E>2OD%:(3Y9!GX=4:)SN@;73ZP%
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M2YI?I3\^:P<)M0*H(X0W'\31@=,M^/R,S?XY$G+X-O2-*/^T;L%'H KS8KM
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M%=&"H)@.3%B8<8[G+$K-K( ;,'%0(J;)C0NIR6HMF-,Y;!*55 .IFW"<F[C
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M/:0FTJ^P;1%ZOZCK27M<$6?"J5FF#"%Z#:B8E'?9E&53EDU9-F679F&M_H5
MEJ ]SF"5I^A+@_(ZMGV/S>4M6:)^N J@WG795]FYRA8I6Z1LD2X<".&H8!"W
M 88("G6'B,I0FRX"B8$"\9!I\82H5/:.J'.Y5VZ$&?GI-NY6)3AOP(]CTY."
M8%R?<IXIJY" K$R9GA\"^*3,(T05=I L@B+_;JP-V0$(X8)I$_;(TVKH'$J.
M\V@D- T(2+3\1FW7N),":G?.]5_Z*V:3G$UR-LG9)#_"2<1J$K7I=>VIK GQ
M&-#?Y4WGA)AHXBT&^C/D'S - D"FUC;4K>BZ _78@/8@LKD(DIS(^=>.R(=
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M*'5N5FC8&TT/^27%>T OQ\L8LR ';_T05\H/N7/#J5@=25./VM#][S?$Z.R
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MHL1"X"=TE0-FMJT_MT]<(D*_(.AKG%LV IE,?I3^ N_(A2;(Z('C24R&==E
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M"*;M /QA\-.O@4;G!WJ!;]L&1(;@6U^U94?$7^$JR"N&LCL74?@P:5YI^/K
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M!$F(\G%?K:LAI2.>JMW/Z;P#?BB1_WN&V)6WG#3<,RUC  XA+S,1H95$R.9
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MCW"RUED_XGQ'S^>YHR=W]#SICIZG8@B_FP2DAF:7*Q*/$&5E-V!&@E4]"W5
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M<<V#!##F)9$.[TC9+L,#%]=H2DKM*\C)7XA]98M*0-P/ 2.04C7V->';DU*
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M69.NH#RB?!ER+JS' WRA-LCFXDK!#3&ZXB"!0,3RL4<X<2@3K-SUZE5=5H?
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M,]-(%A"/4*0LU -)5Q%&.72W7!D^4QG^)%>&<V7X25>&?ZMF7]:YQ ,J,$X
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M?$(,1%?Z&YCW]7^_/X6,%R4/IS\3-ATX?AT=CA],'CX8/[1<:T4<_*;BHD)
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MU3__/GIR^'S$G'^D)G965-H"LL4&B&UT1;(\^-'[N$KB/Z)_9<6$Q/!/8D7
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M#'NV%33;%FY=7%R'_P GH2(]N'#%-,M24N&:[FUGM>,9'67**86@RDZ\_ #
M54\.OCJ6Q27FJ(-G?]UC3%O3<67MCNV;V#&8+(8C25 PPGX:A3?TCMX*68DM
MSA4L>I&;61E4R8R,V[(QKDUGY#L0@GM+4K*G?*9$KDH+)$*HF+4X+U=";W>[
MG->UES=RM9D>!(XVC.BUA)L;D_@:%)4%8<F)EKGG2"5J)7FGO'[6E"S'PCIW
M/6N4X$;3M)RBXLL6RP\0N%[&+*I.WK_&U4/2G!.ET"_!I_D9^U(YRNDE)L*,
MP77B54UO59)R?ZQ+<BCY-XL%W! $NT0":<'] .7C]!.6II6)B;[X">&:N81
MXW9,%MS44E7%-.7@L&0^7#%]W"Z269'W:4<BZR$/K/1G'[%=@4"[XY8^;H_U
MRMHI!96]P4>(6>=2/HP2!1*Q))-U*$=<VS"!-$#1XA:XLE*"GIC#S+G@M0 T
M2\,+<RLK' 0Y(UM,$4,E<5*$650"D @"T*]YG"+$ ZD3Y!Y%5."7K/L\H]NG
M>#9'&=MEJ@95P,]B'*%\P"]%V!N5T<Y4('J:D=+*[8$AST*:%NT0E<DUP]()
M#6R/4=Q!X? A<+'%7-R838O>R!V?."?] TF"@71F%>22<W\,F5;35O.*M15P
M2'"I85Q$<4/^>LDQ:'HI>_*=.(%FM<QBF14K@S7X1PM#YJ (^B&4N.2YM .
M2.0R732+(*JY4W2)%;G2JII'8?1!@[P76G!BC>OV<7!P=SPX?C8>?'?T^"HZ
M6>]<V&V5+7.M8Z=M6 ^==('4YY3YSG8_L+GXGW'>Q.4J&N$])B:F0W/,@+9/
M=)IS@CGXDL3"[=E#'8AES%T=*FFL$FC]Z&@\ )\__@^KC^NBWC7@%T:+BJ#)
MYFCDE#M*$OCS*51&$I>Z"Y01<E:%OK[VKD *:@YDG8*'T:^Y]'AN)G N<:IL
M[LGUE6R\R'842A6KD'UP\&L&"==HN4ZG33:.+2_8Q6QI-R6A@4D2G(\EP8GW
MUYLVRL58VG7#F= 3Z&*QY$4$A&PBZP'E.>ZCIXV1.+LN><:N#O?K;"3R882N
M/T?R[6D+6]R<*U0HB/X/'?JG@IXNY).D+0:H2J,K1G<:EZWR5[65FHTCUWXK
M.=?J^R\3_#TV1H^-<7\@(7ILC "L-%Z@M)%%4US- UT0U&0$#A22'CI?G,7P
M>4IR(JG:7MF =4-B1.GTZ&"]3.IE4B^3=I=)-E&)OA/QF\D#/D-(0UV!H&4D
M-,)=T6K+RG*5'DE*1G5:S4W2PXCU8JD72[U8NIE8VAV%R=H_&U(D>PXH=L/4
M"7S>H(D1L9>2KMHV(TY- K@(UY4#N<VF8\E!#FFOBAA^EF-R%GF6,2KN8+ 2
M6$@(6B0&Q;!,%CN<#N=] 05$](!V6_ZRE-[FW'4LY>7VV?) (_E<Z?VDSSAM
M6W"'^R*M@Y#;FTO!S^%N-D0WI]-FT0B>F<3+>$;;U *<^0[V@590H^X864Q>
M<E5)0G-!EX 0J?V2EI8B\Z"^  ?O+?P7P^S,4I^_*1N;;<,67>_+Z9M7G%B>
MF"PUYWH,R('N<(X\>ZXV92X86YN^,R R1)">OA7-BPLZN"P[X'D-G"WEQ"VG
M31A'C B(BR02-+]F*W]+9L#D;*NC!G)I?M X@\1QRC<]-VYONJ:H6E6U67#J
M=F%J6PJ8YN@5)>8(4\-!(E\*HWW1].]-<B;)=3I1DC5<RG&@;8XV;QTW&>#S
MI)*6?L253DEQ08]FB#NN2[3=LA!I*4!DA",5_@5=W$-DQ"-S&>/3@=)U$$OW
M?<$%FN>-RV6D>9Q D M$#>:Y<QNE)>&8$R!B[M%V.?5)4J L0; R03!NN-98
M"R+T =RP'_MN;8O/AW:+59AO"LBF&]-V%*)GQ;F_Q;FT/VB)#/J@Z?H1A[.B
MB3N$!<JJXM!Q7X-W10W>T[X&KZ_!ZVOPUCD#GF!CL2?KB\(ERY>F6(HFGP"A
MEA1YD(Y$R5?)ZJBE4:I.=U @T$6*;=0L:K6&.FD @1^4;2D^HU,'@AT&:TXK
MVG/7MB/VG-E3J^V&9NU'M:NX; (! [F,.*-3:A64D'GPNYFZ$Y4Z;VN5L<8%
MG(PII9P!!QX#!3+SR* *+@0M6:'&+.:$3="-R[K[!@,Q]_,"KC.;B9I*,1($
M"%31^GQ"+*B%D6N0NB @L? =B:$G]Z5UCV3F>)@4#ST0WIE%Q^PB]8;? ;F?
M(V&,Z1>9A8T6A\9"Y:&5E@R15&_.HE>272[WC9]-Y[!H)4_81?-07Q$5?.M$
M$B4%OXSLUNG<ENZZY;GBP*L.:QB=$N]G<0GQ@)<$Y3DJ)?RYSHOH@A[D"9E(
M"WVG=)YG1(@F1%LL2L<D50<ZL,EG\7DA  Q^01/D<3MXN9T#:5<8HNQG?;E5
ML."I% UP0:P"#<DH1YB+6J4G=-'>4&G.&CV2[A)05]/FN<ZB?IO#W[JPN+5K
M)^Y6P\=-3H=?+0J_<MYFN%XILK O]:ROK^?^D.LZ.R=F39#<$X'\R[R-D-2M
M=9,T>+?.342$H)2V82%P:[D=,G$A?:Q2>=WN8E7(9^5YZQA[R#=;X< \+-AP
M3M([/!%?B[B?=W$=+$7W6+E8D N/?5FS2+V-Z%TJ7UIQ"-O:N0Z.)=![K2_K
MTP2B0HHN!5DJYZH'#Q_,X0Q1)#XT O(H&>:7%]K=C(,C<-?%,8D-8-V\L/4%
MN^4-D$O%TKBD V&0,^9JZ:QN$V9;;2WB-!=<--<AWPUDL.D7+,N=];"-MV.A
M<=;AN#-SQDC_'LO&8\ Z=K"- $F:=+&Y^(FBO4#[C+7C&*(V\<(RB4.%U6?;
M(CE9&*IX!4J)0<7"+DM;[<G8/"FB*8.6LG6G@[1/B7^FJ &$T2!+X;>R]Y]J
M%^6&"[^#/"@VB8^8B>(22:C"RQ:@-I5<E'17!(?+U[]&V_:@(X^+[Z$5.=01
ME!I+,2]M[$! 2RP-X;?9JA,CJJ];<Y9^,ME6[$6^=_Q)2!,L 14H8:!BPMQB
M0U!"R!)XHL?&$XM.K3$Y!U.HY9,AR!^Q@UG6#I!O61"EK,11LJ6<5DN7ZQBB
MF-% ]P0493X_OS8!/5A(2%9,+_>H#LNFKJ[3;]_O59'E] SYV2CVDEBJ.HO<
MVUN>,T3?YGK L!#6U;I*R+W:$+W;3QZYH<WPP?>WJ;-;80@,.5LDLA*-]I8,
MY4C_ ,0.BTHI":2K+LJE!BBB!XI[\FK.JL;CG+"QONEQDQ708[G0\Z7^)SY_
M;3+4Z#*V+-^Z-% 1,1T@SLI"7DOV0F@,1#'I52!#U"Y.B7Y5Q(FMBS)1"-L
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M=N7^LI*JJ>#IW1,DW9<^_ZZPTD"?FZ9+R.&EI"TEC%K-@_F.&F#OQ+"T]*$
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MA*=-N&(P9F3XL06&O)U8J=\#/'@M)4F*9"I853UX?"1)2'"[;$E""^A+]A*
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M+J0$4FJ6%NUO?WU_TGGW=Z1%1*^,D <+E +\ O/Q=1 ];<[8+#E:E>'G.LH
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MNXX],/+D#2@IF?93IU:7B#YC!E]GI*IV6-A8<<[$RC-K3FVTX'I BO#'2.!
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MDZ6(V==HRDAW/<_^HHZ4)?Z*W^7K-'Q+:,")M D0/LC:"._*:>_Y/?&EBH%
MTB1)AT!0^7'UT([R1M?CU8A>6 [K"\6TSO]<)@E5N&W)8NF-QDX&WB-TIJZ.
M,")2 28W"3%#*'5AE[Y,P2YKO39M-=I=8MTWQ+^I"QV?K[KE+TBJ0!.T/G/(
M0JK_7==DBBF;T,+ZTU+ELJ2.@%:GB#V.<6BT\*LR[]+4&26%EJ[M'%BL1R8S
MO!@'I=.?ADJ[^YF4VDW<E?XDC/;*39!5]X;2H$0CG5)5V*<NI%OR0ZO,%$&
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M&UEI(@V )'N,IM >R0%Z9S.P6+C+RN5L0F.VG+M]VUCQ],)?SX6P2OF<763
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M=4[>1*Z;[T^^(\8A36STQ+,[G0Z[JQD;9F9?#C).*G ]/SG\;VTEKE$1)<E
M X2-.5/'&'(PH1!JQFT.(3/9G'+;(7T(:J$U\_9@TQ[Y=ZE"\LB4*)&3&XHJ
MUJW>-34X1D..+_BBC?-,MU:DMX)Z **A?U+M8J@>^7--*>41]_5,PJQ)!%M5
MBV1IB,$$,"%*&;72KOD6XXW!#:E@W[WQJ87A>MJ/S+G,3-0ZDZ)FL/JHP9<@
MP4JI%0L\.MNZ(/*=RW+LJ_+YGOBQO0&:<> Y?IQC&B\[9>12BKR>\2)3*'6'
M2CT<+SKPUC*3#1<LM*; ^?L/J1;ZGABP=?>WJ8!_<5?<R5E ))E^GRU6%4AK
MG!R\Y[$6U4N%UU()!4(4"*+4BD$Z!!TNQ:'7U,'?X&:;,,!^'PSHI?\;E@L/
M<WP:EGFL1U5(KQBJ'#DES1&<+'5Z-RH(##UH05A$0*]-ZPGX]4@V(8K[/HC2
MT"3]1C27SA$[C;R^29YS51NU848F0SJ:8BX:ZC#0*!<C2"*YXO60UN;)_;MB
MWH1R_ONBW%[-W",Y;SRE:F12]$[3B,J\(+=K%$((F0/R$#QUCPN\]7K_'2%N
M-+/(OG?NM;/B'F9VOA5P'TE>4,;B(9J:O<E5@1AE $>/@,D8F/6MT[\WP;41
MJ>Y[]7I_,SQ;&JQ=];@PGM8P\,VTUO!\4RYD W]+!8X,D\N9U" R<O?&2:(Y
M.F!)*V%C#K+Y(:J;(=N(3M_;+'0/1GMP=46TU\RF;.A!07IA3D.LM?H40Q83
MEQ;+=UQ7A']G4^!#9$W+\VWFN,1^;FGR37D^[E8^@+3LVSD>C8^/N@M;>] )
M7DRL@=6R5%LM1$E2EN7@?&0NL>9;$[9#NA%AU7<V!N_!J,/84S,*C-4*9A:R
MJ)FI])"0)/&D>-$I$;(,TC8_WG@7P UJ+9^[\"CF%$P]_(64/EF,VT!>E&29
MYD(Q)E)4IH?BRN<0#"G!8W],6E-Y>5NK-'V.;C]H,6:9L^ )N+<65"D*0@H(
MO!09K%-6-#^-I=GAEP]BB\E./&IOPUZK5+P,X_D2TF\4-Q[/5[KG?>WE^==9
M61SBBVXQ/JH9JV??7!5[N*EGU^UQ?XZ+,)YL5>MB[QA;5,RXWX[=L>[&<A5G
MDV?H.<;%N8,Y+AW9<2)=5MG.(UZ(\TJ(>C!RJ?58=#WSP9$VUD8GE@M]OM&*
M6V-@.\OO2Q>_=.OSMWH:NG$W\DY:*[P '0,%"=%(<#IF""B-CD+3,--:\-P5
MXQ TP;V3\(HD[]/00Q'CM3)6+AZ*JA4!@U<0<RF0698R.RV<;KUJT%",WX_H
M&!Q1]T>!-OD:N_?=F0\=L5"4\DF <;:F,BI#VLU9T+I@Y(HEE?6>O,P9J-8>
MYMLM+P(82:%]"BZ"D;4:I$4'0?, 5AADWF0I<O/#C#?$]AUYE.W(=ILW:6+4
M@7@1J[UC6!@4^DE#5D@0?.90JY&*XC17KG55R__W(BW)N3_SMYL%OZLZ<S8Q
M8PQ"M#4YV2""ST9!5O4\<NEM;EXF;S<9WKQ/4CH^.EYN1_W[?-9U?TSG&"85
M0%W\>XIE-L=:)5H75CQS!23C9$Y4D:1(4D ]Y+QB(CK9.CVN"? AN)R]L/..
M@4H/9M_74WPM]+ID_0UZ31UD)567R4E!LU+%<V(0Z\%Y*K*$IO44:1/@@]KR
M]B HN[W=>Z/LM4+.H _.:P<^A @JTDLD/PF%4#L7I#*EM2IJJ<[WE1)PK[QK
M8KSO:L9^="F'9YAS]B/^(&?M+W?N$.?M,;/ :@(#3W7^J=0#FUD1P+U ^A>8
MX/(V.CS >?M-78YC.K%Z)F]1HAYGK<%+S2"9S%+FGAFWYRBBG=3H/4WVWOG:
MDPRY R?N73E?%/UUB3MFFT!I*\G-:0L^9D9>3R)J97U)K?=*[BW6>R S./?/
MYNTI,<#U@)*-=%%!9)F>Q:(]Q*P5,!^]ETP8#'%/WNN:]8#[4=N#(>N]6KQ7
MI;[<0'92 2Q,SDY+&4_IR5K9YGTZQ'P\(0UY4N;E])"B<++][-GQ?$Y_LBKS
MLD,*35]06FCNO713HX-H+M[_8A6>$Q"CE-#:9 QPJ^J6+4$Q8S+UA#9K)3,B
M,ZX;N] -8#6HJ##KQHON8ENS5<)''B'4T]B5E0J\HU:;5(00)H<D6ZO?M4"&
M--7;FB-KBBOL:(EV)_5=;1EB\+D6%M;9<5#HR 5H\@.<9V[J.3:AL,:,N(WL
M]YN*VC<==K1!PQJBY]MY"L5:SA.G (ACW8\0A 5'T0]D)VS2.F(,K>FP%L@0
M)->^&+&[)08DBU8[#\.Y<V-^Q\7>E-"-=]^_^-F\,YKIG6L.[UF>*U\8\3][
ML,QX4$DFXFB.@(4'Y$XJ+WHX .Q:/ V*(*^_]C(Z'G$9);48P?!2=X10@!,L
MJP<F!\N=LQ3CM)X9N1G1L#1/(YZL*7C<RB@M]UN>3IR<+W1%OT]6._:F^?RF
MO>L/P,)0(L6C'J12E@;YXB!ZE\ *;;62BNG2?+*M$?9!K53WQKY[L?1@G.])
M59S+P?:Y2CA[\L.; ]FW2]ZRBQIYYTME7,^4Y)5J1J<:D&2>9:3SZF-0C[[V
M!D)1&:1D&97+Q8G6>TWOBK%-2'I]#_ 46$X6M*R[]%E0JV5\88M&7Z@C7.L>
MN$M[[SE)K4\^K8];FQBJF6=_02/7["OBR2$=:V"EY))!)\')2(+#Y)I<Q,BY
M)*Y-]%%C:9UA?RNH(<UV[)5";<W59NWJI*4D!0IV'758F+Q$[,Y/4X^,9\Y;
M3%"43J!\L=1FEJ$(2V$]1>9*;U9[=(.;#6GB8R_DZ,4*36NUK %V-DF3+-.1
MQ&J*]6P88Q@X82(D],JE0F'-Y3VR36JR7(]H2.7-]SJV-#14OX+^0NGU[L-L
M$2;+7^N"["[Z?)/K-I';=VY (_5\=I,1DUX76R)H5^OTH K@#.<@D84BG<)H
M6B?FGMU\UP'E'V$^KD_#M];HJ#5:64#QJ$ 5H6O%/P7%&<$B<L55Z]9< 3$D
M5;N=G2^/![OU<[L5MPM/RQ)',JX8ZQ)@]#04>4Y#D=<&? HZ!FD\#ZU]QE44
M0]*@;0R^8T\WK%E^DCW\#4?.DG0+JT?&V@!**@^N1 %U"=C5;"V36D^\7T4Q
M)&'9QN([]O0^W?QO87&2!S4KZP]?V7%V;H?;]2 *MF]N,ZW0=8C7''-S>L3G
M\V,<91E$YHJ$H*ZSS9(I($$H(!6,3 4IK&PO)3;#MNM M.E]_AO#_,/GV:@(
M;@5Z7==F9,V"3J2^DP2+U#4ZL\)4:[]T1XC#4BD],.SR"->G"=M,G]R(\,/L
M*;X-X_RD+'!>,;Z<'<]'!;5/T4KP?%EIM03PC$O0%(99GW,QN%E=J;O?>UBJ
MIT<"[<,VS1331CWQ#H_"F#S#_$UY.>[(=!7SR-CD%!,%@JOSA8'$78C60O**
MNB9$GECK%=GMT0Y+@0UE^-K=L/LE(G7*[Z12/GS&R2?\;39=''8C'C'P0#&&
M#2&#,@DIQD@9;-$A)16%YZTKQ&V+=4@3A,,AX:Y&W3L%EQZ?J(0CPJ0LVEI?
M:+EY364(B=NZ^T>4@EG9TCJXO#/((1VJ."C2;6?&>V';4A]8%9P73$*.7(&R
MP0&%U!R\25KXPGA,]S70W47C[>OXQL%Q[<Y&W'"2Y.3S^A+I]K_^\']02P,$
M%     @ _8"I5@1W@-F970  43L$ !4   !S;G1I+3(P,C,P,S,Q7V1E9BYX
M;6SLO5MW6SF2+OA^?D5.GM=!)>Z76EU]EB_I.EZ3F?;8SJS3\\*%2\!F)T6Z
M2<II]:^?P":I"T52)#<V25'JZG))LDQ\B/@ 1 0B O_VO[Y?#'[X!N-)?S3\
MQX_L;_3''V 81ZD__/R/'W__](;8'__7O_^/__%O_Q<A_^?EAU]^>#V*EQ<P
MG/[P:@Q^"NF'O_K3+S_\*\'DSQ_R>'3QP[]&XS_[WSPA_][\HU>CKU?C_N<O
MTQ\XY6+Y;\=_-SY+0UT@X/$/Z:T@ :(AW -0%4!DX?[OSW\/P3(6DB2.&T^D
M98%XGP5),3O-HC(\I^9#!_WAGW\O?P0_@1]P<L-)\^T_?OPRG7[]^T\__?77
M7W_['L:#OXW&GW_BE(J?%K_]X_S7O]_[_;]$\]O,.?=3\[?7OSKIK_I%_%CV
MT__Y]9>/\0M<>-(?3J9^&&\&P.'3]/H?WD:C?IK])?[JI/_W2?/O?QE%/VW4
M\^ 4?EC[&^4[LO@U4GY$&">"_>W[)/WX[__CAQ]FDO/C.!X-X /D'^9?_O[A
M[7VD_>'TI]2_^&G^.S_YP0 1-Y\PO?H*__AQTK_X.H#%S[Z,(:]%OYAR :4*
MG/]9/NVGUIB^()!QO Q \*<P+ 2OB''5I[?'?/U9)$'VEX-I1<3W/[LJWM&%
M[]<4\+V/KH"V^2!R 1<!QC6AWOG<6S@7()<1EH^<X";:#_W1W^+HXJ<&WJO1
MMVU@3?#?D;*94C%;OO]S]@]OC8L*[@_[9<_X!;^=_^LRQNX(X/L4A@G2CS_T
MTS]^[%-PD%(6E!LIK=>!9FYQ<X9,D^#:]F8?4: LP Q&\<XG#LIV-KH>9N #
M#)J?]A+T>S\CING5BY3&,)G !/'#VRE<3'H1HF(I1V*UX7@"""!>^$28,X8K
MQ6F0YK[^)@L^3"#^[?/HVT\X!BJ1\_)%D2*?:7##R#/![C>;Q6GY"7^WYUT*
M03A)+'B&,\@6Y\(,B2Q$I1V>=G0% W>8P>W1[J*^(<2+\0+_?%7LN6S*65]9
M:]-1!<'-M(+0?_QA-$XP_L>/M(8"_]]+/Y[">'#U ;Z.QM.>E2YJKX$H4<P6
MJ1()BFL" JV4:)BFG%71Y=+ 9Z+6-N*\KV%60\/O8=P?I9^'Z36:M3WM<7-U
M/)*</-J;QCCBL]=H;X)R GR$)*OH]\ZP9Z+=_45Y7[>\RO8[]FA*%$G.^08L
M>A.91*IQ2R380&Q.@41KT,%PV>AHZVS%2R.?B89;"?2^DD4;)<\F^:8_@-\N
MBRAZPEG*1'!$4H:$$];@9F(E45EY&1.>);F&I7 SXB-7:BL!WE>F;*_,#_"Y
M/YDBQZ:_^0OH96>T-DJ2I".>#@S]?A=Q=F"9<H9S34V[U;IJU+-0:@M!WE>L
M:J_8M\,X&N.&T<0S/D[Q>'@UNAQ.QU>O1@GA&1>H@H2'A$/>9:.(#9H1+P7U
M:"%(ZML955N . NUUQ/S?1;H]BSXY+^_3<7YS/U99&N^[UB5A18(3#$%N.\$
MM/C1>"!998O;471H_U?0_YKAST+S-41[7^>FO<[G,YW_3YDNZRFC@?H023 ,
MV<B0@\XH01)3"#-[L"[5<^EO#WT6NFXKTOMZMM7T_ J_?#?^-/IKV)-&,P8I
MDB@Y'CK!"]QNK"!,Q<18"#[;BH&;FX'/2<=[BO.^AETU#3?'RKOQ^_'H6W\8
MH8?#&^?0P\LT4[0< QXH+BD2M*5*9I&AI4NU:?1STG4;P:Z(C;0*?]T!]GXT
MF?K!_]?_VE@1:#%H=.TYR4#1XZ/:$NLHNGU4^H ;#<0J1OFJL<])V_L+=86N
M6P7"RA[S8@R^ 2)"MD&!)+1$Y9!EB> 7F8"0-$JT(2#Q5MJ]/=HCU^?>@ENA
MP5;AKG)1/'C_931<./(L4),8VGH\)D&D<IQ8ZQ4Q,2?K(M)+ZE9:7![QD6NR
ME0!7:+-57.LCQ,LQSH_Q\*D_'4 O.2]Y5N7>(]EBVPGBC5,D9N.19\PQ%UII
M<WG$1Z[-5@)<H<U6@:U/8U]R:CY>7831H,=!.6I3)I1)C48<;O&!"TJ$RU;C
M!%UP[:X7[@SWR/6XO^A6*+%5$&O!J)^_QR]^^!F:H!H%RB.U)=9=XM\Z*&(9
MHLHA":&435S569:W1WWD*FTMR!6:K1"8>G4Y'L-P.KO3*)1#4_QRTF,Q"*8\
M(XE:G"7#'20XFHD64N'!$(1RL8*INWKT1Z[I:H)=H?$*8:FWPRF,?9SVO\%K
M/_5SG+T<,^74:N*31B>;^TP\+^F&AEN>C-<JM$O5V#3Z66B\@F!7:+Q"@*K<
M<XU?H8O]>32^0H<K1YD8S@\8&G@"*)KK-A%EJ!9" M5*5+HKO![T+/2[OQA7
MJ+5"5.KCA1\,7EY.<'J320^M.8A<H=L534:[73$29*(D^J08@ZQYR_2<%8.>
MA5KW%^.*U(T*H:>?+V#\&0^,?XY'?TV_O!I=?/7#JQYCV8N$0*BED4B?T<FV
MQA$9A6#,*! ^5U#ORL'/0LWMQ;I"W:VB3W-<WV\R2V991#WC-)H#TA#0$3EH
MM"-!X6PCC2$ ;C(BUS"^[H]\'HIN)] 56FX5H9IO,E]@,%B03@LMA5&61(E>
MG)1>DN#!DF!4B%Y(;74[]^G^F&>AV;V%N$*G%?*O$,E%R348Q3\_?O$XU7>7
MTU+U4CSW7@C911=P3XDEXR @1LNC)-YS1]$&9)95<: V8#@+G5<3\@H.5$C;
M>H46_M@/W@X3?/]_X*JG:$#[CW("+AG<:21.%KUXH@/:^<XYEE,-*VQIV//0
M= M1KE!NJZC7W'=[TY]$/_@/\.-%9F_0*8+-2#&FRA1M)"XK26)F)HMLI:7M
MHICK1G[D*JXBT!5:;A4!6Z3VWJ!Z@S^9]+BF",M9PIE(N*VP1&RYE^2(%$R6
M*6E7)55Z:>!'KN,:XERAXE8AK[N89N;@#%70 3T];8AA 8AD+J--J!SA5@21
M5>:&MSN@UPY]5FK>5Z0K%-TJTO4"(:4&UL!_[GGI+./1D  X(RFE)BXP3SQ'
MI\[P8*UIEV9W9[A'KM#]1;="B?6RK6#RR8<!])S0(D!&5OF,TS(VHY&7%)$Y
M&Y53]$'5,*GNCEI1I;<*Q0^99;./^%;5F?TP*_W]>QR,)I#^\>-T? DW/QP-
MI_!]^O, "G_^\>,$/E_<"^>WXL#\BU(4^>)[?])3BJ)1Z!VA"9T]J5$LH834
M8[#)<T@LAAH)T^O&K\B+#<7Z&WFRAUK7<Z2->"M7)=Z"\KK9!;<"TUOJ&K#?
M;KX\=,T=?5U_@XU*;J6746VA=JYI:T!%21/AO@1S*'ABC6'%ZT.+(F2/-N1C
MT/"=CA!'4O NLJRLV#>C\06,YY!^;6R8GA=,:XE6(,U4$C0N @D);43GH[$<
MJ) M V$K!CVL0=92!:-Z\EO;">#??EJ2!!H;?^[?M&.8D/"0\(O):-!/I2G2
M2S\H_7X^?@&83N[BV;:CQX.?6J7=QV[8EWJ!1*-$R=2 )$!&9[T/6HH00BZU
M^['T GGP\_=;7I<3\MG[K[TF5;[86#?FHN-&:^<D<2R6:N3 T5RD&GDG J7*
M6M";3*+L)Z&A_GR(V3*#P72R^,G->EN/8M]M8_&)+W!3G$Y>A%*Z&:<]QE.,
MU*$#DDI6N&!HW@B!KHA!CY)'2+#1.]]G3G<1'&X+J:39Q3Y20: 5&XHLT+SR
MDR\OAJG\S\__==G_Y@<XT<F+Z2L_'E_UAY__\(-+Z.G@0\R6DFQ*MJI,FH1L
M!-$,7 #.DX1-!1;[:'TK8(<G0QOMC;H6?46KX7J^,99RW<D'B( 0T</Y#::+
M#"H7O$A29Y*UUR6#*A)O2KV!4\#0.O*X)=?>##;@>=1LJ";HBGU+KG? +Z/Q
M]!.,+]X.O\%D6O;"20^8#BI (AXY6!Q=-(R;VS[<&:46,5"O:I]N*W \:J6W
M%FS%_B4+3._'\-7WT\_?OQ9["3>H=],O:/LVDU[P4:/C@],UQ'*<KBP==:P/
MBAB+^*1#RY=N*LG:1_=;P'K45*@M]HK-4.[.=@%&*::CQ)/("G1]I#*!.&<4
M$=EEP5S.L#$TL+\E> [:WE^4%7NA+,!\P*UGW(_H$!5;I&=C,E:*1*S+.#F5
M@3A>JB"8M.!SC$S6WMCO(GC4FFTAS(H-3FYVE=%7&$^OWJ.C.\5-I1B:7\LQ
M@\9%CRN=M,/C!7U]/%X4HVA:6D'P1\X)::*BFTHR]]O%U^-YU&JO)NB*'4\6
MV-XA,E]*77X!/X$/I0/VN_P['C)E^CV?'4U4)Z(3-T1&ZI&AB-7RK*-+F7&W
MZ1IO'Q9L!/2H:5!/U!4[HER#N[$H?AL-X_SP\3I('J@FW!<'4WGD)=>!))YL
M",%FSFKO BN!/&Z]MQ9MQ?XH=^?7B\I&="(L8;IX$2XR$HQDA(LLT-ET.:3:
MY_ELY$>MT3V$5[/CR0+&+WT?^@,4&TSP5&G2;;^,!OCADW+"3*^NYRI3\0UY
M(%SZ4A\3*7%)H&^0\/1QWB:O:@>;M\7VZ$.VG2BAPV#=>W]5 D@+]P*="ZX2
MTA>GFDHGET!">=Q":QXU[D%6L*["='>1')X(W6AN3>BNA=@[(,.;_K!<;C6&
MR$(,B^+GG@#)%4V"> Y )"]5L!8]SL!E-HC:JES;>=^$YTR)44T%%6.ZY8*W
M][,?#ZY^_@[CV%^!+#NEO32E*DLQ1 :.V,R "!-<TC0;SY<*D>_?&C\\S)GI
MO+)<.PCLOAH-F^G]JS_]\NIR,AU=P/@>1L:H$BI8DFWI,J19(B'@J>FEMX%%
M+D6N?M.W!:XS(TMG*NDBZGOW=+N.3,<XOH1T2TP+O)Q1U#&ZM3E&Q"N%(T$D
M0W*0BOG,J:H>/]P5XYG2J5-5=1!XOALMN4=\+PR:Z!2ED+4C$B@K+W$X8B0"
M,YY&#;5S338C.E/:5%1#!R'L%;2E):0>LR=1&#2=$K?$,J6(Y3XIR9(+;%.G
ME):^[GF3H:6X.PA?K[2B;T79F*44$DBB@*$_[U4D/CE-F!;*)QLB;'S+JIHO
M<\Q0YO'<F3T5T45X>_4V=@M@EH%)%@+Q2I67.S,E@:$!#AFM<FV24KJV<?L@
MJ#/E2EUE=! <7S06>C6Z",CK(O)BC2-B!%>2A/L)9H]6K *OO:-)JD 8LQ:I
MG@*QRBL"0F0=N!,BU(Z?M )\IBP[G!)KQO8WA INH4,['(R)@+:Y+'V/J"+>
M94X\]\PK8\'0)8KM%(4Y6V[4EV[-[N8K1%"N)BA7P9=W$PSNA FQ("^)LSI:
MG4+.:5/;H9;F[)FIOZV :S9"OPGS7%ST9]F=)>%[L4/%@LVG1*WED5#F2Z=9
M8<L=L4<7G.,9"#Q[4]O)W0#G3,E02P$U^ZK?W%6NG;(7+B0:T(PN?TAO([$@
MBFEM1&8H E7]3O>4;G$/0HU*XJ_9H_U62G &/*YF4Y^5@_#25SPE1YSCJ:0
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M]7N!G4Y&?(L[CA9B/)6,^.LIS*_J\"0:#9LN,R574Q@3C*- =-2XG*V3.*.
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M90+_1+&_A#P:0[EN5VB7V^;Y2F,L[M61$6L,$ ^.:H$[->6U;S:K '_"3.Q
MLUVT3]YS$B47X&82)N".+0(0GEDI]9.&6 FE^R)/5CLEHJT>FZL!_)F>-37;
MQ>.Y:X5T=SH];E.TV>#B<09Q.I#$)2F(8<:Q&%VVU5. ML7VE$A613^U$\"W
ML4^75L?2M.Z8%3UOM- F>B)]D$2JG(A7D AC6J0HC YAB6MK\L$K SM'HAU=
M@15SQ2O-Y3I.U>,1 DL9C07M&0K42(+^DB;* &A*#;I.[D!$O ;U3,+*BNL@
M=7LSS%F6D>'4TY0YR;'$\X/7)"0JB;?1&9&,M:)V5MX6L Z6JG>P$[2V+DXE
MM>^:["^OKK_\WWT8([(O5[_ -Q@T^2HY695L\Y9@>3W&&4YLUL7(9-$D7 S1
MU(Y@;X?L6,E^U?FP_ AU?;UT$)5;>6MS'^_\.G,;L!VE".X$]#BI@UUH?!VI
M.E/7T3GF+'6@&"?1<#0<M=3$2V5+"UDJK1(FV-HY)B? K0=R$4^.6KMHJ4M*
MO1U^O9Q.&@FP13855\H:Y4B@Y>DBEM#FBRX0(0R5R3''9>VTQ0UP#F^F=ZC(
M=91IJ84.+CU70>-S:-E'SX76A";5]+,O(9*0"34\:J&R8KGV,]8;X#PU@NRC
MA2YVD/[0#V/?#]X.T;>\+#)HME!+O37E%56C!)I\$BD;P%,B%$W2EHZ'4-U.
M7@WE; WC"I+OHLUDZ6>?8=P\>=74@S>M$%:@G7S"CYRL_JOYHMEF+AT9RC7G
M<20[N@9!EKN>'EN[7739K3DG9Y)@/FIB1<;M6.)7P3H@%K)(N50DN.I-5$^>
MJ0]9Y:=.U%V4V@%!?QT-X>I7/_X3IF\NAVF1P<R %?N/$AY\L2A4*GVI+;&1
MY9@$#2K6OL1>C>0(#9V/IMU1==5T8+7__O'3N+%)KVX,D(4_8:W5)>/=0FF"
MX .NJ6 4FAV.EN?E#*C:]\[KT3QAXE1240>[S>\?_SGZ!N-ALPU_!IS[\N7X
MHOHN.1,,Y81RDXBT/A-KT#9V229N9$(AU/;_ML7VI(G5@?HZ\!-*-6=IC%9*
M^="K6CQRQ+7DN$<2M/I*C_SL\,A'YS9KKJP6(;'81:WL/2!/F$#M%=-!VM^K
MT;CTR)_"2BH;)X)2W)(L'2TYB9DX!HZXR"D>Q"RS7/ON=R.@)\V>6HKJ(#OO
MI1_@G.'C%X#I+^6WBTZ*IQ%T"L[12!2DDF"#>Z$K7T'43#=-ZUSM:-4Z+.<:
MKJHB^PYVEE6XYNM@&V0=19_6HSI.+*F.]K:@1 O1=V +;T"82RF:87@"TE(Y
M#DX1#SSBM]90&IG(MG93R$.3XH&PS:$YL8O$NVCL,DN96TJI6]S"X-;G<Y"$
M&5->6$@XY<1RZ6J3: :71*[>R6\#GL,;(+7TMJ)4KXK0*T99Y@^TWDZEG /R
MD4KCLB:>TU(;XR+Q4@!:.QQ"3-X UUOEMZ[Z]$>OTSIRZ^*=FA75\=<=AKC(
MD1J20D1DF45BD75$&2NDY2'QZC&.]6@>/0,J"WQM5.* ;3E>??'#SS#I#V]U
M8VCNY\5*!ZNKSAO[P>B\N48%Z2SUSTC,)# Q1D6II)8&$Y)TPBK'.+HF]('^
M&?L!JI1#\TO?A_Y@[@\WX-*[X8?B<Y4'!)KJW]^'HS!!_[VX6TVR1^FBCK &
M?3_7S3R%&Z*3* &+AQT>>])J0UQ.C)C(P4ATJIG6E3>F+N;114[DO_K3+_?&
MG]P%,+D+=S&CJUFY V7"2S0JB%9X*$GM+'&\A"F8-LEXF2-TEOI6<R)'S(DZ
M%M>W2<<\+$&ZS,K;<5)KYE0*O$L5[=MA'%SB5OMVN.B5U7/,^!1*_JLJ[3F]
M<,1*CM\FFX.R:)S)SLH=NI[<\^HX42(=*'>^_3;@-5K!F@H2H\1M0 B/HM>"
ME$Z3Z(U2D%#[L> #G!-'M7!F@68J>;+4!=Q0HRSUABA82Q5*-VJ?F M0O7=J
M[3D<JO+O=/>48Y#AD543^B2YAFR)4!KEC+X-<0D]:<A<4>:,TZ)VMN!I5Q,>
MESS[E1[NHL2CEX5M _:Y]+"FQEO5A^VCKJ-SS$7N,QX?Z!A%3J0LSQH)PW#A
M<6:HTRGE0[C/C[+T\'#4VD5+!RH]%(LT$32J?<H>YV\M.@N6$A^I)=D(*9SU
M7LO.CL7[<$Z^LFP716Y16;:/%KH,<KR\NO967@W\9/9NB.:@K&N:=BM='J**
MQ/J "+W%8YU%GI9[&M6TG.X#>C:8JJJL@X33BI):GMY\(6XSP:YMJZXF=W1[
MK"VANO-2*[*ARW.VLXER3QE-(1 :/9X3(BOBN1 $E("0(-K071WXXZ+[]B;B
MHV/[+B2HR/)9I[/1L+RW7IX8\^/AZ')ZC7#QRHO,P<J HG.EI;+D@H2F #]Z
M"98:X_Q2KMZZOG,/C/2HKQ1J:';4E5K6&IA5<SV:UX*N,P&N7Z[K#_-H?-$(
M:=%H;93?CT=HITVO_#"5U+2OY1=_@VF+%(^*HU?([.A*%DL)'9YSD &"T(9*
M39WCQH(*(DBG7*:^5Q%'NY-T\>'O!WXX?7%KA)NXN3"X(_O$"5/!$&F0S%;;
M1(),SJML<E"U(Q\/HVIK0:P=H6G$W(M46%7>S$I:)O05G2+H+R02+3 E*(\\
MUWY?8#.BPV_"E9FQ?'I75$ 7KR#>=.9^#5_'$&>G"7X]@$;LPS3O9MO\?.UD
M>L)YRFG"X\66XX"9,$O],S%$[K+B]3/J:V$_.\H=1:D=>#]K@>&IT&/19Q Y
M$6.-*[FF0%P4AN3@DPXL\YQKO]>]"<_9D:B:\#N(!MTTS%V+<A8/XXHZ6FH4
MO2QNEW>9!)$<$0SME(1&B[&U8]';8CM4BD''-.E$%:>2"+!V2B^O2B'NK,]-
M<D;%4L+"2\,'E!EZ6.5U2VX%.)MTY >SH&Y@'2NBW0T=MMV:]E3+(8^N G#1
M06L+B!U%G+> =YR8<775;DN=EGHY$H5BUL7/#D1H*"7YU!*K8FSZC7KTQLL;
MR.="G0?BKZ? G%W443N.^HL/I77#:'QUC6P>J4M A3=HMH.DO&3OHCV?'7J<
M7LC@>#1R.1]S30!U[1 G9/SNJXU1=5%VX*W_ GX"7T:#]/;BZWCT#6[7WME(
M!:5>EQ9 IO3;R\3*[!&IR5)HD9VN;>IN@',^C*@M^_KW)Q=?+Z<POIYO:2(S
MRM.__!@6N2 Y O,<X449<>]S%*<-GC!!=;19N@!;/B'UX%CGH_<NA-M%8L3E
M&"5\.09$]J;_O7RU8*4,S++L2T!1XY%7@HS.,TY,9M%J'ZS7U<M_UJ(Y'V)4
MEGPG_;::*MA8Y/NVA/<^([3K&FU%50C"(AB;\0A#;)8;3D#'1+-$TB99F16;
M\)P?+ZI)?VT/K;JWIB@,7ZYZFP-N\IL?EV^_09NKT <^LL;]YBZHERXMI>9*
M.,EC5@[/ZN1IR$XF!B5K5P#T'OKPMD;<9 +0?/1KF,1Q_^O=\AV64E:X9Q"M
ME"0R\1(CB8HHRAGCW$<=:M>E/0"IO=E:/OZN5$L#B7>Y9!F,?9SV9-),2UP7
M,@96#&M)+#.*2..<<B8:)FJ?50^C.OS>5),;]PW8JEKHQ+VYC_ ##.$O/RA
M>S31XG]I(ITN.<TLD"#1Z!+<@$I6*ZC>GOT!2.?/D'WE7SV\L0+;;Y=%5N_R
M'..[1A03A"DEC3(1B@XYD6 E"8I2HKT'/,F]-89NY>YL/^9Y\*!+05=T?1J8
MGV"(YMLM7_P#]"_"Y7@R<\Q[ ;PW*5HBHDU$9E/ZMR='.!KB,ELA57[0CMEF
MH#/2?$V15O1J5F-[,1B,_BKMK7HR<@<NHI]E>2HU#Y;XDJ3@?6::4BE#EOMI
M^GJ,<U;R?H*LV-_W 5B_3_N#\I9V+P=MH["4.!40G@J.6",R'D%4H$OEO/5[
MKNA[8ST)?>\EV/MZ5W6LON6ISVZ),QXB4@A'M$WE+4?'R]OIE("0$(.E&LW2
M@_A"!TW9Z-[&:R_M4TG1:&:R<& N9X9J<]?'E4\F!$ZH3Q2%)"CZ,A:I37E(
MY4TBZ6JWE5^'Y5C)&-5TO>HJI*W,.[@Q7X5K40>Q!;*.<BW6HSI.BD4=[6U!
MB1:B/RPYHI;1@_0$%.?E%4Z#-@^+Q"B9(6GG0_60^*%)\4#RQ*$YL8O$ZU^8
MSA^Y^-_@TW]=^O$4QHOPO#/>^\@L89PY-($IGJP!G1TM4 X@E+.>;V5C;ACD
M&,9E'46,.I!B[=;>+P;^ I*?(PD!&,OE[65G\8\(@82('HX1SK@44K!^NU#0
MG8\]#PWN+ZFU*[+JQ=3'Z2C^61(ND%CECFYZ]1H_-_:GY8VCT;#YZP]02B(A
MY='XS66Y@7T[F5P6YZ;%[565<2M<<=6?_](]6!;:<\F%]3I*CKN\ JL=BP V
M\0"V5P5!RZOL4LOZ+C=#W3A AAGMLDZDU)HB8T,DGHF2L$XI+^DV2==.>UP)
MI,8S:G,YOO)?^U,_^/C%CV&R$.J;9:'V)%<N>F.)-.6&)GM*?/'_H@N.4QL5
MK]YS;F>0A]\>V[-DU3MJW6FF@[NSF\3[!O3+617XS-?3R3B:<5M'"+*\62^(
MY]H0:U@T*1L:>.W:O UP#A5%J4^*6C(^E=C)B[_\.%TG1WMI.0W "0\1":R$
M),Y(1K)G-@./RJO: 9,[ (Y?LM)2J\M5F'M+MY-74G#W>HE&9"HIC2B2V8-/
MXW%Y4:&YWGEY=?,[[_U5$RHN,[B9QC"5E*G?T&I<]#?<8DX=!56ZF,]QPC$M
M:'+O8983T?%CX:])$&@I8!7413RR\52PV65",WCN1+1*U7\?Z+'P]H&(T8G3
M=A?5=I"1O[ =WU^.XQ>$_>+S&.!6'8GV,:84%:'!!2*UU\1:$8@6Y6$* QKH
M=G&)A\<ZO#5^?(6.NM-&!Z;[SQ=?!Z,K@ ;C++=F#HQQKYR*IH1B$I&"*>(<
M8[C*( GG8K"^=B?]M6">,(_J*JJ#T_'F7;X&VN^HF<F'C[\OJA&$RX)'='2$
M+N7]Y::?44X$<Y+QR"2SM5^;V@CHF4D5%58[K^[6=OG[,,TJGV:U$HOHOO=9
M)F8L,AP<GO4&2&!"$)&2TR8)FWC:]>Q:/=03)DH'NNB@T.C.AKC8"IUE@.XR
MT<F6=UVI)"'A5NASDKI((JG:O9U7P'C"U*FEG-HI?O<Z2MZB]QR>2D$)$<L3
M]4W]@01B%<=],&MO,\[8Q&VO7Q\:ZPD3I MM=) 7. N^WQ)5F?IBW^/>.J84
M41Q=39G1U?3H:B+(D%VBEB9>>Y/9 .<)<ZFVLN[S2!_I:OF>L]CQE?+:\0YT
ME;S=?)>ND)U+QI94#PE)\D0#BPY/%@7.91NXV.H*>>W(75P=)\IDC%F5TH50
M\AX]\=*73/?L0(L4*=2^"ZMZ==QLWA_]]77%K_Y[_^+RXL7%Z!)7^.7TRVC<
M)'5[ZF/V/I$@():TD$B"1-\4'5(=C,X6DMOJ*'UXK%.Y[]U%M7?.PLKBK)W2
M= O>K%[S>J'T@M.*Z?+@4&(482E)/ 1+4K#&VBQD6HY@/ZSEI3'.2;MMQ%<[
M2GP+UJ*\;I9B4#(*RNNKG_ PG_BFC< GU-VD[*(](8%QT)$XCVY>DV40?&DY
MHBUUPC.A[7;.]U[#GQ,7.A)Z[7C,+<0/(WT/XUAX;;UP,8GR[J<513Z:6*,E
MX2;%C*Y>RGGGS7_KT<^))-V(O'9QY"W K_N36(ZN#WX*<VC^,_1*28>FH-#;
MSX9(FAT)+CD2/4./#BS7:KL:R0>'.B?M5Q!F[2#*;71H(U\A)1.Z\7^,!I<7
M\.(;_JCDK;P9C1=&]7VBJL"3+I==JB3ZEI1?JR@0].F3"W@0FKCS";(?E+.B
M2O?*J!AB68E^9O-^&KV$CXCPYO2CE*; :2 )2GDH>(9[G"DMHB-5+&7*XW9W
MU5L.>':TJ"'8M7&1%O&U'6RAGO:4ZA(!#*53LZ2E+%QYAUB]-LK**)8O?=H'
MW'; ]Y@YT[D^[G/'5-LX1O&R>%+OQ_#5CYO WQN 28_R!#Q;11CCKG3W1L?*
M.4L,Y=2S)$-<SCC>8L]8/=9C5GT7XKRO;5M+VXM<]U>CR732$R$SG4P@G!FT
M>$.R)6M&$9#X'P7.2K6SCN^,<$Z:W5]T]_7I*N[\I5EA/\&,:Q\@0O];>7KN
M]E;#72I]3#-1O&1'<5&Z/CD@46G%35!*5>]'MQ/ QTR3[C6R(FS5::V)<E(S
MD&C4)(\'DRYADHC?*F\5>L$BLUC[$;63K35IQ8A*,CZ56I/KI_]FMT#EJG T
M+!>5LS)SB6=8-I%(P_7LM7*G B5<*1VE%)!-]4SL38!.L19E)ZW?NYZM)?T.
MLA>7,"W:1FP!JJ/BDI6 CE,=4E%QR^E!U:1^.$J 85XK1JP4: 8;JDJT1)-(
MM1)&6.%C[>+7 U+A@8*+@S-A!V%WP(#[Z4@E[550"L1X_$/*A$X0#YPXED"8
M\M0"0&7MGT#66 7EK"]MWD.R790N7P:T>/M^?'7+#&Y8[81'8Q9MIQPC)S*F
M@BE;XH**RFI;LNMKFP7KP)R=25!%ZAV\:'$[#N8O\,M;KL^<_ML@[*KP]$%T
M1S(4ZJAS0TRRHBZZ*!!]&*FQB8K !(&H<+48C>Y84/AM5I0G*KVRM5^,/19;
M'K(ECD66751PA+),)9QRUAH2*$-3JN3(>R\-X4FE4F&1-5]BR&,JRZRLGAV+
M+'>1;0=&QJ_@)Y?C!M#;X=?+Z77ILLU:>RV ,*T2&C^(T"7+B Y"9^J85*ZV
M6;D.R[F9&%5DWD'9TBI<B[<_MT#6D66Q'M5Q+(HZVMN"$BU$WX$AL0$AND?4
MLA!)UAYF70YLZ;='$\=5HE,(K':4\M"D>,!P.#0G=I'X ;AP.R%L<:Q)'P3P
M1!1:3F@P>4W0,0?B13).L)SK&Y4/HSJ\<5%+AP]0HZ4"UMH5AZHN6JJY6_QM
M%X5%&X?JMJ9H^UDNE1-1B]N%],E1M#%D#%:A0:I *=Q5LF)A4SG1QD';;0,O
M+R?](4PF+R)^Z*21U<UX=^YK;^[^J,C!>%T>@BU1631R21#*D^"#UE:GF'3M
M;FI[P&SE4'V ;Z@&7!AQUB&Q_]]^PY@SA<PRFGHJYR!5R(1J;G!/T):$LH8I
MH(M)A0+.M\M'WA_#X??(KFETQR,[D')JUSKM WN1+5?\6?1D)CT7.>-,"L)5
M>8[9(/; J224.2ZE*5W,MZN*JH'FF6=U%58[++3_0GD/X_D,>B*ED',VQ$?C
M2T*7(,[@MRH&&944*<-V!3<UT#PSKJ[":I=T[3.!N56#,^B/9CV#WH_[$3Z-
M^Y\_EX[[TG&>8R)",32"E:/H?ADH)K>(1II Y79O8]7']LS&+I59NY2L]72N
MRQOFQ3"O_=6DYX-$HR$&XHHQ(;- 'RTI23(7@><DC%CN8]<5/5?!>V9HQRJM
M7017;T;E%R%>EL>];T\./2N(F@F2H\?):1E):>)'N N:>W JT>UJY+I&^DS=
MPRFZ=OW=/I-KGF%F7$NNK2(9<-7)$"WQ/F6B7#9""P'<Z,[8>9Q7KT^>=3LK
MIF)!W_Z@%ZOC7?X/\./)F]'XU9?206K^)/QHT$LT1\D"FB$2<(&$LD"B\T09
MXW2T5!K=G6/S,+YG)G:MU-K%@[M-Z8WOC__P@TOH(5SI$E>$>E,Z74(B7KCR
M)!V =8922[>K-ML3P#/36JNE8F7BLHQ>C2Y"?[@)\B]]'_H#7!\]Z610G);7
MZ<I]E/&*6(=_ #A-HV$E!:JCR/P.,,^7;X?270>%DVOP->DR_=R']&)^*W6]
M0,J%Y6!4[C![RG*KO407*<M$)*= O#.<4)? *A 44NT2^C9XSY^ !]-F%S68
MVZ^>VUU!9Y; V^&L)<7,(MBTX%@O2FFUXT!XAM*\TS%B@V(D2F6C1?/6V-IO
MXQYH:N=/\%/DR(JUT#[W^SI_<86$)R^O'I;W+->1I^BDY(8$*U+IQI.)"\(1
M$'CL!%>:9%>O=*\#_5!USH=F\#$T>RH5TVLF]/+J.NF.)]#2VK+D!/IQJB17
MQR0(& "NO')9UZZU?Q#4\7.8#\B4[0R*/37625'EZIG?).MM ["C_.<'P1TG
M#;JR4K>C3$N-'(4Z@2F/WKXEP$O[>.Y*3:H)Z*5)D-8;9ZOW<#@291Y(DCXV
M8W911/TBJ]7H9FD7[X:+K%VNLK*E Y+33A.I*26!^4!\\A*%8+)BVSXBM-6
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M'4 ]%7L0/FBF_7,\FDQZSD5JR^VBB+$\2"!RZ6ZL2#39)2FB!=U%KZ[UB)X
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M,U9-X,FQ_7CJ7T'FUO>S2T[,W>NV6U':CY?A/R%./XUNGJ%[-WY5FN<.!HT
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M?;<Z<!KS:H3D"I\1EIX[&1;J VN^/*7- XLE.RU!&A5L)UO1X69GHO1!9#M
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MBJQQ I8"DD.@A72\T^C GZ@O9P1M[^K6V4?J1^N_Z +R%^[6V4N'!S5B'**
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M^NKFQ>;5@P6[;S_\ZL?U(\(<__F/_P-02P,$%     @ _8"I5@/&TW?ZXP
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M$$N9\8A$4E&G[+LNG4^-N-:1$ >)#M=JO-RMT^K< :V'33Z=ZT?H/!D.C?O
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MFW@JK:W'LFA##H:O FF#R#ANJ;0A83XHFC9H9]>D"M[=6Y3; HJIXJ$0)N"
M*;TFF&@PS%(*"8_2..%$<";=LP6?ZFYJY+ZW8W8L'' !6CM2]@?8;8Y\2O#S
M(&4C[7#QFBKX9&<WR!9\2?'C"8,OON4SW?B'35Y8&B22A2B B)N2(_JO$)-,
M0,ZSF$<T9FGJY$%ZH;^IL<BY]-D?^B;MO82Y"[MX07(D>ND+HJ=$Y ?0#)J,
M_,-M<MQ:JFZ7E/SPM1YGDC_)XKLL]!ZZ+5+Y^?WGM^_R!5UP369UQ4J]V5X5
MA12O5I7>9_]#5N9,=$8X3D5(0BBR#)O,8R:F!J<0\XP1'@0IBF+K<\J>0DR-
MCAHUZJ/*HE$$&$V 6JL"N-'%'&TV"5'U9I;R^IJR!$_TI:X49-Y>'WK*)C+*
MTCJZ:CPM#D!'&*7!K_0W _2E.T ;+4"M!ECK ;0B]:F>5J6^PAEA(!Q.4$<8
MD)%.58<;&+?CUBL1/7L$V[?M\8YEK]1^YZCVVK;ZV<OKSFA1O;3>BC@(LS0T
M9?@RD>J%*L@@2Q&& E.1RCB->.I4+>.PBZDM0YL99$3LZ?EY!$@[N_<Z> ;F
M?T=DG"W;T\I[,F:/=#"J_7I:P7V3]<R3_:;V9SV2'_78UOF@(Q8CP;($AB(A
M$$FA(-4&%4PCA!0V$SX-7"9UM_&I36<C&S#"]<JMO0.;W13N"\; D]<:!^=I
M>TQA3Q-VI^E1I^HQI?8GZ=%G>I8U>:;YW&Q@WBT+DW9MF\/_C635]E\S3BA*
MD @@8RF#*,@(9$C&4*4LB6,<R21S2J%OV_'4IO7;LLH?Z]7H'<T+\#<Z7SFZ
M95M#;C?MAP!R8$HP@G4JC=R!C0Y0+0MHM/!81<01'U^%0FR[';<6B",8!^4^
M7-^_+B=PDP%>_^-B%LA9%B&*LD!"&G(*4:(BO7/ $0P3AK,D"ZA"]H')O428
M&E-MT^>7W?S .PF!>V7,[S= %B=5@\,^,*_MI9]M!\#\P"X1[>!CT"\C\#!C
M<9N4P/[&I'=.8'<X;9,".[1\DZS [IJ?2@O<HR4_,8HFZ1G7UM^;_#D7<B$Z
ML70R0D$4(@4YRA!$7.]P,=&;6VTE\TBF&2.QDX5LW_745IZMC2Q:6<%++FWY
MK0?T=I;R,( .?O=Q$,ZXEANL!1\KKO$R8 /%-Y[I^*9QCI<!N13O:-'"%1[1
MK\ZXUI6M;]VK?=^Z3_4M=:DM?"7S:F7X=?%9%OE2_%T:5SLI[I]E0;_+M[_)
M@N>E_%SD7,Y0(,*,(0P3DG)S0)!!S,(8"A'B.(D4B6*KJARW4F!J)-J*+QLK
M72SG<UHT-7=JB[V/&_68GX,=)4]YD(?>+%@X7Y<7O*];$.Y !P;CG=  <0?6
M4( 6"[ & ]1H>';.OL$X^O3;'E/\\5VZ;S X1[V];R%'7R=.+89)?F22[:WH
MW*0Z:N]42< R%":1_I+,89,*M:G/$@$II9A'F :$645[7NYJ:JM2+2GHB-ID
MY^YW6WT&8;OEPP]N Q-]7\AZ.&A>0L.;;^;)CD9VR[RD\*%'YL4W>B8Q>WR:
M+U^D_"J+9TT]QZGNXW)AXN)D$[Y2UG7NN[\W_C6-3\T7R9??%_E_2[%MJ7GI
M4_4@BV\/=-%RXHQ2$F0BT(9VP&-M=Z<"$FXR<O*,HRS5WV3@%*1X,TVF1G5&
MASIV_476\>NM&G= UM7-C7?;LI'<,3O;S3X5.U+]77P (QKG&YM[:ZC<@8W^
M:U/\[>:C:+2YJUT?:V='\_U\Z7P_3=%[C_GJ;CU@OG+BW4R/<?/NW7JX#G+[
MW5R@ZUS+6I,QBV,LF0PAPR*$2# ),>4$LBR@B#-,9>9T +7;_-16IXY;52_;
M>P\\NZ6A/R0#\[4#&KW=S 8QI?<:OXFKV7F3^<13_H*K-XF;UCGNOTC3DS#W
M>^_RDM.Y2>(T(TF41%E&(0MCI.U<@2%)A(()2SBB2G"LK!+S72_*U*C W G?
M ;4L@.97;:FV(AO/#_,#DY3^^CAMRU&RW;>/@?W@^WJW+')?N@/3:%3GE!LV
M!-P-U@'#PRT%N7GHN!M@-F'ECBWVO.^K:%7O33ZIU[1\>#=?_EHZUL,YU\2$
MYMU&3#./C*"@EG200C<VD/BZ@SC7U;CW!19*'YSMV[SC]F4+F<_>+BH];^Z%
MT!]06??QJ?A<+)]SK<@L1:D,38F A*4$HB1*(<91 &5&$YQR14)FY7!SJ:.I
MK?>-K* 5]@[4XFI(P5I@N]7^(K[G6<,G:@,S1G_ K G#%HTC9%%*_J?OR^<?
M=1,-3^B_;.GA8L.C4(.M>FM:L'Z^WV)G0B_JR(O:AZ;\8(J2AJTO&%4AP6F6
M0)K6%:JB$!+!*.2)2A%#,5:14VZ5,WU-C1AJV4#H9NR?P]+.;O"$T, DL W7
MN6L<Z4J3.Z4&; #7.0M,/-D-YWH:U6RP4'G?:K!YY<K[N&I;&Y9G$LDH%C E
M2C.#S")((\9@RD44R90GFB)ZW915O:K(CF(JM"(V[N\][ZDZ$#K>(/4#9FAK
M8 >3 >;^&?5]WY14(Q?GM5#QY.W"D4=[%NLUUPCF[J&0#W)1YL^R22S\85F6
M'Z7>@7RCOS7>0?KG19-]J?GO9D,L(\J0U+N&E'.3V9>$D(D8PT#2,&1,2HZ=
M#A.O%VEJS%%K!'A7)3#7VCA6[;U^J.PH9]P!&)BA&NQWM%GG+?_!*/3'.Z!U
M,L<?6JMA"OQZ@]-7V=_K!1JW&+ W  ]*!/MK>>1<Z^VM[R=MZ55T87PE]KPW
MFW/1.M'0CH=6-).9H@+C ,8HS,S=+H88(P0)R1(<I1FCRLETNX$.DR/XK0J
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M5G^?7NQ?[$<Y'V5E/'OJ&WPAQ:N7OY8FY\[&U>V>5_ESD[@0HSA%' 4PC++
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M.5775:E=$_*UZ+Y#U\\-BQWA#@OVP 1[(91]H\303HG]01PVNOV< %.(<K<
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MC44J@#@BD@O&@SBP.JFRZ&MJ+-:("C:R@K6PO<)XSH%L9])X@FY@PNN-6I]
MP4MX^ L-/-G3V,& EU0^$OYW\95^M%&7[#&N585\D'H'\"R;OCXLRX,;K.W=
MUC?ZVTQPE604QQ"KA$#$ P&Q2#,8T%#A2!&NS2074NDMR=0HYZ^+0IH<'5*
M[S1? #UK\KH.4AUN[D8X_8?'CHY& 7U@LOKT^OT=L+@NOP-_,</Q@]'MCW>
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MY[)XO2JKY:.>;G7\M$"<,9*&D.C=%421D)"$QNN5IX$V4V),L)4E>+SYJ3'
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M:*7)CDEH]T8_0[ -A_M,B^KE6T$7I4E UBWDB*60)$X3F&8BA"C (<013Z!
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MDXL=CISRQ!: PZ0GUF_VJ*Z3+_+'U=J CS/C$QP+&*@TA2B.(FW3* Y)C..
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M3%VVS4=[F9J5VPH)9"-E:6X'^'Q54\!3^SLCM^-5P7&$[;C@:MP&IH,U9*V
M=Z 5T6-"^W,(^$I@?[2/<1/6GU/S($']V8=[)*0_>O5@"G/D\U4EQ=O/7S>>
M@BK%6&0IA3$*&40"*ZCY(*PM@BR44<"QU8&:8[]3XXK#.S*'].0.<%_8"P\'
MXJWN&)LB/8WH0,MNX[]Y%<(.J=Z'07JDI.[6B'M*V.X.UMG4[ [-C9>$W5W'
MG73K/5Z?6I;;=\M"R;PRY8KWZJ77&0O?T$IN FAF:4 18GI/GG <0*1D!K%(
M$ QE$L4J2A.4.D6F3$.MJ2U-K>Q2^"MU?'.,;YY#=Z@/8NCM^F@9=CL W8$U
M1*#%J,F_"PQ*8!O.^7M(PMMGW">?HM=)J7^2!+Y]!G*\]+Z]I.OK$J:E>[U<
MU';%BLY-7;,Z<61$"(V".()QH/3.#D<24B0I3*0,>"Q-DJK(S?/K>$=36R]K
M.4%'4%"7Y^N3G/,DMG;+EP_$!EY0^H'5PU7K/!+>/+).=#.RX]5Y90_]JRX\
MW[<0>IT 3[>9/TO-.'1]5*D"E":!"&"F&(6(2@X9%P2FR#A I#C$J94+Q*6.
MID8,C:R@(ZRQ8.C%,TXW=,]3@T_,AC[2Z0E7CY+JY[&XHKSZB89'+K5^7KW#
MLNL7GN]Y9D#GZ^IN34EW_8\Z4J*I#_=^\4U;)J7I=;F8!4+@E&B+0:) 0,1(
M JG$',HLPW&,@Q!G3LGO7#J?&FTT C<%E(W((&\**?8O5.,R$I8;Y8'P'7H[
MJ\4VP-:"WX$MTHWPZY*5&NB._!ZWF3U0\[49=.EZW"U;#U .-E9]VNA):_Q!
MBI7I[G.Q?))%]?)9?V+5_:+>I-4UZ+_5Z2;U$! 5BQBF7.CM$$(!9)E"," B
MB&3*TR1T\ARW[7AJ=+:6]@[4\M:W!1N)P<^US([;).LQL"2S 9 =_-[\&E#=
MB<L1(5^D9=OMN(3E",8!6;F^?_-BN-L4 SPB22B2&!K74HA,P# S"<)228E*
M(QYG@5-]A"&$G!H!?ET]/M+BQ9@9KQ_,25]=1ZY30%7_XH-\UD,8@W?Y@FJ5
MZ+Q[7GZS:KBNJ25N/9H#DVXWD61'PW5220%,P,]^KLC#!)-[^25;MAXFA?N0
M(S*]2KDWRJ0Q),@#UL/UE;GCI^5"OOQ$BU]D]6ZU$&5;T(6+@ 0R5A 3D^,'
M"P)Q@A D 4LD$CQDH5/EKN/=3(WL:RG!8RTF4$9.QXHYQ\&TX]_K(1J801MT
M&@E!+>(0%6_.HN"KNLWQ3L:M9'-6T8.J->>?[IM4KZ+Y0HJU)]*Z!&B:R@ )
M"E&B-\!(*LT"2FFK$8<B3;B,0S<S\7@W4YO[]YRO'E=SDW,<O)$JY[GE&?\%
M-.TF__48#3SYUP*"C2?A$'4]SX'@+67?T4Y&3N!W3M'#='YGG^Z9L>OQ:;Y\
MD?*K-C%R+H\[-WQ<+IYE:=P1C!]#6<?N=7__>EE6'Y?5/V1MG'Q?Y/_=EAEM
M'1MF64*5(H&"84:U&1%%%+(DE9!E,J!A'$9(.5')*%)/C9F,O&"QK,"+7G>+
MC<AW8-G(ZYB[:I2!MV.]R0WGT#<8QQSMM@Y$=V"CZ]K_KM'A#M3?P,?V&_C2
M^0;N'TVHLL?<7&,.B:]<7Z/(/&[NL#&'X2 7V:B=]UN_WN3/N9#:$GY=Y_>K
M6WY-RP>3\R<.,FX6&KW:H% DD,8T@RB-)9-A*B1&+DO.J8XFMTIHF8!8"PN$
MY'-JCK7,Y<)3G56KFPG1;<TX";8=S?N <&!FWHAHJ+:&J;UE-G+Z8]=+2'@B
MQ)/=C,IAEY3=IYV+S_>(;>SMM'N_6*SH?%WZ[?WB?E4]+(N:Q.J[Z6U9AEE&
M:)K0(( DC!E$,8H@,85>0Y7*E#/,XM0J:>)8 D^-N1K)0;ZNAY@O -T(WSK-
MW)D0EDM526XS_.<Y<(J#.J*5VS/LI/TD-B4RW^N7MY_$U_:3L"A4<YM/PB&J
M=&*?QDCAJ%/Z1-P"6T<<K[,1L6/(,5XH[8BH[L3@CMGO50$[935CB!&$2 K3
M6.CM#!((D@ASJ/\EN5!<ZNV-2ZZP3<M.]L!H*<+F]:SF6KY>43BE;9*57C ,
MO(*VV9%?GU.^;U1-Z3M_RK;=6\3-E"?SI!P^T#?!\&8WTE[I)$F*E"(1Q F7
M$(4J@<1$R"0,Q1BE2"3,J?;-00]3L]"[6V+7Q,'[X-G-RJL@&7AV=M$8X!;L
MI.K>\@'OMS]R%N 3ZAWF_CWUX+6^WU;GF_?S>JCTWSZI[0EF4X[:L$JY]:\+
M.<_"* R@0C&!*$L32%%&8)#(5*9*A(EPNN4:3-*I\<K%^Y VR55SBOF:/N7:
M,K"Z]QCY"[ CM4F,ZZVON"X-Z: >E8./@'??>=]RWLC9?B"X3WOG#]5AO[5G
M'=?T13XMBSI3ZE?YO78/GQ&JUXJ,:A,R51PBHO=V3 095)&V*0E1.(N=$B^<
M[FIJ[+\-X"LVLH*R%=:-V<_@:T?-?E ;F%NW@&W%!%\O >9,DI>Q\,1R9SH:
ME:8N*[S/,Q9O7'G<4R^"6P,C3GF49"B%-,6IWG(R C&.% QBE651*C/$DA[I
M6?;[F1I%V!R$..'H>";4'YWQ3H@&-9@N(.'["&FOE]L<*!U7]>3QTHG'^]:(
MH%53@6).R[*-BJZ3".$H"L,LB&& N&: %"/(HI3!1!$A.4D%H4Y^+2=[FAH'
MU/)MXOY[968ZC:KEQLT'5D.?2CG!U",+_P4(O"7C/]7/R#GY+ZA[F)K_T@O]
M".'5JLP7LC0^,2Q?M)YU"U-9S_2U7)2YD$UYK$V1O1E-D R92B"/$8*(Q11B
MDL:0\3!&"H4I$4[Y6'K(,#D2V<@+>%?@.S!?B^Q&*7W&Q8YL!D9[8!I:2P\Z
MXM^!#ORO=^'_<!%^9ZJZ D!/)-9'@E'I[0J(]HGOFJ:NM)&:-"$LC",I"(>,
MZ?T12M( ,B(3&"N)& M8@F/<RS":9$*6C70]DZ_L8N=H_DPMD8H]&/WMG4%2
MH^PV?AO+YGR:D^-/];Q!I^6#^;_)D/),_W_NWG7);1Q+%WT51,R..=410F\2
M $G@]*_TK;<CJFT?V]43$_5#@:M3T[*4(RJSRO/T!^!%EY1$ 13(I/?$M"N=
M)HFUOD5^6 #69>FV2>Y6ZLO]>K-UU2O?5XD$]6Z=PHDT*5'0)*[A)M(&<L(Y
M-%)0QE214AVTS^$_]-0^="?U#$@7U:_WPL^J8Y/2R0^WKO;J8J]!X,F\OU$\
MC^P'@7KH55.%<I4[\?8YRI7HL*IP^]X#Y?"#_F# 8D4 ^ \\;FA ," G,0/A
M3YA:3XU_5DE5[U?U*=3UW@B42R*H5E#CJE('S2%3]@^%F$D%XX76$VFK$:C9
MU BY%K]B!OVGWLA%Z:;&&=#V%VL#ZJZ4$^^Z$?IR>?J'4Y%W0A/+>+TWFO?2
MOG<U2O\W->#H:?_)]^ (U>O_DC8</<TY7B>.O@+V/>PM2ZT_/E3[(ZMOU8G2
M9[W2?]15_><X(885!7&-%C-(2*(AHWD"BY0;KJC"(@N:VJ^,-[4)M^XVL:D%
M!&ZU$WH&W VO[UEP-- &/Q-VDKJ:$8VLH#DE;L2MFG7$/!KV B;:$7'W:",?
M%7NI?GID['=;> >/-TW:WO_WR#?V0UG^J -3YMQ@5!0)A5AH2R.4""B$P;!
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MJR#0_(O^M%E(/2]RRHA*,4P8IY#PW!*0X@A*Q"1FF38F[)QU)+FG1F7GZ_(
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M\&45Z3<,WD9;>!%+H,YX!HEVK2L4$5 90;G] )+,!#==C8OV\'U2W]8O]+!
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M]  @7^P>/<18O2,1U]]=UX F8N>57FFSV,Z+E!!N*(6X( *2 G$H7.=HE\B
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M[<ZTY]9YY,04"AK!"219HB%%/(%YHAE%.!>&!.5>=0\W-=H_:?=X>NC?N][
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M^! F5#!!$U@H:5?0C"DH*#<PIQ1E>:8R*71H$+W_\)/CUKWTU9=[)']X6'J
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M^.Y:5*J;W)= D_D>00UEB,&/IZYX*2X"L#;37OZ8AU=]<(MVL!4T^,B'7GV
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M!JDH>4GO2'QS\OA1*>.2<L^_^HO7]0C&//80JXIQ6I5M2;EYFDHEJ,B@IH)
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MZV_1M"@*IHB20;G/L02;&D&T(H-M);,[LRT/I.ZU 7:[]8(VSD:UR3@;;BY
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M2P(*P1P3C>U[PG#B%?'J-=K4R.#M43H[6.Z+W;M"(_;];QN0/+A2?;ZI57[
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MK*]7<!P497=YJ*GQ4K4QU@I[P];816A]-\-B #;\]M<.J8&WNZZA$6V#Z^)
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MA4?A$=.I3QC79F/5)HPD];3J$L8U17!-PLC#]VT^(-U);MM!"B<"4^8\F)1
MDN?6H9&:09DD1F:88T.":G<?/7UJ*YQ&N-#. (=X^?%X;Q0&9MM&K@&*;I_5
M.%K=_L-GCUR<_XQ:IQ7XSUW4(T+B'_R'4]YMQ[6?IV$RY0I#D2(*"2?V\\28
M0H.IP(E*DMPOF/C\XZ?V?5H!:Y??B1AP:'V*FT?DP$UH#/R='@'1)P_J%)&
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M@QRB6Y\+K! ]-SE6_[#O@N^T+;_??A?KC[OU6G.I;C9">=2Z4N40CD9Y2H.
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MK-B@9&\^^A#P93(NCC.NF>A3]\PT]-[@D.SU]?:FSK6)>":5(Q+ @!'ECO
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M;/P"RVF:)"=-S!8HLG848]?V!\%G8(ZK'&+DQ)L;&#AK0L:=[?,4L-E?WAV
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MM+*J!-O:#7N$G'%O^H9"4VL]C&UO7LY/OYS19UW)I]:BS\OJ+Y+R9<U&22A
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M8< (N!D>#A/G,TFF6Z</OFE3X[O;)P_AD>[$Q3 ^J5"25%_'8^5ZBV^%9(#
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MHQ1\>C%=?GM'J3AIBBFGK(-:5@3*6@&Q]EUAM,'$)*1-W<PXW)VM,WTZ:VA
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M'=.%G"L:9:P6R5J]DS-Z^EL[04:?%62&D'('KNC(_.;WF])HIC.E,^A!HBA
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M:I?TZW5T,%'"<2REFH^JUB0-4!:#D)!+JV0JTCS9AM*.G)V0:,\2B:=7U]@
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M9A]TEJUH&G>JP9"N=!2M#=\YOOF#^DL,"_P__^O_ U!+ 0(4 Q0    ( /R
MJ58W]$L1L@@  #(L   5              "  0    !A,C R,S S,S$Q,'%E
M>#,Q,2YH=&U02P$"% ,4    " #\@*E6BXD7T\T(  !C+   %0
M    @ 'E"   83(P,C,P,S,Q,3!Q97@S,3(N:'1M4$L! A0#%     @ _("I
M5CB:940@!0  XA4  !4              ( !Y1$  &$R,#(S,#,S,3$P<65X
M,S(Q+FAT;5!+ 0(4 Q0    ( /R J5:E "C\/@4  #$6   5
M  "  3@7  !A,C R,S S,S$Q,'%E>#,R,BYH=&U02P$"% ,4    " #\@*E6
M\YR1O(8U   A,@$ '@              @ &I'   <V5N=&DM96UP;&]Y;65N
M=&%G<F5E;65N=&LN:'1M4$L! A0#%     @ _("I5HM[?B%,0@, D44> !$
M             ( !:U(  '-N=&DM,C R,S S,S$N:'1M4$L! A0#%     @
M_("I5D-'D5$2$P  4-   !$              ( !YI0# '-N=&DM,C R,S S
M,S$N>'-D4$L! A0#%     @ _("I5N=3H*@)&@  _0 ! !4
M ( !)Z@# '-N=&DM,C R,S S,S%?8V%L+GAM;%!+ 0(4 Q0    ( /V J58$
M=X#9F5T  %$[!  5              "  6/" P!S;G1I+3(P,C,P,S,Q7V1E
M9BYX;6Q02P$"% ,4    " #]@*E6 \;3=_KC  "#OPD %0
M@ $O( 0 <VYT:2TR,#(S,#,S,5]L86(N>&UL4$L! A0#%     @ _8"I5I)&
MS,2&AP  \T<& !4              ( !7 0% '-N=&DM,C R,S S,S%?<')E
:+GAM;%!+!08     "P + .("   5C 4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
